patient_id,trial_id,age_at_enrollment,sex,race_ethnicity,genetic_mutation,disease_severity_score,prior_treatments_count,treatment_arm,dose_level,enrollment_date,consent_type,country,site_id
PT-000001,XS-OD-0001,40,Male,White,,47.3,1,Active_Drug,Standard,2022-10-16,Standard,Austria,SITE-009
PT-000002,XS-OD-0001,65,Female,White,p.R301Q,74.2,0,SOC,Standard,2022-09-01,Standard,Canada,SITE-008
PT-000003,XS-OD-0001,55,Male,White,c.1226A>G (N370S),62.1,0,Combination,Standard,2022-12-23,Standard,South Korea,SITE-005
PT-000004,XS-OD-0001,34,Male,Hispanic or Latino,p.A456P,64.4,7,Active_Drug,Standard,2022-10-08,Standard,Norway,SITE-011
PT-000005,XS-OD-0001,39,Male,White,c.1226A>G (N370S),49.8,2,SOC,Standard,2022-09-07,Standard,United States,SITE-006
PT-000006,XS-OD-0001,47,Male,White,,79.2,6,Combination,Standard,2022-10-04,Standard,United Kingdom,SITE-004
PT-000007,XS-OD-0001,47,Female,Black or African American,p.A456P,84.6,2,Active_Drug,Standard,2022-08-30,Standard,Japan,SITE-009
PT-000008,XS-OD-0001,2,Male,White,,39.1,6,SOC,Standard,2022-11-14,Pediatric_Assent,United States,SITE-004
PT-000009,XS-OD-0001,49,Male,Black or African American,IVS2+1G>A,80.0,2,Combination,Standard,2022-07-24,Standard,Australia,SITE-003
PT-000010,XS-OD-0001,16,Female,Hispanic or Latino,p.G269S,54.1,2,Active_Drug,Standard,2022-11-25,Pediatric_Assent,Taiwan,SITE-011
PT-000011,XS-OD-0001,18,Male,White,c.1226A>G (N370S),64.3,1,SOC,Standard,2022-10-12,Standard,Netherlands,SITE-003
PT-000012,XS-OD-0001,43,Female,American Indian or Alaska Native,p.R301Q,65.0,2,Combination,Standard,2022-12-14,Standard,Switzerland,SITE-006
PT-000013,XS-OD-0001,25,Female,Black or African American,,49.0,4,Active_Drug,Standard,2022-07-04,Standard,South Korea,SITE-011
PT-000014,XS-OD-0001,57,Female,White,,61.5,2,SOC,Standard,2022-08-14,Standard,Japan,SITE-004
PT-000015,XS-OD-0001,39,Male,White,p.A456P,37.2,2,Combination,Standard,2022-10-14,Standard,Taiwan,SITE-004
PT-000016,XS-OD-0001,55,Male,White,p.G269S,85.1,1,Active_Drug,Standard,2022-10-06,Standard,Sweden,SITE-009
PT-000017,XS-OD-0001,3,Female,Asian,c.1448T>C (L444P),50.8,3,SOC,Standard,2022-10-16,Pediatric_Assent,Sweden,SITE-005
PT-000018,XS-OD-0001,54,Male,Black or African American,IVS2+1G>A,16.0,1,Combination,Standard,2022-12-11,Standard,Norway,SITE-001
PT-000019,XS-OD-0001,73,Female,White,,40.3,0,Active_Drug,Standard,2022-08-26,Standard,Canada,SITE-005
PT-000020,XS-OD-0001,39,Male,White,p.G269S,73.3,0,SOC,Standard,2022-11-28,Standard,Spain,SITE-007
PT-000021,XS-OD-0001,19,Female,White,,47.8,3,Combination,Standard,2022-09-27,Standard,Germany,SITE-009
PT-000022,XS-OD-0001,40,Female,American Indian or Alaska Native,c.1226A>G (N370S),95.0,0,Active_Drug,Standard,2022-08-11,Standard,Switzerland,SITE-006
PT-000023,XS-OD-0001,26,Female,White,,67.5,5,SOC,Standard,2022-09-04,Standard,France,SITE-005
PT-000024,XS-OD-0001,35,Male,White,c.1448T>C (L444P),76.9,3,Combination,Standard,2022-12-23,Standard,Australia,SITE-003
PT-000025,XS-OD-0001,34,Male,White,,77.2,2,Active_Drug,Standard,2022-09-20,Standard,United States,SITE-004
PT-000026,XS-OD-0001,55,Male,White,,49.2,1,SOC,Standard,2022-10-18,Standard,United States,SITE-002
PT-000027,XS-OD-0001,76,Male,White,c.1226A>G (N370S),42.7,2,Combination,Standard,2022-08-09,Standard,Sweden,SITE-004
PT-000028,XS-OD-0001,44,Female,American Indian or Alaska Native,IVS2+1G>A,34.9,3,Active_Drug,Standard,2022-10-17,Standard,Israel,SITE-007
PT-000029,XS-OD-0001,50,Female,White,p.G269S,36.6,2,SOC,Standard,2022-11-19,Standard,France,SITE-011
PT-000030,XS-OD-0001,39,Female,White,,42.6,2,Combination,Standard,2022-07-25,Standard,Japan,SITE-001
PT-000031,XS-OD-0001,31,Female,White,p.A456P,31.9,4,Active_Drug,Standard,2022-12-03,Standard,Israel,SITE-009
PT-000032,XS-OD-0001,46,Female,White,c.1448T>C (L444P),84.0,3,SOC,Standard,2022-10-19,Standard,United States,SITE-012
PT-000033,XS-OD-0001,2,Female,Hispanic or Latino,p.G269S,30.6,1,Combination,Standard,2022-09-16,Pediatric_Assent,Denmark,SITE-011
PT-000034,XS-OD-0001,32,Female,White,c.1448T>C (L444P),38.3,3,Active_Drug,Standard,2022-09-21,Standard,South Korea,SITE-008
PT-000035,XS-OD-0001,27,Male,Hispanic or Latino,p.G269S,50.3,4,SOC,Standard,2022-11-13,Standard,United Kingdom,SITE-006
PT-000036,XS-OD-0001,10,Male,Black or African American,,55.2,5,Combination,Standard,2022-06-28,Pediatric_Assent,Switzerland,SITE-009
PT-000037,XS-OD-0001,44,Female,Black or African American,IVS2+1G>A,38.7,3,Active_Drug,Standard,2022-08-23,Standard,Australia,SITE-011
PT-000038,XS-OD-0001,37,Male,White,c.1226A>G (N370S),59.9,1,SOC,Standard,2022-07-04,Standard,Denmark,SITE-003
PT-000039,XS-OD-0001,56,Female,White,c.1448T>C (L444P),87.9,2,Combination,Standard,2022-10-24,Standard,Israel,SITE-007
PT-000040,XS-OD-0001,44,Male,White,,66.6,1,Active_Drug,Standard,2022-06-27,Standard,Taiwan,SITE-012
PT-000041,XS-OD-0001,25,Male,White,IVS2+1G>A,53.9,2,SOC,Standard,2022-07-17,Standard,Norway,SITE-006
PT-000042,XS-OD-0001,34,Male,Hispanic or Latino,,28.9,3,Combination,Standard,2022-11-22,Standard,Israel,SITE-007
PT-000043,XS-OD-0001,46,Male,Asian,IVS2+1G>A,60.1,3,Active_Drug,Standard,2022-07-07,Standard,Germany,SITE-012
PT-000044,XS-OD-0001,38,Female,Black or African American,,73.0,5,SOC,Standard,2022-08-07,Standard,Belgium,SITE-003
PT-000045,XS-OD-0001,57,Female,White,,44.4,2,Combination,Standard,2022-10-29,Standard,Taiwan,SITE-008
PT-000046,XS-OD-0001,42,Female,White,,51.0,1,Active_Drug,Standard,2022-08-07,Standard,Taiwan,SITE-008
PT-000047,XS-OD-0001,36,Male,Black or African American,c.1448T>C (L444P),45.5,3,SOC,Standard,2022-08-01,Standard,Netherlands,SITE-003
PT-000048,XS-OD-0001,34,Male,White,,74.7,2,Combination,Standard,2022-10-19,Standard,Spain,SITE-011
PT-000049,XS-OD-0001,9,Female,White,,46.5,3,Active_Drug,Standard,2022-07-03,Pediatric_Assent,Switzerland,SITE-006
PT-000050,XS-OD-0001,53,Male,White,,75.3,1,SOC,Standard,2022-10-15,Emergency,Israel,SITE-001
PT-000051,XS-OD-0001,41,Female,Asian,p.A456P,10.0,3,Combination,Standard,2022-12-18,Standard,Denmark,SITE-009
PT-000052,XS-OD-0001,47,Female,White,,49.1,0,Active_Drug,Standard,2022-07-07,Standard,Switzerland,SITE-004
PT-000053,XS-OD-0001,13,Male,American Indian or Alaska Native,p.R301Q,51.2,1,SOC,Standard,2022-08-11,Pediatric_Assent,United Kingdom,SITE-004
PT-000054,XS-OD-0001,34,Female,White,p.A456P,51.4,1,Combination,Standard,2022-10-21,Standard,Sweden,SITE-004
PT-000055,XS-OD-0001,44,Male,White,,66.5,5,Active_Drug,Standard,2022-07-07,Standard,Brazil,SITE-011
PT-000056,XS-OD-0001,47,Female,Black or African American,c.1448T>C (L444P),58.7,4,SOC,Standard,2022-06-30,Standard,Austria,SITE-009
PT-000057,XS-OD-0001,41,Male,White,c.1226A>G (N370S),52.9,3,Combination,Standard,2022-09-20,Standard,Denmark,SITE-009
PT-000058,XS-OD-0001,38,Female,White,c.1448T>C (L444P),50.5,4,Active_Drug,Standard,2022-09-02,Standard,Sweden,SITE-005
PT-000059,XS-OD-0001,31,Male,White,IVS2+1G>A,48.5,1,SOC,Standard,2022-10-20,Standard,United Kingdom,SITE-006
PT-000060,XS-OD-0001,30,Male,Asian,c.1448T>C (L444P),65.0,2,Combination,Standard,2022-07-31,Standard,Taiwan,SITE-008
PT-000061,XS-OD-0001,24,Male,Hispanic or Latino,p.R301Q,56.0,3,Active_Drug,Standard,2022-08-22,Standard,Italy,SITE-010
PT-000062,XS-OD-0001,47,Male,Black or African American,,54.3,2,SOC,Standard,2022-08-01,Standard,Japan,SITE-010
PT-000063,XS-OD-0001,30,Female,Black or African American,p.R301Q,54.7,2,Combination,Standard,2022-10-28,Standard,Denmark,SITE-004
PT-000064,XS-OD-0001,8,Male,White,c.1448T>C (L444P),43.3,0,Active_Drug,Standard,2022-09-20,Pediatric_Assent,Belgium,SITE-009
PT-000065,XS-OD-0001,29,Male,White,p.G269S,95.0,2,SOC,Standard,2022-10-29,Standard,Australia,SITE-007
PT-000066,XS-OD-0001,48,Male,Hispanic or Latino,,91.2,1,Combination,Standard,2022-08-07,Standard,Switzerland,SITE-010
PT-000067,XS-OD-0001,19,Female,White,p.R301Q,68.1,6,Active_Drug,Standard,2022-07-07,Standard,Israel,SITE-012
PT-000068,XS-OD-0001,62,Male,Hispanic or Latino,IVS2+1G>A,58.8,3,SOC,Standard,2022-07-14,Standard,Israel,SITE-011
PT-000069,XS-OD-0001,2,Male,White,c.1448T>C (L444P),61.6,1,Combination,Standard,2022-07-03,Pediatric_Assent,Sweden,SITE-012
PT-000070,XS-OD-0001,40,Female,White,,35.1,0,Active_Drug,Standard,2022-10-31,Standard,Sweden,SITE-008
PT-000071,XS-OD-0001,31,Male,White,p.G269S,50.6,3,SOC,Standard,2022-12-13,Standard,Israel,SITE-008
PT-000072,XS-OD-0001,61,Female,White,IVS2+1G>A,72.4,0,Combination,Standard,2022-12-18,Standard,Israel,SITE-011
PT-000073,XS-OD-0001,19,Female,Black or African American,c.1226A>G (N370S),78.4,0,Active_Drug,Standard,2022-07-29,Standard,South Korea,SITE-012
PT-000074,XS-OD-0001,39,Male,Hispanic or Latino,,38.9,1,SOC,Standard,2022-10-13,Standard,Taiwan,SITE-012
PT-000075,XS-OD-0001,22,Female,White,,81.5,1,Combination,Standard,2022-08-06,Standard,Belgium,SITE-011
PT-000076,XS-OD-0001,40,Female,Hispanic or Latino,p.A456P,45.6,5,Active_Drug,Standard,2022-08-14,Standard,Germany,SITE-007
PT-000077,XS-OD-0001,42,Female,Asian,,30.9,2,SOC,Standard,2022-12-10,Standard,Netherlands,SITE-003
PT-000078,XS-OD-0001,25,Male,White,IVS2+1G>A,25.8,0,Combination,Standard,2022-10-08,Standard,Switzerland,SITE-010
PT-000079,XS-OD-0001,63,Female,White,c.1226A>G (N370S),57.3,2,Active_Drug,Standard,2022-10-29,Emergency,South Korea,SITE-004
PT-000080,XS-OD-0001,16,Male,White,,82.0,0,SOC,Standard,2022-08-10,Pediatric_Assent,Switzerland,SITE-009
PT-000081,XS-OD-0001,25,Male,White,p.A456P,29.0,1,Combination,Standard,2022-06-30,Standard,Denmark,SITE-005
PT-000082,XS-OD-0001,44,Female,White,p.R301Q,65.4,2,Active_Drug,Standard,2022-11-23,Standard,Spain,SITE-006
PT-000083,XS-OD-0002,11,Male,White,p.R301Q,63.2,2,Active_Drug,Standard,2021-10-07,Pediatric_Assent,Canada,SITE-005
PT-000084,XS-OD-0002,21,Male,White,p.G269S,46.5,2,Active_Drug,Standard,2021-07-02,Standard,Spain,SITE-004
PT-000085,XS-OD-0002,47,Female,Asian,,50.2,5,Active_Drug,Standard,2021-08-30,Standard,Italy,SITE-010
PT-000086,XS-OD-0002,63,Female,Hispanic or Latino,p.R301Q,75.0,2,Active_Drug,Standard,2021-06-22,Standard,Italy,SITE-007
PT-000087,XS-OD-0002,65,Male,Asian,,84.9,0,Active_Drug,Standard,2021-08-08,Standard,Spain,SITE-002
PT-000088,XS-OD-0002,28,Male,Black or African American,p.R301Q,67.9,7,Active_Drug,Standard,2021-10-24,Standard,Netherlands,SITE-008
PT-000089,XS-OD-0002,25,Male,Asian,,66.2,3,Active_Drug,Standard,2021-06-18,Standard,Germany,SITE-010
PT-000090,XS-OD-0002,42,Male,White,p.A456P,42.5,1,Active_Drug,Standard,2021-07-10,Standard,Spain,SITE-005
PT-000091,XS-OD-0002,48,Male,White,,19.5,2,Active_Drug,Standard,2021-09-04,Standard,Netherlands,SITE-002
PT-000092,XS-OD-0002,49,Female,Hispanic or Latino,p.G269S,55.0,2,Active_Drug,Standard,2021-06-13,Standard,Japan,SITE-006
PT-000093,XS-OD-0002,58,Male,White,,45.1,2,Active_Drug,Standard,2021-08-19,Standard,Spain,SITE-010
PT-000094,XS-OD-0002,47,Male,White,,51.9,3,Active_Drug,Standard,2021-08-24,Standard,Italy,SITE-006
PT-000095,XS-OD-0002,25,Male,White,c.1448T>C (L444P),10.0,4,Active_Drug,Standard,2021-07-23,Standard,Netherlands,SITE-001
PT-000096,XS-OD-0002,31,Male,White,,28.3,2,Active_Drug,Standard,2021-09-05,Standard,Spain,SITE-002
PT-000097,XS-OD-0002,20,Male,White,p.G269S,61.0,1,Active_Drug,Standard,2021-05-13,Standard,Italy,SITE-009
PT-000098,XS-OD-0002,36,Male,Black or African American,,69.4,4,Active_Drug,Standard,2021-07-05,Standard,France,SITE-009
PT-000099,XS-OD-0002,29,Male,Black or African American,,52.4,0,Active_Drug,Standard,2021-07-19,Standard,Netherlands,SITE-004
PT-000100,XS-OD-0002,17,Female,White,c.1448T>C (L444P),67.2,3,Active_Drug,Standard,2021-05-15,Pediatric_Assent,United Kingdom,SITE-003
PT-000101,XS-OD-0002,80,Female,White,c.1226A>G (N370S),80.5,0,Active_Drug,Standard,2021-07-12,Standard,Italy,SITE-001
PT-000102,XS-OD-0002,35,Female,Hispanic or Latino,,56.5,3,Active_Drug,Standard,2021-09-01,Standard,Spain,SITE-010
PT-000103,XS-OD-0002,42,Male,Hispanic or Latino,IVS2+1G>A,41.5,2,Active_Drug,Standard,2021-10-05,Standard,Netherlands,SITE-010
PT-000104,XS-OD-0002,21,Female,White,p.A456P,67.0,2,Active_Drug,Standard,2021-07-16,Standard,Canada,SITE-001
PT-000105,XS-OD-0002,33,Male,Asian,p.G269S,58.5,3,Active_Drug,Standard,2021-10-18,Standard,United Kingdom,SITE-007
PT-000106,XS-OD-0002,40,Female,American Indian or Alaska Native,IVS2+1G>A,65.9,2,Active_Drug,Standard,2021-08-10,Standard,Australia,SITE-009
PT-000107,XS-OD-0002,41,Intersex,Asian,p.G269S,74.5,3,Active_Drug,Standard,2021-05-24,Emergency,Australia,SITE-002
PT-000108,XS-OD-0002,41,Male,White,IVS2+1G>A,87.0,6,Active_Drug,Standard,2021-07-02,Standard,Canada,SITE-007
PT-000109,XS-OD-0002,54,Male,White,,73.5,0,Active_Drug,Standard,2021-09-18,Standard,Australia,SITE-007
PT-000110,XS-OD-0002,26,Male,White,,49.6,1,Active_Drug,Standard,2021-07-01,Standard,United States,SITE-002
PT-000111,XS-OD-0002,29,Female,Hispanic or Latino,p.R301Q,47.1,4,Active_Drug,Standard,2021-08-04,Standard,United Kingdom,SITE-006
PT-000112,XS-OD-0002,63,Female,Hispanic or Latino,,56.6,3,Active_Drug,Standard,2021-05-21,Compassionate,United States,SITE-005
PT-000113,XS-OD-0002,47,Male,White,c.1226A>G (N370S),72.8,2,Active_Drug,Standard,2021-07-01,Standard,Germany,SITE-005
PT-000114,XS-OD-0002,28,Male,White,c.1448T>C (L444P),95.0,4,Active_Drug,Standard,2021-10-27,Standard,United Kingdom,SITE-004
PT-000115,XS-OD-0002,35,Male,Hispanic or Latino,,70.8,1,Active_Drug,Standard,2021-09-17,Standard,Australia,SITE-004
PT-000116,XS-OD-0002,30,Male,White,,51.5,1,Active_Drug,Standard,2021-07-08,Standard,Canada,SITE-001
PT-000117,XS-OD-0002,18,Female,White,,29.4,3,Active_Drug,Standard,2021-10-12,Standard,Canada,SITE-010
PT-000118,XS-OD-0002,41,Female,White,c.1448T>C (L444P),68.5,2,Active_Drug,Standard,2021-06-10,Standard,United Kingdom,SITE-008
PT-000119,XS-OD-0002,75,Female,Black or African American,c.1448T>C (L444P),54.8,2,Active_Drug,Standard,2021-10-08,Standard,Spain,SITE-008
PT-000120,XS-OD-0002,12,Male,White,,42.6,0,Active_Drug,Standard,2021-06-29,Pediatric_Assent,Spain,SITE-006
PT-000121,XS-OD-0002,45,Male,White,p.R301Q,54.9,2,Active_Drug,Standard,2021-05-20,Standard,Australia,SITE-008
PT-000122,XS-OD-0002,17,Female,White,p.G269S,10.4,3,Active_Drug,Standard,2021-08-08,Pediatric_Assent,Spain,SITE-006
PT-000123,XS-OD-0002,26,Female,Asian,,55.0,1,Active_Drug,Standard,2021-08-28,Standard,United Kingdom,SITE-008
PT-000124,XS-OD-0002,5,Male,Hispanic or Latino,,38.7,2,Active_Drug,Standard,2021-06-22,Pediatric_Assent,Germany,SITE-010
PT-000125,XS-OD-0002,52,Male,Hispanic or Latino,c.1226A>G (N370S),65.0,4,Active_Drug,Standard,2021-10-02,Standard,France,SITE-004
PT-000126,XS-OD-0002,52,Male,White,,52.1,1,Active_Drug,Standard,2021-10-05,Standard,Netherlands,SITE-007
PT-000127,XS-OD-0002,9,Female,White,c.1448T>C (L444P),35.7,1,Active_Drug,Standard,2021-06-09,Pediatric_Assent,Italy,SITE-002
PT-000128,XS-OD-0002,46,Male,Hispanic or Latino,c.1448T>C (L444P),63.1,0,Active_Drug,Standard,2021-07-24,Standard,United Kingdom,SITE-001
PT-000129,XS-OD-0002,40,Female,White,p.A456P,28.4,4,Active_Drug,Standard,2021-05-26,Standard,Germany,SITE-003
PT-000130,XS-OD-0002,37,Male,Black or African American,,61.2,0,Active_Drug,Standard,2021-06-14,Standard,Spain,SITE-007
PT-000131,XS-OD-0002,42,Male,White,,52.9,1,Active_Drug,Standard,2021-07-12,Standard,Canada,SITE-002
PT-000132,XS-OD-0002,62,Female,White,c.1448T>C (L444P),74.7,2,Active_Drug,Standard,2021-10-02,Standard,Netherlands,SITE-003
PT-000133,XS-OD-0002,7,Female,White,p.G269S,54.1,2,Active_Drug,Standard,2021-06-29,Pediatric_Assent,Italy,SITE-005
PT-000134,XS-OD-0002,11,Male,Hispanic or Latino,c.1448T>C (L444P),59.0,1,Active_Drug,Standard,2021-06-12,Pediatric_Assent,Japan,SITE-007
PT-000135,XS-OD-0002,36,Male,White,,64.1,2,Active_Drug,Standard,2021-08-03,Standard,France,SITE-009
PT-000136,XS-OD-0002,70,Female,White,,56.7,2,Active_Drug,Standard,2021-09-13,Standard,Canada,SITE-006
PT-000137,XS-OD-0002,66,Female,White,p.G269S,44.8,2,Active_Drug,Standard,2021-08-19,Standard,Spain,SITE-009
PT-000138,XS-OD-0002,44,Female,Black or African American,,36.3,2,Active_Drug,Standard,2021-05-23,Standard,Japan,SITE-009
PT-000139,XS-OD-0002,34,Female,Native Hawaiian or Other Pacific Islander,p.G269S,57.9,2,Active_Drug,Standard,2021-10-15,Standard,United Kingdom,SITE-003
PT-000140,XS-OD-0002,53,Female,Black or African American,p.G269S,53.5,3,Active_Drug,Standard,2021-10-11,Standard,United States,SITE-010
PT-000141,XS-OD-0002,51,Female,Hispanic or Latino,,51.9,1,Active_Drug,Standard,2021-06-25,Standard,Canada,SITE-004
PT-000142,XS-OD-0002,12,Female,Native Hawaiian or Other Pacific Islander,,45.7,1,Active_Drug,Standard,2021-06-06,Pediatric_Assent,United Kingdom,SITE-003
PT-000143,XS-OD-0002,45,Female,Hispanic or Latino,,47.5,2,Active_Drug,Standard,2021-06-07,Standard,Japan,SITE-008
PT-000144,XS-OD-0002,30,Female,Hispanic or Latino,p.G269S,70.3,1,Active_Drug,Standard,2021-05-22,Standard,Japan,SITE-005
PT-000145,XS-OD-0002,33,Female,White,p.A456P,62.7,2,Active_Drug,Standard,2021-09-10,Standard,Australia,SITE-005
PT-000146,XS-OD-0002,12,Female,White,,77.7,2,Active_Drug,Standard,2021-06-13,Pediatric_Assent,Australia,SITE-006
PT-000147,XS-OD-0002,59,Female,White,IVS2+1G>A,49.4,0,Active_Drug,Standard,2021-05-14,Standard,Italy,SITE-004
PT-000148,XS-OD-0002,57,Female,Hispanic or Latino,,82.1,1,Active_Drug,Standard,2021-08-28,Standard,Canada,SITE-004
PT-000149,XS-OD-0002,38,Female,Asian,p.A456P,50.2,1,Active_Drug,Standard,2021-09-01,Standard,Italy,SITE-009
PT-000150,XS-OD-0002,35,Female,Hispanic or Latino,c.1226A>G (N370S),35.5,3,Active_Drug,Standard,2021-09-01,Compassionate,Germany,SITE-009
PT-000151,XS-OD-0003,69,Male,Black or African American,IVS2+1G>A,89.4,4,Active_Drug,Standard,2023-07-12,Standard,Italy,SITE-004
PT-000152,XS-OD-0003,29,Male,White,,45.4,4,Active_Drug,Standard,2023-06-30,Standard,Netherlands,SITE-003
PT-000153,XS-OD-0003,24,Female,White,p.G269S,38.0,3,Active_Drug,Standard,2023-02-27,Standard,United Kingdom,SITE-004
PT-000154,XS-OD-0003,69,Male,Hispanic or Latino,,62.9,3,Active_Drug,Standard,2023-06-11,Standard,Japan,SITE-005
PT-000155,XS-OD-0003,52,Male,Black or African American,IVS2+1G>A,31.8,2,Active_Drug,Standard,2023-04-27,Standard,United States,SITE-004
PT-000156,XS-OD-0003,75,Male,White,,44.5,3,Active_Drug,Standard,2023-06-11,Standard,Spain,SITE-004
PT-000157,XS-OD-0003,46,Female,White,IVS2+1G>A,63.6,1,Active_Drug,Standard,2023-04-16,Standard,Netherlands,SITE-001
PT-000158,XS-OD-0003,30,Female,White,p.R301Q,51.9,2,Active_Drug,Standard,2023-06-25,Standard,Japan,SITE-004
PT-000159,XS-OD-0003,57,Female,Hispanic or Latino,,52.9,3,Active_Drug,Standard,2023-02-26,Standard,Spain,SITE-001
PT-000160,XS-OD-0003,44,Female,White,,25.5,1,Active_Drug,Standard,2023-04-15,Standard,Germany,SITE-001
PT-000161,XS-OD-0003,36,Intersex,Asian,,56.2,1,Active_Drug,Standard,2023-06-21,Standard,Japan,SITE-002
PT-000162,XS-OD-0003,55,Male,Black or African American,c.1448T>C (L444P),71.7,2,Active_Drug,Standard,2023-07-30,Standard,United Kingdom,SITE-004
PT-000163,XS-OD-0003,64,Male,Hispanic or Latino,c.1226A>G (N370S),36.7,3,Active_Drug,Standard,2023-07-22,Standard,Japan,SITE-002
PT-000164,XS-OD-0003,37,Male,White,,48.2,0,Active_Drug,Standard,2023-05-06,Standard,France,SITE-003
PT-000165,XS-OD-0003,49,Female,Hispanic or Latino,p.A456P,37.6,1,Active_Drug,Standard,2023-03-08,Standard,Italy,SITE-002
PT-000166,XS-OD-0003,35,Male,White,c.1226A>G (N370S),51.4,2,Active_Drug,Standard,2023-03-02,Standard,United States,SITE-004
PT-000167,XS-OD-0003,6,Male,Hispanic or Latino,c.1448T>C (L444P),66.8,5,Active_Drug,Standard,2023-05-01,Pediatric_Assent,Japan,SITE-005
PT-000168,XS-OD-0003,66,Female,White,,39.4,0,Active_Drug,Standard,2023-07-29,Standard,Australia,SITE-005
PT-000169,XS-OD-0003,57,Female,White,IVS2+1G>A,48.1,3,Active_Drug,Standard,2023-05-17,Standard,Australia,SITE-005
PT-000170,XS-OD-0003,33,Female,Hispanic or Latino,c.1448T>C (L444P),57.2,2,Active_Drug,Standard,2023-03-19,Standard,Spain,SITE-004
PT-000171,XS-OD-0003,42,Female,Two or More Races,IVS2+1G>A,18.8,1,Active_Drug,Standard,2023-04-07,Standard,United States,SITE-004
PT-000172,XS-OD-0003,41,Male,Black or African American,p.A456P,21.7,3,Active_Drug,Standard,2023-04-26,Standard,Netherlands,SITE-005
PT-000173,XS-OD-0003,20,Female,Native Hawaiian or Other Pacific Islander,,24.5,3,Active_Drug,Standard,2023-04-11,Standard,France,SITE-004
PT-000174,XS-OD-0003,26,Male,Hispanic or Latino,p.G269S,71.5,4,Active_Drug,Standard,2023-05-13,Standard,United Kingdom,SITE-005
PT-000175,XS-OD-0003,33,Male,White,c.1448T>C (L444P),37.2,0,Active_Drug,Standard,2023-06-26,Standard,United Kingdom,SITE-003
PT-000176,XS-OD-0003,63,Female,Hispanic or Latino,,53.7,2,Active_Drug,Standard,2023-07-18,Standard,Spain,SITE-003
PT-000177,XS-OD-0003,23,Male,White,IVS2+1G>A,31.7,1,Active_Drug,Standard,2023-03-03,Standard,Italy,SITE-004
PT-000178,XS-OD-0003,27,Male,White,,42.6,0,Active_Drug,Standard,2023-04-13,Standard,Spain,SITE-002
PT-000179,XS-OD-0003,45,Male,White,,44.7,6,Active_Drug,Standard,2023-07-02,Standard,Spain,SITE-003
PT-000180,XS-OD-0003,57,Male,Black or African American,c.1448T>C (L444P),68.2,2,Active_Drug,Standard,2023-03-10,Standard,Japan,SITE-003
PT-000181,XS-OD-0003,18,Female,Black or African American,,68.5,0,Active_Drug,Standard,2023-04-13,Standard,France,SITE-005
PT-000182,XS-OD-0003,34,Male,White,,35.1,4,Active_Drug,Standard,2023-04-17,Standard,Japan,SITE-005
PT-000183,XS-OD-0003,63,Female,White,IVS2+1G>A,90.3,3,Active_Drug,Standard,2023-04-29,Standard,Canada,SITE-004
PT-000184,XS-OD-0003,37,Female,White,,68.9,5,Active_Drug,Standard,2023-07-06,Standard,Canada,SITE-002
PT-000185,XS-OD-0003,44,Male,Hispanic or Latino,,58.6,1,Active_Drug,Standard,2023-07-09,Standard,Spain,SITE-001
PT-000186,XS-OD-0004,50,Female,White,IVS2+1G>A,43.0,3,Active_Drug,Standard,2019-01-14,Compassionate,Canada,SITE-005
PT-000187,XS-OD-0004,30,Male,White,,51.2,4,Placebo,Standard,2018-10-25,Standard,Netherlands,SITE-003
PT-000188,XS-OD-0004,21,Male,White,,49.9,0,Active_Drug_High_Dose,Standard,2018-12-09,Standard,Spain,SITE-003
PT-000189,XS-OD-0004,42,Male,Black or African American,p.A456P,64.7,1,Active_Drug,Standard,2019-01-09,Emergency,Japan,SITE-002
PT-000190,XS-OD-0004,54,Female,Black or African American,,50.8,0,Placebo,Standard,2019-04-13,Standard,United Kingdom,SITE-003
PT-000191,XS-OD-0004,43,Male,White,p.G269S,46.9,3,Active_Drug_High_Dose,Standard,2019-04-18,Standard,Japan,SITE-005
PT-000192,XS-OD-0004,22,Male,Black or African American,c.1448T>C (L444P),67.1,2,Active_Drug,Standard,2019-01-11,Standard,Belgium,SITE-006
PT-000193,XS-OD-0004,31,Female,Two or More Races,,15.0,0,Placebo,Standard,2019-03-01,Standard,Italy,SITE-005
PT-000194,XS-OD-0004,40,Female,White,,10.0,0,Active_Drug_High_Dose,Standard,2019-01-11,Standard,Belgium,SITE-002
PT-000195,XS-OD-0004,57,Male,White,,45.5,2,Active_Drug,Standard,2019-01-15,Standard,Norway,SITE-006
PT-000196,XS-OD-0004,30,Female,Black or African American,p.G269S,50.0,1,Placebo,Standard,2018-10-30,Standard,Taiwan,SITE-002
PT-000197,XS-OD-0004,13,Female,White,p.R301Q,58.4,4,Active_Drug_High_Dose,Standard,2018-11-03,Pediatric_Assent,Norway,SITE-004
PT-000198,XS-OD-0004,43,Female,Asian,p.G269S,61.1,2,Active_Drug,Standard,2019-02-09,Emergency,Taiwan,SITE-005
PT-000199,XS-OD-0004,2,Female,White,IVS2+1G>A,43.4,3,Placebo,Standard,2019-03-03,Pediatric_Assent,South Korea,SITE-002
PT-000200,XS-OD-0004,24,Male,Asian,c.1448T>C (L444P),37.5,1,Active_Drug_High_Dose,Standard,2018-12-05,Standard,France,SITE-001
PT-000201,XS-OD-0004,62,Female,Asian,,29.9,2,Active_Drug,Standard,2019-01-05,Standard,Brazil,SITE-003
PT-000202,XS-OD-0004,30,Male,Asian,,57.5,2,Placebo,Standard,2019-01-26,Standard,Austria,SITE-001
PT-000203,XS-OD-0004,36,Male,White,,50.5,3,Active_Drug_High_Dose,Standard,2018-11-06,Standard,Norway,SITE-006
PT-000204,XS-OD-0004,2,Male,White,c.1448T>C (L444P),46.1,4,Active_Drug,Standard,2018-11-01,Pediatric_Assent,Japan,SITE-001
PT-000205,XS-OD-0004,3,Female,White,c.1226A>G (N370S),93.4,3,Placebo,Standard,2019-02-21,Pediatric_Assent,France,SITE-001
PT-000206,XS-OD-0004,51,Female,White,p.R301Q,38.0,3,Active_Drug_High_Dose,Standard,2019-01-08,Standard,France,SITE-005
PT-000207,XS-OD-0004,57,Male,White,,73.7,1,Active_Drug,Standard,2018-11-29,Standard,Austria,SITE-001
PT-000208,XS-OD-0004,27,Male,Black or African American,c.1226A>G (N370S),84.8,0,Placebo,Standard,2019-02-11,Standard,Norway,SITE-002
PT-000209,XS-OD-0004,61,Female,Black or African American,,45.2,2,Active_Drug_High_Dose,Standard,2019-03-10,Standard,Italy,SITE-003
PT-000210,XS-OD-0004,48,Female,Hispanic or Latino,p.G269S,62.1,1,Active_Drug,Standard,2019-03-03,Standard,Belgium,SITE-005
PT-000211,XS-OD-0004,52,Male,Black or African American,c.1448T>C (L444P),41.7,1,Placebo,Standard,2019-02-09,Standard,United Kingdom,SITE-005
PT-000212,XS-OD-0004,52,Male,White,,72.0,1,Active_Drug_High_Dose,Standard,2019-02-24,Standard,Belgium,SITE-005
PT-000213,XS-OD-0004,36,Female,White,,49.4,1,Active_Drug,Standard,2019-03-14,Standard,Taiwan,SITE-001
PT-000214,XS-OD-0004,37,Female,White,p.R301Q,64.4,1,Placebo,Standard,2019-01-29,Standard,Sweden,SITE-001
PT-000215,XS-OD-0004,71,Male,White,,61.8,2,Active_Drug_High_Dose,Standard,2018-11-18,Standard,Sweden,SITE-005
PT-000216,XS-OD-0004,7,Female,Black or African American,,71.4,0,Active_Drug,Standard,2019-03-21,Pediatric_Assent,Denmark,SITE-005
PT-000217,XS-OD-0004,45,Female,White,,69.6,7,Placebo,Standard,2019-03-27,Standard,Taiwan,SITE-004
PT-000218,XS-OD-0004,48,Male,White,IVS2+1G>A,44.8,1,Active_Drug_High_Dose,Standard,2019-02-19,Standard,Taiwan,SITE-006
PT-000219,XS-OD-0004,45,Male,White,,80.0,3,Active_Drug,Standard,2018-12-09,Standard,Brazil,SITE-003
PT-000220,XS-OD-0004,56,Female,White,,61.3,4,Placebo,Standard,2018-10-25,Standard,Japan,SITE-005
PT-000221,XS-OD-0004,42,Female,White,,24.4,1,Active_Drug_High_Dose,Standard,2018-12-03,Standard,Italy,SITE-004
PT-000222,XS-OD-0004,13,Female,Asian,p.G269S,45.2,2,Active_Drug,Standard,2018-11-23,Pediatric_Assent,Italy,SITE-002
PT-000223,XS-OD-0004,43,Female,White,,44.2,2,Placebo,Standard,2019-03-20,Standard,Norway,SITE-001
PT-000224,XS-OD-0004,51,Female,White,p.A456P,72.7,3,Active_Drug_High_Dose,Standard,2018-12-21,Standard,Taiwan,SITE-005
PT-000225,XS-OD-0004,23,Female,Hispanic or Latino,p.G269S,80.8,4,Active_Drug,Standard,2019-03-07,Standard,Austria,SITE-004
PT-000226,XS-OD-0004,25,Female,Asian,,51.4,2,Placebo,Standard,2019-02-23,Standard,Brazil,SITE-003
PT-000227,XS-OD-0004,29,Female,Black or African American,p.G269S,62.9,1,Active_Drug_High_Dose,Standard,2019-03-20,Standard,Netherlands,SITE-006
PT-000228,XS-OD-0004,67,Female,White,,40.3,0,Active_Drug,Standard,2019-02-10,Standard,Austria,SITE-001
PT-000229,XS-OD-0004,53,Male,White,,68.0,2,Placebo,Standard,2018-12-25,Standard,Netherlands,SITE-001
PT-000230,XS-OD-0004,51,Male,White,c.1448T>C (L444P),40.7,2,Active_Drug_High_Dose,Standard,2019-01-23,Standard,Germany,SITE-005
PT-000231,XS-OD-0004,39,Male,Asian,c.1448T>C (L444P),83.2,5,Active_Drug,Standard,2019-02-19,Standard,Spain,SITE-004
PT-000232,XS-OD-0005,32,Male,White,c.1226A>G (N370S),80.8,2,Active_Drug,Standard,2025-07-27,Standard,Japan,SITE-001
PT-000233,XS-OD-0005,5,Male,White,c.1448T>C (L444P),67.9,1,Placebo,Standard,2025-09-01,Pediatric_Assent,United States,SITE-003
PT-000234,XS-OD-0005,16,Male,Asian,c.1226A>G (N370S),52.1,3,Active_Drug_High_Dose,Standard,2025-06-26,Pediatric_Assent,Japan,SITE-003
PT-000235,XS-OD-0005,48,Male,White,c.1448T>C (L444P),50.8,2,Active_Drug,Standard,2025-08-19,Standard,Spain,SITE-002
PT-000236,XS-OD-0005,30,Female,White,,49.6,1,Placebo,Standard,2025-10-02,Standard,France,SITE-001
PT-000237,XS-OD-0005,45,Female,Black or African American,,47.8,1,Active_Drug_High_Dose,Standard,2025-08-21,Standard,Canada,SITE-001
PT-000238,XS-OD-0005,79,Female,White,c.1448T>C (L444P),49.9,3,Active_Drug,Standard,2025-05-26,Standard,Australia,SITE-002
PT-000239,XS-OD-0005,27,Female,White,,67.7,3,Placebo,Standard,2025-10-15,Standard,Australia,SITE-001
PT-000240,XS-OD-0005,22,Female,White,c.1448T>C (L444P),57.2,5,Active_Drug_High_Dose,Standard,2025-09-28,Standard,Canada,SITE-001
PT-000241,XS-OD-0005,2,Male,Asian,c.1226A>G (N370S),75.8,1,Active_Drug,Standard,2025-09-09,Pediatric_Assent,United Kingdom,SITE-003
PT-000242,XS-OD-0005,20,Male,White,p.G269S,37.5,3,Placebo,Standard,2025-09-26,Standard,Canada,SITE-001
PT-000243,XS-OD-0005,43,Male,White,p.A456P,54.2,0,Active_Drug_High_Dose,Standard,2025-07-18,Standard,Canada,SITE-002
PT-000244,XS-OD-0005,46,Female,White,p.A456P,48.8,2,Active_Drug,Standard,2025-10-30,Standard,United Kingdom,SITE-001
PT-000245,XS-OD-0005,60,Female,Hispanic or Latino,,71.6,1,Placebo,Standard,2025-05-30,Standard,Spain,SITE-002
PT-000246,XS-OD-0005,21,Female,White,,95.0,0,Active_Drug_High_Dose,Standard,2025-09-19,Standard,United Kingdom,SITE-003
PT-000247,XS-OD-0005,48,Female,White,,27.8,0,Active_Drug,Standard,2025-10-05,Standard,Netherlands,SITE-002
PT-000248,XS-OD-0005,39,Intersex,White,,41.1,3,Placebo,Standard,2025-11-04,Standard,Australia,SITE-002
PT-000249,XS-OD-0005,2,Male,White,c.1226A>G (N370S),66.8,1,Active_Drug_High_Dose,Standard,2025-06-04,Pediatric_Assent,Canada,SITE-003
PT-000250,XS-OD-0005,58,Male,Hispanic or Latino,,73.3,4,Active_Drug,Standard,2025-06-19,Standard,Australia,SITE-001
PT-000251,XS-OD-0005,25,Female,White,IVS2+1G>A,35.5,3,Placebo,Standard,2025-07-27,Standard,Australia,SITE-003
PT-000252,XS-OD-0005,69,Female,White,,32.6,0,Active_Drug_High_Dose,Standard,2025-06-25,Standard,United Kingdom,SITE-001
PT-000253,XS-OD-0005,25,Male,White,p.R301Q,31.9,2,Active_Drug,Standard,2025-07-22,Standard,Canada,SITE-001
PT-000254,XS-OD-0005,38,Female,White,p.R301Q,48.6,2,Placebo,Standard,2025-11-11,Standard,United Kingdom,SITE-003
PT-000255,XS-OD-0005,35,Male,White,,39.2,2,Active_Drug_High_Dose,Standard,2025-08-10,Standard,Japan,SITE-003
PT-000256,XS-OD-0005,38,Female,White,,57.1,2,Active_Drug,Standard,2025-09-17,Emergency,United Kingdom,SITE-003
PT-000257,XS-OD-0005,2,Male,White,c.1226A>G (N370S),62.6,1,Placebo,Standard,2025-10-01,Pediatric_Assent,France,SITE-002
PT-000258,XS-OD-0005,63,Female,White,p.R301Q,55.4,0,Active_Drug_High_Dose,Standard,2025-08-21,Standard,Spain,SITE-001
PT-000259,XS-OD-0005,20,Male,American Indian or Alaska Native,c.1226A>G (N370S),69.5,3,Active_Drug,Standard,2025-08-19,Standard,Japan,SITE-002
PT-000260,XS-OD-0005,53,Female,White,,32.5,2,Placebo,Standard,2025-11-13,Standard,Spain,SITE-001
PT-000261,XS-OD-0005,32,Female,Black or African American,p.G269S,69.3,2,Active_Drug_High_Dose,Standard,2025-07-09,Standard,Germany,SITE-001
PT-000262,XS-OD-0005,21,Male,Asian,,69.1,2,Active_Drug,Standard,2025-11-06,Standard,United States,SITE-001
PT-000263,XS-OD-0005,25,Female,Black or African American,p.G269S,70.7,0,Placebo,Standard,2025-09-14,Standard,Germany,SITE-002
PT-000264,XS-OD-0005,24,Female,Black or African American,c.1448T>C (L444P),31.9,4,Active_Drug_High_Dose,Standard,2025-07-05,Emergency,Germany,SITE-002
PT-000265,XS-OD-0005,36,Male,White,,38.4,1,Active_Drug,Standard,2025-09-10,Standard,Japan,SITE-002
PT-000266,XS-OD-0005,53,Male,White,IVS2+1G>A,34.9,3,Placebo,Standard,2025-08-05,Standard,Australia,SITE-002
PT-000267,XS-OD-0006,88,Male,Hispanic or Latino,SMN1 deletion,51.5,1,Active_Drug,Medium,2022-10-07,Standard,Germany,SITE-003
PT-000268,XS-OD-0006,47,Male,White,Exon 51 deletion,79.9,2,Active_Drug,Medium,2022-05-12,Standard,Austria,SITE-002
PT-000269,XS-OD-0006,47,Male,Asian,SCN1A R1648H,88.5,2,Active_Drug,High,2022-10-17,Standard,Canada,SITE-001
PT-000270,XS-OD-0006,38,Female,Black or African American,,67.7,0,Active_Drug,Medium,2022-05-23,Emergency,Netherlands,SITE-001
PT-000271,XS-OD-0006,52,Male,White,SOD1 A4V,90.8,2,Active_Drug,Medium,2022-08-14,Standard,Japan,SITE-001
PT-000272,XS-OD-0006,5,Female,Hispanic or Latino,SCN1A R1648H,57.5,2,Active_Drug,Medium,2022-10-11,Pediatric_Assent,Switzerland,SITE-003
PT-000273,XS-OD-0006,34,Male,Black or African American,,50.0,3,Active_Drug,Low,2022-06-16,Standard,Netherlands,SITE-003
PT-000274,XS-OD-0006,50,Male,Asian,,64.3,2,Active_Drug,Medium,2022-10-01,Standard,Japan,SITE-002
PT-000275,XS-OD-0006,23,Female,White,,74.4,1,Active_Drug,High,2022-08-06,Compassionate,United Kingdom,SITE-002
PT-000276,XS-OD-0006,44,Female,Hispanic or Latino,CAG repeat expansion,72.7,0,Active_Drug,Low,2022-06-30,Standard,Sweden,SITE-003
PT-000277,XS-OD-0006,63,Male,White,Exon 51 deletion,61.6,1,Active_Drug,Medium,2022-08-18,Standard,United Kingdom,SITE-001
PT-000278,XS-OD-0006,68,Male,Black or African American,,24.4,0,Active_Drug,Medium,2022-08-24,Standard,Belgium,SITE-001
PT-000279,XS-OD-0006,32,Female,White,SMN1 deletion,65.3,2,Active_Drug,High,2022-06-06,Standard,United Kingdom,SITE-001
PT-000280,XS-OD-0006,63,Male,White,,46.2,0,Active_Drug,Low,2022-07-18,Standard,South Korea,SITE-001
PT-000281,XS-OD-0006,36,Male,White,SMN1 deletion,64.3,1,Active_Drug,Low,2022-08-12,Standard,Sweden,SITE-001
PT-000282,XS-OD-0007,41,Female,Asian,SMN1 deletion,25.8,2,Active_Drug,Standard,2018-06-22,Standard,Japan,SITE-009
PT-000283,XS-OD-0007,50,Male,Black or African American,SMN1 deletion,41.0,2,Placebo,Standard,2018-10-12,Standard,United Kingdom,SITE-001
PT-000284,XS-OD-0007,43,Female,Hispanic or Latino,,30.3,3,Active_Drug,Standard,2018-05-30,Emergency,Italy,SITE-005
PT-000285,XS-OD-0007,30,Female,White,SCN1A R1648H,46.7,1,Placebo,Standard,2018-06-30,Standard,South Korea,SITE-006
PT-000286,XS-OD-0007,39,Male,White,SCN1A R1648H,51.5,3,Active_Drug,Standard,2018-06-24,Standard,Australia,SITE-009
PT-000287,XS-OD-0007,44,Female,White,SOD1 A4V,58.5,1,Placebo,Standard,2018-07-26,Standard,Netherlands,SITE-001
PT-000288,XS-OD-0007,43,Female,White,SOD1 A4V,44.2,2,Active_Drug,Standard,2018-10-11,Standard,South Korea,SITE-004
PT-000289,XS-OD-0007,53,Female,White,SMN1 deletion,61.4,1,Placebo,Standard,2018-08-27,Standard,Spain,SITE-004
PT-000290,XS-OD-0007,32,Male,Asian,,39.1,4,Active_Drug,Standard,2018-07-17,Standard,Germany,SITE-006
PT-000291,XS-OD-0007,40,Male,White,,30.6,5,Placebo,Standard,2018-09-04,Standard,Brazil,SITE-005
PT-000292,XS-OD-0007,35,Female,White,,72.3,0,Active_Drug,Standard,2018-05-21,Standard,Denmark,SITE-002
PT-000293,XS-OD-0007,16,Male,Hispanic or Latino,,82.9,2,Placebo,Standard,2018-06-06,Pediatric_Assent,France,SITE-009
PT-000294,XS-OD-0007,35,Male,Asian,,45.2,1,Active_Drug,Standard,2018-07-09,Standard,Belgium,SITE-008
PT-000295,XS-OD-0007,21,Female,White,CAG repeat expansion,64.2,3,Placebo,Standard,2018-10-30,Standard,Norway,SITE-008
PT-000296,XS-OD-0007,25,Male,Asian,,77.1,2,Active_Drug,Standard,2018-10-18,Standard,Canada,SITE-005
PT-000297,XS-OD-0007,19,Male,Hispanic or Latino,SOD1 A4V,27.9,3,Placebo,Standard,2018-10-15,Compassionate,United States,SITE-009
PT-000298,XS-OD-0007,50,Female,Hispanic or Latino,SOD1 A4V,37.7,4,Active_Drug,Standard,2018-05-26,Standard,Norway,SITE-006
PT-000299,XS-OD-0007,34,Female,White,,49.0,2,Placebo,Standard,2018-08-25,Standard,United Kingdom,SITE-007
PT-000300,XS-OD-0007,20,Male,American Indian or Alaska Native,Exon 51 deletion,56.4,1,Active_Drug,Standard,2018-11-03,Standard,Israel,SITE-001
PT-000301,XS-OD-0007,23,Female,Black or African American,SOD1 A4V,27.6,2,Placebo,Standard,2018-07-11,Standard,Norway,SITE-003
PT-000302,XS-OD-0007,78,Intersex,Asian,SOD1 A4V,59.6,3,Active_Drug,Standard,2018-07-09,Standard,Taiwan,SITE-004
PT-000303,XS-OD-0007,15,Female,White,CAG repeat expansion,65.1,0,Placebo,Standard,2018-07-25,Pediatric_Assent,Brazil,SITE-004
PT-000304,XS-OD-0007,29,Male,White,SMN1 deletion,69.1,0,Active_Drug,Standard,2018-08-27,Standard,Taiwan,SITE-008
PT-000305,XS-OD-0007,17,Male,White,SCN1A R1648H,24.5,2,Placebo,Standard,2018-10-09,Pediatric_Assent,Italy,SITE-002
PT-000306,XS-OD-0007,49,Female,White,SMN1 deletion,66.1,1,Active_Drug,Standard,2018-11-02,Standard,Germany,SITE-007
PT-000307,XS-OD-0007,36,Male,Asian,Exon 51 deletion,43.5,2,Placebo,Standard,2018-06-13,Standard,United States,SITE-008
PT-000308,XS-OD-0007,27,Male,White,,66.9,1,Active_Drug,Standard,2018-10-14,Standard,Italy,SITE-003
PT-000309,XS-OD-0007,51,Male,White,,30.0,2,Placebo,Standard,2018-05-29,Standard,Spain,SITE-008
PT-000310,XS-OD-0007,23,Female,Black or African American,SCN1A R1648H,73.9,2,Active_Drug,Standard,2018-10-24,Standard,Brazil,SITE-005
PT-000311,XS-OD-0007,39,Female,Hispanic or Latino,Exon 51 deletion,39.2,3,Placebo,Standard,2018-10-22,Compassionate,Switzerland,SITE-008
PT-000312,XS-OD-0007,25,Male,White,CAG repeat expansion,45.4,1,Active_Drug,Standard,2018-08-19,Standard,Italy,SITE-006
PT-000313,XS-OD-0007,21,Male,Asian,Exon 51 deletion,63.0,1,Placebo,Standard,2018-10-03,Standard,Austria,SITE-002
PT-000314,XS-OD-0007,22,Female,White,,50.9,1,Active_Drug,Standard,2018-09-11,Standard,France,SITE-005
PT-000315,XS-OD-0007,36,Female,White,,59.9,1,Placebo,Standard,2018-06-09,Standard,Taiwan,SITE-004
PT-000316,XS-OD-0007,43,Female,White,,56.5,1,Active_Drug,Standard,2018-08-11,Compassionate,Norway,SITE-006
PT-000317,XS-OD-0007,43,Male,White,SMN1 deletion,41.2,2,Placebo,Standard,2018-08-28,Compassionate,United Kingdom,SITE-008
PT-000318,XS-OD-0007,46,Male,Two or More Races,,47.2,3,Active_Drug,Standard,2018-08-26,Standard,United States,SITE-009
PT-000319,XS-OD-0007,36,Male,White,,57.9,3,Placebo,Standard,2018-07-30,Standard,Norway,SITE-008
PT-000320,XS-OD-0007,24,Male,Hispanic or Latino,Exon 51 deletion,54.3,1,Active_Drug,Standard,2018-09-11,Standard,Canada,SITE-002
PT-000321,XS-OD-0007,47,Male,Hispanic or Latino,SMN1 deletion,53.6,0,Placebo,Standard,2018-08-25,Standard,South Korea,SITE-001
PT-000322,XS-OD-0007,58,Male,Hispanic or Latino,Exon 51 deletion,64.5,1,Active_Drug,Standard,2018-08-18,Standard,United Kingdom,SITE-004
PT-000323,XS-OD-0007,75,Female,White,,47.5,0,Placebo,Standard,2018-08-31,Standard,Netherlands,SITE-007
PT-000324,XS-OD-0007,44,Female,White,SCN1A R1648H,62.5,1,Active_Drug,Standard,2018-09-25,Standard,Australia,SITE-008
PT-000325,XS-OD-0007,39,Female,White,SCN1A R1648H,67.2,3,Placebo,Standard,2018-10-12,Standard,France,SITE-007
PT-000326,XS-OD-0007,56,Female,White,SOD1 A4V,51.2,1,Active_Drug,Standard,2018-09-30,Standard,Netherlands,SITE-003
PT-000327,XS-OD-0007,2,Female,Hispanic or Latino,CAG repeat expansion,53.2,4,Placebo,Standard,2018-11-01,Pediatric_Assent,Brazil,SITE-008
PT-000328,XS-OD-0007,46,Male,Black or African American,Exon 51 deletion,38.7,5,Active_Drug,Standard,2018-11-12,Standard,France,SITE-002
PT-000329,XS-OD-0007,48,Male,White,,53.9,1,Placebo,Standard,2018-09-17,Standard,Austria,SITE-001
PT-000330,XS-OD-0007,27,Female,White,SCN1A R1648H,85.9,0,Active_Drug,Standard,2018-08-13,Standard,Sweden,SITE-008
PT-000331,XS-OD-0007,29,Male,White,SCN1A R1648H,47.6,3,Placebo,Standard,2018-05-28,Standard,Sweden,SITE-001
PT-000332,XS-OD-0007,52,Female,Black or African American,,70.1,3,Active_Drug,Standard,2018-09-02,Standard,Switzerland,SITE-005
PT-000333,XS-OD-0007,19,Male,White,,57.8,0,Placebo,Standard,2018-11-02,Standard,France,SITE-005
PT-000334,XS-OD-0007,35,Female,White,,52.3,5,Active_Drug,Standard,2018-05-22,Standard,United Kingdom,SITE-007
PT-000335,XS-OD-0007,37,Male,White,CAG repeat expansion,38.4,3,Placebo,Standard,2018-09-19,Standard,Australia,SITE-006
PT-000336,XS-OD-0007,27,Female,Asian,Exon 51 deletion,52.5,3,Active_Drug,Standard,2018-05-24,Standard,Netherlands,SITE-007
PT-000337,XS-OD-0007,23,Male,White,,43.4,4,Placebo,Standard,2018-09-13,Standard,Sweden,SITE-004
PT-000338,XS-OD-0007,39,Female,White,SMN1 deletion,62.1,2,Active_Drug,Standard,2018-05-26,Standard,Germany,SITE-008
PT-000339,XS-OD-0008,14,Male,White,,56.1,2,Active_Drug,Standard,2022-05-23,Pediatric_Assent,Switzerland,SITE-001
PT-000340,XS-OD-0008,18,Male,White,SOD1 A4V,78.8,3,Placebo,Standard,2022-06-16,Standard,Netherlands,SITE-002
PT-000341,XS-OD-0008,10,Male,White,,32.7,0,Active_Drug,Standard,2022-08-14,Pediatric_Assent,Italy,SITE-004
PT-000342,XS-OD-0008,9,Male,Black or African American,CAG repeat expansion,71.0,1,Placebo,Standard,2022-07-31,Pediatric_Assent,Canada,SITE-002
PT-000343,XS-OD-0008,6,Female,Asian,CAG repeat expansion,47.8,0,Active_Drug,Standard,2022-08-12,Pediatric_Assent,Sweden,SITE-005
PT-000344,XS-OD-0008,4,Male,Two or More Races,,64.2,2,Placebo,Standard,2022-04-28,Pediatric_Assent,Australia,SITE-001
PT-000345,XS-OD-0008,15,Male,Hispanic or Latino,,48.9,3,Active_Drug,Standard,2022-03-07,Pediatric_Assent,Taiwan,SITE-006
PT-000346,XS-OD-0008,9,Male,Hispanic or Latino,,36.1,4,Placebo,Standard,2022-07-02,Pediatric_Assent,Spain,SITE-007
PT-000347,XS-OD-0008,15,Male,White,SMN1 deletion,65.3,1,Active_Drug,Standard,2022-06-13,Pediatric_Assent,United Kingdom,SITE-001
PT-000348,XS-OD-0008,4,Male,White,,50.8,4,Placebo,Standard,2022-06-06,Pediatric_Assent,United Kingdom,SITE-003
PT-000349,XS-OD-0008,7,Male,White,CAG repeat expansion,56.9,2,Active_Drug,Standard,2022-04-01,Pediatric_Assent,Spain,SITE-006
PT-000350,XS-OD-0008,17,Male,White,SMN1 deletion,25.2,1,Placebo,Standard,2022-07-18,Pediatric_Assent,Norway,SITE-007
PT-000351,XS-OD-0008,7,Male,Two or More Races,,37.7,2,Active_Drug,Standard,2022-06-05,Pediatric_Assent,Denmark,SITE-004
PT-000352,XS-OD-0008,14,Male,White,,73.7,1,Placebo,Standard,2022-04-20,Pediatric_Assent,United States,SITE-004
PT-000353,XS-OD-0008,18,Male,White,,44.0,3,Active_Drug,Standard,2022-08-16,Standard,Japan,SITE-005
PT-000354,XS-OD-0008,4,Male,Asian,SCN1A R1648H,59.8,1,Placebo,Standard,2022-03-31,Pediatric_Assent,United Kingdom,SITE-002
PT-000355,XS-OD-0008,16,Male,Hispanic or Latino,CAG repeat expansion,66.6,3,Active_Drug,Standard,2022-06-26,Pediatric_Assent,South Korea,SITE-003
PT-000356,XS-OD-0008,13,Male,White,Exon 51 deletion,95.0,0,Placebo,Standard,2022-03-22,Pediatric_Assent,South Korea,SITE-002
PT-000357,XS-OD-0008,11,Male,White,Exon 51 deletion,58.0,2,Active_Drug,Standard,2022-04-07,Pediatric_Assent,Denmark,SITE-005
PT-000358,XS-OD-0008,13,Male,White,SCN1A R1648H,66.3,1,Placebo,Standard,2022-05-15,Pediatric_Assent,Sweden,SITE-004
PT-000359,XS-OD-0008,17,Male,White,,36.7,4,Active_Drug,Standard,2022-04-23,Pediatric_Assent,Canada,SITE-005
PT-000360,XS-OD-0008,11,Male,White,CAG repeat expansion,55.2,3,Placebo,Standard,2022-06-05,Pediatric_Assent,South Korea,SITE-003
PT-000361,XS-OD-0008,19,Male,Hispanic or Latino,SOD1 A4V,51.5,3,Active_Drug,Standard,2022-07-14,Standard,Spain,SITE-006
PT-000362,XS-OD-0008,16,Male,Asian,SCN1A R1648H,41.2,2,Placebo,Standard,2022-06-09,Pediatric_Assent,Italy,SITE-002
PT-000363,XS-OD-0008,19,Male,Black or African American,,74.7,1,Active_Drug,Standard,2022-04-24,Standard,United Kingdom,SITE-007
PT-000364,XS-OD-0008,13,Male,Asian,SMN1 deletion,72.6,4,Placebo,Standard,2022-06-26,Pediatric_Assent,France,SITE-006
PT-000365,XS-OD-0008,23,Male,White,SCN1A R1648H,59.5,2,Active_Drug,Standard,2022-06-20,Standard,Australia,SITE-004
PT-000366,XS-OD-0008,4,Male,White,,50.5,3,Placebo,Standard,2022-08-01,Pediatric_Assent,Taiwan,SITE-001
PT-000367,XS-OD-0008,9,Male,White,,40.5,6,Active_Drug,Standard,2022-05-14,Pediatric_Assent,United States,SITE-001
PT-000368,XS-OD-0008,11,Male,White,,39.8,0,Placebo,Standard,2022-06-26,Pediatric_Assent,Spain,SITE-006
PT-000369,XS-OD-0008,12,Male,White,,40.5,1,Active_Drug,Standard,2022-02-28,Pediatric_Assent,Canada,SITE-003
PT-000370,XS-OD-0008,5,Male,White,SCN1A R1648H,33.0,4,Placebo,Standard,2022-05-04,Pediatric_Assent,United Kingdom,SITE-001
PT-000371,XS-OD-0008,8,Male,White,CAG repeat expansion,46.7,2,Active_Drug,Standard,2022-06-10,Pediatric_Assent,Germany,SITE-002
PT-000372,XS-OD-0009,63,Female,White,SMN1 deletion,55.1,0,Active_Drug,Standard,2020-02-26,Standard,Australia,SITE-004
PT-000373,XS-OD-0009,26,Female,White,CAG repeat expansion,53.4,0,Placebo,Standard,2020-03-07,Standard,Australia,SITE-004
PT-000374,XS-OD-0009,72,Male,White,SCN1A R1648H,82.3,2,Active_Drug,Standard,2020-06-23,Standard,United States,SITE-005
PT-000375,XS-OD-0009,62,Female,White,,35.4,2,Placebo,Standard,2020-01-31,Standard,Australia,SITE-006
PT-000376,XS-OD-0009,29,Male,Asian,,73.1,2,Active_Drug,Standard,2020-05-24,Standard,Germany,SITE-002
PT-000377,XS-OD-0009,26,Female,Black or African American,,50.9,1,Placebo,Standard,2020-02-13,Standard,United States,SITE-006
PT-000378,XS-OD-0009,42,Female,White,SCN1A R1648H,60.4,0,Active_Drug,Standard,2020-02-11,Standard,Canada,SITE-005
PT-000379,XS-OD-0009,68,Female,White,SMN1 deletion,66.2,2,Placebo,Standard,2020-04-04,Standard,France,SITE-006
PT-000380,XS-OD-0009,42,Male,Black or African American,,76.5,4,Active_Drug,Standard,2020-03-20,Standard,Canada,SITE-001
PT-000381,XS-OD-0009,48,Female,Black or African American,CAG repeat expansion,57.0,1,Placebo,Standard,2020-01-18,Standard,United Kingdom,SITE-001
PT-000382,XS-OD-0009,33,Male,Black or African American,,56.2,2,Active_Drug,Standard,2020-05-25,Standard,Italy,SITE-003
PT-000383,XS-OD-0009,12,Female,White,SMN1 deletion,72.9,1,Placebo,Standard,2020-02-21,Pediatric_Assent,United States,SITE-005
PT-000384,XS-OD-0009,20,Male,White,Exon 51 deletion,48.3,1,Active_Drug,Standard,2020-06-10,Standard,United States,SITE-003
PT-000385,XS-OD-0009,69,Male,White,,20.3,4,Placebo,Standard,2020-05-22,Standard,Canada,SITE-003
PT-000386,XS-OD-0009,43,Male,White,CAG repeat expansion,71.4,5,Active_Drug,Standard,2020-06-12,Standard,United States,SITE-005
PT-000387,XS-OD-0009,26,Female,Hispanic or Latino,CAG repeat expansion,29.3,3,Placebo,Standard,2020-03-17,Standard,United Kingdom,SITE-002
PT-000388,XS-OD-0009,67,Female,White,CAG repeat expansion,53.7,1,Active_Drug,Standard,2020-01-10,Standard,Japan,SITE-007
PT-000389,XS-OD-0009,2,Male,White,SMN1 deletion,36.9,0,Placebo,Standard,2020-05-21,Pediatric_Assent,Spain,SITE-003
PT-000390,XS-OD-0009,38,Female,Black or African American,SMN1 deletion,39.7,3,Active_Drug,Standard,2020-04-29,Standard,Netherlands,SITE-003
PT-000391,XS-OD-0009,30,Male,Asian,,91.9,4,Placebo,Standard,2020-03-01,Standard,France,SITE-001
PT-000392,XS-OD-0009,43,Male,Native Hawaiian or Other Pacific Islander,,43.9,1,Active_Drug,Standard,2020-03-24,Standard,Spain,SITE-007
PT-000393,XS-OD-0009,66,Male,Hispanic or Latino,SMN1 deletion,53.3,1,Placebo,Standard,2020-04-22,Standard,Canada,SITE-001
PT-000394,XS-OD-0009,56,Male,White,,53.6,2,Active_Drug,Standard,2020-06-12,Standard,Germany,SITE-006
PT-000395,XS-OD-0009,62,Male,White,Exon 51 deletion,45.4,3,Placebo,Standard,2020-02-23,Standard,Spain,SITE-003
PT-000396,XS-OD-0009,24,Male,Hispanic or Latino,,72.4,2,Active_Drug,Standard,2020-01-17,Standard,United States,SITE-007
PT-000397,XS-OD-0009,49,Male,White,SOD1 A4V,24.5,2,Placebo,Standard,2020-01-21,Standard,United States,SITE-001
PT-000398,XS-OD-0009,21,Male,Hispanic or Latino,,51.1,0,Active_Drug,Standard,2019-12-28,Standard,Canada,SITE-003
PT-000399,XS-OD-0009,42,Female,White,SOD1 A4V,74.6,0,Placebo,Standard,2020-06-12,Standard,Italy,SITE-003
PT-000400,XS-OD-0009,24,Male,White,,54.4,4,Active_Drug,Standard,2020-02-10,Standard,Canada,SITE-005
PT-000401,XS-OD-0009,9,Female,White,SCN1A R1648H,51.7,4,Placebo,Standard,2020-04-25,Pediatric_Assent,France,SITE-003
PT-000402,XS-OD-0009,31,Female,White,SOD1 A4V,65.7,1,Active_Drug,Standard,2020-03-06,Standard,Canada,SITE-005
PT-000403,XS-OD-0009,27,Female,Asian,,43.8,3,Placebo,Standard,2020-04-14,Standard,United Kingdom,SITE-001
PT-000404,XS-OD-0009,44,Intersex,White,CAG repeat expansion,73.6,4,Active_Drug,Standard,2020-04-23,Standard,United States,SITE-005
PT-000405,XS-OD-0009,51,Female,Asian,Exon 51 deletion,55.2,1,Placebo,Standard,2020-02-16,Standard,Netherlands,SITE-001
PT-000406,XS-OD-0009,39,Male,Native Hawaiian or Other Pacific Islander,SOD1 A4V,62.5,2,Active_Drug,Standard,2020-02-13,Standard,Netherlands,SITE-007
PT-000407,XS-OD-0009,48,Male,Asian,Exon 51 deletion,54.1,2,Placebo,Standard,2020-01-13,Standard,Japan,SITE-004
PT-000408,XS-OD-0009,66,Male,Black or African American,SMN1 deletion,43.4,1,Active_Drug,Standard,2020-03-19,Standard,Japan,SITE-006
PT-000409,XS-OD-0009,62,Female,Asian,SCN1A R1648H,45.4,1,Placebo,Standard,2020-05-12,Standard,Spain,SITE-007
PT-000410,XS-OD-0009,31,Male,White,SMN1 deletion,63.9,0,Active_Drug,Standard,2020-02-22,Standard,Australia,SITE-001
PT-000411,XS-OD-0009,25,Female,White,CAG repeat expansion,86.9,5,Placebo,Standard,2020-02-17,Standard,France,SITE-006
PT-000412,XS-OD-0009,81,Female,Asian,,17.4,3,Active_Drug,Standard,2020-02-20,Standard,Spain,SITE-004
PT-000413,XS-OD-0009,38,Female,White,SOD1 A4V,55.6,1,Placebo,Standard,2020-04-01,Compassionate,United States,SITE-005
PT-000414,XS-OD-0009,21,Female,White,SOD1 A4V,78.1,1,Active_Drug,Standard,2020-04-03,Standard,Spain,SITE-004
PT-000415,XS-OD-0009,15,Female,White,SMN1 deletion,24.9,2,Placebo,Standard,2020-02-23,Pediatric_Assent,Netherlands,SITE-007
PT-000416,XS-OD-0009,42,Female,White,Exon 51 deletion,36.4,0,Active_Drug,Standard,2020-06-13,Standard,Spain,SITE-005
PT-000417,XS-OD-0009,58,Male,White,SMN1 deletion,74.6,3,Placebo,Standard,2020-01-14,Standard,France,SITE-007
PT-000418,XS-OD-0009,33,Male,White,SMN1 deletion,83.6,1,Active_Drug,Standard,2020-04-26,Compassionate,Italy,SITE-006
PT-000419,XS-OD-0009,45,Female,White,,42.6,3,Placebo,Standard,2020-01-27,Standard,United States,SITE-005
PT-000420,XS-OD-0010,11,Female,White,CAG repeat expansion,60.9,3,Active_Drug,Standard,2019-01-28,Pediatric_Assent,Japan,SITE-010
PT-000421,XS-OD-0010,8,Female,White,SCN1A R1648H,66.2,0,Placebo,Standard,2018-09-16,Pediatric_Assent,United Kingdom,SITE-010
PT-000422,XS-OD-0010,2,Female,Hispanic or Latino,SCN1A R1648H,30.7,1,Active_Drug_High_Dose,Standard,2018-11-08,Pediatric_Assent,Canada,SITE-009
PT-000423,XS-OD-0010,10,Male,Asian,,80.7,1,Active_Drug,Standard,2018-11-22,Pediatric_Assent,United States,SITE-006
PT-000424,XS-OD-0010,3,Female,White,SCN1A R1648H,56.0,0,Placebo,Standard,2018-12-19,Pediatric_Assent,Spain,SITE-007
PT-000425,XS-OD-0010,2,Male,Asian,SOD1 A4V,55.8,2,Active_Drug_High_Dose,Standard,2018-09-27,Pediatric_Assent,United Kingdom,SITE-013
PT-000426,XS-OD-0010,5,Male,White,SOD1 A4V,17.1,1,Active_Drug,Standard,2019-01-18,Pediatric_Assent,United Kingdom,SITE-006
PT-000427,XS-OD-0010,9,Female,Black or African American,CAG repeat expansion,40.1,3,Placebo,Standard,2018-10-19,Pediatric_Assent,France,SITE-007
PT-000428,XS-OD-0010,7,Female,White,Exon 51 deletion,63.2,1,Active_Drug_High_Dose,Standard,2018-12-16,Pediatric_Assent,United States,SITE-001
PT-000429,XS-OD-0010,4,Male,White,,61.1,1,Active_Drug,Standard,2018-09-22,Pediatric_Assent,United Kingdom,SITE-003
PT-000430,XS-OD-0010,8,Male,White,SOD1 A4V,60.1,2,Placebo,Standard,2018-08-20,Pediatric_Assent,United States,SITE-013
PT-000431,XS-OD-0010,11,Male,White,CAG repeat expansion,42.3,1,Active_Drug_High_Dose,Standard,2018-11-09,Pediatric_Assent,United Kingdom,SITE-010
PT-000432,XS-OD-0010,5,Female,White,SCN1A R1648H,85.4,2,Active_Drug,Standard,2018-12-23,Pediatric_Assent,United States,SITE-002
PT-000433,XS-OD-0010,9,Female,White,SMN1 deletion,52.6,4,Placebo,Standard,2018-09-21,Pediatric_Assent,Japan,SITE-013
PT-000434,XS-OD-0010,3,Female,Two or More Races,,39.9,0,Active_Drug_High_Dose,Standard,2018-11-05,Pediatric_Assent,United Kingdom,SITE-001
PT-000435,XS-OD-0010,5,Male,White,,74.8,1,Active_Drug,Standard,2018-10-13,Pediatric_Assent,Spain,SITE-011
PT-000436,XS-OD-0010,13,Female,Black or African American,Exon 51 deletion,31.4,2,Placebo,Standard,2018-11-27,Pediatric_Assent,Canada,SITE-013
PT-000437,XS-OD-0010,6,Female,White,,42.7,0,Active_Drug_High_Dose,Standard,2019-01-07,Pediatric_Assent,Italy,SITE-008
PT-000438,XS-OD-0010,8,Female,White,Exon 51 deletion,55.0,1,Active_Drug,Standard,2019-01-19,Pediatric_Assent,France,SITE-009
PT-000439,XS-OD-0010,11,Male,Native Hawaiian or Other Pacific Islander,SMN1 deletion,32.4,3,Placebo,Standard,2019-01-20,Pediatric_Assent,Italy,SITE-013
PT-000440,XS-OD-0010,3,Female,Black or African American,,48.5,1,Active_Drug_High_Dose,Standard,2019-01-06,Pediatric_Assent,United States,SITE-007
PT-000441,XS-OD-0010,11,Male,Native Hawaiian or Other Pacific Islander,SCN1A R1648H,48.3,4,Active_Drug,Standard,2018-09-08,Pediatric_Assent,Canada,SITE-004
PT-000442,XS-OD-0010,11,Male,White,SMN1 deletion,37.0,3,Placebo,Standard,2018-10-15,Pediatric_Assent,Canada,SITE-005
PT-000443,XS-OD-0010,11,Male,White,SCN1A R1648H,68.9,2,Active_Drug_High_Dose,Standard,2018-10-03,Pediatric_Assent,France,SITE-004
PT-000444,XS-OD-0010,11,Female,White,CAG repeat expansion,49.9,2,Active_Drug,Standard,2019-02-03,Pediatric_Assent,United Kingdom,SITE-011
PT-000445,XS-OD-0010,4,Male,White,,53.4,2,Placebo,Standard,2018-09-23,Pediatric_Assent,Italy,SITE-003
PT-000446,XS-OD-0010,7,Male,White,SMN1 deletion,45.6,2,Active_Drug_High_Dose,Standard,2018-09-29,Pediatric_Assent,France,SITE-010
PT-000447,XS-OD-0010,2,Female,White,Exon 51 deletion,58.9,0,Active_Drug,Standard,2018-11-13,Pediatric_Assent,United Kingdom,SITE-010
PT-000448,XS-OD-0010,7,Female,Hispanic or Latino,SCN1A R1648H,60.9,7,Placebo,Standard,2018-10-09,Pediatric_Assent,Germany,SITE-001
PT-000449,XS-OD-0010,2,Female,Native Hawaiian or Other Pacific Islander,Exon 51 deletion,43.4,3,Active_Drug_High_Dose,Standard,2018-10-05,Pediatric_Assent,United Kingdom,SITE-010
PT-000450,XS-OD-0010,6,Male,White,SMN1 deletion,60.5,1,Active_Drug,Standard,2019-02-09,Pediatric_Assent,Germany,SITE-002
PT-000451,XS-OD-0010,4,Male,White,SCN1A R1648H,29.8,3,Placebo,Standard,2019-02-01,Pediatric_Assent,United States,SITE-010
PT-000452,XS-OD-0010,11,Female,White,SMN1 deletion,59.2,2,Active_Drug_High_Dose,Standard,2019-02-02,Pediatric_Assent,Germany,SITE-011
PT-000453,XS-OD-0010,8,Male,White,CAG repeat expansion,59.4,0,Active_Drug,Standard,2018-12-16,Pediatric_Assent,Canada,SITE-013
PT-000454,XS-OD-0010,7,Female,White,,40.5,2,Placebo,Standard,2018-10-08,Pediatric_Assent,United States,SITE-001
PT-000455,XS-OD-0010,2,Female,White,Exon 51 deletion,60.3,4,Active_Drug_High_Dose,Standard,2018-09-09,Pediatric_Assent,United Kingdom,SITE-009
PT-000456,XS-OD-0010,7,Female,White,SCN1A R1648H,54.0,0,Active_Drug,Standard,2018-08-22,Pediatric_Assent,Canada,SITE-002
PT-000457,XS-OD-0010,4,Female,White,SMN1 deletion,72.6,4,Placebo,Standard,2019-01-31,Pediatric_Assent,Netherlands,SITE-009
PT-000458,XS-OD-0010,5,Female,American Indian or Alaska Native,SCN1A R1648H,55.1,3,Active_Drug_High_Dose,Standard,2018-10-09,Pediatric_Assent,France,SITE-009
PT-000459,XS-OD-0010,7,Female,White,,22.6,1,Active_Drug,Standard,2018-11-02,Pediatric_Assent,Canada,SITE-001
PT-000460,XS-OD-0010,6,Male,White,SMN1 deletion,35.5,1,Placebo,Standard,2018-11-24,Pediatric_Assent,Italy,SITE-010
PT-000461,XS-OD-0010,5,Male,White,SMN1 deletion,79.9,1,Active_Drug_High_Dose,Standard,2018-12-25,Pediatric_Assent,Germany,SITE-004
PT-000462,XS-OD-0010,9,Male,White,SCN1A R1648H,55.2,1,Active_Drug,Standard,2018-09-15,Pediatric_Assent,Germany,SITE-012
PT-000463,XS-OD-0010,10,Male,Asian,,65.2,1,Placebo,Standard,2018-12-07,Pediatric_Assent,Australia,SITE-004
PT-000464,XS-OD-0010,11,Female,White,Exon 51 deletion,40.6,1,Active_Drug_High_Dose,Standard,2018-11-26,Pediatric_Assent,Australia,SITE-008
PT-000465,XS-OD-0010,5,Male,Black or African American,SMN1 deletion,81.6,2,Active_Drug,Standard,2018-12-07,Pediatric_Assent,Netherlands,SITE-012
PT-000466,XS-OD-0010,7,Female,Hispanic or Latino,,60.6,2,Placebo,Standard,2018-10-01,Pediatric_Assent,Australia,SITE-011
PT-000467,XS-OD-0010,7,Female,White,,65.5,2,Active_Drug_High_Dose,Standard,2018-10-24,Pediatric_Assent,United States,SITE-003
PT-000468,XS-OD-0010,11,Female,Two or More Races,SMN1 deletion,67.7,6,Active_Drug,Standard,2018-11-25,Pediatric_Assent,Spain,SITE-010
PT-000469,XS-OD-0010,9,Male,White,SCN1A R1648H,60.5,1,Placebo,Standard,2018-09-26,Pediatric_Assent,Japan,SITE-010
PT-000470,XS-OD-0010,10,Male,White,SOD1 A4V,80.4,4,Active_Drug_High_Dose,Standard,2018-08-24,Pediatric_Assent,Canada,SITE-004
PT-000471,XS-OD-0010,7,Female,White,Exon 51 deletion,44.5,1,Active_Drug,Standard,2018-11-13,Pediatric_Assent,Italy,SITE-007
PT-000472,XS-OD-0010,2,Female,White,,68.7,2,Placebo,Standard,2018-11-03,Pediatric_Assent,United Kingdom,SITE-001
PT-000473,XS-OD-0010,14,Male,American Indian or Alaska Native,,66.9,4,Active_Drug_High_Dose,Standard,2018-11-23,Pediatric_Assent,United Kingdom,SITE-003
PT-000474,XS-OD-0010,15,Male,Black or African American,CAG repeat expansion,62.0,1,Active_Drug,Standard,2018-10-27,Pediatric_Assent,Canada,SITE-012
PT-000475,XS-OD-0010,13,Female,White,Exon 51 deletion,77.0,4,Placebo,Standard,2018-12-09,Pediatric_Assent,Australia,SITE-001
PT-000476,XS-OD-0010,7,Male,Hispanic or Latino,,51.5,1,Active_Drug_High_Dose,Standard,2019-01-18,Pediatric_Assent,United States,SITE-002
PT-000477,XS-OD-0010,4,Male,Asian,,39.0,0,Active_Drug,Standard,2018-09-01,Pediatric_Assent,Germany,SITE-004
PT-000478,XS-OD-0010,5,Female,Black or African American,SOD1 A4V,77.3,1,Placebo,Standard,2018-11-21,Pediatric_Assent,Italy,SITE-011
PT-000479,XS-OD-0010,15,Female,White,,61.6,1,Active_Drug_High_Dose,Standard,2018-08-31,Pediatric_Assent,Spain,SITE-006
PT-000480,XS-OD-0010,6,Male,Black or African American,,54.7,5,Active_Drug,Standard,2018-12-30,Pediatric_Assent,Italy,SITE-001
PT-000481,XS-OD-0010,10,Male,Hispanic or Latino,CAG repeat expansion,78.7,2,Placebo,Standard,2018-10-17,Pediatric_Assent,Canada,SITE-005
PT-000482,XS-OD-0010,6,Male,White,SOD1 A4V,69.2,4,Active_Drug_High_Dose,Standard,2018-11-24,Pediatric_Assent,France,SITE-012
PT-000483,XS-OD-0010,7,Male,White,Exon 51 deletion,59.5,0,Active_Drug,Standard,2018-09-17,Pediatric_Assent,Germany,SITE-006
PT-000484,XS-OD-0010,13,Female,White,SCN1A R1648H,24.7,3,Placebo,Standard,2018-12-25,Pediatric_Assent,Australia,SITE-008
PT-000485,XS-OD-0010,7,Male,White,,78.6,3,Active_Drug_High_Dose,Standard,2019-01-03,Pediatric_Assent,Japan,SITE-002
PT-000486,XS-OD-0010,2,Female,Two or More Races,SCN1A R1648H,48.9,5,Active_Drug,Standard,2018-11-02,Pediatric_Assent,Germany,SITE-010
PT-000487,XS-OD-0010,9,Male,Black or African American,Exon 51 deletion,49.1,3,Placebo,Standard,2019-02-06,Pediatric_Assent,Canada,SITE-002
PT-000488,XS-OD-0010,2,Male,Hispanic or Latino,,80.5,1,Active_Drug_High_Dose,Standard,2018-08-26,Pediatric_Assent,United Kingdom,SITE-006
PT-000489,XS-OD-0010,2,Male,Hispanic or Latino,,64.9,4,Active_Drug,Standard,2019-01-20,Pediatric_Assent,Italy,SITE-009
PT-000490,XS-OD-0010,16,Male,White,SOD1 A4V,50.3,2,Placebo,Standard,2018-11-21,Pediatric_Assent,Australia,SITE-001
PT-000491,XS-OD-0010,10,Male,Black or African American,,10.0,1,Active_Drug_High_Dose,Standard,2018-11-21,Pediatric_Assent,Netherlands,SITE-006
PT-000492,XS-OD-0010,14,Female,Asian,SMN1 deletion,47.6,0,Active_Drug,Standard,2018-09-09,Pediatric_Assent,United States,SITE-013
PT-000493,XS-OD-0010,14,Male,White,,29.3,2,Placebo,Standard,2018-11-30,Pediatric_Assent,France,SITE-013
PT-000494,XS-OD-0010,5,Male,Black or African American,SOD1 A4V,46.0,1,Active_Drug_High_Dose,Standard,2019-02-01,Pediatric_Assent,Australia,SITE-009
PT-000495,XS-OD-0010,6,Female,White,SMN1 deletion,46.4,2,Active_Drug,Standard,2018-10-12,Pediatric_Assent,United States,SITE-003
PT-000496,XS-OD-0010,11,Male,White,SCN1A R1648H,52.0,1,Placebo,Standard,2018-09-23,Pediatric_Assent,Italy,SITE-013
PT-000497,XS-OD-0010,12,Female,Asian,SCN1A R1648H,41.3,4,Active_Drug_High_Dose,Standard,2018-08-21,Pediatric_Assent,Japan,SITE-010
PT-000498,XS-OD-0010,9,Female,White,Exon 51 deletion,76.6,1,Active_Drug,Standard,2019-01-21,Pediatric_Assent,United Kingdom,SITE-008
PT-000499,XS-OD-0010,7,Intersex,White,SOD1 A4V,36.0,1,Placebo,Standard,2018-11-10,Pediatric_Assent,France,SITE-006
PT-000500,XS-OD-0010,5,Male,Black or African American,SOD1 A4V,40.9,1,Active_Drug_High_Dose,Standard,2019-02-12,Pediatric_Assent,Japan,SITE-007
PT-000501,XS-OD-0010,9,Female,White,Exon 51 deletion,42.8,1,Active_Drug,Standard,2018-08-30,Pediatric_Assent,Australia,SITE-001
PT-000502,XS-OD-0010,4,Female,Black or African American,SCN1A R1648H,23.1,0,Placebo,Standard,2018-10-11,Pediatric_Assent,Italy,SITE-009
PT-000503,XS-OD-0010,9,Female,White,SMN1 deletion,73.5,5,Active_Drug_High_Dose,Standard,2018-11-22,Pediatric_Assent,Canada,SITE-008
PT-000504,XS-OD-0011,31,Male,White,Factor VIII intron 22 inv,51.1,1,Active_Drug,Standard,2025-03-12,Standard,Switzerland,SITE-012
PT-000505,XS-OD-0011,17,Male,Asian,Factor VIII intron 22 inv,47.9,5,Placebo,Standard,2025-05-10,Pediatric_Assent,Australia,SITE-023
PT-000506,XS-OD-0011,40,Male,Asian,Factor VIII intron 22 inv,43.3,0,Crossover,Standard,2025-01-16,Compassionate,Austria,SITE-013
PT-000507,XS-OD-0011,31,Male,White,F9 R338L,48.9,2,Active_Drug,Standard,2024-12-19,Standard,Norway,SITE-011
PT-000508,XS-OD-0011,10,Female,White,HBB E6V (sickle),49.6,1,Placebo,Standard,2025-04-08,Pediatric_Assent,Japan,SITE-011
PT-000509,XS-OD-0011,39,Female,White,F9 R338L,63.0,1,Crossover,Standard,2024-12-25,Standard,France,SITE-012
PT-000510,XS-OD-0011,28,Male,White,HBB E6V (sickle),43.5,2,Active_Drug,Standard,2025-02-22,Standard,South Korea,SITE-020
PT-000511,XS-OD-0011,27,Female,Black or African American,F9 R338L,75.6,2,Placebo,Standard,2025-05-08,Standard,United States,SITE-027
PT-000512,XS-OD-0011,28,Female,White,F9 R338L,67.0,3,Crossover,Standard,2025-03-24,Standard,Netherlands,SITE-030
PT-000513,XS-OD-0011,73,Male,Black or African American,HBB IVS-I-110 G>A,45.0,2,Active_Drug,Standard,2025-02-09,Standard,Sweden,SITE-034
PT-000514,XS-OD-0011,52,Male,Black or African American,,17.2,2,Placebo,Standard,2025-02-10,Emergency,Sweden,SITE-018
PT-000515,XS-OD-0011,38,Male,White,Factor VIII intron 22 inv,43.2,2,Crossover,Standard,2025-03-25,Standard,Canada,SITE-018
PT-000516,XS-OD-0011,8,Female,Asian,F9 R338L,49.9,2,Active_Drug,Standard,2024-12-31,Pediatric_Assent,Israel,SITE-038
PT-000517,XS-OD-0011,23,Female,Hispanic or Latino,Factor VIII intron 22 inv,28.1,1,Placebo,Standard,2025-05-17,Standard,United States,SITE-015
PT-000518,XS-OD-0011,59,Male,American Indian or Alaska Native,HBB IVS-I-110 G>A,74.0,1,Crossover,Standard,2025-04-06,Standard,Israel,SITE-007
PT-000519,XS-OD-0011,18,Female,White,Factor VIII intron 22 inv,75.8,3,Active_Drug,Standard,2024-12-28,Standard,Netherlands,SITE-013
PT-000520,XS-OD-0011,30,Male,Hispanic or Latino,,32.4,1,Placebo,Standard,2025-04-09,Standard,United States,SITE-025
PT-000521,XS-OD-0011,69,Male,White,Factor VIII intron 22 inv,67.7,1,Crossover,Standard,2025-02-16,Standard,Israel,SITE-017
PT-000522,XS-OD-0011,41,Male,White,HBB IVS-I-110 G>A,67.1,1,Active_Drug,Standard,2025-04-15,Standard,Netherlands,SITE-016
PT-000523,XS-OD-0011,47,Male,Hispanic or Latino,HBB E6V (sickle),56.3,1,Placebo,Standard,2024-12-24,Standard,Australia,SITE-029
PT-000524,XS-OD-0011,57,Male,White,HBB E6V (sickle),52.6,1,Crossover,Standard,2025-02-18,Standard,Sweden,SITE-032
PT-000525,XS-OD-0011,40,Female,White,Factor VIII intron 22 inv,44.1,2,Active_Drug,Standard,2025-01-09,Standard,Brazil,SITE-015
PT-000526,XS-OD-0011,27,Male,Black or African American,,68.8,3,Placebo,Standard,2025-02-06,Standard,Netherlands,SITE-039
PT-000527,XS-OD-0011,37,Female,White,HBB IVS-I-110 G>A,57.0,3,Crossover,Standard,2025-02-24,Standard,Denmark,SITE-028
PT-000528,XS-OD-0011,66,Female,White,,20.6,1,Active_Drug,Standard,2025-04-19,Standard,Canada,SITE-020
PT-000529,XS-OD-0011,40,Female,Asian,HBB IVS-I-110 G>A,60.7,3,Placebo,Standard,2025-01-03,Standard,Spain,SITE-023
PT-000530,XS-OD-0011,69,Female,White,HBB IVS-I-110 G>A,52.0,3,Crossover,Standard,2025-01-31,Standard,Canada,SITE-016
PT-000531,XS-OD-0011,27,Female,Hispanic or Latino,HBB IVS-I-110 G>A,70.2,0,Active_Drug,Standard,2024-12-26,Standard,Denmark,SITE-017
PT-000532,XS-OD-0011,34,Female,Hispanic or Latino,HBB IVS-I-110 G>A,69.7,0,Placebo,Standard,2025-05-20,Standard,Switzerland,SITE-013
PT-000533,XS-OD-0011,13,Female,Two or More Races,,64.7,1,Crossover,Standard,2024-12-12,Pediatric_Assent,Spain,SITE-004
PT-000534,XS-OD-0011,32,Male,White,HBB E6V (sickle),89.1,4,Active_Drug,Standard,2025-02-18,Standard,Brazil,SITE-022
PT-000535,XS-OD-0011,48,Female,White,HBB IVS-I-110 G>A,56.6,1,Placebo,Standard,2025-01-16,Standard,Canada,SITE-015
PT-000536,XS-OD-0011,34,Female,White,HBB IVS-I-110 G>A,48.4,3,Crossover,Standard,2025-04-28,Standard,Taiwan,SITE-007
PT-000537,XS-OD-0011,31,Female,Two or More Races,,43.0,0,Active_Drug,Standard,2025-04-20,Standard,Italy,SITE-029
PT-000538,XS-OD-0011,30,Male,Asian,,67.8,3,Placebo,Standard,2025-04-23,Standard,Israel,SITE-021
PT-000539,XS-OD-0011,57,Female,Hispanic or Latino,,79.7,1,Crossover,Standard,2025-02-18,Standard,Israel,SITE-040
PT-000540,XS-OD-0011,42,Male,White,HBB IVS-I-110 G>A,40.4,3,Active_Drug,Standard,2024-12-23,Standard,Germany,SITE-029
PT-000541,XS-OD-0011,53,Female,White,,63.4,0,Placebo,Standard,2025-01-30,Compassionate,Netherlands,SITE-005
PT-000542,XS-OD-0011,37,Male,White,F9 R338L,29.9,3,Crossover,Standard,2025-01-21,Standard,Spain,SITE-022
PT-000543,XS-OD-0011,42,Male,White,HBB E6V (sickle),63.0,6,Active_Drug,Standard,2025-03-23,Standard,United States,SITE-033
PT-000544,XS-OD-0011,34,Male,White,F9 R338L,50.9,1,Placebo,Standard,2025-06-04,Standard,Norway,SITE-001
PT-000545,XS-OD-0011,26,Female,Black or African American,F9 R338L,42.8,2,Crossover,Standard,2025-01-17,Standard,United Kingdom,SITE-004
PT-000546,XS-OD-0011,21,Male,Hispanic or Latino,,69.7,4,Active_Drug,Standard,2025-05-12,Standard,Australia,SITE-037
PT-000547,XS-OD-0011,38,Female,Black or African American,,63.2,1,Placebo,Standard,2025-03-20,Standard,Sweden,SITE-031
PT-000548,XS-OD-0011,28,Female,Asian,,43.7,5,Crossover,Standard,2024-12-10,Standard,Spain,SITE-011
PT-000549,XS-OD-0011,43,Female,Hispanic or Latino,HBB E6V (sickle),33.7,2,Active_Drug,Standard,2025-04-26,Standard,Australia,SITE-009
PT-000550,XS-OD-0011,57,Male,Black or African American,,56.1,2,Placebo,Standard,2024-12-17,Standard,Japan,SITE-023
PT-000551,XS-OD-0011,28,Female,White,,13.7,2,Crossover,Standard,2025-05-26,Compassionate,Netherlands,SITE-038
PT-000552,XS-OD-0011,23,Female,White,,38.9,2,Active_Drug,Standard,2025-04-17,Standard,Norway,SITE-028
PT-000553,XS-OD-0011,47,Male,Asian,,62.4,4,Placebo,Standard,2025-02-16,Standard,Brazil,SITE-021
PT-000554,XS-OD-0011,28,Female,Hispanic or Latino,,60.1,1,Crossover,Standard,2025-04-13,Standard,Sweden,SITE-006
PT-000555,XS-OD-0011,23,Female,Black or African American,,58.3,3,Active_Drug,Standard,2025-04-02,Standard,Spain,SITE-007
PT-000556,XS-OD-0011,19,Male,Asian,,33.8,1,Placebo,Standard,2025-03-06,Compassionate,Norway,SITE-008
PT-000557,XS-OD-0011,38,Male,Two or More Races,F9 R338L,36.8,1,Crossover,Standard,2025-01-08,Standard,Japan,SITE-010
PT-000558,XS-OD-0011,19,Male,Hispanic or Latino,HBB IVS-I-110 G>A,22.7,1,Active_Drug,Standard,2025-02-24,Standard,United States,SITE-010
PT-000559,XS-OD-0011,45,Female,White,HBB IVS-I-110 G>A,31.9,1,Placebo,Standard,2025-05-23,Standard,Japan,SITE-011
PT-000560,XS-OD-0011,36,Male,White,F9 R338L,74.9,2,Crossover,Standard,2024-12-20,Standard,Japan,SITE-042
PT-000561,XS-OD-0011,9,Female,Asian,HBB E6V (sickle),46.7,3,Active_Drug,Standard,2025-04-08,Pediatric_Assent,Israel,SITE-024
PT-000562,XS-OD-0011,42,Male,White,,59.4,4,Placebo,Standard,2025-01-16,Standard,Netherlands,SITE-001
PT-000563,XS-OD-0011,49,Male,Native Hawaiian or Other Pacific Islander,HBB E6V (sickle),63.6,2,Crossover,Standard,2024-12-10,Standard,Sweden,SITE-018
PT-000564,XS-OD-0011,41,Male,American Indian or Alaska Native,HBB E6V (sickle),69.8,1,Active_Drug,Standard,2025-05-18,Standard,Norway,SITE-018
PT-000565,XS-OD-0011,62,Male,White,,58.4,1,Placebo,Standard,2024-12-12,Standard,Denmark,SITE-026
PT-000566,XS-OD-0011,19,Female,White,HBB IVS-I-110 G>A,51.0,3,Crossover,Standard,2025-03-28,Standard,Brazil,SITE-009
PT-000567,XS-OD-0011,16,Female,Black or African American,F9 R338L,72.4,1,Active_Drug,Standard,2025-01-24,Pediatric_Assent,Norway,SITE-023
PT-000568,XS-OD-0011,32,Male,Hispanic or Latino,,45.2,0,Placebo,Standard,2025-02-18,Standard,Germany,SITE-027
PT-000569,XS-OD-0011,23,Female,White,,46.8,0,Crossover,Standard,2025-04-09,Standard,Japan,SITE-024
PT-000570,XS-OD-0011,61,Male,White,HBB E6V (sickle),63.5,2,Active_Drug,Standard,2025-02-12,Standard,Canada,SITE-008
PT-000571,XS-OD-0011,60,Male,Black or African American,,55.1,3,Placebo,Standard,2025-04-18,Standard,Canada,SITE-041
PT-000572,XS-OD-0011,56,Male,Hispanic or Latino,F9 R338L,84.6,1,Crossover,Standard,2025-05-17,Standard,Australia,SITE-007
PT-000573,XS-OD-0011,26,Intersex,White,HBB E6V (sickle),47.4,0,Active_Drug,Standard,2024-12-21,Standard,Austria,SITE-004
PT-000574,XS-OD-0011,62,Female,Two or More Races,F9 R338L,28.8,2,Placebo,Standard,2024-12-24,Standard,Australia,SITE-020
PT-000575,XS-OD-0011,21,Female,White,HBB E6V (sickle),58.4,3,Crossover,Standard,2024-12-24,Standard,Japan,SITE-041
PT-000576,XS-OD-0011,56,Male,Black or African American,HBB E6V (sickle),66.8,4,Active_Drug,Standard,2025-05-20,Standard,Switzerland,SITE-039
PT-000577,XS-OD-0011,42,Male,Black or African American,HBB IVS-I-110 G>A,29.3,2,Placebo,Standard,2025-02-09,Standard,Switzerland,SITE-005
PT-000578,XS-OD-0011,24,Male,Asian,HBB IVS-I-110 G>A,22.1,2,Crossover,Standard,2025-04-16,Standard,Norway,SITE-027
PT-000579,XS-OD-0011,32,Male,Hispanic or Latino,HBB IVS-I-110 G>A,58.5,3,Active_Drug,Standard,2024-12-30,Standard,Italy,SITE-026
PT-000580,XS-OD-0011,49,Male,Hispanic or Latino,HBB IVS-I-110 G>A,43.3,0,Placebo,Standard,2025-03-12,Standard,Germany,SITE-038
PT-000581,XS-OD-0011,26,Male,White,,45.4,2,Crossover,Standard,2025-03-12,Standard,Spain,SITE-024
PT-000582,XS-OD-0011,60,Female,Asian,,65.1,1,Active_Drug,Standard,2024-12-16,Standard,United Kingdom,SITE-035
PT-000583,XS-OD-0011,21,Male,White,,95.0,2,Placebo,Standard,2025-03-12,Standard,Switzerland,SITE-038
PT-000584,XS-OD-0011,42,Male,White,,64.7,1,Crossover,Standard,2025-04-28,Standard,Austria,SITE-004
PT-000585,XS-OD-0011,20,Female,White,F9 R338L,27.5,2,Active_Drug,Standard,2025-02-17,Standard,Germany,SITE-012
PT-000586,XS-OD-0011,30,Male,Asian,,35.1,3,Placebo,Standard,2025-03-26,Standard,Canada,SITE-033
PT-000587,XS-OD-0011,37,Male,Two or More Races,Factor VIII intron 22 inv,42.0,2,Crossover,Standard,2025-01-02,Standard,South Korea,SITE-036
PT-000588,XS-OD-0011,20,Female,White,Factor VIII intron 22 inv,43.8,0,Active_Drug,Standard,2025-02-25,Standard,Switzerland,SITE-041
PT-000589,XS-OD-0011,23,Female,White,,41.7,2,Placebo,Standard,2025-03-13,Standard,Sweden,SITE-023
PT-000590,XS-OD-0011,22,Female,White,HBB E6V (sickle),57.0,1,Crossover,Standard,2025-05-05,Standard,Norway,SITE-008
PT-000591,XS-OD-0011,59,Male,Two or More Races,,53.5,3,Active_Drug,Standard,2025-03-19,Standard,Australia,SITE-030
PT-000592,XS-OD-0011,47,Male,Asian,HBB IVS-I-110 G>A,49.9,2,Placebo,Standard,2025-01-26,Standard,Brazil,SITE-006
PT-000593,XS-OD-0011,42,Male,Hispanic or Latino,,41.4,1,Crossover,Standard,2025-05-11,Standard,South Korea,SITE-016
PT-000594,XS-OD-0011,58,Female,White,HBB IVS-I-110 G>A,34.1,1,Active_Drug,Standard,2024-12-13,Standard,Switzerland,SITE-014
PT-000595,XS-OD-0011,88,Female,White,HBB E6V (sickle),66.4,3,Placebo,Standard,2025-03-22,Standard,United Kingdom,SITE-041
PT-000596,XS-OD-0011,30,Female,Hispanic or Latino,HBB E6V (sickle),72.8,5,Crossover,Standard,2025-05-17,Standard,Australia,SITE-037
PT-000597,XS-OD-0011,47,Male,Hispanic or Latino,HBB IVS-I-110 G>A,56.7,2,Active_Drug,Standard,2025-01-26,Standard,Sweden,SITE-035
PT-000598,XS-OD-0011,43,Male,Black or African American,,71.6,1,Placebo,Standard,2025-02-11,Standard,Israel,SITE-035
PT-000599,XS-OD-0011,58,Female,White,HBB E6V (sickle),69.6,1,Crossover,Standard,2025-02-16,Standard,Canada,SITE-040
PT-000600,XS-OD-0011,17,Male,White,,68.1,1,Active_Drug,Standard,2025-05-21,Pediatric_Assent,Austria,SITE-022
PT-000601,XS-OD-0011,50,Male,Hispanic or Latino,,83.1,2,Placebo,Standard,2025-03-30,Standard,Denmark,SITE-029
PT-000602,XS-OD-0011,38,Male,White,,57.6,1,Crossover,Standard,2025-02-08,Standard,Germany,SITE-015
PT-000603,XS-OD-0011,39,Female,Black or African American,Factor VIII intron 22 inv,49.6,1,Active_Drug,Standard,2025-02-06,Standard,Austria,SITE-026
PT-000604,XS-OD-0011,52,Male,White,,42.3,3,Placebo,Standard,2025-01-29,Standard,Norway,SITE-042
PT-000605,XS-OD-0011,20,Female,White,F9 R338L,48.8,2,Crossover,Standard,2025-01-15,Compassionate,Brazil,SITE-018
PT-000606,XS-OD-0011,50,Male,White,F9 R338L,33.8,1,Active_Drug,Standard,2025-05-03,Standard,United Kingdom,SITE-016
PT-000607,XS-OD-0011,47,Male,Hispanic or Latino,HBB E6V (sickle),57.7,1,Placebo,Standard,2025-01-12,Standard,United Kingdom,SITE-026
PT-000608,XS-OD-0011,38,Male,White,HBB E6V (sickle),51.0,4,Crossover,Standard,2025-04-18,Standard,Brazil,SITE-024
PT-000609,XS-OD-0011,31,Male,White,HBB E6V (sickle),74.3,0,Active_Drug,Standard,2025-03-16,Standard,Italy,SITE-008
PT-000610,XS-OD-0011,25,Male,White,,66.1,4,Placebo,Standard,2025-01-20,Standard,South Korea,SITE-023
PT-000611,XS-OD-0011,40,Male,White,HBB E6V (sickle),70.8,2,Crossover,Standard,2025-03-26,Standard,Germany,SITE-018
PT-000612,XS-OD-0011,40,Male,Hispanic or Latino,HBB E6V (sickle),66.8,0,Active_Drug,Standard,2025-02-03,Standard,United States,SITE-039
PT-000613,XS-OD-0011,34,Female,White,HBB IVS-I-110 G>A,58.0,2,Placebo,Standard,2025-01-29,Standard,Australia,SITE-018
PT-000614,XS-OD-0011,66,Female,White,,23.5,0,Crossover,Standard,2025-02-24,Standard,Sweden,SITE-015
PT-000615,XS-OD-0011,18,Male,Asian,HBB IVS-I-110 G>A,53.5,3,Active_Drug,Standard,2025-01-14,Standard,Denmark,SITE-008
PT-000616,XS-OD-0011,21,Female,White,HBB E6V (sickle),49.3,2,Placebo,Standard,2025-02-12,Standard,South Korea,SITE-025
PT-000617,XS-OD-0011,41,Male,Hispanic or Latino,,34.6,0,Crossover,Standard,2025-01-27,Standard,Italy,SITE-042
PT-000618,XS-OD-0011,46,Male,White,HBB IVS-I-110 G>A,64.6,2,Active_Drug,Standard,2025-04-14,Standard,United States,SITE-033
PT-000619,XS-OD-0011,28,Male,White,HBB E6V (sickle),48.7,1,Placebo,Standard,2025-01-08,Standard,Austria,SITE-015
PT-000620,XS-OD-0011,72,Female,Black or African American,,57.5,2,Crossover,Standard,2025-03-11,Standard,Italy,SITE-011
PT-000621,XS-OD-0011,23,Male,White,,35.5,1,Active_Drug,Standard,2025-01-17,Standard,Norway,SITE-029
PT-000622,XS-OD-0011,30,Male,Asian,HBB E6V (sickle),85.5,3,Placebo,Standard,2025-06-03,Standard,Japan,SITE-042
PT-000623,XS-OD-0011,35,Male,White,HBB E6V (sickle),43.4,1,Crossover,Standard,2025-04-02,Standard,Netherlands,SITE-019
PT-000624,XS-OD-0011,52,Male,White,HBB E6V (sickle),74.0,2,Active_Drug,Standard,2025-05-19,Standard,Denmark,SITE-026
PT-000625,XS-OD-0011,42,Female,White,,86.0,3,Placebo,Standard,2025-04-20,Standard,Sweden,SITE-042
PT-000626,XS-OD-0011,54,Female,Asian,,72.9,1,Crossover,Standard,2025-04-05,Standard,South Korea,SITE-008
PT-000627,XS-OD-0011,50,Male,Hispanic or Latino,F9 R338L,32.9,2,Active_Drug,Standard,2025-03-07,Emergency,South Korea,SITE-014
PT-000628,XS-OD-0011,39,Male,White,HBB E6V (sickle),27.5,4,Placebo,Standard,2024-12-12,Standard,South Korea,SITE-033
PT-000629,XS-OD-0011,38,Male,Asian,HBB E6V (sickle),29.3,3,Crossover,Standard,2024-12-15,Standard,Netherlands,SITE-008
PT-000630,XS-OD-0011,46,Male,White,,45.8,3,Active_Drug,Standard,2025-03-24,Standard,Switzerland,SITE-013
PT-000631,XS-OD-0011,27,Female,White,HBB IVS-I-110 G>A,28.2,3,Placebo,Standard,2025-03-19,Standard,United States,SITE-041
PT-000632,XS-OD-0011,43,Female,White,HBB E6V (sickle),51.4,1,Crossover,Standard,2024-12-12,Standard,Sweden,SITE-024
PT-000633,XS-OD-0011,40,Female,White,,13.8,1,Active_Drug,Standard,2025-01-13,Standard,Brazil,SITE-007
PT-000634,XS-OD-0011,42,Female,Black or African American,Factor VIII intron 22 inv,23.2,2,Placebo,Standard,2025-03-10,Standard,United Kingdom,SITE-038
PT-000635,XS-OD-0011,8,Male,White,,62.8,1,Crossover,Standard,2025-03-19,Pediatric_Assent,United Kingdom,SITE-038
PT-000636,XS-OD-0011,61,Male,White,HBB E6V (sickle),90.7,4,Active_Drug,Standard,2025-01-30,Standard,Norway,SITE-030
PT-000637,XS-OD-0011,54,Male,White,F9 R338L,15.9,2,Placebo,Standard,2025-05-01,Standard,Canada,SITE-041
PT-000638,XS-OD-0011,47,Female,Black or African American,,45.3,2,Crossover,Standard,2025-05-03,Standard,Israel,SITE-035
PT-000639,XS-OD-0011,35,Male,White,,38.2,3,Active_Drug,Standard,2025-01-06,Standard,Austria,SITE-041
PT-000640,XS-OD-0011,20,Male,Black or African American,HBB IVS-I-110 G>A,26.1,3,Placebo,Standard,2025-03-03,Standard,United States,SITE-024
PT-000641,XS-OD-0011,47,Male,White,F9 R338L,66.3,3,Crossover,Standard,2025-05-31,Standard,France,SITE-031
PT-000642,XS-OD-0011,45,Male,White,HBB IVS-I-110 G>A,49.1,2,Active_Drug,Standard,2025-01-11,Standard,France,SITE-028
PT-000643,XS-OD-0011,71,Female,Hispanic or Latino,HBB IVS-I-110 G>A,23.1,1,Placebo,Standard,2025-01-29,Standard,Norway,SITE-013
PT-000644,XS-OD-0011,40,Female,White,F9 R338L,48.6,3,Crossover,Standard,2025-04-27,Standard,South Korea,SITE-032
PT-000645,XS-OD-0011,27,Male,White,F9 R338L,54.4,3,Active_Drug,Standard,2025-05-26,Standard,Switzerland,SITE-031
PT-000646,XS-OD-0011,46,Male,Black or African American,,48.9,0,Placebo,Standard,2025-03-24,Standard,Japan,SITE-021
PT-000647,XS-OD-0011,27,Male,White,HBB E6V (sickle),30.8,4,Crossover,Standard,2025-06-02,Standard,United States,SITE-034
PT-000648,XS-OD-0011,2,Male,Asian,,60.2,2,Active_Drug,Standard,2025-03-27,Pediatric_Assent,United Kingdom,SITE-027
PT-000649,XS-OD-0011,43,Female,White,HBB IVS-I-110 G>A,63.5,2,Placebo,Standard,2025-03-06,Standard,Taiwan,SITE-040
PT-000650,XS-OD-0011,59,Female,Black or African American,,57.6,1,Crossover,Standard,2025-03-31,Standard,Belgium,SITE-020
PT-000651,XS-OD-0011,35,Female,Hispanic or Latino,,59.6,3,Active_Drug,Standard,2025-03-12,Standard,Austria,SITE-010
PT-000652,XS-OD-0011,2,Male,Black or African American,HBB E6V (sickle),68.4,3,Placebo,Standard,2025-05-25,Pediatric_Assent,Denmark,SITE-032
PT-000653,XS-OD-0011,32,Female,Hispanic or Latino,HBB IVS-I-110 G>A,66.3,5,Crossover,Standard,2025-04-18,Standard,France,SITE-010
PT-000654,XS-OD-0011,54,Female,White,Factor VIII intron 22 inv,36.9,0,Active_Drug,Standard,2025-04-20,Standard,Brazil,SITE-028
PT-000655,XS-OD-0011,41,Female,White,,58.6,0,Placebo,Standard,2025-02-06,Standard,South Korea,SITE-029
PT-000656,XS-OD-0011,4,Female,White,Factor VIII intron 22 inv,53.3,2,Crossover,Standard,2025-06-02,Pediatric_Assent,Norway,SITE-025
PT-000657,XS-OD-0011,22,Female,White,,36.0,1,Active_Drug,Standard,2025-01-04,Standard,Taiwan,SITE-037
PT-000658,XS-OD-0011,28,Male,White,HBB IVS-I-110 G>A,71.3,4,Placebo,Standard,2025-02-16,Standard,United States,SITE-035
PT-000659,XS-OD-0011,23,Female,Black or African American,HBB E6V (sickle),56.1,2,Crossover,Standard,2025-01-23,Standard,Austria,SITE-032
PT-000660,XS-OD-0011,24,Female,White,HBB IVS-I-110 G>A,87.0,3,Active_Drug,Standard,2025-02-15,Standard,France,SITE-023
PT-000661,XS-OD-0011,35,Intersex,White,Factor VIII intron 22 inv,36.2,2,Placebo,Standard,2025-02-07,Standard,France,SITE-016
PT-000662,XS-OD-0011,38,Female,Black or African American,Factor VIII intron 22 inv,64.0,2,Crossover,Standard,2025-02-19,Standard,Sweden,SITE-020
PT-000663,XS-OD-0011,32,Male,White,,49.7,0,Active_Drug,Standard,2025-02-04,Standard,Sweden,SITE-023
PT-000664,XS-OD-0011,25,Female,White,,33.8,6,Placebo,Standard,2024-12-21,Standard,Australia,SITE-030
PT-000665,XS-OD-0011,54,Male,White,HBB E6V (sickle),66.2,1,Crossover,Standard,2024-12-27,Standard,United States,SITE-041
PT-000666,XS-OD-0011,32,Female,Asian,,62.6,3,Active_Drug,Standard,2025-04-17,Compassionate,Sweden,SITE-002
PT-000667,XS-OD-0011,64,Male,Native Hawaiian or Other Pacific Islander,,50.3,0,Placebo,Standard,2024-12-07,Standard,Sweden,SITE-001
PT-000668,XS-OD-0011,40,Female,Black or African American,Factor VIII intron 22 inv,48.1,4,Crossover,Standard,2025-05-26,Standard,Norway,SITE-002
PT-000669,XS-OD-0011,17,Male,Black or African American,HBB E6V (sickle),72.3,0,Active_Drug,Standard,2025-05-08,Pediatric_Assent,Taiwan,SITE-009
PT-000670,XS-OD-0011,63,Female,Asian,F9 R338L,41.9,1,Placebo,Standard,2025-05-07,Standard,Australia,SITE-036
PT-000671,XS-OD-0011,23,Female,White,,33.8,2,Crossover,Standard,2025-01-18,Standard,Sweden,SITE-035
PT-000672,XS-OD-0011,30,Female,Asian,,90.7,5,Active_Drug,Standard,2024-12-13,Compassionate,Sweden,SITE-001
PT-000673,XS-OD-0011,44,Female,Asian,HBB E6V (sickle),45.8,2,Placebo,Standard,2025-04-02,Standard,United States,SITE-031
PT-000674,XS-OD-0011,27,Female,White,Factor VIII intron 22 inv,21.8,0,Crossover,Standard,2025-05-23,Standard,South Korea,SITE-042
PT-000675,XS-OD-0011,19,Female,Asian,,39.1,2,Active_Drug,Standard,2025-04-30,Standard,Canada,SITE-039
PT-000676,XS-OD-0011,22,Male,White,Factor VIII intron 22 inv,54.4,3,Placebo,Standard,2025-02-21,Standard,Belgium,SITE-029
PT-000677,XS-OD-0011,72,Male,Asian,HBB IVS-I-110 G>A,11.3,2,Crossover,Standard,2025-03-05,Standard,Switzerland,SITE-028
PT-000678,XS-OD-0011,25,Male,White,Factor VIII intron 22 inv,51.4,1,Active_Drug,Standard,2025-05-10,Standard,Brazil,SITE-028
PT-000679,XS-OD-0011,6,Male,White,F9 R338L,27.9,0,Placebo,Standard,2025-01-23,Pediatric_Assent,Japan,SITE-003
PT-000680,XS-OD-0011,17,Female,White,Factor VIII intron 22 inv,65.3,1,Crossover,Standard,2024-12-11,Pediatric_Assent,Brazil,SITE-011
PT-000681,XS-OD-0011,55,Male,Black or African American,,36.5,0,Active_Drug,Standard,2024-12-22,Standard,South Korea,SITE-035
PT-000682,XS-OD-0011,39,Male,Hispanic or Latino,,49.5,1,Placebo,Standard,2025-01-14,Standard,Australia,SITE-022
PT-000683,XS-OD-0011,8,Female,White,,43.9,1,Crossover,Standard,2025-05-01,Pediatric_Assent,Sweden,SITE-020
PT-000684,XS-OD-0011,60,Female,White,F9 R338L,78.9,1,Active_Drug,Standard,2024-12-09,Standard,Norway,SITE-004
PT-000685,XS-OD-0011,44,Male,Hispanic or Latino,,44.4,5,Placebo,Standard,2025-04-27,Standard,South Korea,SITE-014
PT-000686,XS-OD-0011,23,Male,White,HBB IVS-I-110 G>A,28.4,3,Crossover,Standard,2025-05-27,Standard,Israel,SITE-011
PT-000687,XS-OD-0011,42,Male,Black or African American,HBB IVS-I-110 G>A,43.4,3,Active_Drug,Standard,2025-04-17,Standard,Canada,SITE-015
PT-000688,XS-OD-0011,14,Female,Asian,Factor VIII intron 22 inv,51.2,4,Placebo,Standard,2025-05-13,Pediatric_Assent,Sweden,SITE-005
PT-000689,XS-OD-0011,19,Female,White,HBB IVS-I-110 G>A,45.9,3,Crossover,Standard,2025-04-16,Standard,France,SITE-024
PT-000690,XS-OD-0011,33,Male,White,F9 R338L,80.2,1,Active_Drug,Standard,2025-01-31,Standard,South Korea,SITE-024
PT-000691,XS-OD-0011,31,Female,White,HBB E6V (sickle),48.7,1,Placebo,Standard,2024-12-26,Standard,Spain,SITE-002
PT-000692,XS-OD-0011,61,Male,Asian,HBB IVS-I-110 G>A,50.5,3,Crossover,Standard,2025-02-23,Standard,Austria,SITE-038
PT-000693,XS-OD-0011,34,Male,Hispanic or Latino,F9 R338L,52.3,3,Active_Drug,Standard,2024-12-28,Standard,Canada,SITE-035
PT-000694,XS-OD-0011,21,Male,White,F9 R338L,56.7,4,Placebo,Standard,2025-02-07,Standard,Spain,SITE-010
PT-000695,XS-OD-0011,40,Male,White,F9 R338L,80.4,1,Crossover,Standard,2025-03-02,Standard,Spain,SITE-032
PT-000696,XS-OD-0011,48,Female,Black or African American,,46.6,1,Active_Drug,Standard,2025-05-08,Standard,Italy,SITE-001
PT-000697,XS-OD-0011,24,Male,Black or African American,Factor VIII intron 22 inv,56.4,4,Placebo,Standard,2025-01-29,Standard,France,SITE-008
PT-000698,XS-OD-0011,57,Female,White,F9 R338L,37.8,6,Crossover,Standard,2025-02-21,Standard,France,SITE-027
PT-000699,XS-OD-0011,24,Male,Asian,HBB E6V (sickle),62.0,0,Active_Drug,Standard,2025-03-12,Standard,Canada,SITE-040
PT-000700,XS-OD-0011,41,Male,White,,49.3,2,Placebo,Standard,2025-03-02,Standard,Belgium,SITE-002
PT-000701,XS-OD-0011,43,Male,White,HBB E6V (sickle),44.4,1,Crossover,Standard,2025-03-09,Standard,Sweden,SITE-023
PT-000702,XS-OD-0011,40,Female,White,,36.6,5,Active_Drug,Standard,2025-02-14,Standard,South Korea,SITE-042
PT-000703,XS-OD-0011,52,Male,Hispanic or Latino,,49.2,0,Placebo,Standard,2025-03-03,Standard,South Korea,SITE-022
PT-000704,XS-OD-0011,70,Female,Asian,Factor VIII intron 22 inv,77.5,0,Crossover,Standard,2025-02-16,Standard,Spain,SITE-015
PT-000705,XS-OD-0011,12,Female,Black or African American,,17.5,2,Active_Drug,Standard,2025-05-05,Pediatric_Assent,South Korea,SITE-014
PT-000706,XS-OD-0011,14,Female,White,HBB IVS-I-110 G>A,55.9,3,Placebo,Standard,2025-05-10,Pediatric_Assent,Israel,SITE-013
PT-000707,XS-OD-0011,49,Male,White,,70.7,1,Crossover,Standard,2025-04-06,Standard,Spain,SITE-033
PT-000708,XS-OD-0012,32,Male,White,F9 R338L,77.7,5,Active_Drug,High,2023-12-09,Standard,France,SITE-005
PT-000709,XS-OD-0012,61,Female,White,HBB IVS-I-110 G>A,76.0,3,Active_Drug,Medium,2024-01-29,Standard,Brazil,SITE-005
PT-000710,XS-OD-0012,78,Male,White,F9 R338L,84.0,2,Active_Drug,Low,2023-12-14,Standard,United Kingdom,SITE-003
PT-000711,XS-OD-0012,69,Male,Black or African American,,66.0,2,Active_Drug,Low,2023-12-21,Standard,Spain,SITE-003
PT-000712,XS-OD-0012,31,Female,White,HBB E6V (sickle),50.2,1,Active_Drug,High,2024-04-21,Standard,Germany,SITE-004
PT-000713,XS-OD-0012,38,Male,White,HBB IVS-I-110 G>A,78.8,1,Active_Drug,Medium,2024-04-13,Standard,Canada,SITE-005
PT-000714,XS-OD-0012,39,Female,Hispanic or Latino,HBB E6V (sickle),50.2,0,Active_Drug,Low,2024-05-05,Standard,Canada,SITE-002
PT-000715,XS-OD-0012,22,Male,White,F9 R338L,47.0,1,Active_Drug,Low,2024-04-15,Standard,Sweden,SITE-005
PT-000716,XS-OD-0012,2,Male,White,,58.0,2,Active_Drug,Medium,2024-02-22,Pediatric_Assent,Austria,SITE-001
PT-000717,XS-OD-0012,34,Female,Black or African American,,41.0,4,Active_Drug,Low,2024-04-21,Standard,South Korea,SITE-002
PT-000718,XS-OD-0012,37,Male,White,HBB E6V (sickle),33.4,2,Active_Drug,High,2023-12-30,Standard,United Kingdom,SITE-005
PT-000719,XS-OD-0012,41,Female,White,,33.1,3,Active_Drug,Medium,2023-11-25,Standard,South Korea,SITE-001
PT-000720,XS-OD-0012,61,Male,Asian,,52.8,3,Active_Drug,Medium,2023-11-27,Standard,South Korea,SITE-002
PT-000721,XS-OD-0012,55,Female,Black or African American,,37.9,2,Active_Drug,Medium,2023-12-21,Standard,Sweden,SITE-003
PT-000722,XS-OD-0012,38,Male,White,Factor VIII intron 22 inv,71.4,0,Active_Drug,Medium,2024-02-21,Standard,Switzerland,SITE-005
PT-000723,XS-OD-0012,64,Female,White,,33.7,1,Active_Drug,Low,2024-03-20,Standard,Belgium,SITE-001
PT-000724,XS-OD-0012,23,Male,Black or African American,,49.7,2,Active_Drug,Medium,2024-02-15,Standard,Belgium,SITE-002
PT-000725,XS-OD-0012,16,Male,Hispanic or Latino,HBB IVS-I-110 G>A,57.8,3,Active_Drug,Medium,2023-12-15,Pediatric_Assent,France,SITE-003
PT-000726,XS-OD-0012,38,Male,White,,77.7,1,Active_Drug,High,2023-12-07,Standard,Sweden,SITE-003
PT-000727,XS-OD-0012,75,Male,White,,57.9,1,Active_Drug,High,2023-11-17,Standard,Netherlands,SITE-001
PT-000728,XS-OD-0012,77,Male,White,,54.0,3,Active_Drug,High,2024-01-13,Standard,Austria,SITE-001
PT-000729,XS-OD-0012,39,Male,American Indian or Alaska Native,,59.2,3,Active_Drug,Medium,2024-05-04,Standard,Canada,SITE-001
PT-000730,XS-OD-0012,45,Female,American Indian or Alaska Native,,67.7,2,Active_Drug,High,2023-12-10,Standard,Belgium,SITE-005
PT-000731,XS-OD-0012,22,Male,White,Factor VIII intron 22 inv,41.6,1,Active_Drug,Medium,2024-03-24,Standard,Norway,SITE-005
PT-000732,XS-OD-0012,72,Male,White,,45.3,1,Active_Drug,Medium,2023-12-23,Standard,Norway,SITE-005
PT-000733,XS-OD-0012,49,Male,White,Factor VIII intron 22 inv,38.2,1,Active_Drug,Medium,2023-11-12,Standard,United States,SITE-005
PT-000734,XS-OD-0012,2,Male,White,HBB E6V (sickle),36.8,3,Active_Drug,High,2024-05-07,Pediatric_Assent,Switzerland,SITE-005
PT-000735,XS-OD-0012,65,Female,Black or African American,HBB E6V (sickle),53.8,2,Active_Drug,Low,2024-03-08,Standard,Spain,SITE-003
PT-000736,XS-OD-0012,42,Male,Black or African American,Factor VIII intron 22 inv,60.5,1,Active_Drug,Low,2024-02-02,Standard,France,SITE-002
PT-000737,XS-OD-0012,12,Female,White,Factor VIII intron 22 inv,58.5,0,Active_Drug,Low,2024-02-23,Pediatric_Assent,Austria,SITE-005
PT-000738,XS-OD-0012,53,Female,American Indian or Alaska Native,HBB IVS-I-110 G>A,37.7,1,Active_Drug,Medium,2024-02-08,Emergency,United Kingdom,SITE-005
PT-000739,XS-OD-0012,50,Female,Hispanic or Latino,,60.1,1,Active_Drug,Low,2024-01-21,Standard,Netherlands,SITE-001
PT-000740,XS-OD-0012,49,Male,White,,51.4,3,Active_Drug,Low,2023-12-20,Standard,United Kingdom,SITE-001
PT-000741,XS-OD-0012,29,Male,White,Factor VIII intron 22 inv,72.5,1,Active_Drug,High,2024-01-31,Standard,Norway,SITE-002
PT-000742,XS-OD-0013,55,Female,White,,67.6,3,Active_Drug,Standard,2020-08-03,Standard,Netherlands,SITE-017
PT-000743,XS-OD-0013,43,Female,White,,86.1,4,Placebo,Standard,2020-08-19,Standard,Canada,SITE-009
PT-000744,XS-OD-0013,88,Male,White,F9 R338L,39.0,0,Active_Drug_High_Dose,Standard,2020-11-03,Standard,Spain,SITE-013
PT-000745,XS-OD-0013,30,Female,Native Hawaiian or Other Pacific Islander,HBB E6V (sickle),33.7,3,Active_Drug,Standard,2020-12-20,Standard,Japan,SITE-018
PT-000746,XS-OD-0013,53,Female,Hispanic or Latino,,51.2,2,Placebo,Standard,2020-10-06,Standard,Canada,SITE-001
PT-000747,XS-OD-0013,33,Male,Black or African American,HBB IVS-I-110 G>A,66.3,0,Active_Drug_High_Dose,Standard,2020-12-01,Standard,Japan,SITE-006
PT-000748,XS-OD-0013,47,Male,Hispanic or Latino,,72.1,3,Active_Drug,Standard,2020-12-22,Standard,Netherlands,SITE-009
PT-000749,XS-OD-0013,26,Male,Hispanic or Latino,,41.9,0,Placebo,Standard,2020-12-24,Standard,Spain,SITE-014
PT-000750,XS-OD-0013,43,Female,Asian,HBB IVS-I-110 G>A,59.2,1,Active_Drug_High_Dose,Standard,2020-07-01,Standard,Italy,SITE-001
PT-000751,XS-OD-0013,39,Female,Hispanic or Latino,HBB E6V (sickle),54.6,0,Active_Drug,Standard,2020-07-23,Compassionate,Spain,SITE-013
PT-000752,XS-OD-0013,80,Male,Two or More Races,,63.6,2,Placebo,Standard,2020-09-21,Standard,France,SITE-001
PT-000753,XS-OD-0013,59,Male,Asian,F9 R338L,54.2,0,Active_Drug_High_Dose,Standard,2020-10-14,Standard,Netherlands,SITE-011
PT-000754,XS-OD-0013,35,Female,White,Factor VIII intron 22 inv,68.6,3,Active_Drug,Standard,2020-10-13,Standard,Australia,SITE-006
PT-000755,XS-OD-0013,15,Male,Asian,,53.9,0,Placebo,Standard,2020-10-29,Pediatric_Assent,United States,SITE-012
PT-000756,XS-OD-0013,40,Male,Asian,Factor VIII intron 22 inv,41.5,3,Active_Drug_High_Dose,Standard,2020-09-17,Standard,Canada,SITE-013
PT-000757,XS-OD-0013,61,Male,Hispanic or Latino,,54.1,2,Active_Drug,Standard,2020-12-10,Standard,Spain,SITE-017
PT-000758,XS-OD-0013,27,Male,White,HBB E6V (sickle),65.3,1,Placebo,Standard,2020-11-28,Standard,Spain,SITE-011
PT-000759,XS-OD-0013,42,Male,White,HBB E6V (sickle),51.3,4,Active_Drug_High_Dose,Standard,2020-12-15,Standard,Australia,SITE-003
PT-000760,XS-OD-0013,38,Female,White,,24.8,3,Active_Drug,Standard,2020-08-12,Standard,Germany,SITE-007
PT-000761,XS-OD-0013,41,Female,Asian,,69.8,2,Placebo,Standard,2020-07-09,Standard,Australia,SITE-011
PT-000762,XS-OD-0013,66,Male,Black or African American,F9 R338L,40.9,1,Active_Drug_High_Dose,Standard,2020-08-28,Standard,Spain,SITE-019
PT-000763,XS-OD-0013,20,Male,Hispanic or Latino,HBB IVS-I-110 G>A,67.4,1,Active_Drug,Standard,2020-12-02,Standard,France,SITE-014
PT-000764,XS-OD-0013,46,Female,Asian,F9 R338L,94.0,2,Placebo,Standard,2020-10-12,Standard,Germany,SITE-009
PT-000765,XS-OD-0013,35,Female,White,HBB IVS-I-110 G>A,66.6,6,Active_Drug_High_Dose,Standard,2020-07-16,Standard,Canada,SITE-004
PT-000766,XS-OD-0013,55,Female,Asian,HBB E6V (sickle),50.6,2,Active_Drug,Standard,2020-12-08,Standard,Germany,SITE-018
PT-000767,XS-OD-0013,59,Male,White,,70.9,6,Placebo,Standard,2020-07-12,Standard,Germany,SITE-015
PT-000768,XS-OD-0013,24,Male,American Indian or Alaska Native,HBB IVS-I-110 G>A,70.7,3,Active_Drug_High_Dose,Standard,2020-07-30,Standard,Germany,SITE-006
PT-000769,XS-OD-0013,2,Female,White,F9 R338L,72.6,1,Active_Drug,Standard,2020-08-31,Pediatric_Assent,France,SITE-019
PT-000770,XS-OD-0013,45,Male,White,,42.0,3,Placebo,Standard,2020-11-27,Standard,United States,SITE-012
PT-000771,XS-OD-0013,55,Male,White,F9 R338L,52.1,1,Active_Drug_High_Dose,Standard,2020-08-04,Standard,United Kingdom,SITE-004
PT-000772,XS-OD-0013,45,Female,White,,85.2,2,Active_Drug,Standard,2020-12-14,Standard,Australia,SITE-007
PT-000773,XS-OD-0013,37,Female,White,,50.2,4,Placebo,Standard,2020-10-22,Standard,Spain,SITE-004
PT-000774,XS-OD-0013,55,Male,Hispanic or Latino,,56.2,1,Active_Drug_High_Dose,Standard,2020-10-07,Standard,Netherlands,SITE-004
PT-000775,XS-OD-0013,15,Male,White,F9 R338L,41.7,1,Active_Drug,Standard,2020-12-13,Pediatric_Assent,Canada,SITE-014
PT-000776,XS-OD-0013,26,Male,Two or More Races,HBB E6V (sickle),50.7,1,Placebo,Standard,2020-08-31,Emergency,United States,SITE-013
PT-000777,XS-OD-0013,24,Female,White,HBB IVS-I-110 G>A,33.4,2,Active_Drug_High_Dose,Standard,2020-07-03,Standard,United States,SITE-014
PT-000778,XS-OD-0013,34,Female,White,HBB E6V (sickle),41.4,1,Active_Drug,Standard,2020-12-26,Standard,Australia,SITE-011
PT-000779,XS-OD-0013,55,Female,Black or African American,F9 R338L,32.4,3,Placebo,Standard,2020-10-17,Standard,United Kingdom,SITE-015
PT-000780,XS-OD-0013,27,Female,Hispanic or Latino,,42.6,1,Active_Drug_High_Dose,Standard,2020-11-14,Standard,Germany,SITE-015
PT-000781,XS-OD-0013,46,Female,Black or African American,,80.1,3,Active_Drug,Standard,2020-08-03,Standard,Canada,SITE-013
PT-000782,XS-OD-0013,41,Male,White,,75.4,2,Placebo,Standard,2020-09-16,Standard,Japan,SITE-009
PT-000783,XS-OD-0013,40,Female,Hispanic or Latino,,61.3,1,Active_Drug_High_Dose,Standard,2020-10-30,Standard,Spain,SITE-008
PT-000784,XS-OD-0013,43,Female,Asian,,50.2,2,Active_Drug,Standard,2020-12-16,Standard,Netherlands,SITE-019
PT-000785,XS-OD-0013,2,Female,Asian,,50.5,2,Placebo,Standard,2020-10-24,Pediatric_Assent,Australia,SITE-003
PT-000786,XS-OD-0013,18,Male,Black or African American,,88.3,0,Active_Drug_High_Dose,Standard,2020-09-01,Standard,Germany,SITE-012
PT-000787,XS-OD-0013,24,Male,Asian,,52.6,3,Active_Drug,Standard,2020-10-24,Standard,Spain,SITE-016
PT-000788,XS-OD-0013,64,Female,White,Factor VIII intron 22 inv,38.8,1,Placebo,Standard,2020-11-24,Standard,France,SITE-007
PT-000789,XS-OD-0013,69,Male,White,,34.4,2,Active_Drug_High_Dose,Standard,2020-12-02,Compassionate,United States,SITE-018
PT-000790,XS-OD-0013,44,Female,Asian,,65.4,2,Active_Drug,Standard,2020-07-03,Standard,France,SITE-001
PT-000791,XS-OD-0013,80,Female,White,,47.3,2,Placebo,Standard,2020-07-15,Standard,Spain,SITE-006
PT-000792,XS-OD-0013,43,Male,White,F9 R338L,40.8,0,Active_Drug_High_Dose,Standard,2020-08-04,Standard,Spain,SITE-007
PT-000793,XS-OD-0013,52,Female,White,HBB E6V (sickle),43.4,1,Active_Drug,Standard,2020-10-11,Standard,Spain,SITE-015
PT-000794,XS-OD-0013,55,Female,White,Factor VIII intron 22 inv,79.9,1,Placebo,Standard,2020-12-12,Standard,Japan,SITE-009
PT-000795,XS-OD-0013,60,Male,Asian,HBB E6V (sickle),50.7,2,Active_Drug_High_Dose,Standard,2020-09-19,Emergency,France,SITE-015
PT-000796,XS-OD-0013,68,Male,White,HBB IVS-I-110 G>A,41.0,4,Active_Drug,Standard,2020-10-10,Compassionate,Australia,SITE-001
PT-000797,XS-OD-0013,9,Male,White,Factor VIII intron 22 inv,46.0,1,Placebo,Standard,2020-09-26,Pediatric_Assent,France,SITE-019
PT-000798,XS-OD-0013,58,Female,White,Factor VIII intron 22 inv,65.3,1,Active_Drug_High_Dose,Standard,2020-12-14,Standard,Spain,SITE-019
PT-000799,XS-OD-0013,46,Female,White,,48.0,3,Active_Drug,Standard,2020-10-13,Standard,Spain,SITE-018
PT-000800,XS-OD-0013,36,Female,Black or African American,F9 R338L,44.5,3,Placebo,Standard,2020-12-12,Standard,Japan,SITE-016
PT-000801,XS-OD-0013,31,Female,White,Factor VIII intron 22 inv,62.4,2,Active_Drug_High_Dose,Standard,2020-09-29,Standard,Italy,SITE-012
PT-000802,XS-OD-0013,70,Male,White,HBB IVS-I-110 G>A,11.6,1,Active_Drug,Standard,2020-07-03,Standard,Italy,SITE-013
PT-000803,XS-OD-0013,49,Female,White,Factor VIII intron 22 inv,71.0,2,Placebo,Standard,2020-09-06,Standard,Japan,SITE-012
PT-000804,XS-OD-0013,27,Female,White,Factor VIII intron 22 inv,46.0,3,Active_Drug_High_Dose,Standard,2020-10-22,Standard,United States,SITE-008
PT-000805,XS-OD-0013,28,Male,White,HBB IVS-I-110 G>A,50.0,3,Active_Drug,Standard,2020-07-12,Emergency,Italy,SITE-011
PT-000806,XS-OD-0013,57,Male,Hispanic or Latino,Factor VIII intron 22 inv,55.4,1,Placebo,Standard,2020-09-13,Standard,Germany,SITE-013
PT-000807,XS-OD-0013,45,Male,Native Hawaiian or Other Pacific Islander,HBB E6V (sickle),41.3,2,Active_Drug_High_Dose,Standard,2020-10-04,Standard,Australia,SITE-013
PT-000808,XS-OD-0013,46,Male,White,F9 R338L,63.0,4,Active_Drug,Standard,2020-10-30,Standard,Canada,SITE-017
PT-000809,XS-OD-0013,37,Male,Asian,,57.3,2,Placebo,Standard,2020-07-12,Standard,France,SITE-015
PT-000810,XS-OD-0013,43,Female,White,,60.2,1,Active_Drug_High_Dose,Standard,2020-12-08,Standard,Canada,SITE-018
PT-000811,XS-OD-0013,24,Female,White,,53.3,2,Active_Drug,Standard,2020-11-06,Standard,United States,SITE-006
PT-000812,XS-OD-0013,59,Male,White,HBB IVS-I-110 G>A,69.4,0,Placebo,Standard,2020-07-29,Standard,Italy,SITE-001
PT-000813,XS-OD-0013,56,Male,White,HBB IVS-I-110 G>A,59.2,3,Active_Drug_High_Dose,Standard,2020-09-20,Standard,France,SITE-016
PT-000814,XS-OD-0013,46,Male,White,HBB IVS-I-110 G>A,37.8,4,Active_Drug,Standard,2020-11-23,Standard,United States,SITE-007
PT-000815,XS-OD-0013,59,Male,White,,84.7,2,Placebo,Standard,2020-08-23,Standard,Spain,SITE-013
PT-000816,XS-OD-0013,19,Female,Hispanic or Latino,,90.3,3,Active_Drug_High_Dose,Standard,2020-10-11,Standard,Australia,SITE-004
PT-000817,XS-OD-0013,39,Female,White,Factor VIII intron 22 inv,47.4,2,Active_Drug,Standard,2020-11-02,Standard,Italy,SITE-014
PT-000818,XS-OD-0013,43,Female,Hispanic or Latino,F9 R338L,53.5,4,Placebo,Standard,2020-12-24,Standard,Italy,SITE-009
PT-000819,XS-OD-0013,33,Male,Asian,HBB IVS-I-110 G>A,61.1,1,Active_Drug_High_Dose,Standard,2020-09-27,Standard,Germany,SITE-010
PT-000820,XS-OD-0013,26,Male,Asian,Factor VIII intron 22 inv,53.9,0,Active_Drug,Standard,2020-07-25,Standard,Canada,SITE-019
PT-000821,XS-OD-0013,2,Male,Black or African American,F9 R338L,75.4,1,Placebo,Standard,2020-09-16,Pediatric_Assent,Netherlands,SITE-018
PT-000822,XS-OD-0013,36,Male,White,,85.9,1,Active_Drug_High_Dose,Standard,2020-12-16,Standard,Spain,SITE-004
PT-000823,XS-OD-0013,2,Male,White,HBB IVS-I-110 G>A,35.3,2,Active_Drug,Standard,2020-08-15,Pediatric_Assent,Japan,SITE-003
PT-000824,XS-OD-0013,42,Male,Black or African American,HBB E6V (sickle),31.3,1,Placebo,Standard,2020-11-14,Standard,Australia,SITE-016
PT-000825,XS-OD-0013,41,Female,Asian,HBB IVS-I-110 G>A,14.5,0,Active_Drug_High_Dose,Standard,2020-10-08,Standard,Australia,SITE-001
PT-000826,XS-OD-0013,50,Male,White,HBB E6V (sickle),73.3,0,Active_Drug,Standard,2020-10-19,Standard,Spain,SITE-018
PT-000827,XS-OD-0013,31,Male,Hispanic or Latino,,80.4,4,Placebo,Standard,2020-10-22,Standard,United States,SITE-008
PT-000828,XS-OD-0013,62,Female,White,HBB E6V (sickle),71.3,0,Active_Drug_High_Dose,Standard,2020-10-23,Standard,United States,SITE-009
PT-000829,XS-OD-0013,15,Female,White,,41.6,5,Active_Drug,Standard,2020-08-13,Pediatric_Assent,Canada,SITE-012
PT-000830,XS-OD-0013,39,Female,Black or African American,F9 R338L,63.9,1,Placebo,Standard,2020-10-22,Standard,Netherlands,SITE-012
PT-000831,XS-OD-0013,49,Female,White,,68.7,5,Active_Drug_High_Dose,Standard,2020-07-15,Standard,Netherlands,SITE-009
PT-000832,XS-OD-0013,54,Male,Black or African American,,67.3,2,Active_Drug,Standard,2020-07-16,Standard,Japan,SITE-003
PT-000833,XS-OD-0013,23,Male,Asian,Factor VIII intron 22 inv,69.2,1,Placebo,Standard,2020-10-06,Standard,Germany,SITE-010
PT-000834,XS-OD-0013,26,Male,Asian,,21.9,1,Active_Drug_High_Dose,Standard,2020-07-05,Standard,Australia,SITE-009
PT-000835,XS-OD-0013,65,Male,White,Factor VIII intron 22 inv,23.4,1,Active_Drug,Standard,2020-12-01,Standard,Italy,SITE-011
PT-000836,XS-OD-0013,41,Female,White,,52.7,1,Placebo,Standard,2020-10-04,Standard,United Kingdom,SITE-017
PT-000837,XS-OD-0013,29,Female,White,F9 R338L,59.8,3,Active_Drug_High_Dose,Standard,2020-11-24,Standard,Germany,SITE-004
PT-000838,XS-OD-0013,87,Female,Native Hawaiian or Other Pacific Islander,,49.4,2,Active_Drug,Standard,2020-10-03,Standard,United States,SITE-015
PT-000839,XS-OD-0013,31,Male,White,HBB E6V (sickle),62.0,1,Placebo,Standard,2020-08-25,Standard,United States,SITE-008
PT-000840,XS-OD-0013,28,Female,Asian,,41.2,0,Active_Drug_High_Dose,Standard,2020-07-11,Standard,Netherlands,SITE-011
PT-000841,XS-OD-0013,44,Female,Asian,F9 R338L,29.0,0,Active_Drug,Standard,2020-08-17,Standard,Japan,SITE-006
PT-000842,XS-OD-0013,28,Female,Black or African American,HBB IVS-I-110 G>A,33.6,1,Placebo,Standard,2020-09-02,Standard,Spain,SITE-018
PT-000843,XS-OD-0013,69,Female,Asian,,13.3,4,Active_Drug_High_Dose,Standard,2020-12-06,Standard,United States,SITE-008
PT-000844,XS-OD-0013,28,Female,White,HBB E6V (sickle),49.1,1,Active_Drug,Standard,2020-09-20,Standard,Japan,SITE-006
PT-000845,XS-OD-0013,19,Female,Black or African American,Factor VIII intron 22 inv,78.6,4,Placebo,Standard,2020-08-05,Standard,Canada,SITE-006
PT-000846,XS-OD-0013,25,Female,Hispanic or Latino,Factor VIII intron 22 inv,24.4,3,Active_Drug_High_Dose,Standard,2020-11-15,Standard,Italy,SITE-009
PT-000847,XS-OD-0013,8,Female,White,HBB IVS-I-110 G>A,66.9,1,Active_Drug,Standard,2020-11-25,Pediatric_Assent,Canada,SITE-005
PT-000848,XS-OD-0013,45,Male,Black or African American,HBB E6V (sickle),11.7,3,Placebo,Standard,2020-07-05,Standard,Canada,SITE-006
PT-000849,XS-OD-0013,34,Female,White,,43.1,4,Active_Drug_High_Dose,Standard,2020-12-18,Standard,Japan,SITE-002
PT-000850,XS-OD-0013,50,Female,Asian,Factor VIII intron 22 inv,83.7,1,Active_Drug,Standard,2020-07-20,Standard,Germany,SITE-005
PT-000851,XS-OD-0013,47,Male,White,HBB E6V (sickle),43.5,0,Placebo,Standard,2020-08-01,Standard,Spain,SITE-017
PT-000852,XS-OD-0013,81,Female,White,Factor VIII intron 22 inv,36.4,2,Active_Drug_High_Dose,Standard,2020-10-03,Standard,Australia,SITE-015
PT-000853,XS-OD-0013,2,Male,Asian,Factor VIII intron 22 inv,42.7,1,Active_Drug,Standard,2020-12-19,Pediatric_Assent,France,SITE-010
PT-000854,XS-OD-0013,33,Male,White,Factor VIII intron 22 inv,47.6,0,Placebo,Standard,2020-11-27,Standard,Australia,SITE-008
PT-000855,XS-OD-0013,40,Female,White,HBB E6V (sickle),79.4,2,Active_Drug_High_Dose,Standard,2020-07-22,Standard,United Kingdom,SITE-008
PT-000856,XS-OD-0013,38,Male,White,,91.9,2,Active_Drug,Standard,2020-11-26,Standard,Canada,SITE-001
PT-000857,XS-OD-0013,28,Female,White,HBB E6V (sickle),27.7,2,Placebo,Standard,2020-10-21,Standard,Germany,SITE-004
PT-000858,XS-OD-0013,2,Female,White,F9 R338L,49.9,2,Active_Drug_High_Dose,Standard,2020-07-04,Pediatric_Assent,Canada,SITE-019
PT-000859,XS-OD-0013,22,Male,White,,62.2,0,Active_Drug,Standard,2020-09-07,Standard,Canada,SITE-015
PT-000860,XS-OD-0013,28,Female,Asian,HBB IVS-I-110 G>A,55.0,4,Placebo,Standard,2020-11-26,Standard,Germany,SITE-003
PT-000861,XS-OD-0013,31,Male,Hispanic or Latino,HBB E6V (sickle),70.2,2,Active_Drug_High_Dose,Standard,2020-08-13,Standard,United States,SITE-003
PT-000862,XS-OD-0013,33,Male,White,F9 R338L,70.4,0,Active_Drug,Standard,2020-10-11,Standard,France,SITE-016
PT-000863,XS-OD-0013,14,Female,White,,39.7,2,Placebo,Standard,2020-07-29,Pediatric_Assent,Canada,SITE-004
PT-000864,XS-OD-0013,26,Male,White,,95.0,2,Active_Drug_High_Dose,Standard,2020-09-23,Standard,Canada,SITE-001
PT-000865,XS-OD-0013,4,Female,Hispanic or Latino,,62.5,1,Active_Drug,Standard,2020-08-30,Pediatric_Assent,United States,SITE-011
PT-000866,XS-OD-0013,57,Male,Black or African American,HBB E6V (sickle),92.8,2,Placebo,Standard,2020-11-13,Standard,Italy,SITE-017
PT-000867,XS-OD-0013,38,Male,White,HBB IVS-I-110 G>A,58.4,1,Active_Drug_High_Dose,Standard,2020-10-24,Standard,Germany,SITE-008
PT-000868,XS-OD-0013,25,Male,Two or More Races,HBB IVS-I-110 G>A,63.2,2,Active_Drug,Standard,2020-11-04,Standard,Spain,SITE-017
PT-000869,XS-OD-0013,50,Female,Black or African American,Factor VIII intron 22 inv,73.8,1,Placebo,Standard,2020-11-22,Standard,Japan,SITE-017
PT-000870,XS-OD-0013,56,Female,White,F9 R338L,46.6,1,Active_Drug_High_Dose,Standard,2020-08-15,Standard,Japan,SITE-013
PT-000871,XS-OD-0013,26,Male,Two or More Races,HBB IVS-I-110 G>A,61.2,4,Active_Drug,Standard,2020-11-08,Standard,Netherlands,SITE-009
PT-000872,XS-OD-0013,71,Male,Hispanic or Latino,Factor VIII intron 22 inv,36.6,3,Placebo,Standard,2020-08-27,Standard,Australia,SITE-003
PT-000873,XS-OD-0013,31,Female,White,,53.6,0,Active_Drug_High_Dose,Standard,2020-11-29,Standard,Netherlands,SITE-001
PT-000874,XS-OD-0013,41,Female,White,Factor VIII intron 22 inv,81.2,2,Active_Drug,Standard,2020-09-19,Standard,Netherlands,SITE-010
PT-000875,XS-OD-0013,46,Male,Two or More Races,Factor VIII intron 22 inv,16.7,2,Placebo,Standard,2020-09-30,Standard,Japan,SITE-004
PT-000876,XS-OD-0013,30,Female,White,HBB IVS-I-110 G>A,53.1,0,Active_Drug_High_Dose,Standard,2020-12-08,Standard,Spain,SITE-008
PT-000877,XS-OD-0013,53,Female,White,F9 R338L,69.8,3,Active_Drug,Standard,2020-10-04,Standard,United States,SITE-003
PT-000878,XS-OD-0013,17,Female,White,Factor VIII intron 22 inv,52.3,2,Placebo,Standard,2020-07-29,Pediatric_Assent,Italy,SITE-013
PT-000879,XS-OD-0013,47,Female,White,HBB E6V (sickle),46.6,1,Active_Drug_High_Dose,Standard,2020-09-06,Standard,France,SITE-003
PT-000880,XS-OD-0013,37,Female,Hispanic or Latino,HBB E6V (sickle),71.6,2,Active_Drug,Standard,2020-12-07,Standard,United Kingdom,SITE-018
PT-000881,XS-OD-0013,63,Male,White,,59.2,1,Placebo,Standard,2020-08-15,Standard,France,SITE-008
PT-000882,XS-OD-0013,28,Female,Asian,,56.3,2,Active_Drug_High_Dose,Standard,2020-08-10,Standard,Japan,SITE-014
PT-000883,XS-OD-0013,26,Female,Asian,,58.0,7,Active_Drug,Standard,2020-12-06,Standard,Germany,SITE-014
PT-000884,XS-OD-0013,37,Female,White,,61.5,2,Placebo,Standard,2020-12-26,Standard,Netherlands,SITE-007
PT-000885,XS-OD-0013,47,Male,White,Factor VIII intron 22 inv,73.8,1,Active_Drug_High_Dose,Standard,2020-08-29,Standard,Italy,SITE-008
PT-000886,XS-OD-0013,25,Male,White,HBB E6V (sickle),56.7,2,Active_Drug,Standard,2020-08-15,Standard,Italy,SITE-009
PT-000887,XS-OD-0013,75,Female,Hispanic or Latino,,41.9,0,Placebo,Standard,2020-08-14,Standard,Germany,SITE-006
PT-000888,XS-OD-0013,31,Male,White,Factor VIII intron 22 inv,60.9,2,Active_Drug_High_Dose,Standard,2020-11-25,Standard,France,SITE-003
PT-000889,XS-OD-0013,33,Female,White,,63.7,1,Active_Drug,Standard,2020-11-27,Standard,France,SITE-016
PT-000890,XS-OD-0013,26,Female,Black or African American,Factor VIII intron 22 inv,46.6,2,Placebo,Standard,2020-11-25,Standard,United States,SITE-015
PT-000891,XS-OD-0013,43,Female,White,Factor VIII intron 22 inv,65.5,2,Active_Drug_High_Dose,Standard,2020-11-15,Standard,Germany,SITE-011
PT-000892,XS-OD-0013,45,Male,Hispanic or Latino,HBB IVS-I-110 G>A,31.2,1,Active_Drug,Standard,2020-08-23,Standard,Germany,SITE-004
PT-000893,XS-OD-0013,36,Male,White,F9 R338L,61.7,0,Placebo,Standard,2020-10-11,Standard,Germany,SITE-010
PT-000894,XS-OD-0013,56,Male,White,HBB E6V (sickle),49.9,0,Active_Drug_High_Dose,Standard,2020-10-20,Standard,Canada,SITE-013
PT-000895,XS-OD-0013,60,Female,White,Factor VIII intron 22 inv,76.2,5,Active_Drug,Standard,2020-07-18,Standard,United Kingdom,SITE-013
PT-000896,XS-OD-0013,74,Male,White,Factor VIII intron 22 inv,59.1,0,Placebo,Standard,2020-10-01,Standard,Canada,SITE-012
PT-000897,XS-OD-0013,75,Female,White,HBB IVS-I-110 G>A,57.9,1,Active_Drug_High_Dose,Standard,2020-12-01,Standard,Germany,SITE-001
PT-000898,XS-OD-0013,51,Male,White,,65.8,0,Active_Drug,Standard,2020-07-30,Standard,Japan,SITE-004
PT-000899,XS-OD-0013,59,Male,White,,41.1,1,Placebo,Standard,2020-07-11,Standard,Netherlands,SITE-007
PT-000900,XS-OD-0013,42,Female,White,,61.9,3,Active_Drug_High_Dose,Standard,2020-09-04,Standard,Canada,SITE-008
PT-000901,XS-OD-0013,38,Female,White,F9 R338L,81.2,1,Active_Drug,Standard,2020-12-24,Standard,Italy,SITE-011
PT-000902,XS-OD-0013,43,Male,White,,62.7,0,Placebo,Standard,2020-08-29,Standard,Italy,SITE-006
PT-000903,XS-OD-0013,23,Male,White,HBB E6V (sickle),59.9,0,Active_Drug_High_Dose,Standard,2020-07-25,Standard,France,SITE-012
PT-000904,XS-OD-0013,41,Male,American Indian or Alaska Native,HBB E6V (sickle),45.9,1,Active_Drug,Standard,2020-09-03,Standard,Australia,SITE-016
PT-000905,XS-OD-0013,20,Male,Asian,,92.1,5,Placebo,Standard,2020-08-25,Standard,France,SITE-006
PT-000906,XS-OD-0013,5,Female,White,HBB IVS-I-110 G>A,62.4,2,Active_Drug_High_Dose,Standard,2020-09-07,Pediatric_Assent,Italy,SITE-003
PT-000907,XS-OD-0013,58,Female,American Indian or Alaska Native,HBB IVS-I-110 G>A,66.0,4,Active_Drug,Standard,2020-10-18,Compassionate,United States,SITE-004
PT-000908,XS-OD-0013,38,Male,White,,64.5,2,Placebo,Standard,2020-08-07,Compassionate,Italy,SITE-014
PT-000909,XS-OD-0013,44,Female,Black or African American,F9 R338L,53.7,4,Active_Drug_High_Dose,Standard,2020-12-20,Standard,United Kingdom,SITE-001
PT-000910,XS-OD-0013,25,Male,White,HBB E6V (sickle),54.7,0,Active_Drug,Standard,2020-10-31,Compassionate,United Kingdom,SITE-016
PT-000911,XS-OD-0013,60,Male,White,F9 R338L,44.3,4,Placebo,Standard,2020-12-03,Standard,Italy,SITE-003
PT-000912,XS-OD-0013,53,Male,Black or African American,F9 R338L,56.0,4,Active_Drug_High_Dose,Standard,2020-10-27,Standard,Spain,SITE-011
PT-000913,XS-OD-0013,38,Male,White,,84.6,3,Active_Drug,Standard,2020-10-21,Standard,United States,SITE-011
PT-000914,XS-OD-0013,74,Female,White,,48.3,5,Placebo,Standard,2020-10-27,Standard,Netherlands,SITE-012
PT-000915,XS-OD-0013,66,Male,Asian,HBB E6V (sickle),79.9,2,Active_Drug_High_Dose,Standard,2020-10-05,Standard,United States,SITE-016
PT-000916,XS-OD-0013,39,Male,White,F9 R338L,40.5,1,Active_Drug,Standard,2020-10-19,Standard,United States,SITE-013
PT-000917,XS-OD-0013,49,Female,White,Factor VIII intron 22 inv,58.1,3,Placebo,Standard,2020-08-07,Standard,Germany,SITE-017
PT-000918,XS-OD-0013,72,Female,White,HBB IVS-I-110 G>A,83.1,2,Active_Drug_High_Dose,Standard,2020-11-09,Standard,Netherlands,SITE-009
PT-000919,XS-OD-0013,59,Male,Hispanic or Latino,Factor VIII intron 22 inv,59.2,2,Active_Drug,Standard,2020-07-03,Standard,Japan,SITE-005
PT-000920,XS-OD-0013,37,Female,White,,65.1,3,Placebo,Standard,2020-11-16,Standard,Japan,SITE-015
PT-000921,XS-OD-0013,48,Female,Asian,F9 R338L,48.7,5,Active_Drug_High_Dose,Standard,2020-12-01,Standard,Australia,SITE-004
PT-000922,XS-OD-0013,16,Male,Asian,F9 R338L,36.3,1,Active_Drug,Standard,2020-08-29,Pediatric_Assent,Australia,SITE-003
PT-000923,XS-OD-0013,42,Male,Black or African American,Factor VIII intron 22 inv,66.2,4,Placebo,Standard,2020-09-01,Standard,United Kingdom,SITE-014
PT-000924,XS-OD-0013,75,Female,White,,95.0,2,Active_Drug_High_Dose,Standard,2020-12-01,Standard,Australia,SITE-003
PT-000925,XS-OD-0013,45,Female,Asian,,40.6,3,Active_Drug,Standard,2020-07-04,Standard,Netherlands,SITE-013
PT-000926,XS-OD-0013,33,Male,White,,59.3,2,Placebo,Standard,2020-07-09,Standard,United States,SITE-018
PT-000927,XS-OD-0013,49,Female,Asian,,62.1,1,Active_Drug_High_Dose,Standard,2020-08-08,Standard,Australia,SITE-013
PT-000928,XS-OD-0013,43,Female,White,Factor VIII intron 22 inv,57.4,3,Active_Drug,Standard,2020-07-25,Standard,Canada,SITE-004
PT-000929,XS-OD-0013,36,Male,White,,48.6,2,Placebo,Standard,2020-07-27,Standard,Germany,SITE-011
PT-000930,XS-OD-0013,63,Male,White,HBB IVS-I-110 G>A,68.3,2,Active_Drug_High_Dose,Standard,2020-12-14,Standard,Canada,SITE-003
PT-000931,XS-OD-0013,17,Male,White,,51.8,1,Active_Drug,Standard,2020-09-14,Pediatric_Assent,Japan,SITE-018
PT-000932,XS-OD-0013,31,Male,White,,18.7,1,Placebo,Standard,2020-09-17,Standard,France,SITE-014
PT-000933,XS-OD-0013,40,Female,Two or More Races,HBB IVS-I-110 G>A,70.3,1,Active_Drug_High_Dose,Standard,2020-09-24,Standard,United Kingdom,SITE-017
PT-000934,XS-OD-0013,49,Male,White,,55.3,3,Active_Drug,Standard,2020-11-02,Standard,Italy,SITE-009
PT-000935,XS-OD-0013,14,Female,White,F9 R338L,50.1,3,Placebo,Standard,2020-10-05,Pediatric_Assent,Japan,SITE-015
PT-000936,XS-OD-0013,79,Female,Hispanic or Latino,,49.5,4,Active_Drug_High_Dose,Standard,2020-11-15,Standard,United States,SITE-012
PT-000937,XS-OD-0013,22,Female,White,HBB E6V (sickle),43.3,5,Active_Drug,Standard,2020-10-28,Standard,France,SITE-005
PT-000938,XS-OD-0013,40,Male,White,Factor VIII intron 22 inv,72.7,3,Placebo,Standard,2020-09-21,Standard,Japan,SITE-014
PT-000939,XS-OD-0013,35,Male,Black or African American,HBB E6V (sickle),30.1,0,Active_Drug_High_Dose,Standard,2020-09-23,Standard,Spain,SITE-011
PT-000940,XS-OD-0013,48,Female,White,HBB E6V (sickle),29.9,3,Active_Drug,Standard,2020-07-16,Standard,Germany,SITE-007
PT-000941,XS-OD-0013,35,Female,White,Factor VIII intron 22 inv,45.2,1,Placebo,Standard,2020-12-25,Standard,Italy,SITE-019
PT-000942,XS-OD-0013,54,Female,Hispanic or Latino,Factor VIII intron 22 inv,87.4,2,Active_Drug_High_Dose,Standard,2020-08-14,Standard,Canada,SITE-009
PT-000943,XS-OD-0013,7,Male,White,HBB IVS-I-110 G>A,65.6,1,Active_Drug,Standard,2020-09-04,Pediatric_Assent,Japan,SITE-007
PT-000944,XS-OD-0013,78,Female,Hispanic or Latino,HBB E6V (sickle),62.5,3,Placebo,Standard,2020-10-28,Standard,Italy,SITE-008
PT-000945,XS-OD-0013,44,Female,White,Factor VIII intron 22 inv,65.5,2,Active_Drug_High_Dose,Standard,2020-07-01,Standard,United States,SITE-019
PT-000946,XS-OD-0013,64,Female,White,,55.9,3,Active_Drug,Standard,2020-09-14,Standard,Germany,SITE-013
PT-000947,XS-OD-0013,35,Female,White,HBB IVS-I-110 G>A,39.0,1,Placebo,Standard,2020-08-05,Standard,Australia,SITE-006
PT-000948,XS-OD-0013,15,Male,Hispanic or Latino,,31.3,1,Active_Drug_High_Dose,Standard,2020-10-31,Pediatric_Assent,Germany,SITE-015
PT-000949,XS-OD-0013,52,Female,Black or African American,HBB IVS-I-110 G>A,64.6,1,Active_Drug,Standard,2020-07-27,Emergency,Italy,SITE-011
PT-000950,XS-OD-0013,69,Female,Hispanic or Latino,Factor VIII intron 22 inv,58.3,2,Placebo,Standard,2020-09-01,Standard,Australia,SITE-008
PT-000951,XS-OD-0013,54,Female,White,,81.8,2,Active_Drug_High_Dose,Standard,2020-10-04,Standard,United States,SITE-008
PT-000952,XS-OD-0013,39,Female,Asian,HBB IVS-I-110 G>A,65.5,3,Active_Drug,Standard,2020-08-15,Standard,United States,SITE-018
PT-000953,XS-OD-0013,57,Female,Asian,Factor VIII intron 22 inv,45.4,5,Placebo,Standard,2020-10-20,Standard,Japan,SITE-016
PT-000954,XS-OD-0013,29,Female,Hispanic or Latino,,57.8,3,Active_Drug_High_Dose,Standard,2020-08-01,Emergency,United States,SITE-013
PT-000955,XS-OD-0013,53,Female,White,,34.0,1,Active_Drug,Standard,2020-08-16,Standard,Italy,SITE-016
PT-000956,XS-OD-0013,19,Male,White,HBB IVS-I-110 G>A,89.6,2,Placebo,Standard,2020-12-17,Compassionate,Australia,SITE-017
PT-000957,XS-OD-0013,59,Female,Black or African American,HBB IVS-I-110 G>A,32.6,3,Active_Drug_High_Dose,Standard,2020-12-22,Standard,Canada,SITE-001
PT-000958,XS-OD-0013,38,Male,White,F9 R338L,56.2,2,Active_Drug,Standard,2020-12-15,Standard,Spain,SITE-004
PT-000959,XS-OD-0013,32,Male,Black or African American,HBB IVS-I-110 G>A,45.5,1,Placebo,Standard,2020-07-20,Standard,Italy,SITE-009
PT-000960,XS-OD-0014,28,Male,White,,59.4,0,Active_Drug,High,2025-02-17,Standard,United States,SITE-003
PT-000961,XS-OD-0014,38,Male,White,Factor VIII intron 22 inv,53.4,3,Active_Drug,High,2025-02-03,Standard,Brazil,SITE-004
PT-000962,XS-OD-0014,28,Male,Hispanic or Latino,Factor VIII intron 22 inv,23.1,2,Active_Drug,High,2024-11-25,Standard,Taiwan,SITE-001
PT-000963,XS-OD-0014,29,Male,White,Factor VIII intron 22 inv,88.1,3,Active_Drug,Low,2024-10-22,Standard,Switzerland,SITE-002
PT-000964,XS-OD-0014,47,Male,Hispanic or Latino,Factor VIII intron 22 inv,35.4,0,Active_Drug,High,2024-10-17,Standard,Spain,SITE-004
PT-000965,XS-OD-0014,29,Male,White,HBB E6V (sickle),43.7,4,Active_Drug,Low,2024-11-01,Standard,Denmark,SITE-004
PT-000966,XS-OD-0014,21,Male,White,HBB E6V (sickle),61.8,2,Active_Drug,High,2025-02-07,Standard,Spain,SITE-001
PT-000967,XS-OD-0014,35,Male,Black or African American,F9 R338L,67.1,3,Active_Drug,Low,2024-12-11,Standard,South Korea,SITE-001
PT-000968,XS-OD-0014,62,Male,White,,44.1,1,Active_Drug,High,2025-02-03,Standard,South Korea,SITE-001
PT-000969,XS-OD-0014,2,Male,American Indian or Alaska Native,Factor VIII intron 22 inv,48.1,3,Active_Drug,High,2024-10-13,Pediatric_Assent,Austria,SITE-003
PT-000970,XS-OD-0014,59,Male,White,HBB IVS-I-110 G>A,45.9,3,Active_Drug,Medium,2025-01-06,Standard,Israel,SITE-001
PT-000971,XS-OD-0014,54,Male,White,,35.5,2,Active_Drug,High,2024-11-06,Standard,United States,SITE-001
PT-000972,XS-OD-0014,31,Male,Black or African American,HBB E6V (sickle),67.2,2,Active_Drug,High,2024-12-21,Standard,Belgium,SITE-002
PT-000973,XS-OD-0014,37,Male,White,Factor VIII intron 22 inv,40.9,2,Active_Drug,High,2025-03-10,Compassionate,Switzerland,SITE-004
PT-000974,XS-OD-0014,45,Male,White,,72.9,1,Active_Drug,High,2024-11-06,Standard,Sweden,SITE-002
PT-000975,XS-OD-0014,13,Male,White,F9 R338L,22.4,1,Active_Drug,High,2025-02-03,Pediatric_Assent,Belgium,SITE-001
PT-000976,XS-OD-0014,52,Male,White,,58.6,0,Active_Drug,Medium,2024-10-23,Standard,France,SITE-002
PT-000977,XS-OD-0014,49,Male,White,Factor VIII intron 22 inv,77.0,8,Active_Drug,High,2024-10-28,Standard,Sweden,SITE-004
PT-000978,XS-OD-0014,10,Male,White,Factor VIII intron 22 inv,35.1,3,Active_Drug,Medium,2025-02-26,Pediatric_Assent,Italy,SITE-004
PT-000979,XS-OD-0014,14,Male,White,HBB IVS-I-110 G>A,68.4,2,Active_Drug,Medium,2025-03-08,Pediatric_Assent,Brazil,SITE-002
PT-000980,XS-OD-0014,60,Male,White,HBB E6V (sickle),12.1,4,Active_Drug,Medium,2024-11-01,Standard,South Korea,SITE-001
PT-000981,XS-OD-0014,54,Male,White,HBB IVS-I-110 G>A,54.2,3,Active_Drug,Medium,2024-09-30,Standard,Canada,SITE-004
PT-000982,XS-OD-0014,43,Male,Black or African American,F9 R338L,51.7,2,Active_Drug,High,2025-03-15,Standard,Belgium,SITE-001
PT-000983,XS-OD-0014,29,Male,American Indian or Alaska Native,,57.3,3,Active_Drug,Medium,2025-03-20,Standard,Netherlands,SITE-004
PT-000984,XS-OD-0014,2,Male,Asian,HBB IVS-I-110 G>A,47.2,3,Active_Drug,Low,2024-10-28,Pediatric_Assent,Switzerland,SITE-004
PT-000985,XS-OD-0014,33,Male,Native Hawaiian or Other Pacific Islander,Factor VIII intron 22 inv,40.5,4,Active_Drug,High,2024-12-27,Standard,Austria,SITE-003
PT-000986,XS-OD-0015,52,Male,White,HBB E6V (sickle),71.7,2,Active_Drug,Standard,2025-12-08,Standard,Canada,SITE-010
PT-000987,XS-OD-0015,58,Male,White,HBB IVS-I-110 G>A,51.0,2,Placebo,Standard,2025-11-14,Standard,Spain,SITE-019
PT-000988,XS-OD-0015,84,Male,Hispanic or Latino,,50.1,2,Active_Drug,Standard,2025-11-21,Standard,United States,SITE-013
PT-000989,XS-OD-0015,17,Male,White,F9 R338L,60.5,2,Placebo,Standard,2025-11-08,Pediatric_Assent,Germany,SITE-008
PT-000990,XS-OD-0015,27,Male,White,,60.2,2,Active_Drug,Standard,2025-08-25,Standard,Netherlands,SITE-002
PT-000991,XS-OD-0015,52,Male,White,HBB IVS-I-110 G>A,78.1,1,Placebo,Standard,2025-08-01,Standard,Australia,SITE-011
PT-000992,XS-OD-0015,33,Male,White,,36.9,0,Active_Drug,Standard,2025-11-04,Standard,Italy,SITE-007
PT-000993,XS-OD-0015,51,Male,White,HBB IVS-I-110 G>A,61.8,3,Placebo,Standard,2025-12-04,Standard,Australia,SITE-005
PT-000994,XS-OD-0015,30,Male,Hispanic or Latino,HBB IVS-I-110 G>A,69.4,0,Active_Drug,Standard,2025-10-23,Standard,Spain,SITE-012
PT-000995,XS-OD-0015,12,Male,Asian,,62.8,5,Placebo,Standard,2025-08-19,Pediatric_Assent,Netherlands,SITE-011
PT-000996,XS-OD-0015,74,Male,White,HBB E6V (sickle),51.4,0,Active_Drug,Standard,2025-12-03,Standard,Germany,SITE-006
PT-000997,XS-OD-0015,48,Female,White,,39.3,1,Placebo,Standard,2026-01-11,Standard,United Kingdom,SITE-003
PT-000998,XS-OD-0015,43,Male,White,,52.8,3,Active_Drug,Standard,2026-01-19,Standard,United States,SITE-011
PT-000999,XS-OD-0015,58,Male,White,HBB E6V (sickle),66.7,1,Placebo,Standard,2026-01-25,Standard,Netherlands,SITE-012
PT-001000,XS-OD-0015,37,Male,White,,48.9,3,Active_Drug,Standard,2025-12-04,Standard,Italy,SITE-018
PT-001001,XS-OD-0015,15,Male,White,F9 R338L,33.9,3,Placebo,Standard,2026-01-14,Pediatric_Assent,Italy,SITE-002
PT-001002,XS-OD-0015,49,Male,Hispanic or Latino,Factor VIII intron 22 inv,53.4,2,Active_Drug,Standard,2025-12-25,Standard,France,SITE-006
PT-001003,XS-OD-0015,2,Male,Asian,F9 R338L,54.4,3,Placebo,Standard,2025-12-27,Pediatric_Assent,Spain,SITE-017
PT-001004,XS-OD-0015,68,Male,White,HBB IVS-I-110 G>A,57.1,0,Active_Drug,Standard,2025-10-10,Standard,Italy,SITE-004
PT-001005,XS-OD-0015,46,Male,White,F9 R338L,55.3,5,Placebo,Standard,2025-12-04,Standard,Netherlands,SITE-016
PT-001006,XS-OD-0015,38,Male,White,HBB IVS-I-110 G>A,39.2,2,Active_Drug,Standard,2025-12-03,Compassionate,France,SITE-018
PT-001007,XS-OD-0015,37,Male,Black or African American,HBB E6V (sickle),17.3,2,Placebo,Standard,2026-01-19,Standard,Japan,SITE-008
PT-001008,XS-OD-0015,43,Male,White,,59.9,2,Active_Drug,Standard,2025-09-12,Standard,United Kingdom,SITE-019
PT-001009,XS-OD-0015,12,Male,Two or More Races,HBB E6V (sickle),35.6,0,Placebo,Standard,2026-01-07,Pediatric_Assent,United States,SITE-016
PT-001010,XS-OD-0015,77,Male,Asian,HBB E6V (sickle),61.4,4,Active_Drug,Standard,2025-10-30,Standard,Australia,SITE-006
PT-001011,XS-OD-0015,46,Male,Asian,HBB E6V (sickle),79.2,2,Placebo,Standard,2025-10-04,Standard,Australia,SITE-015
PT-001012,XS-OD-0015,47,Male,White,,71.6,1,Active_Drug,Standard,2025-08-24,Standard,Netherlands,SITE-007
PT-001013,XS-OD-0015,15,Male,White,HBB IVS-I-110 G>A,55.9,1,Placebo,Standard,2025-09-13,Pediatric_Assent,Spain,SITE-013
PT-001014,XS-OD-0015,51,Male,White,Factor VIII intron 22 inv,72.6,3,Active_Drug,Standard,2025-10-05,Standard,France,SITE-019
PT-001015,XS-OD-0015,52,Male,Asian,HBB E6V (sickle),66.6,2,Placebo,Standard,2025-10-30,Standard,France,SITE-010
PT-001016,XS-OD-0015,41,Male,White,F9 R338L,39.5,2,Active_Drug,Standard,2025-12-02,Standard,Germany,SITE-016
PT-001017,XS-OD-0015,52,Male,Hispanic or Latino,HBB E6V (sickle),52.8,2,Placebo,Standard,2025-07-31,Standard,Germany,SITE-011
PT-001018,XS-OD-0015,10,Male,Two or More Races,,38.9,1,Active_Drug,Standard,2025-10-25,Pediatric_Assent,United Kingdom,SITE-017
PT-001019,XS-OD-0015,79,Male,Hispanic or Latino,F9 R338L,58.3,2,Placebo,Standard,2025-08-24,Standard,Canada,SITE-009
PT-001020,XS-OD-0015,49,Male,Hispanic or Latino,,61.8,1,Active_Drug,Standard,2025-12-05,Standard,Australia,SITE-013
PT-001021,XS-OD-0015,29,Male,Asian,F9 R338L,71.8,1,Placebo,Standard,2026-01-23,Standard,United States,SITE-006
PT-001022,XS-OD-0015,36,Male,Hispanic or Latino,F9 R338L,24.7,0,Active_Drug,Standard,2025-07-31,Standard,Spain,SITE-015
PT-001023,XS-OD-0015,28,Male,White,,61.8,0,Placebo,Standard,2026-01-13,Standard,United Kingdom,SITE-004
PT-001024,XS-OD-0015,35,Male,Hispanic or Latino,,55.9,3,Active_Drug,Standard,2025-08-21,Standard,Australia,SITE-001
PT-001025,XS-OD-0015,43,Male,White,Factor VIII intron 22 inv,61.3,4,Placebo,Standard,2026-01-20,Standard,Canada,SITE-008
PT-001026,XS-OD-0015,71,Male,Asian,,57.1,3,Active_Drug,Standard,2025-12-03,Standard,Canada,SITE-019
PT-001027,XS-OD-0015,26,Male,Hispanic or Latino,,43.3,2,Placebo,Standard,2025-12-27,Standard,United Kingdom,SITE-017
PT-001028,XS-OD-0015,2,Female,White,HBB E6V (sickle),57.0,1,Active_Drug,Standard,2025-11-04,Pediatric_Assent,Italy,SITE-017
PT-001029,XS-OD-0015,39,Female,White,Factor VIII intron 22 inv,33.1,1,Placebo,Standard,2025-08-06,Standard,France,SITE-010
PT-001030,XS-OD-0015,33,Male,Hispanic or Latino,HBB IVS-I-110 G>A,60.1,0,Active_Drug,Standard,2025-10-21,Standard,United Kingdom,SITE-010
PT-001031,XS-OD-0015,58,Male,Asian,,43.7,3,Placebo,Standard,2026-01-17,Standard,France,SITE-005
PT-001032,XS-OD-0015,13,Male,Hispanic or Latino,HBB E6V (sickle),56.5,2,Active_Drug,Standard,2025-10-24,Pediatric_Assent,United Kingdom,SITE-019
PT-001033,XS-OD-0015,63,Male,White,HBB IVS-I-110 G>A,58.9,2,Placebo,Standard,2025-12-26,Standard,United States,SITE-002
PT-001034,XS-OD-0015,38,Male,American Indian or Alaska Native,HBB E6V (sickle),53.2,3,Active_Drug,Standard,2025-10-09,Standard,Spain,SITE-011
PT-001035,XS-OD-0015,27,Female,Asian,HBB IVS-I-110 G>A,75.3,3,Placebo,Standard,2025-10-12,Standard,United States,SITE-009
PT-001036,XS-OD-0015,21,Male,Asian,Factor VIII intron 22 inv,16.7,0,Active_Drug,Standard,2025-09-25,Standard,Italy,SITE-011
PT-001037,XS-OD-0015,46,Male,Black or African American,F9 R338L,81.9,0,Placebo,Standard,2025-08-11,Standard,Italy,SITE-011
PT-001038,XS-OD-0015,33,Male,White,,78.7,2,Active_Drug,Standard,2025-09-26,Standard,Canada,SITE-012
PT-001039,XS-OD-0015,41,Male,Asian,HBB IVS-I-110 G>A,61.2,1,Placebo,Standard,2025-10-26,Compassionate,Australia,SITE-010
PT-001040,XS-OD-0015,22,Male,White,HBB E6V (sickle),70.5,1,Active_Drug,Standard,2025-11-19,Standard,Netherlands,SITE-012
PT-001041,XS-OD-0015,64,Male,American Indian or Alaska Native,,50.4,5,Placebo,Standard,2026-01-12,Standard,Australia,SITE-016
PT-001042,XS-OD-0015,68,Male,Asian,HBB E6V (sickle),65.2,1,Active_Drug,Standard,2025-10-15,Standard,Germany,SITE-015
PT-001043,XS-OD-0015,71,Male,Black or African American,HBB IVS-I-110 G>A,42.4,1,Placebo,Standard,2025-10-07,Standard,Germany,SITE-008
PT-001044,XS-OD-0015,31,Male,White,HBB E6V (sickle),36.0,2,Active_Drug,Standard,2025-08-30,Standard,Germany,SITE-010
PT-001045,XS-OD-0015,39,Male,White,HBB E6V (sickle),30.9,4,Placebo,Standard,2025-12-12,Standard,Netherlands,SITE-017
PT-001046,XS-OD-0015,34,Male,White,HBB IVS-I-110 G>A,56.8,1,Active_Drug,Standard,2025-11-29,Standard,Netherlands,SITE-014
PT-001047,XS-OD-0015,49,Male,White,,33.5,4,Placebo,Standard,2025-09-23,Standard,Italy,SITE-006
PT-001048,XS-OD-0015,22,Male,Hispanic or Latino,HBB IVS-I-110 G>A,74.7,5,Active_Drug,Standard,2025-09-04,Standard,Italy,SITE-019
PT-001049,XS-OD-0015,18,Male,Hispanic or Latino,F9 R338L,37.7,3,Placebo,Standard,2025-12-12,Standard,Spain,SITE-009
PT-001050,XS-OD-0015,72,Male,Asian,,77.5,5,Active_Drug,Standard,2025-12-04,Standard,Germany,SITE-003
PT-001051,XS-OD-0015,47,Male,Black or African American,F9 R338L,23.5,3,Placebo,Standard,2026-01-04,Standard,Italy,SITE-018
PT-001052,XS-OD-0015,57,Male,Black or African American,,64.8,1,Active_Drug,Standard,2026-01-21,Standard,United States,SITE-006
PT-001053,XS-OD-0015,36,Male,Black or African American,F9 R338L,65.5,3,Placebo,Standard,2025-12-12,Standard,Netherlands,SITE-007
PT-001054,XS-OD-0015,28,Male,White,,56.0,3,Active_Drug,Standard,2025-08-01,Standard,Netherlands,SITE-006
PT-001055,XS-OD-0015,78,Male,Black or African American,F9 R338L,82.8,2,Placebo,Standard,2025-08-06,Emergency,Spain,SITE-005
PT-001056,XS-OD-0015,3,Male,White,HBB IVS-I-110 G>A,86.5,2,Active_Drug,Standard,2025-11-08,Pediatric_Assent,France,SITE-009
PT-001057,XS-OD-0015,58,Male,Asian,HBB IVS-I-110 G>A,26.9,4,Placebo,Standard,2025-10-22,Standard,Spain,SITE-013
PT-001058,XS-OD-0015,32,Male,White,HBB E6V (sickle),45.9,5,Active_Drug,Standard,2025-11-19,Standard,United States,SITE-001
PT-001059,XS-OD-0015,40,Male,Hispanic or Latino,HBB E6V (sickle),68.8,0,Placebo,Standard,2025-11-21,Standard,France,SITE-018
PT-001060,XS-OD-0015,55,Male,White,F9 R338L,34.9,0,Active_Drug,Standard,2025-10-18,Standard,United Kingdom,SITE-013
PT-001061,XS-OD-0015,25,Male,White,,54.0,4,Placebo,Standard,2025-10-06,Standard,Germany,SITE-014
PT-001062,XS-OD-0015,29,Male,White,,50.4,4,Active_Drug,Standard,2025-10-23,Standard,Japan,SITE-001
PT-001063,XS-OD-0015,70,Male,White,Factor VIII intron 22 inv,43.5,2,Placebo,Standard,2026-01-14,Emergency,Germany,SITE-018
PT-001064,XS-OD-0015,40,Male,White,Factor VIII intron 22 inv,57.5,1,Active_Drug,Standard,2025-12-03,Standard,United Kingdom,SITE-017
PT-001065,XS-OD-0015,22,Male,Asian,F9 R338L,71.0,3,Placebo,Standard,2025-09-30,Standard,United Kingdom,SITE-005
PT-001066,XS-OD-0015,2,Male,American Indian or Alaska Native,HBB E6V (sickle),51.3,2,Active_Drug,Standard,2025-10-29,Pediatric_Assent,Italy,SITE-018
PT-001067,XS-OD-0015,26,Male,White,HBB E6V (sickle),40.2,2,Placebo,Standard,2025-10-21,Standard,United States,SITE-018
PT-001068,XS-OD-0015,45,Male,Hispanic or Latino,F9 R338L,63.1,3,Active_Drug,Standard,2026-01-01,Standard,Germany,SITE-014
PT-001069,XS-OD-0015,41,Male,White,F9 R338L,60.7,2,Placebo,Standard,2025-10-03,Standard,United States,SITE-008
PT-001070,XS-OD-0015,51,Male,White,,37.0,3,Active_Drug,Standard,2025-09-30,Standard,Germany,SITE-007
PT-001071,XS-OD-0015,37,Male,Hispanic or Latino,HBB IVS-I-110 G>A,65.0,1,Placebo,Standard,2025-08-30,Standard,Japan,SITE-013
PT-001072,XS-OD-0015,37,Male,White,F9 R338L,44.2,1,Active_Drug,Standard,2025-10-03,Standard,Spain,SITE-005
PT-001073,XS-OD-0015,33,Male,White,HBB E6V (sickle),79.1,0,Placebo,Standard,2025-12-22,Standard,Italy,SITE-009
PT-001074,XS-OD-0015,26,Male,Black or African American,HBB IVS-I-110 G>A,68.9,2,Active_Drug,Standard,2025-10-15,Standard,Canada,SITE-014
PT-001075,XS-OD-0015,42,Male,White,,53.4,4,Placebo,Standard,2026-01-23,Standard,Netherlands,SITE-013
PT-001076,XS-OD-0015,42,Male,White,,26.1,3,Active_Drug,Standard,2025-12-11,Standard,United States,SITE-004
PT-001077,XS-OD-0015,39,Male,White,,58.6,0,Placebo,Standard,2025-08-24,Standard,Italy,SITE-016
PT-001078,XS-OD-0015,41,Male,Hispanic or Latino,,43.3,1,Active_Drug,Standard,2025-12-08,Standard,United Kingdom,SITE-014
PT-001079,XS-OD-0015,78,Male,Hispanic or Latino,Factor VIII intron 22 inv,69.4,2,Placebo,Standard,2025-08-26,Standard,Germany,SITE-017
PT-001080,XS-OD-0015,42,Male,White,F9 R338L,44.6,2,Active_Drug,Standard,2025-12-21,Standard,Spain,SITE-011
PT-001081,XS-OD-0015,42,Male,White,F9 R338L,47.1,1,Placebo,Standard,2025-11-06,Standard,Australia,SITE-010
PT-001082,XS-OD-0015,59,Male,Two or More Races,HBB IVS-I-110 G>A,37.5,2,Active_Drug,Standard,2025-11-14,Standard,United Kingdom,SITE-013
PT-001083,XS-OD-0015,50,Male,White,,58.7,1,Placebo,Standard,2025-09-13,Standard,United States,SITE-005
PT-001084,XS-OD-0015,41,Male,White,,43.9,3,Active_Drug,Standard,2025-11-06,Standard,Australia,SITE-005
PT-001085,XS-OD-0015,53,Male,White,HBB E6V (sickle),40.5,3,Placebo,Standard,2025-11-17,Standard,United States,SITE-004
PT-001086,XS-OD-0015,35,Male,Black or African American,,52.7,3,Active_Drug,Standard,2025-08-20,Standard,France,SITE-011
PT-001087,XS-OD-0015,40,Female,White,,58.6,0,Placebo,Standard,2025-10-27,Standard,Australia,SITE-002
PT-001088,XS-OD-0015,69,Male,Asian,,56.3,1,Active_Drug,Standard,2025-07-31,Standard,Japan,SITE-008
PT-001089,XS-OD-0015,15,Male,White,Factor VIII intron 22 inv,28.5,3,Placebo,Standard,2025-10-30,Pediatric_Assent,Canada,SITE-009
PT-001090,XS-OD-0015,78,Male,Asian,,53.8,3,Active_Drug,Standard,2026-01-10,Standard,Japan,SITE-008
PT-001091,XS-OD-0015,43,Male,Hispanic or Latino,,69.8,2,Placebo,Standard,2025-10-15,Standard,United States,SITE-013
PT-001092,XS-OD-0015,38,Male,White,,70.6,2,Active_Drug,Standard,2026-01-22,Standard,Italy,SITE-019
PT-001093,XS-OD-0015,43,Female,White,Factor VIII intron 22 inv,56.2,2,Placebo,Standard,2026-01-18,Standard,Netherlands,SITE-006
PT-001094,XS-OD-0015,65,Male,White,,46.7,3,Active_Drug,Standard,2025-12-07,Standard,Netherlands,SITE-003
PT-001095,XS-OD-0015,27,Male,Asian,HBB E6V (sickle),41.3,2,Placebo,Standard,2025-11-08,Standard,Netherlands,SITE-018
PT-001096,XS-OD-0015,18,Male,White,HBB E6V (sickle),58.8,1,Active_Drug,Standard,2025-11-17,Emergency,Spain,SITE-015
PT-001097,XS-OD-0015,58,Female,Hispanic or Latino,,20.6,0,Placebo,Standard,2026-01-09,Standard,France,SITE-004
PT-001098,XS-OD-0015,58,Male,White,,48.0,2,Active_Drug,Standard,2026-01-22,Standard,France,SITE-007
PT-001099,XS-OD-0015,28,Male,White,Factor VIII intron 22 inv,57.6,1,Placebo,Standard,2026-01-17,Standard,Germany,SITE-018
PT-001100,XS-OD-0015,54,Male,White,,31.8,1,Active_Drug,Standard,2026-01-20,Standard,United Kingdom,SITE-002
PT-001101,XS-OD-0015,58,Male,White,HBB E6V (sickle),58.2,4,Placebo,Standard,2025-11-12,Standard,Japan,SITE-014
PT-001102,XS-OD-0015,49,Male,White,HBB E6V (sickle),64.6,4,Active_Drug,Standard,2025-11-19,Standard,Japan,SITE-001
PT-001103,XS-OD-0015,73,Male,White,,81.6,2,Placebo,Standard,2025-08-11,Standard,United Kingdom,SITE-001
PT-001104,XS-OD-0015,51,Male,White,Factor VIII intron 22 inv,54.9,2,Active_Drug,Standard,2025-09-02,Standard,Canada,SITE-009
PT-001105,XS-OD-0015,41,Female,White,Factor VIII intron 22 inv,53.6,2,Placebo,Standard,2025-11-30,Standard,Germany,SITE-017
PT-001106,XS-OD-0015,51,Male,Two or More Races,HBB IVS-I-110 G>A,58.1,1,Active_Drug,Standard,2025-12-06,Standard,United States,SITE-019
PT-001107,XS-OD-0015,30,Male,Black or African American,HBB IVS-I-110 G>A,16.8,2,Placebo,Standard,2025-10-17,Standard,Italy,SITE-017
PT-001108,XS-OD-0015,72,Female,Black or African American,HBB IVS-I-110 G>A,54.8,2,Active_Drug,Standard,2025-12-21,Standard,United Kingdom,SITE-016
PT-001109,XS-OD-0015,49,Male,White,F9 R338L,95.0,1,Placebo,Standard,2025-11-22,Standard,Spain,SITE-019
PT-001110,XS-OD-0015,28,Male,White,HBB E6V (sickle),34.6,1,Active_Drug,Standard,2025-10-04,Standard,Italy,SITE-014
PT-001111,XS-OD-0015,48,Female,White,F9 R338L,59.3,3,Placebo,Standard,2025-11-29,Standard,United States,SITE-001
PT-001112,XS-OD-0015,47,Male,Black or African American,F9 R338L,56.6,0,Active_Drug,Standard,2025-12-11,Standard,Germany,SITE-008
PT-001113,XS-OD-0015,62,Male,Hispanic or Latino,Factor VIII intron 22 inv,47.9,2,Placebo,Standard,2025-09-12,Standard,Germany,SITE-013
PT-001114,XS-OD-0015,34,Male,White,,31.3,0,Active_Drug,Standard,2025-09-17,Standard,United Kingdom,SITE-013
PT-001115,XS-OD-0015,8,Male,White,HBB IVS-I-110 G>A,57.0,2,Placebo,Standard,2025-11-26,Pediatric_Assent,Australia,SITE-017
PT-001116,XS-OD-0015,50,Female,White,HBB IVS-I-110 G>A,57.9,1,Active_Drug,Standard,2025-12-12,Standard,Netherlands,SITE-004
PT-001117,XS-OD-0015,72,Male,White,F9 R338L,61.4,1,Placebo,Standard,2026-01-08,Standard,Italy,SITE-001
PT-001118,XS-OD-0015,47,Male,Hispanic or Latino,HBB E6V (sickle),61.2,3,Active_Drug,Standard,2025-08-13,Standard,France,SITE-018
PT-001119,XS-OD-0015,58,Male,Asian,Factor VIII intron 22 inv,73.8,3,Placebo,Standard,2025-11-20,Emergency,Germany,SITE-019
PT-001120,XS-OD-0015,56,Male,White,,34.0,2,Active_Drug,Standard,2025-09-27,Standard,United States,SITE-010
PT-001121,XS-OD-0016,41,Female,White,BAP1 loss,22.0,3,Active_Drug,High,2020-11-01,Standard,Japan,SITE-001
PT-001122,XS-OD-0016,67,Female,Asian,PDGFRA D842V,37.0,4,Placebo,High,2020-11-26,Standard,Canada,SITE-005
PT-001123,XS-OD-0016,25,Male,Hispanic or Latino,IDH1 R132H,38.4,3,Active_Drug_High_Dose,Medium,2021-03-15,Standard,Brazil,SITE-003
PT-001124,XS-OD-0016,57,Female,Black or African American,PDGFRA D842V,74.8,0,Active_Drug,Low,2020-09-23,Standard,Germany,SITE-004
PT-001125,XS-OD-0016,36,Male,White,PDGFRA D842V,40.0,1,Placebo,Low,2020-12-21,Standard,Netherlands,SITE-005
PT-001126,XS-OD-0016,73,Female,Hispanic or Latino,BAP1 loss,65.9,1,Active_Drug_High_Dose,Low,2021-02-19,Standard,United Kingdom,SITE-005
PT-001127,XS-OD-0016,60,Male,White,KIT D816V,55.1,1,Active_Drug,Low,2021-01-07,Standard,Israel,SITE-004
PT-001128,XS-OD-0016,7,Male,Hispanic or Latino,PDGFRA D842V,71.9,4,Placebo,High,2020-10-21,Pediatric_Assent,Belgium,SITE-003
PT-001129,XS-OD-0016,43,Male,Asian,IDH1 R132H,77.5,2,Active_Drug_High_Dose,Low,2021-02-05,Standard,Austria,SITE-003
PT-001130,XS-OD-0016,57,Male,White,BAP1 loss,40.0,0,Active_Drug,Medium,2020-12-21,Standard,Belgium,SITE-003
PT-001131,XS-OD-0016,37,Male,White,KIT D816V,64.5,0,Placebo,High,2020-12-25,Standard,Canada,SITE-003
PT-001132,XS-OD-0016,36,Male,Black or African American,BAP1 loss,51.1,4,Active_Drug_High_Dose,Medium,2021-02-18,Standard,United States,SITE-003
PT-001133,XS-OD-0016,30,Male,Black or African American,KIT D816V,46.0,6,Active_Drug,Low,2021-01-24,Emergency,Norway,SITE-004
PT-001134,XS-OD-0016,43,Female,Black or African American,,79.2,3,Placebo,Low,2020-12-26,Standard,Japan,SITE-003
PT-001135,XS-OD-0016,29,Male,White,,66.0,1,Active_Drug_High_Dose,High,2020-10-20,Standard,Germany,SITE-003
PT-001136,XS-OD-0016,46,Female,Black or African American,,73.2,1,Active_Drug,Low,2020-10-04,Standard,Taiwan,SITE-002
PT-001137,XS-OD-0016,55,Female,White,,53.4,0,Placebo,Low,2020-10-31,Standard,Belgium,SITE-002
PT-001138,XS-OD-0016,40,Male,White,BAP1 loss,58.9,2,Active_Drug_High_Dose,Low,2020-10-06,Standard,Norway,SITE-005
PT-001139,XS-OD-0016,46,Female,White,PDGFRA D842V,58.6,0,Active_Drug,High,2021-01-10,Compassionate,Switzerland,SITE-001
PT-001140,XS-OD-0016,58,Male,White,,40.5,0,Placebo,Low,2021-02-21,Standard,Canada,SITE-005
PT-001141,XS-OD-0016,34,Male,Two or More Races,,57.7,0,Active_Drug_High_Dose,High,2021-03-12,Standard,Italy,SITE-004
PT-001142,XS-OD-0016,19,Male,White,,44.0,0,Active_Drug,Low,2021-01-25,Standard,United States,SITE-002
PT-001143,XS-OD-0017,29,Female,Asian,KIT D816V,48.5,1,Active_Drug,Standard,2020-05-17,Compassionate,United States,SITE-003
PT-001144,XS-OD-0017,50,Female,Hispanic or Latino,IDH1 R132H,59.9,3,Placebo,Standard,2020-04-30,Standard,Netherlands,SITE-006
PT-001145,XS-OD-0017,35,Female,White,,52.9,0,Active_Drug,Standard,2020-05-07,Standard,United States,SITE-011
PT-001146,XS-OD-0017,15,Female,White,IDH1 R132H,37.1,2,Placebo,Standard,2020-08-30,Pediatric_Assent,United States,SITE-004
PT-001147,XS-OD-0017,35,Female,Asian,,39.8,0,Active_Drug,Standard,2020-09-20,Standard,Germany,SITE-013
PT-001148,XS-OD-0017,69,Male,White,PDGFRA D842V,45.0,2,Placebo,Standard,2020-09-19,Standard,Australia,SITE-012
PT-001149,XS-OD-0017,41,Female,Asian,KIT D816V,48.6,1,Active_Drug,Standard,2020-05-13,Standard,Japan,SITE-009
PT-001150,XS-OD-0017,10,Male,White,BAP1 loss,70.5,2,Placebo,Standard,2020-05-14,Pediatric_Assent,Australia,SITE-011
PT-001151,XS-OD-0017,30,Female,White,IDH1 R132H,62.4,5,Active_Drug,Standard,2020-07-25,Standard,Germany,SITE-005
PT-001152,XS-OD-0017,43,Male,White,,49.0,2,Placebo,Standard,2020-05-26,Compassionate,Italy,SITE-003
PT-001153,XS-OD-0017,16,Female,White,,64.1,1,Active_Drug,Standard,2020-05-19,Pediatric_Assent,Australia,SITE-004
PT-001154,XS-OD-0017,33,Female,White,,61.5,4,Placebo,Standard,2020-07-27,Standard,Spain,SITE-006
PT-001155,XS-OD-0017,60,Male,Black or African American,PDGFRA D842V,49.2,4,Active_Drug,Standard,2020-09-30,Standard,France,SITE-004
PT-001156,XS-OD-0017,42,Female,White,KIT D816V,56.0,0,Placebo,Standard,2020-07-28,Standard,France,SITE-002
PT-001157,XS-OD-0017,10,Male,White,,38.8,2,Active_Drug,Standard,2020-07-08,Pediatric_Assent,France,SITE-003
PT-001158,XS-OD-0017,39,Female,White,BAP1 loss,51.2,5,Placebo,Standard,2020-07-10,Standard,Netherlands,SITE-004
PT-001159,XS-OD-0017,32,Female,Asian,BAP1 loss,32.9,3,Active_Drug,Standard,2020-04-13,Standard,Spain,SITE-005
PT-001160,XS-OD-0017,20,Female,White,PDGFRA D842V,82.7,1,Placebo,Standard,2020-10-05,Standard,France,SITE-011
PT-001161,XS-OD-0017,53,Male,White,BAP1 loss,76.9,4,Active_Drug,Standard,2020-06-09,Standard,Germany,SITE-002
PT-001162,XS-OD-0017,37,Male,Asian,,67.9,1,Placebo,Standard,2020-07-18,Standard,Netherlands,SITE-007
PT-001163,XS-OD-0017,34,Male,White,PDGFRA D842V,11.2,2,Active_Drug,Standard,2020-09-16,Standard,Germany,SITE-003
PT-001164,XS-OD-0017,32,Female,Asian,PDGFRA D842V,61.0,2,Placebo,Standard,2020-07-03,Standard,Japan,SITE-012
PT-001165,XS-OD-0017,22,Male,Black or African American,IDH1 R132H,49.9,0,Active_Drug,Standard,2020-07-20,Standard,United States,SITE-007
PT-001166,XS-OD-0017,17,Female,White,,44.2,1,Placebo,Standard,2020-08-13,Pediatric_Assent,Italy,SITE-009
PT-001167,XS-OD-0017,23,Male,White,BAP1 loss,23.1,2,Active_Drug,Standard,2020-09-19,Standard,Netherlands,SITE-003
PT-001168,XS-OD-0017,5,Female,Asian,KIT D816V,48.7,3,Placebo,Standard,2020-08-08,Pediatric_Assent,Canada,SITE-009
PT-001169,XS-OD-0017,65,Male,Black or African American,BAP1 loss,66.6,4,Active_Drug,Standard,2020-08-22,Standard,Australia,SITE-001
PT-001170,XS-OD-0017,42,Male,Asian,PDGFRA D842V,75.9,2,Placebo,Standard,2020-07-22,Standard,United States,SITE-001
PT-001171,XS-OD-0017,36,Male,Hispanic or Latino,IDH1 R132H,52.9,1,Active_Drug,Standard,2020-08-16,Standard,United Kingdom,SITE-001
PT-001172,XS-OD-0017,60,Female,Asian,,95.0,2,Placebo,Standard,2020-06-16,Standard,United States,SITE-011
PT-001173,XS-OD-0017,52,Female,White,,64.8,2,Active_Drug,Standard,2020-07-21,Emergency,United States,SITE-003
PT-001174,XS-OD-0017,13,Male,White,IDH1 R132H,44.1,2,Placebo,Standard,2020-07-23,Pediatric_Assent,Canada,SITE-002
PT-001175,XS-OD-0017,65,Male,White,IDH1 R132H,44.2,4,Active_Drug,Standard,2020-05-06,Standard,France,SITE-003
PT-001176,XS-OD-0017,31,Male,Asian,BAP1 loss,33.9,2,Placebo,Standard,2020-08-17,Emergency,Canada,SITE-012
PT-001177,XS-OD-0017,78,Female,Hispanic or Latino,PDGFRA D842V,74.8,5,Active_Drug,Standard,2020-07-02,Standard,Japan,SITE-002
PT-001178,XS-OD-0017,39,Female,Hispanic or Latino,BAP1 loss,53.3,0,Placebo,Standard,2020-08-05,Standard,France,SITE-003
PT-001179,XS-OD-0017,8,Male,White,,95.0,2,Active_Drug,Standard,2020-10-01,Pediatric_Assent,United States,SITE-002
PT-001180,XS-OD-0017,40,Female,Hispanic or Latino,KIT D816V,30.7,2,Placebo,Standard,2020-05-13,Emergency,United States,SITE-012
PT-001181,XS-OD-0017,3,Male,White,IDH1 R132H,63.3,1,Active_Drug,Standard,2020-09-24,Pediatric_Assent,Australia,SITE-013
PT-001182,XS-OD-0017,50,Male,Hispanic or Latino,,39.5,1,Placebo,Standard,2020-08-13,Standard,Japan,SITE-012
PT-001183,XS-OD-0017,65,Female,Black or African American,PDGFRA D842V,74.2,0,Active_Drug,Standard,2020-07-16,Standard,Italy,SITE-005
PT-001184,XS-OD-0017,39,Male,White,,62.1,1,Placebo,Standard,2020-08-01,Standard,United States,SITE-003
PT-001185,XS-OD-0017,51,Male,American Indian or Alaska Native,PDGFRA D842V,38.8,3,Active_Drug,Standard,2020-07-18,Standard,France,SITE-011
PT-001186,XS-OD-0017,47,Female,White,BAP1 loss,58.4,1,Placebo,Standard,2020-04-30,Standard,Japan,SITE-001
PT-001187,XS-OD-0017,33,Female,Two or More Races,,71.1,2,Active_Drug,Standard,2020-07-16,Standard,United Kingdom,SITE-013
PT-001188,XS-OD-0017,51,Male,White,,52.2,3,Placebo,Standard,2020-09-11,Standard,Netherlands,SITE-012
PT-001189,XS-OD-0017,57,Female,Black or African American,,65.1,3,Active_Drug,Standard,2020-05-17,Standard,Spain,SITE-001
PT-001190,XS-OD-0017,42,Male,White,BAP1 loss,51.8,1,Placebo,Standard,2020-04-21,Standard,Spain,SITE-002
PT-001191,XS-OD-0017,37,Female,Hispanic or Latino,PDGFRA D842V,80.1,1,Active_Drug,Standard,2020-09-24,Standard,Germany,SITE-007
PT-001192,XS-OD-0017,59,Female,White,,27.3,4,Placebo,Standard,2020-04-22,Standard,Japan,SITE-013
PT-001193,XS-OD-0017,16,Female,White,,41.6,6,Active_Drug,Standard,2020-04-26,Pediatric_Assent,Italy,SITE-007
PT-001194,XS-OD-0017,45,Male,Asian,,53.2,1,Placebo,Standard,2020-05-04,Standard,United Kingdom,SITE-013
PT-001195,XS-OD-0017,51,Female,White,IDH1 R132H,23.6,2,Active_Drug,Standard,2020-09-23,Standard,Italy,SITE-005
PT-001196,XS-OD-0017,33,Male,White,PDGFRA D842V,50.6,4,Placebo,Standard,2020-09-04,Standard,Italy,SITE-006
PT-001197,XS-OD-0017,49,Male,White,IDH1 R132H,46.0,2,Active_Drug,Standard,2020-09-10,Standard,United States,SITE-006
PT-001198,XS-OD-0017,60,Male,White,,43.4,3,Placebo,Standard,2020-09-25,Standard,Spain,SITE-004
PT-001199,XS-OD-0017,61,Male,White,BAP1 loss,59.6,4,Active_Drug,Standard,2020-08-18,Standard,Japan,SITE-012
PT-001200,XS-OD-0017,31,Male,Asian,PDGFRA D842V,56.2,2,Placebo,Standard,2020-07-21,Standard,France,SITE-010
PT-001201,XS-OD-0017,29,Female,White,,69.1,1,Active_Drug,Standard,2020-10-05,Standard,Germany,SITE-003
PT-001202,XS-OD-0017,33,Female,Black or African American,KIT D816V,56.7,1,Placebo,Standard,2020-05-23,Standard,Australia,SITE-011
PT-001203,XS-OD-0017,30,Male,American Indian or Alaska Native,KIT D816V,61.3,1,Active_Drug,Standard,2020-07-21,Standard,United States,SITE-008
PT-001204,XS-OD-0017,22,Female,White,PDGFRA D842V,55.0,1,Placebo,Standard,2020-06-25,Standard,United Kingdom,SITE-011
PT-001205,XS-OD-0017,47,Male,White,KIT D816V,58.5,1,Active_Drug,Standard,2020-08-20,Compassionate,United Kingdom,SITE-008
PT-001206,XS-OD-0017,32,Female,Asian,KIT D816V,67.5,5,Placebo,Standard,2020-04-21,Standard,Japan,SITE-009
PT-001207,XS-OD-0017,59,Male,White,KIT D816V,24.7,1,Active_Drug,Standard,2020-05-02,Standard,Spain,SITE-006
PT-001208,XS-OD-0017,36,Male,White,,48.3,3,Placebo,Standard,2020-06-03,Standard,Netherlands,SITE-005
PT-001209,XS-OD-0017,76,Female,White,IDH1 R132H,77.7,0,Active_Drug,Standard,2020-04-20,Standard,Spain,SITE-005
PT-001210,XS-OD-0017,23,Male,White,IDH1 R132H,60.6,1,Placebo,Standard,2020-09-01,Standard,Netherlands,SITE-005
PT-001211,XS-OD-0017,47,Male,Two or More Races,PDGFRA D842V,50.3,4,Active_Drug,Standard,2020-06-14,Standard,Germany,SITE-010
PT-001212,XS-OD-0017,35,Female,Black or African American,,38.1,3,Placebo,Standard,2020-07-28,Standard,Japan,SITE-003
PT-001213,XS-OD-0017,42,Female,Black or African American,KIT D816V,46.3,1,Active_Drug,Standard,2020-06-22,Standard,France,SITE-002
PT-001214,XS-OD-0017,42,Male,White,,69.5,1,Placebo,Standard,2020-08-09,Standard,United Kingdom,SITE-005
PT-001215,XS-OD-0017,53,Female,White,PDGFRA D842V,62.7,1,Active_Drug,Standard,2020-04-26,Standard,Germany,SITE-007
PT-001216,XS-OD-0017,65,Male,Hispanic or Latino,,56.9,2,Placebo,Standard,2020-08-05,Emergency,Netherlands,SITE-006
PT-001217,XS-OD-0017,2,Female,White,BAP1 loss,65.1,1,Active_Drug,Standard,2020-08-29,Pediatric_Assent,Germany,SITE-011
PT-001218,XS-OD-0017,33,Male,White,,60.0,3,Placebo,Standard,2020-10-05,Standard,Germany,SITE-002
PT-001219,XS-OD-0017,6,Female,Hispanic or Latino,PDGFRA D842V,63.4,5,Active_Drug,Standard,2020-07-08,Pediatric_Assent,Netherlands,SITE-002
PT-001220,XS-OD-0017,56,Male,Hispanic or Latino,KIT D816V,20.7,2,Placebo,Standard,2020-06-04,Standard,Japan,SITE-011
PT-001221,XS-OD-0017,44,Male,White,,38.3,1,Active_Drug,Standard,2020-08-04,Standard,Spain,SITE-009
PT-001222,XS-OD-0017,49,Male,Native Hawaiian or Other Pacific Islander,,56.5,2,Placebo,Standard,2020-09-04,Standard,Spain,SITE-006
PT-001223,XS-OD-0017,48,Male,Hispanic or Latino,KIT D816V,50.6,2,Active_Drug,Standard,2020-07-10,Standard,Japan,SITE-013
PT-001224,XS-OD-0017,62,Male,White,KIT D816V,70.0,6,Placebo,Standard,2020-10-02,Standard,Netherlands,SITE-003
PT-001225,XS-OD-0017,26,Male,White,BAP1 loss,45.9,5,Active_Drug,Standard,2020-06-19,Compassionate,France,SITE-003
PT-001226,XS-OD-0017,42,Female,White,,42.5,1,Placebo,Standard,2020-05-11,Standard,Netherlands,SITE-007
PT-001227,XS-OD-0017,50,Male,Asian,,46.5,0,Active_Drug,Standard,2020-06-30,Standard,United States,SITE-011
PT-001228,XS-OD-0017,45,Male,Hispanic or Latino,,65.2,2,Placebo,Standard,2020-09-16,Standard,United Kingdom,SITE-002
PT-001229,XS-OD-0017,54,Female,White,KIT D816V,31.9,1,Active_Drug,Standard,2020-07-08,Standard,Japan,SITE-011
PT-001230,XS-OD-0017,35,Male,White,,19.3,0,Placebo,Standard,2020-09-12,Standard,United States,SITE-013
PT-001231,XS-OD-0017,79,Female,White,,61.1,2,Active_Drug,Standard,2020-05-09,Standard,Japan,SITE-009
PT-001232,XS-OD-0017,20,Female,Hispanic or Latino,,44.1,1,Placebo,Standard,2020-04-25,Emergency,Australia,SITE-002
PT-001233,XS-OD-0017,22,Male,White,,70.3,0,Active_Drug,Standard,2020-10-01,Standard,Japan,SITE-009
PT-001234,XS-OD-0017,29,Female,White,,50.8,2,Placebo,Standard,2020-06-21,Standard,Spain,SITE-004
PT-001235,XS-OD-0017,42,Female,Hispanic or Latino,KIT D816V,46.7,2,Active_Drug,Standard,2020-10-02,Standard,United States,SITE-008
PT-001236,XS-OD-0017,32,Female,Hispanic or Latino,KIT D816V,54.5,3,Placebo,Standard,2020-07-06,Standard,France,SITE-013
PT-001237,XS-OD-0017,40,Female,White,,95.0,2,Active_Drug,Standard,2020-07-08,Standard,Italy,SITE-007
PT-001238,XS-OD-0018,40,Male,White,,54.2,4,Active_Drug,Standard,2024-10-04,Compassionate,Canada,SITE-023
PT-001239,XS-OD-0018,5,Female,Asian,BAP1 loss,45.6,0,Placebo,Standard,2024-06-16,Pediatric_Assent,Spain,SITE-021
PT-001240,XS-OD-0018,19,Female,White,,53.3,4,Active_Drug,Standard,2024-09-06,Compassionate,Canada,SITE-022
PT-001241,XS-OD-0018,12,Male,White,PDGFRA D842V,69.9,2,Placebo,Standard,2024-04-22,Pediatric_Assent,Canada,SITE-019
PT-001242,XS-OD-0018,23,Female,Hispanic or Latino,KIT D816V,58.9,2,Active_Drug,Standard,2024-07-25,Standard,United States,SITE-013
PT-001243,XS-OD-0018,43,Male,White,BAP1 loss,43.8,0,Placebo,Standard,2024-09-02,Standard,France,SITE-029
PT-001244,XS-OD-0018,26,Male,White,,43.3,1,Active_Drug,Standard,2024-06-16,Standard,Canada,SITE-029
PT-001245,XS-OD-0018,49,Male,White,IDH1 R132H,77.7,2,Placebo,Standard,2024-07-24,Standard,Germany,SITE-015
PT-001246,XS-OD-0018,36,Female,White,IDH1 R132H,41.7,1,Active_Drug,Standard,2024-06-06,Standard,United States,SITE-002
PT-001247,XS-OD-0018,66,Male,Hispanic or Latino,BAP1 loss,60.6,2,Placebo,Standard,2024-08-05,Standard,United States,SITE-024
PT-001248,XS-OD-0018,48,Female,White,,42.7,5,Active_Drug,Standard,2024-05-02,Standard,Australia,SITE-021
PT-001249,XS-OD-0018,48,Male,White,BAP1 loss,74.7,3,Placebo,Standard,2024-09-28,Standard,United Kingdom,SITE-021
PT-001250,XS-OD-0018,76,Male,White,KIT D816V,83.5,1,Active_Drug,Standard,2024-04-23,Standard,Spain,SITE-012
PT-001251,XS-OD-0018,38,Female,White,KIT D816V,76.5,2,Placebo,Standard,2024-10-08,Standard,Germany,SITE-006
PT-001252,XS-OD-0018,38,Male,Asian,,95.0,1,Active_Drug,Standard,2024-05-04,Standard,France,SITE-008
PT-001253,XS-OD-0018,48,Male,Asian,,84.9,2,Placebo,Standard,2024-08-13,Standard,United States,SITE-033
PT-001254,XS-OD-0018,53,Female,Black or African American,,52.8,3,Active_Drug,Standard,2024-06-29,Standard,United Kingdom,SITE-031
PT-001255,XS-OD-0018,43,Female,White,PDGFRA D842V,43.8,1,Placebo,Standard,2024-07-15,Standard,Spain,SITE-017
PT-001256,XS-OD-0018,34,Female,Hispanic or Latino,IDH1 R132H,46.3,2,Active_Drug,Standard,2024-04-15,Standard,France,SITE-019
PT-001257,XS-OD-0018,37,Male,White,PDGFRA D842V,44.6,2,Placebo,Standard,2024-08-26,Standard,Australia,SITE-020
PT-001258,XS-OD-0018,50,Male,Black or African American,IDH1 R132H,76.1,0,Active_Drug,Standard,2024-09-25,Standard,United Kingdom,SITE-021
PT-001259,XS-OD-0018,28,Male,Asian,,55.2,2,Placebo,Standard,2024-04-19,Compassionate,United States,SITE-015
PT-001260,XS-OD-0018,72,Male,White,IDH1 R132H,31.2,1,Active_Drug,Standard,2024-07-04,Standard,United Kingdom,SITE-010
PT-001261,XS-OD-0018,31,Male,Asian,PDGFRA D842V,68.9,1,Placebo,Standard,2024-08-27,Standard,France,SITE-029
PT-001262,XS-OD-0018,34,Male,Hispanic or Latino,IDH1 R132H,35.9,4,Active_Drug,Standard,2024-07-22,Standard,United States,SITE-027
PT-001263,XS-OD-0018,11,Female,White,,67.3,5,Placebo,Standard,2024-06-22,Pediatric_Assent,France,SITE-014
PT-001264,XS-OD-0018,29,Female,White,IDH1 R132H,38.3,3,Active_Drug,Standard,2024-06-21,Standard,Spain,SITE-016
PT-001265,XS-OD-0018,36,Female,White,,28.3,2,Placebo,Standard,2024-04-29,Standard,Germany,SITE-034
PT-001266,XS-OD-0018,81,Female,White,KIT D816V,41.9,4,Active_Drug,Standard,2024-06-20,Standard,Canada,SITE-029
PT-001267,XS-OD-0018,53,Male,Asian,IDH1 R132H,69.2,3,Placebo,Standard,2024-07-24,Standard,United Kingdom,SITE-022
PT-001268,XS-OD-0018,53,Male,American Indian or Alaska Native,,75.6,0,Active_Drug,Standard,2024-05-10,Standard,France,SITE-005
PT-001269,XS-OD-0018,55,Male,Asian,KIT D816V,59.2,1,Placebo,Standard,2024-09-23,Standard,Germany,SITE-026
PT-001270,XS-OD-0018,49,Female,White,,80.9,2,Active_Drug,Standard,2024-06-17,Standard,Japan,SITE-002
PT-001271,XS-OD-0018,55,Male,Black or African American,PDGFRA D842V,41.2,1,Placebo,Standard,2024-06-06,Standard,Italy,SITE-031
PT-001272,XS-OD-0018,61,Female,White,IDH1 R132H,73.8,2,Active_Drug,Standard,2024-07-25,Standard,Japan,SITE-012
PT-001273,XS-OD-0018,31,Female,White,IDH1 R132H,38.6,0,Placebo,Standard,2024-05-20,Standard,Netherlands,SITE-006
PT-001274,XS-OD-0018,34,Female,Native Hawaiian or Other Pacific Islander,PDGFRA D842V,42.3,1,Active_Drug,Standard,2024-06-25,Standard,France,SITE-017
PT-001275,XS-OD-0018,58,Female,White,,62.2,1,Placebo,Standard,2024-07-06,Standard,Italy,SITE-022
PT-001276,XS-OD-0018,41,Female,Asian,,60.5,1,Active_Drug,Standard,2024-07-26,Standard,Australia,SITE-001
PT-001277,XS-OD-0018,56,Male,White,BAP1 loss,64.1,2,Placebo,Standard,2024-09-11,Standard,France,SITE-013
PT-001278,XS-OD-0018,34,Male,White,,82.6,1,Active_Drug,Standard,2024-06-07,Standard,United Kingdom,SITE-011
PT-001279,XS-OD-0018,78,Female,White,BAP1 loss,39.0,2,Placebo,Standard,2024-08-07,Standard,Australia,SITE-013
PT-001280,XS-OD-0018,43,Female,Asian,PDGFRA D842V,52.2,2,Active_Drug,Standard,2024-10-06,Standard,United Kingdom,SITE-002
PT-001281,XS-OD-0018,22,Male,White,,79.2,0,Placebo,Standard,2024-07-09,Standard,Netherlands,SITE-006
PT-001282,XS-OD-0018,12,Male,White,KIT D816V,53.4,2,Active_Drug,Standard,2024-06-28,Pediatric_Assent,Netherlands,SITE-013
PT-001283,XS-OD-0018,47,Female,White,BAP1 loss,66.1,2,Placebo,Standard,2024-06-22,Standard,Germany,SITE-033
PT-001284,XS-OD-0018,41,Female,Black or African American,,28.1,2,Active_Drug,Standard,2024-08-10,Standard,France,SITE-031
PT-001285,XS-OD-0018,38,Male,Black or African American,IDH1 R132H,65.9,6,Placebo,Standard,2024-07-27,Standard,United Kingdom,SITE-017
PT-001286,XS-OD-0018,56,Male,White,BAP1 loss,55.7,2,Active_Drug,Standard,2024-07-20,Standard,France,SITE-010
PT-001287,XS-OD-0018,40,Male,White,BAP1 loss,65.6,2,Placebo,Standard,2024-09-05,Standard,United States,SITE-007
PT-001288,XS-OD-0018,32,Male,White,IDH1 R132H,57.6,0,Active_Drug,Standard,2024-08-13,Standard,France,SITE-018
PT-001289,XS-OD-0018,33,Male,White,,55.4,2,Placebo,Standard,2024-08-27,Standard,Netherlands,SITE-031
PT-001290,XS-OD-0018,67,Male,White,,30.8,1,Active_Drug,Standard,2024-05-08,Standard,France,SITE-008
PT-001291,XS-OD-0018,48,Female,Hispanic or Latino,KIT D816V,94.1,3,Placebo,Standard,2024-08-20,Standard,Spain,SITE-007
PT-001292,XS-OD-0018,55,Female,Black or African American,,43.8,2,Active_Drug,Standard,2024-05-03,Standard,United States,SITE-021
PT-001293,XS-OD-0018,18,Female,White,,72.9,2,Placebo,Standard,2024-06-05,Standard,Netherlands,SITE-012
PT-001294,XS-OD-0018,31,Male,White,KIT D816V,76.9,4,Active_Drug,Standard,2024-10-02,Standard,Netherlands,SITE-018
PT-001295,XS-OD-0018,39,Male,White,KIT D816V,64.5,1,Placebo,Standard,2024-10-02,Standard,Germany,SITE-029
PT-001296,XS-OD-0018,42,Male,White,KIT D816V,57.7,2,Active_Drug,Standard,2024-09-30,Standard,United States,SITE-009
PT-001297,XS-OD-0018,39,Male,White,BAP1 loss,73.9,1,Placebo,Standard,2024-08-20,Standard,United Kingdom,SITE-032
PT-001298,XS-OD-0018,26,Male,White,,41.8,0,Active_Drug,Standard,2024-07-29,Standard,France,SITE-016
PT-001299,XS-OD-0018,31,Female,Black or African American,BAP1 loss,75.7,1,Placebo,Standard,2024-07-28,Standard,United States,SITE-028
PT-001300,XS-OD-0018,27,Male,Asian,,77.8,2,Active_Drug,Standard,2024-07-09,Standard,Spain,SITE-032
PT-001301,XS-OD-0018,37,Male,Black or African American,PDGFRA D842V,85.6,0,Placebo,Standard,2024-09-29,Standard,United Kingdom,SITE-016
PT-001302,XS-OD-0018,60,Male,White,,56.0,1,Active_Drug,Standard,2024-07-21,Emergency,France,SITE-033
PT-001303,XS-OD-0018,36,Female,White,,38.4,0,Placebo,Standard,2024-05-01,Compassionate,Italy,SITE-024
PT-001304,XS-OD-0018,54,Female,White,IDH1 R132H,53.3,0,Active_Drug,Standard,2024-09-26,Standard,United States,SITE-003
PT-001305,XS-OD-0018,34,Female,Black or African American,BAP1 loss,42.4,5,Placebo,Standard,2024-05-31,Standard,United Kingdom,SITE-033
PT-001306,XS-OD-0018,35,Male,White,KIT D816V,50.5,1,Active_Drug,Standard,2024-09-14,Standard,France,SITE-019
PT-001307,XS-OD-0018,7,Female,White,IDH1 R132H,64.4,3,Placebo,Standard,2024-06-26,Pediatric_Assent,Germany,SITE-028
PT-001308,XS-OD-0018,46,Female,White,IDH1 R132H,66.7,3,Active_Drug,Standard,2024-05-20,Standard,Japan,SITE-010
PT-001309,XS-OD-0018,40,Male,Hispanic or Latino,BAP1 loss,66.2,1,Placebo,Standard,2024-08-23,Standard,United Kingdom,SITE-025
PT-001310,XS-OD-0018,69,Female,White,PDGFRA D842V,56.1,1,Active_Drug,Standard,2024-06-05,Standard,Japan,SITE-007
PT-001311,XS-OD-0018,45,Male,White,IDH1 R132H,74.0,0,Placebo,Standard,2024-07-02,Standard,Japan,SITE-017
PT-001312,XS-OD-0018,2,Male,White,IDH1 R132H,95.0,1,Active_Drug,Standard,2024-08-15,Pediatric_Assent,Italy,SITE-017
PT-001313,XS-OD-0018,57,Female,Hispanic or Latino,,31.2,3,Placebo,Standard,2024-06-09,Standard,Italy,SITE-011
PT-001314,XS-OD-0018,55,Male,Hispanic or Latino,KIT D816V,42.4,3,Active_Drug,Standard,2024-09-14,Standard,United States,SITE-018
PT-001315,XS-OD-0018,2,Female,Black or African American,IDH1 R132H,50.8,6,Placebo,Standard,2024-06-11,Pediatric_Assent,Japan,SITE-006
PT-001316,XS-OD-0018,3,Female,White,KIT D816V,70.1,3,Active_Drug,Standard,2024-09-12,Pediatric_Assent,Italy,SITE-030
PT-001317,XS-OD-0018,32,Male,White,,71.8,5,Placebo,Standard,2024-10-04,Standard,United States,SITE-019
PT-001318,XS-OD-0018,24,Male,White,BAP1 loss,71.0,3,Active_Drug,Standard,2024-07-07,Standard,Germany,SITE-027
PT-001319,XS-OD-0018,29,Male,Hispanic or Latino,,91.6,4,Placebo,Standard,2024-09-26,Standard,Australia,SITE-019
PT-001320,XS-OD-0018,59,Male,White,,68.1,3,Active_Drug,Standard,2024-06-26,Standard,United Kingdom,SITE-018
PT-001321,XS-OD-0018,32,Male,Black or African American,,87.2,3,Placebo,Standard,2024-08-10,Standard,United States,SITE-019
PT-001322,XS-OD-0018,31,Female,White,IDH1 R132H,79.3,3,Active_Drug,Standard,2024-08-16,Standard,Australia,SITE-023
PT-001323,XS-OD-0018,53,Female,White,BAP1 loss,59.1,4,Placebo,Standard,2024-05-13,Standard,Australia,SITE-013
PT-001324,XS-OD-0018,47,Male,White,KIT D816V,79.1,1,Active_Drug,Standard,2024-04-22,Standard,Australia,SITE-006
PT-001325,XS-OD-0018,42,Female,White,KIT D816V,55.1,2,Placebo,Standard,2024-06-10,Standard,France,SITE-001
PT-001326,XS-OD-0018,16,Male,White,IDH1 R132H,53.2,3,Active_Drug,Standard,2024-04-30,Pediatric_Assent,United States,SITE-004
PT-001327,XS-OD-0018,37,Female,White,IDH1 R132H,56.5,3,Placebo,Standard,2024-07-01,Standard,United States,SITE-021
PT-001328,XS-OD-0018,2,Female,White,,37.6,1,Active_Drug,Standard,2024-09-09,Pediatric_Assent,Netherlands,SITE-025
PT-001329,XS-OD-0018,54,Female,White,KIT D816V,56.1,4,Placebo,Standard,2024-07-21,Standard,France,SITE-019
PT-001330,XS-OD-0018,37,Female,White,,55.0,4,Active_Drug,Standard,2024-06-03,Standard,France,SITE-025
PT-001331,XS-OD-0018,37,Female,Asian,,51.8,2,Placebo,Standard,2024-08-07,Standard,Spain,SITE-026
PT-001332,XS-OD-0018,28,Female,White,KIT D816V,50.7,3,Active_Drug,Standard,2024-05-23,Standard,France,SITE-029
PT-001333,XS-OD-0018,48,Female,White,,35.6,3,Placebo,Standard,2024-05-09,Standard,Australia,SITE-014
PT-001334,XS-OD-0018,11,Male,Asian,IDH1 R132H,95.0,1,Active_Drug,Standard,2024-04-29,Pediatric_Assent,Canada,SITE-009
PT-001335,XS-OD-0018,46,Male,Black or African American,IDH1 R132H,47.8,3,Placebo,Standard,2024-06-02,Standard,Japan,SITE-019
PT-001336,XS-OD-0018,64,Female,Hispanic or Latino,KIT D816V,83.0,3,Active_Drug,Standard,2024-04-26,Standard,Spain,SITE-001
PT-001337,XS-OD-0018,43,Male,Hispanic or Latino,PDGFRA D842V,26.8,2,Placebo,Standard,2024-09-08,Emergency,United Kingdom,SITE-007
PT-001338,XS-OD-0018,31,Male,White,KIT D816V,19.5,3,Active_Drug,Standard,2024-09-03,Standard,United Kingdom,SITE-002
PT-001339,XS-OD-0018,32,Female,Hispanic or Latino,,34.8,2,Placebo,Standard,2024-06-30,Standard,Spain,SITE-025
PT-001340,XS-OD-0018,65,Male,White,IDH1 R132H,60.9,1,Active_Drug,Standard,2024-09-19,Standard,Netherlands,SITE-011
PT-001341,XS-OD-0018,17,Male,White,,69.8,3,Placebo,Standard,2024-09-06,Pediatric_Assent,Canada,SITE-016
PT-001342,XS-OD-0018,39,Male,White,BAP1 loss,59.7,0,Active_Drug,Standard,2024-08-29,Standard,Italy,SITE-031
PT-001343,XS-OD-0018,50,Male,White,BAP1 loss,45.7,0,Placebo,Standard,2024-05-04,Standard,France,SITE-019
PT-001344,XS-OD-0018,22,Female,White,BAP1 loss,63.2,1,Active_Drug,Standard,2024-09-25,Standard,Italy,SITE-005
PT-001345,XS-OD-0018,61,Male,Hispanic or Latino,,56.3,1,Placebo,Standard,2024-09-24,Standard,Japan,SITE-032
PT-001346,XS-OD-0018,37,Male,White,KIT D816V,54.2,1,Active_Drug,Standard,2024-04-16,Standard,Netherlands,SITE-007
PT-001347,XS-OD-0018,63,Female,White,PDGFRA D842V,16.3,4,Placebo,Standard,2024-05-20,Standard,France,SITE-005
PT-001348,XS-OD-0018,57,Male,Hispanic or Latino,PDGFRA D842V,47.6,1,Active_Drug,Standard,2024-05-12,Standard,Australia,SITE-015
PT-001349,XS-OD-0018,13,Male,White,BAP1 loss,26.4,1,Placebo,Standard,2024-07-23,Pediatric_Assent,Germany,SITE-013
PT-001350,XS-OD-0018,39,Male,White,IDH1 R132H,50.5,2,Active_Drug,Standard,2024-09-17,Standard,Netherlands,SITE-020
PT-001351,XS-OD-0018,37,Female,White,PDGFRA D842V,10.0,0,Placebo,Standard,2024-09-17,Standard,France,SITE-032
PT-001352,XS-OD-0018,22,Male,Hispanic or Latino,,53.4,1,Active_Drug,Standard,2024-10-07,Standard,Germany,SITE-015
PT-001353,XS-OD-0018,43,Male,Hispanic or Latino,BAP1 loss,85.2,2,Placebo,Standard,2024-05-12,Standard,Spain,SITE-032
PT-001354,XS-OD-0018,15,Female,White,,67.9,1,Active_Drug,Standard,2024-07-25,Pediatric_Assent,Australia,SITE-028
PT-001355,XS-OD-0018,34,Female,Black or African American,IDH1 R132H,77.7,2,Placebo,Standard,2024-07-08,Standard,United States,SITE-019
PT-001356,XS-OD-0018,49,Male,Two or More Races,KIT D816V,39.4,4,Active_Drug,Standard,2024-05-04,Standard,Australia,SITE-032
PT-001357,XS-OD-0018,31,Female,White,PDGFRA D842V,42.1,3,Placebo,Standard,2024-06-20,Standard,Netherlands,SITE-028
PT-001358,XS-OD-0018,47,Female,Black or African American,,34.0,1,Active_Drug,Standard,2024-07-16,Standard,Canada,SITE-005
PT-001359,XS-OD-0018,27,Female,Black or African American,,76.4,2,Placebo,Standard,2024-04-17,Standard,Japan,SITE-026
PT-001360,XS-OD-0018,49,Female,White,BAP1 loss,54.6,3,Active_Drug,Standard,2024-09-07,Standard,Spain,SITE-018
PT-001361,XS-OD-0018,53,Male,Black or African American,IDH1 R132H,33.7,2,Placebo,Standard,2024-09-08,Standard,Netherlands,SITE-019
PT-001362,XS-OD-0018,4,Male,White,,68.1,0,Active_Drug,Standard,2024-07-29,Pediatric_Assent,Germany,SITE-017
PT-001363,XS-OD-0018,30,Male,White,IDH1 R132H,42.1,3,Placebo,Standard,2024-09-19,Standard,Netherlands,SITE-004
PT-001364,XS-OD-0018,3,Female,White,BAP1 loss,49.7,1,Active_Drug,Standard,2024-05-05,Pediatric_Assent,Germany,SITE-017
PT-001365,XS-OD-0018,36,Male,Hispanic or Latino,IDH1 R132H,66.4,2,Placebo,Standard,2024-07-29,Standard,United Kingdom,SITE-018
PT-001366,XS-OD-0018,25,Male,White,PDGFRA D842V,69.5,1,Active_Drug,Standard,2024-07-20,Standard,Spain,SITE-022
PT-001367,XS-OD-0018,44,Male,White,,50.0,1,Placebo,Standard,2024-06-10,Standard,Netherlands,SITE-031
PT-001368,XS-OD-0018,34,Female,White,PDGFRA D842V,56.1,0,Active_Drug,Standard,2024-09-23,Standard,United Kingdom,SITE-013
PT-001369,XS-OD-0018,25,Male,Black or African American,IDH1 R132H,57.5,4,Placebo,Standard,2024-08-14,Standard,Germany,SITE-029
PT-001370,XS-OD-0018,43,Male,Hispanic or Latino,IDH1 R132H,64.0,2,Active_Drug,Standard,2024-07-10,Standard,Germany,SITE-007
PT-001371,XS-OD-0018,45,Intersex,White,,62.8,1,Placebo,Standard,2024-04-16,Standard,United States,SITE-030
PT-001372,XS-OD-0018,68,Male,Hispanic or Latino,,52.6,4,Active_Drug,Standard,2024-04-26,Standard,Japan,SITE-019
PT-001373,XS-OD-0018,16,Female,White,,43.3,0,Placebo,Standard,2024-04-30,Pediatric_Assent,Canada,SITE-002
PT-001374,XS-OD-0018,56,Male,White,KIT D816V,65.1,4,Active_Drug,Standard,2024-10-08,Standard,Germany,SITE-001
PT-001375,XS-OD-0018,60,Female,American Indian or Alaska Native,PDGFRA D842V,37.2,0,Placebo,Standard,2024-09-05,Standard,Italy,SITE-014
PT-001376,XS-OD-0018,50,Female,Hispanic or Latino,IDH1 R132H,19.9,1,Active_Drug,Standard,2024-08-04,Standard,Netherlands,SITE-020
PT-001377,XS-OD-0018,59,Female,White,IDH1 R132H,63.1,3,Placebo,Standard,2024-05-16,Standard,United States,SITE-024
PT-001378,XS-OD-0018,28,Male,White,,88.0,4,Active_Drug,Standard,2024-09-24,Standard,United States,SITE-015
PT-001379,XS-OD-0018,53,Female,White,PDGFRA D842V,54.2,1,Placebo,Standard,2024-05-09,Standard,Spain,SITE-033
PT-001380,XS-OD-0018,56,Male,Hispanic or Latino,KIT D816V,84.9,2,Active_Drug,Standard,2024-08-18,Standard,Germany,SITE-021
PT-001381,XS-OD-0018,40,Female,Hispanic or Latino,BAP1 loss,43.4,1,Placebo,Standard,2024-08-16,Standard,Netherlands,SITE-010
PT-001382,XS-OD-0018,19,Female,Black or African American,IDH1 R132H,56.3,3,Active_Drug,Standard,2024-10-07,Standard,Germany,SITE-022
PT-001383,XS-OD-0018,45,Female,Hispanic or Latino,BAP1 loss,71.8,1,Placebo,Standard,2024-06-27,Standard,United States,SITE-002
PT-001384,XS-OD-0018,29,Male,Hispanic or Latino,PDGFRA D842V,26.7,1,Active_Drug,Standard,2024-05-05,Standard,United Kingdom,SITE-003
PT-001385,XS-OD-0018,42,Male,White,,28.2,5,Placebo,Standard,2024-05-17,Standard,Japan,SITE-033
PT-001386,XS-OD-0018,66,Male,White,PDGFRA D842V,36.3,0,Active_Drug,Standard,2024-08-23,Standard,Italy,SITE-006
PT-001387,XS-OD-0018,62,Male,White,PDGFRA D842V,49.4,1,Placebo,Standard,2024-05-20,Standard,United Kingdom,SITE-022
PT-001388,XS-OD-0018,56,Male,White,PDGFRA D842V,34.0,0,Active_Drug,Standard,2024-07-14,Standard,Australia,SITE-017
PT-001389,XS-OD-0018,30,Female,White,BAP1 loss,61.1,1,Placebo,Standard,2024-06-05,Standard,France,SITE-033
PT-001390,XS-OD-0018,19,Male,White,,73.9,3,Active_Drug,Standard,2024-05-13,Standard,United Kingdom,SITE-011
PT-001391,XS-OD-0018,35,Male,White,KIT D816V,39.6,2,Placebo,Standard,2024-07-16,Standard,France,SITE-032
PT-001392,XS-OD-0018,28,Male,Hispanic or Latino,BAP1 loss,68.6,3,Active_Drug,Standard,2024-10-07,Standard,Australia,SITE-029
PT-001393,XS-OD-0018,52,Female,Asian,,80.7,0,Placebo,Standard,2024-05-30,Standard,Netherlands,SITE-014
PT-001394,XS-OD-0018,60,Female,White,BAP1 loss,26.6,1,Active_Drug,Standard,2024-04-24,Standard,Spain,SITE-009
PT-001395,XS-OD-0018,27,Female,Black or African American,,86.2,5,Placebo,Standard,2024-07-10,Standard,Australia,SITE-007
PT-001396,XS-OD-0018,49,Male,Asian,BAP1 loss,51.4,2,Active_Drug,Standard,2024-07-24,Standard,France,SITE-015
PT-001397,XS-OD-0018,49,Female,White,,63.2,4,Placebo,Standard,2024-08-21,Standard,Netherlands,SITE-001
PT-001398,XS-OD-0018,38,Female,White,BAP1 loss,34.5,1,Active_Drug,Standard,2024-10-03,Standard,Japan,SITE-006
PT-001399,XS-OD-0018,47,Male,Hispanic or Latino,,57.6,2,Placebo,Standard,2024-10-06,Standard,Italy,SITE-018
PT-001400,XS-OD-0018,51,Female,Hispanic or Latino,IDH1 R132H,53.1,3,Active_Drug,Standard,2024-06-14,Standard,France,SITE-024
PT-001401,XS-OD-0018,20,Male,White,,41.4,2,Placebo,Standard,2024-07-11,Emergency,Netherlands,SITE-026
PT-001402,XS-OD-0018,30,Female,Asian,IDH1 R132H,46.5,1,Active_Drug,Standard,2024-06-18,Standard,United Kingdom,SITE-001
PT-001403,XS-OD-0018,41,Male,White,KIT D816V,62.4,3,Placebo,Standard,2024-09-22,Standard,Japan,SITE-015
PT-001404,XS-OD-0018,44,Male,Black or African American,IDH1 R132H,30.1,4,Active_Drug,Standard,2024-06-20,Standard,Netherlands,SITE-013
PT-001405,XS-OD-0018,13,Male,Black or African American,PDGFRA D842V,66.1,3,Placebo,Standard,2024-05-31,Pediatric_Assent,Japan,SITE-009
PT-001406,XS-OD-0018,67,Female,White,KIT D816V,39.7,2,Active_Drug,Standard,2024-09-06,Standard,Spain,SITE-002
PT-001407,XS-OD-0018,24,Female,White,,20.9,0,Placebo,Standard,2024-06-12,Standard,Australia,SITE-002
PT-001408,XS-OD-0018,23,Male,White,PDGFRA D842V,51.8,2,Active_Drug,Standard,2024-09-28,Standard,Japan,SITE-007
PT-001409,XS-OD-0018,47,Female,Black or African American,IDH1 R132H,41.2,2,Placebo,Standard,2024-04-16,Standard,United States,SITE-008
PT-001410,XS-OD-0018,58,Female,Hispanic or Latino,IDH1 R132H,60.5,0,Active_Drug,Standard,2024-04-18,Standard,Italy,SITE-028
PT-001411,XS-OD-0018,32,Male,White,IDH1 R132H,63.1,3,Placebo,Standard,2024-08-31,Standard,Germany,SITE-022
PT-001412,XS-OD-0018,40,Male,White,IDH1 R132H,54.6,1,Active_Drug,Standard,2024-04-12,Standard,Netherlands,SITE-034
PT-001413,XS-OD-0018,57,Male,White,KIT D816V,64.2,1,Placebo,Standard,2024-08-14,Standard,United Kingdom,SITE-018
PT-001414,XS-OD-0018,25,Female,White,PDGFRA D842V,54.5,5,Active_Drug,Standard,2024-08-10,Standard,Italy,SITE-015
PT-001415,XS-OD-0018,20,Female,Asian,IDH1 R132H,60.8,2,Placebo,Standard,2024-04-28,Standard,Canada,SITE-023
PT-001416,XS-OD-0018,8,Male,White,,65.6,5,Active_Drug,Standard,2024-08-11,Pediatric_Assent,United States,SITE-006
PT-001417,XS-OD-0018,60,Female,White,,22.8,1,Placebo,Standard,2024-09-30,Standard,Canada,SITE-005
PT-001418,XS-OD-0018,26,Male,White,BAP1 loss,70.5,0,Active_Drug,Standard,2024-09-18,Compassionate,United States,SITE-014
PT-001419,XS-OD-0018,65,Female,Black or African American,KIT D816V,57.1,4,Placebo,Standard,2024-06-07,Standard,United Kingdom,SITE-022
PT-001420,XS-OD-0018,57,Female,White,,48.7,2,Active_Drug,Standard,2024-09-14,Standard,United States,SITE-020
PT-001421,XS-OD-0018,38,Male,Hispanic or Latino,,42.1,2,Placebo,Standard,2024-07-25,Standard,Canada,SITE-014
PT-001422,XS-OD-0018,45,Female,White,,46.5,6,Active_Drug,Standard,2024-06-25,Standard,Australia,SITE-020
PT-001423,XS-OD-0018,64,Female,White,PDGFRA D842V,56.0,0,Placebo,Standard,2024-10-02,Standard,Spain,SITE-006
PT-001424,XS-OD-0018,57,Male,White,,65.7,2,Active_Drug,Standard,2024-09-17,Standard,Japan,SITE-003
PT-001425,XS-OD-0018,41,Male,Asian,,89.5,3,Placebo,Standard,2024-05-15,Compassionate,United Kingdom,SITE-007
PT-001426,XS-OD-0018,53,Female,White,,48.1,1,Active_Drug,Standard,2024-07-12,Standard,Netherlands,SITE-023
PT-001427,XS-OD-0018,49,Male,White,BAP1 loss,63.9,3,Placebo,Standard,2024-07-07,Standard,United Kingdom,SITE-006
PT-001428,XS-OD-0018,80,Male,White,,51.5,2,Active_Drug,Standard,2024-08-02,Standard,Italy,SITE-022
PT-001429,XS-OD-0018,2,Female,White,,86.0,2,Placebo,Standard,2024-04-15,Pediatric_Assent,Australia,SITE-004
PT-001430,XS-OD-0018,59,Female,Hispanic or Latino,,54.2,1,Active_Drug,Standard,2024-05-06,Standard,Japan,SITE-027
PT-001431,XS-OD-0018,42,Male,White,PDGFRA D842V,35.2,2,Placebo,Standard,2024-10-07,Standard,United Kingdom,SITE-021
PT-001432,XS-OD-0018,38,Female,White,,66.2,1,Active_Drug,Standard,2024-09-07,Standard,Spain,SITE-007
PT-001433,XS-OD-0018,27,Male,White,BAP1 loss,60.7,0,Placebo,Standard,2024-09-15,Standard,France,SITE-009
PT-001434,XS-OD-0018,55,Male,Asian,BAP1 loss,77.4,1,Active_Drug,Standard,2024-08-23,Standard,Germany,SITE-002
PT-001435,XS-OD-0018,31,Male,White,IDH1 R132H,80.7,3,Placebo,Standard,2024-09-28,Standard,Spain,SITE-010
PT-001436,XS-OD-0018,20,Female,White,BAP1 loss,65.2,4,Active_Drug,Standard,2024-09-24,Standard,Netherlands,SITE-029
PT-001437,XS-OD-0018,61,Female,White,,57.3,1,Placebo,Standard,2024-05-07,Standard,France,SITE-012
PT-001438,XS-OD-0018,73,Female,Black or African American,,47.1,2,Active_Drug,Standard,2024-07-13,Standard,Australia,SITE-024
PT-001439,XS-OD-0018,32,Female,Asian,,49.6,1,Placebo,Standard,2024-06-12,Standard,United States,SITE-010
PT-001440,XS-OD-0018,53,Male,Asian,PDGFRA D842V,50.4,2,Active_Drug,Standard,2024-09-14,Standard,Netherlands,SITE-019
PT-001441,XS-OD-0018,37,Female,White,,57.5,3,Placebo,Standard,2024-08-20,Standard,Italy,SITE-015
PT-001442,XS-OD-0018,60,Female,White,BAP1 loss,28.3,3,Active_Drug,Standard,2024-05-13,Standard,United Kingdom,SITE-004
PT-001443,XS-OD-0018,39,Male,Hispanic or Latino,PDGFRA D842V,37.1,1,Placebo,Standard,2024-07-16,Standard,Canada,SITE-011
PT-001444,XS-OD-0018,36,Female,White,PDGFRA D842V,43.0,3,Active_Drug,Standard,2024-08-21,Standard,Japan,SITE-024
PT-001445,XS-OD-0018,52,Female,White,KIT D816V,54.0,2,Placebo,Standard,2024-07-20,Standard,Italy,SITE-034
PT-001446,XS-OD-0018,20,Male,White,PDGFRA D842V,19.8,2,Active_Drug,Standard,2024-07-24,Standard,France,SITE-020
PT-001447,XS-OD-0018,45,Female,White,,44.0,1,Placebo,Standard,2024-08-10,Compassionate,Japan,SITE-002
PT-001448,XS-OD-0018,47,Female,White,,45.5,3,Active_Drug,Standard,2024-05-28,Standard,France,SITE-002
PT-001449,XS-OD-0018,52,Male,White,,65.1,3,Placebo,Standard,2024-08-05,Standard,United States,SITE-022
PT-001450,XS-OD-0018,46,Female,Black or African American,,49.9,1,Active_Drug,Standard,2024-06-18,Standard,United States,SITE-014
PT-001451,XS-OD-0018,45,Male,White,IDH1 R132H,41.7,1,Placebo,Standard,2024-06-03,Standard,Japan,SITE-032
PT-001452,XS-OD-0019,16,Female,White,KIT D816V,41.3,1,Active_Drug,Standard,2018-12-26,Pediatric_Assent,Spain,SITE-002
PT-001453,XS-OD-0019,63,Male,White,BAP1 loss,60.7,3,Active_Drug,Standard,2018-11-24,Standard,Switzerland,SITE-002
PT-001454,XS-OD-0019,34,Female,White,IDH1 R132H,74.2,3,Active_Drug,Standard,2019-04-15,Standard,United States,SITE-001
PT-001455,XS-OD-0019,19,Male,White,KIT D816V,45.6,3,Active_Drug,Standard,2019-04-14,Standard,South Korea,SITE-001
PT-001456,XS-OD-0019,40,Male,White,KIT D816V,85.5,1,Active_Drug,Standard,2019-01-31,Standard,Norway,SITE-002
PT-001457,XS-OD-0019,44,Female,Asian,,48.6,0,Active_Drug,Standard,2019-04-06,Standard,Japan,SITE-002
PT-001458,XS-OD-0019,37,Male,Hispanic or Latino,,56.7,2,Active_Drug,Standard,2019-03-13,Standard,South Korea,SITE-001
PT-001459,XS-OD-0019,52,Female,White,,51.6,2,Active_Drug,Standard,2019-04-16,Standard,United Kingdom,SITE-002
PT-001460,XS-OD-0019,7,Female,Asian,IDH1 R132H,36.1,2,Active_Drug,Standard,2019-02-04,Pediatric_Assent,Canada,SITE-002
PT-001461,XS-OD-0019,33,Male,White,,48.8,1,Active_Drug,Standard,2018-12-04,Standard,Italy,SITE-001
PT-001462,XS-OD-0019,28,Male,White,PDGFRA D842V,47.3,1,Active_Drug,Standard,2018-12-21,Standard,Sweden,SITE-002
PT-001463,XS-OD-0019,31,Male,Black or African American,KIT D816V,51.6,3,Active_Drug,Standard,2019-05-07,Standard,South Korea,SITE-001
PT-001464,XS-OD-0019,53,Male,White,,52.1,3,Active_Drug,Standard,2018-12-24,Standard,Spain,SITE-002
PT-001465,XS-OD-0019,23,Female,Two or More Races,,60.4,5,Active_Drug,Standard,2019-03-28,Standard,Switzerland,SITE-001
PT-001466,XS-OD-0019,62,Male,Hispanic or Latino,KIT D816V,33.5,1,Active_Drug,Standard,2019-04-12,Standard,Germany,SITE-002
PT-001467,XS-OD-0019,41,Female,White,,17.4,2,Active_Drug,Standard,2019-03-18,Standard,Switzerland,SITE-001
PT-001468,XS-OD-0020,5,Male,White,,60.2,0,Active_Drug,High,2024-04-20,Pediatric_Assent,Italy,SITE-001
PT-001469,XS-OD-0020,4,Female,White,,38.3,4,Placebo,High,2024-01-18,Pediatric_Assent,Israel,SITE-001
PT-001470,XS-OD-0020,2,Male,White,,61.8,6,Active_Drug_High_Dose,Low,2024-06-13,Pediatric_Assent,South Korea,SITE-001
PT-001471,XS-OD-0020,7,Male,Black or African American,IDH1 R132H,54.2,1,Active_Drug,Medium,2024-03-22,Pediatric_Assent,Denmark,SITE-003
PT-001472,XS-OD-0020,6,Male,Black or African American,,61.5,4,Placebo,High,2024-01-20,Pediatric_Assent,Taiwan,SITE-001
PT-001473,XS-OD-0020,6,Female,White,BAP1 loss,72.9,1,Active_Drug_High_Dose,Medium,2024-01-15,Pediatric_Assent,Austria,SITE-001
PT-001474,XS-OD-0020,1,Male,White,PDGFRA D842V,49.4,0,Active_Drug,High,2024-03-16,Pediatric_Assent,France,SITE-002
PT-001475,XS-OD-0020,9,Female,White,,39.5,0,Placebo,Medium,2024-02-04,Pediatric_Assent,Sweden,SITE-001
PT-001476,XS-OD-0020,2,Male,Asian,IDH1 R132H,29.8,2,Active_Drug_High_Dose,Medium,2024-03-03,Pediatric_Assent,Taiwan,SITE-001
PT-001477,XS-OD-0020,2,Male,White,PDGFRA D842V,80.8,7,Active_Drug,Low,2024-02-25,Pediatric_Assent,Norway,SITE-003
PT-001478,XS-OD-0020,1,Female,Black or African American,KIT D816V,42.3,1,Placebo,Low,2024-01-18,Pediatric_Assent,Canada,SITE-003
PT-001479,XS-OD-0020,2,Male,White,PDGFRA D842V,45.3,2,Active_Drug_High_Dose,Low,2023-12-25,Pediatric_Assent,Belgium,SITE-003
PT-001480,XS-OD-0020,1,Female,Black or African American,PDGFRA D842V,62.1,0,Active_Drug,Medium,2024-03-02,Pediatric_Assent,Australia,SITE-001
PT-001481,XS-OD-0020,9,Male,Asian,IDH1 R132H,87.1,1,Placebo,Medium,2024-01-15,Pediatric_Assent,Austria,SITE-002
PT-001482,XS-OD-0020,2,Male,White,KIT D816V,91.7,2,Active_Drug_High_Dose,Low,2024-02-25,Pediatric_Assent,Netherlands,SITE-002
PT-001483,XS-OD-0020,10,Female,Black or African American,,84.1,0,Active_Drug,Low,2024-06-06,Pediatric_Assent,Austria,SITE-001
PT-001484,XS-OD-0020,8,Female,White,IDH1 R132H,45.6,1,Placebo,High,2024-03-21,Pediatric_Assent,Switzerland,SITE-001
PT-001485,XS-OD-0020,4,Female,Black or African American,PDGFRA D842V,16.6,1,Active_Drug_High_Dose,Low,2024-03-31,Pediatric_Assent,Belgium,SITE-001
PT-001486,XS-OD-0020,1,Female,White,IDH1 R132H,73.1,3,Active_Drug,Low,2024-06-05,Pediatric_Assent,Denmark,SITE-002
PT-001487,XS-OD-0020,2,Male,Hispanic or Latino,PDGFRA D842V,66.2,0,Placebo,High,2024-04-05,Pediatric_Assent,Israel,SITE-003
PT-001488,XS-OD-0020,4,Male,White,PDGFRA D842V,41.0,2,Active_Drug_High_Dose,Medium,2024-01-21,Pediatric_Assent,South Korea,SITE-003
PT-001489,XS-OD-0020,2,Female,White,KIT D816V,42.2,3,Active_Drug,Low,2024-02-08,Pediatric_Assent,France,SITE-002
PT-001490,XS-OD-0020,7,Female,White,,30.0,3,Placebo,Medium,2024-05-29,Pediatric_Assent,Norway,SITE-003
PT-001491,XS-OD-0021,16,Female,White,,50.9,2,Active_Drug,Standard,2022-06-03,Pediatric_Assent,France,SITE-024
PT-001492,XS-OD-0021,13,Female,White,,53.9,0,Placebo,Standard,2022-03-07,Pediatric_Assent,United Kingdom,SITE-002
PT-001493,XS-OD-0021,37,Female,Asian,,42.4,3,Active_Drug,Standard,2022-01-03,Standard,France,SITE-005
PT-001494,XS-OD-0021,40,Female,White,SERPING1 c.1396C>T,77.8,1,Placebo,Standard,2022-01-02,Standard,United Kingdom,SITE-014
PT-001495,XS-OD-0021,13,Female,Asian,,53.5,0,Active_Drug,Standard,2022-03-08,Pediatric_Assent,United States,SITE-028
PT-001496,XS-OD-0021,55,Female,White,C5 p.R885H,75.8,2,Placebo,Standard,2022-04-16,Standard,Netherlands,SITE-019
PT-001497,XS-OD-0021,41,Female,Hispanic or Latino,,56.8,0,Active_Drug,Standard,2022-05-25,Emergency,Spain,SITE-008
PT-001498,XS-OD-0021,20,Male,Black or African American,C5 p.R885H,60.4,4,Placebo,Standard,2021-12-30,Standard,Japan,SITE-024
PT-001499,XS-OD-0021,38,Male,White,SERPING1 c.1396C>T,95.0,1,Active_Drug,Standard,2022-01-15,Standard,Canada,SITE-014
PT-001500,XS-OD-0021,33,Male,Two or More Races,,65.9,3,Placebo,Standard,2022-01-10,Standard,United Kingdom,SITE-026
PT-001501,XS-OD-0021,5,Male,Hispanic or Latino,,27.1,3,Active_Drug,Standard,2022-05-15,Pediatric_Assent,Australia,SITE-018
PT-001502,XS-OD-0021,34,Male,White,NLRP3 R260W,75.7,1,Placebo,Standard,2022-02-24,Standard,United States,SITE-002
PT-001503,XS-OD-0021,35,Male,White,,79.3,1,Active_Drug,Standard,2022-02-01,Standard,United Kingdom,SITE-011
PT-001504,XS-OD-0021,38,Male,White,,28.2,0,Placebo,Standard,2022-01-22,Standard,France,SITE-007
PT-001505,XS-OD-0021,40,Male,American Indian or Alaska Native,,38.8,1,Active_Drug,Standard,2022-05-19,Standard,Canada,SITE-019
PT-001506,XS-OD-0021,38,Male,White,,30.0,0,Placebo,Standard,2022-05-14,Compassionate,Australia,SITE-019
PT-001507,XS-OD-0021,14,Male,White,C5 p.R885H,95.0,3,Active_Drug,Standard,2022-05-28,Pediatric_Assent,Germany,SITE-001
PT-001508,XS-OD-0021,2,Male,Asian,SERPING1 c.1396C>T,74.6,5,Placebo,Standard,2022-01-24,Pediatric_Assent,Italy,SITE-014
PT-001509,XS-OD-0021,30,Female,White,SERPING1 c.1396C>T,62.4,4,Active_Drug,Standard,2022-06-06,Standard,Australia,SITE-003
PT-001510,XS-OD-0021,14,Male,White,,66.9,3,Placebo,Standard,2022-04-25,Pediatric_Assent,Japan,SITE-016
PT-001511,XS-OD-0021,7,Male,White,NLRP3 R260W,50.5,0,Active_Drug,Standard,2022-03-07,Pediatric_Assent,United Kingdom,SITE-017
PT-001512,XS-OD-0021,32,Male,White,NLRP3 R260W,42.0,1,Placebo,Standard,2022-05-27,Standard,Netherlands,SITE-003
PT-001513,XS-OD-0021,43,Female,White,C5 p.R885H,47.6,1,Active_Drug,Standard,2022-05-08,Standard,Italy,SITE-022
PT-001514,XS-OD-0021,24,Male,Hispanic or Latino,,65.6,1,Placebo,Standard,2022-04-18,Standard,France,SITE-007
PT-001515,XS-OD-0021,23,Male,Hispanic or Latino,,57.1,0,Active_Drug,Standard,2022-04-21,Standard,Germany,SITE-008
PT-001516,XS-OD-0021,23,Male,White,,56.2,2,Placebo,Standard,2021-12-28,Standard,United States,SITE-004
PT-001517,XS-OD-0021,35,Female,White,C5 p.R885H,51.1,3,Active_Drug,Standard,2022-02-13,Standard,Australia,SITE-006
PT-001518,XS-OD-0021,50,Male,White,NLRP3 R260W,80.1,0,Placebo,Standard,2022-04-03,Compassionate,Australia,SITE-027
PT-001519,XS-OD-0021,6,Female,White,,38.7,0,Active_Drug,Standard,2022-03-22,Pediatric_Assent,United States,SITE-013
PT-001520,XS-OD-0021,2,Male,White,C5 p.R885H,76.1,2,Placebo,Standard,2022-01-07,Pediatric_Assent,Australia,SITE-001
PT-001521,XS-OD-0021,44,Female,White,NLRP3 R260W,80.6,3,Active_Drug,Standard,2022-01-21,Standard,Japan,SITE-028
PT-001522,XS-OD-0021,8,Female,White,NLRP3 R260W,70.7,3,Placebo,Standard,2022-03-26,Pediatric_Assent,United States,SITE-022
PT-001523,XS-OD-0021,19,Male,Hispanic or Latino,NLRP3 R260W,95.0,4,Active_Drug,Standard,2022-05-12,Standard,Germany,SITE-025
PT-001524,XS-OD-0021,26,Male,White,C5 p.R885H,33.4,1,Placebo,Standard,2022-05-04,Standard,United States,SITE-011
PT-001525,XS-OD-0021,38,Male,White,NLRP3 R260W,60.5,0,Active_Drug,Standard,2022-03-02,Standard,Germany,SITE-013
PT-001526,XS-OD-0021,33,Male,White,SERPING1 c.1396C>T,69.2,3,Placebo,Standard,2022-04-12,Standard,Spain,SITE-014
PT-001527,XS-OD-0021,45,Male,Black or African American,C5 p.R885H,51.2,4,Active_Drug,Standard,2022-03-08,Standard,Netherlands,SITE-005
PT-001528,XS-OD-0021,54,Female,White,,56.7,3,Placebo,Standard,2022-05-06,Standard,Canada,SITE-018
PT-001529,XS-OD-0021,42,Female,White,,48.9,0,Active_Drug,Standard,2022-01-04,Standard,Japan,SITE-022
PT-001530,XS-OD-0021,46,Male,White,,75.5,3,Placebo,Standard,2021-12-26,Standard,Netherlands,SITE-024
PT-001531,XS-OD-0021,43,Female,White,SERPING1 c.1396C>T,63.2,1,Active_Drug,Standard,2022-02-05,Standard,United States,SITE-023
PT-001532,XS-OD-0021,16,Male,Hispanic or Latino,,81.7,1,Placebo,Standard,2022-05-01,Pediatric_Assent,Japan,SITE-016
PT-001533,XS-OD-0021,42,Male,White,,46.4,3,Active_Drug,Standard,2022-05-11,Standard,Italy,SITE-028
PT-001534,XS-OD-0021,23,Male,White,SERPING1 c.1396C>T,61.7,2,Placebo,Standard,2022-02-05,Standard,Italy,SITE-023
PT-001535,XS-OD-0021,77,Female,Two or More Races,C5 p.R885H,56.5,1,Active_Drug,Standard,2022-03-09,Standard,Germany,SITE-008
PT-001536,XS-OD-0021,16,Female,Asian,NLRP3 R260W,67.3,2,Placebo,Standard,2022-03-24,Pediatric_Assent,Canada,SITE-019
PT-001537,XS-OD-0021,34,Female,White,,33.8,3,Active_Drug,Standard,2022-02-07,Standard,Germany,SITE-008
PT-001538,XS-OD-0021,42,Male,Hispanic or Latino,,40.3,1,Placebo,Standard,2022-05-04,Standard,United States,SITE-020
PT-001539,XS-OD-0021,51,Male,Hispanic or Latino,,48.3,1,Active_Drug,Standard,2021-12-20,Standard,Canada,SITE-015
PT-001540,XS-OD-0021,52,Female,White,SERPING1 c.1396C>T,36.7,2,Placebo,Standard,2022-04-10,Standard,Australia,SITE-005
PT-001541,XS-OD-0021,72,Male,Hispanic or Latino,SERPING1 c.1396C>T,28.8,2,Active_Drug,Standard,2022-02-19,Standard,Germany,SITE-024
PT-001542,XS-OD-0021,15,Male,White,SERPING1 c.1396C>T,74.2,5,Placebo,Standard,2022-04-29,Pediatric_Assent,Germany,SITE-028
PT-001543,XS-OD-0021,37,Male,White,,55.9,2,Active_Drug,Standard,2021-12-29,Standard,Italy,SITE-025
PT-001544,XS-OD-0021,30,Male,Hispanic or Latino,,58.8,3,Placebo,Standard,2022-02-08,Standard,Netherlands,SITE-015
PT-001545,XS-OD-0021,61,Male,Black or African American,SERPING1 c.1396C>T,64.7,4,Active_Drug,Standard,2022-04-18,Standard,United States,SITE-005
PT-001546,XS-OD-0021,6,Intersex,White,,79.7,0,Placebo,Standard,2022-02-19,Pediatric_Assent,United States,SITE-010
PT-001547,XS-OD-0021,55,Female,Black or African American,,75.9,0,Active_Drug,Standard,2022-01-28,Standard,France,SITE-011
PT-001548,XS-OD-0021,45,Male,Black or African American,NLRP3 R260W,70.3,2,Placebo,Standard,2022-01-20,Standard,Spain,SITE-027
PT-001549,XS-OD-0021,72,Male,White,,84.1,4,Active_Drug,Standard,2022-05-17,Standard,Canada,SITE-009
PT-001550,XS-OD-0021,34,Male,Black or African American,C5 p.R885H,29.2,3,Placebo,Standard,2021-12-14,Standard,Australia,SITE-024
PT-001551,XS-OD-0021,47,Female,White,NLRP3 R260W,68.7,1,Active_Drug,Standard,2022-02-05,Standard,United States,SITE-011
PT-001552,XS-OD-0021,68,Male,White,NLRP3 R260W,66.9,4,Placebo,Standard,2022-04-01,Standard,United States,SITE-006
PT-001553,XS-OD-0021,38,Female,White,SERPING1 c.1396C>T,46.1,2,Active_Drug,Standard,2022-01-24,Standard,Canada,SITE-002
PT-001554,XS-OD-0021,31,Male,White,C5 p.R885H,48.6,1,Placebo,Standard,2022-03-03,Standard,Australia,SITE-023
PT-001555,XS-OD-0021,40,Female,White,,36.1,2,Active_Drug,Standard,2022-01-21,Standard,Spain,SITE-023
PT-001556,XS-OD-0021,74,Female,White,NLRP3 R260W,77.5,6,Placebo,Standard,2022-05-19,Standard,Netherlands,SITE-001
PT-001557,XS-OD-0021,29,Male,Hispanic or Latino,,67.1,3,Active_Drug,Standard,2022-03-25,Standard,Germany,SITE-023
PT-001558,XS-OD-0021,26,Male,Black or African American,SERPING1 c.1396C>T,70.5,2,Placebo,Standard,2022-01-27,Standard,Italy,SITE-016
PT-001559,XS-OD-0021,2,Male,White,C5 p.R885H,34.5,3,Active_Drug,Standard,2022-05-04,Pediatric_Assent,Australia,SITE-008
PT-001560,XS-OD-0021,42,Female,Hispanic or Latino,C5 p.R885H,70.7,2,Placebo,Standard,2022-04-12,Standard,Canada,SITE-006
PT-001561,XS-OD-0021,19,Male,White,NLRP3 R260W,29.0,3,Active_Drug,Standard,2022-02-22,Standard,Netherlands,SITE-016
PT-001562,XS-OD-0021,28,Female,White,,40.2,0,Placebo,Standard,2022-05-19,Compassionate,Italy,SITE-025
PT-001563,XS-OD-0021,43,Male,Asian,,53.0,0,Active_Drug,Standard,2022-01-28,Standard,Germany,SITE-027
PT-001564,XS-OD-0021,37,Male,White,SERPING1 c.1396C>T,59.9,3,Placebo,Standard,2022-04-29,Standard,Canada,SITE-001
PT-001565,XS-OD-0021,33,Female,White,,53.6,0,Active_Drug,Standard,2022-04-21,Standard,Japan,SITE-021
PT-001566,XS-OD-0021,16,Male,Asian,SERPING1 c.1396C>T,95.0,3,Placebo,Standard,2022-02-12,Pediatric_Assent,France,SITE-005
PT-001567,XS-OD-0021,53,Female,White,,40.6,0,Active_Drug,Standard,2022-02-07,Standard,Australia,SITE-017
PT-001568,XS-OD-0021,33,Female,White,NLRP3 R260W,36.9,2,Placebo,Standard,2022-02-06,Standard,Germany,SITE-003
PT-001569,XS-OD-0021,15,Male,White,,58.0,3,Active_Drug,Standard,2022-02-08,Pediatric_Assent,Netherlands,SITE-007
PT-001570,XS-OD-0021,50,Female,Hispanic or Latino,,22.7,3,Placebo,Standard,2021-12-28,Standard,United Kingdom,SITE-007
PT-001571,XS-OD-0021,30,Female,Asian,SERPING1 c.1396C>T,46.5,0,Active_Drug,Standard,2022-03-22,Standard,Australia,SITE-003
PT-001572,XS-OD-0021,32,Female,Black or African American,SERPING1 c.1396C>T,67.3,1,Placebo,Standard,2022-05-06,Standard,France,SITE-023
PT-001573,XS-OD-0021,73,Female,Asian,,74.1,2,Active_Drug,Standard,2022-04-27,Standard,United Kingdom,SITE-007
PT-001574,XS-OD-0021,55,Male,Black or African American,,37.1,2,Placebo,Standard,2022-02-10,Standard,Spain,SITE-019
PT-001575,XS-OD-0021,44,Male,White,,72.1,2,Active_Drug,Standard,2022-04-30,Standard,United Kingdom,SITE-004
PT-001576,XS-OD-0021,19,Female,White,,89.1,2,Placebo,Standard,2021-12-31,Standard,Spain,SITE-019
PT-001577,XS-OD-0021,67,Female,Native Hawaiian or Other Pacific Islander,C5 p.R885H,59.3,2,Active_Drug,Standard,2022-04-03,Standard,Italy,SITE-025
PT-001578,XS-OD-0021,82,Female,White,NLRP3 R260W,28.7,1,Placebo,Standard,2022-03-28,Standard,Italy,SITE-012
PT-001579,XS-OD-0021,45,Female,White,,76.1,2,Active_Drug,Standard,2022-04-08,Standard,Canada,SITE-012
PT-001580,XS-OD-0021,63,Male,White,C5 p.R885H,46.3,0,Placebo,Standard,2022-01-02,Standard,Germany,SITE-002
PT-001581,XS-OD-0021,2,Male,White,C5 p.R885H,44.7,1,Active_Drug,Standard,2021-12-19,Pediatric_Assent,Spain,SITE-013
PT-001582,XS-OD-0021,2,Male,White,SERPING1 c.1396C>T,58.9,4,Placebo,Standard,2021-12-29,Pediatric_Assent,United States,SITE-023
PT-001583,XS-OD-0021,44,Female,Asian,,74.5,3,Active_Drug,Standard,2022-04-08,Standard,Netherlands,SITE-003
PT-001584,XS-OD-0021,41,Female,White,,42.7,1,Placebo,Standard,2022-01-24,Standard,Japan,SITE-006
PT-001585,XS-OD-0021,41,Male,Hispanic or Latino,,24.4,1,Active_Drug,Standard,2022-03-06,Standard,Italy,SITE-007
PT-001586,XS-OD-0021,21,Female,White,NLRP3 R260W,41.8,0,Placebo,Standard,2022-04-09,Standard,Italy,SITE-003
PT-001587,XS-OD-0021,66,Female,Hispanic or Latino,C5 p.R885H,10.0,1,Active_Drug,Standard,2021-12-24,Standard,Netherlands,SITE-025
PT-001588,XS-OD-0021,44,Male,White,C5 p.R885H,34.1,2,Placebo,Standard,2022-01-02,Standard,France,SITE-026
PT-001589,XS-OD-0021,37,Female,White,SERPING1 c.1396C>T,38.1,1,Active_Drug,Standard,2022-04-03,Standard,Germany,SITE-022
PT-001590,XS-OD-0021,2,Male,Asian,,52.3,1,Placebo,Standard,2022-02-11,Pediatric_Assent,Australia,SITE-021
PT-001591,XS-OD-0021,32,Male,White,NLRP3 R260W,84.8,3,Active_Drug,Standard,2022-02-24,Emergency,Spain,SITE-017
PT-001592,XS-OD-0021,22,Male,White,NLRP3 R260W,45.0,3,Placebo,Standard,2021-12-22,Standard,France,SITE-011
PT-001593,XS-OD-0021,37,Female,Black or African American,,52.9,3,Active_Drug,Standard,2022-04-22,Standard,United States,SITE-011
PT-001594,XS-OD-0021,49,Male,White,NLRP3 R260W,42.5,0,Placebo,Standard,2022-05-12,Standard,United Kingdom,SITE-009
PT-001595,XS-OD-0021,9,Female,White,,76.4,3,Active_Drug,Standard,2022-01-17,Pediatric_Assent,France,SITE-020
PT-001596,XS-OD-0021,41,Male,American Indian or Alaska Native,,73.3,1,Placebo,Standard,2022-03-08,Standard,United States,SITE-027
PT-001597,XS-OD-0021,33,Female,Asian,NLRP3 R260W,49.8,2,Active_Drug,Standard,2022-02-04,Standard,Italy,SITE-005
PT-001598,XS-OD-0021,48,Female,White,SERPING1 c.1396C>T,80.9,2,Placebo,Standard,2022-01-20,Standard,Italy,SITE-013
PT-001599,XS-OD-0021,35,Male,Asian,NLRP3 R260W,26.3,3,Active_Drug,Standard,2022-01-19,Standard,France,SITE-019
PT-001600,XS-OD-0021,61,Female,White,SERPING1 c.1396C>T,68.1,3,Placebo,Standard,2022-04-22,Standard,France,SITE-013
PT-001601,XS-OD-0021,27,Female,Asian,,25.4,2,Active_Drug,Standard,2022-05-17,Standard,Australia,SITE-010
PT-001602,XS-OD-0021,47,Male,White,NLRP3 R260W,21.8,0,Placebo,Standard,2022-03-21,Standard,Japan,SITE-017
PT-001603,XS-OD-0021,17,Male,Hispanic or Latino,C5 p.R885H,72.3,3,Active_Drug,Standard,2022-04-01,Pediatric_Assent,United States,SITE-003
PT-001604,XS-OD-0021,23,Male,White,NLRP3 R260W,71.9,2,Placebo,Standard,2022-02-22,Compassionate,United States,SITE-026
PT-001605,XS-OD-0021,43,Female,White,C5 p.R885H,42.9,2,Active_Drug,Standard,2022-05-08,Standard,Japan,SITE-024
PT-001606,XS-OD-0021,43,Male,Asian,,63.6,1,Placebo,Standard,2022-05-14,Standard,United States,SITE-027
PT-001607,XS-OD-0021,2,Female,Black or African American,SERPING1 c.1396C>T,87.7,1,Active_Drug,Standard,2022-02-14,Pediatric_Assent,Canada,SITE-012
PT-001608,XS-OD-0021,15,Male,White,NLRP3 R260W,75.4,0,Placebo,Standard,2022-03-04,Pediatric_Assent,Germany,SITE-008
PT-001609,XS-OD-0021,88,Female,White,,56.4,0,Active_Drug,Standard,2022-04-12,Standard,Japan,SITE-023
PT-001610,XS-OD-0021,44,Female,Black or African American,NLRP3 R260W,52.7,3,Placebo,Standard,2022-05-05,Standard,Germany,SITE-015
PT-001611,XS-OD-0021,24,Male,White,NLRP3 R260W,44.2,1,Active_Drug,Standard,2022-02-28,Standard,United States,SITE-021
PT-001612,XS-OD-0021,39,Male,Hispanic or Latino,,69.8,1,Placebo,Standard,2022-02-02,Standard,Canada,SITE-008
PT-001613,XS-OD-0021,46,Female,White,,61.1,3,Active_Drug,Standard,2022-02-03,Standard,Italy,SITE-005
PT-001614,XS-OD-0021,31,Male,White,C5 p.R885H,25.0,0,Placebo,Standard,2022-06-06,Standard,United Kingdom,SITE-026
PT-001615,XS-OD-0021,44,Male,White,NLRP3 R260W,62.2,2,Active_Drug,Standard,2022-03-26,Standard,Japan,SITE-002
PT-001616,XS-OD-0021,29,Female,Black or African American,SERPING1 c.1396C>T,59.5,2,Placebo,Standard,2022-04-30,Standard,United Kingdom,SITE-024
PT-001617,XS-OD-0021,38,Female,Two or More Races,C5 p.R885H,51.6,0,Active_Drug,Standard,2021-12-19,Standard,Japan,SITE-019
PT-001618,XS-OD-0021,49,Female,White,C5 p.R885H,54.1,3,Placebo,Standard,2022-06-01,Standard,Canada,SITE-016
PT-001619,XS-OD-0021,53,Male,White,,26.9,1,Active_Drug,Standard,2022-03-17,Standard,Netherlands,SITE-020
PT-001620,XS-OD-0021,33,Male,White,SERPING1 c.1396C>T,70.0,3,Placebo,Standard,2022-01-09,Standard,United States,SITE-019
PT-001621,XS-OD-0021,67,Male,White,,45.0,0,Active_Drug,Standard,2022-04-09,Standard,Japan,SITE-010
PT-001622,XS-OD-0021,38,Male,White,NLRP3 R260W,46.7,1,Placebo,Standard,2022-03-03,Standard,France,SITE-015
PT-001623,XS-OD-0021,35,Male,White,SERPING1 c.1396C>T,70.6,0,Active_Drug,Standard,2022-03-29,Standard,Italy,SITE-027
PT-001624,XS-OD-0021,49,Female,Asian,NLRP3 R260W,43.9,1,Placebo,Standard,2022-02-16,Standard,Japan,SITE-004
PT-001625,XS-OD-0021,42,Female,White,,75.0,3,Active_Drug,Standard,2022-01-22,Standard,United States,SITE-014
PT-001626,XS-OD-0021,47,Female,White,C5 p.R885H,37.1,1,Placebo,Standard,2022-01-03,Standard,Germany,SITE-001
PT-001627,XS-OD-0021,76,Male,White,SERPING1 c.1396C>T,73.1,3,Active_Drug,Standard,2022-02-04,Standard,Australia,SITE-006
PT-001628,XS-OD-0021,33,Female,White,SERPING1 c.1396C>T,43.7,1,Placebo,Standard,2022-01-29,Standard,United States,SITE-025
PT-001629,XS-OD-0021,45,Female,Asian,C5 p.R885H,72.9,1,Active_Drug,Standard,2022-05-21,Standard,Canada,SITE-020
PT-001630,XS-OD-0021,54,Female,White,C5 p.R885H,78.4,0,Placebo,Standard,2021-12-29,Standard,United States,SITE-002
PT-001631,XS-OD-0021,15,Female,Two or More Races,NLRP3 R260W,62.9,1,Active_Drug,Standard,2022-01-10,Pediatric_Assent,United Kingdom,SITE-010
PT-001632,XS-OD-0021,48,Male,White,SERPING1 c.1396C>T,64.3,0,Placebo,Standard,2022-02-08,Standard,United Kingdom,SITE-020
PT-001633,XS-OD-0021,65,Male,Hispanic or Latino,,55.6,1,Active_Drug,Standard,2022-02-11,Standard,Germany,SITE-027
PT-001634,XS-OD-0021,2,Female,White,C5 p.R885H,51.0,1,Placebo,Standard,2021-12-26,Pediatric_Assent,Australia,SITE-025
PT-001635,XS-OD-0021,44,Male,Black or African American,NLRP3 R260W,87.1,3,Active_Drug,Standard,2022-03-25,Emergency,France,SITE-020
PT-001636,XS-OD-0021,39,Male,White,,78.6,1,Placebo,Standard,2021-12-28,Standard,Italy,SITE-013
PT-001637,XS-OD-0021,29,Female,White,,68.0,1,Active_Drug,Standard,2022-01-08,Standard,Spain,SITE-002
PT-001638,XS-OD-0021,43,Male,White,,53.7,5,Placebo,Standard,2022-04-29,Standard,Germany,SITE-015
PT-001639,XS-OD-0021,49,Male,Asian,SERPING1 c.1396C>T,69.0,1,Active_Drug,Standard,2022-05-21,Standard,Netherlands,SITE-006
PT-001640,XS-OD-0021,19,Female,Black or African American,,61.5,2,Placebo,Standard,2022-02-07,Standard,Italy,SITE-026
PT-001641,XS-OD-0021,23,Male,White,SERPING1 c.1396C>T,75.3,1,Active_Drug,Standard,2022-01-29,Standard,Canada,SITE-007
PT-001642,XS-OD-0021,28,Intersex,White,SERPING1 c.1396C>T,61.3,3,Placebo,Standard,2022-04-14,Standard,Japan,SITE-027
PT-001643,XS-OD-0021,31,Female,White,SERPING1 c.1396C>T,64.2,2,Active_Drug,Standard,2022-02-21,Standard,Germany,SITE-021
PT-001644,XS-OD-0021,37,Female,Black or African American,,40.8,3,Placebo,Standard,2022-02-27,Standard,Australia,SITE-028
PT-001645,XS-OD-0021,59,Male,Hispanic or Latino,,61.1,0,Active_Drug,Standard,2022-02-27,Standard,Germany,SITE-022
PT-001646,XS-OD-0021,65,Male,White,C5 p.R885H,59.0,3,Placebo,Standard,2021-12-30,Standard,Canada,SITE-015
PT-001647,XS-OD-0021,43,Male,Hispanic or Latino,C5 p.R885H,52.6,4,Active_Drug,Standard,2022-01-05,Standard,Germany,SITE-010
PT-001648,XS-OD-0021,38,Male,Black or African American,C5 p.R885H,45.6,2,Placebo,Standard,2022-02-04,Standard,Canada,SITE-010
PT-001649,XS-OD-0021,35,Male,Two or More Races,NLRP3 R260W,40.9,0,Active_Drug,Standard,2021-12-26,Standard,Canada,SITE-008
PT-001650,XS-OD-0021,30,Male,White,SERPING1 c.1396C>T,88.2,1,Placebo,Standard,2022-01-07,Standard,Germany,SITE-010
PT-001651,XS-OD-0021,22,Female,White,NLRP3 R260W,58.2,0,Active_Drug,Standard,2022-05-01,Standard,Italy,SITE-021
PT-001652,XS-OD-0021,56,Male,Asian,,59.1,1,Placebo,Standard,2022-02-18,Standard,Spain,SITE-016
PT-001653,XS-OD-0021,57,Female,White,,77.8,2,Active_Drug,Standard,2022-05-19,Standard,Japan,SITE-017
PT-001654,XS-OD-0021,56,Female,Hispanic or Latino,,94.1,2,Placebo,Standard,2022-04-20,Standard,Germany,SITE-005
PT-001655,XS-OD-0021,34,Male,Native Hawaiian or Other Pacific Islander,SERPING1 c.1396C>T,80.8,2,Active_Drug,Standard,2022-05-26,Standard,Italy,SITE-018
PT-001656,XS-OD-0021,40,Male,Asian,,66.7,0,Placebo,Standard,2022-05-29,Standard,Canada,SITE-015
PT-001657,XS-OD-0021,50,Male,Black or African American,C5 p.R885H,74.0,2,Active_Drug,Standard,2022-01-24,Standard,Netherlands,SITE-007
PT-001658,XS-OD-0021,36,Male,Asian,C5 p.R885H,55.6,4,Placebo,Standard,2022-03-27,Standard,Italy,SITE-006
PT-001659,XS-OD-0021,49,Female,White,,47.1,5,Active_Drug,Standard,2022-05-16,Standard,Germany,SITE-018
PT-001660,XS-OD-0021,22,Male,Hispanic or Latino,NLRP3 R260W,50.8,2,Placebo,Standard,2021-12-18,Standard,France,SITE-009
PT-001661,XS-OD-0021,40,Female,Black or African American,C5 p.R885H,82.3,0,Active_Drug,Standard,2022-03-10,Standard,United Kingdom,SITE-004
PT-001662,XS-OD-0022,34,Female,Black or African American,SERPING1 c.1396C>T,49.5,2,Active_Drug,High,2026-02-24,Standard,United Kingdom,SITE-002
PT-001663,XS-OD-0022,48,Female,Hispanic or Latino,,65.7,1,Active_Drug,Low,2026-02-06,Standard,Spain,SITE-001
PT-001664,XS-OD-0022,66,Female,White,,55.7,1,Active_Drug,Medium,2026-01-14,Standard,Australia,SITE-003
PT-001665,XS-OD-0022,32,Female,White,C5 p.R885H,59.8,0,Active_Drug,Medium,2026-02-04,Standard,United Kingdom,SITE-003
PT-001666,XS-OD-0022,47,Male,Asian,C5 p.R885H,37.2,2,Active_Drug,High,2026-04-23,Standard,Australia,SITE-002
PT-001667,XS-OD-0022,41,Female,White,SERPING1 c.1396C>T,57.2,2,Active_Drug,High,2026-03-24,Standard,Spain,SITE-001
PT-001668,XS-OD-0022,17,Male,Hispanic or Latino,C5 p.R885H,30.1,3,Active_Drug,Medium,2026-05-29,Pediatric_Assent,Germany,SITE-001
PT-001669,XS-OD-0022,38,Female,Hispanic or Latino,SERPING1 c.1396C>T,43.3,0,Active_Drug,Low,2026-01-12,Standard,France,SITE-002
PT-001670,XS-OD-0022,69,Female,White,SERPING1 c.1396C>T,55.7,3,Active_Drug,Medium,2026-04-26,Standard,United States,SITE-002
PT-001671,XS-OD-0022,81,Male,White,SERPING1 c.1396C>T,35.0,1,Active_Drug,Medium,2026-01-08,Standard,Spain,SITE-003
PT-001672,XS-OD-0022,52,Intersex,Black or African American,NLRP3 R260W,33.4,3,Active_Drug,Medium,2025-12-10,Standard,United States,SITE-001
PT-001673,XS-OD-0022,2,Male,Hispanic or Latino,NLRP3 R260W,46.6,2,Active_Drug,Medium,2026-01-05,Pediatric_Assent,Australia,SITE-003
PT-001674,XS-OD-0022,53,Female,Hispanic or Latino,SERPING1 c.1396C>T,59.9,4,Active_Drug,Low,2025-12-24,Standard,Japan,SITE-002
PT-001675,XS-OD-0022,38,Male,Asian,NLRP3 R260W,52.2,2,Active_Drug,Medium,2026-02-26,Standard,Netherlands,SITE-003
PT-001676,XS-OD-0023,51,Female,Asian,NLRP3 R260W,17.8,2,Active_Drug,High,2023-12-22,Standard,Denmark,SITE-001
PT-001677,XS-OD-0023,25,Male,Hispanic or Latino,,27.4,1,SOC,Medium,2024-03-10,Standard,Brazil,SITE-002
PT-001678,XS-OD-0023,62,Female,Black or African American,C5 p.R885H,68.7,2,Combination,Low,2024-04-11,Compassionate,Japan,SITE-001
PT-001679,XS-OD-0023,31,Male,White,,51.3,2,Active_Drug,High,2024-05-18,Standard,Israel,SITE-001
PT-001680,XS-OD-0023,48,Female,White,NLRP3 R260W,41.6,2,SOC,High,2024-06-05,Standard,South Korea,SITE-001
PT-001681,XS-OD-0023,57,Male,White,,92.3,1,Combination,High,2024-05-06,Standard,France,SITE-001
PT-001682,XS-OD-0023,47,Female,White,C5 p.R885H,21.9,5,Active_Drug,Low,2024-01-07,Standard,Sweden,SITE-002
PT-001683,XS-OD-0023,37,Male,White,NLRP3 R260W,30.3,2,SOC,Low,2024-03-28,Standard,Australia,SITE-002
PT-001684,XS-OD-0023,65,Female,White,,68.8,0,Combination,High,2024-02-08,Standard,Spain,SITE-001
PT-001685,XS-OD-0023,53,Female,White,,62.2,1,Active_Drug,Medium,2024-03-28,Standard,Spain,SITE-002
PT-001686,XS-OD-0023,45,Female,Hispanic or Latino,,31.6,3,SOC,High,2024-03-30,Standard,United States,SITE-001
PT-001687,XS-OD-0023,58,Female,Asian,,75.7,3,Combination,Low,2024-02-05,Standard,Sweden,SITE-002
PT-001688,XS-OD-0023,57,Female,Black or African American,C5 p.R885H,39.5,2,Active_Drug,Low,2024-01-09,Standard,South Korea,SITE-001
PT-001689,XS-OD-0023,46,Male,White,NLRP3 R260W,32.9,6,SOC,Low,2024-02-08,Standard,Israel,SITE-002
PT-001690,XS-OD-0023,33,Male,White,NLRP3 R260W,42.5,7,Combination,Medium,2023-12-28,Standard,Norway,SITE-001
PT-001691,XS-OD-0024,22,Female,Hispanic or Latino,TERT p.R865H,30.2,3,Active_Drug,High,2021-02-03,Standard,Italy,SITE-004
PT-001692,XS-OD-0024,51,Male,Asian,,45.7,2,Active_Drug,Low,2021-02-03,Standard,Japan,SITE-003
PT-001693,XS-OD-0024,40,Male,White,TERT p.R865H,47.4,2,Active_Drug,Low,2021-04-28,Standard,Germany,SITE-003
PT-001694,XS-OD-0024,52,Female,White,,38.1,3,Active_Drug,Medium,2021-06-29,Standard,United States,SITE-001
PT-001695,XS-OD-0024,32,Male,White,MUC5B rs35705950,87.2,5,Active_Drug,Medium,2021-05-23,Standard,Italy,SITE-001
PT-001696,XS-OD-0024,38,Male,White,MUC5B rs35705950,44.1,1,Active_Drug,Medium,2021-03-16,Standard,Spain,SITE-002
PT-001697,XS-OD-0024,15,Female,American Indian or Alaska Native,,45.9,1,Active_Drug,Low,2021-03-03,Pediatric_Assent,United States,SITE-001
PT-001698,XS-OD-0024,52,Female,Asian,TERT p.R865H,63.8,2,Active_Drug,Medium,2021-07-27,Standard,Spain,SITE-004
PT-001699,XS-OD-0024,65,Female,White,MUC5B rs35705950,80.6,2,Active_Drug,Medium,2021-05-26,Standard,Spain,SITE-004
PT-001700,XS-OD-0024,57,Male,Asian,,44.1,4,Active_Drug,Low,2021-07-11,Standard,United Kingdom,SITE-003
PT-001701,XS-OD-0024,25,Male,White,BMPR2 c.354+1G>A,41.8,2,Active_Drug,High,2021-03-22,Standard,France,SITE-001
PT-001702,XS-OD-0024,17,Female,Black or African American,,49.7,0,Active_Drug,High,2021-05-21,Pediatric_Assent,France,SITE-001
PT-001703,XS-OD-0024,23,Male,White,TERT p.R865H,48.0,3,Active_Drug,High,2021-04-08,Standard,United States,SITE-004
PT-001704,XS-OD-0024,38,Male,White,,55.1,6,Active_Drug,Medium,2021-05-17,Standard,Italy,SITE-001
PT-001705,XS-OD-0024,63,Female,White,,76.2,1,Active_Drug,High,2021-04-27,Standard,United States,SITE-002
PT-001706,XS-OD-0024,80,Male,Asian,BMPR2 c.354+1G>A,33.7,1,Active_Drug,High,2021-04-18,Standard,France,SITE-005
PT-001707,XS-OD-0024,41,Female,Hispanic or Latino,MUC5B rs35705950,76.6,3,Active_Drug,High,2021-03-22,Standard,Australia,SITE-001
PT-001708,XS-OD-0024,45,Male,Hispanic or Latino,BMPR2 c.354+1G>A,59.7,1,Active_Drug,Low,2021-02-21,Standard,United States,SITE-002
PT-001709,XS-OD-0024,24,Male,White,,15.2,2,Active_Drug,Low,2021-05-23,Standard,Canada,SITE-003
PT-001710,XS-OD-0024,39,Male,Hispanic or Latino,,40.9,2,Active_Drug,Medium,2021-04-03,Standard,Japan,SITE-001
PT-001711,XS-OD-0024,52,Female,White,,47.9,1,Active_Drug,Medium,2021-03-19,Standard,United Kingdom,SITE-002
PT-001712,XS-OD-0024,24,Male,White,MUC5B rs35705950,41.3,2,Active_Drug,High,2021-03-02,Standard,Japan,SITE-004
PT-001713,XS-OD-0024,24,Female,White,MUC5B rs35705950,74.2,0,Active_Drug,Low,2021-03-30,Standard,United Kingdom,SITE-005
PT-001714,XS-OD-0024,33,Male,White,,69.1,1,Active_Drug,Medium,2021-05-13,Standard,France,SITE-002
PT-001715,XS-OD-0024,33,Female,Hispanic or Latino,,63.1,2,Active_Drug,High,2021-04-18,Compassionate,Spain,SITE-002
PT-001716,XS-OD-0024,13,Male,White,,38.0,4,Active_Drug,High,2021-02-01,Pediatric_Assent,Italy,SITE-001
PT-001717,XS-OD-0024,78,Male,White,,62.2,4,Active_Drug,Medium,2021-02-04,Standard,Germany,SITE-001
PT-001718,XS-OD-0025,62,Female,White,,64.6,2,Active_Drug,High,2026-03-07,Standard,Japan,SITE-002
PT-001719,XS-OD-0025,28,Male,American Indian or Alaska Native,MUC5B rs35705950,58.5,0,Placebo,Medium,2025-12-22,Standard,Spain,SITE-001
PT-001720,XS-OD-0025,35,Female,White,,45.3,2,Active_Drug_High_Dose,Low,2026-05-14,Standard,Spain,SITE-001
PT-001721,XS-OD-0025,53,Female,Hispanic or Latino,TERT p.R865H,68.7,2,Active_Drug,Low,2026-03-01,Standard,France,SITE-002
PT-001722,XS-OD-0025,56,Male,Asian,MUC5B rs35705950,31.5,0,Placebo,Low,2026-02-05,Standard,Germany,SITE-001
PT-001723,XS-OD-0025,49,Female,Two or More Races,,56.7,3,Active_Drug_High_Dose,High,2026-02-22,Standard,Italy,SITE-002
PT-001724,XS-OD-0025,31,Female,Black or African American,,22.0,3,Active_Drug,Low,2026-01-12,Standard,United States,SITE-002
PT-001725,XS-OD-0025,53,Male,White,MUC5B rs35705950,13.4,2,Placebo,Medium,2026-04-02,Standard,Spain,SITE-002
PT-001726,XS-OD-0025,51,Female,White,BMPR2 c.354+1G>A,37.7,2,Active_Drug_High_Dose,High,2026-05-03,Standard,Canada,SITE-001
PT-001727,XS-OD-0025,57,Female,Hispanic or Latino,,50.5,4,Active_Drug,Low,2026-01-27,Standard,Italy,SITE-001
PT-001728,XS-OD-0025,61,Male,White,TERT p.R865H,57.9,1,Placebo,High,2026-05-21,Standard,Japan,SITE-002
PT-001729,XS-OD-0025,41,Male,White,,30.5,0,Active_Drug_High_Dose,High,2026-03-30,Standard,Japan,SITE-002
PT-001730,XS-OD-0025,7,Male,Black or African American,MUC5B rs35705950,40.7,0,Active_Drug,Medium,2026-05-04,Pediatric_Assent,France,SITE-001
PT-001731,XS-OD-0026,34,Male,White,p.R301Q,36.8,1,Active_Drug,High,2020-01-04,Standard,Australia,SITE-001
PT-001732,XS-OD-0026,46,Female,White,c.1226A>G (N370S),55.5,1,Active_Drug,Medium,2019-11-04,Standard,United States,SITE-001
PT-001733,XS-OD-0026,31,Intersex,Two or More Races,p.G269S,54.1,0,Active_Drug,Low,2020-01-01,Standard,Norway,SITE-003
PT-001734,XS-OD-0026,32,Male,White,p.R301Q,54.5,6,Active_Drug,Medium,2020-01-05,Standard,Canada,SITE-005
PT-001735,XS-OD-0026,49,Intersex,American Indian or Alaska Native,c.1226A>G (N370S),33.1,0,Active_Drug,Low,2020-01-01,Standard,United States,SITE-001
PT-001736,XS-OD-0026,54,Male,Black or African American,p.G269S,64.7,1,Active_Drug,Low,2019-12-22,Standard,Denmark,SITE-005
PT-001737,XS-OD-0026,33,Female,White,IVS2+1G>A,54.5,4,Active_Drug,Low,2019-12-07,Compassionate,Germany,SITE-003
PT-001738,XS-OD-0026,54,Male,Black or African American,p.R301Q,69.5,2,Active_Drug,Medium,2020-02-29,Standard,Germany,SITE-001
PT-001739,XS-OD-0026,52,Male,Two or More Races,c.1448T>C (L444P),62.9,3,Active_Drug,Medium,2019-12-09,Standard,Switzerland,SITE-006
PT-001740,XS-OD-0026,49,Intersex,White,c.1448T>C (L444P),56.5,1,Active_Drug,Low,2020-01-16,Standard,Austria,SITE-005
PT-001741,XS-OD-0026,25,Female,Black or African American,p.A456P,73.0,1,Active_Drug,Medium,2019-10-14,Standard,Spain,SITE-003
PT-001742,XS-OD-0026,59,Female,White,p.G269S,47.1,0,Active_Drug,Low,2019-12-22,Standard,Belgium,SITE-003
PT-001743,XS-OD-0026,18,Male,Black or African American,p.A456P,41.1,1,Active_Drug,Low,2020-01-02,Standard,Switzerland,SITE-003
PT-001744,XS-OD-0026,43,Male,White,p.A456P,10.0,4,Active_Drug,Low,2019-11-22,Standard,Spain,SITE-002
PT-001745,XS-OD-0026,30,Male,Black or African American,,48.4,5,Active_Drug,High,2019-09-23,Standard,United States,SITE-002
PT-001746,XS-OD-0026,39,Female,White,,71.8,3,Active_Drug,Medium,2019-11-18,Standard,South Korea,SITE-003
PT-001747,XS-OD-0026,23,Male,Asian,p.G269S,45.0,1,Active_Drug,Low,2020-03-08,Standard,Australia,SITE-005
PT-001748,XS-OD-0026,44,Female,Black or African American,p.G269S,10.0,2,Active_Drug,Medium,2020-01-01,Standard,Taiwan,SITE-002
PT-001749,XS-OD-0026,57,Female,Hispanic or Latino,p.A456P,73.5,4,Active_Drug,Low,2019-12-23,Standard,Taiwan,SITE-005
PT-001750,XS-OD-0026,34,Female,White,p.G269S,45.3,0,Active_Drug,Low,2020-01-15,Standard,France,SITE-004
PT-001751,XS-OD-0026,62,Male,White,IVS2+1G>A,47.2,1,Active_Drug,High,2020-01-17,Standard,Denmark,SITE-004
PT-001752,XS-OD-0026,54,Male,Asian,p.G269S,90.4,4,Active_Drug,Medium,2019-12-13,Standard,Australia,SITE-003
PT-001753,XS-OD-0026,36,Female,Asian,c.1226A>G (N370S),73.4,1,Active_Drug,High,2019-12-15,Standard,Germany,SITE-003
PT-001754,XS-OD-0026,43,Male,White,p.A456P,64.6,3,Active_Drug,Low,2020-01-05,Standard,Germany,SITE-003
PT-001755,XS-OD-0026,41,Female,Black or African American,p.A456P,68.6,4,Active_Drug,High,2019-10-31,Standard,United Kingdom,SITE-006
PT-001756,XS-OD-0026,44,Female,White,p.R301Q,47.9,3,Active_Drug,High,2019-12-17,Standard,Canada,SITE-002
PT-001757,XS-OD-0026,58,Female,Asian,IVS2+1G>A,64.1,1,Active_Drug,Low,2020-01-04,Standard,United States,SITE-004
PT-001758,XS-OD-0026,25,Female,Black or African American,IVS2+1G>A,83.9,1,Active_Drug,High,2020-02-26,Standard,United Kingdom,SITE-001
PT-001759,XS-OD-0026,55,Female,Asian,,46.3,2,Active_Drug,Medium,2020-02-26,Standard,Brazil,SITE-006
PT-001760,XS-OD-0026,28,Female,White,p.G269S,43.6,2,Active_Drug,Medium,2019-12-16,Standard,Brazil,SITE-005
PT-001761,XS-OD-0026,55,Female,Hispanic or Latino,,48.3,3,Active_Drug,Low,2019-12-24,Standard,Norway,SITE-005
PT-001762,XS-OD-0026,63,Male,White,,34.9,2,Active_Drug,Low,2019-11-14,Standard,South Korea,SITE-002
PT-001763,XS-OD-0026,60,Female,Black or African American,p.A456P,65.8,2,Active_Drug,Medium,2019-09-24,Standard,Norway,SITE-006
PT-001764,XS-OD-0026,44,Female,White,p.G269S,58.6,1,Active_Drug,Medium,2019-10-28,Standard,United States,SITE-006
PT-001765,XS-OD-0026,58,Female,White,,36.6,2,Active_Drug,Low,2020-01-05,Standard,Germany,SITE-001
PT-001766,XS-OD-0026,39,Intersex,White,,79.0,7,Active_Drug,High,2019-11-07,Standard,Israel,SITE-002
PT-001767,XS-OD-0026,17,Female,White,p.A456P,34.3,1,Active_Drug,Low,2019-10-24,Pediatric_Assent,Belgium,SITE-002
PT-001768,XS-OD-0026,50,Male,Hispanic or Latino,IVS2+1G>A,75.1,1,Active_Drug,Medium,2020-02-09,Standard,Taiwan,SITE-001
PT-001769,XS-OD-0026,31,Female,White,,46.5,0,Active_Drug,High,2019-09-29,Standard,Sweden,SITE-001
PT-001770,XS-OD-0026,50,Male,White,c.1448T>C (L444P),51.8,2,Active_Drug,Medium,2020-01-15,Standard,Canada,SITE-004
PT-001771,XS-OD-0026,16,Male,White,c.1448T>C (L444P),22.4,0,Active_Drug,Low,2019-12-14,Pediatric_Assent,United Kingdom,SITE-004
PT-001772,XS-OD-0026,46,Male,Asian,,38.2,4,Active_Drug,Medium,2019-10-06,Standard,Spain,SITE-004
PT-001773,XS-OD-0026,38,Female,White,p.A456P,66.1,4,Active_Drug,High,2020-01-01,Standard,United Kingdom,SITE-002
PT-001774,XS-OD-0026,46,Female,White,,47.5,0,Active_Drug,Low,2020-02-09,Standard,Canada,SITE-006
PT-001775,XS-OD-0026,41,Male,White,c.1448T>C (L444P),56.7,1,Active_Drug,Medium,2020-01-11,Standard,Spain,SITE-004
PT-001776,XS-OD-0026,36,Female,White,,44.8,0,Active_Drug,Medium,2019-12-30,Standard,Belgium,SITE-002
PT-001777,XS-OD-0027,41,Female,White,,69.2,4,Active_Drug,Standard,2020-03-27,Standard,Spain,SITE-006
PT-001778,XS-OD-0027,52,Female,White,p.G269S,44.4,0,Active_Drug,Standard,2020-04-27,Standard,United Kingdom,SITE-008
PT-001779,XS-OD-0027,36,Male,White,,42.7,2,Active_Drug,Standard,2020-04-13,Standard,France,SITE-014
PT-001780,XS-OD-0027,45,Male,Hispanic or Latino,,63.1,3,Active_Drug,Standard,2020-02-13,Standard,Italy,SITE-004
PT-001781,XS-OD-0027,59,Male,Black or African American,,76.0,1,Active_Drug,Standard,2020-01-07,Standard,Canada,SITE-008
PT-001782,XS-OD-0027,37,Female,White,IVS2+1G>A,44.7,2,Active_Drug,Standard,2020-05-02,Standard,Netherlands,SITE-001
PT-001783,XS-OD-0027,18,Male,Hispanic or Latino,IVS2+1G>A,56.0,2,Active_Drug,Standard,2020-03-02,Standard,Netherlands,SITE-018
PT-001784,XS-OD-0027,60,Female,Black or African American,IVS2+1G>A,37.8,3,Active_Drug,Standard,2019-11-15,Compassionate,Italy,SITE-009
PT-001785,XS-OD-0027,40,Male,White,,56.3,4,Active_Drug,Standard,2020-04-18,Standard,Canada,SITE-006
PT-001786,XS-OD-0027,57,Male,Hispanic or Latino,p.G269S,50.3,0,Active_Drug,Standard,2020-01-14,Standard,France,SITE-018
PT-001787,XS-OD-0027,20,Male,Asian,IVS2+1G>A,40.5,1,Active_Drug,Standard,2020-02-20,Standard,United States,SITE-009
PT-001788,XS-OD-0027,44,Female,White,c.1226A>G (N370S),95.0,3,Active_Drug,Standard,2020-01-30,Standard,France,SITE-016
PT-001789,XS-OD-0027,17,Male,Black or African American,,45.6,3,Active_Drug,Standard,2020-04-08,Pediatric_Assent,United States,SITE-008
PT-001790,XS-OD-0027,60,Male,White,c.1226A>G (N370S),43.0,2,Active_Drug,Standard,2020-01-06,Standard,Japan,SITE-001
PT-001791,XS-OD-0027,27,Female,Hispanic or Latino,IVS2+1G>A,65.2,1,Active_Drug,Standard,2019-12-23,Standard,Canada,SITE-003
PT-001792,XS-OD-0027,42,Female,White,p.G269S,59.8,1,Active_Drug,Standard,2020-01-07,Standard,United States,SITE-001
PT-001793,XS-OD-0027,63,Female,Asian,IVS2+1G>A,72.1,4,Active_Drug,Standard,2020-01-21,Standard,Japan,SITE-013
PT-001794,XS-OD-0027,47,Male,Black or African American,p.G269S,52.0,1,Active_Drug,Standard,2020-03-09,Standard,Italy,SITE-002
PT-001795,XS-OD-0027,41,Male,Black or African American,p.G269S,55.8,2,Active_Drug,Standard,2019-12-21,Standard,Canada,SITE-012
PT-001796,XS-OD-0027,27,Female,White,,10.6,1,Active_Drug,Standard,2019-11-21,Standard,Japan,SITE-002
PT-001797,XS-OD-0027,21,Female,American Indian or Alaska Native,c.1226A>G (N370S),38.0,3,Active_Drug,Standard,2020-04-24,Standard,Spain,SITE-011
PT-001798,XS-OD-0027,27,Male,White,c.1448T>C (L444P),41.5,2,Active_Drug,Standard,2019-12-05,Standard,Canada,SITE-003
PT-001799,XS-OD-0027,39,Female,White,p.R301Q,28.2,5,Active_Drug,Standard,2020-01-05,Standard,United States,SITE-015
PT-001800,XS-OD-0027,50,Male,White,,49.5,4,Active_Drug,Standard,2020-01-25,Emergency,Spain,SITE-009
PT-001801,XS-OD-0027,40,Female,White,p.R301Q,73.2,2,Active_Drug,Standard,2020-01-16,Standard,United Kingdom,SITE-015
PT-001802,XS-OD-0027,54,Female,Hispanic or Latino,,65.1,1,Active_Drug,Standard,2020-03-26,Emergency,Germany,SITE-018
PT-001803,XS-OD-0027,39,Male,Black or African American,c.1448T>C (L444P),41.1,2,Active_Drug,Standard,2019-11-16,Standard,France,SITE-011
PT-001804,XS-OD-0027,42,Female,White,,48.1,4,Active_Drug,Standard,2020-01-06,Standard,Australia,SITE-009
PT-001805,XS-OD-0027,24,Male,White,c.1226A>G (N370S),61.8,1,Active_Drug,Standard,2019-12-29,Standard,Germany,SITE-018
PT-001806,XS-OD-0027,33,Female,White,,41.8,2,Active_Drug,Standard,2019-11-09,Standard,Netherlands,SITE-014
PT-001807,XS-OD-0027,50,Male,Hispanic or Latino,p.G269S,68.1,2,Active_Drug,Standard,2020-01-16,Standard,Canada,SITE-016
PT-001808,XS-OD-0027,35,Intersex,White,p.A456P,71.9,5,Active_Drug,Standard,2020-03-19,Standard,Italy,SITE-013
PT-001809,XS-OD-0027,43,Male,Asian,IVS2+1G>A,62.2,1,Active_Drug,Standard,2020-03-24,Standard,United States,SITE-014
PT-001810,XS-OD-0027,36,Female,White,c.1226A>G (N370S),35.6,3,Active_Drug,Standard,2020-02-04,Standard,Netherlands,SITE-018
PT-001811,XS-OD-0027,30,Male,White,p.R301Q,61.3,2,Active_Drug,Standard,2020-03-06,Standard,France,SITE-011
PT-001812,XS-OD-0027,65,Male,Asian,,54.8,1,Active_Drug,Standard,2019-12-30,Standard,Canada,SITE-019
PT-001813,XS-OD-0027,56,Male,Hispanic or Latino,p.R301Q,52.7,3,Active_Drug,Standard,2020-02-18,Standard,United Kingdom,SITE-003
PT-001814,XS-OD-0027,59,Male,Asian,,67.0,0,Active_Drug,Standard,2020-02-29,Standard,France,SITE-010
PT-001815,XS-OD-0027,50,Female,White,,89.8,1,Active_Drug,Standard,2020-04-19,Standard,United States,SITE-005
PT-001816,XS-OD-0027,50,Female,Asian,p.G269S,43.7,1,Active_Drug,Standard,2020-01-02,Standard,France,SITE-015
PT-001817,XS-OD-0027,55,Male,White,p.A456P,80.6,2,Active_Drug,Standard,2020-04-29,Standard,Italy,SITE-007
PT-001818,XS-OD-0027,19,Male,White,p.A456P,31.6,0,Active_Drug,Standard,2020-02-22,Standard,United Kingdom,SITE-012
PT-001819,XS-OD-0027,30,Male,White,p.R301Q,65.4,1,Active_Drug,Standard,2020-03-25,Standard,United States,SITE-005
PT-001820,XS-OD-0027,42,Female,Black or African American,,53.4,0,Active_Drug,Standard,2020-03-20,Standard,Canada,SITE-011
PT-001821,XS-OD-0027,45,Female,Asian,c.1226A>G (N370S),30.3,2,Active_Drug,Standard,2020-02-22,Standard,United Kingdom,SITE-006
PT-001822,XS-OD-0027,27,Female,Black or African American,p.G269S,44.0,2,Active_Drug,Standard,2020-01-08,Standard,Japan,SITE-006
PT-001823,XS-OD-0027,44,Female,White,,62.2,2,Active_Drug,Standard,2019-11-12,Standard,Japan,SITE-008
PT-001824,XS-OD-0027,33,Intersex,White,p.A456P,63.2,5,Active_Drug,Standard,2020-02-07,Standard,Canada,SITE-014
PT-001825,XS-OD-0027,66,Female,White,p.A456P,23.9,2,Active_Drug,Standard,2019-12-15,Standard,Spain,SITE-013
PT-001826,XS-OD-0027,63,Male,Hispanic or Latino,p.G269S,23.9,0,Active_Drug,Standard,2019-11-29,Standard,France,SITE-019
PT-001827,XS-OD-0027,32,Female,Hispanic or Latino,c.1226A>G (N370S),55.2,1,Active_Drug,Standard,2020-02-27,Standard,Germany,SITE-003
PT-001828,XS-OD-0027,54,Male,Hispanic or Latino,p.G269S,45.5,2,Active_Drug,Standard,2020-03-15,Standard,Germany,SITE-003
PT-001829,XS-OD-0027,44,Female,White,p.R301Q,22.5,3,Active_Drug,Standard,2020-01-04,Standard,United States,SITE-015
PT-001830,XS-OD-0027,37,Female,White,p.G269S,59.4,2,Active_Drug,Standard,2019-12-01,Standard,Italy,SITE-015
PT-001831,XS-OD-0027,24,Female,Hispanic or Latino,,56.5,1,Active_Drug,Standard,2020-01-18,Standard,Germany,SITE-014
PT-001832,XS-OD-0027,46,Male,Black or African American,p.A456P,81.5,5,Active_Drug,Standard,2020-02-19,Standard,Netherlands,SITE-003
PT-001833,XS-OD-0027,28,Male,White,p.G269S,66.0,1,Active_Drug,Standard,2020-03-17,Standard,Canada,SITE-013
PT-001834,XS-OD-0027,75,Female,White,,32.8,1,Active_Drug,Standard,2019-12-14,Standard,Italy,SITE-018
PT-001835,XS-OD-0027,2,Male,Asian,,18.4,3,Active_Drug,Standard,2020-01-30,Pediatric_Assent,France,SITE-019
PT-001836,XS-OD-0027,49,Female,White,IVS2+1G>A,44.6,1,Active_Drug,Standard,2019-12-16,Standard,Italy,SITE-010
PT-001837,XS-OD-0027,72,Female,White,p.G269S,78.1,2,Active_Drug,Standard,2019-12-22,Standard,United States,SITE-015
PT-001838,XS-OD-0027,54,Male,White,p.G269S,40.4,1,Active_Drug,Standard,2020-01-10,Standard,Spain,SITE-018
PT-001839,XS-OD-0027,26,Female,White,IVS2+1G>A,82.9,3,Active_Drug,Standard,2020-01-25,Standard,France,SITE-007
PT-001840,XS-OD-0027,73,Male,White,p.R301Q,10.2,0,Active_Drug,Standard,2019-12-13,Standard,France,SITE-006
PT-001841,XS-OD-0027,17,Male,White,p.A456P,50.6,3,Active_Drug,Standard,2019-12-11,Pediatric_Assent,Australia,SITE-010
PT-001842,XS-OD-0027,37,Male,White,IVS2+1G>A,60.2,2,Active_Drug,Standard,2020-04-08,Standard,Netherlands,SITE-010
PT-001843,XS-OD-0027,40,Female,Black or African American,c.1448T>C (L444P),81.1,1,Active_Drug,Standard,2020-03-28,Standard,United States,SITE-005
PT-001844,XS-OD-0027,77,Female,Black or African American,,50.8,2,Active_Drug,Standard,2019-11-07,Standard,United States,SITE-012
PT-001845,XS-OD-0027,38,Female,Hispanic or Latino,,57.9,3,Active_Drug,Standard,2020-01-10,Standard,Italy,SITE-017
PT-001846,XS-OD-0027,32,Male,White,c.1226A>G (N370S),54.6,1,Active_Drug,Standard,2020-03-31,Standard,Canada,SITE-009
PT-001847,XS-OD-0027,61,Female,White,p.G269S,51.7,0,Active_Drug,Standard,2019-12-22,Emergency,United States,SITE-005
PT-001848,XS-OD-0027,66,Female,Black or African American,c.1448T>C (L444P),89.3,2,Active_Drug,Standard,2020-01-26,Standard,France,SITE-009
PT-001849,XS-OD-0027,64,Female,White,p.R301Q,48.9,1,Active_Drug,Standard,2020-05-01,Standard,Netherlands,SITE-001
PT-001850,XS-OD-0027,40,Male,White,c.1226A>G (N370S),59.4,2,Active_Drug,Standard,2019-12-26,Standard,France,SITE-018
PT-001851,XS-OD-0027,54,Female,Hispanic or Latino,c.1448T>C (L444P),40.8,3,Active_Drug,Standard,2020-02-27,Standard,Australia,SITE-009
PT-001852,XS-OD-0027,46,Female,Hispanic or Latino,c.1226A>G (N370S),67.1,2,Active_Drug,Standard,2020-01-26,Standard,Canada,SITE-010
PT-001853,XS-OD-0027,27,Male,White,,57.7,3,Active_Drug,Standard,2020-01-15,Standard,United Kingdom,SITE-014
PT-001854,XS-OD-0027,28,Male,Hispanic or Latino,,79.8,1,Active_Drug,Standard,2019-12-17,Standard,United Kingdom,SITE-002
PT-001855,XS-OD-0027,23,Male,White,,83.6,2,Active_Drug,Standard,2019-12-12,Standard,Japan,SITE-013
PT-001856,XS-OD-0027,52,Male,White,p.G269S,40.4,4,Active_Drug,Standard,2020-04-27,Standard,United Kingdom,SITE-015
PT-001857,XS-OD-0027,45,Male,Black or African American,,38.1,3,Active_Drug,Standard,2019-12-21,Standard,France,SITE-006
PT-001858,XS-OD-0027,27,Female,White,p.R301Q,81.2,2,Active_Drug,Standard,2020-01-20,Standard,United Kingdom,SITE-012
PT-001859,XS-OD-0027,51,Male,White,c.1448T>C (L444P),77.4,0,Active_Drug,Standard,2020-01-08,Standard,Spain,SITE-010
PT-001860,XS-OD-0027,38,Female,Black or African American,c.1226A>G (N370S),43.7,2,Active_Drug,Standard,2019-11-12,Standard,Japan,SITE-005
PT-001861,XS-OD-0027,48,Female,White,c.1448T>C (L444P),90.1,1,Active_Drug,Standard,2020-02-11,Standard,Germany,SITE-010
PT-001862,XS-OD-0027,4,Female,White,p.R301Q,45.0,3,Active_Drug,Standard,2020-04-15,Pediatric_Assent,Australia,SITE-015
PT-001863,XS-OD-0027,58,Female,White,IVS2+1G>A,66.1,1,Active_Drug,Standard,2019-12-09,Standard,Italy,SITE-009
PT-001864,XS-OD-0027,28,Male,White,p.A456P,49.8,2,Active_Drug,Standard,2020-01-07,Compassionate,Spain,SITE-001
PT-001865,XS-OD-0027,42,Female,Native Hawaiian or Other Pacific Islander,p.A456P,37.7,2,Active_Drug,Standard,2020-01-31,Standard,United States,SITE-011
PT-001866,XS-OD-0027,20,Female,Black or African American,p.G269S,84.6,0,Active_Drug,Standard,2020-01-23,Standard,Canada,SITE-013
PT-001867,XS-OD-0027,43,Male,White,,23.1,5,Active_Drug,Standard,2020-02-06,Standard,Germany,SITE-006
PT-001868,XS-OD-0027,2,Female,Asian,,54.3,0,Active_Drug,Standard,2020-03-10,Pediatric_Assent,Italy,SITE-004
PT-001869,XS-OD-0027,32,Male,White,p.G269S,41.9,1,Active_Drug,Standard,2019-12-10,Standard,Japan,SITE-001
PT-001870,XS-OD-0027,38,Female,White,p.A456P,60.7,1,Active_Drug,Standard,2019-11-06,Standard,Australia,SITE-004
PT-001871,XS-OD-0027,35,Female,White,IVS2+1G>A,31.2,4,Active_Drug,Standard,2020-01-08,Standard,Netherlands,SITE-003
PT-001872,XS-OD-0027,65,Female,Asian,,52.1,2,Active_Drug,Standard,2020-01-08,Standard,Netherlands,SITE-012
PT-001873,XS-OD-0027,60,Male,White,,60.4,5,Active_Drug,Standard,2020-01-18,Standard,Australia,SITE-016
PT-001874,XS-OD-0027,49,Female,White,,51.3,5,Active_Drug,Standard,2020-02-07,Standard,Italy,SITE-002
PT-001875,XS-OD-0027,48,Female,Black or African American,p.R301Q,53.5,5,Active_Drug,Standard,2019-12-17,Standard,Germany,SITE-014
PT-001876,XS-OD-0027,64,Female,White,p.R301Q,77.3,3,Active_Drug,Standard,2020-02-28,Standard,Japan,SITE-004
PT-001877,XS-OD-0027,65,Female,White,p.G269S,70.3,2,Active_Drug,Standard,2019-11-08,Standard,Germany,SITE-003
PT-001878,XS-OD-0027,13,Male,Hispanic or Latino,,35.4,0,Active_Drug,Standard,2019-12-02,Pediatric_Assent,Italy,SITE-005
PT-001879,XS-OD-0027,44,Male,Two or More Races,c.1226A>G (N370S),37.7,3,Active_Drug,Standard,2020-03-28,Standard,Germany,SITE-009
PT-001880,XS-OD-0027,49,Male,Hispanic or Latino,,67.7,4,Active_Drug,Standard,2020-04-10,Standard,Germany,SITE-014
PT-001881,XS-OD-0027,48,Male,Asian,p.A456P,38.0,0,Active_Drug,Standard,2020-04-06,Standard,Canada,SITE-017
PT-001882,XS-OD-0027,32,Female,Black or African American,p.A456P,25.3,0,Active_Drug,Standard,2020-01-14,Standard,Italy,SITE-005
PT-001883,XS-OD-0027,56,Female,White,c.1226A>G (N370S),33.8,2,Active_Drug,Standard,2020-02-19,Standard,Canada,SITE-001
PT-001884,XS-OD-0027,88,Female,Hispanic or Latino,IVS2+1G>A,17.8,4,Active_Drug,Standard,2020-01-28,Standard,Spain,SITE-011
PT-001885,XS-OD-0028,30,Male,White,,52.3,1,Active_Drug,Standard,2022-02-25,Standard,Canada,SITE-001
PT-001886,XS-OD-0028,30,Female,White,p.A456P,50.8,1,Active_Drug,Standard,2022-04-30,Standard,Austria,SITE-003
PT-001887,XS-OD-0028,42,Female,White,,88.0,0,Active_Drug,Standard,2021-12-09,Standard,Denmark,SITE-001
PT-001888,XS-OD-0028,38,Male,White,,56.6,3,Active_Drug,Standard,2022-03-03,Standard,Denmark,SITE-005
PT-001889,XS-OD-0028,31,Female,Asian,p.G269S,44.2,4,Active_Drug,Standard,2022-02-18,Standard,Spain,SITE-003
PT-001890,XS-OD-0028,23,Female,Asian,p.A456P,66.2,0,Active_Drug,Standard,2022-01-14,Standard,Germany,SITE-005
PT-001891,XS-OD-0028,24,Female,White,p.R301Q,20.7,2,Active_Drug,Standard,2021-12-12,Standard,Spain,SITE-007
PT-001892,XS-OD-0028,27,Male,Asian,IVS2+1G>A,71.2,2,Active_Drug,Standard,2022-04-05,Standard,Brazil,SITE-002
PT-001893,XS-OD-0028,39,Male,White,c.1448T>C (L444P),25.2,2,Active_Drug,Standard,2022-01-20,Standard,Norway,SITE-004
PT-001894,XS-OD-0028,14,Male,White,,48.6,1,Active_Drug,Standard,2022-03-25,Pediatric_Assent,United Kingdom,SITE-001
PT-001895,XS-OD-0028,65,Female,White,p.A456P,50.9,5,Active_Drug,Standard,2022-02-14,Standard,Germany,SITE-006
PT-001896,XS-OD-0028,35,Female,White,p.R301Q,56.0,1,Active_Drug,Standard,2022-03-01,Standard,Italy,SITE-003
PT-001897,XS-OD-0028,36,Male,Black or African American,p.R301Q,25.5,0,Active_Drug,Standard,2022-04-03,Standard,Austria,SITE-001
PT-001898,XS-OD-0028,55,Male,Asian,p.A456P,46.8,0,Active_Drug,Standard,2022-02-12,Standard,Taiwan,SITE-001
PT-001899,XS-OD-0028,5,Male,White,p.A456P,54.8,1,Active_Drug,Standard,2021-12-13,Pediatric_Assent,Spain,SITE-007
PT-001900,XS-OD-0028,22,Male,White,p.G269S,74.4,2,Active_Drug,Standard,2022-03-27,Standard,Switzerland,SITE-004
PT-001901,XS-OD-0028,24,Female,White,p.A456P,46.9,4,Active_Drug,Standard,2021-12-25,Standard,Sweden,SITE-004
PT-001902,XS-OD-0028,30,Male,Asian,,67.5,0,Active_Drug,Standard,2022-02-10,Standard,Israel,SITE-002
PT-001903,XS-OD-0028,43,Female,Black or African American,c.1448T>C (L444P),62.3,2,Active_Drug,Standard,2022-03-08,Standard,Norway,SITE-004
PT-001904,XS-OD-0028,40,Male,American Indian or Alaska Native,c.1448T>C (L444P),58.0,3,Active_Drug,Standard,2022-03-11,Standard,Norway,SITE-005
PT-001905,XS-OD-0028,55,Male,Asian,,60.3,2,Active_Drug,Standard,2022-04-22,Compassionate,Denmark,SITE-002
PT-001906,XS-OD-0028,67,Female,White,,65.4,2,Active_Drug,Standard,2022-01-15,Standard,Italy,SITE-002
PT-001907,XS-OD-0028,44,Female,Hispanic or Latino,p.A456P,60.1,6,Active_Drug,Standard,2022-01-13,Standard,United States,SITE-002
PT-001908,XS-OD-0028,41,Male,White,c.1448T>C (L444P),51.5,1,Active_Drug,Standard,2022-05-07,Standard,Denmark,SITE-001
PT-001909,XS-OD-0028,74,Male,White,p.G269S,39.9,1,Active_Drug,Standard,2021-11-24,Standard,Belgium,SITE-005
PT-001910,XS-OD-0028,38,Female,White,,70.0,2,Active_Drug,Standard,2022-04-13,Emergency,Australia,SITE-003
PT-001911,XS-OD-0028,47,Male,White,,78.8,1,Active_Drug,Standard,2021-12-05,Standard,Netherlands,SITE-002
PT-001912,XS-OD-0028,24,Male,White,c.1448T>C (L444P),21.3,1,Active_Drug,Standard,2021-12-20,Standard,France,SITE-002
PT-001913,XS-OD-0028,40,Female,Hispanic or Latino,,27.8,0,Active_Drug,Standard,2022-03-10,Standard,Canada,SITE-002
PT-001914,XS-OD-0028,43,Female,White,,69.1,3,Active_Drug,Standard,2022-03-12,Standard,Italy,SITE-005
PT-001915,XS-OD-0028,66,Male,Hispanic or Latino,c.1226A>G (N370S),76.5,4,Active_Drug,Standard,2021-11-23,Standard,Israel,SITE-001
PT-001916,XS-OD-0028,43,Male,Hispanic or Latino,,57.9,4,Active_Drug,Standard,2021-11-11,Standard,Sweden,SITE-007
PT-001917,XS-OD-0028,51,Male,Asian,p.G269S,38.3,4,Active_Drug,Standard,2022-05-03,Standard,Canada,SITE-003
PT-001918,XS-OD-0028,83,Female,White,p.A456P,52.1,0,Active_Drug,Standard,2022-01-11,Standard,Israel,SITE-004
PT-001919,XS-OD-0028,37,Female,White,,68.4,6,Active_Drug,Standard,2022-05-06,Standard,Norway,SITE-007
PT-001920,XS-OD-0028,32,Female,White,,67.7,2,Active_Drug,Standard,2021-12-30,Standard,Brazil,SITE-004
PT-001921,XS-OD-0028,41,Male,White,c.1448T>C (L444P),53.8,2,Active_Drug,Standard,2022-01-04,Standard,France,SITE-006
PT-001922,XS-OD-0028,43,Female,White,p.R301Q,66.0,5,Active_Drug,Standard,2021-12-10,Emergency,Belgium,SITE-006
PT-001923,XS-OD-0028,51,Male,White,p.G269S,48.6,0,Active_Drug,Standard,2022-02-07,Standard,Japan,SITE-002
PT-001924,XS-OD-0028,57,Male,White,,25.5,2,Active_Drug,Standard,2022-01-06,Compassionate,Brazil,SITE-001
PT-001925,XS-OD-0028,25,Female,White,p.A456P,41.6,3,Active_Drug,Standard,2022-04-04,Standard,Belgium,SITE-001
PT-001926,XS-OD-0028,40,Male,Black or African American,c.1448T>C (L444P),42.4,1,Active_Drug,Standard,2022-03-04,Standard,Germany,SITE-001
PT-001927,XS-OD-0029,17,Female,White,c.1226A>G (N370S),68.7,2,Active_Drug,Low,2024-08-16,Pediatric_Assent,Netherlands,SITE-001
PT-001928,XS-OD-0029,46,Male,Black or African American,c.1448T>C (L444P),75.4,0,Active_Drug,High,2024-02-28,Standard,Japan,SITE-001
PT-001929,XS-OD-0029,53,Male,White,c.1448T>C (L444P),71.0,1,Active_Drug,High,2024-05-17,Standard,France,SITE-001
PT-001930,XS-OD-0029,31,Male,Hispanic or Latino,p.A456P,56.6,2,Active_Drug,Low,2024-04-10,Standard,United States,SITE-002
PT-001931,XS-OD-0029,14,Female,White,,55.4,0,Active_Drug,Low,2024-02-28,Pediatric_Assent,Australia,SITE-002
PT-001932,XS-OD-0029,37,Male,White,c.1226A>G (N370S),55.5,1,Active_Drug,Low,2024-06-01,Standard,Canada,SITE-002
PT-001933,XS-OD-0029,31,Female,Asian,c.1448T>C (L444P),60.3,3,Active_Drug,High,2024-03-17,Standard,Canada,SITE-002
PT-001934,XS-OD-0029,42,Male,White,,61.6,1,Active_Drug,High,2024-07-17,Standard,Spain,SITE-002
PT-001935,XS-OD-0029,68,Female,White,,58.6,2,Active_Drug,Medium,2024-03-03,Standard,Germany,SITE-002
PT-001936,XS-OD-0029,39,Male,White,c.1226A>G (N370S),58.2,1,Active_Drug,High,2024-02-22,Standard,United Kingdom,SITE-001
PT-001937,XS-OD-0029,43,Male,White,p.G269S,41.4,3,Active_Drug,High,2024-03-16,Standard,United States,SITE-002
PT-001938,XS-OD-0029,36,Female,White,IVS2+1G>A,40.6,1,Active_Drug,Low,2024-07-24,Standard,Germany,SITE-001
PT-001939,XS-OD-0029,56,Female,White,p.A456P,31.7,0,Active_Drug,Medium,2024-07-14,Standard,Canada,SITE-001
PT-001940,XS-OD-0029,43,Male,White,,49.4,1,Active_Drug,High,2024-07-25,Standard,France,SITE-001
PT-001941,XS-OD-0029,24,Female,Black or African American,,54.4,2,Active_Drug,High,2024-06-04,Compassionate,Netherlands,SITE-002
PT-001942,XS-OD-0029,58,Male,Black or African American,c.1226A>G (N370S),31.5,0,Active_Drug,Medium,2024-03-17,Standard,Spain,SITE-001
PT-001943,XS-OD-0029,21,Male,Asian,p.A456P,59.8,2,Active_Drug,High,2024-05-06,Standard,Netherlands,SITE-002
PT-001944,XS-OD-0029,16,Female,Asian,,95.0,3,Active_Drug,Medium,2024-07-03,Pediatric_Assent,Netherlands,SITE-002
PT-001945,XS-OD-0029,38,Male,Asian,,40.7,1,Active_Drug,Low,2024-06-13,Standard,United States,SITE-002
PT-001946,XS-OD-0029,24,Female,White,p.G269S,70.0,2,Active_Drug,Medium,2024-03-29,Standard,Australia,SITE-001
PT-001947,XS-OD-0029,50,Male,White,IVS2+1G>A,36.9,3,Active_Drug,High,2024-02-20,Standard,France,SITE-001
PT-001948,XS-OD-0030,29,Female,Hispanic or Latino,p.G269S,53.6,6,Active_Drug,Low,2020-01-09,Standard,Israel,SITE-001
PT-001949,XS-OD-0030,13,Intersex,Asian,p.R301Q,44.9,1,Active_Drug,Low,2020-01-31,Pediatric_Assent,Israel,SITE-001
PT-001950,XS-OD-0030,5,Female,White,p.G269S,43.5,3,Active_Drug,Low,2020-02-18,Pediatric_Assent,Taiwan,SITE-002
PT-001951,XS-OD-0030,37,Female,White,,50.5,1,Active_Drug,High,2020-01-31,Standard,Italy,SITE-002
PT-001952,XS-OD-0030,40,Female,Hispanic or Latino,p.A456P,38.3,5,Active_Drug,High,2020-02-14,Standard,Japan,SITE-002
PT-001953,XS-OD-0030,65,Female,White,IVS2+1G>A,75.7,3,Active_Drug,Low,2020-05-14,Standard,Italy,SITE-001
PT-001954,XS-OD-0030,38,Male,White,p.R301Q,77.3,0,Active_Drug,Low,2020-03-25,Standard,Taiwan,SITE-001
PT-001955,XS-OD-0030,25,Female,Asian,,88.1,6,Active_Drug,Low,2019-12-31,Standard,France,SITE-002
PT-001956,XS-OD-0030,24,Female,Asian,IVS2+1G>A,84.6,1,Active_Drug,Medium,2020-01-25,Standard,Taiwan,SITE-001
PT-001957,XS-OD-0030,5,Female,Asian,,38.0,1,Active_Drug,Low,2019-12-26,Pediatric_Assent,Spain,SITE-002
PT-001958,XS-OD-0030,81,Female,White,,47.7,3,Active_Drug,High,2019-11-25,Standard,United States,SITE-002
PT-001959,XS-OD-0030,45,Female,White,,18.3,3,Active_Drug,High,2020-03-27,Standard,Germany,SITE-002
PT-001960,XS-OD-0030,67,Male,White,,69.7,1,Active_Drug,High,2020-02-13,Standard,Taiwan,SITE-001
PT-001961,XS-OD-0030,42,Female,Hispanic or Latino,,95.0,0,Active_Drug,High,2020-05-05,Standard,Germany,SITE-002
PT-001962,XS-OD-0030,83,Male,Hispanic or Latino,c.1226A>G (N370S),65.2,3,Active_Drug,Medium,2020-03-07,Standard,Israel,SITE-001
PT-001963,XS-OD-0030,20,Female,Black or African American,IVS2+1G>A,84.8,1,Active_Drug,High,2020-04-02,Standard,Brazil,SITE-002
PT-001964,XS-OD-0030,47,Male,White,c.1448T>C (L444P),56.6,3,Active_Drug,Medium,2019-12-03,Compassionate,Sweden,SITE-002
PT-001965,XS-OD-0030,23,Female,White,IVS2+1G>A,68.7,1,Active_Drug,Medium,2019-12-06,Emergency,Germany,SITE-002
PT-001966,XS-OD-0030,19,Female,White,,64.4,3,Active_Drug,Low,2020-03-19,Standard,United States,SITE-001
PT-001967,XS-OD-0030,23,Male,White,p.A456P,48.3,0,Active_Drug,High,2020-03-12,Standard,South Korea,SITE-002
PT-001968,XS-OD-0030,30,Male,White,IVS2+1G>A,80.9,1,Active_Drug,Medium,2020-05-12,Standard,Denmark,SITE-002
PT-001969,XS-OD-0030,73,Male,Hispanic or Latino,p.R301Q,48.1,2,Active_Drug,Medium,2020-02-22,Standard,Sweden,SITE-001
PT-001970,XS-OD-0030,43,Female,Black or African American,p.G269S,59.8,3,Active_Drug,High,2020-01-17,Standard,Italy,SITE-002
PT-001971,XS-OD-0030,82,Male,White,,61.2,0,Active_Drug,High,2020-03-24,Standard,Denmark,SITE-002
PT-001972,XS-OD-0030,46,Female,Native Hawaiian or Other Pacific Islander,p.A456P,74.0,1,Active_Drug,High,2020-02-28,Standard,Israel,SITE-001
PT-001973,XS-OD-0030,52,Male,Black or African American,c.1226A>G (N370S),57.2,0,Active_Drug,Medium,2020-03-21,Standard,Japan,SITE-002
PT-001974,XS-OD-0031,33,Male,White,SCN1A R1648H,53.4,2,Active_Drug,Standard,2020-01-28,Standard,Taiwan,SITE-043
PT-001975,XS-OD-0031,18,Male,Black or African American,SOD1 A4V,37.2,2,Placebo,Standard,2019-12-09,Standard,Spain,SITE-008
PT-001976,XS-OD-0031,16,Female,White,,70.0,4,Active_Drug,Standard,2019-09-13,Pediatric_Assent,Germany,SITE-017
PT-001977,XS-OD-0031,39,Female,Hispanic or Latino,SCN1A R1648H,55.6,0,Placebo,Standard,2019-12-28,Standard,Denmark,SITE-008
PT-001978,XS-OD-0031,33,Female,White,Exon 51 deletion,78.1,1,Active_Drug,Standard,2019-10-14,Standard,France,SITE-022
PT-001979,XS-OD-0031,56,Male,White,SOD1 A4V,57.0,0,Placebo,Standard,2019-10-04,Standard,Austria,SITE-038
PT-001980,XS-OD-0031,30,Female,Black or African American,CAG repeat expansion,69.1,3,Active_Drug,Standard,2020-01-22,Standard,Italy,SITE-021
PT-001981,XS-OD-0031,24,Female,Hispanic or Latino,SCN1A R1648H,46.0,0,Placebo,Standard,2019-08-28,Standard,Netherlands,SITE-041
PT-001982,XS-OD-0031,35,Female,Hispanic or Latino,CAG repeat expansion,66.5,3,Active_Drug,Standard,2020-02-19,Standard,Austria,SITE-026
PT-001983,XS-OD-0031,39,Female,Asian,,88.2,7,Placebo,Standard,2019-10-15,Standard,Sweden,SITE-006
PT-001984,XS-OD-0031,63,Female,Native Hawaiian or Other Pacific Islander,,68.2,1,Active_Drug,Standard,2020-01-07,Standard,Brazil,SITE-019
PT-001985,XS-OD-0031,26,Male,Hispanic or Latino,SOD1 A4V,50.1,1,Placebo,Standard,2019-12-25,Standard,France,SITE-024
PT-001986,XS-OD-0031,38,Female,White,SOD1 A4V,31.3,2,Active_Drug,Standard,2019-09-10,Standard,Brazil,SITE-014
PT-001987,XS-OD-0031,44,Male,White,CAG repeat expansion,10.0,3,Placebo,Standard,2019-08-27,Standard,United Kingdom,SITE-021
PT-001988,XS-OD-0031,50,Female,Asian,SCN1A R1648H,81.9,2,Active_Drug,Standard,2019-12-25,Standard,Sweden,SITE-040
PT-001989,XS-OD-0031,50,Male,Asian,SMN1 deletion,61.9,3,Placebo,Standard,2019-08-28,Standard,Sweden,SITE-027
PT-001990,XS-OD-0031,41,Female,White,Exon 51 deletion,78.1,1,Active_Drug,Standard,2020-01-02,Standard,United Kingdom,SITE-012
PT-001991,XS-OD-0031,88,Female,White,,43.5,1,Placebo,Standard,2019-12-23,Standard,Sweden,SITE-029
PT-001992,XS-OD-0031,55,Female,Hispanic or Latino,,54.9,0,Active_Drug,Standard,2019-11-04,Standard,South Korea,SITE-010
PT-001993,XS-OD-0031,28,Male,White,CAG repeat expansion,10.0,0,Placebo,Standard,2019-09-06,Standard,Italy,SITE-024
PT-001994,XS-OD-0031,38,Male,Hispanic or Latino,SOD1 A4V,53.9,0,Active_Drug,Standard,2019-12-19,Standard,Austria,SITE-005
PT-001995,XS-OD-0031,27,Female,White,CAG repeat expansion,95.0,0,Placebo,Standard,2020-01-18,Standard,Australia,SITE-007
PT-001996,XS-OD-0031,68,Female,Hispanic or Latino,SOD1 A4V,59.8,3,Active_Drug,Standard,2019-09-17,Standard,Belgium,SITE-031
PT-001997,XS-OD-0031,22,Male,Asian,,51.4,3,Placebo,Standard,2020-02-07,Standard,Italy,SITE-016
PT-001998,XS-OD-0031,37,Male,White,,73.9,0,Active_Drug,Standard,2019-12-05,Standard,Belgium,SITE-021
PT-001999,XS-OD-0031,75,Female,White,SCN1A R1648H,70.7,1,Placebo,Standard,2019-09-28,Standard,Sweden,SITE-016
PT-002000,XS-OD-0031,23,Male,Asian,SOD1 A4V,23.4,2,Active_Drug,Standard,2019-10-24,Standard,Sweden,SITE-021
PT-002001,XS-OD-0031,71,Male,Black or African American,SMN1 deletion,62.7,0,Placebo,Standard,2020-01-23,Standard,Canada,SITE-037
PT-002002,XS-OD-0031,59,Female,Native Hawaiian or Other Pacific Islander,Exon 51 deletion,95.0,4,Active_Drug,Standard,2019-11-28,Standard,Austria,SITE-023
PT-002003,XS-OD-0031,67,Male,Black or African American,SOD1 A4V,24.8,2,Placebo,Standard,2019-12-03,Standard,Taiwan,SITE-043
PT-002004,XS-OD-0031,27,Male,White,,56.3,1,Active_Drug,Standard,2019-11-24,Standard,Taiwan,SITE-022
PT-002005,XS-OD-0031,42,Male,Hispanic or Latino,CAG repeat expansion,51.4,0,Placebo,Standard,2019-11-12,Standard,France,SITE-001
PT-002006,XS-OD-0031,26,Female,Asian,,95.0,2,Active_Drug,Standard,2019-12-04,Standard,Germany,SITE-009
PT-002007,XS-OD-0031,35,Male,White,,58.9,3,Placebo,Standard,2020-02-05,Standard,Spain,SITE-038
PT-002008,XS-OD-0031,46,Female,Black or African American,,51.6,4,Active_Drug,Standard,2019-10-22,Standard,Israel,SITE-034
PT-002009,XS-OD-0031,28,Female,White,Exon 51 deletion,18.1,1,Placebo,Standard,2020-02-04,Standard,Germany,SITE-009
PT-002010,XS-OD-0031,36,Male,White,,57.5,2,Active_Drug,Standard,2019-10-08,Standard,United Kingdom,SITE-016
PT-002011,XS-OD-0031,68,Male,Black or African American,SOD1 A4V,54.9,5,Placebo,Standard,2019-11-30,Standard,South Korea,SITE-008
PT-002012,XS-OD-0031,39,Male,Hispanic or Latino,SMN1 deletion,47.7,1,Active_Drug,Standard,2019-12-04,Standard,Australia,SITE-005
PT-002013,XS-OD-0031,15,Female,Black or African American,CAG repeat expansion,34.9,2,Placebo,Standard,2020-01-17,Pediatric_Assent,Italy,SITE-013
PT-002014,XS-OD-0031,86,Female,White,SOD1 A4V,26.2,3,Active_Drug,Standard,2020-01-10,Standard,Norway,SITE-028
PT-002015,XS-OD-0031,16,Female,White,,79.7,1,Placebo,Standard,2020-02-19,Pediatric_Assent,Taiwan,SITE-008
PT-002016,XS-OD-0031,65,Male,White,SMN1 deletion,30.7,3,Active_Drug,Standard,2019-11-15,Standard,United States,SITE-011
PT-002017,XS-OD-0031,21,Male,Hispanic or Latino,,34.8,2,Placebo,Standard,2019-09-21,Standard,United Kingdom,SITE-040
PT-002018,XS-OD-0031,54,Female,White,,75.2,1,Active_Drug,Standard,2020-02-11,Standard,France,SITE-023
PT-002019,XS-OD-0031,48,Male,White,,59.0,1,Placebo,Standard,2019-12-06,Standard,Belgium,SITE-019
PT-002020,XS-OD-0031,26,Female,Hispanic or Latino,CAG repeat expansion,78.9,2,Active_Drug,Standard,2020-02-05,Standard,Israel,SITE-042
PT-002021,XS-OD-0031,29,Male,White,CAG repeat expansion,64.9,2,Placebo,Standard,2020-01-29,Standard,Belgium,SITE-034
PT-002022,XS-OD-0031,2,Female,White,,60.9,3,Active_Drug,Standard,2019-10-11,Pediatric_Assent,Germany,SITE-002
PT-002023,XS-OD-0031,15,Female,White,SOD1 A4V,36.5,1,Placebo,Standard,2019-12-27,Pediatric_Assent,Australia,SITE-039
PT-002024,XS-OD-0031,6,Female,White,SMN1 deletion,40.5,1,Active_Drug,Standard,2019-10-27,Pediatric_Assent,Australia,SITE-029
PT-002025,XS-OD-0031,66,Male,Hispanic or Latino,,80.0,0,Placebo,Standard,2019-09-07,Standard,Canada,SITE-001
PT-002026,XS-OD-0031,6,Male,White,,53.4,5,Active_Drug,Standard,2019-11-09,Pediatric_Assent,Japan,SITE-004
PT-002027,XS-OD-0031,37,Female,Hispanic or Latino,SMN1 deletion,44.1,3,Placebo,Standard,2019-09-15,Standard,Belgium,SITE-001
PT-002028,XS-OD-0031,29,Male,White,CAG repeat expansion,72.3,4,Active_Drug,Standard,2019-12-09,Standard,Japan,SITE-013
PT-002029,XS-OD-0031,47,Female,White,SCN1A R1648H,28.0,4,Placebo,Standard,2019-11-15,Standard,Spain,SITE-038
PT-002030,XS-OD-0031,49,Male,Two or More Races,Exon 51 deletion,49.4,1,Active_Drug,Standard,2019-11-19,Standard,Switzerland,SITE-037
PT-002031,XS-OD-0031,41,Male,Asian,SOD1 A4V,70.6,4,Placebo,Standard,2019-10-04,Standard,Canada,SITE-030
PT-002032,XS-OD-0031,18,Female,White,SCN1A R1648H,94.6,3,Active_Drug,Standard,2019-09-09,Standard,Switzerland,SITE-020
PT-002033,XS-OD-0031,57,Female,Black or African American,,62.2,4,Placebo,Standard,2020-02-11,Standard,United States,SITE-008
PT-002034,XS-OD-0031,31,Male,White,SCN1A R1648H,47.8,4,Active_Drug,Standard,2019-09-29,Standard,Sweden,SITE-039
PT-002035,XS-OD-0031,28,Female,Asian,SCN1A R1648H,38.1,3,Placebo,Standard,2020-02-20,Standard,Denmark,SITE-036
PT-002036,XS-OD-0031,35,Female,White,,77.1,3,Active_Drug,Standard,2019-10-05,Standard,Brazil,SITE-016
PT-002037,XS-OD-0031,39,Male,White,,73.5,3,Placebo,Standard,2019-11-24,Standard,Taiwan,SITE-037
PT-002038,XS-OD-0031,54,Female,White,,71.9,4,Active_Drug,Standard,2019-09-19,Standard,Norway,SITE-012
PT-002039,XS-OD-0031,27,Female,White,SMN1 deletion,65.4,4,Placebo,Standard,2019-11-22,Standard,Switzerland,SITE-030
PT-002040,XS-OD-0031,37,Female,White,,61.6,3,Active_Drug,Standard,2019-08-31,Standard,Norway,SITE-021
PT-002041,XS-OD-0031,47,Male,Asian,Exon 51 deletion,49.9,3,Placebo,Standard,2019-09-21,Standard,Australia,SITE-029
PT-002042,XS-OD-0031,5,Female,White,,71.8,2,Active_Drug,Standard,2019-10-25,Pediatric_Assent,South Korea,SITE-036
PT-002043,XS-OD-0031,38,Male,White,,44.0,0,Placebo,Standard,2019-10-04,Standard,Australia,SITE-019
PT-002044,XS-OD-0031,44,Female,White,,58.1,1,Active_Drug,Standard,2019-08-30,Standard,Sweden,SITE-040
PT-002045,XS-OD-0031,34,Female,White,SOD1 A4V,41.9,1,Placebo,Standard,2019-12-26,Emergency,Taiwan,SITE-004
PT-002046,XS-OD-0031,11,Female,White,SOD1 A4V,58.2,2,Active_Drug,Standard,2020-01-16,Pediatric_Assent,Spain,SITE-025
PT-002047,XS-OD-0031,41,Male,Asian,,40.0,0,Placebo,Standard,2019-10-07,Standard,Taiwan,SITE-014
PT-002048,XS-OD-0031,63,Female,White,Exon 51 deletion,47.0,1,Active_Drug,Standard,2019-11-19,Standard,Canada,SITE-039
PT-002049,XS-OD-0031,27,Female,Black or African American,SCN1A R1648H,67.4,3,Placebo,Standard,2019-12-13,Emergency,Italy,SITE-007
PT-002050,XS-OD-0031,70,Female,White,SOD1 A4V,72.0,4,Active_Drug,Standard,2020-02-11,Standard,United Kingdom,SITE-041
PT-002051,XS-OD-0031,30,Male,Black or African American,SCN1A R1648H,81.8,4,Placebo,Standard,2019-10-06,Standard,Israel,SITE-032
PT-002052,XS-OD-0031,45,Male,White,Exon 51 deletion,26.4,4,Active_Drug,Standard,2019-09-21,Standard,Sweden,SITE-011
PT-002053,XS-OD-0031,41,Male,White,CAG repeat expansion,36.9,2,Placebo,Standard,2019-10-24,Standard,Italy,SITE-029
PT-002054,XS-OD-0031,51,Female,American Indian or Alaska Native,SCN1A R1648H,39.9,1,Active_Drug,Standard,2019-10-04,Standard,Austria,SITE-032
PT-002055,XS-OD-0031,32,Male,White,SMN1 deletion,70.0,5,Placebo,Standard,2019-11-24,Standard,Switzerland,SITE-041
PT-002056,XS-OD-0031,31,Male,White,SOD1 A4V,55.8,2,Active_Drug,Standard,2019-09-13,Standard,Japan,SITE-009
PT-002057,XS-OD-0031,23,Male,Black or African American,SMN1 deletion,36.5,5,Placebo,Standard,2020-01-16,Standard,Sweden,SITE-013
PT-002058,XS-OD-0031,48,Male,White,Exon 51 deletion,54.6,2,Active_Drug,Standard,2020-02-05,Standard,Switzerland,SITE-008
PT-002059,XS-OD-0031,21,Male,White,Exon 51 deletion,21.0,0,Placebo,Standard,2020-01-27,Standard,Israel,SITE-030
PT-002060,XS-OD-0031,35,Male,White,,51.3,1,Active_Drug,Standard,2020-01-14,Standard,United Kingdom,SITE-027
PT-002061,XS-OD-0031,33,Male,White,,47.7,1,Placebo,Standard,2019-09-29,Standard,Taiwan,SITE-002
PT-002062,XS-OD-0031,36,Female,White,SOD1 A4V,62.2,1,Active_Drug,Standard,2019-10-31,Standard,Israel,SITE-027
PT-002063,XS-OD-0031,63,Female,Black or African American,SMN1 deletion,78.4,2,Placebo,Standard,2019-12-13,Standard,Japan,SITE-015
PT-002064,XS-OD-0031,57,Female,White,,17.8,2,Active_Drug,Standard,2019-11-30,Standard,Sweden,SITE-039
PT-002065,XS-OD-0031,51,Male,Black or African American,,87.0,1,Placebo,Standard,2019-11-21,Standard,Israel,SITE-036
PT-002066,XS-OD-0031,35,Female,White,,50.4,8,Active_Drug,Standard,2020-01-30,Standard,Australia,SITE-021
PT-002067,XS-OD-0031,33,Female,White,SOD1 A4V,56.8,2,Placebo,Standard,2019-10-15,Standard,Germany,SITE-021
PT-002068,XS-OD-0031,26,Male,Black or African American,SCN1A R1648H,34.8,1,Active_Drug,Standard,2020-01-26,Standard,Brazil,SITE-041
PT-002069,XS-OD-0031,71,Female,Asian,SCN1A R1648H,52.8,1,Placebo,Standard,2020-01-26,Standard,Sweden,SITE-035
PT-002070,XS-OD-0031,40,Male,White,CAG repeat expansion,69.1,2,Active_Drug,Standard,2019-11-24,Standard,Germany,SITE-003
PT-002071,XS-OD-0031,30,Male,American Indian or Alaska Native,CAG repeat expansion,43.5,3,Placebo,Standard,2020-01-21,Standard,Spain,SITE-041
PT-002072,XS-OD-0031,43,Male,White,Exon 51 deletion,25.8,1,Active_Drug,Standard,2020-01-26,Standard,United Kingdom,SITE-025
PT-002073,XS-OD-0031,36,Male,American Indian or Alaska Native,,66.9,2,Placebo,Standard,2020-01-17,Compassionate,Belgium,SITE-028
PT-002074,XS-OD-0031,60,Female,White,SOD1 A4V,51.7,5,Active_Drug,Standard,2019-11-10,Standard,Norway,SITE-018
PT-002075,XS-OD-0031,18,Male,White,CAG repeat expansion,78.2,1,Placebo,Standard,2019-10-02,Standard,Taiwan,SITE-006
PT-002076,XS-OD-0031,8,Female,White,SMN1 deletion,39.9,2,Active_Drug,Standard,2020-01-12,Pediatric_Assent,Canada,SITE-041
PT-002077,XS-OD-0031,43,Male,White,CAG repeat expansion,83.0,3,Placebo,Standard,2019-11-01,Standard,Israel,SITE-011
PT-002078,XS-OD-0031,31,Female,White,,38.8,2,Active_Drug,Standard,2020-02-09,Standard,Brazil,SITE-025
PT-002079,XS-OD-0031,15,Female,White,SMN1 deletion,71.1,4,Placebo,Standard,2020-02-18,Pediatric_Assent,Israel,SITE-031
PT-002080,XS-OD-0031,18,Female,White,,60.9,1,Active_Drug,Standard,2019-11-22,Compassionate,Australia,SITE-004
PT-002081,XS-OD-0031,14,Female,Hispanic or Latino,SCN1A R1648H,55.0,4,Placebo,Standard,2020-02-17,Pediatric_Assent,Australia,SITE-027
PT-002082,XS-OD-0031,44,Female,White,SMN1 deletion,78.3,3,Active_Drug,Standard,2019-12-13,Standard,United States,SITE-014
PT-002083,XS-OD-0031,10,Female,White,,49.6,2,Placebo,Standard,2019-08-31,Pediatric_Assent,Netherlands,SITE-026
PT-002084,XS-OD-0031,31,Female,Black or African American,SOD1 A4V,69.3,1,Active_Drug,Standard,2019-11-21,Standard,Japan,SITE-025
PT-002085,XS-OD-0031,56,Female,Asian,SMN1 deletion,88.7,1,Placebo,Standard,2019-10-21,Standard,Switzerland,SITE-040
PT-002086,XS-OD-0031,26,Male,Black or African American,SOD1 A4V,44.7,3,Active_Drug,Standard,2020-01-28,Standard,South Korea,SITE-001
PT-002087,XS-OD-0031,6,Male,Asian,SMN1 deletion,73.5,2,Placebo,Standard,2019-11-04,Pediatric_Assent,United States,SITE-031
PT-002088,XS-OD-0031,11,Male,White,CAG repeat expansion,52.2,1,Active_Drug,Standard,2019-09-29,Pediatric_Assent,Spain,SITE-043
PT-002089,XS-OD-0031,30,Female,White,,91.0,3,Placebo,Standard,2019-09-06,Standard,Japan,SITE-014
PT-002090,XS-OD-0031,37,Male,Black or African American,SMN1 deletion,42.6,3,Active_Drug,Standard,2020-01-18,Standard,Israel,SITE-043
PT-002091,XS-OD-0031,46,Male,White,,50.9,2,Placebo,Standard,2020-01-26,Emergency,Italy,SITE-018
PT-002092,XS-OD-0031,32,Female,Hispanic or Latino,SMN1 deletion,42.5,3,Active_Drug,Standard,2019-12-20,Emergency,Netherlands,SITE-016
PT-002093,XS-OD-0031,71,Female,White,SMN1 deletion,95.0,0,Placebo,Standard,2019-11-13,Standard,Italy,SITE-009
PT-002094,XS-OD-0031,18,Male,White,CAG repeat expansion,62.2,4,Active_Drug,Standard,2019-09-03,Standard,Germany,SITE-043
PT-002095,XS-OD-0031,16,Male,Hispanic or Latino,Exon 51 deletion,57.9,2,Placebo,Standard,2019-10-14,Pediatric_Assent,Spain,SITE-031
PT-002096,XS-OD-0031,69,Male,White,Exon 51 deletion,51.3,2,Active_Drug,Standard,2020-02-07,Standard,Italy,SITE-025
PT-002097,XS-OD-0031,49,Female,Black or African American,SCN1A R1648H,31.5,2,Placebo,Standard,2019-11-26,Standard,Denmark,SITE-019
PT-002098,XS-OD-0031,40,Female,White,,56.3,1,Active_Drug,Standard,2019-10-22,Standard,Japan,SITE-009
PT-002099,XS-OD-0031,35,Male,Hispanic or Latino,,39.7,0,Placebo,Standard,2019-11-19,Standard,Japan,SITE-022
PT-002100,XS-OD-0031,48,Male,Hispanic or Latino,Exon 51 deletion,25.6,2,Active_Drug,Standard,2019-11-15,Standard,Australia,SITE-003
PT-002101,XS-OD-0031,62,Male,American Indian or Alaska Native,Exon 51 deletion,26.6,2,Placebo,Standard,2019-10-18,Standard,Australia,SITE-014
PT-002102,XS-OD-0031,51,Male,White,,49.3,4,Active_Drug,Standard,2020-01-01,Standard,Israel,SITE-040
PT-002103,XS-OD-0031,47,Female,White,SMN1 deletion,10.0,3,Placebo,Standard,2019-09-16,Standard,United Kingdom,SITE-011
PT-002104,XS-OD-0031,52,Female,White,SMN1 deletion,18.4,1,Active_Drug,Standard,2019-10-09,Standard,Austria,SITE-022
PT-002105,XS-OD-0031,55,Male,White,SOD1 A4V,46.8,1,Placebo,Standard,2019-11-23,Standard,Israel,SITE-037
PT-002106,XS-OD-0031,25,Male,Hispanic or Latino,SMN1 deletion,59.4,0,Active_Drug,Standard,2019-12-27,Emergency,Sweden,SITE-011
PT-002107,XS-OD-0031,46,Female,White,SCN1A R1648H,62.0,3,Placebo,Standard,2020-02-19,Standard,United Kingdom,SITE-032
PT-002108,XS-OD-0031,26,Female,Asian,SOD1 A4V,55.3,1,Active_Drug,Standard,2019-10-17,Standard,Canada,SITE-018
PT-002109,XS-OD-0031,56,Female,White,SOD1 A4V,61.7,1,Placebo,Standard,2019-09-29,Standard,France,SITE-014
PT-002110,XS-OD-0031,36,Intersex,Hispanic or Latino,,40.9,1,Active_Drug,Standard,2019-08-31,Standard,Sweden,SITE-022
PT-002111,XS-OD-0031,39,Female,White,SOD1 A4V,64.9,1,Placebo,Standard,2019-09-04,Standard,United Kingdom,SITE-036
PT-002112,XS-OD-0031,9,Male,White,,57.0,2,Active_Drug,Standard,2019-09-03,Pediatric_Assent,Austria,SITE-005
PT-002113,XS-OD-0031,25,Female,American Indian or Alaska Native,,40.8,3,Placebo,Standard,2020-01-21,Standard,Brazil,SITE-038
PT-002114,XS-OD-0031,65,Male,Asian,,55.5,3,Active_Drug,Standard,2020-02-09,Compassionate,Sweden,SITE-033
PT-002115,XS-OD-0031,10,Female,Hispanic or Latino,CAG repeat expansion,39.6,3,Placebo,Standard,2019-11-08,Pediatric_Assent,Denmark,SITE-027
PT-002116,XS-OD-0031,53,Female,White,SOD1 A4V,79.4,1,Active_Drug,Standard,2019-10-07,Standard,Norway,SITE-003
PT-002117,XS-OD-0031,21,Female,White,,70.1,3,Placebo,Standard,2019-11-02,Standard,Austria,SITE-027
PT-002118,XS-OD-0031,60,Female,Asian,SCN1A R1648H,61.8,0,Active_Drug,Standard,2020-02-17,Standard,Canada,SITE-029
PT-002119,XS-OD-0031,71,Female,Asian,,49.8,4,Placebo,Standard,2019-09-29,Standard,United Kingdom,SITE-005
PT-002120,XS-OD-0031,30,Male,White,CAG repeat expansion,45.0,2,Active_Drug,Standard,2019-12-10,Standard,Spain,SITE-004
PT-002121,XS-OD-0031,30,Female,White,SMN1 deletion,70.1,3,Placebo,Standard,2019-10-19,Standard,Germany,SITE-029
PT-002122,XS-OD-0031,52,Male,White,Exon 51 deletion,42.5,3,Active_Drug,Standard,2019-10-08,Standard,Norway,SITE-016
PT-002123,XS-OD-0031,35,Female,Hispanic or Latino,,51.6,3,Placebo,Standard,2019-12-30,Standard,Japan,SITE-001
PT-002124,XS-OD-0031,55,Female,Black or African American,,48.7,1,Active_Drug,Standard,2019-12-14,Standard,South Korea,SITE-028
PT-002125,XS-OD-0031,15,Male,White,SMN1 deletion,52.1,2,Placebo,Standard,2019-12-08,Pediatric_Assent,Japan,SITE-018
PT-002126,XS-OD-0031,61,Female,White,,54.3,3,Active_Drug,Standard,2019-09-22,Standard,Brazil,SITE-030
PT-002127,XS-OD-0031,55,Female,White,Exon 51 deletion,53.8,0,Placebo,Standard,2019-09-14,Standard,France,SITE-041
PT-002128,XS-OD-0031,59,Female,Hispanic or Latino,SCN1A R1648H,71.5,3,Active_Drug,Standard,2020-02-04,Standard,United Kingdom,SITE-040
PT-002129,XS-OD-0031,28,Female,White,,67.2,2,Placebo,Standard,2019-10-25,Standard,Switzerland,SITE-040
PT-002130,XS-OD-0031,35,Male,White,Exon 51 deletion,54.6,1,Active_Drug,Standard,2019-10-06,Standard,Japan,SITE-014
PT-002131,XS-OD-0031,43,Male,Asian,,68.6,3,Placebo,Standard,2019-11-25,Standard,Sweden,SITE-039
PT-002132,XS-OD-0031,44,Female,White,CAG repeat expansion,41.1,1,Active_Drug,Standard,2019-10-17,Standard,Belgium,SITE-012
PT-002133,XS-OD-0031,74,Female,White,CAG repeat expansion,70.4,2,Placebo,Standard,2019-10-21,Standard,Brazil,SITE-043
PT-002134,XS-OD-0031,41,Male,Native Hawaiian or Other Pacific Islander,,41.8,0,Active_Drug,Standard,2019-12-27,Standard,Italy,SITE-036
PT-002135,XS-OD-0031,36,Female,White,Exon 51 deletion,44.1,1,Placebo,Standard,2020-01-27,Standard,Israel,SITE-041
PT-002136,XS-OD-0031,55,Male,White,SOD1 A4V,67.9,4,Active_Drug,Standard,2019-10-07,Standard,Brazil,SITE-037
PT-002137,XS-OD-0031,2,Male,White,SMN1 deletion,63.6,1,Placebo,Standard,2020-02-13,Pediatric_Assent,Netherlands,SITE-023
PT-002138,XS-OD-0031,15,Male,White,Exon 51 deletion,88.9,2,Active_Drug,Standard,2020-01-07,Pediatric_Assent,Germany,SITE-012
PT-002139,XS-OD-0031,47,Male,White,SOD1 A4V,63.2,4,Placebo,Standard,2019-11-19,Standard,France,SITE-030
PT-002140,XS-OD-0031,47,Male,White,,65.0,2,Active_Drug,Standard,2019-09-07,Emergency,Israel,SITE-035
PT-002141,XS-OD-0031,57,Female,White,SCN1A R1648H,62.3,5,Placebo,Standard,2019-12-17,Standard,Sweden,SITE-035
PT-002142,XS-OD-0031,4,Female,Black or African American,,81.3,3,Active_Drug,Standard,2019-10-12,Pediatric_Assent,Canada,SITE-007
PT-002143,XS-OD-0031,43,Male,Black or African American,SMN1 deletion,57.3,1,Placebo,Standard,2020-01-20,Standard,France,SITE-014
PT-002144,XS-OD-0031,4,Female,White,,63.0,2,Active_Drug,Standard,2019-09-27,Pediatric_Assent,Spain,SITE-026
PT-002145,XS-OD-0031,67,Male,Asian,,77.3,0,Placebo,Standard,2019-11-26,Standard,Switzerland,SITE-020
PT-002146,XS-OD-0031,31,Male,White,SOD1 A4V,70.6,2,Active_Drug,Standard,2019-12-06,Standard,Japan,SITE-030
PT-002147,XS-OD-0031,43,Male,Black or African American,SCN1A R1648H,48.3,3,Placebo,Standard,2020-02-01,Standard,United States,SITE-002
PT-002148,XS-OD-0031,32,Male,Black or African American,,45.0,0,Active_Drug,Standard,2020-02-15,Standard,Canada,SITE-042
PT-002149,XS-OD-0031,44,Male,White,Exon 51 deletion,73.3,3,Placebo,Standard,2019-11-13,Standard,Australia,SITE-023
PT-002150,XS-OD-0031,32,Male,Black or African American,,14.6,2,Active_Drug,Standard,2019-11-10,Standard,United States,SITE-032
PT-002151,XS-OD-0031,30,Male,White,SCN1A R1648H,40.1,2,Placebo,Standard,2019-12-16,Standard,Germany,SITE-006
PT-002152,XS-OD-0031,55,Male,Two or More Races,,47.9,2,Active_Drug,Standard,2019-09-14,Standard,Canada,SITE-035
PT-002153,XS-OD-0031,32,Male,Hispanic or Latino,Exon 51 deletion,52.3,2,Placebo,Standard,2019-10-12,Standard,Israel,SITE-018
PT-002154,XS-OD-0031,29,Female,Hispanic or Latino,,85.8,1,Active_Drug,Standard,2019-12-31,Standard,Netherlands,SITE-009
PT-002155,XS-OD-0031,34,Male,Asian,,40.1,6,Placebo,Standard,2019-11-12,Standard,Austria,SITE-022
PT-002156,XS-OD-0031,21,Female,White,CAG repeat expansion,54.9,4,Active_Drug,Standard,2019-11-29,Standard,Austria,SITE-031
PT-002157,XS-OD-0031,42,Female,White,SOD1 A4V,55.8,2,Placebo,Standard,2019-10-01,Standard,Brazil,SITE-025
PT-002158,XS-OD-0031,54,Male,White,,78.1,5,Active_Drug,Standard,2019-11-27,Standard,Switzerland,SITE-005
PT-002159,XS-OD-0031,22,Female,Asian,Exon 51 deletion,68.1,0,Placebo,Standard,2019-11-06,Standard,United Kingdom,SITE-040
PT-002160,XS-OD-0031,31,Female,White,SOD1 A4V,92.4,1,Active_Drug,Standard,2019-11-05,Standard,Australia,SITE-041
PT-002161,XS-OD-0031,4,Female,White,SOD1 A4V,53.1,1,Placebo,Standard,2019-10-20,Pediatric_Assent,France,SITE-014
PT-002162,XS-OD-0031,47,Male,White,SCN1A R1648H,29.5,1,Active_Drug,Standard,2019-10-27,Standard,Australia,SITE-018
PT-002163,XS-OD-0031,66,Male,White,SMN1 deletion,66.6,2,Placebo,Standard,2019-11-29,Standard,Spain,SITE-024
PT-002164,XS-OD-0031,10,Female,White,,49.8,2,Active_Drug,Standard,2019-12-06,Pediatric_Assent,South Korea,SITE-008
PT-002165,XS-OD-0031,2,Male,Black or African American,,60.6,4,Placebo,Standard,2020-02-09,Pediatric_Assent,Canada,SITE-024
PT-002166,XS-OD-0031,72,Male,Hispanic or Latino,,33.4,4,Active_Drug,Standard,2020-02-07,Compassionate,Canada,SITE-038
PT-002167,XS-OD-0031,58,Female,Black or African American,Exon 51 deletion,73.4,2,Placebo,Standard,2019-12-26,Standard,Germany,SITE-022
PT-002168,XS-OD-0031,38,Male,White,CAG repeat expansion,79.8,3,Active_Drug,Standard,2020-01-25,Standard,South Korea,SITE-040
PT-002169,XS-OD-0031,61,Female,Hispanic or Latino,,42.5,3,Placebo,Standard,2019-11-22,Standard,Italy,SITE-029
PT-002170,XS-OD-0031,33,Female,Hispanic or Latino,,57.9,2,Active_Drug,Standard,2019-09-18,Standard,Taiwan,SITE-041
PT-002171,XS-OD-0031,62,Female,Asian,SOD1 A4V,67.1,1,Placebo,Standard,2019-11-19,Standard,Denmark,SITE-031
PT-002172,XS-OD-0031,23,Male,White,SCN1A R1648H,53.8,1,Active_Drug,Standard,2019-10-09,Standard,Brazil,SITE-011
PT-002173,XS-OD-0031,55,Female,White,SOD1 A4V,30.8,0,Placebo,Standard,2019-10-15,Standard,France,SITE-009
PT-002174,XS-OD-0031,79,Male,White,SMN1 deletion,21.5,3,Active_Drug,Standard,2019-10-02,Standard,Japan,SITE-017
PT-002175,XS-OD-0031,31,Female,White,SCN1A R1648H,46.1,2,Placebo,Standard,2019-11-18,Standard,Israel,SITE-038
PT-002176,XS-OD-0031,46,Male,White,CAG repeat expansion,54.3,1,Active_Drug,Standard,2019-11-14,Standard,Spain,SITE-014
PT-002177,XS-OD-0031,50,Female,White,CAG repeat expansion,39.1,2,Placebo,Standard,2020-01-21,Standard,United States,SITE-008
PT-002178,XS-OD-0031,39,Female,Asian,Exon 51 deletion,57.5,3,Active_Drug,Standard,2019-10-18,Emergency,Spain,SITE-031
PT-002179,XS-OD-0031,79,Female,White,SCN1A R1648H,84.9,2,Placebo,Standard,2019-12-10,Standard,Spain,SITE-010
PT-002180,XS-OD-0031,26,Female,Hispanic or Latino,SMN1 deletion,67.8,1,Active_Drug,Standard,2019-10-18,Standard,Belgium,SITE-004
PT-002181,XS-OD-0031,20,Male,White,,56.8,4,Placebo,Standard,2019-09-05,Standard,Germany,SITE-003
PT-002182,XS-OD-0031,34,Female,Black or African American,SOD1 A4V,26.9,4,Active_Drug,Standard,2019-11-16,Standard,Canada,SITE-004
PT-002183,XS-OD-0031,43,Male,Black or African American,SOD1 A4V,79.3,0,Placebo,Standard,2019-10-21,Standard,Spain,SITE-040
PT-002184,XS-OD-0031,48,Female,White,SMN1 deletion,56.7,1,Active_Drug,Standard,2019-12-14,Standard,Netherlands,SITE-010
PT-002185,XS-OD-0031,17,Male,White,Exon 51 deletion,10.0,2,Placebo,Standard,2019-12-29,Pediatric_Assent,Brazil,SITE-034
PT-002186,XS-OD-0031,40,Female,Black or African American,SOD1 A4V,53.1,1,Active_Drug,Standard,2020-01-06,Standard,Belgium,SITE-013
PT-002187,XS-OD-0031,18,Male,White,SCN1A R1648H,60.5,3,Placebo,Standard,2019-12-27,Standard,Spain,SITE-028
PT-002188,XS-OD-0031,60,Female,White,SMN1 deletion,56.7,2,Active_Drug,Standard,2019-10-25,Standard,United States,SITE-024
PT-002189,XS-OD-0031,8,Male,White,,52.5,0,Placebo,Standard,2019-10-15,Pediatric_Assent,United States,SITE-021
PT-002190,XS-OD-0031,40,Female,White,,16.8,1,Active_Drug,Standard,2020-02-07,Standard,Norway,SITE-020
PT-002191,XS-OD-0031,51,Male,White,SCN1A R1648H,54.8,1,Placebo,Standard,2020-02-04,Standard,Japan,SITE-004
PT-002192,XS-OD-0031,22,Female,White,,24.2,3,Active_Drug,Standard,2019-10-13,Standard,South Korea,SITE-023
PT-002193,XS-OD-0031,67,Female,Black or African American,Exon 51 deletion,82.2,0,Placebo,Standard,2019-10-12,Standard,Taiwan,SITE-013
PT-002194,XS-OD-0032,72,Male,White,Exon 51 deletion,16.7,1,Active_Drug,Standard,2024-02-01,Standard,Germany,SITE-002
PT-002195,XS-OD-0032,55,Female,White,,57.3,2,Placebo,Standard,2023-11-07,Standard,Japan,SITE-003
PT-002196,XS-OD-0032,50,Female,White,CAG repeat expansion,56.0,4,Active_Drug,Standard,2024-01-21,Standard,United States,SITE-002
PT-002197,XS-OD-0032,33,Female,White,SMN1 deletion,59.3,1,Placebo,Standard,2023-10-09,Standard,Netherlands,SITE-008
PT-002198,XS-OD-0032,36,Female,Asian,SOD1 A4V,55.4,1,Active_Drug,Standard,2023-12-21,Standard,United States,SITE-003
PT-002199,XS-OD-0032,14,Male,Black or African American,,80.2,2,Placebo,Standard,2024-01-18,Pediatric_Assent,France,SITE-006
PT-002200,XS-OD-0032,41,Male,Two or More Races,SMN1 deletion,66.5,2,Active_Drug,Standard,2023-10-17,Emergency,Australia,SITE-006
PT-002201,XS-OD-0032,29,Female,Black or African American,,52.2,1,Placebo,Standard,2024-02-27,Standard,Germany,SITE-005
PT-002202,XS-OD-0032,40,Female,White,SMN1 deletion,61.2,2,Active_Drug,Standard,2023-11-22,Standard,United Kingdom,SITE-008
PT-002203,XS-OD-0032,44,Female,Hispanic or Latino,Exon 51 deletion,90.5,3,Placebo,Standard,2023-09-16,Standard,Netherlands,SITE-002
PT-002204,XS-OD-0032,29,Male,White,Exon 51 deletion,46.7,1,Active_Drug,Standard,2024-01-29,Standard,United States,SITE-003
PT-002205,XS-OD-0032,79,Female,White,SOD1 A4V,65.0,1,Placebo,Standard,2023-09-28,Standard,Canada,SITE-001
PT-002206,XS-OD-0032,21,Female,Hispanic or Latino,SOD1 A4V,30.1,0,Active_Drug,Standard,2023-12-15,Standard,Spain,SITE-007
PT-002207,XS-OD-0032,29,Male,White,CAG repeat expansion,40.7,4,Placebo,Standard,2024-01-30,Standard,United Kingdom,SITE-005
PT-002208,XS-OD-0032,52,Female,White,,41.5,3,Active_Drug,Standard,2023-12-08,Standard,Germany,SITE-001
PT-002209,XS-OD-0032,39,Male,Black or African American,SCN1A R1648H,36.4,0,Placebo,Standard,2024-02-24,Standard,United Kingdom,SITE-008
PT-002210,XS-OD-0032,39,Female,Black or African American,CAG repeat expansion,65.8,4,Active_Drug,Standard,2023-12-02,Standard,Spain,SITE-006
PT-002211,XS-OD-0032,16,Male,White,,10.0,3,Placebo,Standard,2023-09-19,Pediatric_Assent,Japan,SITE-006
PT-002212,XS-OD-0032,38,Male,Asian,SMN1 deletion,44.2,1,Active_Drug,Standard,2023-11-30,Standard,United States,SITE-002
PT-002213,XS-OD-0032,7,Male,Black or African American,,83.1,0,Placebo,Standard,2023-10-11,Pediatric_Assent,Canada,SITE-002
PT-002214,XS-OD-0032,43,Male,White,,51.1,2,Active_Drug,Standard,2024-02-23,Standard,Netherlands,SITE-004
PT-002215,XS-OD-0032,40,Female,Hispanic or Latino,SOD1 A4V,78.2,0,Placebo,Standard,2023-12-30,Emergency,Australia,SITE-001
PT-002216,XS-OD-0032,30,Female,White,CAG repeat expansion,64.6,3,Active_Drug,Standard,2023-10-13,Standard,Canada,SITE-006
PT-002217,XS-OD-0032,36,Female,White,SCN1A R1648H,40.3,3,Placebo,Standard,2024-02-17,Standard,United Kingdom,SITE-007
PT-002218,XS-OD-0032,53,Female,White,SCN1A R1648H,48.8,1,Active_Drug,Standard,2024-01-23,Standard,Canada,SITE-006
PT-002219,XS-OD-0032,37,Male,White,SMN1 deletion,45.7,4,Placebo,Standard,2024-01-19,Standard,Italy,SITE-001
PT-002220,XS-OD-0032,34,Female,White,SCN1A R1648H,56.4,1,Active_Drug,Standard,2023-10-24,Standard,Germany,SITE-007
PT-002221,XS-OD-0032,49,Male,White,,54.5,2,Placebo,Standard,2023-11-19,Standard,United States,SITE-007
PT-002222,XS-OD-0032,24,Male,Asian,Exon 51 deletion,10.0,1,Active_Drug,Standard,2023-09-12,Standard,United Kingdom,SITE-002
PT-002223,XS-OD-0032,73,Female,White,,77.5,1,Placebo,Standard,2023-10-16,Standard,Netherlands,SITE-002
PT-002224,XS-OD-0032,69,Male,Hispanic or Latino,,87.8,4,Active_Drug,Standard,2024-02-16,Standard,Spain,SITE-007
PT-002225,XS-OD-0032,33,Male,White,,77.8,3,Placebo,Standard,2023-11-30,Standard,Australia,SITE-001
PT-002226,XS-OD-0032,27,Male,White,CAG repeat expansion,77.6,2,Active_Drug,Standard,2024-02-21,Standard,Netherlands,SITE-007
PT-002227,XS-OD-0032,17,Female,Asian,,30.0,2,Placebo,Standard,2023-11-24,Pediatric_Assent,France,SITE-004
PT-002228,XS-OD-0032,37,Male,White,SOD1 A4V,24.8,3,Active_Drug,Standard,2024-01-04,Standard,United States,SITE-007
PT-002229,XS-OD-0032,43,Male,White,SMN1 deletion,75.3,0,Placebo,Standard,2023-09-26,Standard,Italy,SITE-001
PT-002230,XS-OD-0032,15,Female,White,Exon 51 deletion,22.4,0,Active_Drug,Standard,2023-12-01,Pediatric_Assent,Canada,SITE-001
PT-002231,XS-OD-0032,52,Male,White,SCN1A R1648H,45.1,1,Placebo,Standard,2023-11-12,Standard,France,SITE-004
PT-002232,XS-OD-0032,47,Male,Black or African American,CAG repeat expansion,21.1,7,Active_Drug,Standard,2023-09-29,Standard,France,SITE-007
PT-002233,XS-OD-0032,60,Male,White,SMN1 deletion,59.4,1,Placebo,Standard,2024-01-18,Standard,France,SITE-003
PT-002234,XS-OD-0032,16,Male,White,Exon 51 deletion,53.5,1,Active_Drug,Standard,2023-12-01,Pediatric_Assent,Netherlands,SITE-003
PT-002235,XS-OD-0032,48,Male,Asian,SOD1 A4V,95.0,4,Placebo,Standard,2023-10-01,Standard,Spain,SITE-005
PT-002236,XS-OD-0032,54,Intersex,White,CAG repeat expansion,54.1,7,Active_Drug,Standard,2023-10-27,Standard,Australia,SITE-005
PT-002237,XS-OD-0032,38,Male,White,Exon 51 deletion,27.5,4,Placebo,Standard,2023-09-13,Standard,Germany,SITE-005
PT-002238,XS-OD-0032,38,Male,White,,76.3,0,Active_Drug,Standard,2024-01-24,Standard,Spain,SITE-003
PT-002239,XS-OD-0032,47,Female,White,,66.9,2,Placebo,Standard,2024-02-18,Standard,Netherlands,SITE-007
PT-002240,XS-OD-0032,43,Male,American Indian or Alaska Native,SCN1A R1648H,27.0,4,Active_Drug,Standard,2024-02-21,Standard,Japan,SITE-004
PT-002241,XS-OD-0032,43,Female,White,SOD1 A4V,47.8,0,Placebo,Standard,2023-11-06,Standard,Australia,SITE-007
PT-002242,XS-OD-0032,47,Female,White,Exon 51 deletion,49.4,5,Active_Drug,Standard,2023-11-30,Standard,Spain,SITE-006
PT-002243,XS-OD-0032,17,Female,Black or African American,,62.7,1,Placebo,Standard,2023-09-10,Pediatric_Assent,United States,SITE-005
PT-002244,XS-OD-0032,8,Male,Hispanic or Latino,SOD1 A4V,58.8,3,Active_Drug,Standard,2024-03-07,Pediatric_Assent,United Kingdom,SITE-006
PT-002245,XS-OD-0032,24,Male,Black or African American,,45.7,3,Placebo,Standard,2023-11-16,Standard,France,SITE-004
PT-002246,XS-OD-0032,70,Male,White,,57.2,2,Active_Drug,Standard,2023-10-10,Standard,Canada,SITE-002
PT-002247,XS-OD-0032,34,Male,White,CAG repeat expansion,51.6,2,Placebo,Standard,2024-02-04,Compassionate,Spain,SITE-003
PT-002248,XS-OD-0032,28,Male,White,SOD1 A4V,70.8,3,Active_Drug,Standard,2023-09-10,Standard,Australia,SITE-005
PT-002249,XS-OD-0032,17,Male,White,CAG repeat expansion,34.1,2,Placebo,Standard,2024-01-31,Pediatric_Assent,Spain,SITE-006
PT-002250,XS-OD-0032,31,Female,Black or African American,SOD1 A4V,21.1,1,Active_Drug,Standard,2024-03-01,Standard,Italy,SITE-005
PT-002251,XS-OD-0032,35,Female,Asian,,32.7,4,Placebo,Standard,2023-12-16,Standard,France,SITE-005
PT-002252,XS-OD-0032,30,Male,Hispanic or Latino,SCN1A R1648H,33.7,2,Active_Drug,Standard,2023-12-19,Standard,Spain,SITE-007
PT-002253,XS-OD-0032,53,Female,White,SOD1 A4V,66.8,4,Placebo,Standard,2024-02-12,Standard,Spain,SITE-003
PT-002254,XS-OD-0032,48,Female,Black or African American,CAG repeat expansion,95.0,2,Active_Drug,Standard,2023-09-27,Standard,Italy,SITE-002
PT-002255,XS-OD-0032,33,Female,White,SMN1 deletion,32.7,1,Placebo,Standard,2023-11-01,Standard,Netherlands,SITE-007
PT-002256,XS-OD-0032,34,Female,Asian,SMN1 deletion,83.9,6,Active_Drug,Standard,2023-11-08,Standard,Italy,SITE-004
PT-002257,XS-OD-0032,88,Female,White,SMN1 deletion,17.5,3,Placebo,Standard,2023-11-18,Standard,Netherlands,SITE-003
PT-002258,XS-OD-0032,65,Female,Asian,SOD1 A4V,36.8,2,Active_Drug,Standard,2023-11-22,Standard,United States,SITE-002
PT-002259,XS-OD-0032,50,Female,White,,35.9,2,Placebo,Standard,2023-12-11,Standard,Germany,SITE-007
PT-002260,XS-OD-0032,62,Female,White,SCN1A R1648H,18.9,2,Active_Drug,Standard,2024-01-14,Standard,United States,SITE-008
PT-002261,XS-OD-0032,27,Female,Black or African American,SCN1A R1648H,58.1,5,Placebo,Standard,2023-10-20,Standard,Spain,SITE-008
PT-002262,XS-OD-0032,42,Female,White,SOD1 A4V,78.3,2,Active_Drug,Standard,2023-11-19,Standard,Australia,SITE-003
PT-002263,XS-OD-0032,30,Male,White,SCN1A R1648H,37.1,4,Placebo,Standard,2023-10-23,Standard,United States,SITE-005
PT-002264,XS-OD-0032,2,Female,White,Exon 51 deletion,48.8,5,Active_Drug,Standard,2024-02-25,Pediatric_Assent,United States,SITE-001
PT-002265,XS-OD-0032,33,Male,Asian,CAG repeat expansion,33.3,2,Placebo,Standard,2024-01-04,Standard,Netherlands,SITE-003
PT-002266,XS-OD-0032,14,Female,White,,55.2,4,Active_Drug,Standard,2023-11-12,Pediatric_Assent,Spain,SITE-002
PT-002267,XS-OD-0032,26,Male,White,,78.7,1,Placebo,Standard,2024-02-25,Standard,Canada,SITE-002
PT-002268,XS-OD-0032,28,Male,White,SCN1A R1648H,56.8,6,Active_Drug,Standard,2024-01-27,Emergency,Italy,SITE-007
PT-002269,XS-OD-0032,36,Female,White,Exon 51 deletion,43.3,3,Placebo,Standard,2024-02-28,Standard,Spain,SITE-007
PT-002270,XS-OD-0032,12,Female,Black or African American,CAG repeat expansion,47.1,5,Active_Drug,Standard,2023-11-11,Pediatric_Assent,Italy,SITE-004
PT-002271,XS-OD-0032,31,Female,White,CAG repeat expansion,48.5,3,Placebo,Standard,2024-02-10,Standard,Australia,SITE-007
PT-002272,XS-OD-0032,38,Female,White,,49.8,4,Active_Drug,Standard,2023-11-21,Standard,Australia,SITE-002
PT-002273,XS-OD-0032,40,Female,White,SCN1A R1648H,58.1,1,Placebo,Standard,2024-03-04,Standard,Australia,SITE-001
PT-002274,XS-OD-0032,33,Female,White,SMN1 deletion,69.8,0,Active_Drug,Standard,2024-01-23,Standard,Netherlands,SITE-008
PT-002275,XS-OD-0032,47,Female,White,SMN1 deletion,61.3,2,Placebo,Standard,2024-02-17,Standard,Japan,SITE-008
PT-002276,XS-OD-0032,32,Female,White,SCN1A R1648H,50.3,2,Active_Drug,Standard,2023-09-19,Standard,United Kingdom,SITE-007
PT-002277,XS-OD-0032,61,Female,White,Exon 51 deletion,85.7,2,Placebo,Standard,2024-01-18,Standard,United Kingdom,SITE-002
PT-002278,XS-OD-0032,37,Male,Hispanic or Latino,SMN1 deletion,59.2,0,Active_Drug,Standard,2024-03-05,Standard,Canada,SITE-006
PT-002279,XS-OD-0032,48,Male,White,,47.5,0,Placebo,Standard,2023-12-02,Standard,Germany,SITE-007
PT-002280,XS-OD-0032,43,Male,White,SOD1 A4V,15.2,5,Active_Drug,Standard,2024-02-05,Standard,Spain,SITE-008
PT-002281,XS-OD-0032,9,Female,White,SOD1 A4V,91.8,2,Placebo,Standard,2023-12-22,Pediatric_Assent,United Kingdom,SITE-004
PT-002282,XS-OD-0032,39,Female,White,,54.2,1,Active_Drug,Standard,2023-09-25,Standard,Australia,SITE-007
PT-002283,XS-OD-0032,44,Male,White,,47.1,1,Placebo,Standard,2023-11-18,Standard,France,SITE-006
PT-002284,XS-OD-0032,19,Female,American Indian or Alaska Native,SMN1 deletion,54.9,0,Active_Drug,Standard,2023-12-08,Standard,United Kingdom,SITE-007
PT-002285,XS-OD-0032,61,Female,Native Hawaiian or Other Pacific Islander,CAG repeat expansion,62.5,3,Placebo,Standard,2024-01-10,Standard,France,SITE-002
PT-002286,XS-OD-0033,13,Male,White,,69.5,2,Active_Drug,Standard,2025-09-21,Pediatric_Assent,Italy,SITE-054
PT-002287,XS-OD-0033,17,Male,White,,53.0,3,Placebo,Standard,2025-09-30,Pediatric_Assent,Denmark,SITE-042
PT-002288,XS-OD-0033,17,Male,White,,51.6,2,Active_Drug,Standard,2025-08-24,Pediatric_Assent,Australia,SITE-003
PT-002289,XS-OD-0033,10,Male,White,SMN1 deletion,50.2,0,Placebo,Standard,2025-09-03,Pediatric_Assent,Australia,SITE-033
PT-002290,XS-OD-0033,14,Male,White,Exon 51 deletion,57.5,1,Active_Drug,Standard,2025-10-05,Pediatric_Assent,Brazil,SITE-057
PT-002291,XS-OD-0033,21,Male,White,SCN1A R1648H,72.8,2,Placebo,Standard,2025-09-08,Compassionate,France,SITE-033
PT-002292,XS-OD-0033,5,Male,White,Exon 51 deletion,74.0,2,Active_Drug,Standard,2025-06-25,Pediatric_Assent,United States,SITE-027
PT-002293,XS-OD-0033,22,Male,White,Exon 51 deletion,80.3,1,Placebo,Standard,2025-08-06,Compassionate,Norway,SITE-001
PT-002294,XS-OD-0033,11,Male,White,,58.6,1,Active_Drug,Standard,2025-06-04,Pediatric_Assent,Italy,SITE-006
PT-002295,XS-OD-0033,16,Male,Asian,SMN1 deletion,65.0,3,Placebo,Standard,2025-09-26,Pediatric_Assent,Germany,SITE-053
PT-002296,XS-OD-0033,19,Male,White,Exon 51 deletion,52.4,2,Active_Drug,Standard,2025-08-02,Standard,Spain,SITE-028
PT-002297,XS-OD-0033,14,Male,White,SOD1 A4V,50.8,3,Placebo,Standard,2025-07-31,Pediatric_Assent,Denmark,SITE-057
PT-002298,XS-OD-0033,12,Male,White,Exon 51 deletion,78.2,3,Active_Drug,Standard,2025-05-12,Pediatric_Assent,Austria,SITE-019
PT-002299,XS-OD-0033,7,Male,Native Hawaiian or Other Pacific Islander,,59.7,3,Placebo,Standard,2025-10-25,Pediatric_Assent,Brazil,SITE-055
PT-002300,XS-OD-0033,20,Female,Hispanic or Latino,SOD1 A4V,58.8,3,Active_Drug,Standard,2025-09-03,Standard,Belgium,SITE-052
PT-002301,XS-OD-0033,15,Male,White,SOD1 A4V,95.0,2,Placebo,Standard,2025-10-14,Pediatric_Assent,Austria,SITE-010
PT-002302,XS-OD-0033,17,Male,Black or African American,,54.7,5,Active_Drug,Standard,2025-06-08,Pediatric_Assent,Spain,SITE-011
PT-002303,XS-OD-0033,9,Male,White,,81.1,3,Placebo,Standard,2025-05-29,Pediatric_Assent,Australia,SITE-051
PT-002304,XS-OD-0033,15,Male,White,SOD1 A4V,16.7,4,Active_Drug,Standard,2025-05-09,Pediatric_Assent,United Kingdom,SITE-023
PT-002305,XS-OD-0033,13,Male,Black or African American,Exon 51 deletion,45.9,1,Placebo,Standard,2025-07-02,Pediatric_Assent,Denmark,SITE-028
PT-002306,XS-OD-0033,23,Male,White,CAG repeat expansion,40.0,2,Active_Drug,Standard,2025-10-12,Standard,Germany,SITE-060
PT-002307,XS-OD-0033,9,Male,White,SOD1 A4V,18.7,3,Placebo,Standard,2025-07-05,Pediatric_Assent,Brazil,SITE-049
PT-002308,XS-OD-0033,16,Male,Black or African American,SCN1A R1648H,52.6,2,Active_Drug,Standard,2025-08-12,Pediatric_Assent,Austria,SITE-003
PT-002309,XS-OD-0033,9,Male,Hispanic or Latino,,51.2,4,Placebo,Standard,2025-08-18,Pediatric_Assent,Norway,SITE-049
PT-002310,XS-OD-0033,12,Male,White,CAG repeat expansion,51.7,0,Active_Drug,Standard,2025-05-13,Pediatric_Assent,Norway,SITE-025
PT-002311,XS-OD-0033,4,Male,Hispanic or Latino,CAG repeat expansion,65.9,1,Placebo,Standard,2025-07-08,Pediatric_Assent,Australia,SITE-051
PT-002312,XS-OD-0033,15,Male,White,SMN1 deletion,51.1,3,Active_Drug,Standard,2025-07-24,Pediatric_Assent,Austria,SITE-059
PT-002313,XS-OD-0033,12,Male,Two or More Races,CAG repeat expansion,60.0,2,Placebo,Standard,2025-09-14,Pediatric_Assent,Austria,SITE-023
PT-002314,XS-OD-0033,13,Male,Asian,SMN1 deletion,64.9,3,Active_Drug,Standard,2025-10-14,Pediatric_Assent,Austria,SITE-013
PT-002315,XS-OD-0033,19,Male,White,Exon 51 deletion,63.8,1,Placebo,Standard,2025-07-14,Standard,United States,SITE-031
PT-002316,XS-OD-0033,22,Male,Asian,SMN1 deletion,48.8,3,Active_Drug,Standard,2025-08-23,Standard,Israel,SITE-006
PT-002317,XS-OD-0033,8,Male,White,SMN1 deletion,30.0,3,Placebo,Standard,2025-07-11,Pediatric_Assent,Japan,SITE-002
PT-002318,XS-OD-0033,17,Male,White,CAG repeat expansion,36.0,2,Active_Drug,Standard,2025-10-27,Pediatric_Assent,Netherlands,SITE-033
PT-002319,XS-OD-0033,4,Male,White,CAG repeat expansion,82.3,0,Placebo,Standard,2025-08-08,Pediatric_Assent,Canada,SITE-049
PT-002320,XS-OD-0033,10,Male,Black or African American,,56.2,3,Active_Drug,Standard,2025-07-12,Pediatric_Assent,Norway,SITE-059
PT-002321,XS-OD-0033,24,Male,White,SOD1 A4V,22.8,2,Placebo,Standard,2025-06-18,Standard,Italy,SITE-023
PT-002322,XS-OD-0033,15,Male,White,SCN1A R1648H,46.4,2,Active_Drug,Standard,2025-09-10,Pediatric_Assent,United States,SITE-016
PT-002323,XS-OD-0033,15,Male,Hispanic or Latino,CAG repeat expansion,50.8,3,Placebo,Standard,2025-09-16,Pediatric_Assent,France,SITE-043
PT-002324,XS-OD-0033,16,Male,Black or African American,CAG repeat expansion,95.0,1,Active_Drug,Standard,2025-08-13,Pediatric_Assent,Denmark,SITE-040
PT-002325,XS-OD-0033,13,Male,White,CAG repeat expansion,29.8,3,Placebo,Standard,2025-09-19,Pediatric_Assent,Brazil,SITE-027
PT-002326,XS-OD-0033,12,Male,White,Exon 51 deletion,57.6,3,Active_Drug,Standard,2025-06-10,Pediatric_Assent,Taiwan,SITE-015
PT-002327,XS-OD-0033,11,Male,Hispanic or Latino,Exon 51 deletion,45.5,2,Placebo,Standard,2025-06-22,Pediatric_Assent,Canada,SITE-002
PT-002328,XS-OD-0033,13,Female,Black or African American,,44.9,3,Active_Drug,Standard,2025-08-06,Pediatric_Assent,Belgium,SITE-012
PT-002329,XS-OD-0033,11,Male,Asian,,27.2,1,Placebo,Standard,2025-09-09,Pediatric_Assent,United States,SITE-032
PT-002330,XS-OD-0033,16,Male,White,CAG repeat expansion,83.4,0,Active_Drug,Standard,2025-10-11,Pediatric_Assent,Canada,SITE-021
PT-002331,XS-OD-0033,16,Male,White,Exon 51 deletion,58.7,0,Placebo,Standard,2025-07-21,Pediatric_Assent,Denmark,SITE-051
PT-002332,XS-OD-0033,25,Male,Black or African American,SCN1A R1648H,56.1,2,Active_Drug,Standard,2025-08-13,Standard,Italy,SITE-053
PT-002333,XS-OD-0033,18,Male,Hispanic or Latino,SMN1 deletion,29.8,2,Placebo,Standard,2025-10-27,Standard,Brazil,SITE-007
PT-002334,XS-OD-0033,11,Male,American Indian or Alaska Native,CAG repeat expansion,51.3,5,Active_Drug,Standard,2025-06-20,Pediatric_Assent,Netherlands,SITE-038
PT-002335,XS-OD-0033,7,Male,White,SMN1 deletion,55.5,2,Placebo,Standard,2025-08-16,Pediatric_Assent,Spain,SITE-027
PT-002336,XS-OD-0033,16,Male,White,,53.7,4,Active_Drug,Standard,2025-06-17,Pediatric_Assent,Austria,SITE-012
PT-002337,XS-OD-0033,10,Male,White,SCN1A R1648H,26.4,1,Placebo,Standard,2025-06-03,Pediatric_Assent,Australia,SITE-022
PT-002338,XS-OD-0033,8,Male,White,CAG repeat expansion,80.9,3,Active_Drug,Standard,2025-08-01,Pediatric_Assent,South Korea,SITE-052
PT-002339,XS-OD-0033,9,Male,White,SOD1 A4V,57.2,5,Placebo,Standard,2025-05-03,Pediatric_Assent,Switzerland,SITE-047
PT-002340,XS-OD-0033,15,Male,Hispanic or Latino,SMN1 deletion,39.5,2,Active_Drug,Standard,2025-06-29,Pediatric_Assent,Germany,SITE-025
PT-002341,XS-OD-0033,15,Male,Hispanic or Latino,,52.0,0,Placebo,Standard,2025-09-18,Pediatric_Assent,United States,SITE-040
PT-002342,XS-OD-0033,11,Male,Hispanic or Latino,SCN1A R1648H,64.4,2,Active_Drug,Standard,2025-07-04,Pediatric_Assent,Canada,SITE-056
PT-002343,XS-OD-0033,6,Male,White,,70.1,1,Placebo,Standard,2025-09-14,Pediatric_Assent,South Korea,SITE-006
PT-002344,XS-OD-0033,4,Male,Black or African American,,37.6,2,Active_Drug,Standard,2025-09-23,Pediatric_Assent,Spain,SITE-049
PT-002345,XS-OD-0033,11,Male,Hispanic or Latino,,75.4,2,Placebo,Standard,2025-07-23,Pediatric_Assent,Denmark,SITE-054
PT-002346,XS-OD-0033,17,Male,White,SOD1 A4V,57.8,2,Active_Drug,Standard,2025-10-29,Pediatric_Assent,Italy,SITE-033
PT-002347,XS-OD-0033,22,Female,White,,62.7,4,Placebo,Standard,2025-06-01,Standard,United Kingdom,SITE-006
PT-002348,XS-OD-0033,15,Male,Hispanic or Latino,,37.8,6,Active_Drug,Standard,2025-05-20,Pediatric_Assent,South Korea,SITE-033
PT-002349,XS-OD-0033,16,Female,White,SCN1A R1648H,20.6,3,Placebo,Standard,2025-05-30,Pediatric_Assent,South Korea,SITE-058
PT-002350,XS-OD-0033,14,Male,White,,92.0,2,Active_Drug,Standard,2025-09-25,Pediatric_Assent,Australia,SITE-056
PT-002351,XS-OD-0033,16,Male,Hispanic or Latino,,81.9,1,Placebo,Standard,2025-10-28,Pediatric_Assent,Brazil,SITE-026
PT-002352,XS-OD-0033,15,Male,White,SOD1 A4V,25.8,1,Active_Drug,Standard,2025-08-05,Pediatric_Assent,Austria,SITE-038
PT-002353,XS-OD-0033,9,Male,Black or African American,,43.8,6,Placebo,Standard,2025-09-21,Pediatric_Assent,South Korea,SITE-038
PT-002354,XS-OD-0033,14,Male,White,Exon 51 deletion,60.6,4,Active_Drug,Standard,2025-10-14,Pediatric_Assent,Canada,SITE-039
PT-002355,XS-OD-0033,11,Male,White,SOD1 A4V,42.0,5,Placebo,Standard,2025-05-23,Pediatric_Assent,France,SITE-044
PT-002356,XS-OD-0033,10,Male,White,SMN1 deletion,63.2,0,Active_Drug,Standard,2025-10-03,Pediatric_Assent,Japan,SITE-004
PT-002357,XS-OD-0033,4,Male,White,SCN1A R1648H,78.7,0,Placebo,Standard,2025-06-19,Pediatric_Assent,Austria,SITE-022
PT-002358,XS-OD-0033,9,Male,White,,66.0,2,Active_Drug,Standard,2025-05-14,Pediatric_Assent,Switzerland,SITE-061
PT-002359,XS-OD-0033,19,Male,White,CAG repeat expansion,46.3,0,Placebo,Standard,2025-10-17,Standard,Norway,SITE-031
PT-002360,XS-OD-0033,6,Male,White,SCN1A R1648H,56.5,1,Active_Drug,Standard,2025-05-07,Pediatric_Assent,Taiwan,SITE-019
PT-002361,XS-OD-0033,17,Male,White,,51.2,4,Placebo,Standard,2025-10-10,Pediatric_Assent,Germany,SITE-063
PT-002362,XS-OD-0033,12,Male,Black or African American,,72.4,3,Active_Drug,Standard,2025-07-11,Pediatric_Assent,Denmark,SITE-005
PT-002363,XS-OD-0033,8,Male,White,,15.8,2,Placebo,Standard,2025-06-23,Pediatric_Assent,Switzerland,SITE-055
PT-002364,XS-OD-0033,6,Male,White,SCN1A R1648H,18.7,0,Active_Drug,Standard,2025-09-09,Pediatric_Assent,Netherlands,SITE-050
PT-002365,XS-OD-0033,12,Male,White,Exon 51 deletion,58.8,2,Placebo,Standard,2025-05-17,Pediatric_Assent,Austria,SITE-016
PT-002366,XS-OD-0033,18,Male,White,SMN1 deletion,43.7,3,Active_Drug,Standard,2025-09-18,Standard,South Korea,SITE-063
PT-002367,XS-OD-0033,8,Male,White,CAG repeat expansion,39.8,0,Placebo,Standard,2025-08-27,Pediatric_Assent,Norway,SITE-035
PT-002368,XS-OD-0033,8,Male,White,SOD1 A4V,63.2,2,Active_Drug,Standard,2025-08-22,Pediatric_Assent,United States,SITE-046
PT-002369,XS-OD-0033,16,Male,White,,42.2,3,Placebo,Standard,2025-07-17,Pediatric_Assent,United States,SITE-056
PT-002370,XS-OD-0033,4,Male,Hispanic or Latino,SCN1A R1648H,47.5,1,Active_Drug,Standard,2025-08-10,Pediatric_Assent,Belgium,SITE-051
PT-002371,XS-OD-0033,19,Male,Hispanic or Latino,CAG repeat expansion,55.8,4,Placebo,Standard,2025-09-05,Standard,Belgium,SITE-008
PT-002372,XS-OD-0033,6,Male,Hispanic or Latino,Exon 51 deletion,42.3,3,Active_Drug,Standard,2025-07-28,Pediatric_Assent,Brazil,SITE-048
PT-002373,XS-OD-0033,12,Male,White,,56.0,3,Placebo,Standard,2025-06-11,Pediatric_Assent,Denmark,SITE-016
PT-002374,XS-OD-0033,6,Male,Hispanic or Latino,CAG repeat expansion,87.6,4,Active_Drug,Standard,2025-08-09,Pediatric_Assent,France,SITE-017
PT-002375,XS-OD-0033,10,Male,Hispanic or Latino,SOD1 A4V,72.2,1,Placebo,Standard,2025-06-05,Pediatric_Assent,South Korea,SITE-023
PT-002376,XS-OD-0033,13,Male,White,SMN1 deletion,59.7,3,Active_Drug,Standard,2025-05-09,Pediatric_Assent,Austria,SITE-063
PT-002377,XS-OD-0033,14,Male,White,SMN1 deletion,63.0,1,Placebo,Standard,2025-08-09,Pediatric_Assent,Netherlands,SITE-025
PT-002378,XS-OD-0033,4,Male,Hispanic or Latino,,50.1,1,Active_Drug,Standard,2025-10-11,Pediatric_Assent,Norway,SITE-023
PT-002379,XS-OD-0033,7,Male,Hispanic or Latino,SOD1 A4V,42.8,3,Placebo,Standard,2025-08-04,Pediatric_Assent,Netherlands,SITE-008
PT-002380,XS-OD-0033,15,Male,White,SOD1 A4V,26.7,3,Active_Drug,Standard,2025-08-12,Pediatric_Assent,Brazil,SITE-060
PT-002381,XS-OD-0033,5,Male,Black or African American,,44.7,3,Placebo,Standard,2025-07-09,Pediatric_Assent,Spain,SITE-023
PT-002382,XS-OD-0033,15,Female,White,CAG repeat expansion,60.1,3,Active_Drug,Standard,2025-05-23,Pediatric_Assent,Israel,SITE-053
PT-002383,XS-OD-0033,9,Male,White,SCN1A R1648H,66.9,3,Placebo,Standard,2025-09-11,Pediatric_Assent,Canada,SITE-034
PT-002384,XS-OD-0033,18,Male,White,,45.3,0,Active_Drug,Standard,2025-09-30,Standard,Spain,SITE-021
PT-002385,XS-OD-0033,17,Male,Black or African American,Exon 51 deletion,58.9,1,Placebo,Standard,2025-08-05,Pediatric_Assent,Norway,SITE-039
PT-002386,XS-OD-0033,4,Female,Asian,,45.0,2,Active_Drug,Standard,2025-09-24,Pediatric_Assent,Taiwan,SITE-022
PT-002387,XS-OD-0033,6,Male,White,CAG repeat expansion,73.0,2,Placebo,Standard,2025-08-14,Pediatric_Assent,Brazil,SITE-018
PT-002388,XS-OD-0033,7,Male,White,CAG repeat expansion,72.4,0,Active_Drug,Standard,2025-06-27,Pediatric_Assent,France,SITE-051
PT-002389,XS-OD-0033,17,Male,White,CAG repeat expansion,67.2,1,Placebo,Standard,2025-08-23,Pediatric_Assent,Belgium,SITE-030
PT-002390,XS-OD-0033,4,Male,Asian,,72.8,7,Active_Drug,Standard,2025-05-12,Pediatric_Assent,Belgium,SITE-029
PT-002391,XS-OD-0033,20,Male,White,,81.6,3,Placebo,Standard,2025-09-14,Standard,Austria,SITE-029
PT-002392,XS-OD-0033,8,Male,Hispanic or Latino,Exon 51 deletion,56.1,4,Active_Drug,Standard,2025-08-20,Pediatric_Assent,Switzerland,SITE-049
PT-002393,XS-OD-0033,13,Male,American Indian or Alaska Native,CAG repeat expansion,83.3,0,Placebo,Standard,2025-08-11,Pediatric_Assent,United Kingdom,SITE-016
PT-002394,XS-OD-0033,13,Male,White,,54.9,2,Active_Drug,Standard,2025-06-05,Pediatric_Assent,Italy,SITE-014
PT-002395,XS-OD-0033,20,Male,White,SOD1 A4V,36.7,2,Placebo,Standard,2025-06-14,Standard,France,SITE-059
PT-002396,XS-OD-0033,12,Male,Asian,Exon 51 deletion,46.0,4,Active_Drug,Standard,2025-07-02,Pediatric_Assent,Norway,SITE-040
PT-002397,XS-OD-0033,8,Male,Two or More Races,SCN1A R1648H,60.6,1,Placebo,Standard,2025-09-05,Pediatric_Assent,United States,SITE-054
PT-002398,XS-OD-0033,12,Male,Black or African American,,32.1,2,Active_Drug,Standard,2025-08-28,Pediatric_Assent,Austria,SITE-015
PT-002399,XS-OD-0033,14,Male,Hispanic or Latino,SOD1 A4V,61.8,0,Placebo,Standard,2025-10-16,Pediatric_Assent,Spain,SITE-065
PT-002400,XS-OD-0033,14,Male,White,SOD1 A4V,19.1,1,Active_Drug,Standard,2025-09-02,Pediatric_Assent,Spain,SITE-036
PT-002401,XS-OD-0033,9,Male,White,SMN1 deletion,44.6,2,Placebo,Standard,2025-05-23,Pediatric_Assent,Austria,SITE-062
PT-002402,XS-OD-0033,14,Male,White,SMN1 deletion,65.9,0,Active_Drug,Standard,2025-09-01,Pediatric_Assent,South Korea,SITE-024
PT-002403,XS-OD-0033,9,Male,White,,69.3,2,Placebo,Standard,2025-10-12,Pediatric_Assent,Belgium,SITE-049
PT-002404,XS-OD-0033,13,Male,White,Exon 51 deletion,50.5,3,Active_Drug,Standard,2025-07-26,Pediatric_Assent,Israel,SITE-022
PT-002405,XS-OD-0033,4,Male,White,Exon 51 deletion,45.1,2,Placebo,Standard,2025-08-30,Pediatric_Assent,Brazil,SITE-040
PT-002406,XS-OD-0033,18,Male,Black or African American,,95.0,1,Active_Drug,Standard,2025-06-15,Standard,Taiwan,SITE-008
PT-002407,XS-OD-0033,14,Male,White,,55.8,3,Placebo,Standard,2025-10-07,Pediatric_Assent,United Kingdom,SITE-053
PT-002408,XS-OD-0033,10,Male,Black or African American,CAG repeat expansion,69.8,3,Active_Drug,Standard,2025-05-22,Pediatric_Assent,France,SITE-041
PT-002409,XS-OD-0033,9,Male,White,SCN1A R1648H,50.8,0,Placebo,Standard,2025-06-30,Pediatric_Assent,Norway,SITE-014
PT-002410,XS-OD-0033,11,Male,Hispanic or Latino,,32.0,5,Active_Drug,Standard,2025-06-09,Pediatric_Assent,Australia,SITE-049
PT-002411,XS-OD-0033,12,Male,White,SOD1 A4V,84.5,3,Placebo,Standard,2025-08-11,Pediatric_Assent,Norway,SITE-016
PT-002412,XS-OD-0033,10,Male,White,,94.8,3,Active_Drug,Standard,2025-06-29,Pediatric_Assent,South Korea,SITE-030
PT-002413,XS-OD-0033,11,Male,Hispanic or Latino,SOD1 A4V,56.3,2,Placebo,Standard,2025-07-02,Pediatric_Assent,United Kingdom,SITE-061
PT-002414,XS-OD-0033,7,Male,White,,56.6,4,Active_Drug,Standard,2025-05-12,Pediatric_Assent,Spain,SITE-002
PT-002415,XS-OD-0033,13,Male,Asian,SCN1A R1648H,62.3,2,Placebo,Standard,2025-05-29,Pediatric_Assent,Sweden,SITE-054
PT-002416,XS-OD-0033,7,Male,White,,64.9,1,Active_Drug,Standard,2025-06-04,Pediatric_Assent,Sweden,SITE-051
PT-002417,XS-OD-0033,14,Male,White,,57.5,1,Placebo,Standard,2025-07-08,Pediatric_Assent,Canada,SITE-044
PT-002418,XS-OD-0033,11,Male,Black or African American,SCN1A R1648H,61.7,2,Active_Drug,Standard,2025-06-22,Pediatric_Assent,Belgium,SITE-056
PT-002419,XS-OD-0033,6,Male,Black or African American,CAG repeat expansion,45.5,4,Placebo,Standard,2025-06-18,Pediatric_Assent,Japan,SITE-049
PT-002420,XS-OD-0033,6,Male,White,SMN1 deletion,89.6,4,Active_Drug,Standard,2025-07-09,Pediatric_Assent,Germany,SITE-037
PT-002421,XS-OD-0033,4,Male,White,SOD1 A4V,45.8,3,Placebo,Standard,2025-08-02,Pediatric_Assent,Japan,SITE-045
PT-002422,XS-OD-0033,12,Female,Hispanic or Latino,SCN1A R1648H,33.3,0,Active_Drug,Standard,2025-10-08,Pediatric_Assent,Norway,SITE-036
PT-002423,XS-OD-0033,4,Male,Asian,SOD1 A4V,63.3,2,Placebo,Standard,2025-09-10,Pediatric_Assent,Spain,SITE-041
PT-002424,XS-OD-0033,15,Male,White,,73.8,3,Active_Drug,Standard,2025-10-09,Pediatric_Assent,Australia,SITE-043
PT-002425,XS-OD-0033,14,Male,White,SOD1 A4V,33.1,1,Placebo,Standard,2025-05-16,Pediatric_Assent,Japan,SITE-012
PT-002426,XS-OD-0033,8,Male,Hispanic or Latino,,38.0,2,Active_Drug,Standard,2025-06-02,Pediatric_Assent,Spain,SITE-016
PT-002427,XS-OD-0033,10,Male,Hispanic or Latino,SMN1 deletion,75.6,3,Placebo,Standard,2025-07-06,Pediatric_Assent,Netherlands,SITE-035
PT-002428,XS-OD-0033,12,Male,American Indian or Alaska Native,SMN1 deletion,22.6,2,Active_Drug,Standard,2025-06-21,Pediatric_Assent,Taiwan,SITE-004
PT-002429,XS-OD-0033,13,Male,White,,44.1,1,Placebo,Standard,2025-05-27,Pediatric_Assent,Israel,SITE-056
PT-002430,XS-OD-0033,13,Male,White,,48.1,0,Active_Drug,Standard,2025-06-10,Pediatric_Assent,Brazil,SITE-051
PT-002431,XS-OD-0033,9,Male,White,Exon 51 deletion,71.4,4,Placebo,Standard,2025-10-26,Pediatric_Assent,United Kingdom,SITE-016
PT-002432,XS-OD-0033,17,Male,Hispanic or Latino,Exon 51 deletion,75.9,2,Active_Drug,Standard,2025-08-07,Pediatric_Assent,Germany,SITE-048
PT-002433,XS-OD-0033,12,Male,White,SOD1 A4V,28.4,4,Placebo,Standard,2025-10-26,Pediatric_Assent,Austria,SITE-025
PT-002434,XS-OD-0033,16,Male,Hispanic or Latino,,71.1,2,Active_Drug,Standard,2025-06-27,Pediatric_Assent,Israel,SITE-023
PT-002435,XS-OD-0033,15,Male,Hispanic or Latino,,62.4,1,Placebo,Standard,2025-08-17,Pediatric_Assent,United Kingdom,SITE-033
PT-002436,XS-OD-0033,17,Male,White,Exon 51 deletion,52.8,1,Active_Drug,Standard,2025-10-03,Pediatric_Assent,Germany,SITE-011
PT-002437,XS-OD-0033,13,Male,White,CAG repeat expansion,28.6,2,Placebo,Standard,2025-08-21,Pediatric_Assent,Belgium,SITE-060
PT-002438,XS-OD-0033,8,Male,Asian,SMN1 deletion,59.4,5,Active_Drug,Standard,2025-08-08,Pediatric_Assent,Netherlands,SITE-064
PT-002439,XS-OD-0033,14,Male,Hispanic or Latino,SCN1A R1648H,56.5,1,Placebo,Standard,2025-05-25,Pediatric_Assent,Israel,SITE-048
PT-002440,XS-OD-0033,14,Male,White,SCN1A R1648H,50.8,4,Active_Drug,Standard,2025-05-13,Pediatric_Assent,South Korea,SITE-029
PT-002441,XS-OD-0033,12,Male,Hispanic or Latino,,45.8,3,Placebo,Standard,2025-10-16,Pediatric_Assent,Japan,SITE-046
PT-002442,XS-OD-0033,4,Male,Black or African American,,45.0,0,Active_Drug,Standard,2025-09-16,Pediatric_Assent,Australia,SITE-030
PT-002443,XS-OD-0033,16,Male,Asian,SCN1A R1648H,74.3,2,Placebo,Standard,2025-10-26,Pediatric_Assent,Israel,SITE-048
PT-002444,XS-OD-0033,22,Male,Black or African American,CAG repeat expansion,50.6,3,Active_Drug,Standard,2025-09-25,Standard,Austria,SITE-062
PT-002445,XS-OD-0033,10,Male,Hispanic or Latino,Exon 51 deletion,24.1,1,Placebo,Standard,2025-06-05,Pediatric_Assent,Belgium,SITE-063
PT-002446,XS-OD-0033,5,Male,White,SOD1 A4V,70.8,2,Active_Drug,Standard,2025-06-30,Pediatric_Assent,Switzerland,SITE-029
PT-002447,XS-OD-0033,17,Male,White,,32.9,1,Placebo,Standard,2025-09-09,Pediatric_Assent,Canada,SITE-045
PT-002448,XS-OD-0033,6,Male,Black or African American,SOD1 A4V,38.2,0,Active_Drug,Standard,2025-05-28,Pediatric_Assent,Switzerland,SITE-012
PT-002449,XS-OD-0033,4,Male,White,,63.5,3,Placebo,Standard,2025-05-24,Pediatric_Assent,Israel,SITE-025
PT-002450,XS-OD-0033,12,Male,White,,59.9,5,Active_Drug,Standard,2025-10-05,Pediatric_Assent,Canada,SITE-045
PT-002451,XS-OD-0033,13,Male,White,CAG repeat expansion,51.8,4,Placebo,Standard,2025-10-21,Pediatric_Assent,Israel,SITE-005
PT-002452,XS-OD-0033,8,Male,Black or African American,,54.8,2,Active_Drug,Standard,2025-10-25,Pediatric_Assent,South Korea,SITE-002
PT-002453,XS-OD-0033,10,Male,White,,38.8,1,Placebo,Standard,2025-09-30,Pediatric_Assent,Australia,SITE-053
PT-002454,XS-OD-0033,17,Male,White,,10.0,4,Active_Drug,Standard,2025-06-19,Pediatric_Assent,Japan,SITE-023
PT-002455,XS-OD-0033,19,Male,Black or African American,,45.8,1,Placebo,Standard,2025-10-17,Standard,Denmark,SITE-017
PT-002456,XS-OD-0033,13,Male,Hispanic or Latino,,27.4,2,Active_Drug,Standard,2025-08-04,Pediatric_Assent,United States,SITE-041
PT-002457,XS-OD-0033,4,Male,White,,41.0,2,Placebo,Standard,2025-10-24,Pediatric_Assent,Brazil,SITE-047
PT-002458,XS-OD-0033,4,Male,White,SOD1 A4V,33.6,2,Active_Drug,Standard,2025-06-02,Pediatric_Assent,United States,SITE-058
PT-002459,XS-OD-0033,14,Male,White,,89.1,2,Placebo,Standard,2025-07-25,Pediatric_Assent,Israel,SITE-031
PT-002460,XS-OD-0033,14,Male,White,SCN1A R1648H,44.5,4,Active_Drug,Standard,2025-08-11,Pediatric_Assent,United Kingdom,SITE-057
PT-002461,XS-OD-0033,5,Male,White,Exon 51 deletion,42.9,2,Placebo,Standard,2025-05-07,Pediatric_Assent,Taiwan,SITE-062
PT-002462,XS-OD-0033,17,Male,White,CAG repeat expansion,62.7,0,Active_Drug,Standard,2025-09-04,Pediatric_Assent,Denmark,SITE-045
PT-002463,XS-OD-0033,10,Male,Black or African American,SOD1 A4V,49.9,3,Placebo,Standard,2025-08-15,Pediatric_Assent,Brazil,SITE-007
PT-002464,XS-OD-0033,4,Male,White,Exon 51 deletion,78.0,2,Active_Drug,Standard,2025-06-07,Pediatric_Assent,Switzerland,SITE-047
PT-002465,XS-OD-0033,14,Male,Hispanic or Latino,SOD1 A4V,60.6,4,Placebo,Standard,2025-09-01,Pediatric_Assent,Australia,SITE-052
PT-002466,XS-OD-0033,15,Male,Hispanic or Latino,CAG repeat expansion,64.4,2,Active_Drug,Standard,2025-05-20,Pediatric_Assent,Japan,SITE-007
PT-002467,XS-OD-0033,10,Male,Hispanic or Latino,,70.0,1,Placebo,Standard,2025-08-14,Pediatric_Assent,Denmark,SITE-009
PT-002468,XS-OD-0033,10,Male,Hispanic or Latino,,39.7,1,Active_Drug,Standard,2025-05-08,Pediatric_Assent,Australia,SITE-022
PT-002469,XS-OD-0033,12,Male,White,SOD1 A4V,39.5,4,Placebo,Standard,2025-08-04,Pediatric_Assent,Canada,SITE-023
PT-002470,XS-OD-0033,16,Male,Native Hawaiian or Other Pacific Islander,SOD1 A4V,37.7,1,Active_Drug,Standard,2025-10-24,Pediatric_Assent,Italy,SITE-030
PT-002471,XS-OD-0033,4,Male,Native Hawaiian or Other Pacific Islander,SMN1 deletion,54.0,3,Placebo,Standard,2025-10-29,Pediatric_Assent,South Korea,SITE-029
PT-002472,XS-OD-0033,18,Male,Asian,Exon 51 deletion,64.7,4,Active_Drug,Standard,2025-05-17,Standard,Spain,SITE-043
PT-002473,XS-OD-0033,7,Male,White,,61.4,1,Placebo,Standard,2025-10-02,Pediatric_Assent,Spain,SITE-047
PT-002474,XS-OD-0033,16,Male,Black or African American,SMN1 deletion,52.5,1,Active_Drug,Standard,2025-07-16,Pediatric_Assent,Denmark,SITE-021
PT-002475,XS-OD-0033,13,Male,Black or African American,SOD1 A4V,80.1,2,Placebo,Standard,2025-08-16,Pediatric_Assent,France,SITE-022
PT-002476,XS-OD-0033,5,Male,White,SOD1 A4V,57.0,3,Active_Drug,Standard,2025-06-25,Pediatric_Assent,South Korea,SITE-002
PT-002477,XS-OD-0033,8,Female,Black or African American,,75.1,2,Placebo,Standard,2025-06-05,Pediatric_Assent,Sweden,SITE-047
PT-002478,XS-OD-0033,8,Male,White,SOD1 A4V,76.0,4,Active_Drug,Standard,2025-09-14,Pediatric_Assent,Denmark,SITE-006
PT-002479,XS-OD-0033,4,Male,Hispanic or Latino,CAG repeat expansion,37.3,1,Placebo,Standard,2025-09-15,Pediatric_Assent,United States,SITE-046
PT-002480,XS-OD-0033,11,Male,White,,48.6,3,Active_Drug,Standard,2025-07-05,Pediatric_Assent,Israel,SITE-016
PT-002481,XS-OD-0033,14,Male,White,CAG repeat expansion,59.8,2,Placebo,Standard,2025-06-17,Pediatric_Assent,Norway,SITE-056
PT-002482,XS-OD-0033,16,Male,Asian,SMN1 deletion,42.5,1,Active_Drug,Standard,2025-07-09,Pediatric_Assent,United States,SITE-004
PT-002483,XS-OD-0033,4,Male,White,Exon 51 deletion,39.2,3,Placebo,Standard,2025-07-22,Pediatric_Assent,United Kingdom,SITE-012
PT-002484,XS-OD-0033,8,Male,Asian,Exon 51 deletion,66.2,3,Active_Drug,Standard,2025-06-11,Pediatric_Assent,Austria,SITE-002
PT-002485,XS-OD-0033,19,Male,White,SOD1 A4V,36.2,2,Placebo,Standard,2025-08-21,Standard,Italy,SITE-045
PT-002486,XS-OD-0033,9,Male,Asian,,90.9,1,Active_Drug,Standard,2025-08-29,Pediatric_Assent,Italy,SITE-008
PT-002487,XS-OD-0033,13,Male,Black or African American,SMN1 deletion,57.8,2,Placebo,Standard,2025-08-26,Pediatric_Assent,South Korea,SITE-008
PT-002488,XS-OD-0033,7,Male,Two or More Races,SMN1 deletion,69.9,1,Active_Drug,Standard,2025-08-22,Pediatric_Assent,Brazil,SITE-002
PT-002489,XS-OD-0033,9,Male,Asian,SMN1 deletion,79.4,2,Placebo,Standard,2025-09-23,Pediatric_Assent,Japan,SITE-052
PT-002490,XS-OD-0033,15,Male,White,CAG repeat expansion,46.4,3,Active_Drug,Standard,2025-05-24,Pediatric_Assent,Norway,SITE-060
PT-002491,XS-OD-0033,11,Male,White,,51.4,4,Placebo,Standard,2025-06-07,Pediatric_Assent,Belgium,SITE-003
PT-002492,XS-OD-0033,8,Female,Asian,,72.5,3,Active_Drug,Standard,2025-09-19,Pediatric_Assent,Taiwan,SITE-022
PT-002493,XS-OD-0033,17,Male,Asian,Exon 51 deletion,62.0,2,Placebo,Standard,2025-06-06,Pediatric_Assent,Japan,SITE-035
PT-002494,XS-OD-0033,13,Male,Black or African American,Exon 51 deletion,62.9,2,Active_Drug,Standard,2025-10-21,Pediatric_Assent,Italy,SITE-056
PT-002495,XS-OD-0033,9,Male,White,Exon 51 deletion,31.0,0,Placebo,Standard,2025-06-18,Pediatric_Assent,Switzerland,SITE-060
PT-002496,XS-OD-0033,4,Male,Hispanic or Latino,SOD1 A4V,46.3,2,Active_Drug,Standard,2025-05-15,Pediatric_Assent,Switzerland,SITE-020
PT-002497,XS-OD-0033,4,Male,Asian,SMN1 deletion,56.7,1,Placebo,Standard,2025-08-27,Pediatric_Assent,Sweden,SITE-003
PT-002498,XS-OD-0033,11,Male,White,,63.6,3,Active_Drug,Standard,2025-07-04,Pediatric_Assent,Sweden,SITE-035
PT-002499,XS-OD-0033,14,Male,White,Exon 51 deletion,52.2,1,Placebo,Standard,2025-05-16,Pediatric_Assent,France,SITE-032
PT-002500,XS-OD-0033,15,Male,White,,67.9,0,Active_Drug,Standard,2025-08-28,Pediatric_Assent,Switzerland,SITE-059
PT-002501,XS-OD-0033,9,Male,Black or African American,SCN1A R1648H,45.1,0,Placebo,Standard,2025-09-02,Pediatric_Assent,Austria,SITE-039
PT-002502,XS-OD-0033,18,Male,White,SOD1 A4V,15.2,4,Active_Drug,Standard,2025-05-16,Standard,Brazil,SITE-006
PT-002503,XS-OD-0033,9,Male,White,SCN1A R1648H,60.0,2,Placebo,Standard,2025-10-09,Pediatric_Assent,Brazil,SITE-032
PT-002504,XS-OD-0033,17,Male,White,,61.0,4,Active_Drug,Standard,2025-06-25,Pediatric_Assent,Italy,SITE-025
PT-002505,XS-OD-0033,14,Male,White,,31.8,2,Placebo,Standard,2025-10-23,Pediatric_Assent,France,SITE-005
PT-002506,XS-OD-0033,17,Male,White,SCN1A R1648H,65.3,2,Active_Drug,Standard,2025-05-28,Pediatric_Assent,Germany,SITE-063
PT-002507,XS-OD-0033,18,Male,White,Exon 51 deletion,57.2,4,Placebo,Standard,2025-10-15,Standard,Australia,SITE-036
PT-002508,XS-OD-0033,5,Male,White,,58.7,1,Active_Drug,Standard,2025-09-22,Pediatric_Assent,Taiwan,SITE-026
PT-002509,XS-OD-0033,12,Male,White,SCN1A R1648H,56.8,0,Placebo,Standard,2025-09-11,Pediatric_Assent,Brazil,SITE-014
PT-002510,XS-OD-0033,9,Male,White,SOD1 A4V,77.3,2,Active_Drug,Standard,2025-05-05,Pediatric_Assent,Netherlands,SITE-001
PT-002511,XS-OD-0033,10,Male,Hispanic or Latino,,50.3,1,Placebo,Standard,2025-09-16,Pediatric_Assent,Netherlands,SITE-015
PT-002512,XS-OD-0033,4,Male,White,,36.9,0,Active_Drug,Standard,2025-07-01,Pediatric_Assent,Australia,SITE-029
PT-002513,XS-OD-0033,14,Male,White,,46.5,0,Placebo,Standard,2025-08-31,Pediatric_Assent,South Korea,SITE-065
PT-002514,XS-OD-0033,17,Male,White,SCN1A R1648H,60.4,1,Active_Drug,Standard,2025-08-21,Pediatric_Assent,Austria,SITE-065
PT-002515,XS-OD-0033,8,Male,White,,11.8,2,Placebo,Standard,2025-08-26,Pediatric_Assent,Switzerland,SITE-022
PT-002516,XS-OD-0033,18,Male,Hispanic or Latino,CAG repeat expansion,48.1,3,Active_Drug,Standard,2025-07-26,Standard,Taiwan,SITE-042
PT-002517,XS-OD-0033,15,Male,White,Exon 51 deletion,64.5,1,Placebo,Standard,2025-09-18,Pediatric_Assent,Canada,SITE-012
PT-002518,XS-OD-0033,17,Male,White,,61.5,2,Active_Drug,Standard,2025-08-25,Pediatric_Assent,Belgium,SITE-020
PT-002519,XS-OD-0033,4,Male,Two or More Races,SCN1A R1648H,59.5,1,Placebo,Standard,2025-08-12,Pediatric_Assent,Brazil,SITE-032
PT-002520,XS-OD-0033,12,Male,Hispanic or Latino,Exon 51 deletion,54.1,0,Active_Drug,Standard,2025-07-11,Pediatric_Assent,Taiwan,SITE-027
PT-002521,XS-OD-0033,19,Male,White,,26.3,2,Placebo,Standard,2025-06-23,Standard,Australia,SITE-002
PT-002522,XS-OD-0033,12,Male,White,SMN1 deletion,57.2,3,Active_Drug,Standard,2025-08-11,Pediatric_Assent,Norway,SITE-040
PT-002523,XS-OD-0033,13,Male,White,,52.6,4,Placebo,Standard,2025-09-17,Pediatric_Assent,South Korea,SITE-058
PT-002524,XS-OD-0033,15,Male,White,,67.4,1,Active_Drug,Standard,2025-07-31,Pediatric_Assent,Taiwan,SITE-006
PT-002525,XS-OD-0033,4,Male,Asian,,79.9,2,Placebo,Standard,2025-10-28,Pediatric_Assent,Belgium,SITE-048
PT-002526,XS-OD-0033,8,Male,White,,52.0,2,Active_Drug,Standard,2025-10-17,Pediatric_Assent,Canada,SITE-003
PT-002527,XS-OD-0033,16,Male,Black or African American,,59.3,1,Placebo,Standard,2025-08-24,Pediatric_Assent,Australia,SITE-005
PT-002528,XS-OD-0033,19,Male,Black or African American,SOD1 A4V,53.6,1,Active_Drug,Standard,2025-05-31,Standard,Sweden,SITE-057
PT-002529,XS-OD-0033,18,Male,White,,38.3,0,Placebo,Standard,2025-07-20,Standard,Germany,SITE-006
PT-002530,XS-OD-0033,8,Male,Hispanic or Latino,SCN1A R1648H,66.2,0,Active_Drug,Standard,2025-07-04,Pediatric_Assent,Sweden,SITE-002
PT-002531,XS-OD-0033,13,Male,White,,66.6,6,Placebo,Standard,2025-10-29,Pediatric_Assent,Taiwan,SITE-026
PT-002532,XS-OD-0033,15,Male,White,,36.1,2,Active_Drug,Standard,2025-09-04,Pediatric_Assent,Brazil,SITE-043
PT-002533,XS-OD-0033,6,Male,White,Exon 51 deletion,52.6,5,Placebo,Standard,2025-10-25,Pediatric_Assent,Belgium,SITE-015
PT-002534,XS-OD-0033,10,Male,Asian,,91.6,0,Active_Drug,Standard,2025-09-15,Pediatric_Assent,Switzerland,SITE-012
PT-002535,XS-OD-0033,7,Male,White,,49.5,1,Placebo,Standard,2025-05-05,Pediatric_Assent,Belgium,SITE-057
PT-002536,XS-OD-0033,13,Male,White,CAG repeat expansion,69.2,2,Active_Drug,Standard,2025-05-04,Pediatric_Assent,Taiwan,SITE-014
PT-002537,XS-OD-0033,4,Male,Hispanic or Latino,SCN1A R1648H,50.7,2,Placebo,Standard,2025-07-04,Pediatric_Assent,United States,SITE-010
PT-002538,XS-OD-0033,16,Female,Asian,SCN1A R1648H,62.4,4,Active_Drug,Standard,2025-09-13,Pediatric_Assent,Germany,SITE-004
PT-002539,XS-OD-0033,11,Male,Hispanic or Latino,,95.0,1,Placebo,Standard,2025-05-29,Pediatric_Assent,Netherlands,SITE-020
PT-002540,XS-OD-0033,4,Male,White,,63.1,2,Active_Drug,Standard,2025-10-17,Pediatric_Assent,Brazil,SITE-016
PT-002541,XS-OD-0033,15,Female,Hispanic or Latino,SMN1 deletion,56.7,3,Placebo,Standard,2025-07-26,Pediatric_Assent,Sweden,SITE-040
PT-002542,XS-OD-0033,17,Male,Asian,SCN1A R1648H,59.3,4,Active_Drug,Standard,2025-10-21,Pediatric_Assent,Austria,SITE-035
PT-002543,XS-OD-0033,6,Male,Asian,Exon 51 deletion,51.5,3,Placebo,Standard,2025-05-20,Pediatric_Assent,Norway,SITE-035
PT-002544,XS-OD-0033,18,Male,Asian,CAG repeat expansion,75.3,3,Active_Drug,Standard,2025-07-24,Standard,Japan,SITE-045
PT-002545,XS-OD-0033,6,Male,Asian,CAG repeat expansion,26.3,3,Placebo,Standard,2025-10-11,Pediatric_Assent,Norway,SITE-030
PT-002546,XS-OD-0033,14,Male,White,SOD1 A4V,61.8,0,Active_Drug,Standard,2025-07-11,Pediatric_Assent,Belgium,SITE-065
PT-002547,XS-OD-0033,11,Male,White,,54.6,0,Placebo,Standard,2025-08-19,Pediatric_Assent,Australia,SITE-063
PT-002548,XS-OD-0033,19,Female,Native Hawaiian or Other Pacific Islander,Exon 51 deletion,80.5,2,Active_Drug,Standard,2025-09-13,Standard,Germany,SITE-003
PT-002549,XS-OD-0033,12,Male,White,,64.4,1,Placebo,Standard,2025-07-18,Pediatric_Assent,Spain,SITE-015
PT-002550,XS-OD-0033,15,Male,White,,67.1,7,Active_Drug,Standard,2025-09-16,Pediatric_Assent,Belgium,SITE-015
PT-002551,XS-OD-0033,25,Male,Asian,SOD1 A4V,53.6,0,Placebo,Standard,2025-07-26,Standard,Australia,SITE-013
PT-002552,XS-OD-0034,46,Male,White,,10.0,3,Active_Drug,Standard,2023-08-20,Standard,United Kingdom,SITE-007
PT-002553,XS-OD-0034,9,Female,White,,61.8,1,Placebo,Standard,2023-12-15,Pediatric_Assent,Norway,SITE-007
PT-002554,XS-OD-0034,25,Male,White,SCN1A R1648H,38.0,2,Active_Drug,Standard,2023-10-11,Standard,Norway,SITE-005
PT-002555,XS-OD-0034,54,Male,Black or African American,SCN1A R1648H,57.5,4,Placebo,Standard,2023-10-21,Standard,Austria,SITE-023
PT-002556,XS-OD-0034,45,Male,White,SMN1 deletion,64.9,1,Active_Drug,Standard,2023-08-29,Standard,Japan,SITE-021
PT-002557,XS-OD-0034,10,Female,White,Exon 51 deletion,55.8,1,Placebo,Standard,2024-01-11,Pediatric_Assent,Germany,SITE-023
PT-002558,XS-OD-0034,27,Male,White,SOD1 A4V,63.7,0,Active_Drug,Standard,2023-07-31,Standard,Denmark,SITE-007
PT-002559,XS-OD-0034,37,Male,White,Exon 51 deletion,53.7,2,Placebo,Standard,2023-11-12,Standard,Germany,SITE-014
PT-002560,XS-OD-0034,11,Male,American Indian or Alaska Native,,53.7,2,Active_Drug,Standard,2023-09-18,Pediatric_Assent,Norway,SITE-024
PT-002561,XS-OD-0034,44,Female,White,SMN1 deletion,62.3,2,Placebo,Standard,2023-12-09,Standard,Spain,SITE-010
PT-002562,XS-OD-0034,37,Female,Black or African American,SMN1 deletion,43.8,0,Active_Drug,Standard,2024-01-02,Standard,Spain,SITE-023
PT-002563,XS-OD-0034,47,Female,White,SMN1 deletion,54.1,1,Placebo,Standard,2024-01-25,Standard,Norway,SITE-013
PT-002564,XS-OD-0034,33,Female,White,,73.6,1,Active_Drug,Standard,2023-09-30,Standard,Germany,SITE-014
PT-002565,XS-OD-0034,7,Male,White,SCN1A R1648H,89.7,4,Placebo,Standard,2023-10-18,Pediatric_Assent,Canada,SITE-013
PT-002566,XS-OD-0034,38,Male,White,,62.6,1,Active_Drug,Standard,2024-01-18,Standard,United Kingdom,SITE-014
PT-002567,XS-OD-0034,50,Female,White,SOD1 A4V,60.5,4,Placebo,Standard,2023-09-11,Standard,South Korea,SITE-004
PT-002568,XS-OD-0034,22,Male,Hispanic or Latino,,49.0,2,Active_Drug,Standard,2023-08-12,Standard,United Kingdom,SITE-012
PT-002569,XS-OD-0034,11,Female,White,,53.6,2,Placebo,Standard,2023-10-15,Pediatric_Assent,Norway,SITE-010
PT-002570,XS-OD-0034,24,Female,Asian,SCN1A R1648H,32.7,1,Active_Drug,Standard,2023-09-08,Standard,Brazil,SITE-012
PT-002571,XS-OD-0034,75,Female,White,,53.2,2,Placebo,Standard,2024-01-08,Standard,Norway,SITE-020
PT-002572,XS-OD-0034,15,Male,White,SCN1A R1648H,37.6,2,Active_Drug,Standard,2023-08-21,Pediatric_Assent,Norway,SITE-011
PT-002573,XS-OD-0034,61,Female,White,,87.9,1,Placebo,Standard,2023-11-10,Standard,Netherlands,SITE-005
PT-002574,XS-OD-0034,12,Female,White,,37.6,2,Active_Drug,Standard,2024-01-02,Pediatric_Assent,Italy,SITE-004
PT-002575,XS-OD-0034,35,Male,Hispanic or Latino,CAG repeat expansion,46.5,1,Placebo,Standard,2023-11-16,Standard,Canada,SITE-003
PT-002576,XS-OD-0034,36,Male,Black or African American,Exon 51 deletion,70.2,3,Active_Drug,Standard,2023-09-26,Standard,Belgium,SITE-018
PT-002577,XS-OD-0034,61,Female,White,,47.8,2,Placebo,Standard,2023-12-06,Standard,Denmark,SITE-023
PT-002578,XS-OD-0034,52,Male,Hispanic or Latino,CAG repeat expansion,52.6,5,Active_Drug,Standard,2023-11-25,Standard,Austria,SITE-007
PT-002579,XS-OD-0034,41,Male,Two or More Races,SCN1A R1648H,65.8,2,Placebo,Standard,2023-11-05,Standard,Spain,SITE-004
PT-002580,XS-OD-0034,19,Female,White,SCN1A R1648H,69.0,2,Active_Drug,Standard,2023-12-18,Standard,Switzerland,SITE-025
PT-002581,XS-OD-0034,45,Female,Black or African American,CAG repeat expansion,23.0,1,Placebo,Standard,2023-07-31,Standard,South Korea,SITE-021
PT-002582,XS-OD-0034,58,Male,White,CAG repeat expansion,56.0,2,Active_Drug,Standard,2023-12-21,Standard,Netherlands,SITE-010
PT-002583,XS-OD-0034,33,Male,White,SMN1 deletion,21.6,3,Placebo,Standard,2023-08-26,Standard,Sweden,SITE-011
PT-002584,XS-OD-0034,48,Male,White,SMN1 deletion,50.5,2,Active_Drug,Standard,2023-11-25,Standard,France,SITE-008
PT-002585,XS-OD-0034,37,Male,Black or African American,SMN1 deletion,32.8,2,Placebo,Standard,2023-07-31,Standard,Japan,SITE-007
PT-002586,XS-OD-0034,41,Female,Black or African American,,55.6,0,Active_Drug,Standard,2023-11-29,Standard,Norway,SITE-001
PT-002587,XS-OD-0034,37,Female,Native Hawaiian or Other Pacific Islander,,57.2,0,Placebo,Standard,2023-12-24,Standard,South Korea,SITE-021
PT-002588,XS-OD-0034,3,Female,White,SMN1 deletion,26.2,1,Active_Drug,Standard,2024-01-05,Pediatric_Assent,Japan,SITE-002
PT-002589,XS-OD-0034,52,Female,White,,44.4,2,Placebo,Standard,2023-12-12,Standard,Denmark,SITE-010
PT-002590,XS-OD-0034,2,Male,White,SOD1 A4V,89.0,0,Active_Drug,Standard,2023-08-25,Pediatric_Assent,Australia,SITE-001
PT-002591,XS-OD-0034,50,Female,White,SMN1 deletion,83.4,4,Placebo,Standard,2023-08-30,Standard,Canada,SITE-006
PT-002592,XS-OD-0034,14,Male,White,,10.0,5,Active_Drug,Standard,2023-09-30,Pediatric_Assent,Austria,SITE-012
PT-002593,XS-OD-0034,14,Male,White,SOD1 A4V,47.8,0,Placebo,Standard,2023-08-14,Pediatric_Assent,Japan,SITE-010
PT-002594,XS-OD-0034,49,Female,White,,31.9,4,Active_Drug,Standard,2023-08-10,Standard,Japan,SITE-019
PT-002595,XS-OD-0034,50,Female,White,SOD1 A4V,60.7,1,Placebo,Standard,2024-01-12,Standard,Israel,SITE-005
PT-002596,XS-OD-0034,23,Female,Black or African American,CAG repeat expansion,74.7,2,Active_Drug,Standard,2023-08-12,Standard,Canada,SITE-001
PT-002597,XS-OD-0034,17,Female,White,SMN1 deletion,86.4,0,Placebo,Standard,2023-09-06,Pediatric_Assent,Brazil,SITE-017
PT-002598,XS-OD-0034,38,Female,Asian,,51.5,1,Active_Drug,Standard,2023-10-10,Standard,Norway,SITE-018
PT-002599,XS-OD-0034,33,Male,White,SCN1A R1648H,39.0,3,Placebo,Standard,2024-01-07,Standard,Spain,SITE-011
PT-002600,XS-OD-0034,52,Female,White,SMN1 deletion,55.2,2,Active_Drug,Standard,2023-11-07,Standard,Germany,SITE-024
PT-002601,XS-OD-0034,12,Male,Hispanic or Latino,,52.7,1,Placebo,Standard,2023-10-20,Pediatric_Assent,Norway,SITE-025
PT-002602,XS-OD-0034,32,Male,Asian,SMN1 deletion,27.2,2,Active_Drug,Standard,2023-09-03,Standard,Israel,SITE-020
PT-002603,XS-OD-0034,19,Male,Black or African American,,44.5,3,Placebo,Standard,2023-10-04,Standard,Spain,SITE-001
PT-002604,XS-OD-0034,16,Male,Hispanic or Latino,Exon 51 deletion,75.0,2,Active_Drug,Standard,2023-08-06,Pediatric_Assent,United States,SITE-023
PT-002605,XS-OD-0034,46,Male,Native Hawaiian or Other Pacific Islander,Exon 51 deletion,67.0,3,Placebo,Standard,2023-10-23,Emergency,Japan,SITE-012
PT-002606,XS-OD-0034,17,Male,White,SMN1 deletion,48.3,1,Active_Drug,Standard,2024-01-15,Pediatric_Assent,Spain,SITE-017
PT-002607,XS-OD-0034,54,Female,Asian,SMN1 deletion,24.3,4,Placebo,Standard,2023-12-10,Standard,Japan,SITE-005
PT-002608,XS-OD-0034,11,Female,White,SMN1 deletion,51.3,5,Active_Drug,Standard,2023-10-09,Pediatric_Assent,Denmark,SITE-005
PT-002609,XS-OD-0034,28,Male,Asian,SCN1A R1648H,44.4,0,Placebo,Standard,2023-12-25,Standard,Spain,SITE-014
PT-002610,XS-OD-0034,46,Male,Asian,SMN1 deletion,57.7,1,Active_Drug,Standard,2023-08-19,Standard,Denmark,SITE-014
PT-002611,XS-OD-0034,46,Male,White,,66.1,2,Placebo,Standard,2024-01-20,Standard,United States,SITE-022
PT-002612,XS-OD-0034,29,Female,Black or African American,,44.8,4,Active_Drug,Standard,2023-11-23,Standard,Spain,SITE-002
PT-002613,XS-OD-0034,66,Female,White,SOD1 A4V,56.8,0,Placebo,Standard,2023-12-06,Standard,Italy,SITE-021
PT-002614,XS-OD-0034,62,Male,White,CAG repeat expansion,34.2,5,Active_Drug,Standard,2023-08-01,Standard,Belgium,SITE-010
PT-002615,XS-OD-0034,36,Male,White,SMN1 deletion,52.0,4,Placebo,Standard,2023-11-11,Emergency,Switzerland,SITE-004
PT-002616,XS-OD-0034,49,Male,Asian,,71.1,2,Active_Drug,Standard,2023-08-21,Standard,Norway,SITE-022
PT-002617,XS-OD-0034,2,Male,Black or African American,,65.8,0,Placebo,Standard,2023-09-10,Pediatric_Assent,Belgium,SITE-013
PT-002618,XS-OD-0034,36,Female,Hispanic or Latino,,83.3,5,Active_Drug,Standard,2023-09-26,Standard,Italy,SITE-021
PT-002619,XS-OD-0034,30,Male,American Indian or Alaska Native,,81.6,3,Placebo,Standard,2023-09-14,Standard,Taiwan,SITE-013
PT-002620,XS-OD-0034,36,Male,Hispanic or Latino,SCN1A R1648H,31.8,3,Active_Drug,Standard,2023-11-21,Standard,France,SITE-013
PT-002621,XS-OD-0034,16,Male,White,SCN1A R1648H,64.7,0,Placebo,Standard,2023-07-31,Pediatric_Assent,Italy,SITE-003
PT-002622,XS-OD-0034,67,Male,White,,73.0,1,Active_Drug,Standard,2023-12-07,Standard,Taiwan,SITE-001
PT-002623,XS-OD-0034,31,Female,White,SCN1A R1648H,93.9,3,Placebo,Standard,2023-10-13,Standard,South Korea,SITE-015
PT-002624,XS-OD-0034,56,Intersex,White,Exon 51 deletion,51.0,5,Active_Drug,Standard,2023-12-22,Standard,Switzerland,SITE-021
PT-002625,XS-OD-0034,57,Female,Asian,SMN1 deletion,29.0,1,Placebo,Standard,2023-08-10,Standard,South Korea,SITE-009
PT-002626,XS-OD-0034,48,Female,Asian,,48.0,1,Active_Drug,Standard,2023-09-14,Standard,France,SITE-023
PT-002627,XS-OD-0034,7,Male,White,SCN1A R1648H,38.9,5,Placebo,Standard,2023-12-02,Pediatric_Assent,Norway,SITE-004
PT-002628,XS-OD-0034,75,Male,White,CAG repeat expansion,69.9,0,Active_Drug,Standard,2023-11-09,Standard,South Korea,SITE-018
PT-002629,XS-OD-0034,83,Male,Black or African American,CAG repeat expansion,44.9,4,Placebo,Standard,2023-09-16,Standard,France,SITE-023
PT-002630,XS-OD-0034,64,Intersex,White,,28.4,1,Active_Drug,Standard,2023-10-14,Standard,United Kingdom,SITE-017
PT-002631,XS-OD-0034,77,Male,White,SMN1 deletion,67.6,4,Placebo,Standard,2023-10-03,Standard,Switzerland,SITE-020
PT-002632,XS-OD-0034,39,Female,White,,28.2,0,Active_Drug,Standard,2023-08-15,Standard,Taiwan,SITE-017
PT-002633,XS-OD-0034,30,Female,White,CAG repeat expansion,32.0,1,Placebo,Standard,2023-12-31,Standard,Germany,SITE-002
PT-002634,XS-OD-0034,41,Female,Asian,SMN1 deletion,21.6,1,Active_Drug,Standard,2023-09-21,Standard,Israel,SITE-006
PT-002635,XS-OD-0034,41,Female,Hispanic or Latino,CAG repeat expansion,34.9,8,Placebo,Standard,2023-10-31,Standard,Norway,SITE-007
PT-002636,XS-OD-0034,41,Female,White,,33.0,2,Active_Drug,Standard,2023-09-17,Standard,Canada,SITE-005
PT-002637,XS-OD-0034,68,Male,Asian,Exon 51 deletion,82.9,1,Placebo,Standard,2023-11-25,Standard,Austria,SITE-011
PT-002638,XS-OD-0034,28,Female,White,SMN1 deletion,50.3,4,Active_Drug,Standard,2023-11-17,Standard,Spain,SITE-024
PT-002639,XS-OD-0034,44,Female,Asian,Exon 51 deletion,49.2,1,Placebo,Standard,2023-08-01,Standard,Australia,SITE-006
PT-002640,XS-OD-0034,25,Female,White,Exon 51 deletion,63.0,3,Active_Drug,Standard,2023-10-13,Standard,Canada,SITE-017
PT-002641,XS-OD-0034,11,Male,Hispanic or Latino,,27.1,3,Placebo,Standard,2023-10-03,Pediatric_Assent,Israel,SITE-025
PT-002642,XS-OD-0034,46,Female,White,Exon 51 deletion,58.9,2,Active_Drug,Standard,2023-10-11,Compassionate,France,SITE-010
PT-002643,XS-OD-0034,30,Female,White,SOD1 A4V,34.6,2,Placebo,Standard,2023-08-04,Standard,Sweden,SITE-006
PT-002644,XS-OD-0034,60,Male,White,,77.8,4,Active_Drug,Standard,2023-08-01,Standard,Japan,SITE-020
PT-002645,XS-OD-0034,73,Intersex,White,Exon 51 deletion,65.9,1,Placebo,Standard,2023-10-13,Standard,United States,SITE-017
PT-002646,XS-OD-0034,39,Male,Hispanic or Latino,SOD1 A4V,61.6,0,Active_Drug,Standard,2024-01-04,Standard,Denmark,SITE-005
PT-002647,XS-OD-0034,51,Male,White,,69.1,1,Placebo,Standard,2023-10-26,Standard,France,SITE-001
PT-002648,XS-OD-0034,68,Male,White,,52.4,0,Active_Drug,Standard,2023-09-13,Standard,Brazil,SITE-010
PT-002649,XS-OD-0034,47,Female,Hispanic or Latino,SCN1A R1648H,58.2,5,Placebo,Standard,2023-11-13,Standard,Sweden,SITE-025
PT-002650,XS-OD-0034,20,Female,White,SMN1 deletion,28.0,1,Active_Drug,Standard,2023-09-12,Standard,Denmark,SITE-010
PT-002651,XS-OD-0034,50,Male,Hispanic or Latino,,38.1,2,Placebo,Standard,2023-12-06,Standard,Denmark,SITE-012
PT-002652,XS-OD-0034,17,Female,Black or African American,SOD1 A4V,58.0,2,Active_Drug,Standard,2023-12-02,Pediatric_Assent,Taiwan,SITE-015
PT-002653,XS-OD-0034,25,Female,Black or African American,SOD1 A4V,53.0,1,Placebo,Standard,2024-01-19,Standard,Canada,SITE-008
PT-002654,XS-OD-0034,51,Female,Black or African American,Exon 51 deletion,51.3,3,Active_Drug,Standard,2024-01-13,Standard,Australia,SITE-006
PT-002655,XS-OD-0034,46,Female,White,,10.0,4,Placebo,Standard,2023-10-03,Standard,Italy,SITE-006
PT-002656,XS-OD-0034,30,Female,White,SOD1 A4V,60.3,2,Active_Drug,Standard,2023-09-19,Standard,Sweden,SITE-004
PT-002657,XS-OD-0034,67,Female,Hispanic or Latino,,49.7,1,Placebo,Standard,2023-11-20,Standard,Brazil,SITE-005
PT-002658,XS-OD-0034,59,Female,Hispanic or Latino,CAG repeat expansion,68.8,2,Active_Drug,Standard,2024-01-08,Standard,United Kingdom,SITE-001
PT-002659,XS-OD-0034,34,Female,Black or African American,,18.8,4,Placebo,Standard,2023-08-03,Standard,Germany,SITE-019
PT-002660,XS-OD-0034,36,Male,White,SOD1 A4V,56.9,4,Active_Drug,Standard,2023-10-21,Standard,Belgium,SITE-011
PT-002661,XS-OD-0034,42,Female,Hispanic or Latino,,49.9,4,Placebo,Standard,2023-11-04,Standard,Switzerland,SITE-005
PT-002662,XS-OD-0034,51,Female,White,SOD1 A4V,64.6,2,Active_Drug,Standard,2023-09-04,Standard,Italy,SITE-023
PT-002663,XS-OD-0034,34,Male,Hispanic or Latino,SCN1A R1648H,36.1,1,Placebo,Standard,2023-09-16,Standard,Taiwan,SITE-006
PT-002664,XS-OD-0034,34,Male,White,,79.3,3,Active_Drug,Standard,2024-01-19,Standard,Germany,SITE-004
PT-002665,XS-OD-0034,35,Female,White,CAG repeat expansion,42.9,1,Placebo,Standard,2023-12-13,Standard,France,SITE-012
PT-002666,XS-OD-0034,50,Female,White,SMN1 deletion,75.5,3,Active_Drug,Standard,2023-10-19,Standard,Israel,SITE-002
PT-002667,XS-OD-0034,19,Male,White,,54.2,1,Placebo,Standard,2024-01-18,Standard,France,SITE-001
PT-002668,XS-OD-0034,22,Female,White,SMN1 deletion,60.7,4,Active_Drug,Standard,2023-10-25,Standard,France,SITE-013
PT-002669,XS-OD-0034,49,Male,Asian,SMN1 deletion,85.1,3,Placebo,Standard,2023-10-11,Standard,Spain,SITE-016
PT-002670,XS-OD-0034,52,Female,White,SMN1 deletion,67.0,3,Active_Drug,Standard,2023-09-29,Standard,Israel,SITE-008
PT-002671,XS-OD-0034,49,Male,White,,73.0,3,Placebo,Standard,2024-01-11,Standard,Brazil,SITE-021
PT-002672,XS-OD-0034,45,Male,American Indian or Alaska Native,,53.4,3,Active_Drug,Standard,2023-09-02,Standard,Brazil,SITE-013
PT-002673,XS-OD-0034,36,Male,White,,47.4,1,Placebo,Standard,2023-09-19,Standard,Norway,SITE-015
PT-002674,XS-OD-0034,31,Male,Black or African American,,78.7,0,Active_Drug,Standard,2023-12-06,Standard,Denmark,SITE-010
PT-002675,XS-OD-0034,30,Male,Hispanic or Latino,SCN1A R1648H,25.8,0,Placebo,Standard,2023-09-26,Standard,Denmark,SITE-019
PT-002676,XS-OD-0034,62,Female,Black or African American,Exon 51 deletion,31.0,3,Active_Drug,Standard,2023-11-09,Standard,Belgium,SITE-008
PT-002677,XS-OD-0034,45,Male,White,,40.1,4,Placebo,Standard,2023-09-07,Standard,Brazil,SITE-019
PT-002678,XS-OD-0034,69,Male,White,CAG repeat expansion,81.8,0,Active_Drug,Standard,2023-09-11,Standard,Australia,SITE-019
PT-002679,XS-OD-0034,42,Male,White,,58.8,2,Placebo,Standard,2023-12-03,Standard,France,SITE-017
PT-002680,XS-OD-0034,58,Female,White,,95.0,3,Active_Drug,Standard,2024-01-12,Standard,South Korea,SITE-018
PT-002681,XS-OD-0034,61,Female,White,,63.8,4,Placebo,Standard,2023-09-06,Standard,Denmark,SITE-012
PT-002682,XS-OD-0034,31,Female,White,,79.9,0,Active_Drug,Standard,2023-10-18,Standard,Germany,SITE-021
PT-002683,XS-OD-0034,70,Female,White,SMN1 deletion,78.7,4,Placebo,Standard,2023-09-27,Standard,Israel,SITE-012
PT-002684,XS-OD-0034,2,Male,White,,67.4,0,Active_Drug,Standard,2023-10-05,Pediatric_Assent,Israel,SITE-001
PT-002685,XS-OD-0034,48,Male,White,,55.5,3,Placebo,Standard,2024-01-14,Standard,Italy,SITE-015
PT-002686,XS-OD-0034,44,Male,White,Exon 51 deletion,61.8,3,Active_Drug,Standard,2023-10-31,Standard,Austria,SITE-021
PT-002687,XS-OD-0034,59,Male,Black or African American,CAG repeat expansion,23.9,4,Placebo,Standard,2023-08-18,Standard,Belgium,SITE-016
PT-002688,XS-OD-0034,42,Female,White,,40.3,3,Active_Drug,Standard,2023-08-10,Standard,Australia,SITE-004
PT-002689,XS-OD-0034,58,Female,Black or African American,,51.7,3,Placebo,Standard,2023-08-06,Standard,Taiwan,SITE-003
PT-002690,XS-OD-0034,34,Male,White,CAG repeat expansion,20.6,1,Active_Drug,Standard,2023-10-21,Standard,Australia,SITE-018
PT-002691,XS-OD-0034,44,Female,White,SMN1 deletion,74.5,2,Placebo,Standard,2023-11-14,Standard,South Korea,SITE-014
PT-002692,XS-OD-0034,49,Female,White,CAG repeat expansion,58.2,2,Active_Drug,Standard,2023-12-21,Standard,Spain,SITE-005
PT-002693,XS-OD-0034,30,Female,American Indian or Alaska Native,Exon 51 deletion,89.6,2,Placebo,Standard,2023-09-08,Standard,Norway,SITE-004
PT-002694,XS-OD-0034,29,Male,White,CAG repeat expansion,37.8,2,Active_Drug,Standard,2023-12-14,Emergency,Sweden,SITE-005
PT-002695,XS-OD-0034,22,Male,White,SOD1 A4V,62.5,2,Placebo,Standard,2023-11-09,Standard,Japan,SITE-021
PT-002696,XS-OD-0034,2,Female,White,Exon 51 deletion,37.6,1,Active_Drug,Standard,2024-01-10,Pediatric_Assent,United Kingdom,SITE-010
PT-002697,XS-OD-0034,22,Male,Asian,,71.9,5,Placebo,Standard,2023-12-04,Standard,France,SITE-022
PT-002698,XS-OD-0034,54,Male,Black or African American,CAG repeat expansion,53.1,1,Active_Drug,Standard,2024-01-23,Standard,Austria,SITE-024
PT-002699,XS-OD-0034,88,Female,White,,41.3,2,Placebo,Standard,2023-12-20,Standard,Canada,SITE-006
PT-002700,XS-OD-0034,41,Female,Asian,SOD1 A4V,79.5,1,Active_Drug,Standard,2023-11-09,Standard,Netherlands,SITE-008
PT-002701,XS-OD-0034,2,Male,White,Exon 51 deletion,57.2,1,Placebo,Standard,2023-09-18,Pediatric_Assent,United States,SITE-017
PT-002702,XS-OD-0034,41,Male,White,SOD1 A4V,65.6,3,Active_Drug,Standard,2023-10-08,Standard,Netherlands,SITE-013
PT-002703,XS-OD-0034,50,Male,White,,76.5,4,Placebo,Standard,2023-10-22,Standard,Spain,SITE-024
PT-002704,XS-OD-0034,58,Male,Asian,SMN1 deletion,70.2,4,Active_Drug,Standard,2023-12-29,Standard,Germany,SITE-009
PT-002705,XS-OD-0034,48,Male,White,,34.7,0,Placebo,Standard,2023-11-15,Standard,Israel,SITE-020
PT-002706,XS-OD-0034,49,Male,White,CAG repeat expansion,90.8,2,Active_Drug,Standard,2023-12-24,Standard,Austria,SITE-021
PT-002707,XS-OD-0034,54,Female,Hispanic or Latino,SMN1 deletion,58.5,3,Placebo,Standard,2023-12-01,Standard,Italy,SITE-011
PT-002708,XS-OD-0034,58,Female,American Indian or Alaska Native,,48.0,2,Active_Drug,Standard,2023-08-12,Standard,Spain,SITE-016
PT-002709,XS-OD-0034,50,Male,White,Exon 51 deletion,77.5,0,Placebo,Standard,2023-12-23,Standard,Israel,SITE-018
PT-002710,XS-OD-0034,41,Male,Hispanic or Latino,SCN1A R1648H,62.8,2,Active_Drug,Standard,2023-11-20,Standard,Austria,SITE-024
PT-002711,XS-OD-0034,62,Female,Black or African American,,53.8,4,Placebo,Standard,2023-11-05,Standard,Belgium,SITE-022
PT-002712,XS-OD-0034,13,Female,Black or African American,SOD1 A4V,48.4,3,Active_Drug,Standard,2023-10-08,Pediatric_Assent,Brazil,SITE-008
PT-002713,XS-OD-0034,36,Male,White,CAG repeat expansion,64.3,2,Placebo,Standard,2023-09-25,Standard,Denmark,SITE-023
PT-002714,XS-OD-0034,70,Male,White,SOD1 A4V,62.2,1,Active_Drug,Standard,2023-10-23,Compassionate,Canada,SITE-012
PT-002715,XS-OD-0034,40,Male,White,,47.2,0,Placebo,Standard,2023-08-19,Standard,France,SITE-019
PT-002716,XS-OD-0034,33,Female,Hispanic or Latino,SMN1 deletion,48.0,4,Active_Drug,Standard,2023-10-27,Standard,Australia,SITE-004
PT-002717,XS-OD-0034,47,Female,Hispanic or Latino,,71.8,1,Placebo,Standard,2023-08-13,Standard,Norway,SITE-014
PT-002718,XS-OD-0034,41,Female,Hispanic or Latino,Exon 51 deletion,24.4,0,Active_Drug,Standard,2023-11-07,Standard,Norway,SITE-003
PT-002719,XS-OD-0034,57,Male,Native Hawaiian or Other Pacific Islander,Exon 51 deletion,50.2,1,Placebo,Standard,2023-09-09,Standard,Israel,SITE-015
PT-002720,XS-OD-0034,31,Female,White,Exon 51 deletion,22.5,3,Active_Drug,Standard,2023-09-24,Standard,France,SITE-014
PT-002721,XS-OD-0034,68,Male,White,SOD1 A4V,52.1,3,Placebo,Standard,2023-12-02,Standard,United States,SITE-003
PT-002722,XS-OD-0034,21,Male,White,SMN1 deletion,34.8,3,Active_Drug,Standard,2023-08-16,Standard,Australia,SITE-013
PT-002723,XS-OD-0034,32,Male,White,CAG repeat expansion,53.9,3,Placebo,Standard,2023-08-29,Standard,United States,SITE-002
PT-002724,XS-OD-0034,17,Male,Hispanic or Latino,,37.6,1,Active_Drug,Standard,2023-12-20,Pediatric_Assent,Japan,SITE-014
PT-002725,XS-OD-0034,49,Female,Asian,,75.8,5,Placebo,Standard,2023-11-04,Standard,Spain,SITE-022
PT-002726,XS-OD-0034,48,Male,Hispanic or Latino,CAG repeat expansion,46.9,1,Active_Drug,Standard,2024-01-23,Standard,Canada,SITE-007
PT-002727,XS-OD-0034,23,Female,Black or African American,SCN1A R1648H,64.6,2,Placebo,Standard,2023-08-03,Standard,Austria,SITE-020
PT-002728,XS-OD-0034,46,Male,White,SMN1 deletion,47.5,1,Active_Drug,Standard,2023-11-03,Standard,Netherlands,SITE-024
PT-002729,XS-OD-0035,4,Female,Black or African American,SCN1A R1648H,40.2,3,Active_Drug,Standard,2024-02-25,Pediatric_Assent,Canada,SITE-002
PT-002730,XS-OD-0035,2,Female,Asian,CAG repeat expansion,64.2,2,Active_Drug,Standard,2024-02-22,Pediatric_Assent,Israel,SITE-002
PT-002731,XS-OD-0035,7,Female,White,SCN1A R1648H,36.4,1,Active_Drug,Standard,2024-01-27,Pediatric_Assent,Austria,SITE-001
PT-002732,XS-OD-0035,8,Male,White,,55.1,2,Active_Drug,Standard,2024-01-22,Pediatric_Assent,Denmark,SITE-002
PT-002733,XS-OD-0035,9,Male,Asian,SOD1 A4V,64.9,1,Active_Drug,Standard,2024-03-09,Pediatric_Assent,Canada,SITE-001
PT-002734,XS-OD-0035,2,Female,Asian,CAG repeat expansion,55.5,3,Active_Drug,Standard,2023-12-21,Pediatric_Assent,Brazil,SITE-002
PT-002735,XS-OD-0035,8,Female,Hispanic or Latino,,30.9,3,Active_Drug,Standard,2024-04-08,Pediatric_Assent,Switzerland,SITE-001
PT-002736,XS-OD-0035,10,Female,White,,52.4,1,Active_Drug,Standard,2024-02-04,Pediatric_Assent,Canada,SITE-002
PT-002737,XS-OD-0035,6,Male,White,SOD1 A4V,65.7,1,Active_Drug,Standard,2024-03-31,Pediatric_Assent,Netherlands,SITE-004
PT-002738,XS-OD-0035,17,Male,Hispanic or Latino,,34.9,3,Active_Drug,Standard,2023-12-01,Pediatric_Assent,Sweden,SITE-002
PT-002739,XS-OD-0035,9,Male,White,Exon 51 deletion,95.0,2,Active_Drug,Standard,2024-04-17,Pediatric_Assent,Spain,SITE-003
PT-002740,XS-OD-0035,10,Male,White,,65.1,4,Active_Drug,Standard,2023-12-04,Pediatric_Assent,United States,SITE-004
PT-002741,XS-OD-0035,2,Male,White,Exon 51 deletion,53.7,2,Active_Drug,Standard,2024-03-13,Pediatric_Assent,Canada,SITE-002
PT-002742,XS-OD-0035,7,Male,American Indian or Alaska Native,,41.2,0,Active_Drug,Standard,2024-02-21,Pediatric_Assent,Italy,SITE-004
PT-002743,XS-OD-0035,17,Male,White,,64.3,1,Active_Drug,Standard,2024-02-22,Pediatric_Assent,Canada,SITE-001
PT-002744,XS-OD-0035,2,Male,Black or African American,Exon 51 deletion,70.0,2,Active_Drug,Standard,2024-01-03,Pediatric_Assent,South Korea,SITE-004
PT-002745,XS-OD-0035,17,Intersex,White,CAG repeat expansion,61.1,2,Active_Drug,Standard,2023-11-29,Pediatric_Assent,Denmark,SITE-004
PT-002746,XS-OD-0035,16,Male,American Indian or Alaska Native,,60.1,1,Active_Drug,Standard,2024-04-25,Pediatric_Assent,Spain,SITE-003
PT-002747,XS-OD-0035,8,Male,Black or African American,,40.3,2,Active_Drug,Standard,2024-04-05,Pediatric_Assent,Italy,SITE-001
PT-002748,XS-OD-0035,11,Male,Hispanic or Latino,SOD1 A4V,32.5,0,Active_Drug,Standard,2023-12-21,Pediatric_Assent,Belgium,SITE-002
PT-002749,XS-OD-0035,9,Female,White,SCN1A R1648H,86.0,2,Active_Drug,Standard,2024-03-19,Pediatric_Assent,Taiwan,SITE-004
PT-002750,XS-OD-0035,18,Male,White,,41.3,2,Active_Drug,Standard,2023-12-24,Standard,Norway,SITE-002
PT-002751,XS-OD-0035,12,Female,White,,56.9,4,Active_Drug,Standard,2024-01-19,Pediatric_Assent,Denmark,SITE-003
PT-002752,XS-OD-0035,4,Female,White,SCN1A R1648H,29.2,2,Active_Drug,Standard,2024-02-03,Pediatric_Assent,Sweden,SITE-002
PT-002753,XS-OD-0035,7,Male,Hispanic or Latino,SCN1A R1648H,77.4,2,Active_Drug,Standard,2024-03-09,Pediatric_Assent,South Korea,SITE-003
PT-002754,XS-OD-0035,13,Male,White,,73.2,3,Active_Drug,Standard,2024-01-20,Pediatric_Assent,France,SITE-004
PT-002755,XS-OD-0035,6,Female,White,,95.0,2,Active_Drug,Standard,2024-01-14,Pediatric_Assent,Taiwan,SITE-003
PT-002756,XS-OD-0035,3,Male,Asian,SOD1 A4V,48.2,2,Active_Drug,Standard,2023-11-06,Pediatric_Assent,United States,SITE-003
PT-002757,XS-OD-0035,4,Male,Black or African American,Exon 51 deletion,64.1,0,Active_Drug,Standard,2024-04-05,Pediatric_Assent,Taiwan,SITE-004
PT-002758,XS-OD-0035,2,Male,Hispanic or Latino,SMN1 deletion,56.6,1,Active_Drug,Standard,2024-01-29,Pediatric_Assent,Germany,SITE-001
PT-002759,XS-OD-0035,9,Female,White,,82.4,3,Active_Drug,Standard,2024-01-13,Pediatric_Assent,Japan,SITE-003
PT-002760,XS-OD-0035,12,Male,White,SMN1 deletion,65.7,2,Active_Drug,Standard,2024-01-13,Pediatric_Assent,United Kingdom,SITE-001
PT-002761,XS-OD-0035,7,Female,White,SCN1A R1648H,70.1,0,Active_Drug,Standard,2024-01-19,Pediatric_Assent,Israel,SITE-001
PT-002762,XS-OD-0035,13,Female,Asian,SOD1 A4V,61.5,1,Active_Drug,Standard,2024-04-26,Pediatric_Assent,France,SITE-003
PT-002763,XS-OD-0035,6,Female,White,SMN1 deletion,63.1,0,Active_Drug,Standard,2024-03-17,Pediatric_Assent,Brazil,SITE-001
PT-002764,XS-OD-0035,16,Female,White,,46.1,1,Active_Drug,Standard,2024-01-27,Pediatric_Assent,Canada,SITE-001
PT-002765,XS-OD-0035,13,Female,Asian,SMN1 deletion,51.2,1,Active_Drug,Standard,2024-03-22,Pediatric_Assent,France,SITE-001
PT-002766,XS-OD-0035,12,Male,White,SMN1 deletion,26.5,2,Active_Drug,Standard,2024-03-04,Pediatric_Assent,Netherlands,SITE-003
PT-002767,XS-OD-0035,2,Male,White,,27.5,2,Active_Drug,Standard,2023-11-28,Pediatric_Assent,Austria,SITE-001
PT-002768,XS-OD-0035,8,Female,Hispanic or Latino,CAG repeat expansion,73.6,2,Active_Drug,Standard,2024-02-14,Pediatric_Assent,South Korea,SITE-001
PT-002769,XS-OD-0035,11,Male,White,SCN1A R1648H,40.2,2,Active_Drug,Standard,2024-03-12,Pediatric_Assent,Brazil,SITE-004
PT-002770,XS-OD-0035,9,Male,White,SMN1 deletion,16.9,1,Active_Drug,Standard,2023-11-17,Pediatric_Assent,Denmark,SITE-004
PT-002771,XS-OD-0035,9,Female,Hispanic or Latino,CAG repeat expansion,75.7,2,Active_Drug,Standard,2024-01-04,Pediatric_Assent,Spain,SITE-002
PT-002772,XS-OD-0035,6,Female,White,SOD1 A4V,53.9,0,Active_Drug,Standard,2024-02-22,Pediatric_Assent,Switzerland,SITE-001
PT-002773,XS-OD-0035,3,Female,White,Exon 51 deletion,24.1,2,Active_Drug,Standard,2024-01-13,Pediatric_Assent,Canada,SITE-001
PT-002774,XS-OD-0035,2,Male,Hispanic or Latino,CAG repeat expansion,68.5,2,Active_Drug,Standard,2024-01-24,Pediatric_Assent,Italy,SITE-003
PT-002775,XS-OD-0035,7,Female,White,,57.8,3,Active_Drug,Standard,2023-11-25,Pediatric_Assent,Australia,SITE-003
PT-002776,XS-OD-0035,8,Male,White,CAG repeat expansion,55.8,1,Active_Drug,Standard,2024-02-01,Pediatric_Assent,Canada,SITE-003
PT-002777,XS-OD-0035,16,Male,White,SOD1 A4V,65.5,3,Active_Drug,Standard,2024-01-02,Pediatric_Assent,Netherlands,SITE-002
PT-002778,XS-OD-0035,7,Female,White,SCN1A R1648H,70.9,3,Active_Drug,Standard,2023-11-19,Pediatric_Assent,Brazil,SITE-003
PT-002779,XS-OD-0035,11,Male,White,Exon 51 deletion,49.4,5,Active_Drug,Standard,2024-01-30,Pediatric_Assent,Norway,SITE-002
PT-002780,XS-OD-0035,9,Male,Black or African American,,39.3,2,Active_Drug,Standard,2024-04-21,Pediatric_Assent,Norway,SITE-001
PT-002781,XS-OD-0035,4,Female,Black or African American,SCN1A R1648H,69.2,2,Active_Drug,Standard,2023-11-26,Pediatric_Assent,Switzerland,SITE-001
PT-002782,XS-OD-0035,17,Male,Hispanic or Latino,SCN1A R1648H,56.9,3,Active_Drug,Standard,2024-04-09,Pediatric_Assent,Germany,SITE-004
PT-002783,XS-OD-0035,10,Male,White,Exon 51 deletion,22.9,2,Active_Drug,Standard,2024-03-01,Pediatric_Assent,South Korea,SITE-002
PT-002784,XS-OD-0035,10,Male,White,SOD1 A4V,67.8,4,Active_Drug,Standard,2024-03-16,Pediatric_Assent,Israel,SITE-003
PT-002785,XS-OD-0036,28,Female,White,HBB IVS-I-110 G>A,85.0,0,Active_Drug,High,2022-08-31,Standard,Japan,SITE-005
PT-002786,XS-OD-0036,62,Female,White,F9 R338L,44.8,2,Active_Drug,Medium,2022-11-26,Emergency,Germany,SITE-005
PT-002787,XS-OD-0036,54,Female,Hispanic or Latino,,49.7,3,Active_Drug,Medium,2022-11-07,Standard,United States,SITE-004
PT-002788,XS-OD-0036,62,Male,White,F9 R338L,64.4,1,Active_Drug,High,2022-10-09,Standard,Germany,SITE-004
PT-002789,XS-OD-0036,40,Male,White,F9 R338L,61.7,3,Active_Drug,Low,2022-08-29,Standard,United States,SITE-004
PT-002790,XS-OD-0036,19,Female,Hispanic or Latino,HBB E6V (sickle),78.7,1,Active_Drug,High,2022-11-15,Standard,Spain,SITE-002
PT-002791,XS-OD-0036,19,Male,Black or African American,F9 R338L,77.8,4,Active_Drug,Medium,2022-10-08,Standard,United Kingdom,SITE-003
PT-002792,XS-OD-0036,53,Male,White,,39.2,4,Active_Drug,Low,2022-12-16,Standard,Australia,SITE-006
PT-002793,XS-OD-0036,43,Female,Hispanic or Latino,,64.7,3,Active_Drug,Medium,2022-08-09,Standard,Canada,SITE-005
PT-002794,XS-OD-0036,52,Male,White,Factor VIII intron 22 inv,72.2,2,Active_Drug,Low,2022-11-17,Standard,Australia,SITE-001
PT-002795,XS-OD-0036,38,Male,Native Hawaiian or Other Pacific Islander,HBB E6V (sickle),24.8,3,Active_Drug,High,2022-10-09,Standard,Germany,SITE-002
PT-002796,XS-OD-0036,19,Female,White,HBB E6V (sickle),43.0,0,Active_Drug,High,2022-07-20,Standard,France,SITE-005
PT-002797,XS-OD-0036,41,Female,White,F9 R338L,54.2,2,Active_Drug,High,2022-07-16,Standard,Netherlands,SITE-002
PT-002798,XS-OD-0036,41,Female,White,HBB IVS-I-110 G>A,45.8,1,Active_Drug,Low,2022-10-28,Standard,United States,SITE-001
PT-002799,XS-OD-0036,56,Female,White,,50.2,0,Active_Drug,High,2022-11-13,Standard,United States,SITE-006
PT-002800,XS-OD-0036,23,Female,White,HBB IVS-I-110 G>A,61.1,1,Active_Drug,High,2022-07-30,Compassionate,Canada,SITE-002
PT-002801,XS-OD-0036,34,Female,Hispanic or Latino,HBB E6V (sickle),57.1,1,Active_Drug,Low,2022-08-11,Standard,United Kingdom,SITE-003
PT-002802,XS-OD-0036,28,Female,White,HBB IVS-I-110 G>A,75.5,2,Active_Drug,Medium,2022-07-25,Standard,Spain,SITE-006
PT-002803,XS-OD-0036,42,Female,White,,71.7,1,Active_Drug,Medium,2022-08-28,Standard,Italy,SITE-001
PT-002804,XS-OD-0036,50,Male,Asian,,77.7,2,Active_Drug,High,2022-09-11,Standard,United States,SITE-003
PT-002805,XS-OD-0036,39,Female,Asian,F9 R338L,85.2,1,Active_Drug,High,2022-09-10,Standard,United Kingdom,SITE-001
PT-002806,XS-OD-0036,23,Female,Asian,HBB E6V (sickle),65.7,2,Active_Drug,High,2022-12-22,Standard,Australia,SITE-001
PT-002807,XS-OD-0036,24,Male,White,,48.2,1,Active_Drug,Medium,2022-11-12,Standard,Netherlands,SITE-006
PT-002808,XS-OD-0036,2,Female,Asian,Factor VIII intron 22 inv,73.6,1,Active_Drug,Medium,2022-08-20,Pediatric_Assent,Japan,SITE-004
PT-002809,XS-OD-0036,24,Male,Black or African American,F9 R338L,67.9,4,Active_Drug,High,2022-08-17,Standard,United Kingdom,SITE-004
PT-002810,XS-OD-0036,8,Female,White,F9 R338L,51.4,1,Active_Drug,Low,2022-07-15,Pediatric_Assent,Germany,SITE-005
PT-002811,XS-OD-0036,53,Female,White,,56.5,3,Active_Drug,High,2022-10-26,Standard,Netherlands,SITE-002
PT-002812,XS-OD-0036,46,Male,White,F9 R338L,60.1,0,Active_Drug,Medium,2022-08-18,Standard,Italy,SITE-003
PT-002813,XS-OD-0036,72,Male,White,,79.6,3,Active_Drug,Low,2022-08-07,Standard,United Kingdom,SITE-005
PT-002814,XS-OD-0036,30,Female,Hispanic or Latino,,63.3,1,Active_Drug,High,2022-12-11,Standard,France,SITE-001
PT-002815,XS-OD-0036,37,Female,White,HBB E6V (sickle),54.5,1,Active_Drug,High,2022-08-20,Standard,Netherlands,SITE-004
PT-002816,XS-OD-0036,2,Female,White,,65.1,0,Active_Drug,Medium,2022-09-30,Pediatric_Assent,Italy,SITE-001
PT-002817,XS-OD-0036,10,Male,White,F9 R338L,65.7,1,Active_Drug,Low,2022-12-30,Pediatric_Assent,Netherlands,SITE-006
PT-002818,XS-OD-0036,48,Male,White,,56.4,3,Active_Drug,Low,2022-12-05,Standard,Germany,SITE-003
PT-002819,XS-OD-0036,39,Male,Asian,,51.0,2,Active_Drug,Medium,2022-09-15,Standard,Canada,SITE-001
PT-002820,XS-OD-0036,2,Male,Black or African American,,63.7,2,Active_Drug,High,2022-11-23,Pediatric_Assent,Netherlands,SITE-001
PT-002821,XS-OD-0036,35,Male,Asian,F9 R338L,62.7,1,Active_Drug,High,2022-10-29,Standard,France,SITE-003
PT-002822,XS-OD-0036,58,Female,Black or African American,HBB E6V (sickle),89.6,2,Active_Drug,High,2022-09-12,Standard,Japan,SITE-004
PT-002823,XS-OD-0036,42,Female,White,HBB IVS-I-110 G>A,79.4,4,Active_Drug,High,2022-10-18,Standard,France,SITE-001
PT-002824,XS-OD-0036,30,Male,American Indian or Alaska Native,Factor VIII intron 22 inv,55.6,4,Active_Drug,High,2022-10-12,Compassionate,Italy,SITE-006
PT-002825,XS-OD-0036,58,Female,Hispanic or Latino,HBB E6V (sickle),54.7,2,Active_Drug,Medium,2022-10-09,Standard,Spain,SITE-003
PT-002826,XS-OD-0036,39,Female,Black or African American,Factor VIII intron 22 inv,59.5,1,Active_Drug,High,2022-11-09,Standard,Japan,SITE-001
PT-002827,XS-OD-0036,48,Female,Asian,Factor VIII intron 22 inv,77.8,3,Active_Drug,Medium,2022-12-06,Standard,United Kingdom,SITE-003
PT-002828,XS-OD-0036,70,Male,White,,56.6,1,Active_Drug,High,2022-09-10,Standard,France,SITE-005
PT-002829,XS-OD-0036,59,Male,Asian,F9 R338L,59.8,7,Active_Drug,Low,2022-09-13,Standard,Germany,SITE-003
PT-002830,XS-OD-0036,33,Male,Hispanic or Latino,Factor VIII intron 22 inv,29.1,2,Active_Drug,Low,2022-07-07,Standard,Italy,SITE-003
PT-002831,XS-OD-0036,55,Female,White,Factor VIII intron 22 inv,95.0,0,Active_Drug,Low,2022-08-13,Standard,Canada,SITE-004
PT-002832,XS-OD-0036,25,Female,White,HBB E6V (sickle),56.9,5,Active_Drug,High,2022-12-24,Standard,Canada,SITE-003
PT-002833,XS-OD-0036,54,Male,White,HBB IVS-I-110 G>A,47.2,4,Active_Drug,High,2022-10-29,Standard,Germany,SITE-001
PT-002834,XS-OD-0036,79,Female,White,F9 R338L,53.4,5,Active_Drug,Medium,2022-12-04,Standard,Germany,SITE-004
PT-002835,XS-OD-0036,34,Female,White,,60.7,1,Active_Drug,High,2022-12-13,Standard,United Kingdom,SITE-004
PT-002836,XS-OD-0037,16,Female,Hispanic or Latino,HBB IVS-I-110 G>A,32.2,0,Active_Drug,Standard,2021-12-27,Pediatric_Assent,Germany,SITE-005
PT-002837,XS-OD-0037,27,Female,White,,45.1,2,Placebo,Standard,2021-11-18,Standard,Spain,SITE-016
PT-002838,XS-OD-0037,57,Female,Asian,Factor VIII intron 22 inv,56.4,1,Active_Drug,Standard,2022-02-12,Standard,Brazil,SITE-019
PT-002839,XS-OD-0037,65,Female,Asian,Factor VIII intron 22 inv,71.3,1,Placebo,Standard,2021-11-12,Standard,Japan,SITE-014
PT-002840,XS-OD-0037,45,Female,Asian,HBB IVS-I-110 G>A,64.1,4,Active_Drug,Standard,2021-12-24,Standard,Sweden,SITE-015
PT-002841,XS-OD-0037,51,Female,White,Factor VIII intron 22 inv,49.9,2,Placebo,Standard,2021-10-23,Standard,Australia,SITE-017
PT-002842,XS-OD-0037,39,Male,White,,60.2,1,Active_Drug,Standard,2021-11-22,Standard,Austria,SITE-002
PT-002843,XS-OD-0037,17,Male,Black or African American,HBB E6V (sickle),88.5,1,Placebo,Standard,2021-11-18,Pediatric_Assent,Israel,SITE-011
PT-002844,XS-OD-0037,62,Female,White,,53.3,2,Active_Drug,Standard,2022-01-20,Emergency,Italy,SITE-007
PT-002845,XS-OD-0037,34,Female,White,HBB IVS-I-110 G>A,42.4,2,Placebo,Standard,2021-11-20,Standard,Brazil,SITE-003
PT-002846,XS-OD-0037,18,Female,White,HBB IVS-I-110 G>A,38.4,0,Active_Drug,Standard,2022-02-14,Standard,Netherlands,SITE-016
PT-002847,XS-OD-0037,29,Female,White,,39.0,3,Placebo,Standard,2022-03-12,Standard,France,SITE-012
PT-002848,XS-OD-0037,33,Female,White,,51.6,3,Active_Drug,Standard,2021-11-04,Standard,France,SITE-019
PT-002849,XS-OD-0037,82,Female,Black or African American,Factor VIII intron 22 inv,67.5,3,Placebo,Standard,2021-11-27,Standard,Brazil,SITE-014
PT-002850,XS-OD-0037,56,Male,Black or African American,HBB E6V (sickle),67.3,3,Active_Drug,Standard,2021-12-22,Standard,Austria,SITE-007
PT-002851,XS-OD-0037,70,Male,Black or African American,F9 R338L,71.4,3,Placebo,Standard,2022-01-17,Standard,Brazil,SITE-020
PT-002852,XS-OD-0037,31,Male,White,HBB IVS-I-110 G>A,45.0,1,Active_Drug,Standard,2021-12-31,Standard,Australia,SITE-007
PT-002853,XS-OD-0037,48,Female,Hispanic or Latino,F9 R338L,30.7,1,Placebo,Standard,2022-01-19,Standard,South Korea,SITE-011
PT-002854,XS-OD-0037,23,Female,Asian,F9 R338L,57.0,1,Active_Drug,Standard,2022-02-22,Standard,United States,SITE-009
PT-002855,XS-OD-0037,43,Female,Hispanic or Latino,,45.4,3,Placebo,Standard,2022-02-15,Standard,Spain,SITE-019
PT-002856,XS-OD-0037,42,Female,White,F9 R338L,20.7,0,Active_Drug,Standard,2021-11-02,Standard,United Kingdom,SITE-013
PT-002857,XS-OD-0037,38,Male,White,,75.5,3,Placebo,Standard,2022-02-25,Standard,United Kingdom,SITE-016
PT-002858,XS-OD-0037,57,Female,Hispanic or Latino,HBB IVS-I-110 G>A,62.7,0,Active_Drug,Standard,2022-03-03,Standard,South Korea,SITE-012
PT-002859,XS-OD-0037,44,Male,Hispanic or Latino,,65.0,3,Placebo,Standard,2021-11-10,Standard,Spain,SITE-003
PT-002860,XS-OD-0037,75,Male,White,HBB IVS-I-110 G>A,71.6,2,Active_Drug,Standard,2021-10-13,Standard,Israel,SITE-012
PT-002861,XS-OD-0037,42,Male,White,HBB IVS-I-110 G>A,91.2,1,Placebo,Standard,2021-09-24,Standard,Israel,SITE-016
PT-002862,XS-OD-0037,35,Male,Asian,F9 R338L,37.7,4,Active_Drug,Standard,2021-10-06,Standard,Denmark,SITE-014
PT-002863,XS-OD-0037,63,Female,White,HBB IVS-I-110 G>A,15.0,2,Placebo,Standard,2021-12-07,Standard,Canada,SITE-009
PT-002864,XS-OD-0037,27,Male,Black or African American,Factor VIII intron 22 inv,61.1,1,Active_Drug,Standard,2021-10-16,Standard,Italy,SITE-004
PT-002865,XS-OD-0037,17,Female,Hispanic or Latino,Factor VIII intron 22 inv,10.0,1,Placebo,Standard,2021-10-18,Pediatric_Assent,France,SITE-008
PT-002866,XS-OD-0037,27,Female,White,,61.7,1,Active_Drug,Standard,2022-03-14,Standard,France,SITE-012
PT-002867,XS-OD-0037,47,Male,White,F9 R338L,21.0,3,Placebo,Standard,2021-10-16,Standard,France,SITE-012
PT-002868,XS-OD-0037,64,Male,White,,37.4,3,Active_Drug,Standard,2022-02-09,Standard,Taiwan,SITE-008
PT-002869,XS-OD-0037,34,Male,White,F9 R338L,68.1,1,Placebo,Standard,2022-01-11,Standard,Germany,SITE-002
PT-002870,XS-OD-0037,50,Male,Asian,HBB E6V (sickle),78.2,6,Active_Drug,Standard,2022-01-30,Standard,Sweden,SITE-016
PT-002871,XS-OD-0037,2,Male,White,HBB IVS-I-110 G>A,65.5,1,Placebo,Standard,2021-09-25,Pediatric_Assent,United Kingdom,SITE-020
PT-002872,XS-OD-0037,42,Female,Hispanic or Latino,HBB IVS-I-110 G>A,59.7,2,Active_Drug,Standard,2022-02-01,Standard,Brazil,SITE-006
PT-002873,XS-OD-0037,59,Male,Asian,F9 R338L,52.3,3,Placebo,Standard,2021-10-12,Standard,Sweden,SITE-011
PT-002874,XS-OD-0037,32,Female,White,HBB IVS-I-110 G>A,40.9,2,Active_Drug,Standard,2022-01-30,Standard,Germany,SITE-001
PT-002875,XS-OD-0037,24,Female,White,Factor VIII intron 22 inv,33.7,0,Placebo,Standard,2022-01-09,Standard,Japan,SITE-002
PT-002876,XS-OD-0037,2,Male,White,,67.8,4,Active_Drug,Standard,2022-03-08,Pediatric_Assent,South Korea,SITE-009
PT-002877,XS-OD-0037,19,Male,White,,20.3,4,Placebo,Standard,2022-02-15,Standard,Germany,SITE-001
PT-002878,XS-OD-0037,38,Male,White,F9 R338L,35.7,2,Active_Drug,Standard,2022-02-24,Standard,Denmark,SITE-014
PT-002879,XS-OD-0037,30,Female,White,HBB IVS-I-110 G>A,36.6,1,Placebo,Standard,2022-02-17,Standard,Netherlands,SITE-016
PT-002880,XS-OD-0037,46,Female,White,F9 R338L,80.5,1,Active_Drug,Standard,2021-10-09,Standard,United States,SITE-013
PT-002881,XS-OD-0037,6,Female,White,Factor VIII intron 22 inv,36.2,3,Placebo,Standard,2021-10-10,Pediatric_Assent,South Korea,SITE-011
PT-002882,XS-OD-0037,32,Male,Hispanic or Latino,F9 R338L,55.5,2,Active_Drug,Standard,2022-01-10,Standard,South Korea,SITE-004
PT-002883,XS-OD-0037,24,Female,Black or African American,HBB E6V (sickle),35.7,0,Placebo,Standard,2021-12-09,Standard,Italy,SITE-017
PT-002884,XS-OD-0037,60,Female,Hispanic or Latino,Factor VIII intron 22 inv,48.2,5,Active_Drug,Standard,2022-01-05,Standard,Germany,SITE-006
PT-002885,XS-OD-0037,69,Female,Black or African American,HBB IVS-I-110 G>A,47.2,1,Placebo,Standard,2021-12-05,Standard,Spain,SITE-010
PT-002886,XS-OD-0037,43,Male,Black or African American,,93.3,2,Active_Drug,Standard,2021-10-30,Standard,Switzerland,SITE-016
PT-002887,XS-OD-0037,43,Male,Hispanic or Latino,Factor VIII intron 22 inv,90.8,1,Placebo,Standard,2021-10-13,Standard,Switzerland,SITE-006
PT-002888,XS-OD-0037,37,Female,White,F9 R338L,74.4,2,Active_Drug,Standard,2022-02-18,Standard,Switzerland,SITE-006
PT-002889,XS-OD-0037,53,Female,White,F9 R338L,35.1,1,Placebo,Standard,2021-12-02,Standard,France,SITE-014
PT-002890,XS-OD-0037,62,Male,White,HBB IVS-I-110 G>A,48.4,2,Active_Drug,Standard,2022-02-16,Standard,Germany,SITE-013
PT-002891,XS-OD-0037,72,Male,White,,36.8,4,Placebo,Standard,2022-02-14,Standard,Sweden,SITE-011
PT-002892,XS-OD-0037,54,Male,Hispanic or Latino,Factor VIII intron 22 inv,58.4,5,Active_Drug,Standard,2022-02-07,Standard,Netherlands,SITE-017
PT-002893,XS-OD-0037,2,Male,Asian,HBB E6V (sickle),49.5,3,Placebo,Standard,2022-02-07,Pediatric_Assent,United States,SITE-011
PT-002894,XS-OD-0037,34,Male,White,,30.0,2,Active_Drug,Standard,2022-02-06,Standard,Belgium,SITE-017
PT-002895,XS-OD-0037,37,Male,White,,72.1,1,Placebo,Standard,2022-01-07,Standard,Denmark,SITE-009
PT-002896,XS-OD-0037,48,Female,White,,40.0,0,Active_Drug,Standard,2022-03-06,Standard,Italy,SITE-017
PT-002897,XS-OD-0037,2,Male,Asian,,58.0,4,Placebo,Standard,2021-12-04,Pediatric_Assent,Sweden,SITE-020
PT-002898,XS-OD-0037,61,Male,White,,59.0,0,Active_Drug,Standard,2021-10-11,Standard,Australia,SITE-015
PT-002899,XS-OD-0037,51,Female,Hispanic or Latino,,16.1,3,Placebo,Standard,2022-03-09,Standard,Israel,SITE-005
PT-002900,XS-OD-0037,37,Male,White,F9 R338L,64.7,4,Active_Drug,Standard,2021-10-16,Standard,Australia,SITE-012
PT-002901,XS-OD-0037,47,Male,Hispanic or Latino,Factor VIII intron 22 inv,63.6,4,Placebo,Standard,2021-10-05,Standard,Belgium,SITE-009
PT-002902,XS-OD-0037,44,Male,White,F9 R338L,67.6,0,Active_Drug,Standard,2021-11-04,Standard,Japan,SITE-010
PT-002903,XS-OD-0037,32,Male,Hispanic or Latino,HBB E6V (sickle),70.2,1,Placebo,Standard,2021-12-31,Standard,Sweden,SITE-016
PT-002904,XS-OD-0037,25,Female,White,Factor VIII intron 22 inv,69.4,3,Active_Drug,Standard,2021-10-16,Standard,Denmark,SITE-004
PT-002905,XS-OD-0037,37,Female,White,HBB IVS-I-110 G>A,60.4,3,Placebo,Standard,2021-12-17,Standard,Israel,SITE-007
PT-002906,XS-OD-0037,36,Male,Asian,HBB E6V (sickle),48.0,1,Active_Drug,Standard,2021-12-18,Standard,Austria,SITE-010
PT-002907,XS-OD-0037,28,Male,White,HBB E6V (sickle),75.1,2,Placebo,Standard,2022-01-25,Standard,Japan,SITE-010
PT-002908,XS-OD-0037,47,Female,American Indian or Alaska Native,HBB IVS-I-110 G>A,35.5,3,Active_Drug,Standard,2022-03-10,Standard,Taiwan,SITE-010
PT-002909,XS-OD-0037,48,Female,White,F9 R338L,44.1,0,Placebo,Standard,2021-12-27,Emergency,Brazil,SITE-007
PT-002910,XS-OD-0037,36,Female,White,HBB E6V (sickle),29.2,1,Active_Drug,Standard,2021-11-28,Standard,Denmark,SITE-004
PT-002911,XS-OD-0037,63,Female,Hispanic or Latino,HBB IVS-I-110 G>A,59.6,1,Placebo,Standard,2021-10-13,Standard,Canada,SITE-010
PT-002912,XS-OD-0037,3,Female,White,HBB E6V (sickle),39.5,1,Active_Drug,Standard,2021-12-19,Pediatric_Assent,United Kingdom,SITE-003
PT-002913,XS-OD-0037,24,Male,White,,60.4,1,Placebo,Standard,2022-02-14,Standard,Brazil,SITE-017
PT-002914,XS-OD-0037,29,Female,Hispanic or Latino,,73.0,2,Active_Drug,Standard,2022-01-27,Standard,France,SITE-002
PT-002915,XS-OD-0037,43,Male,White,Factor VIII intron 22 inv,42.4,0,Placebo,Standard,2021-12-29,Standard,Spain,SITE-012
PT-002916,XS-OD-0037,39,Male,White,HBB IVS-I-110 G>A,65.3,0,Active_Drug,Standard,2022-03-13,Standard,Australia,SITE-012
PT-002917,XS-OD-0037,26,Female,Black or African American,Factor VIII intron 22 inv,44.1,2,Placebo,Standard,2022-02-20,Standard,Taiwan,SITE-014
PT-002918,XS-OD-0037,17,Female,White,F9 R338L,27.7,1,Active_Drug,Standard,2021-10-27,Pediatric_Assent,South Korea,SITE-006
PT-002919,XS-OD-0037,33,Male,Hispanic or Latino,,65.4,1,Placebo,Standard,2021-11-28,Standard,Australia,SITE-009
PT-002920,XS-OD-0037,36,Female,White,HBB E6V (sickle),42.8,4,Active_Drug,Standard,2022-01-25,Standard,Brazil,SITE-001
PT-002921,XS-OD-0037,35,Male,White,Factor VIII intron 22 inv,88.9,2,Placebo,Standard,2021-12-14,Standard,Denmark,SITE-011
PT-002922,XS-OD-0037,31,Female,White,Factor VIII intron 22 inv,37.7,3,Active_Drug,Standard,2021-12-09,Standard,Australia,SITE-009
PT-002923,XS-OD-0037,19,Male,White,HBB E6V (sickle),55.9,2,Placebo,Standard,2021-11-08,Standard,Germany,SITE-002
PT-002924,XS-OD-0037,36,Male,White,Factor VIII intron 22 inv,45.7,3,Active_Drug,Standard,2022-01-28,Standard,Israel,SITE-014
PT-002925,XS-OD-0037,2,Female,Hispanic or Latino,HBB IVS-I-110 G>A,51.5,1,Placebo,Standard,2022-01-18,Pediatric_Assent,Switzerland,SITE-002
PT-002926,XS-OD-0037,37,Male,Asian,HBB E6V (sickle),73.9,2,Active_Drug,Standard,2021-10-22,Standard,Canada,SITE-011
PT-002927,XS-OD-0037,70,Male,Asian,Factor VIII intron 22 inv,39.1,4,Placebo,Standard,2021-10-20,Standard,Spain,SITE-012
PT-002928,XS-OD-0037,44,Male,Black or African American,Factor VIII intron 22 inv,32.0,0,Active_Drug,Standard,2021-12-24,Standard,Germany,SITE-005
PT-002929,XS-OD-0037,34,Female,Hispanic or Latino,HBB IVS-I-110 G>A,57.2,0,Placebo,Standard,2021-11-24,Standard,United Kingdom,SITE-011
PT-002930,XS-OD-0037,10,Female,Asian,,53.1,1,Active_Drug,Standard,2021-09-30,Pediatric_Assent,Switzerland,SITE-005
PT-002931,XS-OD-0037,2,Male,Hispanic or Latino,F9 R338L,51.9,3,Placebo,Standard,2021-09-18,Pediatric_Assent,Belgium,SITE-007
PT-002932,XS-OD-0037,25,Female,White,Factor VIII intron 22 inv,72.8,4,Active_Drug,Standard,2021-12-15,Standard,Spain,SITE-002
PT-002933,XS-OD-0037,28,Male,White,HBB E6V (sickle),69.9,4,Placebo,Standard,2021-11-05,Standard,Sweden,SITE-008
PT-002934,XS-OD-0037,38,Female,White,HBB IVS-I-110 G>A,33.8,5,Active_Drug,Standard,2022-02-06,Standard,Canada,SITE-009
PT-002935,XS-OD-0037,34,Female,White,HBB IVS-I-110 G>A,36.5,4,Placebo,Standard,2021-12-19,Emergency,Brazil,SITE-003
PT-002936,XS-OD-0037,64,Female,Black or African American,HBB E6V (sickle),57.9,1,Active_Drug,Standard,2021-12-28,Standard,Taiwan,SITE-001
PT-002937,XS-OD-0037,36,Female,Black or African American,F9 R338L,54.2,1,Placebo,Standard,2022-02-14,Compassionate,United Kingdom,SITE-004
PT-002938,XS-OD-0037,8,Male,White,,37.9,1,Active_Drug,Standard,2021-11-20,Pediatric_Assent,Israel,SITE-011
PT-002939,XS-OD-0037,48,Female,Black or African American,,55.5,4,Placebo,Standard,2021-10-22,Standard,Israel,SITE-005
PT-002940,XS-OD-0037,63,Female,White,F9 R338L,29.3,3,Active_Drug,Standard,2022-01-08,Standard,Australia,SITE-013
PT-002941,XS-OD-0037,27,Male,Black or African American,HBB E6V (sickle),55.5,5,Placebo,Standard,2022-02-02,Standard,Netherlands,SITE-012
PT-002942,XS-OD-0037,46,Male,White,HBB E6V (sickle),60.0,4,Active_Drug,Standard,2022-01-30,Standard,South Korea,SITE-018
PT-002943,XS-OD-0037,56,Female,Black or African American,,34.3,4,Placebo,Standard,2021-12-10,Standard,Belgium,SITE-001
PT-002944,XS-OD-0037,46,Female,Asian,,26.0,4,Active_Drug,Standard,2022-01-16,Standard,Austria,SITE-017
PT-002945,XS-OD-0037,46,Male,Asian,Factor VIII intron 22 inv,61.8,0,Placebo,Standard,2021-11-15,Standard,South Korea,SITE-002
PT-002946,XS-OD-0037,32,Female,Two or More Races,HBB E6V (sickle),67.6,4,Active_Drug,Standard,2021-12-16,Standard,Austria,SITE-007
PT-002947,XS-OD-0037,27,Male,White,F9 R338L,71.1,3,Placebo,Standard,2022-02-03,Standard,Austria,SITE-004
PT-002948,XS-OD-0037,39,Male,Hispanic or Latino,HBB E6V (sickle),60.5,1,Active_Drug,Standard,2021-12-10,Standard,Netherlands,SITE-005
PT-002949,XS-OD-0037,47,Female,Two or More Races,F9 R338L,47.3,1,Placebo,Standard,2021-10-10,Standard,United States,SITE-006
PT-002950,XS-OD-0037,39,Male,White,,73.6,1,Active_Drug,Standard,2021-09-22,Standard,Belgium,SITE-003
PT-002951,XS-OD-0037,72,Female,White,HBB E6V (sickle),59.9,2,Placebo,Standard,2022-01-25,Standard,South Korea,SITE-011
PT-002952,XS-OD-0037,45,Male,Black or African American,,71.6,2,Active_Drug,Standard,2021-11-13,Standard,Belgium,SITE-004
PT-002953,XS-OD-0037,45,Female,Black or African American,Factor VIII intron 22 inv,37.0,2,Placebo,Standard,2021-11-21,Standard,Switzerland,SITE-007
PT-002954,XS-OD-0037,32,Male,Black or African American,HBB IVS-I-110 G>A,26.9,1,Active_Drug,Standard,2021-11-24,Standard,Norway,SITE-016
PT-002955,XS-OD-0037,33,Female,Asian,,46.1,3,Placebo,Standard,2022-02-23,Standard,Belgium,SITE-014
PT-002956,XS-OD-0037,65,Female,Black or African American,HBB IVS-I-110 G>A,26.2,1,Active_Drug,Standard,2021-11-29,Standard,Spain,SITE-003
PT-002957,XS-OD-0037,43,Male,Two or More Races,,73.6,2,Placebo,Standard,2021-09-24,Standard,Netherlands,SITE-015
PT-002958,XS-OD-0037,38,Female,White,,28.5,0,Active_Drug,Standard,2022-02-18,Standard,Sweden,SITE-006
PT-002959,XS-OD-0037,45,Male,White,,82.9,0,Placebo,Standard,2021-12-19,Standard,Japan,SITE-004
PT-002960,XS-OD-0037,9,Male,Asian,,82.8,1,Active_Drug,Standard,2021-12-28,Pediatric_Assent,Netherlands,SITE-002
PT-002961,XS-OD-0037,42,Female,Asian,F9 R338L,25.2,5,Placebo,Standard,2021-10-10,Standard,Japan,SITE-010
PT-002962,XS-OD-0037,27,Male,Black or African American,HBB IVS-I-110 G>A,63.2,3,Active_Drug,Standard,2021-10-25,Standard,Denmark,SITE-020
PT-002963,XS-OD-0037,19,Female,White,,57.0,1,Placebo,Standard,2022-02-14,Standard,Spain,SITE-002
PT-002964,XS-OD-0037,30,Male,Asian,F9 R338L,78.4,4,Active_Drug,Standard,2021-09-24,Standard,United Kingdom,SITE-018
PT-002965,XS-OD-0037,30,Intersex,Hispanic or Latino,F9 R338L,40.4,2,Placebo,Standard,2021-11-06,Standard,Germany,SITE-015
PT-002966,XS-OD-0037,43,Male,Asian,F9 R338L,84.1,1,Active_Drug,Standard,2022-02-24,Emergency,Spain,SITE-019
PT-002967,XS-OD-0037,77,Male,White,F9 R338L,39.5,3,Placebo,Standard,2021-12-03,Standard,Taiwan,SITE-018
PT-002968,XS-OD-0037,35,Male,White,F9 R338L,53.7,3,Active_Drug,Standard,2021-09-27,Standard,United States,SITE-009
PT-002969,XS-OD-0037,40,Female,Black or African American,Factor VIII intron 22 inv,50.8,1,Placebo,Standard,2022-01-30,Standard,Italy,SITE-006
PT-002970,XS-OD-0037,60,Male,White,F9 R338L,88.8,0,Active_Drug,Standard,2021-11-22,Standard,Norway,SITE-008
PT-002971,XS-OD-0037,21,Female,White,HBB IVS-I-110 G>A,51.5,3,Placebo,Standard,2021-12-01,Standard,Switzerland,SITE-018
PT-002972,XS-OD-0038,19,Male,White,HBB E6V (sickle),74.5,2,Active_Drug,Standard,2025-04-03,Standard,France,SITE-004
PT-002973,XS-OD-0038,35,Male,Hispanic or Latino,,55.3,2,SOC,Standard,2025-01-27,Standard,United Kingdom,SITE-028
PT-002974,XS-OD-0038,61,Female,American Indian or Alaska Native,HBB IVS-I-110 G>A,62.8,1,Combination,Standard,2025-03-23,Standard,Japan,SITE-006
PT-002975,XS-OD-0038,47,Female,Asian,,61.3,2,Active_Drug,Standard,2025-06-04,Standard,Spain,SITE-037
PT-002976,XS-OD-0038,44,Male,Black or African American,F9 R338L,80.6,0,SOC,Standard,2025-01-31,Standard,Japan,SITE-038
PT-002977,XS-OD-0038,46,Male,White,,53.1,3,Combination,Standard,2025-04-27,Standard,France,SITE-018
PT-002978,XS-OD-0038,5,Female,White,,81.2,1,Active_Drug,Standard,2025-01-07,Pediatric_Assent,Netherlands,SITE-035
PT-002979,XS-OD-0038,28,Male,Two or More Races,Factor VIII intron 22 inv,72.8,1,SOC,Standard,2025-05-17,Standard,Netherlands,SITE-015
PT-002980,XS-OD-0038,55,Female,Asian,,45.8,2,Combination,Standard,2025-06-01,Standard,United Kingdom,SITE-008
PT-002981,XS-OD-0038,18,Male,White,Factor VIII intron 22 inv,51.0,3,Active_Drug,Standard,2025-01-13,Standard,Canada,SITE-002
PT-002982,XS-OD-0038,42,Male,White,HBB IVS-I-110 G>A,73.7,4,SOC,Standard,2024-12-26,Compassionate,Canada,SITE-034
PT-002983,XS-OD-0038,36,Male,White,HBB IVS-I-110 G>A,47.9,2,Combination,Standard,2025-03-19,Standard,United Kingdom,SITE-026
PT-002984,XS-OD-0038,36,Male,Hispanic or Latino,,38.7,2,Active_Drug,Standard,2025-04-14,Standard,Canada,SITE-034
PT-002985,XS-OD-0038,18,Male,White,HBB E6V (sickle),24.3,2,SOC,Standard,2025-05-16,Standard,Italy,SITE-016
PT-002986,XS-OD-0038,47,Male,White,F9 R338L,80.9,2,Combination,Standard,2025-05-14,Standard,United Kingdom,SITE-041
PT-002987,XS-OD-0038,48,Female,Asian,Factor VIII intron 22 inv,38.0,0,Active_Drug,Standard,2025-06-19,Standard,Japan,SITE-001
PT-002988,XS-OD-0038,42,Female,White,,73.8,1,SOC,Standard,2025-05-19,Standard,Germany,SITE-032
PT-002989,XS-OD-0038,62,Male,Hispanic or Latino,HBB E6V (sickle),68.8,1,Combination,Standard,2025-05-13,Standard,Netherlands,SITE-035
PT-002990,XS-OD-0038,18,Male,White,HBB E6V (sickle),10.0,1,Active_Drug,Standard,2025-02-25,Standard,Canada,SITE-011
PT-002991,XS-OD-0038,54,Male,Asian,HBB E6V (sickle),45.5,4,SOC,Standard,2025-03-23,Standard,Italy,SITE-033
PT-002992,XS-OD-0038,44,Female,White,HBB E6V (sickle),65.7,2,Combination,Standard,2025-05-19,Standard,France,SITE-011
PT-002993,XS-OD-0038,59,Female,White,HBB E6V (sickle),52.1,4,Active_Drug,Standard,2025-02-16,Standard,Netherlands,SITE-019
PT-002994,XS-OD-0038,32,Male,White,,80.2,2,SOC,Standard,2025-03-29,Standard,United Kingdom,SITE-034
PT-002995,XS-OD-0038,47,Female,Two or More Races,HBB E6V (sickle),23.5,3,Combination,Standard,2025-05-19,Standard,United Kingdom,SITE-042
PT-002996,XS-OD-0038,33,Female,White,,66.8,3,Active_Drug,Standard,2025-02-22,Standard,Germany,SITE-024
PT-002997,XS-OD-0038,57,Female,White,HBB E6V (sickle),51.7,4,SOC,Standard,2025-06-19,Standard,Spain,SITE-019
PT-002998,XS-OD-0038,38,Intersex,Black or African American,,62.1,2,Combination,Standard,2025-04-20,Standard,Japan,SITE-032
PT-002999,XS-OD-0038,25,Female,Asian,,64.2,1,Active_Drug,Standard,2025-03-29,Standard,United States,SITE-005
PT-003000,XS-OD-0038,14,Male,White,HBB E6V (sickle),45.9,2,SOC,Standard,2025-05-13,Pediatric_Assent,Canada,SITE-038
PT-003001,XS-OD-0038,46,Female,Black or African American,,95.0,4,Combination,Standard,2025-03-16,Standard,Canada,SITE-015
PT-003002,XS-OD-0038,38,Male,Black or African American,,31.7,4,Active_Drug,Standard,2025-01-18,Standard,United States,SITE-040
PT-003003,XS-OD-0038,55,Female,Two or More Races,HBB IVS-I-110 G>A,64.7,3,SOC,Standard,2025-02-24,Standard,Spain,SITE-031
PT-003004,XS-OD-0038,69,Female,White,HBB E6V (sickle),70.9,1,Combination,Standard,2025-02-27,Standard,Canada,SITE-016
PT-003005,XS-OD-0038,6,Female,Asian,HBB E6V (sickle),25.2,2,Active_Drug,Standard,2025-03-25,Pediatric_Assent,Netherlands,SITE-035
PT-003006,XS-OD-0038,6,Female,White,,56.6,2,SOC,Standard,2025-04-13,Pediatric_Assent,Canada,SITE-002
PT-003007,XS-OD-0038,59,Female,White,,80.9,2,Combination,Standard,2025-05-09,Standard,Japan,SITE-025
PT-003008,XS-OD-0038,25,Female,Hispanic or Latino,HBB E6V (sickle),67.2,1,Active_Drug,Standard,2025-04-05,Standard,Spain,SITE-003
PT-003009,XS-OD-0038,3,Female,White,F9 R338L,41.0,1,SOC,Standard,2025-05-11,Pediatric_Assent,Japan,SITE-032
PT-003010,XS-OD-0038,26,Male,Black or African American,F9 R338L,32.8,3,Combination,Standard,2024-12-24,Standard,Netherlands,SITE-034
PT-003011,XS-OD-0038,24,Male,White,,79.8,1,Active_Drug,Standard,2025-03-10,Emergency,United States,SITE-040
PT-003012,XS-OD-0038,41,Male,White,HBB E6V (sickle),41.2,0,SOC,Standard,2024-12-24,Standard,Italy,SITE-035
PT-003013,XS-OD-0038,56,Female,White,F9 R338L,58.6,2,Combination,Standard,2025-02-17,Standard,Japan,SITE-029
PT-003014,XS-OD-0038,20,Male,White,HBB IVS-I-110 G>A,71.1,5,Active_Drug,Standard,2025-03-28,Standard,Netherlands,SITE-016
PT-003015,XS-OD-0038,41,Male,White,,31.4,0,SOC,Standard,2025-04-26,Standard,United Kingdom,SITE-022
PT-003016,XS-OD-0038,60,Male,Black or African American,HBB IVS-I-110 G>A,50.0,1,Combination,Standard,2025-01-12,Standard,Italy,SITE-030
PT-003017,XS-OD-0038,36,Male,White,,78.5,1,Active_Drug,Standard,2025-02-05,Standard,United States,SITE-028
PT-003018,XS-OD-0038,18,Male,Black or African American,HBB E6V (sickle),68.2,2,SOC,Standard,2025-03-18,Standard,France,SITE-037
PT-003019,XS-OD-0038,54,Male,Black or African American,,23.0,4,Combination,Standard,2025-05-01,Standard,Germany,SITE-008
PT-003020,XS-OD-0038,33,Male,White,,34.0,4,Active_Drug,Standard,2025-03-19,Standard,United States,SITE-006
PT-003021,XS-OD-0038,10,Female,White,,57.5,2,SOC,Standard,2024-12-29,Pediatric_Assent,United Kingdom,SITE-026
PT-003022,XS-OD-0038,32,Female,Asian,F9 R338L,65.1,6,Combination,Standard,2025-03-17,Standard,Spain,SITE-027
PT-003023,XS-OD-0038,40,Male,White,F9 R338L,49.3,2,Active_Drug,Standard,2025-03-22,Standard,United Kingdom,SITE-036
PT-003024,XS-OD-0038,47,Male,Hispanic or Latino,,46.9,2,SOC,Standard,2025-01-05,Standard,Japan,SITE-006
PT-003025,XS-OD-0038,61,Female,White,F9 R338L,73.6,2,Combination,Standard,2025-01-25,Standard,Japan,SITE-013
PT-003026,XS-OD-0038,48,Male,Black or African American,F9 R338L,36.1,1,Active_Drug,Standard,2025-05-13,Standard,Japan,SITE-009
PT-003027,XS-OD-0038,65,Male,Hispanic or Latino,F9 R338L,44.5,2,SOC,Standard,2025-03-03,Standard,Germany,SITE-027
PT-003028,XS-OD-0038,49,Male,White,,42.7,0,Combination,Standard,2024-12-29,Standard,Netherlands,SITE-002
PT-003029,XS-OD-0038,41,Male,White,HBB IVS-I-110 G>A,75.2,1,Active_Drug,Standard,2025-01-14,Standard,Italy,SITE-035
PT-003030,XS-OD-0038,26,Male,Black or African American,Factor VIII intron 22 inv,59.0,1,SOC,Standard,2025-06-18,Standard,Italy,SITE-012
PT-003031,XS-OD-0038,18,Male,White,,56.2,4,Combination,Standard,2024-12-24,Standard,Canada,SITE-004
PT-003032,XS-OD-0038,38,Male,Hispanic or Latino,HBB IVS-I-110 G>A,50.5,2,Active_Drug,Standard,2025-05-03,Standard,Netherlands,SITE-031
PT-003033,XS-OD-0038,88,Female,Hispanic or Latino,F9 R338L,68.8,3,SOC,Standard,2025-01-27,Compassionate,Netherlands,SITE-014
PT-003034,XS-OD-0038,44,Male,Black or African American,Factor VIII intron 22 inv,54.0,4,Combination,Standard,2025-04-22,Standard,United States,SITE-023
PT-003035,XS-OD-0038,11,Female,Black or African American,,62.5,6,Active_Drug,Standard,2025-02-19,Pediatric_Assent,United Kingdom,SITE-020
PT-003036,XS-OD-0038,60,Female,White,HBB E6V (sickle),83.4,2,SOC,Standard,2025-02-14,Standard,United Kingdom,SITE-017
PT-003037,XS-OD-0038,28,Female,Hispanic or Latino,HBB IVS-I-110 G>A,78.1,0,Combination,Standard,2025-06-18,Standard,Spain,SITE-021
PT-003038,XS-OD-0038,46,Female,White,Factor VIII intron 22 inv,69.4,2,Active_Drug,Standard,2025-06-05,Standard,United States,SITE-025
PT-003039,XS-OD-0038,37,Male,White,,72.3,1,SOC,Standard,2025-06-09,Standard,Italy,SITE-039
PT-003040,XS-OD-0038,39,Female,Hispanic or Latino,,91.0,4,Combination,Standard,2025-01-17,Standard,United States,SITE-034
PT-003041,XS-OD-0038,54,Female,Black or African American,,31.5,1,Active_Drug,Standard,2025-02-12,Standard,Australia,SITE-040
PT-003042,XS-OD-0038,47,Female,Black or African American,,86.6,2,SOC,Standard,2025-03-20,Standard,France,SITE-041
PT-003043,XS-OD-0038,64,Female,American Indian or Alaska Native,,31.7,3,Combination,Standard,2024-12-31,Standard,United Kingdom,SITE-037
PT-003044,XS-OD-0038,23,Female,Hispanic or Latino,HBB IVS-I-110 G>A,48.3,2,Active_Drug,Standard,2025-03-27,Standard,Canada,SITE-020
PT-003045,XS-OD-0038,49,Male,Black or African American,HBB E6V (sickle),18.5,1,SOC,Standard,2025-04-24,Emergency,Australia,SITE-004
PT-003046,XS-OD-0038,59,Female,White,Factor VIII intron 22 inv,76.0,1,Combination,Standard,2025-01-01,Standard,Australia,SITE-031
PT-003047,XS-OD-0038,66,Male,White,F9 R338L,54.3,1,Active_Drug,Standard,2025-05-07,Standard,Australia,SITE-034
PT-003048,XS-OD-0038,79,Male,White,HBB IVS-I-110 G>A,42.5,1,SOC,Standard,2025-01-26,Standard,United States,SITE-011
PT-003049,XS-OD-0038,56,Female,Asian,,66.0,2,Combination,Standard,2025-06-14,Standard,Germany,SITE-029
PT-003050,XS-OD-0038,22,Female,Asian,,39.4,6,Active_Drug,Standard,2025-05-28,Standard,Spain,SITE-030
PT-003051,XS-OD-0038,23,Male,Black or African American,F9 R338L,84.8,0,SOC,Standard,2025-01-09,Standard,Japan,SITE-017
PT-003052,XS-OD-0038,26,Male,White,,42.8,0,Combination,Standard,2025-01-04,Compassionate,Italy,SITE-026
PT-003053,XS-OD-0038,26,Female,Asian,,75.4,4,Active_Drug,Standard,2025-06-11,Standard,Spain,SITE-036
PT-003054,XS-OD-0038,45,Female,Asian,,54.9,4,SOC,Standard,2025-03-20,Standard,Australia,SITE-022
PT-003055,XS-OD-0038,33,Female,White,,35.7,0,Combination,Standard,2025-05-19,Standard,Germany,SITE-022
PT-003056,XS-OD-0038,30,Male,White,HBB IVS-I-110 G>A,68.8,2,Active_Drug,Standard,2025-02-22,Standard,Spain,SITE-014
PT-003057,XS-OD-0038,48,Female,White,HBB IVS-I-110 G>A,56.6,1,SOC,Standard,2025-05-11,Standard,France,SITE-026
PT-003058,XS-OD-0038,51,Male,American Indian or Alaska Native,Factor VIII intron 22 inv,86.8,2,Combination,Standard,2025-04-16,Standard,France,SITE-010
PT-003059,XS-OD-0038,69,Female,White,HBB IVS-I-110 G>A,66.5,3,Active_Drug,Standard,2025-02-06,Standard,United States,SITE-020
PT-003060,XS-OD-0038,64,Female,American Indian or Alaska Native,HBB IVS-I-110 G>A,43.0,2,SOC,Standard,2025-06-20,Standard,Spain,SITE-015
PT-003061,XS-OD-0038,60,Female,Hispanic or Latino,,55.9,5,Combination,Standard,2025-02-18,Standard,United States,SITE-031
PT-003062,XS-OD-0038,28,Male,Hispanic or Latino,F9 R338L,35.1,1,Active_Drug,Standard,2025-03-13,Standard,Italy,SITE-041
PT-003063,XS-OD-0038,44,Male,White,HBB E6V (sickle),71.1,2,SOC,Standard,2025-04-29,Standard,Spain,SITE-023
PT-003064,XS-OD-0038,29,Male,Asian,HBB IVS-I-110 G>A,35.1,1,Combination,Standard,2025-05-22,Standard,Germany,SITE-041
PT-003065,XS-OD-0038,61,Male,White,F9 R338L,63.6,2,Active_Drug,Standard,2025-05-15,Standard,Canada,SITE-019
PT-003066,XS-OD-0038,55,Female,White,F9 R338L,53.0,1,SOC,Standard,2025-04-27,Standard,Canada,SITE-021
PT-003067,XS-OD-0038,58,Female,Hispanic or Latino,HBB IVS-I-110 G>A,50.1,2,Combination,Standard,2025-02-15,Standard,Australia,SITE-004
PT-003068,XS-OD-0038,59,Female,Black or African American,F9 R338L,76.4,2,Active_Drug,Standard,2025-02-26,Standard,Spain,SITE-021
PT-003069,XS-OD-0038,44,Male,White,,50.3,0,SOC,Standard,2025-02-08,Standard,Japan,SITE-039
PT-003070,XS-OD-0038,34,Male,White,Factor VIII intron 22 inv,47.4,1,Combination,Standard,2025-04-10,Standard,France,SITE-035
PT-003071,XS-OD-0038,14,Female,White,,90.6,2,Active_Drug,Standard,2024-12-27,Pediatric_Assent,Germany,SITE-029
PT-003072,XS-OD-0038,47,Female,White,F9 R338L,60.1,1,SOC,Standard,2025-01-17,Standard,Spain,SITE-017
PT-003073,XS-OD-0038,23,Male,White,Factor VIII intron 22 inv,32.4,5,Combination,Standard,2025-01-19,Standard,Italy,SITE-029
PT-003074,XS-OD-0038,39,Female,Asian,HBB IVS-I-110 G>A,45.9,2,Active_Drug,Standard,2025-02-27,Compassionate,Netherlands,SITE-021
PT-003075,XS-OD-0038,46,Male,Black or African American,,57.4,2,SOC,Standard,2025-04-07,Standard,Netherlands,SITE-002
PT-003076,XS-OD-0038,10,Female,White,,84.4,1,Combination,Standard,2025-03-21,Pediatric_Assent,Netherlands,SITE-025
PT-003077,XS-OD-0038,52,Male,White,HBB IVS-I-110 G>A,61.3,0,Active_Drug,Standard,2025-04-06,Standard,Germany,SITE-020
PT-003078,XS-OD-0038,32,Female,Hispanic or Latino,HBB IVS-I-110 G>A,47.5,3,SOC,Standard,2025-04-08,Standard,Italy,SITE-018
PT-003079,XS-OD-0038,40,Female,White,HBB IVS-I-110 G>A,61.3,1,Combination,Standard,2025-02-11,Standard,Germany,SITE-037
PT-003080,XS-OD-0038,21,Female,Hispanic or Latino,HBB IVS-I-110 G>A,55.5,2,Active_Drug,Standard,2025-01-20,Standard,United States,SITE-042
PT-003081,XS-OD-0038,41,Female,White,Factor VIII intron 22 inv,54.9,3,SOC,Standard,2025-03-22,Standard,Germany,SITE-012
PT-003082,XS-OD-0038,4,Female,White,F9 R338L,42.3,1,Combination,Standard,2025-05-15,Pediatric_Assent,United States,SITE-006
PT-003083,XS-OD-0038,2,Female,White,,80.8,0,Active_Drug,Standard,2025-04-30,Pediatric_Assent,Canada,SITE-033
PT-003084,XS-OD-0038,48,Female,White,,59.6,0,SOC,Standard,2025-02-11,Standard,Spain,SITE-012
PT-003085,XS-OD-0038,72,Male,White,Factor VIII intron 22 inv,69.3,2,Combination,Standard,2025-05-24,Standard,Italy,SITE-006
PT-003086,XS-OD-0038,28,Male,White,F9 R338L,20.5,3,Active_Drug,Standard,2024-12-24,Compassionate,Australia,SITE-015
PT-003087,XS-OD-0038,37,Male,White,HBB E6V (sickle),66.9,2,SOC,Standard,2025-01-07,Standard,Italy,SITE-037
PT-003088,XS-OD-0038,14,Female,White,HBB IVS-I-110 G>A,66.5,1,Combination,Standard,2025-02-18,Pediatric_Assent,France,SITE-006
PT-003089,XS-OD-0038,45,Male,Asian,HBB E6V (sickle),66.9,1,Active_Drug,Standard,2025-03-18,Standard,Australia,SITE-002
PT-003090,XS-OD-0038,18,Male,White,HBB IVS-I-110 G>A,31.5,0,SOC,Standard,2025-02-03,Standard,Germany,SITE-024
PT-003091,XS-OD-0038,58,Female,White,F9 R338L,59.1,0,Combination,Standard,2025-04-19,Standard,Japan,SITE-025
PT-003092,XS-OD-0038,41,Female,Asian,Factor VIII intron 22 inv,40.3,4,Active_Drug,Standard,2025-05-16,Standard,Germany,SITE-017
PT-003093,XS-OD-0038,17,Male,White,Factor VIII intron 22 inv,55.6,3,SOC,Standard,2025-01-12,Pediatric_Assent,Japan,SITE-020
PT-003094,XS-OD-0038,43,Female,Hispanic or Latino,HBB IVS-I-110 G>A,62.4,2,Combination,Standard,2025-05-03,Standard,Japan,SITE-009
PT-003095,XS-OD-0038,12,Female,White,HBB IVS-I-110 G>A,59.3,4,Active_Drug,Standard,2025-06-12,Pediatric_Assent,United States,SITE-033
PT-003096,XS-OD-0038,51,Male,White,,32.1,4,SOC,Standard,2025-02-20,Standard,Netherlands,SITE-028
PT-003097,XS-OD-0038,50,Male,Black or African American,,23.3,6,Combination,Standard,2025-01-04,Standard,France,SITE-023
PT-003098,XS-OD-0038,23,Female,Black or African American,HBB IVS-I-110 G>A,75.2,2,Active_Drug,Standard,2025-01-30,Standard,Netherlands,SITE-021
PT-003099,XS-OD-0038,31,Male,White,HBB IVS-I-110 G>A,71.6,2,SOC,Standard,2025-05-24,Standard,Netherlands,SITE-041
PT-003100,XS-OD-0038,23,Female,White,Factor VIII intron 22 inv,77.2,1,Combination,Standard,2025-06-14,Standard,Canada,SITE-010
PT-003101,XS-OD-0038,40,Female,Asian,,88.8,4,Active_Drug,Standard,2025-03-29,Standard,Australia,SITE-015
PT-003102,XS-OD-0038,46,Male,White,Factor VIII intron 22 inv,61.9,1,SOC,Standard,2025-02-25,Standard,Italy,SITE-004
PT-003103,XS-OD-0038,84,Female,White,Factor VIII intron 22 inv,64.3,2,Combination,Standard,2025-05-12,Standard,Canada,SITE-036
PT-003104,XS-OD-0038,61,Male,White,,56.1,3,Active_Drug,Standard,2025-04-23,Standard,United States,SITE-004
PT-003105,XS-OD-0038,39,Male,White,,82.1,3,SOC,Standard,2025-04-25,Standard,United Kingdom,SITE-010
PT-003106,XS-OD-0038,48,Female,White,Factor VIII intron 22 inv,17.4,2,Combination,Standard,2025-06-15,Standard,Australia,SITE-023
PT-003107,XS-OD-0038,7,Male,Asian,Factor VIII intron 22 inv,34.6,2,Active_Drug,Standard,2025-04-23,Pediatric_Assent,Italy,SITE-034
PT-003108,XS-OD-0038,20,Female,Hispanic or Latino,,51.0,2,SOC,Standard,2025-03-27,Emergency,Australia,SITE-007
PT-003109,XS-OD-0038,52,Male,White,HBB E6V (sickle),48.4,2,Combination,Standard,2025-01-02,Standard,France,SITE-015
PT-003110,XS-OD-0038,44,Male,Asian,F9 R338L,40.5,0,Active_Drug,Standard,2025-02-03,Standard,Australia,SITE-030
PT-003111,XS-OD-0038,31,Male,Asian,HBB E6V (sickle),53.8,2,SOC,Standard,2025-06-06,Standard,United Kingdom,SITE-001
PT-003112,XS-OD-0038,21,Male,Black or African American,HBB E6V (sickle),85.3,0,Combination,Standard,2025-01-07,Standard,France,SITE-042
PT-003113,XS-OD-0038,11,Male,White,HBB IVS-I-110 G>A,58.8,2,Active_Drug,Standard,2025-01-14,Pediatric_Assent,Spain,SITE-042
PT-003114,XS-OD-0038,24,Male,White,,59.1,1,SOC,Standard,2025-03-15,Standard,Canada,SITE-015
PT-003115,XS-OD-0038,35,Male,White,HBB E6V (sickle),49.4,3,Combination,Standard,2025-02-07,Standard,Australia,SITE-028
PT-003116,XS-OD-0038,64,Male,Hispanic or Latino,F9 R338L,56.8,0,Active_Drug,Standard,2025-04-18,Compassionate,United Kingdom,SITE-009
PT-003117,XS-OD-0038,37,Male,Hispanic or Latino,F9 R338L,54.9,5,SOC,Standard,2025-05-28,Standard,Australia,SITE-003
PT-003118,XS-OD-0038,59,Female,White,,54.1,3,Combination,Standard,2025-06-02,Standard,Germany,SITE-023
PT-003119,XS-OD-0038,27,Female,White,F9 R338L,34.7,2,Active_Drug,Standard,2025-04-23,Standard,Canada,SITE-040
PT-003120,XS-OD-0038,44,Female,White,F9 R338L,39.8,2,SOC,Standard,2025-04-13,Standard,Netherlands,SITE-002
PT-003121,XS-OD-0038,42,Female,Hispanic or Latino,HBB E6V (sickle),72.0,2,Combination,Standard,2025-04-23,Standard,Spain,SITE-008
PT-003122,XS-OD-0038,27,Female,Hispanic or Latino,,71.0,0,Active_Drug,Standard,2025-05-21,Standard,United States,SITE-027
PT-003123,XS-OD-0038,44,Female,White,Factor VIII intron 22 inv,25.4,1,SOC,Standard,2024-12-30,Standard,Japan,SITE-016
PT-003124,XS-OD-0038,2,Female,Hispanic or Latino,,51.9,3,Combination,Standard,2025-01-08,Pediatric_Assent,Spain,SITE-004
PT-003125,XS-OD-0038,10,Male,Hispanic or Latino,F9 R338L,47.4,3,Active_Drug,Standard,2025-04-26,Pediatric_Assent,France,SITE-043
PT-003126,XS-OD-0038,21,Male,White,F9 R338L,70.9,6,SOC,Standard,2025-04-11,Standard,Australia,SITE-023
PT-003127,XS-OD-0038,16,Male,White,HBB E6V (sickle),45.1,5,Combination,Standard,2025-02-04,Pediatric_Assent,Spain,SITE-021
PT-003128,XS-OD-0038,58,Female,Hispanic or Latino,F9 R338L,70.2,4,Active_Drug,Standard,2025-02-26,Standard,Spain,SITE-010
PT-003129,XS-OD-0038,42,Male,Asian,,40.5,2,SOC,Standard,2025-04-28,Standard,Netherlands,SITE-034
PT-003130,XS-OD-0038,32,Male,White,,89.9,0,Combination,Standard,2024-12-31,Standard,United States,SITE-018
PT-003131,XS-OD-0038,63,Female,White,Factor VIII intron 22 inv,63.3,6,Active_Drug,Standard,2025-03-13,Standard,Italy,SITE-040
PT-003132,XS-OD-0038,58,Male,Asian,,46.6,1,SOC,Standard,2025-04-25,Standard,Japan,SITE-004
PT-003133,XS-OD-0038,21,Female,White,,84.3,0,Combination,Standard,2025-02-08,Standard,Netherlands,SITE-035
PT-003134,XS-OD-0038,28,Female,White,Factor VIII intron 22 inv,24.8,3,Active_Drug,Standard,2025-05-10,Compassionate,Japan,SITE-042
PT-003135,XS-OD-0038,42,Male,White,HBB E6V (sickle),92.5,2,SOC,Standard,2025-02-06,Standard,Netherlands,SITE-034
PT-003136,XS-OD-0038,17,Male,White,Factor VIII intron 22 inv,67.9,2,Combination,Standard,2025-01-13,Pediatric_Assent,United States,SITE-017
PT-003137,XS-OD-0038,18,Male,Hispanic or Latino,HBB IVS-I-110 G>A,34.6,2,Active_Drug,Standard,2025-03-12,Standard,United States,SITE-024
PT-003138,XS-OD-0038,32,Female,White,F9 R338L,24.9,2,SOC,Standard,2025-01-18,Standard,Spain,SITE-020
PT-003139,XS-OD-0038,11,Female,White,HBB E6V (sickle),74.5,2,Combination,Standard,2025-04-09,Pediatric_Assent,United Kingdom,SITE-031
PT-003140,XS-OD-0038,43,Male,Black or African American,HBB IVS-I-110 G>A,34.7,1,Active_Drug,Standard,2025-05-30,Standard,Japan,SITE-014
PT-003141,XS-OD-0038,40,Female,Hispanic or Latino,,42.8,2,SOC,Standard,2025-03-23,Standard,Japan,SITE-026
PT-003142,XS-OD-0038,62,Male,Asian,HBB E6V (sickle),76.5,4,Combination,Standard,2025-05-31,Standard,United States,SITE-018
PT-003143,XS-OD-0038,69,Female,White,,47.6,2,Active_Drug,Standard,2025-02-20,Standard,United States,SITE-021
PT-003144,XS-OD-0038,14,Male,White,,92.5,0,SOC,Standard,2025-03-13,Pediatric_Assent,Australia,SITE-014
PT-003145,XS-OD-0038,26,Female,Black or African American,,45.8,0,Combination,Standard,2025-05-31,Standard,Japan,SITE-035
PT-003146,XS-OD-0038,60,Female,White,F9 R338L,54.5,4,Active_Drug,Standard,2025-01-16,Standard,France,SITE-019
PT-003147,XS-OD-0038,26,Female,Hispanic or Latino,Factor VIII intron 22 inv,57.8,1,SOC,Standard,2025-05-27,Standard,United States,SITE-021
PT-003148,XS-OD-0038,24,Male,American Indian or Alaska Native,HBB E6V (sickle),68.9,0,Combination,Standard,2025-03-03,Standard,Canada,SITE-041
PT-003149,XS-OD-0038,5,Intersex,Two or More Races,HBB IVS-I-110 G>A,52.4,2,Active_Drug,Standard,2025-04-29,Pediatric_Assent,Canada,SITE-033
PT-003150,XS-OD-0038,41,Female,Asian,HBB E6V (sickle),47.9,3,SOC,Standard,2025-03-22,Standard,Canada,SITE-016
PT-003151,XS-OD-0038,2,Female,Asian,,58.5,1,Combination,Standard,2025-06-19,Pediatric_Assent,Australia,SITE-034
PT-003152,XS-OD-0038,50,Male,White,,51.8,0,Active_Drug,Standard,2025-04-09,Standard,Netherlands,SITE-020
PT-003153,XS-OD-0038,53,Female,White,HBB E6V (sickle),47.1,2,SOC,Standard,2025-02-10,Standard,Spain,SITE-001
PT-003154,XS-OD-0038,25,Female,White,HBB E6V (sickle),74.2,4,Combination,Standard,2025-05-05,Standard,Canada,SITE-029
PT-003155,XS-OD-0038,53,Male,Asian,HBB IVS-I-110 G>A,64.5,1,Active_Drug,Standard,2025-04-16,Standard,Australia,SITE-007
PT-003156,XS-OD-0038,42,Male,White,Factor VIII intron 22 inv,57.9,1,SOC,Standard,2025-03-18,Standard,United Kingdom,SITE-026
PT-003157,XS-OD-0038,38,Female,White,F9 R338L,48.1,1,Combination,Standard,2025-02-24,Standard,Australia,SITE-011
PT-003158,XS-OD-0038,40,Male,White,HBB E6V (sickle),49.9,0,Active_Drug,Standard,2025-01-04,Standard,Spain,SITE-041
PT-003159,XS-OD-0038,28,Male,White,F9 R338L,63.6,0,SOC,Standard,2025-01-25,Standard,Spain,SITE-001
PT-003160,XS-OD-0038,2,Male,Asian,HBB E6V (sickle),66.9,3,Combination,Standard,2025-04-11,Pediatric_Assent,Netherlands,SITE-013
PT-003161,XS-OD-0038,33,Male,White,HBB IVS-I-110 G>A,73.8,1,Active_Drug,Standard,2025-02-19,Standard,France,SITE-035
PT-003162,XS-OD-0038,51,Female,Hispanic or Latino,HBB IVS-I-110 G>A,37.5,2,SOC,Standard,2025-05-07,Standard,Japan,SITE-021
PT-003163,XS-OD-0038,43,Female,Black or African American,,49.2,1,Combination,Standard,2025-05-05,Standard,Canada,SITE-022
PT-003164,XS-OD-0038,73,Male,Two or More Races,HBB IVS-I-110 G>A,71.5,0,Active_Drug,Standard,2025-06-16,Standard,Australia,SITE-042
PT-003165,XS-OD-0038,41,Female,White,F9 R338L,49.8,4,SOC,Standard,2025-06-08,Standard,Netherlands,SITE-039
PT-003166,XS-OD-0038,36,Male,Asian,F9 R338L,58.7,2,Combination,Standard,2025-05-09,Standard,Netherlands,SITE-041
PT-003167,XS-OD-0038,51,Female,Black or African American,F9 R338L,50.3,2,Active_Drug,Standard,2025-02-11,Standard,United Kingdom,SITE-032
PT-003168,XS-OD-0038,42,Male,White,,62.2,2,SOC,Standard,2024-12-30,Standard,Australia,SITE-010
PT-003169,XS-OD-0038,42,Male,Black or African American,HBB IVS-I-110 G>A,60.9,3,Combination,Standard,2025-03-30,Standard,United States,SITE-030
PT-003170,XS-OD-0038,36,Male,Hispanic or Latino,Factor VIII intron 22 inv,57.6,1,Active_Drug,Standard,2025-06-12,Standard,Spain,SITE-011
PT-003171,XS-OD-0038,21,Male,White,,74.9,3,SOC,Standard,2025-01-25,Standard,Italy,SITE-031
PT-003172,XS-OD-0038,24,Female,Black or African American,,54.2,2,Combination,Standard,2025-06-09,Compassionate,France,SITE-004
PT-003173,XS-OD-0038,35,Female,White,HBB E6V (sickle),59.2,1,Active_Drug,Standard,2025-03-16,Standard,Spain,SITE-007
PT-003174,XS-OD-0038,42,Male,White,,84.7,2,SOC,Standard,2025-01-12,Standard,United Kingdom,SITE-033
PT-003175,XS-OD-0038,34,Male,White,F9 R338L,44.8,4,Combination,Standard,2025-05-22,Standard,United States,SITE-017
PT-003176,XS-OD-0038,50,Male,Asian,F9 R338L,39.6,3,Active_Drug,Standard,2025-01-02,Standard,Netherlands,SITE-008
PT-003177,XS-OD-0038,39,Female,Black or African American,Factor VIII intron 22 inv,44.3,1,SOC,Standard,2025-05-07,Standard,Italy,SITE-021
PT-003178,XS-OD-0038,38,Male,White,,39.5,1,Combination,Standard,2025-02-04,Compassionate,United States,SITE-038
PT-003179,XS-OD-0038,11,Male,White,F9 R338L,76.3,3,Active_Drug,Standard,2025-05-05,Pediatric_Assent,Canada,SITE-010
PT-003180,XS-OD-0038,56,Female,White,HBB E6V (sickle),50.2,1,SOC,Standard,2025-04-25,Standard,Netherlands,SITE-027
PT-003181,XS-OD-0038,41,Male,White,HBB IVS-I-110 G>A,15.8,2,Combination,Standard,2025-01-16,Standard,Japan,SITE-031
PT-003182,XS-OD-0038,19,Male,White,F9 R338L,81.7,1,Active_Drug,Standard,2025-04-27,Standard,France,SITE-014
PT-003183,XS-OD-0038,25,Male,White,HBB E6V (sickle),58.4,5,SOC,Standard,2025-02-08,Standard,Spain,SITE-014
PT-003184,XS-OD-0038,47,Male,White,HBB E6V (sickle),65.2,2,Combination,Standard,2025-03-19,Standard,Italy,SITE-037
PT-003185,XS-OD-0038,69,Female,White,,58.6,3,Active_Drug,Standard,2025-02-03,Standard,Australia,SITE-031
PT-003186,XS-OD-0038,51,Male,Black or African American,HBB IVS-I-110 G>A,37.9,3,SOC,Standard,2025-06-12,Standard,Germany,SITE-024
PT-003187,XS-OD-0038,58,Female,Black or African American,HBB IVS-I-110 G>A,83.3,3,Combination,Standard,2025-03-10,Standard,Japan,SITE-003
PT-003188,XS-OD-0038,47,Male,White,HBB IVS-I-110 G>A,45.2,3,Active_Drug,Standard,2025-05-01,Standard,Canada,SITE-018
PT-003189,XS-OD-0038,38,Male,White,Factor VIII intron 22 inv,60.2,4,SOC,Standard,2025-04-26,Standard,Italy,SITE-027
PT-003190,XS-OD-0038,45,Male,White,,55.3,5,Combination,Standard,2025-03-31,Compassionate,France,SITE-028
PT-003191,XS-OD-0038,72,Female,Hispanic or Latino,,60.1,0,Active_Drug,Standard,2025-04-25,Standard,United States,SITE-024
PT-003192,XS-OD-0038,59,Male,Asian,,67.0,5,SOC,Standard,2025-03-13,Standard,Japan,SITE-005
PT-003193,XS-OD-0038,42,Male,White,HBB IVS-I-110 G>A,25.6,4,Combination,Standard,2025-01-14,Standard,Canada,SITE-028
PT-003194,XS-OD-0038,62,Female,Asian,Factor VIII intron 22 inv,57.3,1,Active_Drug,Standard,2025-02-17,Standard,Netherlands,SITE-013
PT-003195,XS-OD-0038,32,Male,White,HBB E6V (sickle),47.2,0,SOC,Standard,2025-06-16,Standard,Australia,SITE-018
PT-003196,XS-OD-0038,43,Male,Hispanic or Latino,,67.0,2,Combination,Standard,2025-02-18,Standard,Spain,SITE-039
PT-003197,XS-OD-0038,64,Male,White,,71.0,1,Active_Drug,Standard,2025-05-24,Standard,United Kingdom,SITE-037
PT-003198,XS-OD-0038,23,Male,White,,15.6,3,SOC,Standard,2025-04-23,Standard,Japan,SITE-018
PT-003199,XS-OD-0038,24,Female,Black or African American,Factor VIII intron 22 inv,65.7,4,Combination,Standard,2025-02-21,Standard,Japan,SITE-012
PT-003200,XS-OD-0038,8,Female,White,F9 R338L,59.6,1,Active_Drug,Standard,2025-02-05,Pediatric_Assent,Japan,SITE-001
PT-003201,XS-OD-0038,64,Female,White,Factor VIII intron 22 inv,39.3,3,SOC,Standard,2025-05-04,Standard,Australia,SITE-011
PT-003202,XS-OD-0038,27,Female,White,HBB E6V (sickle),13.3,2,Combination,Standard,2025-02-19,Standard,Spain,SITE-009
PT-003203,XS-OD-0038,48,Female,Hispanic or Latino,Factor VIII intron 22 inv,77.4,4,Active_Drug,Standard,2025-05-17,Standard,Spain,SITE-027
PT-003204,XS-OD-0038,40,Female,White,HBB IVS-I-110 G>A,29.1,4,SOC,Standard,2025-04-22,Compassionate,Spain,SITE-041
PT-003205,XS-OD-0038,35,Intersex,Black or African American,Factor VIII intron 22 inv,68.2,1,Combination,Standard,2025-06-09,Standard,France,SITE-032
PT-003206,XS-OD-0038,3,Female,White,Factor VIII intron 22 inv,67.6,1,Active_Drug,Standard,2025-03-06,Pediatric_Assent,United States,SITE-005
PT-003207,XS-OD-0038,33,Female,Asian,Factor VIII intron 22 inv,60.9,0,SOC,Standard,2025-02-20,Standard,Australia,SITE-023
PT-003208,XS-OD-0038,47,Male,Asian,HBB E6V (sickle),69.9,3,Combination,Standard,2025-04-20,Standard,Spain,SITE-034
PT-003209,XS-OD-0038,51,Female,White,Factor VIII intron 22 inv,63.5,3,Active_Drug,Standard,2025-05-26,Standard,Spain,SITE-026
PT-003210,XS-OD-0038,51,Female,American Indian or Alaska Native,HBB IVS-I-110 G>A,24.5,1,SOC,Standard,2025-03-26,Standard,United Kingdom,SITE-002
PT-003211,XS-OD-0038,53,Female,Black or African American,HBB E6V (sickle),65.5,2,Combination,Standard,2025-05-24,Standard,United States,SITE-043
PT-003212,XS-OD-0038,61,Female,White,Factor VIII intron 22 inv,55.1,3,Active_Drug,Standard,2025-05-15,Standard,Japan,SITE-006
PT-003213,XS-OD-0038,48,Female,White,HBB E6V (sickle),64.7,0,SOC,Standard,2025-05-27,Standard,Germany,SITE-036
PT-003214,XS-OD-0038,56,Male,Hispanic or Latino,,43.0,2,Combination,Standard,2025-06-18,Standard,United Kingdom,SITE-017
PT-003215,XS-OD-0038,19,Male,Black or African American,,58.4,2,Active_Drug,Standard,2025-06-06,Compassionate,Germany,SITE-023
PT-003216,XS-OD-0038,42,Female,White,HBB E6V (sickle),47.2,3,SOC,Standard,2025-05-08,Standard,United Kingdom,SITE-004
PT-003217,XS-OD-0038,2,Female,Asian,,61.6,3,Combination,Standard,2025-03-22,Pediatric_Assent,Netherlands,SITE-034
PT-003218,XS-OD-0038,58,Male,White,,55.2,0,Active_Drug,Standard,2025-04-04,Standard,Italy,SITE-009
PT-003219,XS-OD-0038,27,Female,White,HBB IVS-I-110 G>A,10.0,1,SOC,Standard,2025-04-24,Standard,Netherlands,SITE-035
PT-003220,XS-OD-0038,5,Male,Hispanic or Latino,,33.6,4,Combination,Standard,2025-06-20,Pediatric_Assent,Australia,SITE-012
PT-003221,XS-OD-0038,50,Male,Asian,Factor VIII intron 22 inv,76.6,3,Active_Drug,Standard,2025-01-13,Standard,Germany,SITE-020
PT-003222,XS-OD-0038,23,Male,White,HBB E6V (sickle),43.1,6,SOC,Standard,2025-01-23,Standard,Spain,SITE-038
PT-003223,XS-OD-0038,29,Female,White,,40.4,2,Combination,Standard,2025-01-15,Standard,France,SITE-027
PT-003224,XS-OD-0038,20,Female,Asian,HBB E6V (sickle),39.6,2,Active_Drug,Standard,2025-05-27,Standard,Canada,SITE-042
PT-003225,XS-OD-0038,56,Male,Asian,HBB E6V (sickle),50.5,2,SOC,Standard,2025-05-20,Standard,Canada,SITE-022
PT-003226,XS-OD-0038,50,Male,White,HBB E6V (sickle),52.9,1,Combination,Standard,2025-04-14,Standard,Canada,SITE-037
PT-003227,XS-OD-0038,23,Female,Asian,,62.6,3,Active_Drug,Standard,2025-01-01,Standard,United Kingdom,SITE-043
PT-003228,XS-OD-0038,60,Female,Black or African American,,72.4,2,SOC,Standard,2025-01-16,Standard,Canada,SITE-025
PT-003229,XS-OD-0038,19,Male,White,HBB E6V (sickle),73.1,0,Combination,Standard,2025-05-31,Standard,Spain,SITE-020
PT-003230,XS-OD-0038,41,Male,White,,69.1,4,Active_Drug,Standard,2025-05-15,Emergency,Netherlands,SITE-042
PT-003231,XS-OD-0038,33,Male,White,,55.4,2,SOC,Standard,2025-06-06,Standard,Germany,SITE-026
PT-003232,XS-OD-0038,46,Female,White,HBB E6V (sickle),68.4,2,Combination,Standard,2025-04-04,Standard,United Kingdom,SITE-040
PT-003233,XS-OD-0038,88,Female,Asian,F9 R338L,40.2,4,Active_Drug,Standard,2025-05-22,Standard,Italy,SITE-012
PT-003234,XS-OD-0038,57,Female,White,Factor VIII intron 22 inv,77.0,3,SOC,Standard,2025-06-19,Standard,United States,SITE-010
PT-003235,XS-OD-0038,56,Female,White,,18.0,3,Combination,Standard,2025-03-20,Standard,United States,SITE-023
PT-003236,XS-OD-0038,30,Male,White,,74.6,3,Active_Drug,Standard,2025-06-20,Standard,France,SITE-012
PT-003237,XS-OD-0038,23,Male,White,F9 R338L,51.1,2,SOC,Standard,2025-06-04,Standard,United Kingdom,SITE-005
PT-003238,XS-OD-0038,20,Male,White,Factor VIII intron 22 inv,59.8,3,Combination,Standard,2025-06-13,Standard,Germany,SITE-042
PT-003239,XS-OD-0038,41,Female,White,Factor VIII intron 22 inv,63.4,3,Active_Drug,Standard,2025-05-17,Standard,France,SITE-011
PT-003240,XS-OD-0038,37,Male,White,HBB IVS-I-110 G>A,27.7,3,SOC,Standard,2025-05-22,Standard,France,SITE-017
PT-003241,XS-OD-0038,80,Female,Black or African American,,88.4,0,Combination,Standard,2025-06-17,Standard,Germany,SITE-009
PT-003242,XS-OD-0038,32,Female,White,,78.2,0,Active_Drug,Standard,2025-06-10,Standard,Australia,SITE-015
PT-003243,XS-OD-0038,36,Female,White,,48.9,5,SOC,Standard,2025-03-03,Standard,Germany,SITE-020
PT-003244,XS-OD-0038,41,Male,Asian,,62.8,2,Combination,Standard,2025-06-18,Standard,Canada,SITE-024
PT-003245,XS-OD-0038,50,Female,White,HBB IVS-I-110 G>A,20.6,3,Active_Drug,Standard,2025-03-10,Standard,United States,SITE-039
PT-003246,XS-OD-0038,50,Female,Hispanic or Latino,HBB IVS-I-110 G>A,89.1,2,SOC,Standard,2025-06-03,Standard,Germany,SITE-029
PT-003247,XS-OD-0039,56,Male,Black or African American,,68.0,2,Active_Drug,Standard,2023-06-09,Standard,Germany,SITE-022
PT-003248,XS-OD-0039,35,Male,White,HBB IVS-I-110 G>A,41.0,0,Placebo,Standard,2023-05-28,Standard,Japan,SITE-016
PT-003249,XS-OD-0039,2,Male,White,,63.7,2,Active_Drug_High_Dose,Standard,2023-09-20,Pediatric_Assent,Australia,SITE-002
PT-003250,XS-OD-0039,82,Male,White,HBB E6V (sickle),75.3,2,Active_Drug,Standard,2023-07-27,Standard,United States,SITE-017
PT-003251,XS-OD-0039,47,Male,White,F9 R338L,65.6,3,Placebo,Standard,2023-05-31,Standard,Netherlands,SITE-018
PT-003252,XS-OD-0039,46,Male,Asian,HBB IVS-I-110 G>A,45.7,0,Active_Drug_High_Dose,Standard,2023-08-23,Standard,Italy,SITE-019
PT-003253,XS-OD-0039,50,Male,White,HBB E6V (sickle),18.8,3,Active_Drug,Standard,2023-09-06,Standard,United Kingdom,SITE-020
PT-003254,XS-OD-0039,22,Male,White,F9 R338L,61.8,3,Placebo,Standard,2023-08-07,Standard,Italy,SITE-024
PT-003255,XS-OD-0039,18,Male,White,HBB E6V (sickle),69.9,1,Active_Drug_High_Dose,Standard,2023-10-23,Standard,Netherlands,SITE-024
PT-003256,XS-OD-0039,4,Male,Hispanic or Latino,,29.7,4,Active_Drug,Standard,2023-10-03,Pediatric_Assent,Germany,SITE-015
PT-003257,XS-OD-0039,49,Male,Black or African American,HBB IVS-I-110 G>A,65.8,1,Placebo,Standard,2023-08-13,Standard,Netherlands,SITE-016
PT-003258,XS-OD-0039,15,Male,Asian,,63.8,3,Active_Drug_High_Dose,Standard,2023-09-22,Pediatric_Assent,Australia,SITE-019
PT-003259,XS-OD-0039,41,Male,Asian,,44.2,2,Active_Drug,Standard,2023-06-27,Standard,United States,SITE-017
PT-003260,XS-OD-0039,31,Male,White,,48.5,0,Placebo,Standard,2023-07-04,Standard,Canada,SITE-003
PT-003261,XS-OD-0039,9,Male,Hispanic or Latino,,54.5,2,Active_Drug_High_Dose,Standard,2023-09-25,Pediatric_Assent,Netherlands,SITE-001
PT-003262,XS-OD-0039,37,Male,White,HBB IVS-I-110 G>A,95.0,3,Active_Drug,Standard,2023-07-04,Standard,Germany,SITE-025
PT-003263,XS-OD-0039,76,Male,White,Factor VIII intron 22 inv,40.8,2,Placebo,Standard,2023-09-04,Standard,France,SITE-008
PT-003264,XS-OD-0039,39,Male,Asian,HBB E6V (sickle),60.4,2,Active_Drug_High_Dose,Standard,2023-10-03,Standard,Italy,SITE-025
PT-003265,XS-OD-0039,21,Male,White,HBB IVS-I-110 G>A,50.0,2,Active_Drug,Standard,2023-10-05,Standard,Canada,SITE-021
PT-003266,XS-OD-0039,39,Male,White,Factor VIII intron 22 inv,90.8,2,Placebo,Standard,2023-11-08,Standard,United Kingdom,SITE-003
PT-003267,XS-OD-0039,50,Male,White,HBB IVS-I-110 G>A,72.1,4,Active_Drug_High_Dose,Standard,2023-08-12,Standard,Spain,SITE-011
PT-003268,XS-OD-0039,23,Male,White,Factor VIII intron 22 inv,85.1,3,Active_Drug,Standard,2023-11-02,Emergency,Germany,SITE-011
PT-003269,XS-OD-0039,32,Male,Hispanic or Latino,Factor VIII intron 22 inv,58.1,1,Placebo,Standard,2023-07-15,Standard,Spain,SITE-008
PT-003270,XS-OD-0039,37,Male,Asian,,48.9,3,Active_Drug_High_Dose,Standard,2023-10-09,Standard,Netherlands,SITE-007
PT-003271,XS-OD-0039,21,Male,Hispanic or Latino,,68.5,4,Active_Drug,Standard,2023-10-21,Standard,United Kingdom,SITE-025
PT-003272,XS-OD-0039,66,Male,White,HBB E6V (sickle),73.9,1,Placebo,Standard,2023-07-20,Standard,Australia,SITE-007
PT-003273,XS-OD-0039,13,Male,White,HBB IVS-I-110 G>A,35.0,2,Active_Drug_High_Dose,Standard,2023-07-12,Pediatric_Assent,Japan,SITE-025
PT-003274,XS-OD-0039,47,Male,White,HBB E6V (sickle),68.1,0,Active_Drug,Standard,2023-09-20,Standard,Australia,SITE-001
PT-003275,XS-OD-0039,51,Male,Black or African American,HBB E6V (sickle),74.0,0,Placebo,Standard,2023-07-25,Compassionate,Netherlands,SITE-018
PT-003276,XS-OD-0039,44,Male,White,Factor VIII intron 22 inv,71.5,0,Active_Drug_High_Dose,Standard,2023-08-01,Standard,France,SITE-007
PT-003277,XS-OD-0039,23,Male,White,HBB E6V (sickle),33.3,0,Active_Drug,Standard,2023-08-18,Standard,Netherlands,SITE-012
PT-003278,XS-OD-0039,51,Male,White,Factor VIII intron 22 inv,61.3,4,Placebo,Standard,2023-06-09,Standard,Australia,SITE-019
PT-003279,XS-OD-0039,42,Male,White,,66.6,5,Active_Drug_High_Dose,Standard,2023-11-19,Standard,France,SITE-023
PT-003280,XS-OD-0039,46,Male,White,Factor VIII intron 22 inv,60.4,4,Active_Drug,Standard,2023-06-04,Standard,Spain,SITE-001
PT-003281,XS-OD-0039,71,Male,Asian,,60.5,1,Placebo,Standard,2023-10-10,Standard,Japan,SITE-013
PT-003282,XS-OD-0039,39,Male,White,Factor VIII intron 22 inv,83.0,1,Active_Drug_High_Dose,Standard,2023-07-16,Standard,Germany,SITE-020
PT-003283,XS-OD-0039,43,Male,White,Factor VIII intron 22 inv,32.8,0,Active_Drug,Standard,2023-10-30,Standard,Germany,SITE-009
PT-003284,XS-OD-0039,54,Male,Asian,,34.5,3,Placebo,Standard,2023-07-04,Standard,Australia,SITE-001
PT-003285,XS-OD-0039,38,Male,Black or African American,,60.7,1,Active_Drug_High_Dose,Standard,2023-06-01,Standard,United Kingdom,SITE-006
PT-003286,XS-OD-0039,28,Male,White,HBB E6V (sickle),56.3,0,Active_Drug,Standard,2023-11-10,Standard,Japan,SITE-003
PT-003287,XS-OD-0039,51,Male,Black or African American,,58.7,0,Placebo,Standard,2023-06-27,Standard,Spain,SITE-007
PT-003288,XS-OD-0039,78,Male,Hispanic or Latino,F9 R338L,77.1,0,Active_Drug_High_Dose,Standard,2023-06-09,Standard,Spain,SITE-012
PT-003289,XS-OD-0039,28,Male,White,,45.7,0,Active_Drug,Standard,2023-07-17,Standard,France,SITE-018
PT-003290,XS-OD-0039,30,Male,White,,28.3,2,Placebo,Standard,2023-06-21,Standard,Spain,SITE-021
PT-003291,XS-OD-0039,34,Male,White,HBB IVS-I-110 G>A,78.4,0,Active_Drug_High_Dose,Standard,2023-09-13,Standard,Germany,SITE-020
PT-003292,XS-OD-0039,48,Male,Hispanic or Latino,HBB IVS-I-110 G>A,45.6,2,Active_Drug,Standard,2023-09-18,Standard,Netherlands,SITE-023
PT-003293,XS-OD-0039,26,Male,Hispanic or Latino,,42.7,0,Placebo,Standard,2023-09-16,Standard,France,SITE-020
PT-003294,XS-OD-0039,11,Male,Black or African American,HBB E6V (sickle),64.8,2,Active_Drug_High_Dose,Standard,2023-06-27,Pediatric_Assent,Canada,SITE-013
PT-003295,XS-OD-0039,55,Male,White,HBB IVS-I-110 G>A,87.4,1,Active_Drug,Standard,2023-11-02,Standard,Italy,SITE-023
PT-003296,XS-OD-0039,38,Male,White,,69.9,3,Placebo,Standard,2023-07-02,Standard,Italy,SITE-019
PT-003297,XS-OD-0039,33,Male,Black or African American,F9 R338L,66.3,2,Active_Drug_High_Dose,Standard,2023-07-03,Standard,Germany,SITE-002
PT-003298,XS-OD-0039,35,Male,Two or More Races,HBB E6V (sickle),64.8,4,Active_Drug,Standard,2023-08-31,Standard,Germany,SITE-007
PT-003299,XS-OD-0039,19,Male,Black or African American,,58.6,1,Placebo,Standard,2023-07-22,Standard,Canada,SITE-013
PT-003300,XS-OD-0039,3,Male,Hispanic or Latino,HBB IVS-I-110 G>A,42.5,4,Active_Drug_High_Dose,Standard,2023-10-28,Pediatric_Assent,Italy,SITE-017
PT-003301,XS-OD-0039,32,Male,Native Hawaiian or Other Pacific Islander,,29.3,3,Active_Drug,Standard,2023-11-21,Standard,Japan,SITE-018
PT-003302,XS-OD-0039,42,Male,Hispanic or Latino,,80.4,2,Placebo,Standard,2023-06-17,Standard,Spain,SITE-016
PT-003303,XS-OD-0039,39,Female,White,,45.2,2,Active_Drug_High_Dose,Standard,2023-06-16,Standard,Japan,SITE-023
PT-003304,XS-OD-0039,52,Male,Hispanic or Latino,F9 R338L,51.8,1,Active_Drug,Standard,2023-11-11,Standard,United Kingdom,SITE-008
PT-003305,XS-OD-0039,23,Male,White,HBB E6V (sickle),32.2,1,Placebo,Standard,2023-08-09,Standard,Canada,SITE-007
PT-003306,XS-OD-0039,15,Male,Asian,Factor VIII intron 22 inv,38.0,2,Active_Drug_High_Dose,Standard,2023-08-07,Pediatric_Assent,France,SITE-024
PT-003307,XS-OD-0039,53,Male,Asian,HBB E6V (sickle),72.8,0,Active_Drug,Standard,2023-07-01,Standard,Canada,SITE-016
PT-003308,XS-OD-0039,47,Male,Hispanic or Latino,HBB IVS-I-110 G>A,71.0,2,Placebo,Standard,2023-09-15,Standard,Netherlands,SITE-015
PT-003309,XS-OD-0039,33,Female,Hispanic or Latino,,42.2,2,Active_Drug_High_Dose,Standard,2023-09-08,Standard,Netherlands,SITE-012
PT-003310,XS-OD-0039,50,Male,White,HBB IVS-I-110 G>A,35.8,2,Active_Drug,Standard,2023-09-27,Standard,Canada,SITE-024
PT-003311,XS-OD-0039,51,Male,Asian,Factor VIII intron 22 inv,47.2,3,Placebo,Standard,2023-07-29,Standard,Netherlands,SITE-015
PT-003312,XS-OD-0039,40,Male,White,HBB E6V (sickle),95.0,1,Active_Drug_High_Dose,Standard,2023-08-25,Standard,Italy,SITE-018
PT-003313,XS-OD-0039,54,Male,White,HBB E6V (sickle),30.8,3,Active_Drug,Standard,2023-10-04,Standard,Canada,SITE-013
PT-003314,XS-OD-0039,59,Male,Asian,,52.6,1,Placebo,Standard,2023-06-18,Standard,Australia,SITE-020
PT-003315,XS-OD-0039,44,Male,White,HBB E6V (sickle),74.9,1,Active_Drug_High_Dose,Standard,2023-09-26,Standard,Italy,SITE-024
PT-003316,XS-OD-0039,33,Male,White,,18.9,1,Active_Drug,Standard,2023-06-16,Standard,France,SITE-017
PT-003317,XS-OD-0039,59,Male,American Indian or Alaska Native,Factor VIII intron 22 inv,40.7,1,Placebo,Standard,2023-11-11,Standard,Germany,SITE-008
PT-003318,XS-OD-0039,48,Male,White,,34.4,5,Active_Drug_High_Dose,Standard,2023-09-11,Standard,Germany,SITE-002
PT-003319,XS-OD-0039,67,Male,Black or African American,,22.5,4,Active_Drug,Standard,2023-10-02,Standard,Germany,SITE-001
PT-003320,XS-OD-0039,25,Male,Native Hawaiian or Other Pacific Islander,,55.8,1,Placebo,Standard,2023-10-17,Standard,United Kingdom,SITE-008
PT-003321,XS-OD-0039,47,Male,White,F9 R338L,41.2,1,Active_Drug_High_Dose,Standard,2023-11-21,Standard,Italy,SITE-001
PT-003322,XS-OD-0039,72,Male,White,F9 R338L,60.1,3,Active_Drug,Standard,2023-11-06,Standard,Spain,SITE-016
PT-003323,XS-OD-0039,19,Male,Asian,HBB E6V (sickle),69.7,2,Placebo,Standard,2023-06-11,Standard,United Kingdom,SITE-016
PT-003324,XS-OD-0039,38,Male,White,HBB IVS-I-110 G>A,22.7,4,Active_Drug_High_Dose,Standard,2023-06-15,Standard,Netherlands,SITE-011
PT-003325,XS-OD-0039,15,Male,Asian,,47.3,3,Active_Drug,Standard,2023-10-26,Pediatric_Assent,Italy,SITE-001
PT-003326,XS-OD-0039,15,Male,White,Factor VIII intron 22 inv,62.4,2,Placebo,Standard,2023-05-31,Pediatric_Assent,France,SITE-001
PT-003327,XS-OD-0039,51,Male,White,HBB E6V (sickle),53.1,3,Active_Drug_High_Dose,Standard,2023-09-29,Standard,Italy,SITE-003
PT-003328,XS-OD-0039,28,Male,White,HBB E6V (sickle),70.4,1,Active_Drug,Standard,2023-07-13,Standard,Netherlands,SITE-006
PT-003329,XS-OD-0039,57,Male,Asian,HBB IVS-I-110 G>A,56.0,1,Placebo,Standard,2023-08-04,Standard,Australia,SITE-011
PT-003330,XS-OD-0039,62,Male,White,HBB E6V (sickle),45.2,0,Active_Drug_High_Dose,Standard,2023-06-18,Standard,United States,SITE-024
PT-003331,XS-OD-0039,71,Male,Asian,HBB E6V (sickle),71.0,1,Active_Drug,Standard,2023-10-08,Standard,Spain,SITE-004
PT-003332,XS-OD-0039,55,Male,Asian,HBB E6V (sickle),45.6,2,Placebo,Standard,2023-06-06,Standard,Italy,SITE-008
PT-003333,XS-OD-0039,21,Male,Asian,Factor VIII intron 22 inv,71.4,1,Active_Drug_High_Dose,Standard,2023-10-03,Standard,United States,SITE-012
PT-003334,XS-OD-0039,45,Male,White,HBB IVS-I-110 G>A,53.3,3,Active_Drug,Standard,2023-09-03,Standard,France,SITE-011
PT-003335,XS-OD-0039,4,Male,White,,70.0,3,Placebo,Standard,2023-08-10,Pediatric_Assent,United Kingdom,SITE-016
PT-003336,XS-OD-0039,24,Male,Asian,HBB IVS-I-110 G>A,41.9,0,Active_Drug_High_Dose,Standard,2023-06-20,Standard,Spain,SITE-021
PT-003337,XS-OD-0039,36,Male,White,,54.3,1,Active_Drug,Standard,2023-10-06,Standard,Netherlands,SITE-002
PT-003338,XS-OD-0039,41,Male,White,,72.5,0,Placebo,Standard,2023-07-03,Standard,Australia,SITE-007
PT-003339,XS-OD-0039,36,Male,White,HBB E6V (sickle),95.0,1,Active_Drug_High_Dose,Standard,2023-09-23,Standard,Canada,SITE-004
PT-003340,XS-OD-0039,2,Male,White,F9 R338L,65.8,0,Active_Drug,Standard,2023-11-09,Pediatric_Assent,Italy,SITE-025
PT-003341,XS-OD-0039,8,Male,Hispanic or Latino,Factor VIII intron 22 inv,61.3,2,Placebo,Standard,2023-11-16,Pediatric_Assent,Japan,SITE-024
PT-003342,XS-OD-0039,37,Male,White,,25.1,3,Active_Drug_High_Dose,Standard,2023-09-04,Standard,France,SITE-004
PT-003343,XS-OD-0039,42,Male,White,HBB E6V (sickle),46.7,2,Active_Drug,Standard,2023-07-16,Standard,Germany,SITE-012
PT-003344,XS-OD-0039,62,Male,Black or African American,,54.4,4,Placebo,Standard,2023-11-10,Standard,France,SITE-015
PT-003345,XS-OD-0039,53,Male,American Indian or Alaska Native,HBB E6V (sickle),75.4,3,Active_Drug_High_Dose,Standard,2023-05-31,Standard,Netherlands,SITE-013
PT-003346,XS-OD-0039,33,Male,Asian,F9 R338L,59.0,2,Active_Drug,Standard,2023-06-26,Standard,Spain,SITE-008
PT-003347,XS-OD-0039,40,Male,Native Hawaiian or Other Pacific Islander,,30.5,0,Placebo,Standard,2023-10-22,Standard,Netherlands,SITE-002
PT-003348,XS-OD-0039,16,Male,White,,51.1,2,Active_Drug_High_Dose,Standard,2023-09-01,Pediatric_Assent,Spain,SITE-003
PT-003349,XS-OD-0039,35,Male,White,F9 R338L,62.7,1,Active_Drug,Standard,2023-07-22,Standard,Netherlands,SITE-025
PT-003350,XS-OD-0039,49,Male,Hispanic or Latino,,23.4,5,Placebo,Standard,2023-08-29,Standard,United States,SITE-016
PT-003351,XS-OD-0039,39,Male,American Indian or Alaska Native,,65.9,1,Active_Drug_High_Dose,Standard,2023-06-08,Standard,Germany,SITE-016
PT-003352,XS-OD-0039,25,Male,White,F9 R338L,54.7,3,Active_Drug,Standard,2023-08-12,Compassionate,Germany,SITE-023
PT-003353,XS-OD-0039,50,Male,White,,46.1,1,Placebo,Standard,2023-10-23,Standard,United States,SITE-020
PT-003354,XS-OD-0039,29,Male,Hispanic or Latino,F9 R338L,10.0,2,Active_Drug_High_Dose,Standard,2023-08-21,Standard,Netherlands,SITE-020
PT-003355,XS-OD-0039,63,Male,White,HBB IVS-I-110 G>A,75.2,2,Active_Drug,Standard,2023-10-26,Standard,Spain,SITE-017
PT-003356,XS-OD-0039,49,Male,Hispanic or Latino,,58.8,1,Placebo,Standard,2023-09-26,Standard,France,SITE-012
PT-003357,XS-OD-0039,51,Male,White,HBB IVS-I-110 G>A,75.7,3,Active_Drug_High_Dose,Standard,2023-11-01,Standard,Germany,SITE-007
PT-003358,XS-OD-0039,23,Male,Asian,HBB IVS-I-110 G>A,46.4,7,Active_Drug,Standard,2023-11-16,Standard,Netherlands,SITE-006
PT-003359,XS-OD-0039,8,Male,Black or African American,,27.2,2,Placebo,Standard,2023-05-31,Pediatric_Assent,Spain,SITE-015
PT-003360,XS-OD-0039,53,Male,Hispanic or Latino,F9 R338L,86.0,5,Active_Drug_High_Dose,Standard,2023-05-28,Standard,Italy,SITE-012
PT-003361,XS-OD-0039,57,Male,White,Factor VIII intron 22 inv,45.2,1,Active_Drug,Standard,2023-07-11,Standard,Germany,SITE-005
PT-003362,XS-OD-0039,35,Male,Asian,,52.4,1,Placebo,Standard,2023-09-17,Standard,France,SITE-009
PT-003363,XS-OD-0039,48,Male,White,HBB E6V (sickle),78.2,4,Active_Drug_High_Dose,Standard,2023-08-22,Standard,United States,SITE-017
PT-003364,XS-OD-0039,59,Male,White,Factor VIII intron 22 inv,35.9,1,Active_Drug,Standard,2023-10-21,Standard,Japan,SITE-013
PT-003365,XS-OD-0039,34,Male,Hispanic or Latino,Factor VIII intron 22 inv,39.6,2,Placebo,Standard,2023-09-28,Standard,United Kingdom,SITE-012
PT-003366,XS-OD-0039,33,Male,White,,33.9,1,Active_Drug_High_Dose,Standard,2023-08-14,Standard,United States,SITE-025
PT-003367,XS-OD-0039,9,Male,Two or More Races,HBB E6V (sickle),58.8,0,Active_Drug,Standard,2023-06-18,Pediatric_Assent,Canada,SITE-008
PT-003368,XS-OD-0039,19,Male,Hispanic or Latino,Factor VIII intron 22 inv,42.2,5,Placebo,Standard,2023-06-02,Standard,Australia,SITE-021
PT-003369,XS-OD-0039,77,Male,White,HBB E6V (sickle),66.2,2,Active_Drug_High_Dose,Standard,2023-11-19,Standard,Canada,SITE-017
PT-003370,XS-OD-0039,59,Male,White,Factor VIII intron 22 inv,77.3,2,Active_Drug,Standard,2023-10-18,Standard,Japan,SITE-008
PT-003371,XS-OD-0039,37,Male,Black or African American,,66.1,3,Placebo,Standard,2023-07-29,Standard,Australia,SITE-004
PT-003372,XS-OD-0039,32,Male,Hispanic or Latino,HBB E6V (sickle),95.0,0,Active_Drug_High_Dose,Standard,2023-06-28,Standard,United Kingdom,SITE-001
PT-003373,XS-OD-0039,45,Male,White,Factor VIII intron 22 inv,92.5,0,Active_Drug,Standard,2023-08-12,Standard,Italy,SITE-019
PT-003374,XS-OD-0039,36,Male,Black or African American,,32.1,1,Placebo,Standard,2023-10-26,Standard,Germany,SITE-008
PT-003375,XS-OD-0039,38,Female,Native Hawaiian or Other Pacific Islander,,46.8,3,Active_Drug_High_Dose,Standard,2023-10-25,Compassionate,Spain,SITE-017
PT-003376,XS-OD-0039,56,Male,Black or African American,Factor VIII intron 22 inv,68.7,8,Active_Drug,Standard,2023-05-29,Standard,France,SITE-024
PT-003377,XS-OD-0039,37,Male,Black or African American,,68.0,2,Placebo,Standard,2023-07-19,Standard,Italy,SITE-018
PT-003378,XS-OD-0039,26,Male,Hispanic or Latino,,39.3,5,Active_Drug_High_Dose,Standard,2023-06-25,Standard,United Kingdom,SITE-022
PT-003379,XS-OD-0039,23,Male,Asian,HBB IVS-I-110 G>A,56.1,4,Active_Drug,Standard,2023-10-06,Standard,United States,SITE-023
PT-003380,XS-OD-0039,31,Male,Hispanic or Latino,Factor VIII intron 22 inv,26.7,2,Placebo,Standard,2023-06-07,Standard,United Kingdom,SITE-011
PT-003381,XS-OD-0039,65,Male,White,,20.5,1,Active_Drug_High_Dose,Standard,2023-06-14,Standard,United Kingdom,SITE-009
PT-003382,XS-OD-0039,47,Male,Asian,,57.3,2,Active_Drug,Standard,2023-09-26,Standard,France,SITE-004
PT-003383,XS-OD-0039,37,Male,White,Factor VIII intron 22 inv,39.3,0,Placebo,Standard,2023-10-08,Standard,Netherlands,SITE-001
PT-003384,XS-OD-0039,37,Male,Asian,,40.3,3,Active_Drug_High_Dose,Standard,2023-09-18,Standard,United Kingdom,SITE-014
PT-003385,XS-OD-0039,35,Male,White,,71.8,2,Active_Drug,Standard,2023-10-26,Standard,Japan,SITE-011
PT-003386,XS-OD-0039,20,Male,White,HBB E6V (sickle),44.2,1,Placebo,Standard,2023-08-06,Standard,Germany,SITE-017
PT-003387,XS-OD-0039,55,Male,Black or African American,,47.6,0,Active_Drug_High_Dose,Standard,2023-06-02,Compassionate,Germany,SITE-025
PT-003388,XS-OD-0039,53,Male,White,HBB IVS-I-110 G>A,41.9,1,Active_Drug,Standard,2023-07-26,Standard,Australia,SITE-010
PT-003389,XS-OD-0039,31,Male,Hispanic or Latino,HBB E6V (sickle),58.5,1,Placebo,Standard,2023-07-07,Standard,Japan,SITE-021
PT-003390,XS-OD-0039,40,Male,Asian,,84.6,4,Active_Drug_High_Dose,Standard,2023-10-21,Standard,United States,SITE-008
PT-003391,XS-OD-0039,50,Male,Black or African American,,63.7,0,Active_Drug,Standard,2023-10-11,Standard,United Kingdom,SITE-025
PT-003392,XS-OD-0039,26,Female,White,HBB IVS-I-110 G>A,43.5,2,Placebo,Standard,2023-08-14,Standard,Canada,SITE-014
PT-003393,XS-OD-0039,47,Male,White,,29.4,2,Active_Drug_High_Dose,Standard,2023-08-31,Standard,United States,SITE-008
PT-003394,XS-OD-0039,40,Male,Asian,,62.6,4,Active_Drug,Standard,2023-07-28,Standard,Japan,SITE-001
PT-003395,XS-OD-0039,22,Male,White,HBB IVS-I-110 G>A,48.1,1,Placebo,Standard,2023-09-12,Standard,Germany,SITE-016
PT-003396,XS-OD-0039,67,Male,White,Factor VIII intron 22 inv,26.6,3,Active_Drug_High_Dose,Standard,2023-06-12,Standard,Japan,SITE-009
PT-003397,XS-OD-0039,33,Male,Hispanic or Latino,,43.8,3,Active_Drug,Standard,2023-10-31,Standard,Spain,SITE-015
PT-003398,XS-OD-0039,48,Male,White,F9 R338L,67.5,4,Placebo,Standard,2023-10-27,Emergency,Netherlands,SITE-011
PT-003399,XS-OD-0039,49,Male,Hispanic or Latino,,21.3,3,Active_Drug_High_Dose,Standard,2023-11-04,Standard,Canada,SITE-022
PT-003400,XS-OD-0039,36,Male,White,Factor VIII intron 22 inv,56.4,3,Active_Drug,Standard,2023-07-22,Standard,United States,SITE-003
PT-003401,XS-OD-0039,48,Male,White,Factor VIII intron 22 inv,60.5,2,Placebo,Standard,2023-11-05,Standard,Australia,SITE-005
PT-003402,XS-OD-0039,44,Male,Black or African American,,72.2,2,Active_Drug_High_Dose,Standard,2023-05-29,Standard,Netherlands,SITE-005
PT-003403,XS-OD-0039,56,Male,Hispanic or Latino,,35.3,2,Active_Drug,Standard,2023-08-25,Standard,Japan,SITE-012
PT-003404,XS-OD-0039,36,Male,White,,44.1,4,Placebo,Standard,2023-09-18,Standard,Spain,SITE-017
PT-003405,XS-OD-0039,40,Male,White,Factor VIII intron 22 inv,75.1,1,Active_Drug_High_Dose,Standard,2023-06-18,Standard,Italy,SITE-004
PT-003406,XS-OD-0039,46,Male,Black or African American,,21.1,2,Active_Drug,Standard,2023-11-08,Standard,Italy,SITE-015
PT-003407,XS-OD-0039,55,Male,White,Factor VIII intron 22 inv,82.2,4,Placebo,Standard,2023-09-16,Emergency,United Kingdom,SITE-025
PT-003408,XS-OD-0039,11,Male,White,,49.1,2,Active_Drug_High_Dose,Standard,2023-11-10,Pediatric_Assent,Netherlands,SITE-002
PT-003409,XS-OD-0039,31,Male,Hispanic or Latino,,36.3,1,Active_Drug,Standard,2023-09-18,Standard,United Kingdom,SITE-020
PT-003410,XS-OD-0039,46,Male,White,Factor VIII intron 22 inv,49.7,2,Placebo,Standard,2023-10-22,Emergency,Japan,SITE-014
PT-003411,XS-OD-0039,69,Male,Black or African American,HBB E6V (sickle),54.8,3,Active_Drug_High_Dose,Standard,2023-08-02,Standard,Spain,SITE-003
PT-003412,XS-OD-0039,20,Male,White,,64.7,2,Active_Drug,Standard,2023-08-29,Standard,Japan,SITE-024
PT-003413,XS-OD-0039,61,Male,White,Factor VIII intron 22 inv,31.9,4,Placebo,Standard,2023-09-02,Standard,Netherlands,SITE-010
PT-003414,XS-OD-0039,33,Male,White,F9 R338L,53.1,0,Active_Drug_High_Dose,Standard,2023-11-05,Standard,Japan,SITE-014
PT-003415,XS-OD-0039,28,Male,Black or African American,Factor VIII intron 22 inv,95.0,2,Active_Drug,Standard,2023-09-07,Standard,United Kingdom,SITE-009
PT-003416,XS-OD-0039,33,Male,Native Hawaiian or Other Pacific Islander,HBB E6V (sickle),53.3,1,Placebo,Standard,2023-08-05,Standard,Canada,SITE-016
PT-003417,XS-OD-0039,48,Male,Asian,HBB E6V (sickle),64.1,2,Active_Drug_High_Dose,Standard,2023-11-08,Standard,Germany,SITE-015
PT-003418,XS-OD-0039,38,Male,White,,62.3,3,Active_Drug,Standard,2023-08-03,Standard,Canada,SITE-014
PT-003419,XS-OD-0039,38,Male,White,,51.8,0,Placebo,Standard,2023-10-23,Standard,Netherlands,SITE-008
PT-003420,XS-OD-0039,2,Male,Black or African American,,83.1,0,Active_Drug_High_Dose,Standard,2023-07-14,Pediatric_Assent,France,SITE-021
PT-003421,XS-OD-0039,34,Male,White,Factor VIII intron 22 inv,32.0,1,Active_Drug,Standard,2023-08-18,Standard,Italy,SITE-013
PT-003422,XS-OD-0039,34,Male,White,Factor VIII intron 22 inv,30.5,2,Placebo,Standard,2023-08-21,Standard,Germany,SITE-007
PT-003423,XS-OD-0039,25,Male,White,,47.3,3,Active_Drug_High_Dose,Standard,2023-09-23,Standard,United Kingdom,SITE-015
PT-003424,XS-OD-0039,37,Male,White,HBB IVS-I-110 G>A,72.0,3,Active_Drug,Standard,2023-08-25,Standard,Germany,SITE-013
PT-003425,XS-OD-0039,18,Male,White,HBB E6V (sickle),56.7,2,Placebo,Standard,2023-07-22,Standard,United States,SITE-017
PT-003426,XS-OD-0039,49,Male,White,HBB IVS-I-110 G>A,55.3,3,Active_Drug_High_Dose,Standard,2023-10-05,Standard,Japan,SITE-020
PT-003427,XS-OD-0039,45,Female,White,HBB IVS-I-110 G>A,50.8,0,Active_Drug,Standard,2023-09-24,Standard,Italy,SITE-004
PT-003428,XS-OD-0039,29,Male,Asian,F9 R338L,89.3,3,Placebo,Standard,2023-08-28,Standard,Japan,SITE-023
PT-003429,XS-OD-0039,35,Female,White,,41.9,3,Active_Drug_High_Dose,Standard,2023-06-11,Standard,Canada,SITE-007
PT-003430,XS-OD-0039,56,Male,White,F9 R338L,46.0,1,Active_Drug,Standard,2023-06-13,Standard,Netherlands,SITE-005
PT-003431,XS-OD-0039,39,Male,Hispanic or Latino,,52.4,4,Placebo,Standard,2023-08-02,Standard,United States,SITE-010
PT-003432,XS-OD-0039,76,Male,Black or African American,Factor VIII intron 22 inv,28.0,0,Active_Drug_High_Dose,Standard,2023-10-22,Standard,Spain,SITE-013
PT-003433,XS-OD-0039,51,Male,White,Factor VIII intron 22 inv,84.5,2,Active_Drug,Standard,2023-10-24,Standard,Australia,SITE-023
PT-003434,XS-OD-0039,33,Male,White,Factor VIII intron 22 inv,28.7,2,Placebo,Standard,2023-06-24,Standard,France,SITE-024
PT-003435,XS-OD-0039,53,Male,White,HBB IVS-I-110 G>A,54.6,5,Active_Drug_High_Dose,Standard,2023-07-20,Standard,United States,SITE-025
PT-003436,XS-OD-0039,2,Male,Asian,Factor VIII intron 22 inv,32.8,1,Active_Drug,Standard,2023-05-29,Pediatric_Assent,United Kingdom,SITE-013
PT-003437,XS-OD-0039,18,Male,White,HBB IVS-I-110 G>A,64.1,2,Placebo,Standard,2023-11-07,Standard,Canada,SITE-002
PT-003438,XS-OD-0039,31,Male,White,,52.1,0,Active_Drug_High_Dose,Standard,2023-09-24,Standard,Netherlands,SITE-012
PT-003439,XS-OD-0039,75,Male,Hispanic or Latino,Factor VIII intron 22 inv,31.7,2,Active_Drug,Standard,2023-08-18,Standard,Australia,SITE-023
PT-003440,XS-OD-0039,21,Male,White,HBB E6V (sickle),95.0,0,Placebo,Standard,2023-09-18,Standard,Japan,SITE-025
PT-003441,XS-OD-0039,20,Male,White,HBB IVS-I-110 G>A,43.7,2,Active_Drug_High_Dose,Standard,2023-11-08,Standard,Spain,SITE-001
PT-003442,XS-OD-0039,38,Male,Asian,HBB E6V (sickle),58.7,3,Active_Drug,Standard,2023-09-11,Standard,Canada,SITE-024
PT-003443,XS-OD-0039,9,Male,Hispanic or Latino,F9 R338L,36.2,4,Placebo,Standard,2023-09-08,Pediatric_Assent,Australia,SITE-022
PT-003444,XS-OD-0039,3,Male,White,F9 R338L,64.0,4,Active_Drug_High_Dose,Standard,2023-07-04,Pediatric_Assent,France,SITE-018
PT-003445,XS-OD-0039,50,Male,Black or African American,F9 R338L,59.5,1,Active_Drug,Standard,2023-07-04,Standard,Australia,SITE-022
PT-003446,XS-OD-0039,68,Male,White,Factor VIII intron 22 inv,50.2,3,Placebo,Standard,2023-08-30,Standard,United Kingdom,SITE-023
PT-003447,XS-OD-0040,29,Male,White,Factor VIII intron 22 inv,40.5,1,Active_Drug,Standard,2021-11-11,Standard,Spain,SITE-002
PT-003448,XS-OD-0040,30,Male,White,Factor VIII intron 22 inv,21.3,1,Placebo,Standard,2021-08-30,Standard,Belgium,SITE-009
PT-003449,XS-OD-0040,44,Male,Hispanic or Latino,,47.4,4,Active_Drug,Standard,2021-10-04,Standard,Brazil,SITE-026
PT-003450,XS-OD-0040,6,Male,Hispanic or Latino,HBB E6V (sickle),80.5,1,Placebo,Standard,2021-10-27,Pediatric_Assent,United Kingdom,SITE-040
PT-003451,XS-OD-0040,60,Male,White,Factor VIII intron 22 inv,64.3,2,Active_Drug,Standard,2021-10-24,Standard,France,SITE-041
PT-003452,XS-OD-0040,37,Male,Hispanic or Latino,,79.9,2,Placebo,Standard,2021-09-26,Standard,Canada,SITE-024
PT-003453,XS-OD-0040,25,Male,Black or African American,HBB IVS-I-110 G>A,80.2,2,Active_Drug,Standard,2021-06-20,Standard,Switzerland,SITE-021
PT-003454,XS-OD-0040,18,Male,American Indian or Alaska Native,,46.5,2,Placebo,Standard,2021-09-16,Standard,United Kingdom,SITE-034
PT-003455,XS-OD-0040,24,Male,Asian,F9 R338L,47.5,4,Active_Drug,Standard,2021-09-13,Standard,Germany,SITE-022
PT-003456,XS-OD-0040,2,Male,White,HBB IVS-I-110 G>A,47.4,2,Placebo,Standard,2021-10-31,Pediatric_Assent,Sweden,SITE-038
PT-003457,XS-OD-0040,78,Male,Hispanic or Latino,HBB IVS-I-110 G>A,46.0,3,Active_Drug,Standard,2021-10-22,Standard,France,SITE-011
PT-003458,XS-OD-0040,56,Male,Native Hawaiian or Other Pacific Islander,F9 R338L,39.3,0,Placebo,Standard,2021-11-15,Standard,Brazil,SITE-013
PT-003459,XS-OD-0040,45,Male,White,Factor VIII intron 22 inv,64.1,2,Active_Drug,Standard,2021-07-13,Standard,Brazil,SITE-044
PT-003460,XS-OD-0040,78,Male,Hispanic or Latino,F9 R338L,74.3,3,Placebo,Standard,2021-09-03,Standard,Canada,SITE-032
PT-003461,XS-OD-0040,26,Male,White,HBB IVS-I-110 G>A,37.6,3,Active_Drug,Standard,2021-11-25,Standard,Switzerland,SITE-036
PT-003462,XS-OD-0040,38,Male,White,HBB E6V (sickle),42.3,3,Placebo,Standard,2021-11-30,Standard,Spain,SITE-003
PT-003463,XS-OD-0040,47,Male,Asian,,37.4,2,Active_Drug,Standard,2021-11-16,Standard,United Kingdom,SITE-029
PT-003464,XS-OD-0040,33,Male,White,HBB IVS-I-110 G>A,47.7,1,Placebo,Standard,2021-09-07,Standard,Brazil,SITE-005
PT-003465,XS-OD-0040,27,Male,Asian,HBB IVS-I-110 G>A,53.8,4,Active_Drug,Standard,2021-09-15,Standard,Canada,SITE-026
PT-003466,XS-OD-0040,38,Male,White,,10.0,2,Placebo,Standard,2021-11-03,Standard,Israel,SITE-023
PT-003467,XS-OD-0040,53,Male,White,,37.3,2,Active_Drug,Standard,2021-09-02,Emergency,Israel,SITE-033
PT-003468,XS-OD-0040,49,Male,White,HBB IVS-I-110 G>A,29.0,3,Placebo,Standard,2021-09-15,Standard,Israel,SITE-008
PT-003469,XS-OD-0040,32,Male,White,Factor VIII intron 22 inv,71.0,1,Active_Drug,Standard,2021-09-18,Standard,France,SITE-011
PT-003470,XS-OD-0040,33,Male,Black or African American,F9 R338L,29.9,1,Placebo,Standard,2021-09-08,Standard,Netherlands,SITE-034
PT-003471,XS-OD-0040,21,Male,White,Factor VIII intron 22 inv,70.1,1,Active_Drug,Standard,2021-08-07,Standard,Canada,SITE-024
PT-003472,XS-OD-0040,62,Male,White,HBB IVS-I-110 G>A,45.5,0,Placebo,Standard,2021-07-04,Standard,United Kingdom,SITE-020
PT-003473,XS-OD-0040,25,Male,White,,55.9,6,Active_Drug,Standard,2021-09-08,Standard,Japan,SITE-015
PT-003474,XS-OD-0040,36,Male,White,,59.6,2,Placebo,Standard,2021-08-11,Standard,Australia,SITE-031
PT-003475,XS-OD-0040,39,Male,Hispanic or Latino,HBB E6V (sickle),84.4,3,Active_Drug,Standard,2021-09-25,Standard,South Korea,SITE-012
PT-003476,XS-OD-0040,22,Male,White,,60.7,2,Placebo,Standard,2021-11-27,Standard,Denmark,SITE-021
PT-003477,XS-OD-0040,37,Male,White,HBB IVS-I-110 G>A,67.0,4,Active_Drug,Standard,2021-09-29,Standard,Austria,SITE-010
PT-003478,XS-OD-0040,36,Male,White,HBB IVS-I-110 G>A,60.1,2,Placebo,Standard,2021-08-26,Standard,Australia,SITE-030
PT-003479,XS-OD-0040,46,Female,White,,34.3,0,Active_Drug,Standard,2021-08-18,Standard,United Kingdom,SITE-028
PT-003480,XS-OD-0040,42,Male,Asian,,70.4,1,Placebo,Standard,2021-08-09,Standard,Canada,SITE-006
PT-003481,XS-OD-0040,56,Male,White,,65.1,2,Active_Drug,Standard,2021-07-03,Standard,Taiwan,SITE-005
PT-003482,XS-OD-0040,42,Male,White,,30.3,2,Placebo,Standard,2021-10-30,Standard,Norway,SITE-029
PT-003483,XS-OD-0040,37,Male,White,F9 R338L,58.0,3,Active_Drug,Standard,2021-07-11,Standard,Austria,SITE-021
PT-003484,XS-OD-0040,38,Female,White,HBB IVS-I-110 G>A,69.0,3,Placebo,Standard,2021-09-16,Standard,Norway,SITE-005
PT-003485,XS-OD-0040,38,Male,White,F9 R338L,75.7,4,Active_Drug,Standard,2021-09-26,Standard,Netherlands,SITE-037
PT-003486,XS-OD-0040,62,Male,White,HBB IVS-I-110 G>A,74.1,2,Placebo,Standard,2021-09-06,Standard,Japan,SITE-042
PT-003487,XS-OD-0040,39,Male,White,F9 R338L,66.3,2,Active_Drug,Standard,2021-08-31,Standard,Australia,SITE-008
PT-003488,XS-OD-0040,61,Male,Hispanic or Latino,HBB E6V (sickle),18.1,1,Placebo,Standard,2021-06-22,Standard,Australia,SITE-025
PT-003489,XS-OD-0040,23,Male,White,Factor VIII intron 22 inv,48.0,1,Active_Drug,Standard,2021-11-02,Compassionate,Netherlands,SITE-011
PT-003490,XS-OD-0040,54,Male,White,,47.5,3,Placebo,Standard,2021-07-29,Standard,Brazil,SITE-008
PT-003491,XS-OD-0040,28,Male,White,,86.9,3,Active_Drug,Standard,2021-10-23,Standard,Switzerland,SITE-038
PT-003492,XS-OD-0040,47,Male,Black or African American,,89.1,1,Placebo,Standard,2021-07-12,Standard,Austria,SITE-003
PT-003493,XS-OD-0040,8,Male,Native Hawaiian or Other Pacific Islander,HBB E6V (sickle),72.8,2,Active_Drug,Standard,2021-10-16,Pediatric_Assent,Denmark,SITE-036
PT-003494,XS-OD-0040,66,Male,White,,49.7,2,Placebo,Standard,2021-06-27,Standard,Canada,SITE-020
PT-003495,XS-OD-0040,48,Male,Asian,,72.6,1,Active_Drug,Standard,2021-09-29,Standard,Netherlands,SITE-006
PT-003496,XS-OD-0040,58,Male,Hispanic or Latino,HBB IVS-I-110 G>A,56.7,1,Placebo,Standard,2021-11-23,Standard,Belgium,SITE-005
PT-003497,XS-OD-0040,22,Male,White,,83.5,1,Active_Drug,Standard,2021-12-06,Standard,Taiwan,SITE-001
PT-003498,XS-OD-0040,68,Male,White,F9 R338L,60.2,3,Placebo,Standard,2021-08-27,Standard,United States,SITE-028
PT-003499,XS-OD-0040,30,Male,White,,74.7,5,Active_Drug,Standard,2021-10-08,Standard,Sweden,SITE-035
PT-003500,XS-OD-0040,21,Male,Asian,HBB E6V (sickle),62.8,2,Placebo,Standard,2021-09-27,Standard,Canada,SITE-030
PT-003501,XS-OD-0040,19,Male,Asian,HBB IVS-I-110 G>A,48.3,2,Active_Drug,Standard,2021-07-04,Standard,Switzerland,SITE-007
PT-003502,XS-OD-0040,31,Male,Hispanic or Latino,HBB E6V (sickle),61.0,3,Placebo,Standard,2021-08-04,Standard,United States,SITE-021
PT-003503,XS-OD-0040,55,Male,White,Factor VIII intron 22 inv,83.8,0,Active_Drug,Standard,2021-10-26,Emergency,United States,SITE-038
PT-003504,XS-OD-0040,14,Male,White,F9 R338L,15.3,3,Placebo,Standard,2021-10-21,Pediatric_Assent,Norway,SITE-027
PT-003505,XS-OD-0040,20,Male,White,Factor VIII intron 22 inv,60.0,2,Active_Drug,Standard,2021-11-07,Standard,Belgium,SITE-033
PT-003506,XS-OD-0040,44,Male,Hispanic or Latino,,77.4,4,Placebo,Standard,2021-11-15,Standard,Spain,SITE-009
PT-003507,XS-OD-0040,55,Male,Asian,,75.8,2,Active_Drug,Standard,2021-11-28,Standard,Netherlands,SITE-026
PT-003508,XS-OD-0040,57,Male,White,Factor VIII intron 22 inv,26.9,1,Placebo,Standard,2021-08-09,Standard,Norway,SITE-007
PT-003509,XS-OD-0040,43,Male,White,,29.9,1,Active_Drug,Standard,2021-07-30,Standard,Switzerland,SITE-035
PT-003510,XS-OD-0040,10,Male,White,,48.7,2,Placebo,Standard,2021-09-24,Pediatric_Assent,Belgium,SITE-038
PT-003511,XS-OD-0040,52,Male,White,,74.0,0,Active_Drug,Standard,2021-07-06,Standard,Brazil,SITE-044
PT-003512,XS-OD-0040,61,Male,White,,67.1,1,Placebo,Standard,2021-11-04,Standard,France,SITE-006
PT-003513,XS-OD-0040,25,Male,White,HBB IVS-I-110 G>A,37.6,5,Active_Drug,Standard,2021-10-03,Standard,France,SITE-019
PT-003514,XS-OD-0040,55,Male,White,F9 R338L,51.7,3,Placebo,Standard,2021-09-30,Standard,Norway,SITE-031
PT-003515,XS-OD-0040,15,Male,White,,84.4,3,Active_Drug,Standard,2021-06-25,Pediatric_Assent,Austria,SITE-014
PT-003516,XS-OD-0040,36,Female,White,,55.7,3,Placebo,Standard,2021-07-01,Standard,United States,SITE-021
PT-003517,XS-OD-0040,16,Male,White,F9 R338L,61.7,0,Active_Drug,Standard,2021-09-15,Pediatric_Assent,Spain,SITE-038
PT-003518,XS-OD-0040,37,Male,White,Factor VIII intron 22 inv,19.0,1,Placebo,Standard,2021-11-22,Standard,Italy,SITE-013
PT-003519,XS-OD-0040,26,Male,Asian,,56.1,1,Active_Drug,Standard,2021-09-04,Standard,Taiwan,SITE-043
PT-003520,XS-OD-0040,3,Male,White,,41.4,2,Placebo,Standard,2021-06-22,Pediatric_Assent,South Korea,SITE-016
PT-003521,XS-OD-0040,41,Male,White,HBB IVS-I-110 G>A,72.5,2,Active_Drug,Standard,2021-09-16,Standard,Taiwan,SITE-039
PT-003522,XS-OD-0040,37,Female,Asian,HBB E6V (sickle),63.2,2,Placebo,Standard,2021-08-18,Standard,Israel,SITE-027
PT-003523,XS-OD-0040,2,Male,White,HBB E6V (sickle),30.4,6,Active_Drug,Standard,2021-08-17,Pediatric_Assent,Brazil,SITE-007
PT-003524,XS-OD-0040,34,Male,Hispanic or Latino,HBB E6V (sickle),10.0,3,Placebo,Standard,2021-10-30,Standard,Italy,SITE-042
PT-003525,XS-OD-0040,43,Male,White,,52.6,1,Active_Drug,Standard,2021-07-02,Standard,Germany,SITE-012
PT-003526,XS-OD-0040,33,Male,White,HBB E6V (sickle),71.4,2,Placebo,Standard,2021-12-05,Standard,Belgium,SITE-022
PT-003527,XS-OD-0040,48,Male,White,HBB IVS-I-110 G>A,95.0,2,Active_Drug,Standard,2021-09-01,Standard,Sweden,SITE-038
PT-003528,XS-OD-0040,38,Male,White,,51.1,3,Placebo,Standard,2021-11-12,Standard,United Kingdom,SITE-024
PT-003529,XS-OD-0040,52,Male,White,,30.2,3,Active_Drug,Standard,2021-10-06,Standard,Italy,SITE-009
PT-003530,XS-OD-0040,69,Male,White,,10.0,1,Placebo,Standard,2021-10-27,Standard,Denmark,SITE-005
PT-003531,XS-OD-0040,2,Male,White,F9 R338L,42.0,2,Active_Drug,Standard,2021-07-07,Pediatric_Assent,Canada,SITE-032
PT-003532,XS-OD-0040,44,Male,White,HBB E6V (sickle),63.2,3,Placebo,Standard,2021-11-26,Standard,Norway,SITE-034
PT-003533,XS-OD-0040,43,Male,White,Factor VIII intron 22 inv,66.9,1,Active_Drug,Standard,2021-10-15,Standard,Brazil,SITE-042
PT-003534,XS-OD-0040,49,Male,Black or African American,,40.5,1,Placebo,Standard,2021-08-15,Standard,Denmark,SITE-008
PT-003535,XS-OD-0040,39,Male,Black or African American,Factor VIII intron 22 inv,72.2,1,Active_Drug,Standard,2021-11-10,Standard,United States,SITE-036
PT-003536,XS-OD-0040,43,Male,White,F9 R338L,58.6,3,Placebo,Standard,2021-10-13,Standard,United States,SITE-010
PT-003537,XS-OD-0040,37,Male,White,HBB E6V (sickle),77.9,4,Active_Drug,Standard,2021-10-24,Standard,Spain,SITE-014
PT-003538,XS-OD-0040,21,Male,White,,57.7,2,Placebo,Standard,2021-11-29,Standard,United States,SITE-036
PT-003539,XS-OD-0040,59,Male,White,Factor VIII intron 22 inv,25.3,4,Active_Drug,Standard,2021-06-20,Standard,Taiwan,SITE-022
PT-003540,XS-OD-0040,17,Male,Black or African American,HBB IVS-I-110 G>A,62.5,2,Placebo,Standard,2021-10-01,Pediatric_Assent,South Korea,SITE-021
PT-003541,XS-OD-0040,51,Male,White,HBB IVS-I-110 G>A,72.4,2,Active_Drug,Standard,2021-07-09,Standard,Denmark,SITE-037
PT-003542,XS-OD-0040,21,Male,Hispanic or Latino,Factor VIII intron 22 inv,56.0,3,Placebo,Standard,2021-06-18,Standard,Spain,SITE-019
PT-003543,XS-OD-0040,42,Female,Hispanic or Latino,HBB IVS-I-110 G>A,14.4,0,Active_Drug,Standard,2021-10-15,Standard,Netherlands,SITE-043
PT-003544,XS-OD-0040,44,Male,White,Factor VIII intron 22 inv,47.6,5,Placebo,Standard,2021-11-24,Standard,Sweden,SITE-044
PT-003545,XS-OD-0040,34,Male,White,HBB IVS-I-110 G>A,46.4,2,Active_Drug,Standard,2021-08-14,Standard,Germany,SITE-040
PT-003546,XS-OD-0040,22,Male,American Indian or Alaska Native,F9 R338L,72.5,1,Placebo,Standard,2021-11-06,Standard,Austria,SITE-044
PT-003547,XS-OD-0040,40,Male,Native Hawaiian or Other Pacific Islander,Factor VIII intron 22 inv,78.0,4,Active_Drug,Standard,2021-11-27,Standard,Canada,SITE-024
PT-003548,XS-OD-0040,4,Male,White,,35.9,2,Placebo,Standard,2021-10-29,Pediatric_Assent,Denmark,SITE-018
PT-003549,XS-OD-0040,22,Male,Hispanic or Latino,Factor VIII intron 22 inv,46.6,3,Active_Drug,Standard,2021-10-16,Standard,Australia,SITE-040
PT-003550,XS-OD-0040,60,Male,Asian,F9 R338L,35.1,2,Placebo,Standard,2021-07-15,Standard,Switzerland,SITE-010
PT-003551,XS-OD-0040,55,Male,White,F9 R338L,32.6,1,Active_Drug,Standard,2021-08-31,Standard,Germany,SITE-032
PT-003552,XS-OD-0040,62,Male,White,,52.2,1,Placebo,Standard,2021-09-27,Standard,Belgium,SITE-037
PT-003553,XS-OD-0040,21,Male,Asian,HBB IVS-I-110 G>A,48.6,2,Active_Drug,Standard,2021-10-03,Standard,Brazil,SITE-010
PT-003554,XS-OD-0040,48,Male,White,,42.9,2,Placebo,Standard,2021-10-13,Standard,Japan,SITE-017
PT-003555,XS-OD-0040,37,Male,White,F9 R338L,30.4,2,Active_Drug,Standard,2021-08-31,Standard,Australia,SITE-026
PT-003556,XS-OD-0040,62,Male,White,HBB IVS-I-110 G>A,42.9,1,Placebo,Standard,2021-10-27,Standard,South Korea,SITE-035
PT-003557,XS-OD-0040,56,Male,White,HBB E6V (sickle),54.7,0,Active_Drug,Standard,2021-08-30,Standard,France,SITE-037
PT-003558,XS-OD-0040,50,Male,White,Factor VIII intron 22 inv,43.5,1,Placebo,Standard,2021-11-10,Standard,United States,SITE-003
PT-003559,XS-OD-0040,24,Male,Black or African American,HBB IVS-I-110 G>A,75.5,1,Active_Drug,Standard,2021-09-11,Standard,Denmark,SITE-020
PT-003560,XS-OD-0040,28,Male,Hispanic or Latino,,42.1,1,Placebo,Standard,2021-11-10,Compassionate,Austria,SITE-027
PT-003561,XS-OD-0040,68,Male,White,,68.3,6,Active_Drug,Standard,2021-07-19,Compassionate,Switzerland,SITE-012
PT-003562,XS-OD-0040,53,Female,Hispanic or Latino,HBB IVS-I-110 G>A,49.8,1,Placebo,Standard,2021-09-11,Standard,Norway,SITE-016
PT-003563,XS-OD-0040,13,Male,Black or African American,HBB IVS-I-110 G>A,41.6,0,Active_Drug,Standard,2021-09-14,Pediatric_Assent,Germany,SITE-016
PT-003564,XS-OD-0040,22,Male,Black or African American,HBB IVS-I-110 G>A,55.8,4,Placebo,Standard,2021-07-13,Standard,Belgium,SITE-036
PT-003565,XS-OD-0040,60,Male,Hispanic or Latino,F9 R338L,36.5,4,Active_Drug,Standard,2021-07-02,Standard,United States,SITE-027
PT-003566,XS-OD-0040,41,Female,White,,67.9,1,Placebo,Standard,2021-07-12,Standard,Italy,SITE-016
PT-003567,XS-OD-0040,44,Male,Black or African American,Factor VIII intron 22 inv,31.3,0,Active_Drug,Standard,2021-11-20,Compassionate,Spain,SITE-007
PT-003568,XS-OD-0040,34,Male,Asian,,58.1,4,Placebo,Standard,2021-08-22,Standard,Netherlands,SITE-031
PT-003569,XS-OD-0040,21,Male,White,,82.9,2,Active_Drug,Standard,2021-11-18,Standard,United Kingdom,SITE-007
PT-003570,XS-OD-0040,49,Male,Asian,F9 R338L,26.2,2,Placebo,Standard,2021-09-05,Standard,Spain,SITE-003
PT-003571,XS-OD-0040,30,Male,Hispanic or Latino,HBB IVS-I-110 G>A,40.4,2,Active_Drug,Standard,2021-10-05,Standard,Canada,SITE-043
PT-003572,XS-OD-0040,45,Male,Hispanic or Latino,HBB E6V (sickle),85.0,0,Placebo,Standard,2021-08-25,Standard,South Korea,SITE-025
PT-003573,XS-OD-0040,43,Male,Asian,Factor VIII intron 22 inv,63.1,5,Active_Drug,Standard,2021-11-29,Standard,Germany,SITE-043
PT-003574,XS-OD-0040,45,Male,Two or More Races,HBB E6V (sickle),67.3,1,Placebo,Standard,2021-10-01,Standard,Brazil,SITE-006
PT-003575,XS-OD-0040,16,Male,Asian,,64.6,1,Active_Drug,Standard,2021-11-21,Pediatric_Assent,Switzerland,SITE-021
PT-003576,XS-OD-0040,41,Male,White,F9 R338L,69.1,2,Placebo,Standard,2021-09-10,Standard,Japan,SITE-022
PT-003577,XS-OD-0040,25,Male,White,HBB IVS-I-110 G>A,75.7,1,Active_Drug,Standard,2021-08-16,Standard,Netherlands,SITE-013
PT-003578,XS-OD-0040,66,Male,White,HBB IVS-I-110 G>A,95.0,1,Placebo,Standard,2021-08-06,Standard,Canada,SITE-040
PT-003579,XS-OD-0040,29,Female,Black or African American,HBB E6V (sickle),71.7,1,Active_Drug,Standard,2021-08-19,Standard,Norway,SITE-023
PT-003580,XS-OD-0040,45,Male,White,HBB IVS-I-110 G>A,63.9,1,Placebo,Standard,2021-08-12,Standard,United States,SITE-016
PT-003581,XS-OD-0040,43,Male,Asian,HBB E6V (sickle),27.4,1,Active_Drug,Standard,2021-08-13,Standard,Germany,SITE-029
PT-003582,XS-OD-0040,2,Male,Black or African American,,81.7,1,Placebo,Standard,2021-12-07,Pediatric_Assent,Taiwan,SITE-024
PT-003583,XS-OD-0040,15,Male,Native Hawaiian or Other Pacific Islander,,73.5,1,Active_Drug,Standard,2021-11-28,Pediatric_Assent,Switzerland,SITE-043
PT-003584,XS-OD-0040,66,Male,White,F9 R338L,63.7,2,Placebo,Standard,2021-10-18,Standard,Germany,SITE-036
PT-003585,XS-OD-0040,69,Male,White,Factor VIII intron 22 inv,63.6,2,Active_Drug,Standard,2021-06-20,Standard,Netherlands,SITE-026
PT-003586,XS-OD-0040,44,Male,White,Factor VIII intron 22 inv,58.5,2,Placebo,Standard,2021-09-22,Emergency,Austria,SITE-037
PT-003587,XS-OD-0040,33,Male,White,,32.0,3,Active_Drug,Standard,2021-08-29,Standard,Israel,SITE-013
PT-003588,XS-OD-0040,48,Male,White,F9 R338L,63.2,1,Placebo,Standard,2021-09-08,Standard,Italy,SITE-024
PT-003589,XS-OD-0040,42,Male,White,HBB IVS-I-110 G>A,60.9,1,Active_Drug,Standard,2021-09-12,Standard,Austria,SITE-037
PT-003590,XS-OD-0040,30,Male,Asian,,41.8,3,Placebo,Standard,2021-11-06,Standard,United States,SITE-033
PT-003591,XS-OD-0040,47,Male,White,F9 R338L,29.5,3,Active_Drug,Standard,2021-11-18,Standard,United Kingdom,SITE-030
PT-003592,XS-OD-0040,34,Male,Black or African American,,38.6,1,Placebo,Standard,2021-09-21,Standard,United Kingdom,SITE-021
PT-003593,XS-OD-0040,48,Male,Hispanic or Latino,Factor VIII intron 22 inv,27.8,0,Active_Drug,Standard,2021-06-17,Standard,Norway,SITE-004
PT-003594,XS-OD-0040,57,Male,White,HBB E6V (sickle),52.8,3,Placebo,Standard,2021-07-20,Standard,Italy,SITE-022
PT-003595,XS-OD-0040,19,Male,White,Factor VIII intron 22 inv,41.5,0,Active_Drug,Standard,2021-11-19,Standard,Germany,SITE-004
PT-003596,XS-OD-0040,6,Male,White,Factor VIII intron 22 inv,73.3,0,Placebo,Standard,2021-10-23,Pediatric_Assent,Taiwan,SITE-030
PT-003597,XS-OD-0040,58,Male,Hispanic or Latino,Factor VIII intron 22 inv,54.8,5,Active_Drug,Standard,2021-11-30,Standard,South Korea,SITE-038
PT-003598,XS-OD-0040,41,Male,Black or African American,,35.8,2,Placebo,Standard,2021-09-15,Standard,Netherlands,SITE-041
PT-003599,XS-OD-0040,58,Male,Asian,Factor VIII intron 22 inv,16.1,2,Active_Drug,Standard,2021-09-30,Standard,Italy,SITE-016
PT-003600,XS-OD-0040,52,Female,Asian,F9 R338L,53.5,2,Placebo,Standard,2021-08-07,Standard,Canada,SITE-019
PT-003601,XS-OD-0040,60,Male,Black or African American,,51.1,2,Active_Drug,Standard,2021-10-27,Standard,Norway,SITE-025
PT-003602,XS-OD-0040,40,Male,White,Factor VIII intron 22 inv,80.8,0,Placebo,Standard,2021-10-30,Standard,Japan,SITE-023
PT-003603,XS-OD-0040,22,Male,White,,59.8,2,Active_Drug,Standard,2021-07-07,Standard,Austria,SITE-038
PT-003604,XS-OD-0040,58,Male,White,,46.6,1,Placebo,Standard,2021-08-17,Standard,United States,SITE-007
PT-003605,XS-OD-0040,55,Male,White,HBB E6V (sickle),50.4,1,Active_Drug,Standard,2021-12-04,Standard,United States,SITE-011
PT-003606,XS-OD-0040,29,Male,White,,17.5,1,Placebo,Standard,2021-07-08,Standard,Canada,SITE-001
PT-003607,XS-OD-0040,36,Female,Asian,,63.6,1,Active_Drug,Standard,2021-11-22,Standard,United States,SITE-001
PT-003608,XS-OD-0040,32,Male,White,HBB E6V (sickle),26.6,5,Placebo,Standard,2021-11-16,Standard,Brazil,SITE-030
PT-003609,XS-OD-0040,29,Male,White,F9 R338L,69.8,1,Active_Drug,Standard,2021-10-03,Standard,Taiwan,SITE-023
PT-003610,XS-OD-0040,68,Male,Black or African American,HBB E6V (sickle),69.6,5,Placebo,Standard,2021-10-21,Standard,Canada,SITE-022
PT-003611,XS-OD-0040,17,Male,Black or African American,HBB IVS-I-110 G>A,10.0,5,Active_Drug,Standard,2021-06-13,Pediatric_Assent,Italy,SITE-022
PT-003612,XS-OD-0040,30,Male,White,,54.5,1,Placebo,Standard,2021-11-12,Standard,Denmark,SITE-038
PT-003613,XS-OD-0040,55,Male,Black or African American,,81.9,1,Active_Drug,Standard,2021-09-12,Standard,United Kingdom,SITE-034
PT-003614,XS-OD-0040,20,Male,White,Factor VIII intron 22 inv,47.6,3,Placebo,Standard,2021-08-26,Standard,Austria,SITE-026
PT-003615,XS-OD-0040,25,Male,Hispanic or Latino,F9 R338L,63.7,7,Active_Drug,Standard,2021-12-05,Standard,Australia,SITE-021
PT-003616,XS-OD-0040,56,Female,Asian,,59.8,1,Placebo,Standard,2021-07-02,Standard,Denmark,SITE-001
PT-003617,XS-OD-0040,14,Male,Hispanic or Latino,F9 R338L,59.9,2,Active_Drug,Standard,2021-10-26,Pediatric_Assent,Netherlands,SITE-008
PT-003618,XS-OD-0040,10,Male,Hispanic or Latino,HBB IVS-I-110 G>A,55.2,2,Placebo,Standard,2021-06-24,Pediatric_Assent,Norway,SITE-032
PT-003619,XS-OD-0040,48,Male,White,HBB E6V (sickle),60.1,3,Active_Drug,Standard,2021-06-23,Standard,Belgium,SITE-030
PT-003620,XS-OD-0040,16,Male,White,,71.2,3,Placebo,Standard,2021-07-01,Pediatric_Assent,United Kingdom,SITE-021
PT-003621,XS-OD-0040,73,Male,Asian,,35.2,0,Active_Drug,Standard,2021-10-23,Standard,Denmark,SITE-003
PT-003622,XS-OD-0040,30,Male,White,,59.6,2,Placebo,Standard,2021-08-12,Standard,Spain,SITE-040
PT-003623,XS-OD-0040,2,Male,White,HBB IVS-I-110 G>A,57.6,2,Active_Drug,Standard,2021-09-05,Pediatric_Assent,Israel,SITE-002
PT-003624,XS-OD-0040,26,Male,Hispanic or Latino,HBB E6V (sickle),48.7,7,Placebo,Standard,2021-10-09,Standard,United Kingdom,SITE-019
PT-003625,XS-OD-0040,38,Male,Black or African American,,36.4,5,Active_Drug,Standard,2021-10-01,Standard,Switzerland,SITE-003
PT-003626,XS-OD-0040,19,Male,White,,58.1,2,Placebo,Standard,2021-08-19,Standard,Brazil,SITE-032
PT-003627,XS-OD-0040,21,Male,Black or African American,,52.3,0,Active_Drug,Standard,2021-09-18,Standard,United Kingdom,SITE-019
PT-003628,XS-OD-0040,48,Male,Two or More Races,F9 R338L,86.6,3,Placebo,Standard,2021-11-18,Standard,Spain,SITE-017
PT-003629,XS-OD-0040,51,Male,White,F9 R338L,63.2,4,Active_Drug,Standard,2021-08-11,Standard,South Korea,SITE-029
PT-003630,XS-OD-0040,50,Male,White,F9 R338L,70.2,1,Placebo,Standard,2021-10-07,Standard,South Korea,SITE-020
PT-003631,XS-OD-0040,33,Male,White,HBB E6V (sickle),78.4,1,Active_Drug,Standard,2021-06-21,Standard,Japan,SITE-030
PT-003632,XS-OD-0040,22,Male,White,HBB IVS-I-110 G>A,84.3,2,Placebo,Standard,2021-08-28,Standard,Japan,SITE-009
PT-003633,XS-OD-0040,57,Male,Hispanic or Latino,,49.3,2,Active_Drug,Standard,2021-06-25,Standard,Norway,SITE-010
PT-003634,XS-OD-0040,28,Male,Asian,,62.7,1,Placebo,Standard,2021-06-18,Standard,France,SITE-043
PT-003635,XS-OD-0040,48,Male,White,Factor VIII intron 22 inv,65.5,4,Active_Drug,Standard,2021-08-05,Standard,Germany,SITE-024
PT-003636,XS-OD-0040,29,Male,White,Factor VIII intron 22 inv,61.0,2,Placebo,Standard,2021-08-09,Standard,Austria,SITE-005
PT-003637,XS-OD-0040,4,Male,White,Factor VIII intron 22 inv,65.0,2,Active_Drug,Standard,2021-09-01,Pediatric_Assent,Sweden,SITE-029
PT-003638,XS-OD-0040,62,Male,White,,46.2,5,Placebo,Standard,2021-07-25,Standard,United Kingdom,SITE-030
PT-003639,XS-OD-0040,36,Male,White,,49.5,0,Active_Drug,Standard,2021-09-28,Standard,Switzerland,SITE-022
PT-003640,XS-OD-0040,14,Male,White,HBB E6V (sickle),67.2,2,Placebo,Standard,2021-07-11,Pediatric_Assent,Germany,SITE-014
PT-003641,XS-OD-0040,39,Male,American Indian or Alaska Native,,31.2,2,Active_Drug,Standard,2021-06-24,Standard,United Kingdom,SITE-034
PT-003642,XS-OD-0040,68,Male,Hispanic or Latino,F9 R338L,67.4,2,Placebo,Standard,2021-11-06,Standard,Netherlands,SITE-026
PT-003643,XS-OD-0040,31,Male,White,HBB E6V (sickle),34.3,4,Active_Drug,Standard,2021-11-02,Standard,Netherlands,SITE-018
PT-003644,XS-OD-0040,51,Male,Asian,,52.1,1,Placebo,Standard,2021-11-14,Standard,Austria,SITE-011
PT-003645,XS-OD-0040,52,Male,Black or African American,F9 R338L,68.5,3,Active_Drug,Standard,2021-11-26,Standard,Italy,SITE-041
PT-003646,XS-OD-0040,39,Male,White,HBB E6V (sickle),59.0,4,Placebo,Standard,2021-10-14,Standard,Israel,SITE-044
PT-003647,XS-OD-0040,48,Male,Hispanic or Latino,F9 R338L,72.3,2,Active_Drug,Standard,2021-09-13,Emergency,Taiwan,SITE-026
PT-003648,XS-OD-0040,33,Male,Hispanic or Latino,HBB IVS-I-110 G>A,45.4,0,Placebo,Standard,2021-08-07,Standard,Australia,SITE-025
PT-003649,XS-OD-0040,57,Male,American Indian or Alaska Native,HBB E6V (sickle),57.6,0,Active_Drug,Standard,2021-07-26,Standard,Spain,SITE-044
PT-003650,XS-OD-0040,42,Male,White,HBB E6V (sickle),48.7,2,Placebo,Standard,2021-06-23,Standard,Sweden,SITE-014
PT-003651,XS-OD-0040,34,Male,White,F9 R338L,61.7,2,Active_Drug,Standard,2021-09-06,Standard,Spain,SITE-035
PT-003652,XS-OD-0040,45,Male,White,,62.8,1,Placebo,Standard,2021-10-02,Standard,Sweden,SITE-042
PT-003653,XS-OD-0041,40,Female,White,,49.9,4,Active_Drug,Standard,2025-01-14,Standard,United Kingdom,SITE-004
PT-003654,XS-OD-0041,8,Female,Asian,PDGFRA D842V,44.6,1,SOC,Standard,2025-01-28,Pediatric_Assent,Japan,SITE-010
PT-003655,XS-OD-0041,24,Female,White,PDGFRA D842V,15.9,2,Combination,Standard,2025-05-05,Standard,France,SITE-015
PT-003656,XS-OD-0041,18,Male,White,KIT D816V,39.8,5,Active_Drug,Standard,2025-01-27,Standard,Spain,SITE-010
PT-003657,XS-OD-0041,10,Male,Hispanic or Latino,BAP1 loss,54.0,2,SOC,Standard,2024-12-13,Pediatric_Assent,United States,SITE-001
PT-003658,XS-OD-0041,21,Female,American Indian or Alaska Native,PDGFRA D842V,59.3,1,Combination,Standard,2025-05-10,Standard,France,SITE-004
PT-003659,XS-OD-0041,45,Female,Black or African American,KIT D816V,39.2,3,Active_Drug,Standard,2024-12-17,Standard,Italy,SITE-001
PT-003660,XS-OD-0041,46,Male,White,KIT D816V,58.2,3,SOC,Standard,2025-03-11,Standard,Japan,SITE-006
PT-003661,XS-OD-0041,51,Male,Hispanic or Latino,IDH1 R132H,39.4,1,Combination,Standard,2025-04-05,Standard,Netherlands,SITE-002
PT-003662,XS-OD-0041,32,Female,White,PDGFRA D842V,53.6,4,Active_Drug,Standard,2025-04-06,Standard,Netherlands,SITE-002
PT-003663,XS-OD-0041,24,Male,Black or African American,KIT D816V,72.8,0,SOC,Standard,2025-01-01,Standard,Italy,SITE-012
PT-003664,XS-OD-0041,25,Male,Hispanic or Latino,KIT D816V,59.3,1,Combination,Standard,2025-02-13,Standard,Spain,SITE-015
PT-003665,XS-OD-0041,40,Female,White,BAP1 loss,40.1,3,Active_Drug,Standard,2024-11-22,Standard,Spain,SITE-013
PT-003666,XS-OD-0041,8,Male,White,PDGFRA D842V,57.4,1,SOC,Standard,2025-04-22,Pediatric_Assent,United Kingdom,SITE-003
PT-003667,XS-OD-0041,22,Female,Hispanic or Latino,BAP1 loss,70.8,3,Combination,Standard,2025-02-06,Standard,France,SITE-011
PT-003668,XS-OD-0041,14,Male,White,PDGFRA D842V,83.9,1,Active_Drug,Standard,2025-02-20,Pediatric_Assent,Spain,SITE-018
PT-003669,XS-OD-0041,54,Male,Hispanic or Latino,PDGFRA D842V,43.3,1,SOC,Standard,2025-05-01,Standard,Canada,SITE-003
PT-003670,XS-OD-0041,15,Female,White,IDH1 R132H,44.6,1,Combination,Standard,2025-03-16,Pediatric_Assent,Germany,SITE-006
PT-003671,XS-OD-0041,16,Male,White,PDGFRA D842V,66.4,3,Active_Drug,Standard,2025-02-13,Pediatric_Assent,Germany,SITE-013
PT-003672,XS-OD-0041,47,Female,American Indian or Alaska Native,KIT D816V,43.2,1,SOC,Standard,2025-02-19,Standard,Germany,SITE-018
PT-003673,XS-OD-0041,46,Female,White,KIT D816V,62.8,1,Combination,Standard,2025-05-03,Standard,Australia,SITE-004
PT-003674,XS-OD-0041,25,Male,White,BAP1 loss,29.8,2,Active_Drug,Standard,2025-02-16,Standard,Netherlands,SITE-013
PT-003675,XS-OD-0041,10,Male,Black or African American,PDGFRA D842V,44.7,4,SOC,Standard,2024-12-02,Pediatric_Assent,France,SITE-014
PT-003676,XS-OD-0041,28,Male,White,KIT D816V,95.0,0,Combination,Standard,2025-01-04,Standard,Italy,SITE-017
PT-003677,XS-OD-0041,54,Male,Hispanic or Latino,,27.1,0,Active_Drug,Standard,2025-03-26,Standard,France,SITE-008
PT-003678,XS-OD-0041,75,Female,White,,54.3,1,SOC,Standard,2025-04-05,Standard,Italy,SITE-010
PT-003679,XS-OD-0041,38,Male,Hispanic or Latino,BAP1 loss,53.0,0,Combination,Standard,2025-02-20,Standard,France,SITE-007
PT-003680,XS-OD-0041,60,Female,White,IDH1 R132H,31.9,4,Active_Drug,Standard,2025-05-10,Standard,United States,SITE-005
PT-003681,XS-OD-0041,23,Female,White,IDH1 R132H,72.1,3,SOC,Standard,2025-01-04,Standard,Italy,SITE-001
PT-003682,XS-OD-0041,66,Female,Black or African American,BAP1 loss,63.8,3,Combination,Standard,2025-01-12,Standard,United States,SITE-018
PT-003683,XS-OD-0041,63,Female,White,,66.8,0,Active_Drug,Standard,2025-02-13,Standard,United Kingdom,SITE-018
PT-003684,XS-OD-0041,22,Male,White,KIT D816V,34.0,3,SOC,Standard,2024-11-21,Standard,Australia,SITE-004
PT-003685,XS-OD-0041,85,Female,White,BAP1 loss,42.8,3,Combination,Standard,2024-12-28,Standard,Italy,SITE-012
PT-003686,XS-OD-0041,37,Male,White,,58.4,3,Active_Drug,Standard,2025-04-07,Emergency,Australia,SITE-012
PT-003687,XS-OD-0041,30,Male,White,,32.3,1,SOC,Standard,2025-01-23,Standard,France,SITE-012
PT-003688,XS-OD-0041,54,Male,White,BAP1 loss,56.7,2,Combination,Standard,2025-04-23,Standard,Italy,SITE-006
PT-003689,XS-OD-0041,19,Male,White,IDH1 R132H,49.7,4,Active_Drug,Standard,2025-04-17,Standard,Japan,SITE-012
PT-003690,XS-OD-0041,49,Male,Hispanic or Latino,IDH1 R132H,51.2,3,SOC,Standard,2025-02-11,Standard,Spain,SITE-017
PT-003691,XS-OD-0041,38,Male,Asian,IDH1 R132H,43.9,0,Combination,Standard,2025-03-04,Standard,Australia,SITE-014
PT-003692,XS-OD-0041,35,Male,Two or More Races,,34.8,3,Active_Drug,Standard,2025-03-17,Compassionate,Netherlands,SITE-007
PT-003693,XS-OD-0041,27,Male,White,KIT D816V,43.8,1,SOC,Standard,2025-03-29,Standard,United States,SITE-018
PT-003694,XS-OD-0041,32,Female,White,,53.3,2,Combination,Standard,2025-04-21,Standard,Japan,SITE-002
PT-003695,XS-OD-0041,66,Male,White,KIT D816V,60.2,0,Active_Drug,Standard,2024-12-12,Standard,United Kingdom,SITE-018
PT-003696,XS-OD-0041,3,Female,Hispanic or Latino,PDGFRA D842V,66.2,0,SOC,Standard,2025-02-25,Pediatric_Assent,Germany,SITE-009
PT-003697,XS-OD-0041,11,Male,White,BAP1 loss,43.4,1,Combination,Standard,2025-02-14,Pediatric_Assent,United Kingdom,SITE-005
PT-003698,XS-OD-0041,29,Female,White,,37.6,5,Active_Drug,Standard,2025-02-15,Standard,Canada,SITE-005
PT-003699,XS-OD-0041,40,Female,White,,40.3,2,SOC,Standard,2024-12-21,Standard,Canada,SITE-015
PT-003700,XS-OD-0041,28,Male,Asian,BAP1 loss,48.2,5,Combination,Standard,2025-03-06,Standard,Japan,SITE-003
PT-003701,XS-OD-0041,18,Female,Hispanic or Latino,BAP1 loss,38.2,3,Active_Drug,Standard,2025-02-05,Standard,United States,SITE-003
PT-003702,XS-OD-0041,17,Female,Hispanic or Latino,,84.8,0,SOC,Standard,2025-04-03,Pediatric_Assent,Australia,SITE-015
PT-003703,XS-OD-0041,37,Female,White,PDGFRA D842V,57.0,0,Combination,Standard,2025-02-20,Standard,Canada,SITE-007
PT-003704,XS-OD-0041,10,Male,White,PDGFRA D842V,26.6,3,Active_Drug,Standard,2025-03-22,Pediatric_Assent,Canada,SITE-002
PT-003705,XS-OD-0041,50,Female,Hispanic or Latino,PDGFRA D842V,32.6,3,SOC,Standard,2025-04-24,Standard,United Kingdom,SITE-018
PT-003706,XS-OD-0041,2,Female,Asian,PDGFRA D842V,68.8,3,Combination,Standard,2025-02-02,Pediatric_Assent,Australia,SITE-005
PT-003707,XS-OD-0041,31,Female,Hispanic or Latino,IDH1 R132H,46.5,1,Active_Drug,Standard,2025-05-11,Standard,Spain,SITE-014
PT-003708,XS-OD-0041,48,Male,White,KIT D816V,61.8,3,SOC,Standard,2024-12-02,Standard,Germany,SITE-013
PT-003709,XS-OD-0041,53,Female,Two or More Races,KIT D816V,66.9,2,Combination,Standard,2025-04-25,Standard,Italy,SITE-008
PT-003710,XS-OD-0041,66,Female,White,PDGFRA D842V,51.7,4,Active_Drug,Standard,2024-11-25,Standard,Netherlands,SITE-007
PT-003711,XS-OD-0041,56,Female,White,KIT D816V,69.6,6,SOC,Standard,2025-03-13,Standard,Italy,SITE-016
PT-003712,XS-OD-0041,42,Male,Hispanic or Latino,,75.4,2,Combination,Standard,2024-11-24,Compassionate,Netherlands,SITE-007
PT-003713,XS-OD-0041,41,Male,White,,63.9,1,Active_Drug,Standard,2025-03-25,Standard,France,SITE-007
PT-003714,XS-OD-0041,18,Female,White,IDH1 R132H,95.0,1,SOC,Standard,2025-03-25,Standard,United Kingdom,SITE-001
PT-003715,XS-OD-0041,56,Female,White,,46.4,1,Combination,Standard,2025-02-16,Standard,Canada,SITE-004
PT-003716,XS-OD-0041,26,Female,Hispanic or Latino,KIT D816V,47.0,0,Active_Drug,Standard,2025-03-23,Emergency,Canada,SITE-004
PT-003717,XS-OD-0041,34,Male,White,PDGFRA D842V,17.0,0,SOC,Standard,2025-02-02,Standard,Australia,SITE-017
PT-003718,XS-OD-0041,21,Female,Asian,BAP1 loss,23.8,3,Combination,Standard,2024-11-22,Standard,Japan,SITE-005
PT-003719,XS-OD-0041,39,Male,Asian,PDGFRA D842V,44.7,3,Active_Drug,Standard,2025-04-29,Standard,Italy,SITE-009
PT-003720,XS-OD-0041,45,Male,White,BAP1 loss,95.0,4,SOC,Standard,2025-05-01,Standard,Germany,SITE-009
PT-003721,XS-OD-0041,8,Male,White,,65.0,2,Combination,Standard,2025-01-12,Pediatric_Assent,Spain,SITE-013
PT-003722,XS-OD-0041,50,Male,Black or African American,BAP1 loss,67.3,1,Active_Drug,Standard,2025-02-16,Standard,Canada,SITE-002
PT-003723,XS-OD-0041,37,Male,White,,17.6,2,SOC,Standard,2025-04-08,Standard,Japan,SITE-012
PT-003724,XS-OD-0041,21,Male,Hispanic or Latino,,50.2,1,Combination,Standard,2025-01-18,Standard,United Kingdom,SITE-009
PT-003725,XS-OD-0041,37,Female,White,BAP1 loss,43.3,3,Active_Drug,Standard,2025-02-14,Standard,Canada,SITE-001
PT-003726,XS-OD-0041,68,Female,Black or African American,BAP1 loss,61.5,2,SOC,Standard,2025-02-26,Standard,Netherlands,SITE-007
PT-003727,XS-OD-0041,54,Female,American Indian or Alaska Native,PDGFRA D842V,52.7,2,Combination,Standard,2025-04-24,Standard,Germany,SITE-011
PT-003728,XS-OD-0041,29,Female,White,IDH1 R132H,36.8,2,Active_Drug,Standard,2025-04-10,Standard,Netherlands,SITE-009
PT-003729,XS-OD-0041,29,Female,Hispanic or Latino,,51.5,0,SOC,Standard,2025-02-13,Standard,France,SITE-013
PT-003730,XS-OD-0041,39,Female,Hispanic or Latino,PDGFRA D842V,56.1,0,Combination,Standard,2025-01-04,Standard,Italy,SITE-004
PT-003731,XS-OD-0041,30,Male,Black or African American,PDGFRA D842V,15.5,3,Active_Drug,Standard,2025-02-07,Standard,Australia,SITE-018
PT-003732,XS-OD-0041,18,Female,White,BAP1 loss,37.9,1,SOC,Standard,2025-03-14,Standard,Spain,SITE-008
PT-003733,XS-OD-0041,26,Female,White,IDH1 R132H,13.2,6,Combination,Standard,2025-01-14,Standard,United Kingdom,SITE-005
PT-003734,XS-OD-0041,43,Female,Black or African American,IDH1 R132H,54.4,1,Active_Drug,Standard,2025-03-14,Standard,Canada,SITE-012
PT-003735,XS-OD-0041,31,Male,Black or African American,,38.8,1,SOC,Standard,2025-04-19,Standard,Spain,SITE-012
PT-003736,XS-OD-0041,22,Female,White,,40.6,1,Combination,Standard,2025-05-01,Standard,Germany,SITE-008
PT-003737,XS-OD-0041,24,Female,Asian,KIT D816V,56.6,2,Active_Drug,Standard,2025-01-17,Standard,Italy,SITE-006
PT-003738,XS-OD-0041,7,Female,Asian,BAP1 loss,80.2,1,SOC,Standard,2025-03-22,Pediatric_Assent,Japan,SITE-011
PT-003739,XS-OD-0041,2,Female,American Indian or Alaska Native,PDGFRA D842V,72.5,1,Combination,Standard,2024-12-22,Pediatric_Assent,Canada,SITE-011
PT-003740,XS-OD-0041,57,Male,Asian,BAP1 loss,68.2,4,Active_Drug,Standard,2025-04-28,Standard,Spain,SITE-015
PT-003741,XS-OD-0041,41,Male,White,PDGFRA D842V,53.6,1,SOC,Standard,2025-02-02,Compassionate,United Kingdom,SITE-008
PT-003742,XS-OD-0041,27,Male,Black or African American,IDH1 R132H,68.0,2,Combination,Standard,2025-04-13,Standard,Japan,SITE-016
PT-003743,XS-OD-0041,10,Female,Asian,KIT D816V,83.6,0,Active_Drug,Standard,2025-04-24,Pediatric_Assent,United States,SITE-016
PT-003744,XS-OD-0041,23,Female,Hispanic or Latino,BAP1 loss,95.0,5,SOC,Standard,2025-02-14,Standard,United States,SITE-008
PT-003745,XS-OD-0041,65,Female,Asian,PDGFRA D842V,47.0,0,Combination,Standard,2025-03-24,Standard,United States,SITE-011
PT-003746,XS-OD-0041,16,Female,White,,34.2,1,Active_Drug,Standard,2024-12-09,Pediatric_Assent,United Kingdom,SITE-018
PT-003747,XS-OD-0041,2,Male,White,PDGFRA D842V,34.8,2,SOC,Standard,2025-03-10,Pediatric_Assent,France,SITE-017
PT-003748,XS-OD-0041,53,Male,White,KIT D816V,64.0,2,Combination,Standard,2025-01-30,Standard,Italy,SITE-004
PT-003749,XS-OD-0041,64,Male,Black or African American,,16.2,1,Active_Drug,Standard,2025-03-28,Standard,Spain,SITE-010
PT-003750,XS-OD-0041,39,Male,White,BAP1 loss,42.6,2,SOC,Standard,2025-01-27,Standard,Germany,SITE-008
PT-003751,XS-OD-0041,45,Male,White,KIT D816V,64.7,2,Combination,Standard,2024-12-04,Standard,Japan,SITE-011
PT-003752,XS-OD-0041,66,Male,White,IDH1 R132H,53.5,3,Active_Drug,Standard,2025-02-03,Standard,Italy,SITE-006
PT-003753,XS-OD-0041,23,Male,White,PDGFRA D842V,43.3,2,SOC,Standard,2025-02-23,Standard,Italy,SITE-007
PT-003754,XS-OD-0041,44,Female,White,,48.5,1,Combination,Standard,2024-11-30,Standard,Japan,SITE-015
PT-003755,XS-OD-0041,51,Male,Black or African American,,55.3,1,Active_Drug,Standard,2025-04-24,Standard,Germany,SITE-008
PT-003756,XS-OD-0041,60,Female,White,,60.8,1,SOC,Standard,2025-02-17,Standard,France,SITE-003
PT-003757,XS-OD-0041,34,Female,Black or African American,KIT D816V,40.5,6,Combination,Standard,2024-11-22,Standard,Australia,SITE-003
PT-003758,XS-OD-0042,37,Female,Black or African American,KIT D816V,32.3,2,Active_Drug,Standard,2022-02-24,Compassionate,Sweden,SITE-009
PT-003759,XS-OD-0042,27,Female,White,BAP1 loss,48.2,4,Placebo,Standard,2022-03-10,Standard,France,SITE-022
PT-003760,XS-OD-0042,2,Male,Black or African American,PDGFRA D842V,54.8,5,Active_Drug,Standard,2022-05-26,Pediatric_Assent,Sweden,SITE-016
PT-003761,XS-OD-0042,19,Female,Asian,,83.5,2,Placebo,Standard,2022-01-31,Standard,Switzerland,SITE-056
PT-003762,XS-OD-0042,29,Female,Black or African American,IDH1 R132H,68.4,0,Active_Drug,Standard,2022-01-20,Standard,Japan,SITE-033
PT-003763,XS-OD-0042,17,Female,Hispanic or Latino,BAP1 loss,71.8,2,Placebo,Standard,2022-01-09,Pediatric_Assent,Sweden,SITE-008
PT-003764,XS-OD-0042,42,Female,White,BAP1 loss,48.3,3,Active_Drug,Standard,2022-06-24,Standard,Norway,SITE-016
PT-003765,XS-OD-0042,58,Female,Two or More Races,PDGFRA D842V,67.0,2,Placebo,Standard,2022-05-20,Emergency,United States,SITE-045
PT-003766,XS-OD-0042,58,Female,White,,46.8,2,Active_Drug,Standard,2022-03-24,Standard,Taiwan,SITE-025
PT-003767,XS-OD-0042,33,Female,White,PDGFRA D842V,64.8,2,Placebo,Standard,2022-06-10,Standard,Italy,SITE-019
PT-003768,XS-OD-0042,55,Male,White,IDH1 R132H,60.3,3,Active_Drug,Standard,2022-02-05,Standard,Germany,SITE-015
PT-003769,XS-OD-0042,58,Male,White,KIT D816V,57.6,3,Placebo,Standard,2021-12-30,Standard,United Kingdom,SITE-013
PT-003770,XS-OD-0042,52,Male,Asian,IDH1 R132H,50.1,2,Active_Drug,Standard,2022-05-29,Standard,United States,SITE-026
PT-003771,XS-OD-0042,26,Female,White,,52.3,2,Placebo,Standard,2022-04-11,Standard,South Korea,SITE-055
PT-003772,XS-OD-0042,46,Female,White,PDGFRA D842V,86.5,3,Active_Drug,Standard,2022-05-03,Standard,Norway,SITE-001
PT-003773,XS-OD-0042,40,Female,Hispanic or Latino,,75.2,0,Placebo,Standard,2022-05-15,Standard,Germany,SITE-008
PT-003774,XS-OD-0042,11,Female,Black or African American,PDGFRA D842V,51.9,5,Active_Drug,Standard,2022-04-30,Pediatric_Assent,Sweden,SITE-006
PT-003775,XS-OD-0042,53,Intersex,White,,44.6,3,Placebo,Standard,2022-01-17,Standard,Belgium,SITE-028
PT-003776,XS-OD-0042,28,Female,White,PDGFRA D842V,62.3,3,Active_Drug,Standard,2022-05-21,Standard,Netherlands,SITE-057
PT-003777,XS-OD-0042,56,Male,White,,25.7,2,Placebo,Standard,2022-04-03,Standard,Sweden,SITE-031
PT-003778,XS-OD-0042,19,Male,White,,74.6,3,Active_Drug,Standard,2022-05-16,Standard,South Korea,SITE-035
PT-003779,XS-OD-0042,10,Male,White,PDGFRA D842V,95.0,1,Placebo,Standard,2022-03-09,Pediatric_Assent,Israel,SITE-004
PT-003780,XS-OD-0042,2,Female,Two or More Races,BAP1 loss,89.0,1,Active_Drug,Standard,2022-01-28,Pediatric_Assent,Japan,SITE-007
PT-003781,XS-OD-0042,43,Male,White,BAP1 loss,47.9,2,Placebo,Standard,2022-01-27,Standard,Norway,SITE-014
PT-003782,XS-OD-0042,57,Male,Hispanic or Latino,KIT D816V,38.9,2,Active_Drug,Standard,2022-03-10,Standard,Netherlands,SITE-019
PT-003783,XS-OD-0042,59,Male,White,BAP1 loss,59.0,2,Placebo,Standard,2022-04-05,Standard,Australia,SITE-038
PT-003784,XS-OD-0042,42,Male,Asian,PDGFRA D842V,39.6,1,Active_Drug,Standard,2022-05-05,Standard,Taiwan,SITE-057
PT-003785,XS-OD-0042,60,Male,Black or African American,,76.2,5,Placebo,Standard,2022-03-02,Standard,Denmark,SITE-036
PT-003786,XS-OD-0042,33,Female,White,KIT D816V,43.1,1,Active_Drug,Standard,2022-03-23,Standard,United Kingdom,SITE-001
PT-003787,XS-OD-0042,53,Female,Black or African American,BAP1 loss,76.3,2,Placebo,Standard,2022-06-05,Standard,Austria,SITE-004
PT-003788,XS-OD-0042,29,Male,Asian,,71.3,4,Active_Drug,Standard,2022-03-08,Standard,Germany,SITE-037
PT-003789,XS-OD-0042,69,Male,White,,43.9,3,Placebo,Standard,2022-01-21,Standard,Brazil,SITE-052
PT-003790,XS-OD-0042,38,Male,White,,50.2,4,Active_Drug,Standard,2022-05-16,Standard,Denmark,SITE-044
PT-003791,XS-OD-0042,41,Male,Hispanic or Latino,,65.8,2,Placebo,Standard,2022-01-28,Standard,South Korea,SITE-008
PT-003792,XS-OD-0042,24,Female,White,KIT D816V,62.3,1,Active_Drug,Standard,2022-04-27,Standard,Switzerland,SITE-028
PT-003793,XS-OD-0042,40,Female,White,IDH1 R132H,60.7,2,Placebo,Standard,2022-06-21,Standard,South Korea,SITE-042
PT-003794,XS-OD-0042,18,Male,White,,63.8,5,Active_Drug,Standard,2022-03-12,Standard,Norway,SITE-055
PT-003795,XS-OD-0042,28,Male,Hispanic or Latino,BAP1 loss,57.9,3,Placebo,Standard,2021-12-30,Standard,Spain,SITE-022
PT-003796,XS-OD-0042,36,Male,Asian,IDH1 R132H,48.2,3,Active_Drug,Standard,2022-02-06,Standard,Italy,SITE-056
PT-003797,XS-OD-0042,48,Male,Black or African American,KIT D816V,46.7,1,Placebo,Standard,2022-04-26,Standard,Spain,SITE-033
PT-003798,XS-OD-0042,31,Female,White,KIT D816V,49.3,2,Active_Drug,Standard,2022-05-31,Standard,Canada,SITE-002
PT-003799,XS-OD-0042,22,Female,American Indian or Alaska Native,KIT D816V,60.1,2,Placebo,Standard,2022-01-18,Standard,Austria,SITE-037
PT-003800,XS-OD-0042,16,Female,Hispanic or Latino,BAP1 loss,48.2,3,Active_Drug,Standard,2022-01-07,Pediatric_Assent,Germany,SITE-015
PT-003801,XS-OD-0042,61,Female,White,PDGFRA D842V,65.2,1,Placebo,Standard,2022-05-07,Standard,Switzerland,SITE-015
PT-003802,XS-OD-0042,4,Female,White,PDGFRA D842V,35.3,3,Active_Drug,Standard,2022-05-28,Pediatric_Assent,Italy,SITE-010
PT-003803,XS-OD-0042,53,Female,Hispanic or Latino,IDH1 R132H,34.6,3,Placebo,Standard,2022-02-02,Standard,Austria,SITE-004
PT-003804,XS-OD-0042,37,Male,Hispanic or Latino,BAP1 loss,40.0,2,Active_Drug,Standard,2022-01-26,Standard,United Kingdom,SITE-013
PT-003805,XS-OD-0042,42,Female,Hispanic or Latino,PDGFRA D842V,73.5,2,Placebo,Standard,2022-03-05,Standard,Italy,SITE-002
PT-003806,XS-OD-0042,17,Male,Asian,KIT D816V,59.2,1,Active_Drug,Standard,2022-05-10,Pediatric_Assent,Brazil,SITE-018
PT-003807,XS-OD-0042,15,Female,Asian,,57.5,2,Placebo,Standard,2022-05-06,Pediatric_Assent,Taiwan,SITE-038
PT-003808,XS-OD-0042,72,Female,Hispanic or Latino,BAP1 loss,90.2,0,Active_Drug,Standard,2022-01-29,Standard,Belgium,SITE-031
PT-003809,XS-OD-0042,52,Male,White,KIT D816V,59.2,1,Placebo,Standard,2022-05-11,Standard,Canada,SITE-011
PT-003810,XS-OD-0042,44,Male,White,,24.6,1,Active_Drug,Standard,2022-05-01,Standard,South Korea,SITE-004
PT-003811,XS-OD-0042,47,Female,White,,46.1,1,Placebo,Standard,2022-03-21,Standard,Sweden,SITE-037
PT-003812,XS-OD-0042,83,Male,Hispanic or Latino,,72.6,2,Active_Drug,Standard,2022-06-18,Standard,Israel,SITE-048
PT-003813,XS-OD-0042,24,Male,Hispanic or Latino,PDGFRA D842V,69.1,3,Placebo,Standard,2022-05-10,Standard,Belgium,SITE-054
PT-003814,XS-OD-0042,49,Female,White,BAP1 loss,33.1,2,Active_Drug,Standard,2022-02-19,Standard,Germany,SITE-026
PT-003815,XS-OD-0042,59,Female,Black or African American,KIT D816V,61.7,5,Placebo,Standard,2022-04-21,Standard,Taiwan,SITE-029
PT-003816,XS-OD-0042,25,Female,White,,63.0,1,Active_Drug,Standard,2022-05-04,Standard,Netherlands,SITE-017
PT-003817,XS-OD-0042,46,Male,White,,63.9,2,Placebo,Standard,2022-03-03,Standard,Austria,SITE-057
PT-003818,XS-OD-0042,40,Male,White,PDGFRA D842V,81.0,3,Active_Drug,Standard,2022-06-17,Standard,Spain,SITE-027
PT-003819,XS-OD-0042,44,Female,White,KIT D816V,67.1,4,Placebo,Standard,2022-04-21,Standard,South Korea,SITE-029
PT-003820,XS-OD-0042,58,Male,Asian,,77.8,0,Active_Drug,Standard,2022-01-26,Standard,Spain,SITE-040
PT-003821,XS-OD-0042,57,Female,Hispanic or Latino,PDGFRA D842V,50.0,4,Placebo,Standard,2022-05-06,Standard,Brazil,SITE-011
PT-003822,XS-OD-0042,31,Male,Asian,BAP1 loss,66.6,2,Active_Drug,Standard,2022-03-01,Standard,Austria,SITE-051
PT-003823,XS-OD-0042,2,Male,Hispanic or Latino,BAP1 loss,56.3,5,Placebo,Standard,2022-03-12,Pediatric_Assent,Netherlands,SITE-037
PT-003824,XS-OD-0042,36,Female,White,PDGFRA D842V,63.3,3,Active_Drug,Standard,2022-03-02,Standard,Italy,SITE-009
PT-003825,XS-OD-0042,50,Female,White,PDGFRA D842V,85.0,2,Placebo,Standard,2021-12-28,Standard,Japan,SITE-014
PT-003826,XS-OD-0042,38,Male,Hispanic or Latino,,38.7,0,Active_Drug,Standard,2022-01-18,Standard,Austria,SITE-028
PT-003827,XS-OD-0042,30,Male,Hispanic or Latino,,34.2,1,Placebo,Standard,2022-03-03,Standard,Italy,SITE-031
PT-003828,XS-OD-0042,37,Female,Black or African American,BAP1 loss,60.4,3,Active_Drug,Standard,2022-05-21,Standard,Denmark,SITE-049
PT-003829,XS-OD-0042,44,Male,Asian,,69.0,0,Placebo,Standard,2022-02-08,Standard,United States,SITE-051
PT-003830,XS-OD-0042,50,Female,White,KIT D816V,68.9,3,Active_Drug,Standard,2022-03-29,Emergency,Taiwan,SITE-045
PT-003831,XS-OD-0042,24,Female,White,PDGFRA D842V,45.1,3,Placebo,Standard,2022-04-26,Standard,Sweden,SITE-034
PT-003832,XS-OD-0042,13,Female,Hispanic or Latino,,55.6,1,Active_Drug,Standard,2022-02-15,Pediatric_Assent,Sweden,SITE-006
PT-003833,XS-OD-0042,40,Male,White,,45.6,1,Placebo,Standard,2022-02-04,Standard,Austria,SITE-030
PT-003834,XS-OD-0042,29,Male,Asian,KIT D816V,69.8,3,Active_Drug,Standard,2022-04-20,Standard,Japan,SITE-023
PT-003835,XS-OD-0042,18,Female,White,,38.4,1,Placebo,Standard,2022-05-06,Standard,France,SITE-005
PT-003836,XS-OD-0042,22,Male,Asian,PDGFRA D842V,36.1,1,Active_Drug,Standard,2022-06-22,Standard,Canada,SITE-005
PT-003837,XS-OD-0042,42,Male,White,IDH1 R132H,67.9,0,Placebo,Standard,2022-02-04,Standard,Italy,SITE-054
PT-003838,XS-OD-0042,57,Male,Hispanic or Latino,IDH1 R132H,53.0,4,Active_Drug,Standard,2022-04-15,Standard,Canada,SITE-001
PT-003839,XS-OD-0042,40,Male,White,KIT D816V,31.1,7,Placebo,Standard,2022-04-16,Standard,Norway,SITE-043
PT-003840,XS-OD-0042,59,Female,Hispanic or Latino,IDH1 R132H,22.8,0,Active_Drug,Standard,2022-03-28,Emergency,Australia,SITE-031
PT-003841,XS-OD-0042,15,Male,White,,57.8,0,Placebo,Standard,2022-02-22,Pediatric_Assent,France,SITE-001
PT-003842,XS-OD-0042,51,Female,White,,39.1,2,Active_Drug,Standard,2022-05-08,Standard,Canada,SITE-035
PT-003843,XS-OD-0042,45,Female,Black or African American,BAP1 loss,45.5,2,Placebo,Standard,2022-03-08,Standard,Germany,SITE-015
PT-003844,XS-OD-0042,35,Male,White,PDGFRA D842V,40.0,2,Active_Drug,Standard,2022-06-11,Standard,Sweden,SITE-007
PT-003845,XS-OD-0042,35,Male,White,,54.8,2,Placebo,Standard,2022-05-08,Standard,Canada,SITE-031
PT-003846,XS-OD-0042,56,Male,Asian,IDH1 R132H,56.0,0,Active_Drug,Standard,2022-02-17,Standard,Belgium,SITE-007
PT-003847,XS-OD-0042,36,Female,Black or African American,,69.9,4,Placebo,Standard,2022-06-16,Standard,United Kingdom,SITE-002
PT-003848,XS-OD-0042,43,Male,Hispanic or Latino,KIT D816V,33.7,1,Active_Drug,Standard,2022-03-01,Standard,Australia,SITE-001
PT-003849,XS-OD-0042,38,Male,Black or African American,,51.5,4,Placebo,Standard,2022-03-27,Compassionate,Belgium,SITE-056
PT-003850,XS-OD-0042,42,Female,White,PDGFRA D842V,69.3,0,Active_Drug,Standard,2022-05-07,Standard,Canada,SITE-048
PT-003851,XS-OD-0042,22,Male,White,KIT D816V,33.0,2,Placebo,Standard,2022-01-05,Standard,Canada,SITE-046
PT-003852,XS-OD-0042,72,Male,Hispanic or Latino,,38.8,3,Active_Drug,Standard,2022-03-17,Standard,Japan,SITE-021
PT-003853,XS-OD-0042,23,Male,White,IDH1 R132H,86.1,1,Placebo,Standard,2022-04-29,Standard,United Kingdom,SITE-008
PT-003854,XS-OD-0042,39,Intersex,White,,59.5,1,Active_Drug,Standard,2022-02-26,Standard,Germany,SITE-005
PT-003855,XS-OD-0042,11,Male,Asian,BAP1 loss,45.4,1,Placebo,Standard,2022-02-23,Pediatric_Assent,Germany,SITE-045
PT-003856,XS-OD-0042,46,Female,White,KIT D816V,45.4,6,Active_Drug,Standard,2022-04-04,Standard,Canada,SITE-016
PT-003857,XS-OD-0042,88,Male,White,,34.8,1,Placebo,Standard,2022-04-14,Standard,Spain,SITE-028
PT-003858,XS-OD-0042,31,Female,Hispanic or Latino,PDGFRA D842V,73.5,1,Active_Drug,Standard,2022-01-15,Standard,United Kingdom,SITE-054
PT-003859,XS-OD-0042,52,Female,White,KIT D816V,68.1,2,Placebo,Standard,2022-01-19,Standard,United Kingdom,SITE-001
PT-003860,XS-OD-0042,39,Male,White,,11.8,3,Active_Drug,Standard,2022-05-16,Standard,France,SITE-010
PT-003861,XS-OD-0042,45,Male,Asian,,79.3,2,Placebo,Standard,2022-04-21,Standard,Japan,SITE-046
PT-003862,XS-OD-0042,35,Male,Hispanic or Latino,KIT D816V,90.5,8,Active_Drug,Standard,2022-06-11,Standard,Germany,SITE-054
PT-003863,XS-OD-0042,32,Male,Asian,BAP1 loss,61.5,0,Placebo,Standard,2022-01-19,Standard,Austria,SITE-020
PT-003864,XS-OD-0042,78,Male,White,PDGFRA D842V,19.8,0,Active_Drug,Standard,2022-05-27,Standard,Austria,SITE-057
PT-003865,XS-OD-0042,37,Female,Asian,BAP1 loss,36.8,2,Placebo,Standard,2022-04-09,Standard,Australia,SITE-054
PT-003866,XS-OD-0042,35,Female,Asian,IDH1 R132H,74.2,3,Active_Drug,Standard,2022-05-03,Standard,Denmark,SITE-040
PT-003867,XS-OD-0042,12,Female,White,BAP1 loss,36.1,2,Placebo,Standard,2022-04-15,Pediatric_Assent,Norway,SITE-023
PT-003868,XS-OD-0042,22,Female,Asian,,73.2,1,Active_Drug,Standard,2022-01-12,Emergency,Sweden,SITE-050
PT-003869,XS-OD-0042,30,Female,White,BAP1 loss,54.1,1,Placebo,Standard,2022-01-14,Emergency,Switzerland,SITE-047
PT-003870,XS-OD-0042,48,Female,White,BAP1 loss,59.1,2,Active_Drug,Standard,2022-02-22,Standard,Norway,SITE-040
PT-003871,XS-OD-0042,39,Female,White,,63.1,1,Placebo,Standard,2022-01-28,Standard,Norway,SITE-009
PT-003872,XS-OD-0042,38,Male,Black or African American,KIT D816V,50.1,2,Active_Drug,Standard,2022-01-04,Standard,Spain,SITE-031
PT-003873,XS-OD-0042,43,Female,Hispanic or Latino,,53.2,2,Placebo,Standard,2022-03-27,Standard,South Korea,SITE-054
PT-003874,XS-OD-0042,62,Female,White,,51.1,3,Active_Drug,Standard,2022-03-01,Standard,Austria,SITE-051
PT-003875,XS-OD-0042,38,Male,Black or African American,PDGFRA D842V,58.8,3,Placebo,Standard,2022-03-01,Standard,France,SITE-017
PT-003876,XS-OD-0042,31,Female,White,,53.9,0,Active_Drug,Standard,2022-02-14,Standard,Netherlands,SITE-028
PT-003877,XS-OD-0042,18,Female,Black or African American,KIT D816V,44.8,3,Placebo,Standard,2022-03-25,Standard,Norway,SITE-047
PT-003878,XS-OD-0042,22,Male,White,,76.0,1,Active_Drug,Standard,2022-02-23,Standard,Israel,SITE-026
PT-003879,XS-OD-0042,59,Male,White,,43.9,2,Placebo,Standard,2022-05-03,Standard,Belgium,SITE-045
PT-003880,XS-OD-0042,48,Male,White,KIT D816V,51.0,0,Active_Drug,Standard,2022-06-18,Standard,United States,SITE-005
PT-003881,XS-OD-0042,58,Female,Hispanic or Latino,PDGFRA D842V,42.3,1,Placebo,Standard,2022-06-05,Emergency,Spain,SITE-025
PT-003882,XS-OD-0042,8,Female,White,BAP1 loss,52.4,1,Active_Drug,Standard,2022-03-11,Pediatric_Assent,Switzerland,SITE-010
PT-003883,XS-OD-0042,25,Female,White,IDH1 R132H,37.0,1,Placebo,Standard,2022-01-01,Standard,Norway,SITE-035
PT-003884,XS-OD-0042,2,Intersex,Black or African American,BAP1 loss,34.6,2,Active_Drug,Standard,2022-03-31,Pediatric_Assent,Norway,SITE-001
PT-003885,XS-OD-0042,50,Female,Asian,,53.2,0,Placebo,Standard,2022-03-29,Standard,Taiwan,SITE-048
PT-003886,XS-OD-0042,31,Male,White,,51.5,2,Active_Drug,Standard,2022-03-18,Standard,Australia,SITE-049
PT-003887,XS-OD-0042,45,Female,White,,38.9,4,Placebo,Standard,2021-12-28,Standard,Austria,SITE-040
PT-003888,XS-OD-0042,75,Female,Black or African American,KIT D816V,61.0,0,Active_Drug,Standard,2022-01-16,Emergency,South Korea,SITE-003
PT-003889,XS-OD-0042,33,Male,White,KIT D816V,60.5,1,Placebo,Standard,2022-06-09,Standard,Austria,SITE-054
PT-003890,XS-OD-0042,40,Female,White,PDGFRA D842V,45.7,1,Active_Drug,Standard,2022-02-07,Standard,Belgium,SITE-024
PT-003891,XS-OD-0042,48,Male,Black or African American,PDGFRA D842V,74.4,2,Placebo,Standard,2022-01-12,Standard,United Kingdom,SITE-022
PT-003892,XS-OD-0042,8,Male,Asian,BAP1 loss,52.0,1,Active_Drug,Standard,2022-05-04,Pediatric_Assent,Switzerland,SITE-055
PT-003893,XS-OD-0042,18,Female,White,KIT D816V,64.3,1,Placebo,Standard,2022-01-11,Standard,Australia,SITE-054
PT-003894,XS-OD-0042,41,Male,Hispanic or Latino,IDH1 R132H,79.0,3,Active_Drug,Standard,2022-02-06,Standard,Spain,SITE-052
PT-003895,XS-OD-0042,41,Female,White,BAP1 loss,81.0,2,Placebo,Standard,2022-03-24,Standard,Japan,SITE-012
PT-003896,XS-OD-0042,33,Male,Black or African American,BAP1 loss,30.3,2,Active_Drug,Standard,2022-02-25,Standard,Italy,SITE-034
PT-003897,XS-OD-0042,68,Male,Black or African American,BAP1 loss,77.9,2,Placebo,Standard,2021-12-29,Standard,Israel,SITE-015
PT-003898,XS-OD-0042,57,Female,White,,53.1,2,Active_Drug,Standard,2022-06-09,Standard,Spain,SITE-056
PT-003899,XS-OD-0042,61,Male,White,,79.2,2,Placebo,Standard,2022-03-28,Standard,Brazil,SITE-021
PT-003900,XS-OD-0042,17,Female,Asian,PDGFRA D842V,55.3,2,Active_Drug,Standard,2022-03-27,Pediatric_Assent,Switzerland,SITE-032
PT-003901,XS-OD-0042,36,Female,Hispanic or Latino,IDH1 R132H,69.6,1,Placebo,Standard,2022-04-20,Standard,Taiwan,SITE-011
PT-003902,XS-OD-0042,53,Female,Asian,KIT D816V,65.7,1,Active_Drug,Standard,2022-03-27,Standard,United Kingdom,SITE-014
PT-003903,XS-OD-0042,2,Male,Hispanic or Latino,PDGFRA D842V,87.6,2,Placebo,Standard,2022-03-09,Pediatric_Assent,Austria,SITE-025
PT-003904,XS-OD-0042,56,Male,Hispanic or Latino,KIT D816V,55.3,1,Active_Drug,Standard,2022-01-10,Emergency,Israel,SITE-009
PT-003905,XS-OD-0042,35,Male,White,,41.9,1,Placebo,Standard,2022-05-18,Standard,United States,SITE-051
PT-003906,XS-OD-0042,79,Female,Hispanic or Latino,,71.2,4,Active_Drug,Standard,2022-03-26,Standard,Australia,SITE-013
PT-003907,XS-OD-0042,58,Female,White,,37.2,2,Placebo,Standard,2022-03-11,Standard,Spain,SITE-009
PT-003908,XS-OD-0042,24,Female,Hispanic or Latino,,47.3,0,Active_Drug,Standard,2022-01-15,Standard,Switzerland,SITE-030
PT-003909,XS-OD-0042,2,Male,Hispanic or Latino,PDGFRA D842V,52.3,0,Placebo,Standard,2022-03-31,Pediatric_Assent,South Korea,SITE-023
PT-003910,XS-OD-0042,34,Female,White,IDH1 R132H,60.6,1,Active_Drug,Standard,2022-01-04,Standard,Norway,SITE-038
PT-003911,XS-OD-0042,26,Male,American Indian or Alaska Native,PDGFRA D842V,61.0,1,Placebo,Standard,2022-02-24,Standard,Netherlands,SITE-003
PT-003912,XS-OD-0042,26,Female,Black or African American,IDH1 R132H,44.7,5,Active_Drug,Standard,2022-05-24,Standard,Brazil,SITE-029
PT-003913,XS-OD-0042,19,Female,White,PDGFRA D842V,53.3,5,Placebo,Standard,2022-03-25,Compassionate,Germany,SITE-002
PT-003914,XS-OD-0042,42,Female,White,KIT D816V,84.7,1,Active_Drug,Standard,2022-04-16,Standard,France,SITE-007
PT-003915,XS-OD-0042,54,Female,White,,73.7,1,Placebo,Standard,2022-04-13,Standard,Austria,SITE-052
PT-003916,XS-OD-0042,65,Female,Hispanic or Latino,,42.2,2,Active_Drug,Standard,2022-06-21,Standard,Canada,SITE-021
PT-003917,XS-OD-0042,30,Male,Hispanic or Latino,KIT D816V,73.1,0,Placebo,Standard,2022-04-19,Standard,Taiwan,SITE-016
PT-003918,XS-OD-0042,33,Female,Hispanic or Latino,BAP1 loss,53.3,2,Active_Drug,Standard,2022-01-08,Emergency,South Korea,SITE-057
PT-003919,XS-OD-0042,37,Female,White,KIT D816V,27.7,3,Placebo,Standard,2022-04-22,Standard,Norway,SITE-022
PT-003920,XS-OD-0042,15,Female,Black or African American,IDH1 R132H,78.2,0,Active_Drug,Standard,2022-06-02,Pediatric_Assent,Switzerland,SITE-050
PT-003921,XS-OD-0042,21,Male,White,,81.8,1,Placebo,Standard,2022-04-21,Standard,Israel,SITE-013
PT-003922,XS-OD-0042,12,Female,Black or African American,PDGFRA D842V,52.1,3,Active_Drug,Standard,2022-01-29,Pediatric_Assent,France,SITE-013
PT-003923,XS-OD-0042,88,Female,White,,36.2,3,Placebo,Standard,2022-06-10,Standard,Austria,SITE-010
PT-003924,XS-OD-0042,8,Male,White,PDGFRA D842V,63.6,4,Active_Drug,Standard,2022-01-28,Pediatric_Assent,Netherlands,SITE-006
PT-003925,XS-OD-0042,45,Male,White,,39.0,3,Placebo,Standard,2022-03-06,Standard,Austria,SITE-019
PT-003926,XS-OD-0042,24,Male,White,KIT D816V,61.2,2,Active_Drug,Standard,2022-01-07,Compassionate,Israel,SITE-042
PT-003927,XS-OD-0042,66,Female,White,,40.6,3,Placebo,Standard,2022-04-11,Standard,Sweden,SITE-057
PT-003928,XS-OD-0042,53,Male,White,,61.1,1,Active_Drug,Standard,2021-12-29,Standard,Brazil,SITE-044
PT-003929,XS-OD-0042,43,Male,White,,56.8,1,Placebo,Standard,2022-06-16,Standard,Norway,SITE-012
PT-003930,XS-OD-0042,22,Male,White,,27.8,1,Active_Drug,Standard,2022-02-06,Standard,Taiwan,SITE-046
PT-003931,XS-OD-0042,52,Male,White,IDH1 R132H,47.8,0,Placebo,Standard,2022-06-23,Standard,Japan,SITE-003
PT-003932,XS-OD-0042,8,Male,American Indian or Alaska Native,,75.5,2,Active_Drug,Standard,2022-04-14,Pediatric_Assent,Australia,SITE-028
PT-003933,XS-OD-0042,42,Male,Black or African American,PDGFRA D842V,28.4,1,Placebo,Standard,2022-03-06,Standard,Sweden,SITE-016
PT-003934,XS-OD-0042,56,Female,White,,48.4,0,Active_Drug,Standard,2022-06-17,Standard,Spain,SITE-056
PT-003935,XS-OD-0042,28,Female,White,IDH1 R132H,60.8,2,Placebo,Standard,2022-03-29,Standard,Taiwan,SITE-031
PT-003936,XS-OD-0042,43,Female,Hispanic or Latino,,42.9,1,Active_Drug,Standard,2022-02-28,Standard,Italy,SITE-044
PT-003937,XS-OD-0042,28,Male,American Indian or Alaska Native,IDH1 R132H,66.9,1,Placebo,Standard,2022-01-15,Standard,Austria,SITE-048
PT-003938,XS-OD-0042,32,Female,Hispanic or Latino,,63.9,1,Active_Drug,Standard,2022-04-23,Standard,Taiwan,SITE-046
PT-003939,XS-OD-0042,42,Female,Asian,,53.8,1,Placebo,Standard,2022-05-03,Standard,Austria,SITE-003
PT-003940,XS-OD-0042,2,Female,White,IDH1 R132H,74.9,4,Active_Drug,Standard,2022-03-18,Pediatric_Assent,Sweden,SITE-011
PT-003941,XS-OD-0042,34,Male,White,,86.9,2,Placebo,Standard,2022-04-19,Standard,United Kingdom,SITE-055
PT-003942,XS-OD-0042,35,Female,Asian,,72.8,2,Active_Drug,Standard,2022-06-13,Standard,Taiwan,SITE-029
PT-003943,XS-OD-0042,18,Male,White,,69.3,2,Placebo,Standard,2022-02-07,Standard,Japan,SITE-056
PT-003944,XS-OD-0042,55,Female,White,,30.4,4,Active_Drug,Standard,2022-02-08,Emergency,Sweden,SITE-051
PT-003945,XS-OD-0042,40,Female,Asian,,24.7,4,Placebo,Standard,2022-02-03,Compassionate,Japan,SITE-010
PT-003946,XS-OD-0042,55,Female,Asian,,69.7,5,Active_Drug,Standard,2022-06-23,Standard,Germany,SITE-036
PT-003947,XS-OD-0042,41,Male,White,,60.4,1,Placebo,Standard,2022-06-21,Standard,Netherlands,SITE-008
PT-003948,XS-OD-0042,40,Female,Asian,IDH1 R132H,52.3,1,Active_Drug,Standard,2022-06-02,Standard,Australia,SITE-018
PT-003949,XS-OD-0042,6,Female,White,KIT D816V,58.1,4,Placebo,Standard,2022-01-29,Pediatric_Assent,Brazil,SITE-053
PT-003950,XS-OD-0042,57,Male,White,KIT D816V,57.5,2,Active_Drug,Standard,2022-01-06,Emergency,Canada,SITE-054
PT-003951,XS-OD-0042,80,Female,Two or More Races,PDGFRA D842V,71.7,3,Placebo,Standard,2022-03-26,Standard,Sweden,SITE-010
PT-003952,XS-OD-0042,40,Male,Hispanic or Latino,IDH1 R132H,43.0,3,Active_Drug,Standard,2022-03-05,Standard,Taiwan,SITE-033
PT-003953,XS-OD-0042,51,Female,Asian,KIT D816V,43.1,3,Placebo,Standard,2022-06-11,Standard,Sweden,SITE-023
PT-003954,XS-OD-0042,41,Female,Asian,BAP1 loss,53.7,5,Active_Drug,Standard,2022-05-08,Standard,Spain,SITE-035
PT-003955,XS-OD-0042,27,Male,White,,62.6,0,Placebo,Standard,2022-01-01,Standard,Israel,SITE-023
PT-003956,XS-OD-0042,2,Female,Asian,BAP1 loss,74.3,6,Active_Drug,Standard,2022-01-20,Pediatric_Assent,Spain,SITE-049
PT-003957,XS-OD-0042,32,Male,White,,68.4,4,Placebo,Standard,2022-03-09,Standard,Australia,SITE-029
PT-003958,XS-OD-0042,25,Male,Black or African American,IDH1 R132H,60.3,4,Active_Drug,Standard,2022-02-11,Standard,Taiwan,SITE-025
PT-003959,XS-OD-0042,39,Female,White,PDGFRA D842V,65.1,0,Placebo,Standard,2022-05-16,Standard,Japan,SITE-004
PT-003960,XS-OD-0042,66,Male,Hispanic or Latino,BAP1 loss,44.9,0,Active_Drug,Standard,2022-06-05,Standard,Italy,SITE-028
PT-003961,XS-OD-0042,40,Male,Hispanic or Latino,BAP1 loss,32.9,2,Placebo,Standard,2022-04-24,Standard,Germany,SITE-036
PT-003962,XS-OD-0042,33,Female,Asian,BAP1 loss,63.0,3,Active_Drug,Standard,2022-03-09,Standard,Spain,SITE-011
PT-003963,XS-OD-0042,21,Male,White,KIT D816V,22.8,3,Placebo,Standard,2022-06-20,Standard,Brazil,SITE-008
PT-003964,XS-OD-0042,14,Male,Black or African American,BAP1 loss,55.8,4,Active_Drug,Standard,2022-06-20,Pediatric_Assent,United Kingdom,SITE-002
PT-003965,XS-OD-0042,59,Male,Hispanic or Latino,KIT D816V,54.2,2,Placebo,Standard,2022-02-25,Standard,Israel,SITE-029
PT-003966,XS-OD-0042,49,Male,Asian,IDH1 R132H,46.4,2,Active_Drug,Standard,2022-03-26,Standard,France,SITE-045
PT-003967,XS-OD-0042,44,Intersex,Hispanic or Latino,KIT D816V,83.3,2,Placebo,Standard,2022-04-14,Standard,Switzerland,SITE-040
PT-003968,XS-OD-0042,30,Female,White,IDH1 R132H,54.7,2,Active_Drug,Standard,2022-03-09,Standard,Switzerland,SITE-012
PT-003969,XS-OD-0042,88,Male,White,,51.6,2,Placebo,Standard,2022-05-16,Standard,Brazil,SITE-054
PT-003970,XS-OD-0042,67,Female,Asian,,80.9,3,Active_Drug,Standard,2021-12-31,Standard,France,SITE-009
PT-003971,XS-OD-0042,46,Female,White,PDGFRA D842V,83.0,3,Placebo,Standard,2022-06-08,Standard,Israel,SITE-034
PT-003972,XS-OD-0042,34,Female,Black or African American,,92.7,3,Active_Drug,Standard,2022-01-07,Standard,Norway,SITE-020
PT-003973,XS-OD-0042,34,Female,Hispanic or Latino,KIT D816V,46.7,1,Placebo,Standard,2022-05-06,Standard,Belgium,SITE-035
PT-003974,XS-OD-0042,40,Female,White,PDGFRA D842V,38.6,2,Active_Drug,Standard,2022-03-05,Standard,Canada,SITE-047
PT-003975,XS-OD-0042,52,Female,Hispanic or Latino,KIT D816V,95.0,3,Placebo,Standard,2022-02-28,Standard,Sweden,SITE-037
PT-003976,XS-OD-0042,14,Male,White,IDH1 R132H,52.5,2,Active_Drug,Standard,2022-02-14,Pediatric_Assent,Norway,SITE-041
PT-003977,XS-OD-0042,36,Male,Asian,IDH1 R132H,63.7,1,Placebo,Standard,2022-02-05,Standard,Italy,SITE-013
PT-003978,XS-OD-0042,52,Male,Hispanic or Latino,BAP1 loss,33.2,2,Active_Drug,Standard,2022-05-19,Standard,Switzerland,SITE-001
PT-003979,XS-OD-0042,59,Female,White,KIT D816V,29.8,3,Placebo,Standard,2022-05-19,Standard,Japan,SITE-003
PT-003980,XS-OD-0042,15,Male,Hispanic or Latino,PDGFRA D842V,59.0,3,Active_Drug,Standard,2022-03-16,Pediatric_Assent,United Kingdom,SITE-051
PT-003981,XS-OD-0042,31,Female,White,KIT D816V,48.4,0,Placebo,Standard,2022-06-12,Standard,Austria,SITE-034
PT-003982,XS-OD-0042,59,Female,White,KIT D816V,46.4,4,Active_Drug,Standard,2022-02-14,Standard,Norway,SITE-037
PT-003983,XS-OD-0042,51,Female,Native Hawaiian or Other Pacific Islander,KIT D816V,61.0,0,Placebo,Standard,2022-01-17,Standard,Italy,SITE-017
PT-003984,XS-OD-0042,55,Male,Asian,BAP1 loss,57.2,2,Active_Drug,Standard,2021-12-29,Standard,Sweden,SITE-004
PT-003985,XS-OD-0042,22,Male,Asian,PDGFRA D842V,53.4,2,Placebo,Standard,2022-01-11,Standard,Italy,SITE-004
PT-003986,XS-OD-0042,23,Male,Asian,BAP1 loss,16.1,2,Active_Drug,Standard,2022-03-17,Standard,Denmark,SITE-012
PT-003987,XS-OD-0042,50,Male,Asian,,63.8,2,Placebo,Standard,2022-03-21,Standard,Italy,SITE-041
PT-003988,XS-OD-0042,61,Female,White,KIT D816V,46.4,0,Active_Drug,Standard,2022-04-21,Standard,Austria,SITE-034
PT-003989,XS-OD-0042,59,Female,Black or African American,,43.2,2,Placebo,Standard,2022-01-01,Standard,Germany,SITE-005
PT-003990,XS-OD-0042,26,Male,White,KIT D816V,55.1,4,Active_Drug,Standard,2022-02-28,Standard,United States,SITE-011
PT-003991,XS-OD-0042,49,Female,White,BAP1 loss,38.8,2,Placebo,Standard,2022-05-28,Standard,Switzerland,SITE-044
PT-003992,XS-OD-0042,55,Male,White,BAP1 loss,35.5,1,Active_Drug,Standard,2022-06-13,Standard,Austria,SITE-006
PT-003993,XS-OD-0042,59,Female,White,BAP1 loss,35.3,4,Placebo,Standard,2022-03-04,Standard,Italy,SITE-014
PT-003994,XS-OD-0042,21,Male,Hispanic or Latino,IDH1 R132H,10.0,4,Active_Drug,Standard,2022-06-20,Standard,Israel,SITE-028
PT-003995,XS-OD-0042,37,Female,White,,44.6,1,Placebo,Standard,2022-04-24,Standard,Israel,SITE-056
PT-003996,XS-OD-0042,39,Male,White,,64.1,2,Active_Drug,Standard,2022-05-25,Standard,Israel,SITE-036
PT-003997,XS-OD-0042,40,Male,White,,32.8,2,Placebo,Standard,2022-03-27,Standard,Spain,SITE-022
PT-003998,XS-OD-0042,81,Female,Black or African American,KIT D816V,34.7,2,Active_Drug,Standard,2022-01-07,Standard,Belgium,SITE-033
PT-003999,XS-OD-0042,68,Male,Hispanic or Latino,,33.0,3,Placebo,Standard,2022-01-14,Standard,Belgium,SITE-045
PT-004000,XS-OD-0042,42,Female,Hispanic or Latino,,48.2,1,Active_Drug,Standard,2022-02-19,Standard,Germany,SITE-035
PT-004001,XS-OD-0042,52,Male,White,,63.5,3,Placebo,Standard,2022-01-24,Standard,Australia,SITE-042
PT-004002,XS-OD-0042,15,Female,White,,51.1,4,Active_Drug,Standard,2022-06-07,Pediatric_Assent,Switzerland,SITE-006
PT-004003,XS-OD-0042,43,Male,White,KIT D816V,95.0,1,Placebo,Standard,2022-05-04,Standard,Canada,SITE-056
PT-004004,XS-OD-0042,43,Male,White,IDH1 R132H,95.0,1,Active_Drug,Standard,2022-06-10,Standard,France,SITE-019
PT-004005,XS-OD-0042,51,Female,American Indian or Alaska Native,BAP1 loss,79.3,0,Placebo,Standard,2022-06-08,Standard,Italy,SITE-057
PT-004006,XS-OD-0042,60,Male,Asian,KIT D816V,32.0,2,Active_Drug,Standard,2021-12-31,Standard,Austria,SITE-017
PT-004007,XS-OD-0042,40,Female,Asian,,56.8,0,Placebo,Standard,2022-04-27,Standard,Taiwan,SITE-027
PT-004008,XS-OD-0042,43,Male,Hispanic or Latino,,42.6,2,Active_Drug,Standard,2022-01-14,Standard,United States,SITE-011
PT-004009,XS-OD-0042,41,Female,White,,71.4,3,Placebo,Standard,2022-03-11,Standard,Italy,SITE-004
PT-004010,XS-OD-0042,61,Male,Hispanic or Latino,PDGFRA D842V,77.5,0,Active_Drug,Standard,2022-01-26,Standard,Italy,SITE-056
PT-004011,XS-OD-0042,55,Female,Asian,,47.7,0,Placebo,Standard,2022-06-18,Standard,United Kingdom,SITE-006
PT-004012,XS-OD-0042,37,Male,White,IDH1 R132H,65.1,4,Active_Drug,Standard,2022-05-25,Emergency,Denmark,SITE-038
PT-004013,XS-OD-0042,49,Male,Two or More Races,,53.0,2,Placebo,Standard,2022-03-27,Standard,Belgium,SITE-005
PT-004014,XS-OD-0042,49,Female,White,KIT D816V,68.1,4,Active_Drug,Standard,2022-02-07,Standard,Australia,SITE-004
PT-004015,XS-OD-0042,49,Male,White,,56.3,4,Placebo,Standard,2022-01-19,Standard,Brazil,SITE-053
PT-004016,XS-OD-0042,53,Male,White,KIT D816V,95.0,2,Active_Drug,Standard,2022-03-21,Standard,Australia,SITE-053
PT-004017,XS-OD-0042,47,Female,Hispanic or Latino,IDH1 R132H,38.4,3,Placebo,Standard,2022-05-24,Standard,Australia,SITE-055
PT-004018,XS-OD-0042,21,Female,White,IDH1 R132H,46.5,1,Active_Drug,Standard,2022-01-16,Standard,Norway,SITE-003
PT-004019,XS-OD-0042,77,Male,White,KIT D816V,83.6,2,Placebo,Standard,2022-06-10,Standard,Switzerland,SITE-012
PT-004020,XS-OD-0042,69,Female,White,PDGFRA D842V,81.2,2,Active_Drug,Standard,2022-06-13,Standard,Spain,SITE-038
PT-004021,XS-OD-0042,37,Male,White,KIT D816V,56.8,2,Placebo,Standard,2022-02-16,Standard,Brazil,SITE-050
PT-004022,XS-OD-0042,29,Female,White,KIT D816V,87.6,2,Active_Drug,Standard,2022-05-29,Standard,Spain,SITE-018
PT-004023,XS-OD-0042,47,Male,White,KIT D816V,18.5,0,Placebo,Standard,2022-06-05,Standard,South Korea,SITE-028
PT-004024,XS-OD-0042,39,Female,Hispanic or Latino,,31.3,0,Active_Drug,Standard,2022-05-29,Standard,Netherlands,SITE-045
PT-004025,XS-OD-0042,53,Male,Hispanic or Latino,,38.5,1,Placebo,Standard,2022-02-08,Standard,United States,SITE-057
PT-004026,XS-OD-0042,57,Male,White,,68.1,1,Active_Drug,Standard,2022-04-10,Standard,Brazil,SITE-041
PT-004027,XS-OD-0042,10,Female,American Indian or Alaska Native,KIT D816V,54.5,1,Placebo,Standard,2022-02-13,Pediatric_Assent,Switzerland,SITE-017
PT-004028,XS-OD-0042,56,Female,White,IDH1 R132H,76.2,2,Active_Drug,Standard,2022-04-04,Standard,Canada,SITE-009
PT-004029,XS-OD-0042,66,Male,White,KIT D816V,62.2,1,Placebo,Standard,2022-01-08,Standard,United States,SITE-047
PT-004030,XS-OD-0042,13,Male,Native Hawaiian or Other Pacific Islander,KIT D816V,95.0,1,Active_Drug,Standard,2022-02-27,Pediatric_Assent,France,SITE-033
PT-004031,XS-OD-0042,49,Male,American Indian or Alaska Native,KIT D816V,48.9,4,Placebo,Standard,2022-03-22,Standard,Taiwan,SITE-025
PT-004032,XS-OD-0042,7,Male,White,,78.1,4,Active_Drug,Standard,2022-02-12,Pediatric_Assent,Japan,SITE-053
PT-004033,XS-OD-0042,53,Male,White,KIT D816V,46.7,0,Placebo,Standard,2022-06-19,Standard,Denmark,SITE-050
PT-004034,XS-OD-0042,63,Male,White,PDGFRA D842V,56.6,1,Active_Drug,Standard,2022-04-29,Standard,United States,SITE-007
PT-004035,XS-OD-0042,22,Female,American Indian or Alaska Native,KIT D816V,43.4,2,Placebo,Standard,2022-01-22,Standard,South Korea,SITE-038
PT-004036,XS-OD-0042,60,Male,White,PDGFRA D842V,11.0,4,Active_Drug,Standard,2022-06-10,Standard,Sweden,SITE-056
PT-004037,XS-OD-0042,19,Male,Hispanic or Latino,KIT D816V,71.4,3,Placebo,Standard,2022-02-08,Standard,United Kingdom,SITE-028
PT-004038,XS-OD-0042,55,Male,White,PDGFRA D842V,68.9,0,Active_Drug,Standard,2022-03-03,Standard,Norway,SITE-009
PT-004039,XS-OD-0042,49,Male,Black or African American,,89.6,1,Placebo,Standard,2022-05-28,Standard,United Kingdom,SITE-057
PT-004040,XS-OD-0042,25,Male,White,,59.7,3,Active_Drug,Standard,2022-02-07,Standard,Brazil,SITE-042
PT-004041,XS-OD-0042,54,Female,White,IDH1 R132H,62.8,0,Placebo,Standard,2022-03-31,Standard,Italy,SITE-035
PT-004042,XS-OD-0042,38,Male,White,BAP1 loss,18.8,2,Active_Drug,Standard,2022-02-19,Standard,Brazil,SITE-037
PT-004043,XS-OD-0042,44,Female,Asian,,34.8,1,Placebo,Standard,2022-02-25,Standard,South Korea,SITE-042
PT-004044,XS-OD-0042,43,Male,Asian,,95.0,2,Active_Drug,Standard,2022-06-21,Standard,United States,SITE-015
PT-004045,XS-OD-0042,67,Female,Asian,,56.1,1,Placebo,Standard,2022-02-12,Standard,Norway,SITE-001
PT-004046,XS-OD-0042,45,Male,Hispanic or Latino,KIT D816V,44.4,4,Active_Drug,Standard,2022-04-12,Standard,Sweden,SITE-042
PT-004047,XS-OD-0042,56,Female,Hispanic or Latino,KIT D816V,16.2,2,Placebo,Standard,2022-05-29,Standard,Spain,SITE-040
PT-004048,XS-OD-0042,72,Female,Black or African American,,36.0,2,Active_Drug,Standard,2022-03-03,Emergency,Denmark,SITE-032
PT-004049,XS-OD-0042,49,Male,White,KIT D816V,50.3,3,Placebo,Standard,2022-04-20,Standard,South Korea,SITE-035
PT-004050,XS-OD-0042,51,Female,White,,24.8,0,Active_Drug,Standard,2022-06-17,Emergency,United States,SITE-037
PT-004051,XS-OD-0042,45,Male,White,,63.0,1,Placebo,Standard,2022-02-23,Standard,Austria,SITE-016
PT-004052,XS-OD-0042,60,Male,White,IDH1 R132H,36.0,1,Active_Drug,Standard,2022-02-14,Standard,Israel,SITE-014
PT-004053,XS-OD-0042,30,Male,Hispanic or Latino,KIT D816V,68.2,2,Placebo,Standard,2022-03-14,Standard,Sweden,SITE-027
PT-004054,XS-OD-0043,29,Male,Hispanic or Latino,,85.1,4,Active_Drug,Standard,2026-01-04,Standard,France,SITE-006
PT-004055,XS-OD-0043,23,Male,White,BAP1 loss,33.0,5,Placebo,Standard,2026-03-20,Standard,South Korea,SITE-002
PT-004056,XS-OD-0043,37,Male,Hispanic or Latino,BAP1 loss,69.4,3,Active_Drug,Standard,2026-02-02,Standard,United States,SITE-004
PT-004057,XS-OD-0043,29,Female,White,KIT D816V,69.7,5,Placebo,Standard,2026-03-30,Standard,Switzerland,SITE-006
PT-004058,XS-OD-0043,39,Female,Black or African American,,28.8,1,Active_Drug,Standard,2026-04-07,Standard,Austria,SITE-005
PT-004059,XS-OD-0043,38,Male,White,BAP1 loss,64.4,1,Placebo,Standard,2026-04-29,Standard,United States,SITE-006
PT-004060,XS-OD-0043,37,Female,White,PDGFRA D842V,26.4,3,Active_Drug,Standard,2026-03-29,Standard,Israel,SITE-008
PT-004061,XS-OD-0043,39,Male,White,,43.9,1,Placebo,Standard,2026-05-25,Standard,United States,SITE-004
PT-004062,XS-OD-0043,15,Intersex,White,,55.2,1,Active_Drug,Standard,2026-05-24,Pediatric_Assent,South Korea,SITE-007
PT-004063,XS-OD-0043,82,Male,Hispanic or Latino,BAP1 loss,48.9,3,Placebo,Standard,2026-03-23,Standard,Italy,SITE-008
PT-004064,XS-OD-0043,48,Female,American Indian or Alaska Native,,39.0,2,Active_Drug,Standard,2026-01-20,Standard,Israel,SITE-008
PT-004065,XS-OD-0043,30,Female,White,BAP1 loss,59.5,1,Placebo,Standard,2026-03-22,Standard,Denmark,SITE-005
PT-004066,XS-OD-0043,58,Female,White,IDH1 R132H,58.2,1,Active_Drug,Standard,2026-01-22,Standard,Sweden,SITE-008
PT-004067,XS-OD-0043,6,Female,White,KIT D816V,85.7,5,Placebo,Standard,2026-04-04,Pediatric_Assent,Japan,SITE-005
PT-004068,XS-OD-0043,29,Female,Hispanic or Latino,,56.2,0,Active_Drug,Standard,2026-05-03,Standard,Spain,SITE-001
PT-004069,XS-OD-0043,28,Male,Hispanic or Latino,KIT D816V,62.9,1,Placebo,Standard,2026-02-25,Standard,Sweden,SITE-005
PT-004070,XS-OD-0043,16,Male,White,KIT D816V,26.7,2,Active_Drug,Standard,2026-04-17,Pediatric_Assent,Israel,SITE-008
PT-004071,XS-OD-0043,49,Male,White,PDGFRA D842V,57.6,0,Placebo,Standard,2026-03-03,Standard,Sweden,SITE-005
PT-004072,XS-OD-0043,32,Female,White,PDGFRA D842V,49.9,4,Active_Drug,Standard,2025-12-11,Standard,Belgium,SITE-007
PT-004073,XS-OD-0043,30,Male,American Indian or Alaska Native,,50.7,3,Placebo,Standard,2025-12-29,Standard,Brazil,SITE-007
PT-004074,XS-OD-0043,10,Male,White,PDGFRA D842V,60.6,3,Active_Drug,Standard,2026-01-16,Pediatric_Assent,Canada,SITE-007
PT-004075,XS-OD-0043,38,Male,White,PDGFRA D842V,25.6,1,Placebo,Standard,2026-04-15,Standard,United Kingdom,SITE-004
PT-004076,XS-OD-0043,28,Male,White,BAP1 loss,53.7,0,Active_Drug,Standard,2026-02-22,Standard,Belgium,SITE-004
PT-004077,XS-OD-0043,29,Female,White,KIT D816V,65.1,3,Placebo,Standard,2026-05-27,Standard,Taiwan,SITE-007
PT-004078,XS-OD-0043,4,Female,White,IDH1 R132H,58.9,0,Active_Drug,Standard,2026-02-22,Pediatric_Assent,Brazil,SITE-004
PT-004079,XS-OD-0043,40,Female,Black or African American,PDGFRA D842V,55.4,2,Placebo,Standard,2026-05-07,Standard,Israel,SITE-006
PT-004080,XS-OD-0043,31,Male,Black or African American,KIT D816V,68.6,2,Active_Drug,Standard,2025-12-15,Standard,Taiwan,SITE-006
PT-004081,XS-OD-0043,29,Male,White,IDH1 R132H,46.4,4,Placebo,Standard,2025-12-12,Standard,Denmark,SITE-003
PT-004082,XS-OD-0043,50,Male,Native Hawaiian or Other Pacific Islander,BAP1 loss,55.7,0,Active_Drug,Standard,2025-12-11,Standard,Canada,SITE-005
PT-004083,XS-OD-0043,59,Female,White,,33.6,0,Placebo,Standard,2026-04-14,Standard,Spain,SITE-008
PT-004084,XS-OD-0043,52,Male,White,,48.3,2,Active_Drug,Standard,2026-02-25,Standard,Norway,SITE-006
PT-004085,XS-OD-0043,30,Male,Hispanic or Latino,BAP1 loss,46.1,1,Placebo,Standard,2026-05-30,Standard,Norway,SITE-002
PT-004086,XS-OD-0043,15,Male,White,,50.6,2,Active_Drug,Standard,2026-06-06,Pediatric_Assent,Spain,SITE-003
PT-004087,XS-OD-0043,47,Female,White,,39.7,2,Placebo,Standard,2026-05-02,Standard,Germany,SITE-001
PT-004088,XS-OD-0043,21,Male,White,KIT D816V,63.7,1,Active_Drug,Standard,2026-01-19,Standard,Austria,SITE-001
PT-004089,XS-OD-0043,39,Female,Black or African American,,23.0,2,Placebo,Standard,2025-12-23,Standard,Brazil,SITE-001
PT-004090,XS-OD-0043,48,Female,White,,75.7,3,Active_Drug,Standard,2026-01-12,Standard,Sweden,SITE-006
PT-004091,XS-OD-0043,10,Female,White,PDGFRA D842V,47.0,0,Placebo,Standard,2026-02-15,Pediatric_Assent,Australia,SITE-001
PT-004092,XS-OD-0043,53,Female,White,,53.1,3,Active_Drug,Standard,2026-04-10,Standard,Canada,SITE-001
PT-004093,XS-OD-0043,36,Male,Hispanic or Latino,,49.7,3,Placebo,Standard,2026-01-17,Standard,Israel,SITE-002
PT-004094,XS-OD-0043,58,Male,Black or African American,,91.0,2,Active_Drug,Standard,2026-03-20,Standard,United States,SITE-005
PT-004095,XS-OD-0043,30,Male,White,PDGFRA D842V,45.3,1,Placebo,Standard,2026-04-12,Standard,Australia,SITE-004
PT-004096,XS-OD-0043,7,Male,White,BAP1 loss,15.7,1,Active_Drug,Standard,2026-04-21,Pediatric_Assent,Taiwan,SITE-005
PT-004097,XS-OD-0043,41,Male,White,PDGFRA D842V,59.9,4,Placebo,Standard,2026-04-16,Standard,Germany,SITE-005
PT-004098,XS-OD-0044,59,Female,Black or African American,BAP1 loss,95.0,1,Active_Drug,Low,2023-11-11,Standard,Japan,SITE-002
PT-004099,XS-OD-0044,45,Female,White,IDH1 R132H,53.9,2,Active_Drug,Low,2023-12-04,Standard,Italy,SITE-002
PT-004100,XS-OD-0044,30,Male,Black or African American,,67.1,3,Active_Drug,Low,2023-11-06,Standard,Australia,SITE-002
PT-004101,XS-OD-0044,49,Female,Black or African American,,51.2,1,Active_Drug,Medium,2024-02-13,Standard,United Kingdom,SITE-001
PT-004102,XS-OD-0044,50,Male,White,,53.7,4,Active_Drug,Medium,2023-10-13,Standard,Italy,SITE-001
PT-004103,XS-OD-0044,63,Female,White,,39.0,3,Active_Drug,High,2023-11-12,Standard,United States,SITE-002
PT-004104,XS-OD-0044,25,Female,White,,57.8,4,Active_Drug,Medium,2024-01-09,Standard,Italy,SITE-001
PT-004105,XS-OD-0044,16,Male,Two or More Races,,70.4,1,Active_Drug,Low,2023-10-29,Pediatric_Assent,Canada,SITE-001
PT-004106,XS-OD-0044,10,Female,White,BAP1 loss,70.1,3,Active_Drug,Medium,2024-02-18,Pediatric_Assent,Spain,SITE-001
PT-004107,XS-OD-0044,44,Male,Two or More Races,BAP1 loss,60.1,3,Active_Drug,High,2024-01-31,Standard,United States,SITE-001
PT-004108,XS-OD-0044,22,Male,Hispanic or Latino,,40.6,3,Active_Drug,Medium,2024-01-10,Standard,France,SITE-001
PT-004109,XS-OD-0044,19,Female,White,PDGFRA D842V,37.9,4,Active_Drug,Medium,2024-02-09,Standard,United Kingdom,SITE-002
PT-004110,XS-OD-0044,58,Male,Hispanic or Latino,KIT D816V,50.3,1,Active_Drug,High,2023-10-23,Standard,Germany,SITE-002
PT-004111,XS-OD-0044,50,Male,Hispanic or Latino,BAP1 loss,51.4,3,Active_Drug,High,2023-10-03,Standard,Spain,SITE-002
PT-004112,XS-OD-0044,31,Male,Black or African American,,65.6,1,Active_Drug,High,2023-10-23,Standard,France,SITE-001
PT-004113,XS-OD-0044,40,Male,White,KIT D816V,59.8,3,Active_Drug,Low,2024-01-09,Standard,Australia,SITE-002
PT-004114,XS-OD-0044,38,Female,White,IDH1 R132H,62.7,2,Active_Drug,Low,2023-09-21,Standard,Italy,SITE-001
PT-004115,XS-OD-0044,58,Female,White,PDGFRA D842V,38.2,1,Active_Drug,High,2023-10-07,Standard,Canada,SITE-001
PT-004116,XS-OD-0044,41,Female,White,,59.1,2,Active_Drug,High,2024-01-07,Standard,Netherlands,SITE-001
PT-004117,XS-OD-0044,48,Male,White,,49.8,4,Active_Drug,High,2024-02-10,Emergency,Spain,SITE-002
PT-004118,XS-OD-0044,4,Male,White,IDH1 R132H,57.9,2,Active_Drug,High,2023-12-08,Pediatric_Assent,Canada,SITE-001
PT-004119,XS-OD-0045,7,Male,White,,71.9,3,Active_Drug,Standard,2021-07-30,Pediatric_Assent,Japan,SITE-009
PT-004120,XS-OD-0045,5,Female,White,KIT D816V,45.4,5,Placebo,Standard,2021-08-11,Pediatric_Assent,Italy,SITE-018
PT-004121,XS-OD-0045,8,Female,Hispanic or Latino,PDGFRA D842V,66.9,3,Active_Drug,Standard,2021-06-01,Pediatric_Assent,United Kingdom,SITE-027
PT-004122,XS-OD-0045,3,Male,White,,25.8,0,Placebo,Standard,2021-04-21,Pediatric_Assent,Germany,SITE-018
PT-004123,XS-OD-0045,1,Female,Black or African American,PDGFRA D842V,61.2,2,Active_Drug,Standard,2021-09-14,Pediatric_Assent,Italy,SITE-014
PT-004124,XS-OD-0045,4,Male,White,,59.7,0,Placebo,Standard,2021-05-08,Pediatric_Assent,Netherlands,SITE-011
PT-004125,XS-OD-0045,4,Female,White,BAP1 loss,89.8,1,Active_Drug,Standard,2021-05-12,Pediatric_Assent,United Kingdom,SITE-004
PT-004126,XS-OD-0045,4,Female,Two or More Races,IDH1 R132H,45.4,0,Placebo,Standard,2021-07-18,Pediatric_Assent,Germany,SITE-025
PT-004127,XS-OD-0045,7,Male,White,IDH1 R132H,58.1,1,Active_Drug,Standard,2021-08-08,Pediatric_Assent,Netherlands,SITE-023
PT-004128,XS-OD-0045,4,Male,White,PDGFRA D842V,45.3,1,Placebo,Standard,2021-05-21,Pediatric_Assent,United Kingdom,SITE-002
PT-004129,XS-OD-0045,9,Female,American Indian or Alaska Native,BAP1 loss,78.5,2,Active_Drug,Standard,2021-06-24,Pediatric_Assent,United States,SITE-001
PT-004130,XS-OD-0045,7,Male,White,IDH1 R132H,39.3,2,Placebo,Standard,2021-07-20,Pediatric_Assent,United States,SITE-017
PT-004131,XS-OD-0045,1,Male,American Indian or Alaska Native,KIT D816V,69.3,0,Active_Drug,Standard,2021-08-17,Pediatric_Assent,Japan,SITE-022
PT-004132,XS-OD-0045,3,Male,Hispanic or Latino,,38.0,1,Placebo,Standard,2021-05-27,Pediatric_Assent,Australia,SITE-020
PT-004133,XS-OD-0045,6,Male,White,IDH1 R132H,30.0,0,Active_Drug,Standard,2021-07-02,Pediatric_Assent,France,SITE-002
PT-004134,XS-OD-0045,6,Female,White,IDH1 R132H,64.1,1,Placebo,Standard,2021-05-14,Pediatric_Assent,Japan,SITE-020
PT-004135,XS-OD-0045,1,Male,American Indian or Alaska Native,PDGFRA D842V,75.9,2,Active_Drug,Standard,2021-06-28,Pediatric_Assent,France,SITE-029
PT-004136,XS-OD-0045,7,Male,White,PDGFRA D842V,81.8,2,Placebo,Standard,2021-07-25,Pediatric_Assent,Netherlands,SITE-009
PT-004137,XS-OD-0045,2,Male,White,,10.0,3,Active_Drug,Standard,2021-05-03,Pediatric_Assent,United States,SITE-030
PT-004138,XS-OD-0045,4,Male,Asian,,51.5,1,Placebo,Standard,2021-09-25,Pediatric_Assent,Spain,SITE-016
PT-004139,XS-OD-0045,2,Male,White,KIT D816V,42.0,6,Active_Drug,Standard,2021-09-29,Pediatric_Assent,Spain,SITE-020
PT-004140,XS-OD-0045,2,Female,White,,53.3,0,Placebo,Standard,2021-08-21,Pediatric_Assent,Spain,SITE-002
PT-004141,XS-OD-0045,7,Male,Asian,PDGFRA D842V,48.8,2,Active_Drug,Standard,2021-06-02,Pediatric_Assent,United Kingdom,SITE-015
PT-004142,XS-OD-0045,5,Male,Two or More Races,IDH1 R132H,55.1,1,Placebo,Standard,2021-09-29,Pediatric_Assent,Germany,SITE-001
PT-004143,XS-OD-0045,1,Male,White,PDGFRA D842V,32.3,1,Active_Drug,Standard,2021-10-01,Pediatric_Assent,United Kingdom,SITE-006
PT-004144,XS-OD-0045,8,Female,Asian,,57.7,2,Placebo,Standard,2021-10-02,Pediatric_Assent,Canada,SITE-006
PT-004145,XS-OD-0045,3,Male,White,,33.0,2,Active_Drug,Standard,2021-05-22,Pediatric_Assent,United States,SITE-016
PT-004146,XS-OD-0045,8,Female,White,IDH1 R132H,32.7,3,Placebo,Standard,2021-06-19,Pediatric_Assent,Germany,SITE-011
PT-004147,XS-OD-0045,4,Female,White,,61.9,1,Active_Drug,Standard,2021-09-06,Pediatric_Assent,Italy,SITE-021
PT-004148,XS-OD-0045,10,Male,White,PDGFRA D842V,40.2,1,Placebo,Standard,2021-04-21,Pediatric_Assent,Japan,SITE-019
PT-004149,XS-OD-0045,1,Male,White,PDGFRA D842V,41.3,3,Active_Drug,Standard,2021-08-21,Pediatric_Assent,Australia,SITE-028
PT-004150,XS-OD-0045,1,Male,Hispanic or Latino,KIT D816V,48.3,1,Placebo,Standard,2021-08-16,Pediatric_Assent,Germany,SITE-016
PT-004151,XS-OD-0045,7,Male,Hispanic or Latino,KIT D816V,63.4,1,Active_Drug,Standard,2021-05-08,Pediatric_Assent,United Kingdom,SITE-021
PT-004152,XS-OD-0045,1,Female,Hispanic or Latino,,57.2,4,Placebo,Standard,2021-09-22,Pediatric_Assent,Italy,SITE-003
PT-004153,XS-OD-0045,3,Male,White,IDH1 R132H,87.2,2,Active_Drug,Standard,2021-06-26,Pediatric_Assent,Germany,SITE-029
PT-004154,XS-OD-0045,3,Female,White,BAP1 loss,45.2,2,Placebo,Standard,2021-07-13,Pediatric_Assent,Australia,SITE-002
PT-004155,XS-OD-0045,4,Female,American Indian or Alaska Native,IDH1 R132H,74.8,2,Active_Drug,Standard,2021-06-10,Pediatric_Assent,United States,SITE-027
PT-004156,XS-OD-0045,3,Female,Two or More Races,IDH1 R132H,43.9,1,Placebo,Standard,2021-09-04,Pediatric_Assent,Canada,SITE-018
PT-004157,XS-OD-0045,2,Female,Two or More Races,,82.2,3,Active_Drug,Standard,2021-09-04,Pediatric_Assent,Canada,SITE-019
PT-004158,XS-OD-0045,4,Female,White,,50.2,0,Placebo,Standard,2021-06-16,Pediatric_Assent,Japan,SITE-024
PT-004159,XS-OD-0045,9,Female,White,IDH1 R132H,58.6,1,Active_Drug,Standard,2021-04-18,Pediatric_Assent,Spain,SITE-020
PT-004160,XS-OD-0045,2,Male,White,PDGFRA D842V,29.0,3,Placebo,Standard,2021-06-12,Pediatric_Assent,Italy,SITE-016
PT-004161,XS-OD-0045,5,Male,White,KIT D816V,52.9,1,Active_Drug,Standard,2021-08-31,Pediatric_Assent,Canada,SITE-020
PT-004162,XS-OD-0045,2,Male,Black or African American,BAP1 loss,72.2,4,Placebo,Standard,2021-07-15,Pediatric_Assent,Italy,SITE-027
PT-004163,XS-OD-0045,7,Male,Black or African American,IDH1 R132H,76.6,1,Active_Drug,Standard,2021-09-23,Pediatric_Assent,Netherlands,SITE-005
PT-004164,XS-OD-0045,5,Male,Black or African American,,29.2,3,Placebo,Standard,2021-05-16,Pediatric_Assent,France,SITE-003
PT-004165,XS-OD-0045,2,Female,White,,80.7,0,Active_Drug,Standard,2021-05-24,Pediatric_Assent,United States,SITE-024
PT-004166,XS-OD-0045,3,Female,White,,61.3,2,Placebo,Standard,2021-05-02,Pediatric_Assent,Japan,SITE-025
PT-004167,XS-OD-0045,2,Female,Asian,KIT D816V,66.4,2,Active_Drug,Standard,2021-08-23,Pediatric_Assent,Japan,SITE-020
PT-004168,XS-OD-0045,4,Female,Black or African American,PDGFRA D842V,40.6,1,Placebo,Standard,2021-06-11,Pediatric_Assent,Canada,SITE-021
PT-004169,XS-OD-0045,5,Male,Black or African American,KIT D816V,51.5,1,Active_Drug,Standard,2021-08-07,Pediatric_Assent,France,SITE-018
PT-004170,XS-OD-0045,7,Female,White,BAP1 loss,38.6,2,Placebo,Standard,2021-05-26,Pediatric_Assent,United Kingdom,SITE-020
PT-004171,XS-OD-0045,6,Male,White,BAP1 loss,67.4,1,Active_Drug,Standard,2021-07-20,Pediatric_Assent,Canada,SITE-010
PT-004172,XS-OD-0045,9,Female,Asian,PDGFRA D842V,58.6,3,Placebo,Standard,2021-08-01,Pediatric_Assent,France,SITE-003
PT-004173,XS-OD-0045,9,Female,Asian,,24.5,3,Active_Drug,Standard,2021-07-16,Pediatric_Assent,Australia,SITE-030
PT-004174,XS-OD-0045,3,Male,Asian,,62.7,5,Placebo,Standard,2021-09-15,Pediatric_Assent,Netherlands,SITE-003
PT-004175,XS-OD-0045,5,Male,Asian,BAP1 loss,46.9,1,Active_Drug,Standard,2021-04-28,Pediatric_Assent,Germany,SITE-022
PT-004176,XS-OD-0045,12,Male,White,,44.8,1,Placebo,Standard,2021-09-10,Pediatric_Assent,France,SITE-030
PT-004177,XS-OD-0045,8,Male,White,IDH1 R132H,80.3,0,Active_Drug,Standard,2021-09-17,Pediatric_Assent,United Kingdom,SITE-017
PT-004178,XS-OD-0045,4,Female,White,PDGFRA D842V,36.9,3,Placebo,Standard,2021-05-07,Pediatric_Assent,Netherlands,SITE-016
PT-004179,XS-OD-0045,10,Male,White,,37.2,2,Active_Drug,Standard,2021-05-08,Pediatric_Assent,France,SITE-009
PT-004180,XS-OD-0045,6,Female,White,PDGFRA D842V,41.2,0,Placebo,Standard,2021-08-19,Pediatric_Assent,Netherlands,SITE-012
PT-004181,XS-OD-0045,2,Male,Asian,PDGFRA D842V,69.6,2,Active_Drug,Standard,2021-09-30,Pediatric_Assent,United Kingdom,SITE-005
PT-004182,XS-OD-0045,5,Female,White,,95.0,3,Placebo,Standard,2021-04-27,Pediatric_Assent,France,SITE-006
PT-004183,XS-OD-0045,6,Male,White,KIT D816V,41.8,3,Active_Drug,Standard,2021-09-15,Pediatric_Assent,Canada,SITE-006
PT-004184,XS-OD-0045,7,Female,American Indian or Alaska Native,IDH1 R132H,26.7,1,Placebo,Standard,2021-04-25,Pediatric_Assent,Japan,SITE-013
PT-004185,XS-OD-0045,2,Male,Black or African American,BAP1 loss,57.6,3,Active_Drug,Standard,2021-06-11,Pediatric_Assent,Spain,SITE-026
PT-004186,XS-OD-0045,5,Male,White,PDGFRA D842V,66.1,2,Placebo,Standard,2021-09-19,Pediatric_Assent,Japan,SITE-013
PT-004187,XS-OD-0045,7,Male,American Indian or Alaska Native,IDH1 R132H,58.8,2,Active_Drug,Standard,2021-07-22,Pediatric_Assent,Spain,SITE-030
PT-004188,XS-OD-0045,8,Male,Black or African American,IDH1 R132H,81.4,0,Placebo,Standard,2021-07-15,Pediatric_Assent,Japan,SITE-028
PT-004189,XS-OD-0045,2,Female,White,KIT D816V,61.7,3,Active_Drug,Standard,2021-05-12,Pediatric_Assent,France,SITE-030
PT-004190,XS-OD-0045,6,Female,Hispanic or Latino,IDH1 R132H,73.0,4,Placebo,Standard,2021-09-06,Pediatric_Assent,Italy,SITE-016
PT-004191,XS-OD-0045,8,Female,Hispanic or Latino,IDH1 R132H,48.3,5,Active_Drug,Standard,2021-09-17,Pediatric_Assent,France,SITE-014
PT-004192,XS-OD-0045,1,Male,Black or African American,PDGFRA D842V,87.0,4,Placebo,Standard,2021-09-27,Pediatric_Assent,Spain,SITE-013
PT-004193,XS-OD-0045,3,Male,Hispanic or Latino,IDH1 R132H,70.3,2,Active_Drug,Standard,2021-05-08,Pediatric_Assent,United Kingdom,SITE-015
PT-004194,XS-OD-0045,3,Female,White,,40.1,3,Placebo,Standard,2021-06-30,Pediatric_Assent,Japan,SITE-001
PT-004195,XS-OD-0045,6,Female,White,,10.0,4,Active_Drug,Standard,2021-06-25,Pediatric_Assent,Spain,SITE-025
PT-004196,XS-OD-0045,3,Male,Hispanic or Latino,KIT D816V,76.6,1,Placebo,Standard,2021-04-22,Pediatric_Assent,Canada,SITE-024
PT-004197,XS-OD-0045,5,Male,White,KIT D816V,22.1,0,Active_Drug,Standard,2021-08-06,Pediatric_Assent,Netherlands,SITE-003
PT-004198,XS-OD-0045,2,Male,Native Hawaiian or Other Pacific Islander,KIT D816V,63.5,5,Placebo,Standard,2021-05-13,Pediatric_Assent,United States,SITE-017
PT-004199,XS-OD-0045,1,Male,Hispanic or Latino,KIT D816V,27.4,1,Active_Drug,Standard,2021-04-29,Pediatric_Assent,Germany,SITE-029
PT-004200,XS-OD-0045,1,Male,American Indian or Alaska Native,KIT D816V,31.4,2,Placebo,Standard,2021-10-04,Pediatric_Assent,Netherlands,SITE-016
PT-004201,XS-OD-0045,7,Female,Asian,BAP1 loss,65.9,2,Active_Drug,Standard,2021-06-07,Pediatric_Assent,Netherlands,SITE-003
PT-004202,XS-OD-0045,4,Male,White,IDH1 R132H,35.8,4,Placebo,Standard,2021-05-27,Pediatric_Assent,Italy,SITE-021
PT-004203,XS-OD-0045,7,Male,Black or African American,KIT D816V,36.9,3,Active_Drug,Standard,2021-05-13,Pediatric_Assent,United States,SITE-009
PT-004204,XS-OD-0045,4,Female,White,IDH1 R132H,66.0,0,Placebo,Standard,2021-07-16,Pediatric_Assent,Japan,SITE-018
PT-004205,XS-OD-0045,5,Female,White,,55.0,2,Active_Drug,Standard,2021-05-31,Pediatric_Assent,Italy,SITE-006
PT-004206,XS-OD-0045,5,Female,White,,69.3,2,Placebo,Standard,2021-04-19,Pediatric_Assent,Italy,SITE-029
PT-004207,XS-OD-0045,5,Male,Black or African American,KIT D816V,68.3,2,Active_Drug,Standard,2021-10-06,Pediatric_Assent,United Kingdom,SITE-014
PT-004208,XS-OD-0045,8,Male,Hispanic or Latino,,82.0,4,Placebo,Standard,2021-08-12,Pediatric_Assent,United Kingdom,SITE-011
PT-004209,XS-OD-0045,8,Female,Black or African American,BAP1 loss,62.9,1,Active_Drug,Standard,2021-05-21,Pediatric_Assent,Japan,SITE-014
PT-004210,XS-OD-0045,4,Male,White,KIT D816V,61.5,1,Placebo,Standard,2021-05-10,Pediatric_Assent,Japan,SITE-004
PT-004211,XS-OD-0045,8,Male,Hispanic or Latino,,48.8,3,Active_Drug,Standard,2021-06-29,Pediatric_Assent,United States,SITE-030
PT-004212,XS-OD-0045,6,Male,White,KIT D816V,72.4,2,Placebo,Standard,2021-04-11,Pediatric_Assent,United States,SITE-015
PT-004213,XS-OD-0045,5,Male,White,IDH1 R132H,74.1,3,Active_Drug,Standard,2021-05-20,Pediatric_Assent,Germany,SITE-001
PT-004214,XS-OD-0045,8,Female,White,IDH1 R132H,26.7,2,Placebo,Standard,2021-08-26,Pediatric_Assent,Germany,SITE-021
PT-004215,XS-OD-0045,9,Male,Asian,BAP1 loss,62.3,2,Active_Drug,Standard,2021-06-01,Pediatric_Assent,Japan,SITE-029
PT-004216,XS-OD-0045,4,Female,Black or African American,BAP1 loss,39.3,3,Placebo,Standard,2021-07-29,Pediatric_Assent,France,SITE-025
PT-004217,XS-OD-0045,6,Male,White,KIT D816V,65.2,1,Active_Drug,Standard,2021-07-11,Pediatric_Assent,Germany,SITE-028
PT-004218,XS-OD-0045,8,Male,Asian,BAP1 loss,24.6,2,Placebo,Standard,2021-04-19,Pediatric_Assent,Netherlands,SITE-014
PT-004219,XS-OD-0045,11,Male,White,KIT D816V,61.2,0,Active_Drug,Standard,2021-07-29,Pediatric_Assent,Spain,SITE-003
PT-004220,XS-OD-0045,5,Female,Asian,,38.3,4,Placebo,Standard,2021-06-13,Pediatric_Assent,Japan,SITE-019
PT-004221,XS-OD-0045,5,Female,Asian,,95.0,3,Active_Drug,Standard,2021-06-19,Pediatric_Assent,United States,SITE-005
PT-004222,XS-OD-0045,5,Female,American Indian or Alaska Native,IDH1 R132H,69.7,1,Placebo,Standard,2021-09-01,Pediatric_Assent,Spain,SITE-029
PT-004223,XS-OD-0045,3,Male,Black or African American,IDH1 R132H,78.0,3,Active_Drug,Standard,2021-07-23,Pediatric_Assent,Germany,SITE-025
PT-004224,XS-OD-0045,3,Male,Hispanic or Latino,PDGFRA D842V,46.9,3,Placebo,Standard,2021-07-07,Pediatric_Assent,France,SITE-009
PT-004225,XS-OD-0045,4,Male,White,KIT D816V,56.1,0,Active_Drug,Standard,2021-04-29,Pediatric_Assent,Italy,SITE-028
PT-004226,XS-OD-0045,1,Intersex,Black or African American,KIT D816V,95.0,1,Placebo,Standard,2021-06-03,Pediatric_Assent,United States,SITE-004
PT-004227,XS-OD-0045,3,Male,White,IDH1 R132H,94.4,0,Active_Drug,Standard,2021-06-15,Pediatric_Assent,Australia,SITE-001
PT-004228,XS-OD-0045,3,Female,Two or More Races,KIT D816V,45.2,1,Placebo,Standard,2021-07-05,Pediatric_Assent,Canada,SITE-021
PT-004229,XS-OD-0045,8,Female,Black or African American,PDGFRA D842V,67.5,1,Active_Drug,Standard,2021-08-13,Pediatric_Assent,United States,SITE-018
PT-004230,XS-OD-0045,1,Male,White,BAP1 loss,55.7,2,Placebo,Standard,2021-06-26,Pediatric_Assent,France,SITE-015
PT-004231,XS-OD-0045,6,Male,Black or African American,KIT D816V,95.0,4,Active_Drug,Standard,2021-09-16,Pediatric_Assent,United States,SITE-007
PT-004232,XS-OD-0045,7,Male,White,IDH1 R132H,57.1,0,Placebo,Standard,2021-07-18,Pediatric_Assent,Germany,SITE-005
PT-004233,XS-OD-0045,1,Male,Asian,KIT D816V,92.8,2,Active_Drug,Standard,2021-08-14,Pediatric_Assent,United States,SITE-016
PT-004234,XS-OD-0045,7,Male,Two or More Races,,55.9,4,Placebo,Standard,2021-05-01,Pediatric_Assent,Canada,SITE-027
PT-004235,XS-OD-0045,1,Female,Black or African American,,32.0,2,Active_Drug,Standard,2021-05-07,Pediatric_Assent,Japan,SITE-018
PT-004236,XS-OD-0045,5,Female,Hispanic or Latino,,35.2,2,Placebo,Standard,2021-09-28,Pediatric_Assent,United States,SITE-004
PT-004237,XS-OD-0045,2,Female,Hispanic or Latino,PDGFRA D842V,29.4,1,Active_Drug,Standard,2021-05-01,Pediatric_Assent,Spain,SITE-018
PT-004238,XS-OD-0045,4,Female,White,BAP1 loss,61.8,4,Placebo,Standard,2021-06-11,Pediatric_Assent,United States,SITE-010
PT-004239,XS-OD-0045,3,Female,Native Hawaiian or Other Pacific Islander,,74.4,4,Active_Drug,Standard,2021-08-16,Pediatric_Assent,Japan,SITE-021
PT-004240,XS-OD-0045,6,Female,White,KIT D816V,66.8,2,Placebo,Standard,2021-07-15,Pediatric_Assent,United Kingdom,SITE-023
PT-004241,XS-OD-0045,7,Female,Black or African American,,81.9,2,Active_Drug,Standard,2021-07-30,Pediatric_Assent,Germany,SITE-003
PT-004242,XS-OD-0045,1,Male,White,,24.1,3,Placebo,Standard,2021-08-24,Pediatric_Assent,Spain,SITE-020
PT-004243,XS-OD-0046,50,Female,Hispanic or Latino,NLRP3 R260W,49.8,3,Active_Drug,Standard,2024-10-15,Standard,Australia,SITE-005
PT-004244,XS-OD-0046,70,Female,White,NLRP3 R260W,40.6,4,Placebo,Standard,2024-11-01,Standard,Italy,SITE-005
PT-004245,XS-OD-0046,47,Female,White,,51.5,3,Active_Drug_High_Dose,Standard,2024-09-08,Standard,United Kingdom,SITE-002
PT-004246,XS-OD-0046,30,Male,White,SERPING1 c.1396C>T,35.5,5,Active_Drug,Standard,2024-08-16,Standard,Australia,SITE-011
PT-004247,XS-OD-0046,50,Male,Black or African American,C5 p.R885H,10.0,3,Placebo,Standard,2024-08-16,Standard,Italy,SITE-005
PT-004248,XS-OD-0046,47,Female,Hispanic or Latino,,38.7,2,Active_Drug_High_Dose,Standard,2024-09-25,Standard,Canada,SITE-005
PT-004249,XS-OD-0046,43,Male,White,SERPING1 c.1396C>T,35.9,1,Active_Drug,Standard,2024-12-09,Standard,United States,SITE-004
PT-004250,XS-OD-0046,53,Female,White,,44.6,3,Placebo,Standard,2024-09-19,Standard,United States,SITE-003
PT-004251,XS-OD-0046,57,Female,White,NLRP3 R260W,68.1,1,Active_Drug_High_Dose,Standard,2024-09-07,Standard,Australia,SITE-003
PT-004252,XS-OD-0046,17,Female,White,SERPING1 c.1396C>T,41.2,1,Active_Drug,Standard,2024-11-21,Pediatric_Assent,United States,SITE-009
PT-004253,XS-OD-0046,38,Female,White,C5 p.R885H,26.7,2,Placebo,Standard,2025-01-19,Standard,United States,SITE-008
PT-004254,XS-OD-0046,57,Male,White,NLRP3 R260W,78.2,2,Active_Drug_High_Dose,Standard,2025-01-02,Standard,Germany,SITE-005
PT-004255,XS-OD-0046,39,Female,White,SERPING1 c.1396C>T,70.9,3,Active_Drug,Standard,2024-10-19,Standard,France,SITE-002
PT-004256,XS-OD-0046,5,Male,Black or African American,,61.7,1,Placebo,Standard,2024-11-30,Pediatric_Assent,France,SITE-010
PT-004257,XS-OD-0046,6,Male,Hispanic or Latino,NLRP3 R260W,75.5,2,Active_Drug_High_Dose,Standard,2024-10-08,Pediatric_Assent,United Kingdom,SITE-002
PT-004258,XS-OD-0046,31,Female,American Indian or Alaska Native,C5 p.R885H,88.2,2,Active_Drug,Standard,2024-08-08,Standard,Germany,SITE-005
PT-004259,XS-OD-0046,31,Female,White,C5 p.R885H,65.5,4,Placebo,Standard,2024-12-28,Standard,Canada,SITE-002
PT-004260,XS-OD-0046,54,Female,White,NLRP3 R260W,24.2,5,Active_Drug_High_Dose,Standard,2024-11-28,Standard,Canada,SITE-012
PT-004261,XS-OD-0046,40,Female,White,C5 p.R885H,73.1,4,Active_Drug,Standard,2024-10-16,Standard,Australia,SITE-001
PT-004262,XS-OD-0046,35,Female,White,NLRP3 R260W,27.8,0,Placebo,Standard,2024-07-29,Standard,Germany,SITE-007
PT-004263,XS-OD-0046,30,Male,White,NLRP3 R260W,48.8,2,Active_Drug_High_Dose,Standard,2024-10-06,Standard,United Kingdom,SITE-007
PT-004264,XS-OD-0046,66,Male,Asian,NLRP3 R260W,54.5,1,Active_Drug,Standard,2024-10-20,Standard,United Kingdom,SITE-003
PT-004265,XS-OD-0046,56,Male,White,NLRP3 R260W,66.9,3,Placebo,Standard,2024-11-26,Standard,Japan,SITE-006
PT-004266,XS-OD-0046,26,Male,White,SERPING1 c.1396C>T,65.6,4,Active_Drug_High_Dose,Standard,2024-10-02,Standard,United States,SITE-004
PT-004267,XS-OD-0046,40,Male,Black or African American,SERPING1 c.1396C>T,59.7,1,Active_Drug,Standard,2024-09-23,Standard,Italy,SITE-002
PT-004268,XS-OD-0046,34,Male,Black or African American,,77.7,3,Placebo,Standard,2024-07-29,Standard,Germany,SITE-011
PT-004269,XS-OD-0046,25,Female,Asian,NLRP3 R260W,67.4,4,Active_Drug_High_Dose,Standard,2024-09-19,Standard,Netherlands,SITE-004
PT-004270,XS-OD-0046,52,Female,White,SERPING1 c.1396C>T,50.1,3,Active_Drug,Standard,2024-10-29,Standard,Japan,SITE-008
PT-004271,XS-OD-0046,23,Female,White,NLRP3 R260W,64.7,2,Placebo,Standard,2025-01-18,Standard,Italy,SITE-012
PT-004272,XS-OD-0046,43,Female,White,,30.6,2,Active_Drug_High_Dose,Standard,2024-09-03,Standard,Australia,SITE-012
PT-004273,XS-OD-0046,37,Male,Asian,C5 p.R885H,89.5,5,Active_Drug,Standard,2024-12-24,Standard,France,SITE-001
PT-004274,XS-OD-0046,30,Male,White,NLRP3 R260W,64.0,4,Placebo,Standard,2024-10-22,Standard,Japan,SITE-001
PT-004275,XS-OD-0046,26,Female,White,C5 p.R885H,57.6,3,Active_Drug_High_Dose,Standard,2024-11-25,Standard,France,SITE-001
PT-004276,XS-OD-0046,38,Female,White,NLRP3 R260W,37.5,2,Active_Drug,Standard,2024-10-04,Standard,Australia,SITE-007
PT-004277,XS-OD-0046,15,Female,White,SERPING1 c.1396C>T,22.9,2,Placebo,Standard,2024-12-22,Pediatric_Assent,Italy,SITE-004
PT-004278,XS-OD-0046,30,Female,White,C5 p.R885H,25.9,4,Active_Drug_High_Dose,Standard,2024-12-06,Standard,Japan,SITE-009
PT-004279,XS-OD-0046,29,Female,White,C5 p.R885H,67.1,2,Active_Drug,Standard,2024-10-30,Compassionate,Australia,SITE-009
PT-004280,XS-OD-0046,26,Female,White,,69.0,3,Placebo,Standard,2024-11-12,Standard,Australia,SITE-003
PT-004281,XS-OD-0046,50,Male,Black or African American,,67.4,0,Active_Drug_High_Dose,Standard,2024-08-10,Standard,United Kingdom,SITE-012
PT-004282,XS-OD-0046,61,Male,White,NLRP3 R260W,81.1,6,Active_Drug,Standard,2025-01-12,Standard,Spain,SITE-005
PT-004283,XS-OD-0046,2,Male,Hispanic or Latino,,27.9,0,Placebo,Standard,2025-01-19,Pediatric_Assent,United Kingdom,SITE-009
PT-004284,XS-OD-0046,42,Female,Black or African American,,79.3,3,Active_Drug_High_Dose,Standard,2024-12-29,Standard,France,SITE-008
PT-004285,XS-OD-0046,44,Female,White,NLRP3 R260W,67.6,2,Active_Drug,Standard,2025-01-03,Standard,Australia,SITE-011
PT-004286,XS-OD-0046,41,Female,White,C5 p.R885H,56.2,1,Placebo,Standard,2025-01-16,Standard,Spain,SITE-012
PT-004287,XS-OD-0046,43,Male,White,C5 p.R885H,63.2,0,Active_Drug_High_Dose,Standard,2024-11-08,Standard,United States,SITE-012
PT-004288,XS-OD-0046,73,Male,White,NLRP3 R260W,53.9,4,Active_Drug,Standard,2024-12-17,Standard,United Kingdom,SITE-012
PT-004289,XS-OD-0046,55,Female,Asian,,40.9,2,Placebo,Standard,2024-10-26,Standard,Australia,SITE-001
PT-004290,XS-OD-0046,52,Male,Black or African American,,71.2,3,Active_Drug_High_Dose,Standard,2024-11-30,Standard,Japan,SITE-007
PT-004291,XS-OD-0046,18,Female,Asian,C5 p.R885H,52.3,3,Active_Drug,Standard,2024-11-21,Standard,United Kingdom,SITE-005
PT-004292,XS-OD-0046,40,Female,White,SERPING1 c.1396C>T,22.0,2,Placebo,Standard,2024-09-20,Standard,Netherlands,SITE-004
PT-004293,XS-OD-0046,49,Male,Asian,NLRP3 R260W,64.4,0,Active_Drug_High_Dose,Standard,2024-12-29,Compassionate,Canada,SITE-004
PT-004294,XS-OD-0046,61,Female,Hispanic or Latino,SERPING1 c.1396C>T,27.4,0,Active_Drug,Standard,2024-08-29,Standard,Netherlands,SITE-011
PT-004295,XS-OD-0046,63,Female,White,,63.9,3,Placebo,Standard,2024-08-27,Standard,United Kingdom,SITE-006
PT-004296,XS-OD-0046,66,Female,White,SERPING1 c.1396C>T,39.4,1,Active_Drug_High_Dose,Standard,2024-10-07,Compassionate,Netherlands,SITE-010
PT-004297,XS-OD-0046,51,Male,Asian,,49.2,5,Active_Drug,Standard,2024-08-27,Standard,Italy,SITE-004
PT-004298,XS-OD-0046,44,Female,White,,47.2,2,Placebo,Standard,2024-10-30,Standard,Germany,SITE-007
PT-004299,XS-OD-0046,50,Female,White,SERPING1 c.1396C>T,57.1,1,Active_Drug_High_Dose,Standard,2024-09-26,Standard,United States,SITE-010
PT-004300,XS-OD-0046,57,Female,White,NLRP3 R260W,35.4,1,Active_Drug,Standard,2024-12-15,Standard,United States,SITE-007
PT-004301,XS-OD-0046,48,Female,Asian,,61.5,2,Placebo,Standard,2024-08-07,Standard,United Kingdom,SITE-006
PT-004302,XS-OD-0046,23,Female,Hispanic or Latino,,52.8,0,Active_Drug_High_Dose,Standard,2024-09-05,Standard,Australia,SITE-012
PT-004303,XS-OD-0046,49,Intersex,White,NLRP3 R260W,33.8,2,Active_Drug,Standard,2024-12-19,Standard,Australia,SITE-007
PT-004304,XS-OD-0046,50,Male,Hispanic or Latino,C5 p.R885H,64.8,0,Placebo,Standard,2024-08-31,Standard,Germany,SITE-010
PT-004305,XS-OD-0046,33,Female,White,,55.8,2,Active_Drug_High_Dose,Standard,2024-10-21,Standard,France,SITE-008
PT-004306,XS-OD-0046,43,Male,American Indian or Alaska Native,SERPING1 c.1396C>T,86.1,1,Active_Drug,Standard,2024-09-09,Standard,Canada,SITE-009
PT-004307,XS-OD-0046,3,Male,Hispanic or Latino,,54.2,3,Placebo,Standard,2025-01-14,Pediatric_Assent,United Kingdom,SITE-012
PT-004308,XS-OD-0046,46,Male,Black or African American,SERPING1 c.1396C>T,49.1,3,Active_Drug_High_Dose,Standard,2024-08-28,Standard,Japan,SITE-006
PT-004309,XS-OD-0046,57,Male,White,SERPING1 c.1396C>T,47.2,2,Active_Drug,Standard,2024-10-14,Standard,Spain,SITE-007
PT-004310,XS-OD-0046,28,Female,White,,58.2,3,Placebo,Standard,2024-09-11,Standard,France,SITE-001
PT-004311,XS-OD-0046,39,Male,Black or African American,SERPING1 c.1396C>T,51.4,4,Active_Drug_High_Dose,Standard,2024-11-07,Standard,Spain,SITE-001
PT-004312,XS-OD-0046,51,Male,White,,69.4,1,Active_Drug,Standard,2024-10-22,Standard,Italy,SITE-002
PT-004313,XS-OD-0046,50,Male,White,NLRP3 R260W,25.8,2,Placebo,Standard,2024-11-15,Standard,United Kingdom,SITE-002
PT-004314,XS-OD-0046,36,Male,White,C5 p.R885H,36.8,3,Active_Drug_High_Dose,Standard,2024-09-15,Standard,Canada,SITE-012
PT-004315,XS-OD-0046,54,Female,White,NLRP3 R260W,55.7,2,Active_Drug,Standard,2024-08-30,Standard,United Kingdom,SITE-003
PT-004316,XS-OD-0046,39,Female,White,SERPING1 c.1396C>T,38.0,1,Placebo,Standard,2024-09-25,Standard,Japan,SITE-006
PT-004317,XS-OD-0046,31,Female,Hispanic or Latino,C5 p.R885H,66.6,1,Active_Drug_High_Dose,Standard,2024-11-08,Standard,Australia,SITE-007
PT-004318,XS-OD-0046,57,Female,White,C5 p.R885H,47.8,4,Active_Drug,Standard,2024-12-01,Standard,United States,SITE-001
PT-004319,XS-OD-0046,19,Male,White,,86.9,3,Placebo,Standard,2025-01-16,Standard,Netherlands,SITE-004
PT-004320,XS-OD-0046,53,Male,Black or African American,,60.2,1,Active_Drug_High_Dose,Standard,2024-10-14,Standard,Japan,SITE-011
PT-004321,XS-OD-0046,33,Female,White,C5 p.R885H,84.9,4,Active_Drug,Standard,2024-11-23,Standard,Canada,SITE-007
PT-004322,XS-OD-0046,26,Male,Black or African American,SERPING1 c.1396C>T,34.4,3,Placebo,Standard,2024-08-16,Standard,Spain,SITE-002
PT-004323,XS-OD-0046,38,Male,White,C5 p.R885H,55.2,0,Active_Drug_High_Dose,Standard,2024-08-07,Standard,France,SITE-007
PT-004324,XS-OD-0046,40,Female,Black or African American,,84.1,3,Active_Drug,Standard,2024-10-16,Standard,Spain,SITE-012
PT-004325,XS-OD-0046,32,Female,Hispanic or Latino,SERPING1 c.1396C>T,68.8,4,Placebo,Standard,2024-09-14,Standard,Germany,SITE-006
PT-004326,XS-OD-0047,72,Female,White,,82.1,1,Active_Drug,Standard,2023-11-20,Standard,Canada,SITE-050
PT-004327,XS-OD-0047,88,Female,White,NLRP3 R260W,33.0,1,Placebo,Standard,2024-01-14,Standard,Japan,SITE-047
PT-004328,XS-OD-0047,38,Female,Asian,SERPING1 c.1396C>T,43.1,1,Active_Drug,Standard,2023-12-22,Standard,United Kingdom,SITE-035
PT-004329,XS-OD-0047,39,Male,White,,56.9,1,Placebo,Standard,2024-03-18,Standard,United States,SITE-013
PT-004330,XS-OD-0047,42,Female,White,SERPING1 c.1396C>T,61.9,1,Active_Drug,Standard,2024-03-14,Standard,Germany,SITE-002
PT-004331,XS-OD-0047,55,Female,Hispanic or Latino,NLRP3 R260W,44.6,3,Placebo,Standard,2023-11-25,Standard,Spain,SITE-022
PT-004332,XS-OD-0047,41,Female,Hispanic or Latino,NLRP3 R260W,69.5,3,Active_Drug,Standard,2024-03-26,Standard,Japan,SITE-047
PT-004333,XS-OD-0047,35,Male,White,,10.0,3,Placebo,Standard,2024-04-21,Standard,United Kingdom,SITE-046
PT-004334,XS-OD-0047,36,Male,White,SERPING1 c.1396C>T,40.2,2,Active_Drug,Standard,2024-03-21,Standard,France,SITE-050
PT-004335,XS-OD-0047,63,Male,White,,52.7,1,Placebo,Standard,2024-01-23,Standard,Spain,SITE-004
PT-004336,XS-OD-0047,12,Female,White,,62.7,2,Active_Drug,Standard,2024-04-09,Pediatric_Assent,Japan,SITE-026
PT-004337,XS-OD-0047,72,Male,Black or African American,NLRP3 R260W,48.6,2,Placebo,Standard,2024-02-20,Standard,Japan,SITE-023
PT-004338,XS-OD-0047,79,Female,White,,45.0,3,Active_Drug,Standard,2024-03-14,Standard,United Kingdom,SITE-020
PT-004339,XS-OD-0047,34,Female,White,C5 p.R885H,22.1,0,Placebo,Standard,2023-12-10,Standard,United States,SITE-005
PT-004340,XS-OD-0047,71,Male,Two or More Races,NLRP3 R260W,71.7,0,Active_Drug,Standard,2024-02-04,Standard,Japan,SITE-025
PT-004341,XS-OD-0047,29,Male,White,,44.2,0,Placebo,Standard,2024-02-14,Standard,Italy,SITE-023
PT-004342,XS-OD-0047,42,Male,White,SERPING1 c.1396C>T,58.7,0,Active_Drug,Standard,2024-03-24,Standard,Japan,SITE-006
PT-004343,XS-OD-0047,68,Male,Native Hawaiian or Other Pacific Islander,,51.3,4,Placebo,Standard,2023-12-19,Standard,Germany,SITE-010
PT-004344,XS-OD-0047,65,Female,Black or African American,SERPING1 c.1396C>T,62.1,1,Active_Drug,Standard,2024-03-15,Standard,France,SITE-002
PT-004345,XS-OD-0047,57,Male,Black or African American,,61.1,3,Placebo,Standard,2024-04-21,Standard,Japan,SITE-040
PT-004346,XS-OD-0047,38,Female,Hispanic or Latino,C5 p.R885H,26.8,0,Active_Drug,Standard,2023-11-15,Standard,United Kingdom,SITE-024
PT-004347,XS-OD-0047,33,Male,White,,68.7,3,Placebo,Standard,2024-04-15,Standard,United States,SITE-042
PT-004348,XS-OD-0047,15,Male,Asian,C5 p.R885H,56.9,2,Active_Drug,Standard,2024-04-18,Pediatric_Assent,Germany,SITE-026
PT-004349,XS-OD-0047,43,Female,White,,63.2,1,Placebo,Standard,2024-04-16,Standard,Spain,SITE-030
PT-004350,XS-OD-0047,52,Female,White,SERPING1 c.1396C>T,49.1,2,Active_Drug,Standard,2024-01-21,Standard,Japan,SITE-040
PT-004351,XS-OD-0047,17,Female,White,,68.7,4,Placebo,Standard,2024-01-03,Pediatric_Assent,United Kingdom,SITE-025
PT-004352,XS-OD-0047,21,Female,White,C5 p.R885H,53.7,1,Active_Drug,Standard,2024-02-18,Standard,United States,SITE-049
PT-004353,XS-OD-0047,13,Female,Black or African American,,43.0,1,Placebo,Standard,2024-01-05,Pediatric_Assent,France,SITE-005
PT-004354,XS-OD-0047,45,Male,Black or African American,SERPING1 c.1396C>T,90.8,1,Active_Drug,Standard,2023-12-20,Standard,Italy,SITE-017
PT-004355,XS-OD-0047,39,Male,White,C5 p.R885H,59.5,2,Placebo,Standard,2024-04-11,Standard,Italy,SITE-010
PT-004356,XS-OD-0047,47,Female,Black or African American,SERPING1 c.1396C>T,63.9,3,Active_Drug,Standard,2024-02-08,Standard,France,SITE-015
PT-004357,XS-OD-0047,21,Female,Asian,NLRP3 R260W,43.9,5,Placebo,Standard,2024-04-06,Compassionate,Spain,SITE-008
PT-004358,XS-OD-0047,46,Male,Black or African American,C5 p.R885H,63.7,3,Active_Drug,Standard,2023-12-20,Standard,Japan,SITE-025
PT-004359,XS-OD-0047,39,Male,White,NLRP3 R260W,50.2,2,Placebo,Standard,2023-12-18,Standard,Australia,SITE-034
PT-004360,XS-OD-0047,35,Female,Asian,,71.4,0,Active_Drug,Standard,2024-03-17,Standard,Italy,SITE-031
PT-004361,XS-OD-0047,19,Male,White,C5 p.R885H,45.2,1,Placebo,Standard,2023-11-12,Standard,France,SITE-012
PT-004362,XS-OD-0047,47,Female,White,SERPING1 c.1396C>T,68.4,0,Active_Drug,Standard,2024-01-27,Standard,Spain,SITE-044
PT-004363,XS-OD-0047,60,Male,White,SERPING1 c.1396C>T,55.2,0,Placebo,Standard,2024-01-25,Standard,Italy,SITE-019
PT-004364,XS-OD-0047,26,Female,White,C5 p.R885H,54.8,3,Active_Drug,Standard,2024-02-15,Standard,Spain,SITE-048
PT-004365,XS-OD-0047,30,Male,Hispanic or Latino,,58.4,2,Placebo,Standard,2023-12-31,Standard,Netherlands,SITE-018
PT-004366,XS-OD-0047,65,Female,White,SERPING1 c.1396C>T,59.7,2,Active_Drug,Standard,2024-01-12,Standard,Australia,SITE-049
PT-004367,XS-OD-0047,42,Female,Hispanic or Latino,,67.8,1,Placebo,Standard,2024-04-04,Standard,Germany,SITE-047
PT-004368,XS-OD-0047,52,Female,White,NLRP3 R260W,66.1,1,Active_Drug,Standard,2024-05-05,Standard,Australia,SITE-044
PT-004369,XS-OD-0047,15,Male,White,NLRP3 R260W,73.3,1,Placebo,Standard,2024-01-16,Pediatric_Assent,Canada,SITE-032
PT-004370,XS-OD-0047,2,Female,Black or African American,,47.5,1,Active_Drug,Standard,2024-04-04,Pediatric_Assent,United Kingdom,SITE-017
PT-004371,XS-OD-0047,42,Male,Hispanic or Latino,,92.9,2,Placebo,Standard,2024-04-19,Standard,Netherlands,SITE-026
PT-004372,XS-OD-0047,2,Male,Asian,C5 p.R885H,30.3,0,Active_Drug,Standard,2024-05-03,Pediatric_Assent,Germany,SITE-011
PT-004373,XS-OD-0047,60,Male,Hispanic or Latino,,64.1,4,Placebo,Standard,2024-05-06,Standard,Italy,SITE-007
PT-004374,XS-OD-0047,9,Male,Hispanic or Latino,C5 p.R885H,39.3,3,Active_Drug,Standard,2024-01-15,Pediatric_Assent,United Kingdom,SITE-016
PT-004375,XS-OD-0047,49,Female,White,NLRP3 R260W,40.5,5,Placebo,Standard,2024-01-16,Standard,Netherlands,SITE-033
PT-004376,XS-OD-0047,48,Female,White,C5 p.R885H,28.5,1,Active_Drug,Standard,2024-02-26,Standard,United States,SITE-019
PT-004377,XS-OD-0047,52,Male,American Indian or Alaska Native,,50.4,3,Placebo,Standard,2023-11-27,Standard,Italy,SITE-014
PT-004378,XS-OD-0047,56,Male,White,,40.3,4,Active_Drug,Standard,2024-02-01,Standard,France,SITE-028
PT-004379,XS-OD-0047,38,Female,Hispanic or Latino,SERPING1 c.1396C>T,49.8,1,Placebo,Standard,2024-02-20,Standard,Italy,SITE-035
PT-004380,XS-OD-0047,59,Male,White,NLRP3 R260W,71.0,1,Active_Drug,Standard,2024-02-16,Standard,France,SITE-005
PT-004381,XS-OD-0047,24,Female,Black or African American,,39.9,2,Placebo,Standard,2024-04-05,Standard,Japan,SITE-015
PT-004382,XS-OD-0047,17,Female,White,NLRP3 R260W,56.5,0,Active_Drug,Standard,2024-02-29,Pediatric_Assent,Canada,SITE-049
PT-004383,XS-OD-0047,75,Female,White,,70.9,1,Placebo,Standard,2024-03-14,Standard,Canada,SITE-017
PT-004384,XS-OD-0047,58,Male,Asian,,37.2,1,Active_Drug,Standard,2024-01-28,Standard,Italy,SITE-038
PT-004385,XS-OD-0047,55,Male,Black or African American,NLRP3 R260W,71.6,2,Placebo,Standard,2024-02-04,Standard,Spain,SITE-012
PT-004386,XS-OD-0047,32,Male,American Indian or Alaska Native,,32.9,1,Active_Drug,Standard,2024-03-15,Standard,Australia,SITE-034
PT-004387,XS-OD-0047,34,Female,White,NLRP3 R260W,50.3,0,Placebo,Standard,2023-11-29,Standard,Germany,SITE-031
PT-004388,XS-OD-0047,42,Male,Hispanic or Latino,,39.5,3,Active_Drug,Standard,2024-03-24,Standard,United Kingdom,SITE-004
PT-004389,XS-OD-0047,40,Female,White,,57.8,2,Placebo,Standard,2024-05-04,Standard,France,SITE-004
PT-004390,XS-OD-0047,15,Female,Black or African American,,51.3,0,Active_Drug,Standard,2024-01-18,Pediatric_Assent,Italy,SITE-002
PT-004391,XS-OD-0047,20,Male,Asian,C5 p.R885H,75.2,0,Placebo,Standard,2024-04-02,Standard,Spain,SITE-038
PT-004392,XS-OD-0047,7,Male,Black or African American,C5 p.R885H,54.7,3,Active_Drug,Standard,2024-03-01,Pediatric_Assent,France,SITE-010
PT-004393,XS-OD-0047,18,Female,Black or African American,NLRP3 R260W,76.3,0,Placebo,Standard,2024-03-24,Standard,Canada,SITE-025
PT-004394,XS-OD-0047,31,Male,White,NLRP3 R260W,52.3,3,Active_Drug,Standard,2024-03-10,Standard,France,SITE-018
PT-004395,XS-OD-0047,25,Male,White,,71.2,3,Placebo,Standard,2024-02-15,Standard,France,SITE-040
PT-004396,XS-OD-0047,57,Female,Black or African American,C5 p.R885H,79.1,2,Active_Drug,Standard,2024-01-22,Standard,Canada,SITE-009
PT-004397,XS-OD-0047,53,Female,White,,57.4,2,Placebo,Standard,2024-05-07,Standard,United Kingdom,SITE-050
PT-004398,XS-OD-0047,57,Male,White,C5 p.R885H,86.6,5,Active_Drug,Standard,2023-11-12,Emergency,Germany,SITE-049
PT-004399,XS-OD-0047,40,Female,White,C5 p.R885H,59.2,0,Placebo,Standard,2024-04-14,Standard,Australia,SITE-019
PT-004400,XS-OD-0047,62,Female,White,SERPING1 c.1396C>T,20.3,1,Active_Drug,Standard,2024-02-28,Standard,Spain,SITE-043
PT-004401,XS-OD-0047,22,Female,White,,66.9,0,Placebo,Standard,2023-11-27,Standard,United Kingdom,SITE-007
PT-004402,XS-OD-0047,40,Female,Asian,NLRP3 R260W,74.4,4,Active_Drug,Standard,2024-01-06,Standard,Japan,SITE-006
PT-004403,XS-OD-0047,38,Male,White,C5 p.R885H,82.6,3,Placebo,Standard,2024-01-21,Emergency,Netherlands,SITE-030
PT-004404,XS-OD-0047,16,Male,Black or African American,C5 p.R885H,57.8,1,Active_Drug,Standard,2024-02-19,Pediatric_Assent,Spain,SITE-012
PT-004405,XS-OD-0047,16,Male,Hispanic or Latino,SERPING1 c.1396C>T,47.5,0,Placebo,Standard,2023-11-28,Pediatric_Assent,United Kingdom,SITE-009
PT-004406,XS-OD-0047,21,Male,Black or African American,,87.8,3,Active_Drug,Standard,2024-01-17,Standard,Germany,SITE-021
PT-004407,XS-OD-0047,57,Male,White,C5 p.R885H,60.8,2,Placebo,Standard,2024-01-08,Standard,Spain,SITE-041
PT-004408,XS-OD-0047,18,Female,White,NLRP3 R260W,91.1,3,Active_Drug,Standard,2024-05-07,Standard,Australia,SITE-051
PT-004409,XS-OD-0047,29,Male,Black or African American,NLRP3 R260W,10.0,0,Placebo,Standard,2024-03-11,Standard,France,SITE-019
PT-004410,XS-OD-0047,24,Female,Black or African American,,79.6,3,Active_Drug,Standard,2024-04-21,Standard,Canada,SITE-027
PT-004411,XS-OD-0047,50,Male,Black or African American,,50.6,0,Placebo,Standard,2024-04-06,Standard,Italy,SITE-036
PT-004412,XS-OD-0047,39,Female,White,C5 p.R885H,63.0,1,Active_Drug,Standard,2024-01-15,Standard,Netherlands,SITE-021
PT-004413,XS-OD-0047,28,Female,White,NLRP3 R260W,81.9,0,Placebo,Standard,2023-12-07,Standard,United Kingdom,SITE-018
PT-004414,XS-OD-0047,2,Male,Black or African American,SERPING1 c.1396C>T,49.7,2,Active_Drug,Standard,2024-01-11,Pediatric_Assent,Australia,SITE-028
PT-004415,XS-OD-0047,38,Male,Black or African American,,43.9,2,Placebo,Standard,2024-03-06,Standard,Canada,SITE-007
PT-004416,XS-OD-0047,56,Male,Two or More Races,,74.9,2,Active_Drug,Standard,2024-01-30,Standard,Japan,SITE-039
PT-004417,XS-OD-0047,44,Female,White,SERPING1 c.1396C>T,63.7,1,Placebo,Standard,2023-12-21,Standard,United States,SITE-002
PT-004418,XS-OD-0047,30,Female,White,C5 p.R885H,65.5,1,Active_Drug,Standard,2024-05-01,Standard,France,SITE-004
PT-004419,XS-OD-0047,32,Male,White,SERPING1 c.1396C>T,50.1,2,Placebo,Standard,2023-12-28,Standard,Netherlands,SITE-036
PT-004420,XS-OD-0047,29,Female,White,,41.6,2,Active_Drug,Standard,2024-02-12,Standard,Netherlands,SITE-046
PT-004421,XS-OD-0047,18,Male,White,,80.7,4,Placebo,Standard,2024-04-16,Standard,Canada,SITE-003
PT-004422,XS-OD-0047,68,Female,Black or African American,NLRP3 R260W,57.6,1,Active_Drug,Standard,2024-02-11,Standard,Australia,SITE-022
PT-004423,XS-OD-0047,46,Male,Asian,C5 p.R885H,39.9,2,Placebo,Standard,2024-04-29,Standard,Australia,SITE-008
PT-004424,XS-OD-0047,15,Female,White,NLRP3 R260W,10.0,1,Active_Drug,Standard,2024-02-13,Pediatric_Assent,Canada,SITE-002
PT-004425,XS-OD-0047,12,Male,White,,30.0,1,Placebo,Standard,2024-02-15,Pediatric_Assent,Spain,SITE-005
PT-004426,XS-OD-0047,16,Male,White,SERPING1 c.1396C>T,67.9,3,Active_Drug,Standard,2023-12-27,Pediatric_Assent,United Kingdom,SITE-033
PT-004427,XS-OD-0047,59,Male,Asian,C5 p.R885H,50.2,2,Placebo,Standard,2023-11-23,Standard,United States,SITE-006
PT-004428,XS-OD-0047,54,Female,White,NLRP3 R260W,32.2,2,Active_Drug,Standard,2024-02-06,Standard,Spain,SITE-025
PT-004429,XS-OD-0047,36,Female,White,NLRP3 R260W,48.2,2,Placebo,Standard,2023-12-01,Standard,Germany,SITE-005
PT-004430,XS-OD-0047,32,Female,White,C5 p.R885H,40.5,1,Active_Drug,Standard,2024-01-11,Standard,France,SITE-017
PT-004431,XS-OD-0047,33,Female,Asian,,76.7,0,Placebo,Standard,2024-03-22,Standard,Italy,SITE-032
PT-004432,XS-OD-0047,56,Female,Hispanic or Latino,C5 p.R885H,33.7,1,Active_Drug,Standard,2024-05-01,Standard,Canada,SITE-036
PT-004433,XS-OD-0047,24,Male,White,SERPING1 c.1396C>T,49.9,3,Placebo,Standard,2024-02-09,Standard,United States,SITE-020
PT-004434,XS-OD-0047,66,Intersex,White,C5 p.R885H,50.6,1,Active_Drug,Standard,2023-12-25,Standard,Japan,SITE-002
PT-004435,XS-OD-0047,55,Male,Black or African American,SERPING1 c.1396C>T,90.0,2,Placebo,Standard,2024-01-20,Standard,United Kingdom,SITE-007
PT-004436,XS-OD-0047,22,Female,White,,48.8,3,Active_Drug,Standard,2024-05-03,Compassionate,Germany,SITE-017
PT-004437,XS-OD-0047,59,Female,White,C5 p.R885H,37.9,1,Placebo,Standard,2024-03-14,Standard,Canada,SITE-026
PT-004438,XS-OD-0047,2,Male,Native Hawaiian or Other Pacific Islander,SERPING1 c.1396C>T,51.2,2,Active_Drug,Standard,2024-03-20,Pediatric_Assent,Australia,SITE-025
PT-004439,XS-OD-0047,33,Male,Asian,C5 p.R885H,31.8,3,Placebo,Standard,2024-05-06,Standard,United Kingdom,SITE-027
PT-004440,XS-OD-0047,52,Female,Hispanic or Latino,NLRP3 R260W,37.0,4,Active_Drug,Standard,2023-11-26,Standard,France,SITE-002
PT-004441,XS-OD-0047,30,Male,Black or African American,,37.4,2,Placebo,Standard,2024-03-13,Standard,Australia,SITE-027
PT-004442,XS-OD-0047,23,Female,Two or More Races,,58.4,3,Active_Drug,Standard,2024-04-01,Standard,Japan,SITE-021
PT-004443,XS-OD-0047,19,Male,White,,24.3,2,Placebo,Standard,2024-01-29,Standard,France,SITE-011
PT-004444,XS-OD-0047,51,Female,White,,76.5,2,Active_Drug,Standard,2024-04-26,Standard,Japan,SITE-036
PT-004445,XS-OD-0047,43,Female,White,SERPING1 c.1396C>T,74.5,0,Placebo,Standard,2023-12-14,Standard,Spain,SITE-048
PT-004446,XS-OD-0047,47,Male,Hispanic or Latino,,58.8,2,Active_Drug,Standard,2023-12-12,Standard,Germany,SITE-046
PT-004447,XS-OD-0047,74,Female,White,C5 p.R885H,61.8,0,Placebo,Standard,2024-01-17,Standard,Netherlands,SITE-008
PT-004448,XS-OD-0047,47,Female,White,C5 p.R885H,74.0,2,Active_Drug,Standard,2024-01-19,Standard,Netherlands,SITE-031
PT-004449,XS-OD-0047,2,Female,Asian,C5 p.R885H,43.7,4,Placebo,Standard,2024-02-17,Pediatric_Assent,Japan,SITE-004
PT-004450,XS-OD-0047,31,Female,Hispanic or Latino,C5 p.R885H,29.3,2,Active_Drug,Standard,2023-12-21,Standard,United States,SITE-034
PT-004451,XS-OD-0047,37,Female,White,,87.7,1,Placebo,Standard,2024-05-06,Standard,United Kingdom,SITE-036
PT-004452,XS-OD-0047,63,Female,Asian,,58.2,0,Active_Drug,Standard,2023-11-24,Standard,France,SITE-008
PT-004453,XS-OD-0047,49,Female,White,NLRP3 R260W,77.8,2,Placebo,Standard,2023-12-14,Standard,Australia,SITE-022
PT-004454,XS-OD-0047,63,Male,Black or African American,C5 p.R885H,95.0,1,Active_Drug,Standard,2024-02-14,Standard,France,SITE-024
PT-004455,XS-OD-0047,35,Male,Black or African American,NLRP3 R260W,54.2,2,Placebo,Standard,2024-03-17,Standard,Australia,SITE-027
PT-004456,XS-OD-0047,54,Female,Black or African American,NLRP3 R260W,46.9,1,Active_Drug,Standard,2024-04-20,Standard,Netherlands,SITE-017
PT-004457,XS-OD-0047,59,Male,American Indian or Alaska Native,,54.3,4,Placebo,Standard,2024-03-17,Standard,Japan,SITE-017
PT-004458,XS-OD-0047,51,Male,Black or African American,,95.0,2,Active_Drug,Standard,2024-04-22,Standard,United Kingdom,SITE-018
PT-004459,XS-OD-0047,47,Male,Asian,NLRP3 R260W,53.9,1,Placebo,Standard,2023-11-22,Standard,Canada,SITE-023
PT-004460,XS-OD-0047,51,Male,Black or African American,C5 p.R885H,23.8,3,Active_Drug,Standard,2024-02-15,Standard,France,SITE-003
PT-004461,XS-OD-0047,36,Male,White,NLRP3 R260W,63.8,0,Placebo,Standard,2024-01-27,Standard,Netherlands,SITE-014
PT-004462,XS-OD-0047,6,Female,White,NLRP3 R260W,14.8,2,Active_Drug,Standard,2024-03-06,Pediatric_Assent,Australia,SITE-047
PT-004463,XS-OD-0047,19,Male,White,NLRP3 R260W,68.0,0,Placebo,Standard,2024-01-13,Standard,Japan,SITE-031
PT-004464,XS-OD-0047,39,Female,Asian,,43.1,1,Active_Drug,Standard,2024-05-01,Standard,Australia,SITE-021
PT-004465,XS-OD-0047,19,Male,Native Hawaiian or Other Pacific Islander,C5 p.R885H,88.3,0,Placebo,Standard,2024-04-18,Emergency,Netherlands,SITE-048
PT-004466,XS-OD-0047,59,Male,White,,60.8,0,Active_Drug,Standard,2024-03-13,Standard,United States,SITE-046
PT-004467,XS-OD-0047,54,Male,White,C5 p.R885H,21.6,1,Placebo,Standard,2023-12-15,Standard,Canada,SITE-047
PT-004468,XS-OD-0047,44,Male,Hispanic or Latino,NLRP3 R260W,38.2,2,Active_Drug,Standard,2023-11-29,Standard,Spain,SITE-036
PT-004469,XS-OD-0047,43,Male,White,SERPING1 c.1396C>T,51.0,3,Placebo,Standard,2024-05-06,Standard,United Kingdom,SITE-005
PT-004470,XS-OD-0047,31,Male,White,,70.9,1,Active_Drug,Standard,2024-01-29,Standard,Australia,SITE-047
PT-004471,XS-OD-0047,37,Female,White,,51.6,2,Placebo,Standard,2024-03-04,Standard,Italy,SITE-020
PT-004472,XS-OD-0047,45,Male,White,,23.0,2,Active_Drug,Standard,2023-12-26,Standard,France,SITE-041
PT-004473,XS-OD-0047,36,Female,Hispanic or Latino,,71.6,1,Placebo,Standard,2024-03-10,Standard,Australia,SITE-008
PT-004474,XS-OD-0047,32,Male,Two or More Races,NLRP3 R260W,79.2,1,Active_Drug,Standard,2024-01-24,Standard,United States,SITE-016
PT-004475,XS-OD-0047,43,Male,White,,55.7,0,Placebo,Standard,2023-12-11,Standard,Germany,SITE-029
PT-004476,XS-OD-0047,60,Male,Black or African American,,77.5,2,Active_Drug,Standard,2024-04-29,Standard,France,SITE-050
PT-004477,XS-OD-0047,38,Female,White,C5 p.R885H,50.7,3,Placebo,Standard,2024-03-25,Standard,Netherlands,SITE-007
PT-004478,XS-OD-0047,39,Male,Black or African American,C5 p.R885H,76.9,4,Active_Drug,Standard,2024-01-12,Standard,United Kingdom,SITE-020
PT-004479,XS-OD-0047,10,Female,Black or African American,,59.8,1,Placebo,Standard,2024-01-03,Pediatric_Assent,United Kingdom,SITE-041
PT-004480,XS-OD-0047,34,Male,White,NLRP3 R260W,62.9,5,Active_Drug,Standard,2024-03-22,Standard,Germany,SITE-040
PT-004481,XS-OD-0047,23,Female,Black or African American,,48.4,1,Placebo,Standard,2024-01-31,Standard,United Kingdom,SITE-003
PT-004482,XS-OD-0047,19,Female,Black or African American,,52.8,3,Active_Drug,Standard,2023-11-29,Standard,Canada,SITE-032
PT-004483,XS-OD-0047,56,Male,White,,52.8,0,Placebo,Standard,2024-01-19,Standard,Germany,SITE-004
PT-004484,XS-OD-0047,54,Female,White,,56.8,1,Active_Drug,Standard,2023-12-26,Standard,United Kingdom,SITE-014
PT-004485,XS-OD-0047,50,Female,White,,60.8,1,Placebo,Standard,2023-11-20,Standard,Spain,SITE-011
PT-004486,XS-OD-0047,51,Male,White,NLRP3 R260W,63.9,3,Active_Drug,Standard,2024-04-17,Standard,Australia,SITE-024
PT-004487,XS-OD-0047,35,Male,American Indian or Alaska Native,C5 p.R885H,20.8,2,Placebo,Standard,2024-01-16,Standard,United Kingdom,SITE-008
PT-004488,XS-OD-0047,54,Female,White,SERPING1 c.1396C>T,64.9,3,Active_Drug,Standard,2024-04-19,Standard,Italy,SITE-047
PT-004489,XS-OD-0047,22,Male,White,NLRP3 R260W,47.6,1,Placebo,Standard,2024-01-11,Standard,United States,SITE-010
PT-004490,XS-OD-0047,56,Male,Black or African American,,64.7,1,Active_Drug,Standard,2023-12-23,Standard,Netherlands,SITE-003
PT-004491,XS-OD-0047,51,Male,Hispanic or Latino,NLRP3 R260W,51.4,2,Placebo,Standard,2023-11-23,Standard,Japan,SITE-001
PT-004492,XS-OD-0047,43,Female,Hispanic or Latino,C5 p.R885H,60.1,2,Active_Drug,Standard,2024-03-19,Standard,Japan,SITE-047
PT-004493,XS-OD-0047,51,Male,White,,67.4,0,Placebo,Standard,2023-12-29,Standard,Italy,SITE-028
PT-004494,XS-OD-0047,50,Female,Hispanic or Latino,NLRP3 R260W,58.9,2,Active_Drug,Standard,2024-05-07,Standard,Australia,SITE-004
PT-004495,XS-OD-0047,52,Female,White,SERPING1 c.1396C>T,63.2,3,Placebo,Standard,2024-03-20,Standard,France,SITE-048
PT-004496,XS-OD-0047,56,Female,Hispanic or Latino,,63.9,1,Active_Drug,Standard,2024-04-20,Standard,Netherlands,SITE-026
PT-004497,XS-OD-0047,31,Female,Asian,,75.2,3,Placebo,Standard,2023-12-31,Standard,United States,SITE-022
PT-004498,XS-OD-0047,44,Female,White,SERPING1 c.1396C>T,95.0,1,Active_Drug,Standard,2024-02-14,Standard,Netherlands,SITE-003
PT-004499,XS-OD-0047,41,Male,White,NLRP3 R260W,55.4,1,Placebo,Standard,2024-02-10,Standard,Japan,SITE-016
PT-004500,XS-OD-0047,37,Male,White,NLRP3 R260W,74.7,3,Active_Drug,Standard,2024-01-26,Standard,Japan,SITE-041
PT-004501,XS-OD-0047,42,Male,Hispanic or Latino,NLRP3 R260W,82.9,1,Placebo,Standard,2024-03-01,Standard,Italy,SITE-030
PT-004502,XS-OD-0047,47,Male,Black or African American,NLRP3 R260W,72.2,4,Active_Drug,Standard,2023-11-14,Standard,Australia,SITE-046
PT-004503,XS-OD-0047,48,Female,Asian,NLRP3 R260W,51.9,2,Placebo,Standard,2023-11-14,Standard,Germany,SITE-039
PT-004504,XS-OD-0047,36,Female,Black or African American,,55.8,1,Active_Drug,Standard,2023-12-25,Emergency,France,SITE-041
PT-004505,XS-OD-0047,15,Male,Asian,,65.3,1,Placebo,Standard,2024-01-29,Pediatric_Assent,Netherlands,SITE-010
PT-004506,XS-OD-0047,42,Female,Asian,NLRP3 R260W,80.9,3,Active_Drug,Standard,2024-01-23,Standard,Australia,SITE-012
PT-004507,XS-OD-0047,20,Female,White,C5 p.R885H,37.2,0,Placebo,Standard,2023-12-04,Standard,Netherlands,SITE-044
PT-004508,XS-OD-0047,24,Female,Hispanic or Latino,SERPING1 c.1396C>T,43.9,0,Active_Drug,Standard,2023-11-30,Standard,Germany,SITE-007
PT-004509,XS-OD-0047,37,Male,Two or More Races,,78.6,2,Placebo,Standard,2024-02-26,Standard,United Kingdom,SITE-013
PT-004510,XS-OD-0047,35,Female,White,SERPING1 c.1396C>T,38.1,4,Active_Drug,Standard,2023-11-26,Standard,Netherlands,SITE-043
PT-004511,XS-OD-0047,10,Male,White,,89.5,4,Placebo,Standard,2024-03-16,Pediatric_Assent,United States,SITE-007
PT-004512,XS-OD-0047,60,Male,Hispanic or Latino,,50.5,2,Active_Drug,Standard,2024-03-19,Standard,United States,SITE-034
PT-004513,XS-OD-0047,61,Female,White,NLRP3 R260W,87.1,3,Placebo,Standard,2024-02-12,Standard,Canada,SITE-041
PT-004514,XS-OD-0047,18,Female,Black or African American,,57.8,0,Active_Drug,Standard,2024-04-02,Standard,Italy,SITE-041
PT-004515,XS-OD-0047,66,Male,White,NLRP3 R260W,56.2,2,Placebo,Standard,2024-03-16,Standard,Canada,SITE-007
PT-004516,XS-OD-0047,41,Female,Black or African American,C5 p.R885H,56.5,6,Active_Drug,Standard,2024-05-03,Standard,Netherlands,SITE-019
PT-004517,XS-OD-0047,54,Male,White,SERPING1 c.1396C>T,68.3,3,Placebo,Standard,2023-11-14,Standard,Canada,SITE-022
PT-004518,XS-OD-0047,51,Female,White,,80.5,1,Active_Drug,Standard,2024-04-29,Standard,United Kingdom,SITE-039
PT-004519,XS-OD-0047,54,Female,Asian,SERPING1 c.1396C>T,41.3,1,Placebo,Standard,2024-01-11,Standard,Netherlands,SITE-024
PT-004520,XS-OD-0047,51,Female,White,C5 p.R885H,70.4,2,Active_Drug,Standard,2024-03-27,Standard,Japan,SITE-012
PT-004521,XS-OD-0047,69,Male,Hispanic or Latino,,42.9,0,Placebo,Standard,2023-12-11,Standard,United Kingdom,SITE-003
PT-004522,XS-OD-0047,15,Female,White,C5 p.R885H,29.4,0,Active_Drug,Standard,2024-03-19,Pediatric_Assent,United States,SITE-024
PT-004523,XS-OD-0047,46,Male,White,C5 p.R885H,50.9,0,Placebo,Standard,2024-03-11,Standard,Japan,SITE-044
PT-004524,XS-OD-0047,38,Male,White,,47.2,3,Active_Drug,Standard,2024-02-15,Standard,Italy,SITE-015
PT-004525,XS-OD-0047,40,Male,White,,55.3,2,Placebo,Standard,2023-11-13,Standard,United Kingdom,SITE-032
PT-004526,XS-OD-0047,61,Male,White,C5 p.R885H,44.9,1,Active_Drug,Standard,2024-04-18,Standard,Canada,SITE-021
PT-004527,XS-OD-0047,29,Female,Black or African American,NLRP3 R260W,64.5,0,Placebo,Standard,2024-04-22,Standard,United Kingdom,SITE-018
PT-004528,XS-OD-0047,22,Female,White,SERPING1 c.1396C>T,46.0,2,Active_Drug,Standard,2023-12-17,Standard,Canada,SITE-009
PT-004529,XS-OD-0047,2,Male,White,C5 p.R885H,60.3,1,Placebo,Standard,2024-04-03,Pediatric_Assent,United States,SITE-025
PT-004530,XS-OD-0047,35,Male,White,C5 p.R885H,69.4,3,Active_Drug,Standard,2024-02-26,Standard,Japan,SITE-024
PT-004531,XS-OD-0047,38,Male,Black or African American,C5 p.R885H,51.5,3,Placebo,Standard,2024-02-02,Standard,Canada,SITE-027
PT-004532,XS-OD-0047,44,Female,Black or African American,SERPING1 c.1396C>T,52.6,1,Active_Drug,Standard,2024-04-29,Standard,United States,SITE-043
PT-004533,XS-OD-0047,19,Female,White,SERPING1 c.1396C>T,35.2,1,Placebo,Standard,2024-01-16,Standard,Italy,SITE-038
PT-004534,XS-OD-0047,63,Male,Native Hawaiian or Other Pacific Islander,C5 p.R885H,42.4,4,Active_Drug,Standard,2024-03-13,Standard,Germany,SITE-038
PT-004535,XS-OD-0047,50,Intersex,Black or African American,C5 p.R885H,77.1,2,Placebo,Standard,2023-11-13,Standard,United States,SITE-004
PT-004536,XS-OD-0047,35,Male,White,SERPING1 c.1396C>T,54.6,3,Active_Drug,Standard,2024-02-07,Standard,Italy,SITE-037
PT-004537,XS-OD-0047,50,Male,White,C5 p.R885H,60.7,1,Placebo,Standard,2024-02-17,Standard,France,SITE-022
PT-004538,XS-OD-0047,33,Female,White,,50.1,3,Active_Drug,Standard,2023-11-16,Standard,Germany,SITE-045
PT-004539,XS-OD-0047,56,Male,American Indian or Alaska Native,NLRP3 R260W,95.0,4,Placebo,Standard,2024-03-18,Standard,United Kingdom,SITE-015
PT-004540,XS-OD-0047,47,Male,Hispanic or Latino,,52.3,0,Active_Drug,Standard,2024-02-14,Standard,Spain,SITE-009
PT-004541,XS-OD-0047,49,Female,Two or More Races,,84.2,2,Placebo,Standard,2024-04-16,Standard,France,SITE-013
PT-004542,XS-OD-0047,30,Female,Hispanic or Latino,NLRP3 R260W,92.7,2,Active_Drug,Standard,2024-02-05,Standard,United States,SITE-003
PT-004543,XS-OD-0047,30,Male,Asian,NLRP3 R260W,49.1,3,Placebo,Standard,2024-04-30,Standard,Netherlands,SITE-003
PT-004544,XS-OD-0047,50,Male,Black or African American,SERPING1 c.1396C>T,45.9,2,Active_Drug,Standard,2023-12-21,Standard,Italy,SITE-009
PT-004545,XS-OD-0047,48,Female,Black or African American,SERPING1 c.1396C>T,66.7,0,Placebo,Standard,2023-12-04,Standard,Italy,SITE-005
PT-004546,XS-OD-0047,18,Female,White,,66.3,2,Active_Drug,Standard,2024-03-24,Standard,Japan,SITE-038
PT-004547,XS-OD-0047,62,Female,Asian,SERPING1 c.1396C>T,66.0,4,Placebo,Standard,2023-11-14,Standard,Italy,SITE-005
PT-004548,XS-OD-0047,29,Male,White,NLRP3 R260W,42.0,1,Active_Drug,Standard,2023-11-28,Standard,Spain,SITE-020
PT-004549,XS-OD-0047,42,Male,Asian,,25.1,3,Placebo,Standard,2024-02-06,Standard,United States,SITE-038
PT-004550,XS-OD-0047,59,Female,White,C5 p.R885H,60.2,2,Active_Drug,Standard,2024-01-07,Standard,Netherlands,SITE-018
PT-004551,XS-OD-0047,23,Male,Black or African American,C5 p.R885H,75.9,0,Placebo,Standard,2024-02-04,Standard,Canada,SITE-013
PT-004552,XS-OD-0047,78,Male,White,C5 p.R885H,52.6,3,Active_Drug,Standard,2024-02-19,Standard,Netherlands,SITE-022
PT-004553,XS-OD-0047,31,Female,White,NLRP3 R260W,11.7,2,Placebo,Standard,2023-12-21,Standard,Australia,SITE-031
PT-004554,XS-OD-0047,79,Male,Hispanic or Latino,SERPING1 c.1396C>T,54.9,4,Active_Drug,Standard,2024-02-28,Standard,Australia,SITE-050
PT-004555,XS-OD-0047,21,Female,Asian,C5 p.R885H,28.3,1,Placebo,Standard,2023-12-08,Standard,France,SITE-035
PT-004556,XS-OD-0047,54,Male,Black or African American,,72.7,0,Active_Drug,Standard,2024-01-03,Standard,Canada,SITE-021
PT-004557,XS-OD-0048,43,Female,Hispanic or Latino,SERPING1 c.1396C>T,76.9,1,Active_Drug,Low,2020-05-09,Standard,France,SITE-002
PT-004558,XS-OD-0048,41,Male,White,NLRP3 R260W,42.7,2,Active_Drug,Medium,2020-03-24,Standard,Germany,SITE-002
PT-004559,XS-OD-0048,55,Male,White,SERPING1 c.1396C>T,40.6,2,Active_Drug,High,2020-06-08,Standard,Japan,SITE-001
PT-004560,XS-OD-0048,47,Female,White,C5 p.R885H,30.1,4,Active_Drug,Low,2020-05-14,Standard,Netherlands,SITE-001
PT-004561,XS-OD-0048,37,Female,White,,70.4,2,Active_Drug,High,2020-04-24,Standard,Germany,SITE-002
PT-004562,XS-OD-0048,48,Female,White,,27.0,3,Active_Drug,High,2020-04-09,Standard,Netherlands,SITE-001
PT-004563,XS-OD-0048,62,Male,White,,26.7,4,Active_Drug,Low,2020-05-02,Standard,Germany,SITE-002
PT-004564,XS-OD-0048,41,Female,Black or African American,,63.6,1,Active_Drug,Medium,2020-06-25,Standard,United Kingdom,SITE-001
PT-004565,XS-OD-0048,59,Female,White,NLRP3 R260W,95.0,1,Active_Drug,High,2020-02-20,Standard,Italy,SITE-003
PT-004566,XS-OD-0048,14,Female,Hispanic or Latino,NLRP3 R260W,49.3,1,Active_Drug,Medium,2020-03-01,Pediatric_Assent,United States,SITE-003
PT-004567,XS-OD-0048,27,Male,White,NLRP3 R260W,54.8,2,Active_Drug,Medium,2020-07-27,Standard,Spain,SITE-001
PT-004568,XS-OD-0048,68,Male,White,NLRP3 R260W,75.3,2,Active_Drug,Low,2020-02-16,Standard,United Kingdom,SITE-001
PT-004569,XS-OD-0048,61,Female,White,,64.7,6,Active_Drug,Medium,2020-02-09,Standard,France,SITE-003
PT-004570,XS-OD-0048,28,Male,White,C5 p.R885H,25.9,2,Active_Drug,Medium,2020-04-06,Standard,Spain,SITE-002
PT-004571,XS-OD-0048,66,Female,White,,51.0,3,Active_Drug,High,2020-02-19,Standard,Netherlands,SITE-002
PT-004572,XS-OD-0048,35,Male,Asian,,81.4,4,Active_Drug,Medium,2020-06-01,Standard,Australia,SITE-003
PT-004573,XS-OD-0048,23,Female,Black or African American,,67.6,0,Active_Drug,Medium,2020-05-07,Standard,Netherlands,SITE-001
PT-004574,XS-OD-0048,12,Female,Asian,SERPING1 c.1396C>T,66.4,2,Active_Drug,High,2020-03-07,Pediatric_Assent,Netherlands,SITE-003
PT-004575,XS-OD-0048,46,Female,American Indian or Alaska Native,,41.1,2,Active_Drug,Low,2020-04-13,Standard,France,SITE-001
PT-004576,XS-OD-0048,50,Male,Black or African American,C5 p.R885H,95.0,1,Active_Drug,Medium,2020-07-01,Standard,Italy,SITE-003
PT-004577,XS-OD-0048,21,Female,White,NLRP3 R260W,45.1,2,Active_Drug,High,2020-07-02,Emergency,Spain,SITE-001
PT-004578,XS-OD-0048,57,Female,Asian,,45.1,3,Active_Drug,High,2020-05-20,Standard,United Kingdom,SITE-001
PT-004579,XS-OD-0048,76,Female,White,SERPING1 c.1396C>T,78.2,2,Active_Drug,High,2020-03-03,Standard,United Kingdom,SITE-003
PT-004580,XS-OD-0048,32,Male,White,SERPING1 c.1396C>T,53.6,0,Active_Drug,Medium,2020-03-12,Standard,Germany,SITE-002
PT-004581,XS-OD-0049,30,Male,Hispanic or Latino,BMPR2 c.354+1G>A,27.7,1,Active_Drug,Standard,2022-03-17,Standard,Norway,SITE-016
PT-004582,XS-OD-0049,47,Female,Asian,,47.1,1,SOC,Standard,2022-04-01,Standard,Italy,SITE-027
PT-004583,XS-OD-0049,22,Female,White,,54.6,5,Combination,Standard,2022-02-28,Standard,Taiwan,SITE-013
PT-004584,XS-OD-0049,54,Female,Two or More Races,TERT p.R865H,39.6,1,Active_Drug,Standard,2022-04-22,Standard,Belgium,SITE-007
PT-004585,XS-OD-0049,33,Female,Black or African American,TERT p.R865H,55.7,3,SOC,Standard,2021-12-30,Standard,Brazil,SITE-016
PT-004586,XS-OD-0049,17,Male,Hispanic or Latino,MUC5B rs35705950,67.5,3,Combination,Standard,2021-12-19,Pediatric_Assent,Italy,SITE-023
PT-004587,XS-OD-0049,29,Male,Black or African American,TERT p.R865H,40.0,2,Active_Drug,Standard,2022-01-19,Emergency,Australia,SITE-008
PT-004588,XS-OD-0049,66,Female,White,MUC5B rs35705950,70.7,2,SOC,Standard,2021-12-21,Standard,Denmark,SITE-023
PT-004589,XS-OD-0049,38,Male,White,,46.5,1,Combination,Standard,2021-12-22,Standard,Denmark,SITE-008
PT-004590,XS-OD-0049,56,Female,Asian,TERT p.R865H,52.3,4,Active_Drug,Standard,2022-01-29,Standard,Switzerland,SITE-015
PT-004591,XS-OD-0049,31,Male,Asian,BMPR2 c.354+1G>A,60.3,2,SOC,Standard,2022-02-02,Standard,South Korea,SITE-026
PT-004592,XS-OD-0049,41,Female,White,BMPR2 c.354+1G>A,22.6,1,Combination,Standard,2022-02-07,Standard,Taiwan,SITE-022
PT-004593,XS-OD-0049,23,Male,White,MUC5B rs35705950,53.1,1,Active_Drug,Standard,2022-03-17,Standard,Switzerland,SITE-026
PT-004594,XS-OD-0049,33,Female,White,MUC5B rs35705950,86.8,4,SOC,Standard,2022-03-30,Standard,Germany,SITE-013
PT-004595,XS-OD-0049,25,Female,Asian,MUC5B rs35705950,63.0,1,Combination,Standard,2022-03-15,Standard,Netherlands,SITE-010
PT-004596,XS-OD-0049,19,Male,White,BMPR2 c.354+1G>A,83.8,1,Active_Drug,Standard,2022-01-22,Standard,Japan,SITE-015
PT-004597,XS-OD-0049,32,Female,Black or African American,BMPR2 c.354+1G>A,63.0,2,SOC,Standard,2022-03-31,Standard,United Kingdom,SITE-018
PT-004598,XS-OD-0049,36,Female,Hispanic or Latino,,54.2,2,Combination,Standard,2022-02-13,Standard,Brazil,SITE-008
PT-004599,XS-OD-0049,9,Female,White,TERT p.R865H,70.4,2,Active_Drug,Standard,2022-03-15,Pediatric_Assent,Austria,SITE-024
PT-004600,XS-OD-0049,42,Male,Hispanic or Latino,TERT p.R865H,60.8,1,SOC,Standard,2022-04-06,Standard,Brazil,SITE-013
PT-004601,XS-OD-0049,40,Male,White,,54.4,1,Combination,Standard,2022-01-06,Standard,Israel,SITE-024
PT-004602,XS-OD-0049,14,Male,White,,41.4,1,Active_Drug,Standard,2022-02-06,Pediatric_Assent,Denmark,SITE-011
PT-004603,XS-OD-0049,16,Female,Two or More Races,,82.8,4,SOC,Standard,2022-03-29,Pediatric_Assent,Canada,SITE-025
PT-004604,XS-OD-0049,16,Female,White,MUC5B rs35705950,61.5,0,Combination,Standard,2022-03-15,Pediatric_Assent,Brazil,SITE-018
PT-004605,XS-OD-0049,30,Female,White,BMPR2 c.354+1G>A,67.2,5,Active_Drug,Standard,2022-01-28,Standard,Switzerland,SITE-008
PT-004606,XS-OD-0049,21,Female,Asian,,37.4,4,SOC,Standard,2022-02-26,Standard,United Kingdom,SITE-008
PT-004607,XS-OD-0049,55,Female,White,BMPR2 c.354+1G>A,69.5,3,Combination,Standard,2021-12-31,Standard,Denmark,SITE-021
PT-004608,XS-OD-0049,49,Female,White,BMPR2 c.354+1G>A,35.0,0,Active_Drug,Standard,2022-02-04,Standard,Denmark,SITE-019
PT-004609,XS-OD-0049,29,Female,White,MUC5B rs35705950,58.1,3,SOC,Standard,2021-12-07,Standard,Taiwan,SITE-025
PT-004610,XS-OD-0049,24,Female,Asian,MUC5B rs35705950,73.4,2,Combination,Standard,2022-03-19,Standard,Canada,SITE-010
PT-004611,XS-OD-0049,37,Intersex,White,,48.2,1,Active_Drug,Standard,2022-01-06,Standard,Denmark,SITE-022
PT-004612,XS-OD-0049,62,Female,White,MUC5B rs35705950,41.1,3,SOC,Standard,2022-02-05,Standard,Brazil,SITE-013
PT-004613,XS-OD-0049,54,Male,Hispanic or Latino,,54.0,0,Combination,Standard,2021-11-10,Standard,South Korea,SITE-016
PT-004614,XS-OD-0049,38,Female,White,TERT p.R865H,61.5,1,Active_Drug,Standard,2022-01-22,Standard,Australia,SITE-022
PT-004615,XS-OD-0049,28,Male,White,TERT p.R865H,32.6,3,SOC,Standard,2022-04-27,Standard,Sweden,SITE-027
PT-004616,XS-OD-0049,36,Female,Black or African American,TERT p.R865H,46.3,3,Combination,Standard,2022-02-07,Standard,Japan,SITE-017
PT-004617,XS-OD-0049,76,Male,Hispanic or Latino,,27.1,2,Active_Drug,Standard,2022-04-18,Standard,Italy,SITE-013
PT-004618,XS-OD-0049,40,Female,White,,50.6,2,SOC,Standard,2021-11-16,Standard,Denmark,SITE-007
PT-004619,XS-OD-0049,46,Female,White,,76.8,1,Combination,Standard,2021-11-17,Standard,Brazil,SITE-013
PT-004620,XS-OD-0049,48,Female,Hispanic or Latino,,47.4,1,Active_Drug,Standard,2022-02-21,Standard,United Kingdom,SITE-010
PT-004621,XS-OD-0049,83,Male,Asian,TERT p.R865H,40.5,3,SOC,Standard,2021-12-09,Standard,Brazil,SITE-009
PT-004622,XS-OD-0049,59,Intersex,White,BMPR2 c.354+1G>A,40.4,2,Combination,Standard,2022-04-10,Standard,Austria,SITE-015
PT-004623,XS-OD-0049,44,Female,Hispanic or Latino,BMPR2 c.354+1G>A,62.4,1,Active_Drug,Standard,2021-12-10,Standard,Canada,SITE-027
PT-004624,XS-OD-0049,59,Female,Black or African American,,42.7,1,SOC,Standard,2022-03-05,Standard,South Korea,SITE-023
PT-004625,XS-OD-0049,28,Male,Hispanic or Latino,MUC5B rs35705950,28.0,1,Combination,Standard,2021-11-23,Standard,Norway,SITE-009
PT-004626,XS-OD-0049,62,Male,Hispanic or Latino,TERT p.R865H,79.3,2,Active_Drug,Standard,2022-02-08,Standard,Taiwan,SITE-009
PT-004627,XS-OD-0049,39,Female,White,,77.5,1,SOC,Standard,2022-01-27,Standard,Canada,SITE-017
PT-004628,XS-OD-0049,32,Male,White,,58.1,3,Combination,Standard,2021-12-28,Standard,United States,SITE-013
PT-004629,XS-OD-0049,36,Male,Black or African American,MUC5B rs35705950,79.9,0,Active_Drug,Standard,2022-01-22,Standard,Brazil,SITE-011
PT-004630,XS-OD-0049,76,Male,White,,68.9,0,SOC,Standard,2022-03-03,Standard,Taiwan,SITE-020
PT-004631,XS-OD-0049,50,Male,White,,72.1,3,Combination,Standard,2021-11-16,Standard,Denmark,SITE-009
PT-004632,XS-OD-0049,44,Female,White,TERT p.R865H,59.6,1,Active_Drug,Standard,2021-12-05,Standard,Israel,SITE-010
PT-004633,XS-OD-0049,43,Male,American Indian or Alaska Native,MUC5B rs35705950,65.7,1,SOC,Standard,2022-04-27,Standard,South Korea,SITE-005
PT-004634,XS-OD-0049,22,Male,White,MUC5B rs35705950,30.8,1,Combination,Standard,2021-11-10,Standard,Taiwan,SITE-002
PT-004635,XS-OD-0049,59,Male,Hispanic or Latino,BMPR2 c.354+1G>A,51.6,1,Active_Drug,Standard,2021-12-24,Standard,United States,SITE-019
PT-004636,XS-OD-0049,7,Female,White,BMPR2 c.354+1G>A,59.6,3,SOC,Standard,2022-04-15,Pediatric_Assent,Taiwan,SITE-024
PT-004637,XS-OD-0049,34,Female,White,MUC5B rs35705950,68.1,1,Combination,Standard,2021-11-17,Standard,Switzerland,SITE-019
PT-004638,XS-OD-0049,14,Male,White,TERT p.R865H,38.4,2,Active_Drug,Standard,2021-11-28,Pediatric_Assent,United Kingdom,SITE-008
PT-004639,XS-OD-0049,42,Male,Hispanic or Latino,MUC5B rs35705950,59.4,5,SOC,Standard,2021-11-04,Standard,Japan,SITE-009
PT-004640,XS-OD-0049,21,Female,Asian,BMPR2 c.354+1G>A,87.7,6,Combination,Standard,2022-01-30,Standard,Denmark,SITE-003
PT-004641,XS-OD-0049,31,Female,Black or African American,,72.3,2,Active_Drug,Standard,2022-03-10,Standard,United Kingdom,SITE-024
PT-004642,XS-OD-0049,41,Female,Black or African American,TERT p.R865H,10.7,1,SOC,Standard,2022-04-16,Standard,Israel,SITE-020
PT-004643,XS-OD-0049,22,Female,White,TERT p.R865H,46.9,2,Combination,Standard,2021-11-17,Standard,Belgium,SITE-007
PT-004644,XS-OD-0049,24,Male,Asian,,66.7,0,Active_Drug,Standard,2021-11-08,Standard,Sweden,SITE-004
PT-004645,XS-OD-0049,35,Male,White,TERT p.R865H,90.0,1,SOC,Standard,2021-11-16,Standard,Austria,SITE-017
PT-004646,XS-OD-0049,29,Male,Hispanic or Latino,,79.3,2,Combination,Standard,2021-11-11,Standard,Denmark,SITE-017
PT-004647,XS-OD-0049,76,Male,White,BMPR2 c.354+1G>A,57.8,1,Active_Drug,Standard,2021-12-28,Standard,France,SITE-018
PT-004648,XS-OD-0049,47,Female,White,TERT p.R865H,65.9,3,SOC,Standard,2021-11-07,Standard,Australia,SITE-015
PT-004649,XS-OD-0049,18,Male,White,BMPR2 c.354+1G>A,23.9,0,Combination,Standard,2022-03-27,Standard,Norway,SITE-011
PT-004650,XS-OD-0049,36,Male,Black or African American,BMPR2 c.354+1G>A,62.1,3,Active_Drug,Standard,2022-02-19,Standard,Sweden,SITE-022
PT-004651,XS-OD-0049,22,Male,Hispanic or Latino,TERT p.R865H,95.0,3,SOC,Standard,2021-11-02,Standard,Brazil,SITE-017
PT-004652,XS-OD-0049,60,Female,Black or African American,,59.2,3,Combination,Standard,2022-04-18,Standard,Australia,SITE-027
PT-004653,XS-OD-0049,54,Female,Hispanic or Latino,MUC5B rs35705950,29.3,0,Active_Drug,Standard,2022-01-29,Standard,Japan,SITE-017
PT-004654,XS-OD-0049,32,Female,Hispanic or Latino,BMPR2 c.354+1G>A,61.7,1,SOC,Standard,2021-12-26,Standard,Italy,SITE-003
PT-004655,XS-OD-0049,48,Female,White,BMPR2 c.354+1G>A,66.6,2,Combination,Standard,2022-04-12,Standard,Italy,SITE-002
PT-004656,XS-OD-0049,40,Female,White,,57.2,1,Active_Drug,Standard,2021-12-13,Standard,United Kingdom,SITE-011
PT-004657,XS-OD-0049,59,Male,White,BMPR2 c.354+1G>A,49.9,4,SOC,Standard,2022-01-27,Standard,Switzerland,SITE-008
PT-004658,XS-OD-0049,29,Female,Black or African American,MUC5B rs35705950,20.7,0,Combination,Standard,2022-03-21,Standard,Italy,SITE-002
PT-004659,XS-OD-0049,32,Female,White,MUC5B rs35705950,43.7,1,Active_Drug,Standard,2022-02-17,Standard,Israel,SITE-017
PT-004660,XS-OD-0049,45,Male,White,BMPR2 c.354+1G>A,61.1,4,SOC,Standard,2022-04-24,Standard,United States,SITE-002
PT-004661,XS-OD-0049,19,Female,Asian,MUC5B rs35705950,87.1,1,Combination,Standard,2022-02-07,Standard,Australia,SITE-018
PT-004662,XS-OD-0049,56,Male,Two or More Races,,15.9,3,Active_Drug,Standard,2021-12-16,Standard,Denmark,SITE-026
PT-004663,XS-OD-0049,24,Female,White,,87.9,3,SOC,Standard,2021-11-24,Standard,Denmark,SITE-017
PT-004664,XS-OD-0049,61,Male,White,,29.6,5,Combination,Standard,2022-03-26,Standard,Israel,SITE-014
PT-004665,XS-OD-0049,33,Male,White,BMPR2 c.354+1G>A,50.4,0,Active_Drug,Standard,2021-12-05,Standard,Brazil,SITE-022
PT-004666,XS-OD-0049,61,Female,White,MUC5B rs35705950,68.5,2,SOC,Standard,2022-03-18,Standard,Spain,SITE-010
PT-004667,XS-OD-0049,63,Female,Asian,,57.5,2,Combination,Standard,2021-12-29,Standard,South Korea,SITE-027
PT-004668,XS-OD-0049,44,Female,Asian,MUC5B rs35705950,50.2,4,Active_Drug,Standard,2021-12-20,Standard,Brazil,SITE-020
PT-004669,XS-OD-0049,50,Male,White,BMPR2 c.354+1G>A,49.9,3,SOC,Standard,2022-04-05,Standard,Belgium,SITE-025
PT-004670,XS-OD-0049,19,Male,Hispanic or Latino,,43.0,4,Combination,Standard,2022-01-13,Standard,Brazil,SITE-023
PT-004671,XS-OD-0049,31,Male,Hispanic or Latino,TERT p.R865H,69.1,1,Active_Drug,Standard,2022-02-14,Standard,Canada,SITE-005
PT-004672,XS-OD-0049,27,Male,Asian,BMPR2 c.354+1G>A,36.5,3,SOC,Standard,2022-01-27,Standard,Austria,SITE-009
PT-004673,XS-OD-0049,49,Male,Hispanic or Latino,,57.9,1,Combination,Standard,2022-01-03,Standard,Denmark,SITE-019
PT-004674,XS-OD-0049,54,Female,White,TERT p.R865H,46.3,1,Active_Drug,Standard,2021-11-13,Standard,Denmark,SITE-006
PT-004675,XS-OD-0049,25,Female,Black or African American,BMPR2 c.354+1G>A,28.9,0,SOC,Standard,2022-04-03,Standard,Canada,SITE-025
PT-004676,XS-OD-0049,36,Female,White,,64.1,4,Combination,Standard,2022-04-08,Standard,Austria,SITE-020
PT-004677,XS-OD-0049,49,Male,Asian,,51.3,3,Active_Drug,Standard,2022-01-18,Standard,United Kingdom,SITE-004
PT-004678,XS-OD-0049,59,Female,Asian,TERT p.R865H,23.7,0,SOC,Standard,2022-02-10,Standard,United States,SITE-002
PT-004679,XS-OD-0049,19,Male,White,,36.8,3,Combination,Standard,2021-11-02,Standard,France,SITE-002
PT-004680,XS-OD-0049,27,Male,White,,48.3,3,Active_Drug,Standard,2022-04-18,Standard,France,SITE-004
PT-004681,XS-OD-0049,46,Male,Hispanic or Latino,MUC5B rs35705950,73.5,1,SOC,Standard,2022-03-20,Standard,Norway,SITE-023
PT-004682,XS-OD-0049,24,Female,Asian,,55.1,2,Combination,Standard,2022-01-19,Standard,Taiwan,SITE-026
PT-004683,XS-OD-0049,13,Female,Hispanic or Latino,,63.7,1,Active_Drug,Standard,2022-04-01,Pediatric_Assent,Canada,SITE-001
PT-004684,XS-OD-0049,42,Female,Asian,MUC5B rs35705950,24.5,2,SOC,Standard,2022-01-12,Standard,United Kingdom,SITE-008
PT-004685,XS-OD-0049,21,Female,White,TERT p.R865H,51.1,3,Combination,Standard,2021-12-27,Standard,Germany,SITE-001
PT-004686,XS-OD-0049,36,Male,White,BMPR2 c.354+1G>A,62.4,2,Active_Drug,Standard,2022-01-21,Standard,Spain,SITE-001
PT-004687,XS-OD-0049,18,Female,Black or African American,BMPR2 c.354+1G>A,71.7,4,SOC,Standard,2022-02-19,Standard,Norway,SITE-006
PT-004688,XS-OD-0049,12,Male,Hispanic or Latino,TERT p.R865H,72.9,4,Combination,Standard,2022-03-23,Pediatric_Assent,United Kingdom,SITE-024
PT-004689,XS-OD-0049,32,Female,White,MUC5B rs35705950,80.0,2,Active_Drug,Standard,2022-01-01,Standard,Belgium,SITE-004
PT-004690,XS-OD-0049,20,Female,Asian,TERT p.R865H,81.0,2,SOC,Standard,2022-04-26,Standard,Italy,SITE-006
PT-004691,XS-OD-0049,40,Male,White,,45.2,2,Combination,Standard,2022-01-23,Standard,Japan,SITE-016
PT-004692,XS-OD-0049,23,Intersex,White,MUC5B rs35705950,61.4,0,Active_Drug,Standard,2022-02-20,Standard,Netherlands,SITE-024
PT-004693,XS-OD-0049,53,Female,Hispanic or Latino,TERT p.R865H,76.9,1,SOC,Standard,2022-01-13,Standard,Netherlands,SITE-013
PT-004694,XS-OD-0049,16,Male,Black or African American,TERT p.R865H,48.2,4,Combination,Standard,2022-04-12,Pediatric_Assent,Spain,SITE-008
PT-004695,XS-OD-0049,55,Female,White,TERT p.R865H,94.7,2,Active_Drug,Standard,2022-04-19,Standard,Sweden,SITE-027
PT-004696,XS-OD-0049,30,Male,White,BMPR2 c.354+1G>A,42.1,2,SOC,Standard,2022-02-07,Standard,Sweden,SITE-014
PT-004697,XS-OD-0049,63,Female,White,,56.4,1,Combination,Standard,2022-02-11,Standard,Spain,SITE-022
PT-004698,XS-OD-0049,53,Male,White,MUC5B rs35705950,46.3,4,Active_Drug,Standard,2021-11-23,Standard,Sweden,SITE-017
PT-004699,XS-OD-0049,65,Female,White,BMPR2 c.354+1G>A,65.4,4,SOC,Standard,2022-02-12,Standard,South Korea,SITE-004
PT-004700,XS-OD-0049,8,Male,Hispanic or Latino,BMPR2 c.354+1G>A,31.3,1,Combination,Standard,2021-11-06,Pediatric_Assent,South Korea,SITE-008
PT-004701,XS-OD-0049,47,Male,Asian,TERT p.R865H,47.6,1,Active_Drug,Standard,2021-12-18,Standard,Canada,SITE-016
PT-004702,XS-OD-0049,40,Male,Asian,MUC5B rs35705950,34.5,2,SOC,Standard,2021-11-17,Standard,Canada,SITE-002
PT-004703,XS-OD-0049,46,Male,White,,66.9,4,Combination,Standard,2021-12-02,Standard,Brazil,SITE-011
PT-004704,XS-OD-0049,57,Female,Asian,TERT p.R865H,73.3,2,Active_Drug,Standard,2022-02-09,Standard,Canada,SITE-009
PT-004705,XS-OD-0049,37,Female,Asian,TERT p.R865H,43.3,5,SOC,Standard,2021-11-28,Standard,Brazil,SITE-025
PT-004706,XS-OD-0049,41,Female,Hispanic or Latino,,80.2,3,Combination,Standard,2021-11-21,Standard,Italy,SITE-008
PT-004707,XS-OD-0049,37,Male,Hispanic or Latino,TERT p.R865H,54.2,5,Active_Drug,Standard,2022-03-16,Standard,Netherlands,SITE-012
PT-004708,XS-OD-0049,17,Female,White,BMPR2 c.354+1G>A,67.2,0,SOC,Standard,2021-11-18,Pediatric_Assent,Sweden,SITE-001
PT-004709,XS-OD-0049,74,Male,Hispanic or Latino,BMPR2 c.354+1G>A,73.1,1,Combination,Standard,2021-11-10,Standard,Denmark,SITE-019
PT-004710,XS-OD-0049,26,Male,Native Hawaiian or Other Pacific Islander,TERT p.R865H,43.3,3,Active_Drug,Standard,2021-12-15,Standard,United Kingdom,SITE-014
PT-004711,XS-OD-0049,45,Female,Asian,TERT p.R865H,73.8,2,SOC,Standard,2022-03-18,Emergency,Italy,SITE-021
PT-004712,XS-OD-0049,58,Male,Asian,BMPR2 c.354+1G>A,37.3,3,Combination,Standard,2021-11-01,Standard,United States,SITE-011
PT-004713,XS-OD-0049,51,Male,White,,65.6,3,Active_Drug,Standard,2022-02-09,Standard,United Kingdom,SITE-001
PT-004714,XS-OD-0049,47,Female,White,BMPR2 c.354+1G>A,11.0,3,SOC,Standard,2022-02-14,Emergency,France,SITE-014
PT-004715,XS-OD-0049,60,Female,White,MUC5B rs35705950,57.3,3,Combination,Standard,2022-01-19,Standard,Switzerland,SITE-027
PT-004716,XS-OD-0049,81,Male,White,TERT p.R865H,83.4,3,Active_Drug,Standard,2022-02-02,Standard,Austria,SITE-026
PT-004717,XS-OD-0049,18,Female,Black or African American,MUC5B rs35705950,48.0,1,SOC,Standard,2022-02-06,Standard,United Kingdom,SITE-011
PT-004718,XS-OD-0049,61,Male,Asian,TERT p.R865H,51.6,3,Combination,Standard,2022-03-08,Standard,Germany,SITE-012
PT-004719,XS-OD-0049,25,Male,White,MUC5B rs35705950,53.7,1,Active_Drug,Standard,2022-03-31,Standard,Canada,SITE-014
PT-004720,XS-OD-0049,60,Intersex,White,,28.3,2,SOC,Standard,2022-03-27,Standard,South Korea,SITE-014
PT-004721,XS-OD-0049,24,Male,Black or African American,,44.0,2,Combination,Standard,2022-04-21,Standard,United States,SITE-023
PT-004722,XS-OD-0049,34,Male,White,BMPR2 c.354+1G>A,30.5,3,Active_Drug,Standard,2022-03-26,Standard,Belgium,SITE-005
PT-004723,XS-OD-0049,28,Male,White,MUC5B rs35705950,68.6,5,SOC,Standard,2021-11-28,Standard,South Korea,SITE-012
PT-004724,XS-OD-0049,46,Female,White,,56.5,2,Combination,Standard,2022-03-05,Standard,Germany,SITE-002
PT-004725,XS-OD-0049,62,Female,Black or African American,MUC5B rs35705950,77.4,2,Active_Drug,Standard,2022-03-11,Standard,South Korea,SITE-004
PT-004726,XS-OD-0049,75,Female,White,TERT p.R865H,44.3,3,SOC,Standard,2022-02-13,Standard,Australia,SITE-020
PT-004727,XS-OD-0049,62,Male,White,,33.2,1,Combination,Standard,2022-03-08,Standard,Spain,SITE-015
PT-004728,XS-OD-0049,21,Male,Black or African American,BMPR2 c.354+1G>A,42.8,1,Active_Drug,Standard,2021-12-25,Standard,Switzerland,SITE-013
PT-004729,XS-OD-0049,34,Male,White,TERT p.R865H,35.7,1,SOC,Standard,2021-12-03,Standard,Austria,SITE-025
PT-004730,XS-OD-0049,49,Female,White,,56.9,1,Combination,Standard,2021-12-24,Standard,United Kingdom,SITE-017
PT-004731,XS-OD-0049,18,Female,White,BMPR2 c.354+1G>A,46.0,1,Active_Drug,Standard,2022-02-12,Standard,United States,SITE-009
PT-004732,XS-OD-0049,76,Male,Hispanic or Latino,MUC5B rs35705950,44.5,1,SOC,Standard,2022-02-02,Standard,Brazil,SITE-016
PT-004733,XS-OD-0049,38,Female,Black or African American,MUC5B rs35705950,51.5,3,Combination,Standard,2021-12-01,Compassionate,Brazil,SITE-022
PT-004734,XS-OD-0049,82,Male,Black or African American,MUC5B rs35705950,65.7,4,Active_Drug,Standard,2022-04-12,Standard,Italy,SITE-017
PT-004735,XS-OD-0049,32,Female,White,,46.0,2,SOC,Standard,2022-01-31,Standard,Norway,SITE-008
PT-004736,XS-OD-0049,55,Male,White,,37.5,1,Combination,Standard,2021-12-05,Standard,Israel,SITE-015
PT-004737,XS-OD-0049,46,Male,Hispanic or Latino,BMPR2 c.354+1G>A,54.2,3,Active_Drug,Standard,2021-12-27,Standard,Taiwan,SITE-009
PT-004738,XS-OD-0049,34,Female,American Indian or Alaska Native,MUC5B rs35705950,44.4,2,SOC,Standard,2022-04-25,Standard,Australia,SITE-006
PT-004739,XS-OD-0049,21,Female,White,MUC5B rs35705950,44.8,1,Combination,Standard,2022-03-09,Standard,Belgium,SITE-012
PT-004740,XS-OD-0049,21,Male,White,,62.5,2,Active_Drug,Standard,2022-01-12,Standard,Italy,SITE-025
PT-004741,XS-OD-0049,35,Female,White,MUC5B rs35705950,47.6,1,SOC,Standard,2022-01-01,Standard,Canada,SITE-024
PT-004742,XS-OD-0049,12,Male,Hispanic or Latino,MUC5B rs35705950,40.3,3,Combination,Standard,2022-04-08,Pediatric_Assent,Denmark,SITE-021
PT-004743,XS-OD-0049,60,Female,White,,66.6,1,Active_Drug,Standard,2021-11-14,Standard,Taiwan,SITE-016
PT-004744,XS-OD-0049,27,Female,Asian,,58.0,2,SOC,Standard,2021-12-18,Standard,Sweden,SITE-005
PT-004745,XS-OD-0049,30,Female,White,MUC5B rs35705950,39.9,0,Combination,Standard,2022-03-13,Standard,Canada,SITE-006
PT-004746,XS-OD-0049,80,Female,Asian,MUC5B rs35705950,64.3,1,Active_Drug,Standard,2021-11-02,Standard,Brazil,SITE-024
PT-004747,XS-OD-0049,21,Female,Asian,,75.3,1,SOC,Standard,2022-04-27,Standard,France,SITE-018
PT-004748,XS-OD-0049,64,Female,White,TERT p.R865H,49.0,3,Combination,Standard,2021-12-05,Standard,Denmark,SITE-025
PT-004749,XS-OD-0049,29,Male,Hispanic or Latino,,91.0,3,Active_Drug,Standard,2021-11-27,Standard,France,SITE-022
PT-004750,XS-OD-0049,49,Female,White,MUC5B rs35705950,37.9,2,SOC,Standard,2022-04-24,Standard,Italy,SITE-009
PT-004751,XS-OD-0049,48,Female,White,TERT p.R865H,68.4,2,Combination,Standard,2021-12-16,Standard,Canada,SITE-012
PT-004752,XS-OD-0049,13,Male,White,MUC5B rs35705950,35.1,2,Active_Drug,Standard,2022-04-19,Pediatric_Assent,Germany,SITE-022
PT-004753,XS-OD-0049,17,Male,White,BMPR2 c.354+1G>A,62.0,2,SOC,Standard,2021-12-09,Pediatric_Assent,United States,SITE-027
PT-004754,XS-OD-0049,29,Female,Native Hawaiian or Other Pacific Islander,,49.0,2,Combination,Standard,2022-02-07,Standard,Taiwan,SITE-026
PT-004755,XS-OD-0049,39,Male,White,BMPR2 c.354+1G>A,39.3,0,Active_Drug,Standard,2021-11-27,Standard,Austria,SITE-006
PT-004756,XS-OD-0049,13,Male,Hispanic or Latino,BMPR2 c.354+1G>A,78.7,3,SOC,Standard,2022-01-08,Pediatric_Assent,Canada,SITE-006
PT-004757,XS-OD-0049,43,Male,American Indian or Alaska Native,TERT p.R865H,78.4,1,Combination,Standard,2021-12-12,Standard,United Kingdom,SITE-016
PT-004758,XS-OD-0049,35,Female,Hispanic or Latino,,50.5,0,Active_Drug,Standard,2022-01-24,Standard,Belgium,SITE-003
PT-004759,XS-OD-0049,51,Female,White,,58.0,1,SOC,Standard,2021-11-21,Standard,Australia,SITE-016
PT-004760,XS-OD-0049,36,Female,Hispanic or Latino,,70.6,4,Combination,Standard,2021-12-29,Standard,United Kingdom,SITE-013
PT-004761,XS-OD-0049,52,Male,White,TERT p.R865H,46.1,1,Active_Drug,Standard,2021-12-13,Standard,Netherlands,SITE-012
PT-004762,XS-OD-0049,32,Male,Hispanic or Latino,TERT p.R865H,47.3,1,SOC,Standard,2021-12-25,Standard,United Kingdom,SITE-024
PT-004763,XS-OD-0049,55,Female,White,,63.3,3,Combination,Standard,2022-04-02,Standard,Italy,SITE-013
PT-004764,XS-OD-0049,66,Male,White,BMPR2 c.354+1G>A,45.7,3,Active_Drug,Standard,2022-01-29,Standard,South Korea,SITE-020
PT-004765,XS-OD-0050,53,Male,White,TERT p.R865H,57.8,2,Active_Drug,Standard,2023-11-17,Standard,Germany,SITE-001
PT-004766,XS-OD-0050,38,Male,White,BMPR2 c.354+1G>A,54.1,1,Placebo,Standard,2024-02-19,Standard,Australia,SITE-004
PT-004767,XS-OD-0050,10,Female,White,,73.1,4,Active_Drug,Standard,2023-11-09,Pediatric_Assent,Germany,SITE-018
PT-004768,XS-OD-0050,41,Male,White,MUC5B rs35705950,47.5,2,Placebo,Standard,2023-10-22,Standard,Japan,SITE-017
PT-004769,XS-OD-0050,23,Female,White,BMPR2 c.354+1G>A,72.1,1,Active_Drug,Standard,2023-09-10,Standard,United Kingdom,SITE-014
PT-004770,XS-OD-0050,16,Male,White,TERT p.R865H,49.0,0,Placebo,Standard,2024-02-15,Pediatric_Assent,United States,SITE-017
PT-004771,XS-OD-0050,63,Female,White,,64.2,1,Active_Drug,Standard,2023-11-12,Standard,Canada,SITE-019
PT-004772,XS-OD-0050,46,Female,White,BMPR2 c.354+1G>A,66.4,2,Placebo,Standard,2023-12-14,Standard,Netherlands,SITE-014
PT-004773,XS-OD-0050,62,Male,Black or African American,TERT p.R865H,43.2,8,Active_Drug,Standard,2023-11-13,Standard,United Kingdom,SITE-010
PT-004774,XS-OD-0050,27,Female,White,,31.0,1,Placebo,Standard,2024-01-07,Standard,Japan,SITE-016
PT-004775,XS-OD-0050,27,Male,White,TERT p.R865H,76.6,1,Active_Drug,Standard,2023-11-02,Standard,Japan,SITE-007
PT-004776,XS-OD-0050,31,Female,White,MUC5B rs35705950,40.8,4,Placebo,Standard,2023-10-15,Standard,Canada,SITE-013
PT-004777,XS-OD-0050,59,Female,Black or African American,TERT p.R865H,46.3,1,Active_Drug,Standard,2023-12-16,Standard,United States,SITE-008
PT-004778,XS-OD-0050,28,Male,White,BMPR2 c.354+1G>A,75.8,3,Placebo,Standard,2024-01-16,Standard,France,SITE-007
PT-004779,XS-OD-0050,41,Female,Hispanic or Latino,BMPR2 c.354+1G>A,61.5,3,Active_Drug,Standard,2023-12-31,Standard,Japan,SITE-010
PT-004780,XS-OD-0050,75,Male,Black or African American,MUC5B rs35705950,74.3,1,Placebo,Standard,2023-08-28,Standard,Germany,SITE-009
PT-004781,XS-OD-0050,39,Male,White,,67.6,1,Active_Drug,Standard,2023-08-29,Standard,Netherlands,SITE-010
PT-004782,XS-OD-0050,19,Female,White,TERT p.R865H,77.0,2,Placebo,Standard,2023-09-30,Standard,Japan,SITE-013
PT-004783,XS-OD-0050,23,Male,Black or African American,,62.8,2,Active_Drug,Standard,2023-11-13,Standard,Germany,SITE-001
PT-004784,XS-OD-0050,35,Male,Black or African American,MUC5B rs35705950,79.2,2,Placebo,Standard,2024-01-24,Standard,United States,SITE-007
PT-004785,XS-OD-0050,59,Male,Native Hawaiian or Other Pacific Islander,,80.8,3,Active_Drug,Standard,2023-12-05,Standard,France,SITE-021
PT-004786,XS-OD-0050,44,Male,White,MUC5B rs35705950,24.3,2,Placebo,Standard,2023-09-29,Standard,Japan,SITE-016
PT-004787,XS-OD-0050,64,Male,White,,32.0,2,Active_Drug,Standard,2023-11-07,Standard,United Kingdom,SITE-006
PT-004788,XS-OD-0050,35,Female,White,,72.9,1,Placebo,Standard,2023-10-31,Standard,Italy,SITE-009
PT-004789,XS-OD-0050,44,Female,Black or African American,MUC5B rs35705950,35.4,4,Active_Drug,Standard,2023-10-13,Standard,Spain,SITE-020
PT-004790,XS-OD-0050,44,Female,Asian,MUC5B rs35705950,43.0,3,Placebo,Standard,2023-12-24,Standard,United States,SITE-012
PT-004791,XS-OD-0050,76,Male,Asian,BMPR2 c.354+1G>A,73.3,7,Active_Drug,Standard,2024-01-06,Standard,Japan,SITE-010
PT-004792,XS-OD-0050,28,Female,White,MUC5B rs35705950,60.0,1,Placebo,Standard,2024-02-17,Standard,France,SITE-003
PT-004793,XS-OD-0050,29,Male,Asian,TERT p.R865H,36.2,4,Active_Drug,Standard,2023-10-19,Standard,Italy,SITE-006
PT-004794,XS-OD-0050,28,Female,White,BMPR2 c.354+1G>A,60.5,1,Placebo,Standard,2023-08-30,Standard,Italy,SITE-021
PT-004795,XS-OD-0050,46,Male,White,MUC5B rs35705950,41.7,1,Active_Drug,Standard,2023-10-27,Standard,Australia,SITE-019
PT-004796,XS-OD-0050,21,Female,Black or African American,,55.7,2,Placebo,Standard,2024-01-13,Standard,United Kingdom,SITE-014
PT-004797,XS-OD-0050,6,Female,White,BMPR2 c.354+1G>A,31.6,0,Active_Drug,Standard,2023-12-05,Pediatric_Assent,United States,SITE-011
PT-004798,XS-OD-0050,46,Female,Asian,MUC5B rs35705950,48.8,2,Placebo,Standard,2023-12-19,Standard,United States,SITE-009
PT-004799,XS-OD-0050,67,Female,Hispanic or Latino,BMPR2 c.354+1G>A,45.8,1,Active_Drug,Standard,2023-09-01,Emergency,Spain,SITE-004
PT-004800,XS-OD-0050,4,Male,American Indian or Alaska Native,,95.0,1,Placebo,Standard,2023-09-16,Pediatric_Assent,Australia,SITE-002
PT-004801,XS-OD-0050,48,Female,White,MUC5B rs35705950,31.3,0,Active_Drug,Standard,2023-09-11,Standard,Netherlands,SITE-013
PT-004802,XS-OD-0050,12,Male,White,TERT p.R865H,69.2,2,Placebo,Standard,2024-01-02,Pediatric_Assent,France,SITE-004
PT-004803,XS-OD-0050,51,Female,White,TERT p.R865H,52.1,1,Active_Drug,Standard,2023-12-10,Standard,Italy,SITE-018
PT-004804,XS-OD-0050,15,Female,White,,24.4,1,Placebo,Standard,2024-01-23,Pediatric_Assent,Spain,SITE-011
PT-004805,XS-OD-0050,41,Female,Hispanic or Latino,BMPR2 c.354+1G>A,53.2,1,Active_Drug,Standard,2024-02-08,Standard,Australia,SITE-015
PT-004806,XS-OD-0050,26,Male,White,MUC5B rs35705950,74.5,3,Placebo,Standard,2023-11-13,Standard,Italy,SITE-006
PT-004807,XS-OD-0050,29,Male,White,,70.5,2,Active_Drug,Standard,2023-10-01,Standard,Germany,SITE-001
PT-004808,XS-OD-0050,32,Female,Asian,BMPR2 c.354+1G>A,26.7,2,Placebo,Standard,2023-09-27,Standard,Canada,SITE-013
PT-004809,XS-OD-0050,15,Male,White,TERT p.R865H,66.6,2,Active_Drug,Standard,2023-10-02,Pediatric_Assent,Japan,SITE-003
PT-004810,XS-OD-0050,25,Female,Asian,TERT p.R865H,71.3,2,Placebo,Standard,2023-10-29,Standard,United States,SITE-013
PT-004811,XS-OD-0050,28,Male,White,BMPR2 c.354+1G>A,39.1,4,Active_Drug,Standard,2023-12-15,Standard,Germany,SITE-002
PT-004812,XS-OD-0050,74,Female,White,BMPR2 c.354+1G>A,60.9,5,Placebo,Standard,2023-12-06,Standard,United States,SITE-001
PT-004813,XS-OD-0050,54,Male,White,BMPR2 c.354+1G>A,70.6,2,Active_Drug,Standard,2024-01-01,Standard,United Kingdom,SITE-017
PT-004814,XS-OD-0050,34,Female,White,,50.0,5,Placebo,Standard,2024-01-14,Standard,United Kingdom,SITE-001
PT-004815,XS-OD-0050,20,Male,White,,95.0,4,Active_Drug,Standard,2023-10-20,Standard,United States,SITE-007
PT-004816,XS-OD-0050,29,Female,Hispanic or Latino,MUC5B rs35705950,63.4,4,Placebo,Standard,2023-09-23,Standard,Germany,SITE-009
PT-004817,XS-OD-0050,32,Female,Asian,MUC5B rs35705950,64.2,4,Active_Drug,Standard,2023-11-06,Standard,Italy,SITE-019
PT-004818,XS-OD-0050,30,Female,White,,71.0,1,Placebo,Standard,2024-01-17,Standard,Germany,SITE-005
PT-004819,XS-OD-0050,79,Female,Hispanic or Latino,TERT p.R865H,73.9,2,Active_Drug,Standard,2023-10-03,Standard,Italy,SITE-008
PT-004820,XS-OD-0050,25,Male,Black or African American,MUC5B rs35705950,54.3,3,Placebo,Standard,2023-10-26,Standard,United Kingdom,SITE-017
PT-004821,XS-OD-0050,41,Female,Black or African American,,77.0,5,Active_Drug,Standard,2023-11-08,Standard,Italy,SITE-003
PT-004822,XS-OD-0050,28,Female,White,MUC5B rs35705950,76.1,0,Placebo,Standard,2024-02-18,Standard,Italy,SITE-012
PT-004823,XS-OD-0050,28,Male,Hispanic or Latino,,66.2,3,Active_Drug,Standard,2023-10-12,Standard,Italy,SITE-018
PT-004824,XS-OD-0050,11,Female,White,,51.0,3,Placebo,Standard,2024-02-14,Pediatric_Assent,Australia,SITE-006
PT-004825,XS-OD-0050,68,Male,White,,43.7,0,Active_Drug,Standard,2024-01-20,Standard,Spain,SITE-019
PT-004826,XS-OD-0050,55,Male,Black or African American,MUC5B rs35705950,30.5,1,Placebo,Standard,2023-10-22,Standard,Germany,SITE-007
PT-004827,XS-OD-0050,23,Female,White,TERT p.R865H,44.1,2,Active_Drug,Standard,2023-11-02,Standard,Canada,SITE-016
PT-004828,XS-OD-0050,50,Male,White,MUC5B rs35705950,49.0,0,Placebo,Standard,2023-10-29,Standard,Italy,SITE-018
PT-004829,XS-OD-0050,38,Male,Black or African American,MUC5B rs35705950,67.5,4,Active_Drug,Standard,2023-08-28,Standard,Netherlands,SITE-015
PT-004830,XS-OD-0050,68,Male,Black or African American,TERT p.R865H,22.1,5,Placebo,Standard,2023-12-11,Standard,United Kingdom,SITE-006
PT-004831,XS-OD-0050,22,Female,White,TERT p.R865H,84.8,6,Active_Drug,Standard,2023-10-30,Standard,United States,SITE-001
PT-004832,XS-OD-0050,40,Male,White,BMPR2 c.354+1G>A,44.9,2,Placebo,Standard,2023-11-04,Standard,United States,SITE-016
PT-004833,XS-OD-0050,20,Female,Asian,MUC5B rs35705950,37.9,1,Active_Drug,Standard,2023-11-17,Standard,Netherlands,SITE-008
PT-004834,XS-OD-0050,47,Male,Two or More Races,,73.1,2,Placebo,Standard,2023-10-27,Standard,France,SITE-006
PT-004835,XS-OD-0050,11,Male,Hispanic or Latino,MUC5B rs35705950,56.2,0,Active_Drug,Standard,2023-10-18,Pediatric_Assent,United States,SITE-008
PT-004836,XS-OD-0050,26,Male,White,BMPR2 c.354+1G>A,95.0,2,Placebo,Standard,2024-02-07,Standard,United Kingdom,SITE-012
PT-004837,XS-OD-0050,33,Male,Black or African American,,45.2,1,Active_Drug,Standard,2023-11-29,Standard,Germany,SITE-013
PT-004838,XS-OD-0050,33,Male,Black or African American,BMPR2 c.354+1G>A,43.8,1,Placebo,Standard,2023-12-06,Standard,Spain,SITE-004
PT-004839,XS-OD-0050,58,Female,White,MUC5B rs35705950,66.1,2,Active_Drug,Standard,2023-11-19,Standard,Netherlands,SITE-006
PT-004840,XS-OD-0050,37,Female,White,,60.5,0,Placebo,Standard,2024-01-18,Standard,Germany,SITE-013
PT-004841,XS-OD-0050,29,Female,Black or African American,,48.1,0,Active_Drug,Standard,2024-01-09,Standard,Canada,SITE-019
PT-004842,XS-OD-0050,29,Male,Hispanic or Latino,,60.0,0,Placebo,Standard,2023-12-01,Standard,Spain,SITE-019
PT-004843,XS-OD-0050,60,Female,White,MUC5B rs35705950,45.5,1,Active_Drug,Standard,2023-10-04,Standard,Italy,SITE-003
PT-004844,XS-OD-0050,41,Female,White,TERT p.R865H,76.0,3,Placebo,Standard,2023-10-22,Standard,United States,SITE-017
PT-004845,XS-OD-0050,33,Female,White,TERT p.R865H,59.8,1,Active_Drug,Standard,2023-12-12,Standard,United States,SITE-013
PT-004846,XS-OD-0050,2,Male,Black or African American,,66.9,0,Placebo,Standard,2023-09-17,Pediatric_Assent,France,SITE-016
PT-004847,XS-OD-0050,43,Male,White,TERT p.R865H,62.3,0,Active_Drug,Standard,2023-09-12,Standard,Netherlands,SITE-019
PT-004848,XS-OD-0050,46,Male,Hispanic or Latino,,73.0,5,Placebo,Standard,2023-11-01,Standard,United States,SITE-004
PT-004849,XS-OD-0050,40,Female,Hispanic or Latino,TERT p.R865H,31.8,0,Active_Drug,Standard,2024-02-04,Standard,Netherlands,SITE-007
PT-004850,XS-OD-0050,14,Male,Asian,,68.5,1,Placebo,Standard,2023-11-11,Pediatric_Assent,United Kingdom,SITE-005
PT-004851,XS-OD-0050,67,Male,White,,63.1,4,Active_Drug,Standard,2023-10-23,Compassionate,Canada,SITE-007
PT-004852,XS-OD-0050,13,Female,White,BMPR2 c.354+1G>A,71.3,1,Placebo,Standard,2024-02-21,Pediatric_Assent,Italy,SITE-005
PT-004853,XS-OD-0050,20,Female,Black or African American,BMPR2 c.354+1G>A,72.1,2,Active_Drug,Standard,2023-10-02,Standard,France,SITE-016
PT-004854,XS-OD-0050,42,Male,White,,70.7,1,Placebo,Standard,2024-02-05,Standard,Spain,SITE-017
PT-004855,XS-OD-0050,29,Male,Black or African American,MUC5B rs35705950,54.9,4,Active_Drug,Standard,2024-02-18,Standard,France,SITE-003
PT-004856,XS-OD-0050,24,Female,White,TERT p.R865H,57.4,5,Placebo,Standard,2023-10-01,Standard,Canada,SITE-021
PT-004857,XS-OD-0050,47,Female,Two or More Races,TERT p.R865H,32.5,1,Active_Drug,Standard,2024-02-15,Standard,Canada,SITE-001
PT-004858,XS-OD-0050,60,Male,White,MUC5B rs35705950,50.0,3,Placebo,Standard,2023-09-04,Standard,Canada,SITE-020
PT-004859,XS-OD-0050,37,Female,Asian,TERT p.R865H,57.1,1,Active_Drug,Standard,2024-01-16,Standard,Italy,SITE-010
PT-004860,XS-OD-0050,20,Male,Asian,TERT p.R865H,46.5,1,Placebo,Standard,2024-01-11,Standard,Australia,SITE-004
PT-004861,XS-OD-0050,80,Female,White,,40.1,1,Active_Drug,Standard,2023-09-25,Standard,Italy,SITE-012
PT-004862,XS-OD-0050,62,Female,Black or African American,TERT p.R865H,83.5,4,Placebo,Standard,2023-09-07,Standard,Spain,SITE-019
PT-004863,XS-OD-0050,24,Male,White,BMPR2 c.354+1G>A,57.0,2,Active_Drug,Standard,2023-11-11,Standard,Netherlands,SITE-001
PT-004864,XS-OD-0050,11,Male,Black or African American,,46.0,1,Placebo,Standard,2023-10-04,Pediatric_Assent,Australia,SITE-017
PT-004865,XS-OD-0050,27,Male,Hispanic or Latino,MUC5B rs35705950,76.4,0,Active_Drug,Standard,2023-09-02,Standard,France,SITE-017
PT-004866,XS-OD-0050,81,Male,American Indian or Alaska Native,,56.6,3,Placebo,Standard,2023-10-08,Standard,France,SITE-020
PT-004867,XS-OD-0050,58,Female,Black or African American,TERT p.R865H,73.5,3,Active_Drug,Standard,2023-12-14,Standard,Canada,SITE-005
PT-004868,XS-OD-0050,46,Female,White,BMPR2 c.354+1G>A,10.0,4,Placebo,Standard,2023-10-11,Standard,Australia,SITE-005
PT-004869,XS-OD-0050,62,Male,White,BMPR2 c.354+1G>A,62.7,0,Active_Drug,Standard,2023-12-31,Standard,Australia,SITE-007
PT-004870,XS-OD-0050,20,Female,White,BMPR2 c.354+1G>A,44.8,4,Placebo,Standard,2024-01-21,Standard,Australia,SITE-012
PT-004871,XS-OD-0050,44,Female,White,TERT p.R865H,55.5,0,Active_Drug,Standard,2023-10-02,Standard,United States,SITE-019
PT-004872,XS-OD-0050,45,Female,White,TERT p.R865H,37.7,5,Placebo,Standard,2023-11-10,Standard,Spain,SITE-002
PT-004873,XS-OD-0050,26,Male,Asian,BMPR2 c.354+1G>A,56.0,2,Active_Drug,Standard,2023-12-30,Standard,United States,SITE-006
PT-004874,XS-OD-0050,47,Male,Asian,TERT p.R865H,21.2,2,Placebo,Standard,2023-11-18,Standard,Spain,SITE-012
PT-004875,XS-OD-0050,20,Female,Black or African American,,62.8,5,Active_Drug,Standard,2024-02-18,Standard,Japan,SITE-015
PT-004876,XS-OD-0050,39,Female,Hispanic or Latino,MUC5B rs35705950,47.7,2,Placebo,Standard,2023-11-11,Standard,Japan,SITE-012
PT-004877,XS-OD-0050,48,Male,White,TERT p.R865H,40.5,2,Active_Drug,Standard,2024-02-19,Standard,Japan,SITE-019
PT-004878,XS-OD-0050,35,Female,White,MUC5B rs35705950,64.2,0,Placebo,Standard,2024-02-05,Standard,Spain,SITE-014
PT-004879,XS-OD-0050,38,Female,Asian,TERT p.R865H,47.0,0,Active_Drug,Standard,2023-12-21,Standard,Italy,SITE-020
PT-004880,XS-OD-0050,34,Female,Native Hawaiian or Other Pacific Islander,TERT p.R865H,38.5,5,Placebo,Standard,2023-12-13,Standard,Australia,SITE-008
PT-004881,XS-OD-0050,21,Male,White,,81.7,4,Active_Drug,Standard,2024-01-12,Standard,Japan,SITE-017
PT-004882,XS-OD-0050,2,Male,Two or More Races,,49.9,3,Placebo,Standard,2023-12-28,Pediatric_Assent,Japan,SITE-017
PT-004883,XS-OD-0050,59,Female,White,TERT p.R865H,56.8,1,Active_Drug,Standard,2024-01-30,Standard,Australia,SITE-016
PT-004884,XS-OD-0050,46,Female,Hispanic or Latino,TERT p.R865H,76.5,2,Placebo,Standard,2023-11-27,Standard,Australia,SITE-007
PT-004885,XS-OD-0050,67,Male,White,,61.7,1,Active_Drug,Standard,2023-11-07,Standard,Germany,SITE-015
PT-004886,XS-OD-0050,48,Intersex,White,,25.8,0,Placebo,Standard,2023-09-19,Standard,Germany,SITE-009
PT-004887,XS-OD-0050,28,Female,White,MUC5B rs35705950,52.7,1,Active_Drug,Standard,2024-02-06,Standard,Australia,SITE-014
PT-004888,XS-OD-0050,35,Male,White,MUC5B rs35705950,95.0,2,Placebo,Standard,2024-01-23,Standard,Spain,SITE-020
PT-004889,XS-OD-0050,40,Female,White,BMPR2 c.354+1G>A,41.4,2,Active_Drug,Standard,2023-12-16,Standard,United Kingdom,SITE-010
PT-004890,XS-OD-0050,51,Male,White,,45.9,3,Placebo,Standard,2023-09-14,Standard,Japan,SITE-018
PT-004891,XS-OD-0050,63,Male,White,TERT p.R865H,24.0,1,Active_Drug,Standard,2023-10-10,Standard,Australia,SITE-019
PT-004892,XS-OD-0050,60,Female,Black or African American,,75.5,1,Placebo,Standard,2023-09-13,Standard,United States,SITE-016
PT-004893,XS-OD-0050,41,Male,Black or African American,,55.7,1,Active_Drug,Standard,2024-02-09,Standard,Germany,SITE-019
PT-004894,XS-OD-0050,76,Male,White,BMPR2 c.354+1G>A,54.6,2,Placebo,Standard,2023-11-12,Standard,Japan,SITE-018
PT-004895,XS-OD-0050,47,Male,Two or More Races,,46.7,3,Active_Drug,Standard,2023-10-14,Standard,Italy,SITE-020
PT-004896,XS-OD-0050,36,Female,Asian,MUC5B rs35705950,38.5,1,Placebo,Standard,2024-01-09,Standard,Spain,SITE-006
PT-004897,XS-OD-0050,46,Female,White,BMPR2 c.354+1G>A,64.1,1,Active_Drug,Standard,2023-10-15,Standard,Netherlands,SITE-003
PT-004898,XS-OD-0050,26,Male,Black or African American,BMPR2 c.354+1G>A,61.1,2,Placebo,Standard,2024-01-15,Compassionate,Canada,SITE-019
PT-004899,XS-OD-0050,31,Female,Asian,,60.9,1,Active_Drug,Standard,2023-09-23,Standard,United States,SITE-020
PT-004900,XS-OD-0050,39,Male,White,MUC5B rs35705950,15.2,1,Placebo,Standard,2023-09-01,Standard,Italy,SITE-012